<SEC-DOCUMENT>0001558370-23-005127.txt : 20230330
<SEC-HEADER>0001558370-23-005127.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330170141
ACCESSION NUMBER:		0001558370-23-005127
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroBo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		23781554

	BUSINESS ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		200 BERKELEY ST.
		STREET 2:		FL 19
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nrbo-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/30/2023 7:48:04 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 38c3456c-2fbb-47f7-aff6-4d430c910038 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:nrbo="http://www.gemphire.com/20221231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" xs:nil="true" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_r5YIjCyGvEK3yHB4n1BpVg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" xs:nil="true" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Zmo1ORFQGUyxA6SSbXkV7Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" xs:nil="true" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" name="us-gaap:PreferredStockValue" id="Hidden_bQq_NMxy_kGeemiwEPt3VA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" xs:nil="true" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" name="us-gaap:PreferredStockValue" id="Hidden_Gc9J0P6c8kegK2GqhDWwPw"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityCentralIndexKey" id="Tc_T5Gmm1J_cEeEoTz2t4fs2A_2_1">0001638287</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:DocumentFiscalYearFocus" id="Tc_gSxZQIhmHU6J8OfFHxqGSA_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:DocumentFiscalPeriodFocus" id="Tc_tS4MdZqYcEmPBkbE5KRJeQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:AmendmentFlag" id="Narr_ShYqrFnj_EqW9YAucBBL3g">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_fP5EDXxBPka1AU3Q6LoP_Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_bb_q-QCsp0yUzMAewPYP5Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Mn5738ISFkmHUd9Ofy-Zkw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_Df2pWX79BkWs2KdKZLAPcA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_tD2RTX7JhEiUN69eOj671g">25436019</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_OuphcIW93km7Lewq_FhozA">888693</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="nrbo:DefinedContributionPlanEmployerMatchingContributionVestingPercentage" id="Hidden_DPeIVkG-okWzbfTbv-bZXQ">P6Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_FyBBTxlXGEGwh1t7bmaxpQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA" name="nrbo:ContractTerm" id="Hidden_F7zo_zW-NUK53QFVdH_Apw">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA" name="nrbo:ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" id="Hidden_2TEjfFmoakSOFBCUgn6ldg">P30D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_7_2020_To_6_7_2020_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_KAwevGFCTkiubmzYUmtJdQ" name="nrbo:ContractTerm" id="Hidden_Y_VNuVMUj02pKiVqh9023w">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_21_2021_To_1_21_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CsdGhmL_B0m66NunxNjvUQ" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Hidden_STCOS7deHEiR00lPkfq1OA">P5Y6M</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_Inik_Nb_jUm6ajNMDQ5Ppg">P3Y6M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="Hidden_ONTN_FfUsEGhQ_nLCwdysw">http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_9_12_2022_To_9_12_2022_kJ01-s11pEi5GhaVIbxoAg" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_-c2kEXqIKUut8eHDA86q6w">0.33</ix:nonFraction><ix:nonNumeric contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ" name="nrbo:CurePeriodForPetitionForBankruptcy" id="Hidden_KYNGeI_ZfkuzqiJCYGB1Ww">P30D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ" name="nrbo:PeriodForFailToCureBreachMayTerminateAgreement" id="Hidden_8VHUHzuV5UqZVxVaa0LNCA">P60D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nrbo-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_z5T8f5E9g0WIA-Y0HVYsRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_2N6TCpmcHEazJ6gu1eY5yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vqWx7AJ5EU2oXUiFHiP21g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_PH52T1NMSkudkBlRsUiAzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2VyAR7dXg060hMZr4FuJGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_LDYXw0uQCUG-gO_0LLFXuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_flmg7ndj70K84Nl5u2HoQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_DNs6bxizX0y5Tfgm4r8p_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FynBgB2tY0y-WXG6tBWeYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_A4jJNd6yZEi4EpzdUzOidQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PrivateInvestmentInPublicEquityAndLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_YwJOb8m61EqDiD7F2y2HpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6gHep_8RnUanvUH7fsIEMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_22_2022_To_12_22_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ljoZFeq7K0W9sSW4K8xV6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yUrtat3dg0uspmB84hfp8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVVU8h7siEiH2naixEFcfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_12_2022_To_9_12_2022_kJ01-s11pEi5GhaVIbxoAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-12</xbrli:startDate><xbrli:endDate>2022-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wWZsd3T6gka9TSP8iKUvZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6fVwVC7cn0mmYOxFysPq3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nvhHRqi-vkm9u_BWawKrYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JkKhTKgT3kS_VWrdj93liA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UnyFFCsxtkO8kwOnTjAf6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nZhvaiz6j0isSIkyaUH_sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8ETAng3t0SmxgpKoZ05kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KMpsO1-fg0q_X-4JOdhaRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XHL-x0fEb0yRGhDBpCdG2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_u97PYsnPakewyhHU5f9QQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zoF33XhQuUy-t80UIXPd1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0sehVfaRLESnA7PGQGiYcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_11_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2018Member_ko1jQnLPBEqgk8fnim0vfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9ZvJ9LtzWUOti8VldYpmzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9VXoK8ZQMkmjMvlnr02F6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_7yFz8TeHqkaHnkGtHM5ODQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2022201And2019PlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022Member_eifF-TPUWEunkLiTyY8FpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2019Member_V9kjpRU_B0mAPphmsOIjvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlan2021Member__jN6B4AZyUeQSX5hmnKlUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_TkENndys2Uaf4fqNaeg3Tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_05S9u_n9JkucaP69CQY6Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_uq04BWb7AE-iy-oszOsfGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_edJRGY-FvUOBcIWcKUF6eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_21_2021_To_1_21_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CsdGhmL_B0m66NunxNjvUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aWQ-JSgQ7Eyj0sP8jouJIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_udpCt7xwTkmIOi0v6glSMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_goh7paQIHkKoksKth-jjfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_jakDXzDB0EqYM_f7RAVDWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_LoFCvnOSokiqESf8sPL2dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_kj6tzIw4ikOotzAukBfIhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember_Ysy_oDW2ZUuQshWJ1usWfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_szvp0G-HgE6LH9q1BEd5Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_mAMpODa2nkKAzLAAMiOi-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_b6Tq9XMF9kWXMJVobfHIhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2022_To_9_14_2022_ZstQZeqBzk69SGCuk3r0kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_SecuritiesPurchaseAgreementMember_xdPppEpN60y-0j1Cm-TgmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_WMNL8kmcJU2TTDRxUzPFXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_EEmJUdpNf0uElf6g12GrWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ZNoLMPLiW0aszZnLPwlyiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_JfiOhNhM4kq-BfVEu0LZXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_KR_YvToqRmZfUCr2F12W7LUeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_KR_G_Rp8jJUYUWnai9tqLfSSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember__f5vapaPiE6z4tp3rFwAtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_FGRQQlyE-kqOj-HImH6Z9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORlXGbVUk0-D7PGg_EkbSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PGFeUl1eO06LDtIaMAVaQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2019_srt_StatementGeographicalAxis_country_KR_HvV-4l0BaEGxJ9yVDcToOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2019_To_5_31_2019_srt_StatementGeographicalAxis_country_KR_4xOvJGybuEay2f4Kwe1YKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_30_2022_To_4_30_2022_srt_StatementGeographicalAxis_country_KR_YsKsKamLv0yflBeWRDvO7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-30</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdL7c281rEWmqG_VeW3mHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52vJLxsaskuscStB9Hd_ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fNzdadyn-0Gw93J5AhwBdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nDBdXISMyEWxxvvugoib-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_5Db9ow_iRkWLj51gC7U6Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2022201And2019PlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_l0ZHVOGbuUOzRBb3KR4MiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_h4TI82YIYEafQM3AvpLuuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1pjv2MX8J0-yfwddaY-lNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_kBvkGV4jekagMWbtRHE_aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_R8tpABL6SEiwPZQ-3VvIFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice7800.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_jBT2fr5VpUOllcLVtoPKDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice5602.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_s3mxPDUhy0OW0_k2L4JVOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice375.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_MMU0eNbMe0utmyloJC2nyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice180.90Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_zL_FjtCahk2IkDsWNpvOeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice112.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_vVxVMB4etkuISAzFnY5dCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_xKdZLeM_RkacOFor73v_Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_fo5C0eYqVUyTvpl1YK8Utg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice7800.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_QPGLTkwobEqQWl1-u_J7ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice5602.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_vzleW1-QjkCN0FSzQTflBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice375.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_AK1S2nZAUUyqC_lMS5p_zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice180.90Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_bysVT-b7fUappax39iT8-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice112.50Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesWarrantExercisePrice3.00Member_9QLfqPRLn06Fhfn6AE5raA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesWarrantExercisePrice3.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesBWarrantExercisePrice3.00Member_GsOHy7n8B0W-TCmc86HAcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesBWarrantExercisePrice3.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_Syw-BUTd2EajoaUuYlNFGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_ZfzL5Dvo60C4s_TLuxoTqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_oDsSUJDF10mKNONqEZSMiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_clpDxqqAN0qB38SnsnjsCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_6mbAVgdr_kKuEsMIk2u25w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrbo:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_X0i0kWRTo0Oc2-qhzLlQFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_wpEzOwDCY02faZHzEsikFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrbo:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAEVu6CnL02lDdU-rjBNQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_N6zssHroH06fo8J6U0yHSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_HJQHlQ__sE6LZHYJuTQyyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_31_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AETHQHuOI0u7EUpHpFV96w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ulqJo4r_k0qlDZTa_a_Bxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-21</xbrli:startDate><xbrli:endDate>2021-01-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0frIUJR_I0OOFhGp2TsYXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_Ry1oAKkWqkWxsb6iJ3oDuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IPbMK5DMBU-arb5dHnRBNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nrbo:AnaTherapeuticsInc.AssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_DrCMGt_Bb0m-pV_jNh3q6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_uh4H-TEI7EyhE2e1wLB-OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Y7ZQpxzhMUm9V49NbXYQOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_IvLn50OmOkCyhBU3LyuqfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_U3QAOXXUOUiR6REQjSJf4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JiGuQjKiyUmwErH_myawlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_jPeszFZjIEqx6fhLN1VR3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrbo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mjtKTnsE70-ZgJb276XuuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wUjqzfyMzUqaUq1JGxWv1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cq7ytvBYmU6naQ7Efn7LIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EowmUlNgF0ijywAkcdtsEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gGUrMvv3ZkSmGD_w_TYU0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrbo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_72IFixvL4kSbmpjM1YSfwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_7_2022_To_6_7_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_ManufacturingAndSupplyAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_mrVIOz70GUG2r1JVXDTTRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-07</xbrli:startDate><xbrli:endDate>2022-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_SharedServicesAgreementMember_bK2yJe4yoU2jm_DEGsbO0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:SharedServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OWD6T-tZC06ThXS0xCkQyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_23_2021_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_GAKGJeHh6UuULfG-TYy7pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:OriginalCvrAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_30_2019_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_oIsPvJwajkGM38Ex40BY6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:OriginalCvrAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierTwoNetSalesMilestoneMember_dpzKVlo1ekGtUs9fT1O3mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierTwoNetSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierThreeNetSalesMilestoneMember_fzSwTYIVmkeJrh9SwkEpKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierThreeNetSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierOneNetSalesMilestoneMember_SES_rbkbP0eNKOMs2xwA_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierOneNetSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierFourNetSalesMilestoneMember_TxpZFkCQ10C-ExxaRCaBqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierFourNetSalesMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e0tClQh0z0msDPqPsOTVmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hjmzNGpAn0213gk2bupY4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_UA9AdohqXUSoaG3NbfF6OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_YWNm-7gVqkq3BnovVKJ0Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2022_To_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_LicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_6hrwWyQFkkGHl0B3-Pe0ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_X91Oqmk7XUCm6SQsu_Avpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_zzR33TSc_Eq3qTKp-rYpEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember__rH0iwnWGEWGagjRIx77dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_MCgUOrSmAUGyN4xH2iEx5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_azdNGhPJu0ixmk2GgSSbKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_JpNwtACeAEisv2eSDupv_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_htnX0uXa7kCB-UHSuxbNSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:OriginalCvrAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_e_U9zOVAtEW8M7Nl3d2N0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1726Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_QniKuwjxwU-VAVU5AQO_tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:Da1726Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1241Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_3M2K_Hs1_kGIY2eTUaM2fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:Da1241Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_GR9OQ9E5cEGdGSBaKaofsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_DMIjvwYsPkGpJljUcZUhyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_HhypM8orekaUV3ZSz7r8gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_qsxaSWG__EyTOF1yU2Gswg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_14_2021_To_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_88MmA4GQEU6X2lD11RT57A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-14</xbrli:startDate><xbrli:endDate>2021-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_-Qb32V34hEG7LHl67hYHEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2020_To_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_bI49wt-rv06inimFCn-hbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_FirstAmendmentToOriginalCvrAgreementMember_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_XHR9_9HRME-lP7dY7J3wUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:FirstAmendmentToOriginalCvrAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nrbo:AnaTherapeuticsInc.AssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanThreeBillionMember_sZhFMyWVrE2W0wp6FIo2LA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThanThreeBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanOneBillionMember_UdP-HCvD0E2O-ZPaLupmow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThanOneBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanFiveBillionMember_Bk3afARaEEa5UtSxvJFFcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThanFiveBillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThan500MillionMember_k1KYYL1K_0-HvDnDN7RX9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThan500MillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_7cfaqECBI0mYM0TA6a38MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_7_2020_To_6_7_2020_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_KAwevGFCTkiubmzYUmtJdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-07</xbrli:startDate><xbrli:endDate>2020-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OkcQ-fcFaECmAneltF__OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:MilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-28</xbrli:startDate><xbrli:endDate>2018-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_wzCrD8W_a0KHVlgiyTYKNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_37I4EYMzakCIpYA1bW04gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_JsyKwAESkU-fzjhg3wvYgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IG_Y6UouBkm4R_t4WrbvGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nrbo:AnaTherapeuticsInc.AssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_xJD90V2mhku1eTe__WHVCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2023_shKXoRPAsEWqXet8afQ58A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_Vote_shares_q2LbOB3SVUaQQK-N2RnI1g"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>nrbo:Vote</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_item_BbpdEDrZSk2GQqI08hy64Q"><xbrli:measure>nrbo:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_vhBxOMRVzkikLm5iLTAdhA"><xbrli:measure>nrbo:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;"> </span></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_c7d779ab_1d55_4ad4_bd0a_994251e4bda0"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:12.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:12.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Form </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:DocumentType" id="Narr_mHJlKcmS9UKKMieYtJc1HQ"><b style="font-size:9pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;min-height:8.0pt;text-align:justify;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(Mark One)</b>&#160;</p><a id="_ff3a5d31_e90d_4b5a_80a1_4a523cc7db63"></a><a id="Tc_vjjKaTX_PkyJaZSEkg1Pvw_1_1"></a><a id="Tc_dEmvVjm8iUqqVpdihG6COg_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:DocumentAnnualReport" id="Tc_VxLgoPgDeUOgQbTzsRTQJA_1_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:DocumentPeriodEndDate" id="Narr_wvTMLhkimkWer8BeSjgrgw"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:CurrentFiscalYearEndDate" id="Narr_69Gh4z6co0i1_YgNp0oG0w"><b style="font-size:8pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2022</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">OR</b>&#160;</p><a id="_64b835f1_e536_49e7_884d_bfc588c2b08f"></a><a id="Tc_DwPWS2YSS0yJ_MDmRDzyZQ_1_1"></a><a id="Tc_X8kqOQGd50W6-S3z-MW74g_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:DocumentTransitionReport" id="Tc_3iNBj3FkZE-yMAGA_j-8yg_1_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934</p></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from&#160;</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;to&#160;</b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;min-height:5.0pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityFileNumber" id="Narr_CBdq8oNAGk-JzX2XfTyz0w"><b style="font-size:8pt;font-weight:bold;">001-37809</b></ix:nonNumeric><span style="font-size:5pt;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityRegistrantName" id="Narr_6Iw-K_uKL0excIkdsFSvyw"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;">(Exact name of Registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;min-height:5.0pt;text-align:center;margin:0pt;">&#160;</p><a id="_5ecc298a_9c5a_4b93_ac0c_8d5d50754fd5"></a><a id="Tc_WzblcdvGGEyKGCTznxTA4Q_0_0"></a><a id="Tc_jGKP5362gkKmdzUXjRDtZw_2_0"></a><a id="Tc_z8wuscMYb0-NQ_hL7NO2jA_2_2"></a><a id="Tc_AYFo8pbrdUuEdai7plj-NQ_4_0"></a><a id="Tc_sYPSvMtEwEehF5f8na4bgQ_5_0"></a><a id="Tc_8MCnT9oexUml1DRUSS_HMQ_5_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;line-height:1.19;margin:0pt;">the </p></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityIncorporationStateCountryCode" id="Tc_883AyHmG602ze4bogiVjuA_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:6.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityTaxIdentificationNumber" id="Tc_m8JT-hze7ke1VExUGUwL3g_1_2"><b style="font-size:6.5pt;font-weight:bold;">47-2389984</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;min-height:6.0pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;min-height:6.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;min-height:6.0pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityAddressAddressLine1" id="Narr_RhQ3PblpGUut1b5YpQiBzQ"><b style="font-size:8pt;font-weight:bold;">200 Berkeley Street, Office 19</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">th</sup><b style="font-size:8pt;font-weight:bold;"> Floor</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityAddressCityOrTown" id="Narr_xkPjB2dAwUiWFlmuUh5DUQ"><b style="font-size:8pt;font-weight:bold;">Boston</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityAddressStateOrProvince" id="Narr_PKpNj1SdkkqUYid8g_fFXg"><b style="font-size:8pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityAddressPostalZipCode" id="Tc_VDbzLTkM70q1F9IM4-PxLQ_4_2"><b style="font-size:8pt;font-weight:bold;">02116</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:CityAreaCode" id="Narr_6W7vAbPTLU2YSblK6GEqYg"><b style="font-size:8pt;font-weight:bold;">857</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:LocalPhoneNumber" id="Narr_aUuwVHnRn02ynZ1lm5berA"><b style="font-size:8pt;font-weight:bold;">702-9600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;min-height:5.0pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities&#160;registered&#160;pursuant&#160;to&#160;Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;min-height:6.0pt;text-align:center;margin:0pt;">&#160;</p><a id="_db101494_73f9_470a_898f_8004be2c6bce"></a><a id="Tc_1w9bEZKT1E-XDisuT27U3g_2_0"></a><a id="Tc_x0-v5Pvc7Eip1Ru0ab97Zw_2_2"></a><a id="Tc_Sy2CGLtwNUSpvqkMEHzz7A_2_4"></a><a id="Tc_d0HITP585EiOVh8GAHKrvA_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:44.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:44.95%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</b></p></td><td style="vertical-align:top;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;"><b style="font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:44.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:Security12bTitle" id="Tc_vdnlOXn8n0OcNjCgmjnERw_3_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:0pt;"><span style="font-size:8pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:TradingSymbol" id="Tc_UwA2xbusFkCbp5XgDaHQog_3_2"><span style="font-size:8pt;">NRBO</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:44.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:SecurityExchangeName" id="Narr_e__4DgZOFkCu8-CQtuNFgQ"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:6.0pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities&#160;registered&#160;pursuant&#160;to&#160;Section&#160;12(g)&#160;of&#160;the&#160;Act:&#160;None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_15cA8HebWkajnm24XMemRg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;min-height:6.0pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act</span><span style="font-size:6pt;">.&#160;&#160;</span><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityVoluntaryFilers" id="Narr_xgDFLKWV90qFLu8zP6hWFQ"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;min-height:6.0pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityCurrentReportingStatus" id="Narr_eadODY4BXUmFhz1Cqb9bUw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;min-height:6.0pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityInteractiveDataCurrent" id="Narr_AmUJjj5kCUmtxoQpbEShMg"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;min-height:8.0pt;text-align:center;margin:0pt;">&#160;</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.4pt;text-align:center;margin:0pt;">Large accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.4pt;text-align:center;margin:0pt;">Accelerated filer&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr style="height:12.7pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.4pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityFilerCategory" id="Narr_-_OdpztBs0eUpum-d-wwew"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.4pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntitySmallBusiness" id="Narr_q7Fh_yKidE6ghqcKZ7RwEA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.4pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.4pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.4pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityEmergingGrowthCompany" id="Narr_r7qwrGP4RE-YGueKS_syYw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.4pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;margin:0pt;"><span style="font-size:8pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:9.0pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:IcfrAuditorAttestationFlag" id="Narr_L4vG_7hvNECvGGBzwi0gIA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;background:#ffffff;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:27.75pt;background:#ffffff;margin:0pt;"><span style="font-size:8pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;background:#ffffff;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Act. Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:EntityShellCompany" id="Narr_hLFPFL0zsUeIWvqYKwec9Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;min-height:8.0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:9.0pt;margin:0pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_xJD90V2mhku1eTe__WHVCg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_ghAZoyJmjkO14KztBoYavg">7.0</ix:nonFraction> million based on the closing price on the Nasdaq Capital Market as of June 30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;min-height:8.0pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">The number of outstanding shares of the registrant&#8217;s common stock, $0.001 par value per share, as of March 24, 2023 was </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_24_2023_shKXoRPAsEWqXet8afQ58A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_d4U9ouOuOEmDXV1z1qJa0Q">27,176,685</ix:nonFraction></span><span style="font-size:8pt;">. </span>&#160;</p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman Bold';font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f8adc5e4_21f4_4d2d_af9c_24c5907669af"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">FORM 10-K</span></p><a id="Toc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">INDEX- </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTI_764553"><span style="font-style:italic;font-weight:bold;">PART I</span></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM1BUSINESS_687476"><i style="font-style:italic;font-weight:normal;">Item 1</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM1BUSINESS_687476"><i style="font-style:italic;font-weight:normal;">Business</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM1ARISKFACTORS_215230"><i style="font-style:italic;font-weight:normal;">Item 1A</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM1ARISKFACTORS_215230"><i style="font-style:italic;font-weight:normal;">Risk Factors</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"><i style="font-style:italic;font-weight:normal;">Item 1B</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"><i style="font-style:italic;font-weight:normal;">Unresolved Staff Comments</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM2PROPERTIES_644950"><i style="font-style:italic;font-weight:normal;">Item 2</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM2PROPERTIES_644950"><i style="font-style:italic;font-weight:normal;">Properties</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_754217"><i style="font-style:italic;font-weight:normal;">Item 3</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM3LEGALPROCEEDINGS_754217"><i style="font-style:italic;font-weight:normal;">Legal Proceedings</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_848551"><i style="font-style:italic;font-weight:normal;">Item 4</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_848551"><i style="font-style:italic;font-weight:normal;">Mine Safety Disclosures</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTII_387386"><span style="font-style:italic;font-weight:bold;">PART II</span></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><i style="font-style:italic;font-weight:normal;">Item 5</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:top;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><i style="font-style:italic;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">69</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_394630"><i style="font-style:italic;font-weight:normal;">Item 6</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM6SELECTEDFINANCIALDATA_394630"><i style="font-style:italic;font-weight:normal;">[Reserved]</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><i style="font-style:italic;font-weight:normal;">Item 7</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><i style="font-style:italic;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><i style="font-style:italic;font-weight:normal;">Item 7A</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><i style="font-style:italic;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">81</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><i style="font-style:italic;font-weight:normal;">Item 8</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><i style="font-style:italic;font-weight:normal;">Financial Statements and Supplementary Data</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">82</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><i style="font-style:italic;font-weight:normal;">Item 9</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><i style="font-style:italic;font-weight:normal;">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">111</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item9A"><i style="font-style:italic;font-weight:normal;">Item 9A</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item9A"><i style="font-style:italic;font-weight:normal;">Controls and Procedures</i></a><i style="font-style:italic;"> </i></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">111</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_848698"><i style="font-style:italic;font-weight:normal;">Item 9B</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9BOTHERINFORMATION_848698"><i style="font-style:italic;font-weight:normal;">Other Information</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">112</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9C_805257"><i style="font-style:italic;font-weight:normal;">Item 9C</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM9C_805257"><i style="font-style:italic;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevents Inspections</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">112</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTIII_373562"><span style="font-style:italic;font-weight:bold;">PART III</span></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><i style="font-style:italic;font-weight:normal;">Item 10</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><i style="font-style:italic;font-weight:normal;background:#ffffff;">Directors, Executive Officers and Corporate Governance</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_607490"><i style="font-style:italic;font-weight:normal;">Item 11</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM11EXECUTIVECOMPENSATION_607490"><i style="font-style:italic;font-weight:normal;background:#ffffff;">Executive Compensation</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">116</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAIN_50405"><i style="font-style:italic;font-weight:normal;">Item 12</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a><i style="font-style:italic;"> </i></p></td><td style="vertical-align:top;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM12SECURITYOWNERSHIPOFCERTAIN_50405"><i style="font-style:italic;font-weight:normal;background:#ffffff;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder&#160;Matters</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">119</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRE_750177"><i style="font-style:italic;font-weight:normal;">Item 13</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM13CERTAINRELATIONSHIPSANDRE_750177"><i style="font-style:italic;font-weight:normal;background:#ffffff;">Certain Relationships and Related Transactions, and Director Independence</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">121</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><i style="font-style:italic;font-weight:normal;">Item 14</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"><i style="font-style:italic;font-weight:normal;background:#ffffff;">Principal Accountant Fees and Services</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">124</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#cceeff;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#PARTIV_836208"><span style="font-style:italic;font-weight:bold;">PART IV</span></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#cceeff;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#cceeff;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM15_562720"><i style="font-style:italic;font-weight:normal;">Item 15</i><i style="font-family:'Symbol';font-style:italic;font-weight:normal;">:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM15_562720"><i style="font-style:italic;font-weight:normal;background:#ffffff;">Exhibits and Financial Statement Schedules</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">125</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM16_822338"><i style="font-style:italic;font-weight:normal;">Item 16:</i></a></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ITEM16_822338"><i style="font-style:italic;font-weight:normal;background:#ffffff;">Form 10-K Summary</i></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">130</p></td></tr><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:90.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#SIGNATURES"><b style="font-style:normal;font-weight:bold;">SIGNATURES</b></a></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">131</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ddaa41e7_9ece_49aa_8f25_010b75430451"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">This Annual Report on Form 10-K for the fiscal year ended December 31, 2022 contains &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, these forward-looking statements contain information about our expectations, beliefs or intentions regarding our product development and commercialization efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. These forward-looking statements are based on management&#8217;s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. These statements may be identified by words such as &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;should,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; and other words of similar meaning.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Actual results could differ materially from those contained in forward-looking statements. Many factors could cause actual results to differ materially from those in forward-looking statements, including those matters discussed below, as well as those listed in Item 1A. Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Other unknown or unpredictable factors that could also adversely affect our business, financial condition and results of operations may arise from time to time. Given these risks and uncertainties, the forward-looking statements discussed in this report may not prove to be accurate. Accordingly, you should not place undue reliance on these forward-looking statements, which only reflect the views of NeuroBo Pharmaceuticals, Inc.&#8217;s management as of the date of this report. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results or expectations, except as required by law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f92126b6_24b6_4b7b_9eea_64be1b1e1738"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUMMARY RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Our business is subject to a number of risks, as fully described&#160;in &#8220;Item 1A. Risk Factors&#8221;&#160;in this Annual Report. The principal factors and uncertainties include, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo expects to incur losses for the foreseeable future and may never achieve or maintain profitability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo will need additional financings to fund operations and such additional financings may cause dilution to existing stockholders, restrict NeuroBo&#8217;s operations or require NeuroBo to relinquish its technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The timing and costs related to the clinical development of NeuroBo&#8217;s products are difficult to predict, and any delays in NeuroBo&#8217;s clinical trials may lead to a delay in the submission of marketing approval applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo may be required to make significant payments under the Dong-A License Agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Undesirable side effects from future product candidates could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, and the development of such product candidates exposes NeuroBo to additional risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo may engage in future acquisitions, in-licenses of technology, strategic alliances or enter into additional licensing arrangements that could disrupt its business, cause dilution to the organization&#8217;s stockholders, harm its financial condition and operating results or result in no benefits being realized from such engagement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside of NeuroBo&#8217;s control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than it does;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo&#8217;s commercial success depends upon attaining significant market acceptance of its product candidates, if approved, among hospitals, physicians, patients and healthcare payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product liability lawsuits against NeuroBo could cause it to incur substantial liabilities and could limit commercialization of any product candidate that it may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo relies on third parties to develop NeuroBo&#8217;s preclinical studies, clinical trials, research programs and product candidates and to manufacture its product candidates and preclinical and clinical drug supplies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or if they engage in misconduct or other improper activities or if NeuroBo is unable to engage with these third parties, it could have a material adverse effect on NeuroBo&#8217;s business and NeuroBo&#8217;s obtaining of regulatory approval and commercialization of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any product candidate for which NeuroBo obtains marketing approval could be subject to marketing restrictions or withdrawal from the market, and NeuroBo may be subject to penalties if it fails to comply with regulatory requirements or if it experiences unanticipated problems with our products;</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:2.5pt;margin:0pt;"><span style="font-size:2.5pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo or any of its potential collaborators may never receive regulatory approval to market NeuroBo&#8217;s product candidates within or outside of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mechanisms that NeuroBo may utilize to expedite and/or reduce the cost for development or approval of its product candidates may not lead to faster or less expensive development, regulatory review or approval process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Legislation may increase the difficulty and cost to obtain marketing approval of and commercialize its product candidates, and governments outside the United States tend to impose strict price controls, which also may adversely affect NeuroBo&#8217;s revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo&#8217;s compliance with legal standards related to foreign trade could impair its ability to compete in domestic and international markets, and NeuroBo could face criminal liability and other serious consequences for violations;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain tax matters, including NeuroBo&#8217;s ability to use its NOLs to offset future taxable income may be subject to certain limitations, could impact its results of operations and financial conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inadequate funding for the FDA and other government agencies could prevent those agencies from performing normal business functions on which the operation of NeuroBo&#8217;s business may rely, which could negatively impact NeuroBo&#8217;s business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If NeuroBo is unable to obtain, maintain and protect sufficient intellectual property rights, its competitive position could be harmed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo may become involved in lawsuits to protect or enforce its intellectual property, which could be expensive, time consuming, unsuccessful and could distract NeuroBo&#8217;s personnel from their normal responsibilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo has identified material weaknesses in its internal control over financial reporting that could, if not remediated, result in material misstatements in its financial statements or impair its ability to produce accurate and timely consolidated financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo&#8217;s obtaining and maintaining patent protection could be reduced or eliminated for non-compliance with certain requirements imposed by governmental patent agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo&#8217;s business and operations would suffer in the event of system failures or unplanned events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any failure, inadequacy, interruption or security lapse of NeuroBo&#8217;s information technology could prevent NeuroBo from accessing critical information or expose NeuroBo to liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If securities analysts do not publish research or reports about NeuroBo&#8217;s business or if they publish negative evaluations of NeuroBo&#8217;s stock the price of NeuroBo&#8217;s stock could decline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo does not anticipate declaring or paying, in the foreseeable future, any cash dividends on its capital stock and, consequently, the ability of its stockholders to achieve a return on their investment will depend on appreciation in the price of NeuroBo&#8217;s common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo&#8217;s Bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by NeuroBo&#8217;s stockholders, which could limit the ability of NeuroBo&#8217;s stockholders to obtain a favorable judicial forum for disputes with NeuroBo or its directors, officers or employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unstable market and economic conditions may have serious adverse consequences on NeuroBo&#8217;s business, financial condition and stock price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 6pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 6pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The liquidity and trading volume of NeuroBo&#8217;s common stock could be low, its ownership will be concentrated and the market price of its common stock may be highly volatile;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">NeuroBo&#8217;s common stock may be delisted from the Nasdaq Capital Market if it fails to comply with the continued listing requirements</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dbead926_c9b7_43fb_81f4_d70b04d5feef"></a><a id="PARTI_764553"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART I</b></p><a id="ITEM1BUSINESS_687476"></a><a id="_Hlk1199602"></a><a id="_Hlk536805308"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">ITEM 1.        BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">NeuroBo Pharmaceuticals, Inc. (the &#8220;Company,&#8221; &#8220;NeuroBo,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a clinical-stage biotechnology company focused primarily on </span>developing and commercializing novel pharmaceuticals to treat <span style="letter-spacing:0.2pt;white-space:pre-wrap;">cardiometabolic diseases.  NeuroBo has two primary programs focused on treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;), obesity and type 2 diabetes (&#8220;T2D&#8221;):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D. Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of NASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;white-space:pre-wrap;">1a and 1b human trials DA-1241 was well tolerated in both healthy volunteers and those with T2D.  We intend to initiate a Phase&#160;2a study with the goal of establishing efficacy of DA-1241 in the treatment of NASH in the third quarter of 2023.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;white-space:pre-wrap;">DA-1726 is a novel oxyntomodulin (&#8220;OXM&#8221;) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity that is to be administered once weekly subcutaneously. DA-1726 as a dual agonist of GLP-1 receptors (&#8220;GLP1R&#8221;) and glucagon receptors (&#8220;GCGR&#8221;), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss, as well as reduced hepatic steatosis, inflammation, and fibrosis compared to semaglutide and cotadutide (another OXM analogue).  We intend to file an </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Investigational New Drug (IND) in the second quarter of 2023.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Each of DA-1241 and DA-1726 is currently being developed for the treatment of NASH. NASH is a severe form of nonalcoholic fatty liver disease (&#8220;NAFLD&#8221;), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma (&#8220;HCC&#8221;) and death. There are currently no approved products for the treatment of NASH.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The prevalence of NAFLD, which affects approximately 25% of the global population, and NASH, which develops in approximately 12% to 14% of NAFLD patients, is growing and is driven primarily by the worldwide obesity epidemic. The critical pathophysiologic mechanisms underlying the development and progression of NASH include reduced ability to handle lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. Patients with NASH frequently have other significant metabolic co-morbidities such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and these further contribute to the risk of cardiovascular disease. The number of NASH cases in the United States is projected to expand from 16.5&#160;million in 2015 to 27&#160;million in 2030, with similar prevalence growth expected in Europe. Diet and exercise are currently the standard of care for NAFLD and NASH, but adherence to this treatment regimen is poor and there remains a high unmet need in the treatment of NASH.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">While we are primarily focused on development of DA-1241 and DA-1726, we also have four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic diseases:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ANA001</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is a proprietary oral niclosamide formulation being developed as a treatment for patients with moderate COVID-19. Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and well-understood safety in humans.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">NB-01</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was primarily focused on the development of a treatment for painful diabetic neuropathy (PDN) as a first-line pain management therapy for PDN. </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">NB-02</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the misfunction of a protein called tau, and with amyloid beta plaque deposition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Gemcabene</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">was </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being developed </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, and was focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG) and we are currently exploring various acute therapeutic indications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our Board of Directors has determined to focus our financial resources and management attention on development of DA-1241 for NASH and T2D and DA-1726 for NASH and obesity.  We will continue to consider licensing and acquisition opportunities with respect to our legacy programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Transactions with Dong-A ST Co., Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">On September 14, 2022, we entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) with Dong-A ST Co., Ltd. (&#8220;Dong-A&#8221;) , a related party, pursuant to which, and subject to the conditions set forth therein, we received an exclusive global license (excluding the Republic of Korea) to two proprietary compounds for specified indications. The License Agreement covers the rights to a compound referred to as DA-1241 for treatment of NASH and a compound referred to as DA-1726 for treatment of obesity and NASH. We may also develop DA-1241 for the treatment of T2D. The 2022 License Agreement became effective on November 8, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the 2022 License Agreement, Dong-A (i) received an upfront payment which was settled in 2,200 shares of a new series of preferred stock of the Company designated as &#8220;Series A Convertible Preferred Stock&#8221;, par value $0.001 per share (the &#8220;Series A Preferred Stock&#8221;), under the terms of the Securities Purchase Agreement (as defined below) (the &#8220;Upfront License Payment&#8221;); (ii) is eligible to receive single digit royalties on net sales received by us from the commercial sale of products covering DA-1241 or DA-1726; (iii) is eligible to receive commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iv) is eligible to receive regulatory milestone payments of up to $178 million for DA-1726 and $138 million for DA-1241, dependent upon the achievement of specific regulatory developments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">On September 14, 2022, in connection with the License Agreement, we entered into a Securities Purchase Agreement with Dong-A (the &#8220;Securities Purchase Agreement&#8221;). Pursuant to the Securities Purchase Agreement, upon the consummation of the 2022 License Agreement and a Qualified Financing (as defined in the Securities Purchase Agreement), which occurred on November 8, 2022 as a result of the Public Offering (as defined below), (i) Dong-A received the Upfront License Payment and (ii) Dong-A purchased 1,500 shares of Series A Preferred Stock and warrants to purchase 10,000,000 shares of our common stock substantially equivalent to those issued to investors in respect of the Qualified Financing (the &#8220;Dong-A Warrants&#8221;) for a purchase price of $15 million (the &#8220;Dong-A Financing&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">On December 22, 2022, our stockholders approved the conversion of the Series A Preferred Stock and the exercise of the Dong-A warrants (the &#8220;Stockholder Approval&#8221;) and all of the Series A Preferred Stock converted into 12,333,333 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">On November 4, 2022, we entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Ladenburg Thalmann &amp; Co. Inc., as underwriter (the &#8220;Underwriter&#8221;), pursuant to which we agreed to issue and sell, in a firm commitment underwritten public offering by us (the &#8220;Public Offering&#8221;), (i) 2,397,003 Class A Units, consisting of (A) one share of common stock, (B) one Series A Warrant (&#8220;Series A Warrant&#8221;) to purchase one share of common stock, and (C) one Series B Warrant to purchase one share of common stock (&#8220;Series B Warrant&#8221;) and (ii) Class B Units, consisting of (A) one share of Series B Convertible Preferred Stock (the &#8220;Series B Preferred Shares&#8221;) each convertible into one share of common stock, (B) one Series A Warrant and (C) one Series B Warrant, priced at a public offering price of $3.00 per Class A Unit or Class B Unit. In addition, pursuant to the Underwriting Agreement, we granted the Underwriter a 45-day option (the &#8220;Overallotment Option&#8221;) to purchase up to (i) 750,000 additional shares of common </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">stock, (ii) 750,000 additional Series A Warrants and (iii) 750,000 additional Class B Warrants, solely to cover over-allotments. The Underwriter fully exercised the Overallotment Option on November 7, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;">On November 8, 2022, the Public Offering closed, and we issued and sold (i) 3,147,003 Class A Units which included 3,147,003 shares of common stock, 3,147,003 Series A Warrants and 3,147,003 Series B Warrants and (ii) 2,692,997 Class B Units which included 2,692,997 shares of Series B Convertible Preferred Stock, 2,692,997 Series A Warrants and 2,692,997 Series B Warrants. We received gross proceeds of approximately $17.3 million from the Public Offering. The exercise price for the Series A Warrants and Series B Warrants (the &#8220;Public Warrants&#8221;) was $3.00 per share and the Public Warrants also included a cashless exercise feature pursuant to which the Public Warrants were exercisable for one share each on a cashless basis. Following the closing of the Public Offering, all of the 2,692,997 shares of Series B Preferred Stock were converted into common stock on a one-for-one basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 6pt 0pt;">Our goal is to discover, develop and commercialize novel therapeutics designed to impact a range of indications primarily in cardiometabolic diseases. The key elements of our business strategy to achieve this goal include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Advance DA-1241 through the FDA regulatory process to obtain approval for the treatment of NASH and T2D initially by starting a Phase&#160;2a trial to establish an early signal of efficacy in NASH and T2D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Explore various avenues to advance DA-1241 to FDA approval, including, if the Phase&#160;2 clinical trials are successful, potentially securing a pharmaceutical partner to advance work on a global Phase&#160;3 program</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">Advance DA-1726 through IND and initiation of human clinical trials with the initial goal of having DA-1726 be IND-ready by the second quarter of 2023.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Product Candidates &#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">DA-1241</span><span style="font-style:italic;font-weight:bold;"> Treatment of Type 2 Diabetes and NASH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">DA-1241 is a new drug candidate with therapeutic potential for NASH and T2D that can be orally administered once a day. Two phase 1 clinical trials for the treatment of T2D have been completed in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">DA-1241 is a novel chemical drug candidate selectively activating G protein-coupled receptor 119 (GPR119) which has shown consistent target-related mechanisms and glucose-lowering effects from nonclinical studies to a Phase&#160;1b exploratory clinical trials in patients with T2D in the US. GPR119 is known to be a regulator of both blood glucose and lipid levels. Non-clinical studies suggest DA-1241 selectively activates GPR119, stimulates the secretion of insulin and incretin hormones such as glucagon-like peptide-1 (GLP-1), and thereby reduces plasma glucose levels without hypoglycemia risk and lowers plasma lipids levels of both triglycerides and cholesterol. Preclinical tests have suggested these therapeutic effects are augmented when co-treated with other oral anti-diabetic agents such as metformin, SGLT2 inhibitors, and DPP4 inhibitors which are widely used for treating patients with T2D in the clinic. Moreover, impaired insulin action and lipid metabolism which are frequently observed in T2D patients are highly associated with the pathogenesis of steatosis and inflammation in NASH. Extensive non-clinical studies have shown DA-1241 has therapeutic potential for the reduction in hepatic steatosis, inflammation, fibrosis, and improved glucose control regardless of body weight reduction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Background</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">T2D, previously referred to as &#8220;noninsulin-dependent diabetes&#8221; or &#8220;adult-onset diabetes,&#8221; accounts for 95% of all diabetes worldwide. This form encompasses individuals who have relative insulin deficiency and have peripheral insulin resistance. Based on CDC data, the U.S. population with diabetes is estimated to be 37.3&#160;million in 2022, which accounts for 11.3% of the population. Approximately one-quarter of these people are undiagnosed. Accordingly, GlobalData Plc estimated global anti-diabetic drug sales to be $48.1&#160;billion in nine major markets in 2019 and projected that the global antidiabetic market will continue to grow to $91.9&#160;billion by 2029 at a compound annual growth rate (CAGR) of 6.7%, with the US market accounting for 58% of the global market due to high drug prices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Patients with T2D have an increased prevalence of lipid abnormalities, contributing to their high risk of atherosclerotic cardiovascular diseases (ASCVD). According to the CDC, the prevalence of high cholesterol (non-HDL &#8805;130 mg/dL) among patients with T2D is 44.3%. ADA recommends the use of moderate-intensity statin therapy in addition to lifestyle therapy for patients with diabetes aged 40 - 75&#160;years regardless of ASCVD.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Despite several classes of anti-diabetic pharmacotherapy, there remains an unmet need for additional pre-insulin options. Metformin remains an anchor therapy, but the use of sulfonylureas (&#8220;SUs&#8221;), thiazolidinediones (&#8220;TZDs&#8221;), and DPP4 inhibitors continues to decline. SUs and TZDs are now only prescribed for patients with major affordability issues. DPP4 inhibitors have ceded share to the sodium-glucose cotransporter 2 (&#8220;SGLT2&#8221;) inhibitors and GLP-1 classes, because of lower A1c and weight loss efficacy, and the lack of compelling outcomes data. SGLT2 inhibitors and GLP-1s have shown efficacy by providing &#8220;glucose plus&#8221; effects (strong A1c, weight, and cardiovascular benefits) and cardiovascular and renal outcomes data in multiple clinical trials. Based on the third party&#8217;s report, an estimated 10% to 15% of T2D patients are still at risk of progressing to insulin. These patients are contraindicated for or unable to tolerate SGLT2 inhibitors and GLP-1 therapies. There is a further unmet need for T2D/dyslipidemia comorbid patients, as 5% of these patients are intolerant to statins, requiring alternative therapies to control their lipid levels. PCSK9 inhibitors are the existing alternative for these patients today, but patients struggle with the injection route of administration and high cost. Beyond oral hypoglycemic agents with a novel mechanism, there is an unmet need for an effective drug therapy to improve lipid metabolism in diabetic patients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">DA-1241 Preclinical Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Extensive preclinical pharmacology, Absorption, Distribution, Metabolism and Excretion (&#8220;ADME&#8221;), safety and toxicology studies have been completed for DA-1241. The pharmacokinetic characteristics of DA-1241 were identified through the full set of preclinical ADME package. The safety and toxicology studies completed are: (i)&#160;central nervous system (CNS), cardiovascular (CV), and respiratory safety in rats and dogs; (ii)&#160;a single-dose, 4-week, 13-week and 26-week oral toxicity studies in rats; (iii)&#160;4-week, 13-week and 39-week oral toxicity studies in dogs; (iv)&#160;pre-natal development studies in rats and rabbits; and (v)&#160;genotoxicity tests of in vitro bacterial reverse mutation, chromosome aberration, and in vivo micronucleus.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Comprehensive non-clinical studies demonstrated DA-1241 distinctively activates GPR119 across species, stimulates the secretion of insulin and GLP-1, a gut peptide hormone with various metabolic benefits, from the pancreas and intestine, respectively, and thereby reduces postprandial glucose and lipid levels after single administration to mice. The postprandial hypoglycemic response by DA-1241 observed in wild type mice disappeared in GPR119-deficient mice, demonstrating target engagement. Notably, DA-1241 treatment did not cause hypoglycemia &lt; 50 mg/dl in overnight fasted mice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In diabetic mice with hypertriglyceridemia, chronic treatment with DA-1241 lowered fasting and non-fasting blood glucose levels, in which DA-1241 prevented the pancreatic beta cell loss and preserved pancreatic function. Moreover, DA-1241 treatment decreased hepatic lipid accumulation in addition to plasma triglycerides levels at the same dose levels. When a DPP4 inhibitor was cotreated with DA-1241 to prolong the biological half-life of plasma GLP-1, plasma concentrations of active GLP-1 increased more than those due to degradation blockade with DPP4 inhibitors, and thereby potentiation of GLP-1 action further improved glucose and lipid metabolism compared to each treatment alone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In a non-diabetic mouse model with pre-established dyslipidemia, DA-1241 completely reduced plasma and hepatic triglycerides to normal control levels and also decreased plasma LDL-cholesterol, independent of glycemic control. Comprehensive mechanism studies have shown that the lipid-lowering effects of DA-1241 are due in part to inhibiting lipid synthesis in the liver and interfering with dietary lipid transport in the intestine.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">With regard to the NASH indication, DA-1241 has shown to improve fatty liver in various types of mouse models with metabolic diseases. Thereafter, therapeutic potential for treating NASH has been evaluated in several NASH mice models with different pathophysiology. Among them, the STAM-NASH mouse model exhibits mild fatty liver and moderate liver inflammation/fibrosis and is rapidly chemically induced. DA-1241 improved hepatic inflammation and fibrosis, showing a decrease in NAFLD activity score (NAS) and relative fibrotic area of the liver compared to the vehicle-treated control. Diet-induced obesity (DIO)-NASH mice are chronically induced through a Western diet and are characterized by marked fatty liver and mild to moderate hepatic </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">inflammation/fibrosis. In DIO-NASH mice, DA-1241 improved hepatic steatosis, inflammation, and fibrosis assessed by histological and biochemical methods regardless of body weight reduction. Of note, DA-1241 improved systemic inflammatory status with reduced plasma inflammatory cytokines (TNF&#945;, IL6) and chemokines (CCL2, CXCL1, CXCL2, CXCL10) contributing to tissue damage. Therefore, DA-1241 treatment reduced the levels of plasma liver enzymes (ALT, AST), which were increased due to liver tissue damage in DIO-NASH mice. In mice with metabolic diseases, the effects of DA-1241 on the NASH phenotypes (steatosis, inflammation, and fibrosis in the liver) are enhanced by the co-treatment with a DPP4 inhibitor compared to each treatment alone due to potentiated GLP-1 actions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Result of Phase&#160;1 U.S. Clinical Trial for DA-1241</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">Completed Phase&#160;1a and 1b trials in the US healthy subjects.</b><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;The first-in-humans Phase&#160;1a study, which was a double-blind, placebo controlled, single ascending dose (&#8220;SAD&#8221;), single-center study in 60 healthy male volunteers to evaluate the safety, tolerability, pharmacokinetics (&#8220;PK&#8221;), pharmacodynamics (&#8220;PD&#8221;), and interaction effect with metformin. Each cohort was given a single oral dose of 12.5, 25, 50, 100, 200, and 400 mg DA-1241 or placebo tablets. The dose level of DA-1241 for the interaction effect (IE) assessment of metformin on the PK of DA-1241 was 100 mg. Therefore, the IE cohort had 2 separate treatment periods. Subjects in the IE cohort received DA-1241 100 mg or placebo alone in Treatment Period 1, and DA-1241 100 mg or placebo with 500 mg metformin (IR formulation) in Treatment Period 2. DA-1241 was well tolerated over a dose range of 12.5 mg to 400 mg. There was no effect of concomitant administration of metformin on DA-1241 PK parameters.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In Phase&#160;1b, Part&#160;1 was a double-blind placebo-controlled, multiple-ascending dose (MAD), single-center study of DA-1241 in healthy subjects. Overall, 24 male subjects were blinded and randomized to receive DA-1241: 50, 100 or 200 mg or placebo, as single daily oral doses for 28&#160;days. Safety data reviews and dose escalation decisions between cohorts took place after all subjects of an ongoing cohort had completed procedures through day 14. All doses tested were well tolerated. There were no Serious Adverse Events (SAEs) and no discontinuations due to Adverse Events (AEs).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><b style="font-size:10pt;font-weight:bold;letter-spacing:-0.2pt;">Completed Phase&#160;1b trial in the US T2D patients.</b><span style="font-size:10pt;letter-spacing:0.2pt;">&#160;&#160;&#160;The Phase&#160;1b study was designed as a placebo and active comparator (sitagliptin 100 mg)-controlled, double-blind, randomized, multi-center study with an objective of evaluating whether DA-1241 delivers improved glucose-lowering efficacy in 83 diabetic patients. Patients were treated with placebo, sitagliptin 100 mg or DA-1241 25 mg, 50 mg and 100 mg once daily for 8 weeks, in combination with stable doses of metformin (13~19 patients/group). In the mixed meal tolerance test to evaluate the ability to reduce postprandial glucose through GPR119 activation, the incremental AUE</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">0-4h</span><span style="font-size:10pt;letter-spacing:0.2pt;">&#160;of plasma glucose (&#8220;iAUE&#8221;) upon nutrient ingestion was measured and compared. Eight-week treatment of DA-1241 25 mg, 50 mg and 100 mg showed the changes of +6.3%,&#160;-2.0%&#160;and&#160;-13.8%&#160;in iAUE levels from the baseline and DA-1241 100 mg showed similar blood glucose improvement with that of sitagliptin 100 mg (-9.0%), and it outperformed placebo (+10.5%).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exploratory P1b Study in the U.S.: Glucose-Lowering Effects</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mean Change in Postprandial Glucose Excursion at Week 8</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:268.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="nrbo-20221231x10k001.jpg" alt="Graphic" style="display:inline-block;height:268.5pt;width:366pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mean Change in Postprandial Glucose Excursion at Week 8</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In the parameters of glycemic variability measured with a Continuous Glucose Monitoring (CGM) system and fasting plasma glucose, the glucose-lowering efficacy by DA-1241 was similar to that of sitagliptin. Moreover, the time-in-range, the&#160;percentage of how long blood glucose value is within 70~180mg/dL, was increased by mitigating the hypoglycemia risk and duration of hyperglycemia whereas such time-in-range was reduced in the placebo group.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Single administration or 8-week repeated administration of DA-1241 increased secretion of gut peptide hormones such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and peptide YY (PYY) in gastrointestinal tracts after taking meals. The amount of secretion of such hormones increased in proportion to the extent of exposure to DA-1241.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exploratory P1b Study in the U.S.: Target-related Biomarker Change</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:236.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-align:center;text-indent:20pt;margin:0pt;"><img src="nrbo-20221231x10k002.jpg" alt="Graphic" style="display:inline-block;height:236.4pt;width:384pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Total GLP-1 Secretion during Mixed Meal Tolerance Test </span></p><a id="_Hlk112377233"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:12pt 0pt 12pt 0pt;">* &amp; ** P&lt;0.05 &amp; P&lt;0.01 versus corresponding baseline values; DA, DA-1241; Sita, Sitagliptin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In terms of safety, no clinically significant adverse events were observed following the 8-week treatment, confirming the tolerability of DA-1241, and the bodyweight showed a tendency to decrease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">DA-1241 Phase&#160;2 Trial Design.</b><span style="letter-spacing:0.2pt;white-space:pre-wrap;">  We currently intend to perform two Phase&#160;2 clinical trials in the United States;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="font-weight:bold;letter-spacing:-0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:20pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">NASH Phase&#160;2a:</b><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;</span>One clinical trial is expected to be a 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical trial to establish safety and an early signal of efficacy in NASH as a next-generation competitive oral agent. The trial is expected to enroll a total of 87 subjects, with a planned maximum of 98 subjects to account for early discontinuations, who will be randomized into 4 treatment groups and will be dosed with: DA-1241 50 mg, DA-1241 100 mg, DA-1241 100 mg/Sitagliptin 100 mg, or Placebo in a 1:2:2:2 ratio. Randomization will be stratified by T2DM status at baseline. The primary efficacy endpoint for the planned study will be the change from baseline in the alanine transaminase (ALT) levels at week 16. The secondary efficacy endpoints will evaluate changes in the following at week 16 including: proportion of subjects with normalization of ALT level of &lt; 30 IU/L; relative percent change liver fat fraction from baseline; absolute change in liver fat from baseline; proportion of subjects with a 30% or more reduction in liver fat from baseline; change in aspartate transaminase (AST), gamma glutamyl transpeptidase, and alkaline phosphatase from baseline; change in hemoglobin A1c (HbA1c) (%); change in non-alcoholic fatty liver disease (NAFLD) Fibrosis Score from baseline; liver stiffness measurement assessed by FibroScan&#174; from baseline; and change in FAST (FibroScan - AST) from baseline. Safety will be evaluated by monitoring adverse events (AEs) including determination of serious adverse events (SAEs) and AEs leading to discontinuation and laboratory abnormalities as characterized by type, frequency, timing, severity (mild, moderate, severe), seriousness and relationship to DA-1241, vital signs measurements, clinical laboratory tests and electrocardiogram (ECG) assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">NASH Phase&#160;2b:</b><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;The Phase&#160;2b study is a dose range finding trial to establish clinical efficacy in histological improvement for NASH treatment similar to Phase&#160;3. This planned Phase&#160;2b trial is 52-week, double-blinded, randomized, placebo-controlled clinical study in approximately 400 biopsy confirmed NASH patients with F2-F3 fibrosis. There are four treatment groups and the three dose levels for the planned treatment groups will be determined based on the results of Phase&#160;2a study. This study will be conducted as a multi-center internal study. The primary endpoint is the proportion of patients whose NAFLD activity score (NAS) or fibrosis score (or fibrotic area) are improved by one or more stage from the baseline to Week 24 and Week 52. Various plasma biomarkers </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.2pt;">that were improved in the preclinical studies performed in mice will also be evaluated to assess changes in systemic inflammatory (TNF&#945;, CCL2, CXCLs) and fibrotic (TIMP-2, type IV collagen) status.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">DA-1726: Treatment of Obesity and NASH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">DA-1726 is a long-acting, novel peptide drug candidate in preclinical development with therapeutic potential for obesity and NASH.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">DA-1726 is a dual agonist that activates both GLP-1 receptors (&#8220;GLP-1R&#8221;) and glucagon receptors (&#8220;GCGR&#8221;). Activation of GLP-1R or GCGR contributes to central anorexic effect (appetite suppression) and activation of GCGR peripherally enhances basal metabolic rate. Accordingly, non-clinical studies have shown that DA-1726 not only reduces food intake but also increases energy expenditure even at the basal resting state, leading to persistent weight loss in diet-induced obese mice and rats. DA-1726 directly lowers blood glucose and lipid levels in addition to the accompanying metabolic improvement by weight loss. Weight reduction is closely related to the alleviation of fatty liver. Having stabilized the fragile peptide through several unique modifications, DA-1726 is predicted to be available as a once-weekly regimen to humans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Background</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Obesity is a disease caused by abnormal or excessive fat accumulation due to an imbalance in energy intake and consumption over a long period of time. According to the World Health Organization (WHO), more than 1.9 billon people worldwide are overweight with 650&#160;million considered to be obese. The comorbidities of obesity include type 2 diabetes, cardiovascular disease, hypertension, NASH, etc., and the risk of these diseases is higher in obese people than in non-obese people.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="font-size:10pt;letter-spacing:0.2pt;">The treatment of obesity can be divided into three mechanisms: (i)&#160;appetite control, (ii)&#160;absorption inhibition, and (iii)&#160;increase of energy expenditure. Currently, there are a total of five approved anti-obesity medications on the market, of which liragluitde (SAXENDA</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">), semaglutide (WEGOVY</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">), phentermine/</span><span style="font-size:10pt;">&#8203;</span><span style="font-size:10pt;letter-spacing:0.2pt;">topiramate (QSYMIA</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">), and naltrexone/bupropion (CONTRAVE</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">) have an appetite suppression mechanism. Another medication, orlistat (XENICAL</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">/ ALLI</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">), controls body weight by inhibiting fat absorption. However, there is still an unmet need in the market as there are no agents with a mechanism to reduce body weight by increasing energy expenditure in peripheral tissue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Nonalcoholic fatty liver disease refers to a spectrum of liver damage that includes a wide range of liver diseases, from steatosis to cirrhosis. NAFLD is one of the most common diseases accompanying obesity and T2D, and obesity and T2D are known to exacerbate the progression of NAFLD to HCC. Although there is still no therapeutic agent on the market, clinical results of treatment improvement by GLP-1 and oxyntomodulin analogues have been reported and are in the spotlight.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:20pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">Oxyntomodulin is a gut hormone released from intestinal L-cells after meal ingestion and represents dual agonism of the GLP-1 receptor and glucagon receptor. It increases energy expenditure through glucagon receptors and increases appetite suppression and insulin secretion through GLP-1 receptor activation, ultimately inducing weight loss and glycemic control. The furthest stage of development of any oxyntomodulin analogue is Phase&#160;2, with five drugs (cotadutide, efinopegdutide, BI-456906, mazdutide, and pemvidutide) being prepared or in progress for Phase&#160;2 trials for the treatment of obesity, NASH, or T2D.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">DA-1726 Preclinical Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">Animal toxicity studies of DA-1726 for the Phase&#160;1 clinical trial have been completed and the results are in various stages of analysis and reporting. The toxicity studies included safety pharmacology studies and general toxicity studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The mode of action and pharmacological effects of DA-1726 were evaluated in various disease models. In high-fat diet-induced obese mice, DA-1726 showed more body weight loss and increasing energy expenditure than a pair-fed group. In comparison with GLP-1 analogue, DA-1726 represented superior body weight loss compared </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;"><span style="letter-spacing:0.2pt;">to semaglutide in obese mice. At the end of the study, DA-1726 significantly increased the expression of thermogenic genes (</span><i style="font-style:italic;letter-spacing:0.2pt;">Ucp-1</i><span style="letter-spacing:0.2pt;">&#160;and&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Ppargc1a</i><span style="letter-spacing:0.2pt;">) in epididymal fat and increased white adipose tissue browning was histologically confirmed. In addition, DA-1726 inhibited adipocyte differentiation&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">in vitro</i><span style="letter-spacing:0.2pt;">. Taken together, it suggests the GCGR action of DA-1726 contributes to reduced adiposity by enhancing fat burning and inhibiting adipogenesis. DA-1726 effectively reduced postprandial glucose excursion in acute oral glucose tolerance test in normal mice. Notably, DA-1726 showed similar glycemic control and excellent weight loss to semaglutide in obese mice with hyperglycemia. Simultaneously, DA-1726 enhanced insulin sensitivity by significantly reducing fasting plasma insulin and glucose levels. Meanwhile, DA-1726 showed no hypoglycemia risk in overnight fasted normal mice, unlike semaglutide.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">In obese NASH mice, DA-1726 significantly reduced plasma clinical chemistry parameters (ALT, AST, ALP, T-BIL, glucose, and cholesterol) and hepatic fat accumulation. In histopathological analysis of steatosis, lobular inflammation, and ballooning in the liver, DA-1726 showed an excellent improvement effect compared to semaglutide. Improvement of liver fibrosis was also observed with DA-1726. In the liver tissue, the expression of inflammation (</span><i style="font-style:italic;letter-spacing:0.2pt;">Tnfa</i><span style="letter-spacing:0.2pt;">,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Il-1&#946;</i><span style="letter-spacing:0.2pt;">, and&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Ccl2</i><span style="letter-spacing:0.2pt;">) and fibrosis (</span><i style="font-style:italic;letter-spacing:0.2pt;">Acta2</i><span style="letter-spacing:0.2pt;">,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Timp1</i><span style="letter-spacing:0.2pt;">,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Col1a1</i><span style="letter-spacing:0.2pt;">,&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Col3a1</i><span style="letter-spacing:0.2pt;">, and&#160;</span><i style="font-style:italic;letter-spacing:0.2pt;">Mmp9</i><span style="letter-spacing:0.2pt;">) related genes were significantly decreased. Taken together, the findings from the pre-clinical trials suggest DA-1726 has therapeutic potential for NASH in addition to obesity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">DA-1726 Phase&#160;1 Trial Design</b><span style="letter-spacing:0.2pt;">:&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;white-space:pre-wrap;">The first-in-human Phase 1 studies are being planned to establish safety, tolerability and pharmacokinetics of DA-1726. The Phase 1 program is to consist of a single ascending dose (SAD) study and multiple ascending dose (MAD) study enrolling approximately 100 subjects consisting of healthy and obese volunteers. Doses to be applied in the planned clinical trials will be determined based on the predicted human effective dose assessed by preclinical ADME and repeated toxicity studies.  For the MAD trial under the same IND, DA-1726 will be injected subcutaneously once weekly for 12 weeks in obese patients to provide an added clinical signal in obesity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">DA-1726 Phase&#160;2a Trial Design:</b><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;A combined Phase&#160;2a clinical trial in the United States is being planned to follow the completion of the Phase&#160;1 clinical trial. The Phase&#160;2a clinical trial is expected to explore a proof-of-concept at the highest tolerated dose to assess the effects of DA-1726 on weight loss as a primary endpoint and on liver fat reduction for a secondary endpoint in approximately 120 obese subjects, including a subset of subjects with NAFLD diagnosed by a MRI-PDFF image method. This study is a double-blind, placebo-controlled, randomized, multi-center trial and DA-1726 will be injected subcutaneously once weekly for 6&#160;months at the highest tolerate dose from Phase&#160;1. The primary endpoint for the planned study will be the change from baseline to Week 2 in body weight. As the secondary pharmacodynamic parameter, the liver fat reduction rate will be assessed by MRI-PDFF and a subgroup analysis will be performed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Other Product Candidates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">Our Board of Directors has determined to focus our financial resources and management attention on development of DA-1241 for NASH and T2D and DA-1726 for NASH and obesity.  We will continue to consider licensing and acquisition opportunities with respect to the following legacy programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">ANA001: Treatment of COVID-19 Symptoms</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">ANA001 is a proprietary oral niclosamide formulation and is being developed as a treatment for patients with moderate COVID-19&#160;(patients not requiring ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and documented safety in humans. Enrollment in the Phase 2 clinical trial of ANA001 for treatment of moderate COVID-19 in hospitalized patients was closed in July 2022 and the clinical trial moved to the data analysis phase. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. In preclinical research by an independent academic group published in&#160;Antimicrobial Agents and Chemotherapy, niclosamide inhibited viral replication&#160;in vitro&#160;and was more potent than remdesivir and chloroquine in the same assay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:14pt 0pt 0pt 0pt;">Specifically, studies have shown niclosamide prevents replication of SARS-CoV-2 at very low concentrations and that the compound appears to exhibit three distinct mechanisms of action: 1) acting as a potent antiviral to a broad homology of other viruses including influenza; 2) reducing inflammation without suppressing the immune system; and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;margin:0pt;">3) providing bronchodilation, which is a useful pulmonary&#160;mechanism for at-risk patients with underlying cardiovascular and/or pulmonary conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">As a result, we believes ANA001 has the potential to reduce the viral load and inflammation associated with cytokine dysregulation, acute respiratory distress syndrome (ARDS), and coagulation abnormalities and thus improve time to clinical improvement as defined as hospital discharge recorded using the World Health Organization (&#8220;WHO&#8221;) Ordinal Scale for Clinical Improvement. We also believe the three key mechanisms of action may also be effective in treating COVID-19 in the outpatient setting or as a prophylaxis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="background:#ffffff;">Following an analysis </span>of<span style="background:#ffffff;"> the clinical trial data, we will be able to begin discussions with the Food and Drug Administration </span>regarding<span style="background:#ffffff;"> the next steps in the clinical development of ANA001 for treatment of COVID-19.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">NB-01</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:14pt 0pt 0pt 0pt;">NB-01 addresses a range of mechanisms that contribute to neuropathic pain and nerve degeneration in diabetic and other peripheral neuropathies. These include a decrease in key inflammatory markers, restoration of nerve growth factor (NGF) to normal levels, and reduction of advanced glycation end products (AGEs). Inflammation is a central factor in pain generation and other peripheral neurodegenerative diseases. NB-01 reduces levels of TNF-<span style="font-family:'Symbol';background:#ffffff;">a</span><span style="background:#ffffff;">&#160;</span>and IL-6, both of which are markers of inflammation. NB-01 also reduces AGEs, which are implicated in diabetes-related complications. AGE inhibitors have been clinically tested as potential treatments for these complications. NB-01 also restores the neurotrophin NGF, which is involved in nerve growth, maintenance and repair. NB-01 has been shown in animal models to alleviate symptoms of PDN</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="white-space:pre-wrap;">In light of the present business environment and our current focus on DA-1241 and DA-1726, we have ceased development of NB-01 on the prior regulatory pathway and will not advance to Phase 3 clinical trials.  We are currently evaluating various alternatives with respect to the future of NB-01,</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">NB-02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:14pt 0pt 0pt 0pt;">NB-02 is in development for the symptomatic and disease modifying treatment of neurodegenerative diseases, including Alzheimer&#39;s disease and tauopathies. In preclinical studies, we have observed the mechanisms of action of NB-02 to include inhibition of tau phosphorylation, acetylcholinesterase (AChE) inhibition, inhibition of Ab toxicity and amyloid plaque formation, and anti-inflammatory effects. Specifically, in both in vitro and in vivo models, NB-02 has demonstrated inhibition of AChE, as is the case with three of the current drugs on the market to treat the symptoms of Alzheimer&#39;s disease. It has also demonstrated inhibition of tau phosphorylation and of amyloid plaque formation, both mechanisms believed to contribute to the progression of neurodegenerative diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">We are currently exploring out-licensing alternatives for NB-02.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">Gemcabene</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Gemcabene is a novel, once-daily, oral therapy designed to target known lipid metabolic pathways to lower levels of LDL-C, hsCRP and triglycerides. Gemcabene shares many of the attributes of statin therapy, including broad therapeutic applications, convenient route of administration and cost-effective manufacturing process, but does not appear to increase the reporting of myalgia when added to statin therapy. Gemcabene has also shown additive LDL-C lowering in combination with stable low, moderate or high-intensity statin therapy. As described below, we licensed global rights to Gemcabene from Pfizer in April 2011. Under the terms of the amended and restated license agreement with Pfizer, Pfizer may terminate the license if we have not made a commercial sale by April 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Gemcabene was being evaluated in a Phase 2 randomized, double-blind, placebo-controlled study to assess its efficacy safety and tolerability in patients with severe hypertriglyceridemia. In January 2016, the Gemcabene Phase 2 clinical study was placed on partial clinical hold as the FDA requested 2-year rat and mouse carcinogenicity studies to be completed and submitted. The study currently remains on partial clinical hold for the treatment of dyslipidemia. NeuroBo is currently assessing the path forward for Gemcabene for additional acute therapeutic indications and does not intend to direct additional resources towards Gemcabene as a cardiovascular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Licensing Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">License Agreement with Dong-A for DA-1241 and DA-1726</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:14pt 0pt 0pt 0pt;"><span style="letter-spacing:0.2pt;">On September&#160;14, 2022, we entered into the 2022 License Agreement with Dong-A pursuant to which, subject to the conditions set forth therein, we received an exclusive license (other than in the Republic of Korea) to two proprietary compounds for specified indications. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. We may also develop DA-1241 for the treatment of T2D. The 2022 License Agreement became effective on November 8, 2022 as a result of the Company closing a Public Offering.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Under the terms of the 2022 License Agreement, Dong-A (i)&#160;received an upfront payment of 2,200 shares of Series&#160;A Convertible Preferred Stock under the terms of the Securities Purchase Agreement, which was convertible into shares of our common stock upon receipt of the Stockholder Approval; (ii)&#160;will be eligible to receive single digit royalties on net sales received by us from the commercial sale of products covering DA-1241 or DA-1726; (iii)&#160;will be eligible to receive commercial-based milestone payments, payable in cash or our common stock dependent upon the achievement of specific commercial developments and (iv) will&#160;be eligible to receive regulatory milestone payments of up to $178&#160;million for DA-1726 and $138&#160;million for DA-1241, payable in cash or our common stock, dependent upon the achievement of specific regulatory developments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Our obligation to pay royalties to Dong-A under the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either we or Dong-A may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within 60&#160;days of notice of such breach; provided that if the breach cannot be cured within the 60-day period and the breaching party started to remedy the breach, if such breach is not cured within 90&#160;days of receipt of written notice, (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a 30-day cure period in the case of a petition for bankruptcy) or (iii)&#160;if we failed to complete the Public Offering by December&#160;31, 2022 (or January&#160;31, 2023 under specified circumstances set forth in the 2022 License Agreement).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Dong-A ST for NB-01</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">On January 18, 2018, we entered into an exclusive license agreement with Dong-A, (the &#8220;2018 License Agreement&#8221;) which agreement was amended on April 18, 2018 and July 24, 2019. Under the terms of the 2018 License Agreement, we obtained an exclusive, royalty-bearing, worldwide (except for the Republic of Korea) license to make, use, offer to sell, sell and import products covered by certain Dong-A ST intellectual property rights in its proprietary compound designated as DA-9801 (NB-01). Our license rights cover any and all applications and markets for the therapeutic, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">health, nutrition or well-being of humans. We may grant sublicenses to any affiliate or third party. We are responsible for all future patent prosecution costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Dong-A retained the exclusive right to conduct clinical studies in the Republic of Korea and sell products to end users in Korea. NeuroBo granted Dong-A an exclusive, royalty free right and license to use, solely for Dong-A&#8217;s commercialization of products in Korea, any inventions, designs and technology developed by us in its performance of the agreement. If Dong-A terminates the 2018 License Agreement due to a breach by us or a bankruptcy event, then this technology is licensed exclusively to Dong-A at no charge. We may also negotiate in good faith to supply product to Dong-A for clinical studies and sale of products to end-users in Korea under a separate supply agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">We are obligated to use commercially reasonable efforts to develop products for use in each of the United States, the European Union, Japan and the People&#39;s Republic of China. If we terminate, discontinue or suspend, for longer than 12 months, the development of any product listed as a product under development in any development plan provided to Dong-A (other than for reasons of force majeure or requirements of applicable law), then we are deemed in breach of this development obligation, and Dong-A may terminate the 2018 License Agreement for cause after a 60-day cure period. We are obligated to use commercially reasonable efforts to commercialize products worldwide throughout the term of the 2018 License Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">In connection with obtaining the licenses under the 2018 License Agreement, we paid Dong-A total consideration of $2 million consisting of a one-time upfront license fee and shares of our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">We may be required to pay development milestone payments of up to an aggregate of $98 million related to publication of Phase 3 clinical trial data, the first NDA submission in any country, and NDA approval in the United States, the European Union, Japan and the People&#39;s Republic of China. We may also be required to pay sales milestone payments in a specified amount, related to the first time that aggregate net sales of products exceed specified amounts in a calendar year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">We are required to pay Dong-A commercial milestone payments of up to an aggregate of $80 million and a royalty between a single digit and a low double digit percentage of net sales of products. The royalty rate increases as annual net sales increase. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The term of the 2018 License Agreement continues on a country-by country and product-by-product basis until the later of the 12<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the first commercial sale of such product in such country or expiration or termination of the last valid claim within the patent rights covering the product. The royalty rate is then reduced by 30% in any country that prohibits the payment of royalties on a patent license beyond the expiration or invalidation of the last valid claim covering the product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Either Dong-A or we may terminate the 2018 License Agreement if the other party is in material breach of the 2018 License Agreement and has not cured or started to cure the breach within 60 days of notice of such breach, or is subject to a bankruptcy or insolvency event. We may terminate the 2018 License Agreement at any time upon 90 days&#8217; written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">We may assign our rights under the agreement in connection with a merger, consolidation, or sale of substantially all of its assets, with prior written notice to Dong-A, and if the successor entity agrees in writing to be bound by the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with YourChoice</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">On December 31, 2020, we acquired ANA Therapeutics, Inc. (&#8220;ANA&#8221;), a privately held biotechnology company developing ANA001. In connection with our acquisition of ANA, we assumed a license agreement (the &#8220;YourChoice Agreement&#8221;) between ANA and YourChoice Therapeutics,&#160;Inc. (&#8220;YourChoice&#8221;). Pursuant to the YourChoice Agreement, YourChoice granted to ANA, during the term of the YourChoice Agreement, an exclusive, worldwide, fee-bearing license derived from the licensed intellectual property throughout the world. The fees due under the YourChoice Agreement include certain single-digit royalty payments and milestone payments in the aggregate of $19.5 million. The </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">term of the YourChoice Agreement will expire on the expiration or invalidation of the last of the licensed patents under the YourChoice Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pfizer License Agreement</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">In August 2018, an Amended and Restated License Agreement with Pfizer (the &#8220;Pfizer Agreement&#8221;) for the research, development, manufacture and commercialization of Gemcabene went into effect. The Pfizer Agreement amended and restated in full the prior license agreement with Pfizer dated April 16, 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The Pfizer Agreement included milestone payments to Pfizer totaling up to $37 million upon the achievement of certain milestones, including the first NDA (or its foreign equivalent) in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of Gemcabene. Future milestone payments under the Pfizer Agreement, if any, would not be expected to begin for at least several years and extend over a number of subsequent years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Pfizer will also receive tiered royalties on a country-by-country basis based upon the annual amount of net sales as specified in the Pfizer Agreement until the later of: (i) five years after the first commercial sale in such country; (ii) the expiration of all regulatory or data exclusivity for Gemcabene in such country; and (iii) the expiration or abandonment of the last valid claim of the licensed patents, including any patent term extensions or supplemental protection certificates in such country. The royalty rates range from the high single digits to the mid-teens depending on the level of net sales. The royalty rates are subject to reduction during certain periods when therapeutically-equivalent generic products represent a certain market share of prescription volume in the country. Under the Pfizer Agreement, commercially reasonable efforts must be used to develop and commercialize Gemcabene. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The Pfizer Agreement will expire upon expiration of the last royalty term. On expiration (but not earlier termination), we will have a perpetual, exclusive, fully paid-up, royalty-free license under the licensed patent rights and related data to make, use, develop, commercialize, import and otherwise exploit the clinical product candidate Gemcabene. Either party may terminate the Pfizer Agreement for the other party&#39;s material breach following a cure period or immediately upon certain insolvency events relating to the other party. Pfizer may immediately terminate the Pfizer Agreement in the event that (i) we or any of our affiliates or sublicenses contests or challenges, or supports or assists any third party to contest or challenge, Pfizer&#39;s ownership of or rights in, or the validity, enforceability or scope of any of the patents licensed under the Pfizer Agreement or (ii) we or any of our affiliates or sublicensees fails to achieve the first commercial sale in at least one country by April 16, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Beijing SL</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms and conditions of a License and Collaboration Agreement dated July 23, 2019 (the &#8220;Beijing SL License Agreement&#8221;), Beijing SL has an exclusive royalty-bearing license to research, develop, manufacture and commercialize pharmaceutical products comprising, as an active ingredient, Gemcabene in the territory comprised of mainland China, Hong Kong, Macau and Taiwan. We retain all rights to Gemcabene outside of the territory. The parties have agreed to collaborate with respect to development and commercialization activities under the Beijing SL License Agreement through a joint steering committee composed of an equal number of representatives of Beijing SL and us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Beijing SL is responsible, at its expense, for developing and commercializing products containing Gemcabene in the territory, with certain assistance from us. To the extent mutually agreed to in writing, the parties will collaborate on the Phase 3 clinical trial for HoFH or other clinical trials, with us as the sponsor, and designed to enroll patients both inside and outside the territory, but Beijing SL will be responsible, at its expense, for the conduct of any such study to the extent solely in the territory. Beijing SL will be responsible for development activities, including non-clinical and clinical studies directed at obtaining regulatory approval of the licensed product in the territory. Beijing SL has agreed to use commercially reasonable efforts to commercialize the licensed products for each indication that receives regulatory approval in the territory and shall prepare and present a commercialization plan that shall be subject to approval by the joint steering committee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Pursuant to the Beijing SL License Agreement, Beijing SL made an upfront gross payment of $2.5 million. Additionally, with respect to each licensed product, Beijing SL will pay (i) payments for specified developmental and regulatory </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">milestones (including submission of a NDA to China&#39;s National Medical Product Administration, dosing of the first patient in a Phase 3 clinical trial in mainland China and regulatory approval for the first and each additional indication of a Licensed Product in the Territory) totaling up to $6 million in the aggregate and (ii) payments for specified global net sales milestones of up to $20 million in the aggregate multiplied by the ratio of the net sales of a licensed product divided by the global net sales of a licensed product, which net sales milestone payments are payable once, upon the first achievement of such milestone. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Beijing SL will also be obligated to pay tiered royalties ranging from the mid-teens to twenty percent on the net sales of all licensed products in the territory until the latest of (a) the date on which any applicable regulatory exclusivity with respect to such Licensed Product expires in such region, (b) the expiration or abandonment of the last valid patent claim or joint patent claim covering such Licensed Product in each region and (c) the fifth anniversary of the first commercial sale of such Licensed Product in such region. Future milestone payments under the Beijing SL License Agreement, if any, are not expected to begin for at least one year and will extend over a number of subsequent years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Either party may terminate the Beijing SL License Agreement (x) with written notice for the other party&#39;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In addition, we may terminate the Beijing SL License Agreement in its entirety if Beijing SL or its affiliates or sublicensees commence a proceeding challenging the validity, enforceability or scope of any of our patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The Beijing SL License Agreement contemplates that parties shall, no later than twelve months prior to the anticipated date of the first commercial sale of a licensed product, if any, negotiate in good faith and execute a commercial supply agreement, pursuant to which Beijing SL shall purchase from us, and we shall use commercially reasonable efforts to supply, Gemcabene or licensed product for clinical or commercial purposes, as applicable, until manufacturing and regulatory transfers are complete. </p><a id="_Hlk536804409"></a><a id="_Ref519162875"></a><a id="_Hlk446934"></a><a id="_Hlk538304"></a><a id="_Hlk536646388"></a><a id="_Toc533112217"></a><a id="_Ref513713592"></a><a id="_Ref513709613"></a><a id="_x0fmbt370y0n"></a><a id="_Ref513792487"></a><a id="_Ref513792777"></a><a id="_Ref505945410"></a><a id="_Hlk544577"></a><a id="_Hlk448135"></a><a id="_Hlk447401"></a><a id="_Hlk453344"></a><a id="_Hlk453290"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;white-space:pre-wrap;">NeuroBo is required to use Dong-A in South Korea to manufacture clinical quantities of DA-1241 and DA-1726 in accordance with the 2022 License Agreement.  As NeuroBo advances the product candidates through clinical development and greater quantities are required, we plan to continue to use third parties including Dong-A ST to manufacture our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">Among the conditions for FDA approval of a pharmaceutical product is the requirement that the manufacturer&#8217;s quality control and manufacturing procedures conform to cGMP, which must be followed at all times. The FDA typically inspects manufacturing facilities every two&#160;years. In complying with cGMP regulations, pharmaceutical manufacturers must expend resources and time to ensure compliance with product specifications as well as production, record keeping, quality control, reporting and other requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b> </p><a id="_Hlk31291394"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Some of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Other firms may also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for our programs. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors with us, particularly through collaborative arrangements with large and established companies. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk31291498"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize therapeutics that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain marketing approvals for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected because in some cases insurers or other third-party payors, including government programs, seek to encourage the use of generic products. This may have the effect of making branded products less attractive, from a cost perspective, to buyers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">DA-1241 and DA-1726-NASH</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">There are currently no medications approved for the treatment of NASH. However, various therapeutics are used off-label for the treatment of NASH, including vitamin E (an antioxidant), insulin sensitizers (e.g.,&#160;metformin, pioglitazone), antihyperlipidemic agents (e.g., gemfibrozil), pentoxifylline and ursodeoxycholic acid (UDCA). There are several product candidates in Phase&#160;3 or earlier clinical or preclinical development for the treatment of NASH, including Madrigal Pharmaceuticals, Inc.&#8217;s THR beta agonist (resmetirom), Novo Nordisk&#8217;s GLP1 agonist (semaglutide), Akero Therapeutics&#8217;s FGF21 analog (efruxifermin), 89 Bio&#8217;s FGF21 analog (pegaozafermin) and Inventiva&#8217;s pan-PPAR agonist (lanifibranor), as well as FXR agonists from Intercept Pharmaceuticals Inc. (obeticholic acid), Novartis AG (tropifexor, nidufexor), Metacrine (MET409, MET642), Terns Pharmaceuticals (TERN-101), Gilead Sciences, Inc. (cilofexor) and Enanta Pharmaceuticals, Inc. (EDP-305).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">Additional pharmaceutical and biotechnology companies with product candidates in development for the treatment of NASH include AstraZeneca plc, Altimmune Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Durect Corporation, Galectin Therapeutics Inc., Galmed Pharmaceuticals Ltd., Immuron Ltd., Ionis Pharmaceuticals, Inc., Islet Sciences, Inc., MediciNova, Inc., MiNA Therapeutics, NGM Biopharmaceuticals, Inc., NuSirt Sciences Inc., Pfizer Inc., Viking Therapeutics, Inc. and Zydus Pharmaceuticals (USA) Inc. NASH is a complex disease and we believe that it is unlikely that any one therapeutic option will be optimal for every NASH patient.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">DA-1726-Obesity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="font-size:10pt;letter-spacing:0.2pt;">Due to the growing overweight and obesity epidemic and consumer demand, there are many competitors in the field of obesity treatment. Obesity treatments range from behavioral modification, to drugs and medical devices, and surgery, generally as a last resort. If DA-1726 were approved for obesity, our primary competition in the obesity treatment market would currently be from approved and marketed products, including liragluitde (SAXENDA</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">), semaglutide (WEGOVY</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">), phentermine/</span><span style="font-size:10pt;">&#8203;</span><span style="font-size:10pt;letter-spacing:0.2pt;">topiramate (QSYMIA</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">), naltrexone/bupropion (CONTRAVE</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">) and orlistat (XENICAL</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">/ ALLI</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;letter-spacing:0.2pt;">). Further competition could arise from products currently in development, including Lilly&#8217;s GLP-1/GIP receptor dual agonist (tirzepatide), Novo Nordisk&#8217;s CagriSema (a combination drug of semaglutide and a novel amylin analogue), Zafgen&#8217;s ZGN-1061 or ZGN-1258 (MetAP2) product candidates and various FGF21 ligands in development. To the extent any of our product candidates are approved for cardio-metabolic indications, particularly obesity, the commercial success of our products will also depend on our ability to demonstrate benefits over the then-prevailing standard of care, including diet and exercise. Finally, morbidly obese patients sometimes undergo the gastric bypass procedure, with salutary effects on the many co-morbid conditions of obesity. Some of these programs have been advanced further in clinical development then our clinical programs or have already received regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.2pt;">DA-1241-T2D</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="letter-spacing:0.2pt;">The market for T2D treatments is competitive and if DA-1241 is approved for T2D it will compete with several classes of drugs for T2D that are approved to improve glucose control, including DPP4 inhibitors, SGLT2 inhibitors, and oral GLP1 analogues as the second or third line therapy for pre-insulin status. Further competition could arise from products currently in development, including: aldose reductase inhibitors (Applied Therapeutics); and GPR40 agonists (Hyundai Pharm.); and small molecule GLP-1 receptor agonists (Pfizer). Some of the agents approved to treat T2D are not generic, are oral once-daily pills and are effective in lowering glucose and A1C. In addition, there are several investigational drugs being studied to treat T2D, and if these investigational therapies were approved, they would also compete with DA-1241.</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:20pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual </b><b style="font-weight:bold;">Property</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application or a Patent Cooperation Treaty (PCT) application to which a U.S. application claims priority. In the United States, a patent&#39;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or the USPTO, in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a U.S. patent that covers a drug or biological product may also be eligible for patent term extension when approval from the FDA is granted, provided statutory and regulatory requirements are met. In the future, our product candidates receive approval from the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and/or other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or other favorable adjustment to the term of any of its patents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates, preclinical compounds, and its core technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, patent applications that we may file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, prior to March 16, 2013, in the United States, patent applications were subject to a &#8220;first to invent&#8221; rule of law. Applications effectively filed on or after March 16, 2013, are subject to a &#8220;first to file&#8221; rule of law. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Discoveries reported in the scientific literature often lag the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We cannot be certain that any existing application will be subject to the &#8220;first to file&#8221; or &#8220;first to invent&#8221; rule of law, that we or our licensor were the first to make the inventions claimed in our existing patent portfolio subject to the prior laws, or that we or our licensor were the first to file for patent protection of such inventions subject to the new laws. If third parties prepare and file patent applications in the United States that also claim technology we have claimed in our patents or patent applications, we may have to participate in interference or derivation proceedings and/or invalidation proceedings in the USPTO, which could result in substantial costs to us, even if the eventual outcome is favorable. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition to patents, we rely upon unpatented trade secrets, know-how, and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with its employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed under those agreements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize product candidates depends in large part on our ability to obtain and maintain intellectual property protection for our product candidates. Our policy is to seek to protect our intellectual property position by, among other methods, filing U.S. and foreign patent applications related to the technology, inventions and improvements that are important to the development and implementation of our business strategy. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary position. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">DA-1241</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">As of December 31, 2022, our exclusively licensed intellectual property portfolio for DA-1241 includes one U.S. patent directed to both composition of matter and a process of making the composition and one U.S. non-provisional patent application directed to both composition of matter and use of the composition. The issued U.S. patent is expected to expire in July&#160;2035, excluding any additional term for patent term adjustments or patent term extensions. NeuroBo&#8217;s intellectual property portfolio for DA-1241 also includes approximately 17&#160;non-U.S. patents and 14 non-U.S. patent applications directed to composition of matter and/or use of the composition. The issued non-U.S. patents is expected to expire between 2035 and 2039, excluding any additional term for patent term adjustments or patent term extensions. The jurisdictions for the non-U.S. patents and applications include: Australia, Brazil, Canada, China, the European Patent Convention, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Philippines, Republic of Korea, Russia, Saudi Arabia, and Singapore.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">DA-1726</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.2pt;">As of December 31, 2022, our exclusively licensed intellectual property portfolio for DA-1726 includes one U.S. patent directed to both composition of matter and use of the composition and one U.S. non-provisional patent application directed to both composition of matter and use of the composition. The issued U.S. patent is expected to expire in 2038, excluding any additional term for patent term adjustments or patent term extensions. Our intellectual property portfolio for DA-1726 would also include (i)&#160;a PCT application that would enter national phases in October&#160;2022 and (ii)&#160;approximately five non-U.S. patents directed to composition of matter and eight non-U.S. patent applications directed to composition of matter and/or use. The issued non-U.S. patents is expected to expire between 2038 and 2040, excluding any additional term for patent term adjustments or patent term extensions. The jurisdictions for the non-U.S. patents and applications include: Australia, Brazil, Canada, China, the European Patent Convention, Japan, Philippines, Republic of Korea, Russia, and Singapore.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ANA001</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;">As of December 31, 2022, our intellectual property portfolio for ANA001 included one US non-provisional application and two non-US applications (Argentina and Europe) directed to niclosamide formulation and one PCT application directed to combined use of niclosamide and gemcabene. &#160;Patent applications may be issued in the U.S. and any countries in which the Company files national phase applications of the PCT application. The patents issued from the national phase applications are estimated to expire 2041 to 2042.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">As described in more detail above under &#8220;Licensing Agreements &#8211; License Agreement with YourChoice,&#8221; pursuant to the YourChoice Agreement, the Company has licensed several patent applications relating to ANA from YourChoice. A PCT application to which claims priority to the U.S. provisional applications was filed in 2021. Patent applications may be issued in any countries in which the Company files national phase applications of the PCT application. The patents issued from the national phase applications are estimated to expire 2041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">NB-01 and NB-02</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, our intellectual property portfolio for NB-01 included four issued U.S. patents, comprised of one patent directed to composition of matter and three patents directed to use, and two pending U.S. non-provisional patent applications, comprised of one directed to composition of matter and another directed to use, and 62 granted foreign patents, all related to its NB-01 programs in peripheral neuropathy and neurological conditions. The issued patents have expiration dates ranging from October 27, 2026 to June 22, 2033. The patent issuing from the application, if any, is expected to expire December 2031. The jurisdictions for the foreign patents and application include: Brazil, Canada, China, the European Patent Convention (including Austria, Belgium, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Switzerland, Turkey, and the United Kingdom), India, Japan, Mexico, the Republic of Korea, and Russia. One patent family including some of the above patents for NB-01 is assigned to University-Industry Cooperation Group of Kyung Hee University, and is exclusively licensed from Kyung Hee University to Dong-A ST and then from Dong-A ST to us pursuant to the terms of the corresponding agreements. The other two patent families including the other above patents and patent applications for NB-01 are assigned to Dong-A ST and exclusively licensed to us. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, our intellectual property portfolio for NB-02 included three issued U.S. patents, one pending U.S. non-provisional patent application, 74 foreign granted patents, and 1 foreign patent application. Patents issuing from these applications, if any, are expected to expire around 2035. The issued patents have an expiration date of December 3, 2035 and December 19, 2035. The jurisdictions for the foreign patents and applications include: Brazil, Canada, China, the European Patent Convention (including Austria, Belgium, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Portugal, Romania, Spain, Switzerland, Turkey, and the United Kingdom), India, Japan, Mexico, the Republic of Korea, and Russia. All of the above patents and patent applications for NB-02 were assigned to us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Gemcabene</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, our intellectual property portfolio relating to Gemcabene included six issued U.S. patents, three pending U.S. patent applications, 43 foreign-granted patents and 21 foreign patent applications directed to formulations, compositions, methods of use and methods of manufacturing. The Gemcabene intellectual property includes both owned and Pfizer-licensed issued and pending patents in the United States and foreign jurisdictions. The issued patents in the United States and foreign countries have expiration dates between December 2031 and November 2036. The patents in the United States and foreign countries that may be issued from pending applications, if any, are expected to expire between December 2031 and October 2039. The jurisdictions for the foreign countries include Argentina, Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Philippines, Korea, Russia, Singapore, South Africa, Taiwan and Thailand.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Regulation</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Government authorities at the federal, state and local level in the United States and in other countries extensively regulate, among other things, the research, development, testing, manufacture (including any manufacturing changes), packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, import and export of pharmaceutical products, such as those we are developing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">United States &#8212; FDA Regulation</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDCA, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as imposition of clinical holds, refusal by the FDA to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, civil penalties and criminal prosecution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical product development in the United States typically involves preclinical or other nonclinical laboratory and animal tests and the submission to the FDA of an Investigational New Drug (IND) application, which must become effective before clinical testing may commence. For commercial approval, the sponsor must submit adequate tests by all methods reasonably applicable to show that the drug is safe for use under the conditions prescribed, recommended or suggested in the proposed labeling. The sponsor must also submit substantial evidence, generally consisting of adequate, well-controlled clinical trials to establish that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended or suggested in the proposed labeling. In certain cases, the FDA may determine that a drug is effective based on one clinical study plus confirmatory evidence. Satisfaction of the FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. For botanical drug products in particular, which may be heterogeneous in nature and may carry additional uncertainty about their active constituents in comparison to synthetic small-molecule drug products, one of the critical issues during drug development is ensuring that the therapeutic effect for marketed drug product batches is consistent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Nonclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal requirements, including the FDA&#39;s good laboratory practice regulations and the U.S. Department of Agriculture&#39;s, or USDA&#39;s, regulations implementing the Animal Welfare Act. The results of nonclinical testing are </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term nonclinical tests, such as animal studies of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not imposed a clinical hold on the IND or otherwise commented or questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with good clinical practice (&#8220;GCP&#8221;), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors (some of which have been codified into U.S. federal regulations), and (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial either is not being conducted in accordance with the FDA requirements or presents an unacceptable risk to the clinical trial patients. The trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or IRB, at each site where a trial will be conducted for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#39;s requirements or may impose other conditions. Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general, in Phase 1, the initial introduction of the drug into healthy human volunteers or, in some cases, patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. The FDA may, however, determine that a drug is effective based on one clinical trial plus confirmatory evidence. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval. In some cases, the FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval to gather additional information on the drug&#39;s effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#39;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#39;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. Under the statute and implementing regulations, the FDA has 180 days (the initial review cycle) from the date of filing to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement between the FDA and the applicant or as a result of the applicant submitting a major amendment. In practice, the performance goals established pursuant to the Prescription Drug User Fee Act have effectively extended the initial review cycle beyond 180 days. The FDA&#39;s current performance goals call for the FDA to complete review of 90% of standard (non-priority) NDAs within 10 months of receipt and within six months for priority NDAs, but two additional months are added to standard and priority NDAs for a new molecular entity, or NME, such that the 10-month and 6-month action goals for NME applications begin to run from the 60-day filing date rather than from receipt of the original NDA submission. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practice (GMP) regulations is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter (CRL) generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#39;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing 90% of NDA resubmissions within two to six months depending on the type of information included in response to the deficiencies identified in the CRL. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and/or elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#39;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;"><i style="font-style:italic;">Fast Track Designation and Accelerated Approval</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">The FDA is authorized to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. These programs include fast track designation, breakthrough therapy designation, priority review designation and other accelerated approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">Under the Fast Track Program, the sponsor of a new drug candidate that is intended to treat a serious condition may request that the FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor&#39;s request. In addition to other benefits such as the ability to engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug&#39;s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#39;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">In 2012, Congress enacted the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory program for products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to designated breakthrough therapies, including: holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The FDA may also designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case- by-case basis, whether the proposed drug represents a significant improvement when </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#39;s goal for taking action on a marketing application from ten months to six months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">Under the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The accelerated approval regulations are codified within Title 21 of the Code of Federal Regulations, as Subpart H under Part 314, the part of the FDA regulations covering applications for FDA approval to market a new drug, and as such the accelerated approval pathway is sometimes referred to as approval under &#8220;Subpart H.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved under Subpart H is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. Unless otherwise informed by the FDA, for an accelerated approval product an applicant must submit to the FDA for consideration during the preapproval review period copies of all promotional materials, including promotional labeling as well as advertisements, intended for dissemination or publication within 120 days following marketing approval. After 120 days following marketing approval, unless otherwise informed by the FDA, the applicant must submit promotional materials at least 30 days prior to the intended time of initial dissemination of the labeling or initial publication of the advertisement. The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;"><i style="font-style:italic;">Orphan Drugs</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals. The U.S. Orphan Drug Designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity and trade name, if any, of the drug and its designated use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Information</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Under the Pediatric Research Equity Act (PREA), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers for submission of data, as well as deferrals for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">be collected before the pediatric studies begin. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">The Best Pharmaceuticals for Children Act (BPCA) provides NDA holders a six-month extension of any exclusivity&#8212;patent or non-patent&#8212;for a drug if certain conditions are met. Conditions for exclusivity include the FDA&#39;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Special Protocol Assessment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">A company may reach an agreement with the FDA under the Special Protocol Assessment, or SPA, process as to the required design and size of clinical trials intended to form the primary basis of an efficacy claim for a new drug product. According to its performance goals, the FDA seeks to evaluate the protocol within 45 days of the request to assess whether the proposed trial is adequate, and that evaluation may result in discussions and a request for additional information. An SPA request must be made before the proposed trial begins, and all open issues must be resolved before the trial begins. If a written agreement is reached, it will be documented and made part of the administrative record. Under the FDCA and FDA guidance implementing the statutory requirement, an SPA is generally binding on the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study begins, public health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and the FDA agree to the change in writing, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Disclosure of Clinical Trial Information</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">Sponsors of clinical trials of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical trial information on a public website maintained by the U.S. National Institutes of Health (NIH). Information related to the product, patient population, phase of investigation, study sites and investigator, and other aspects of the clinical trial is made public as part of the registration. Sponsors are also obligated to disclose the results of these trials after completion. Disclosure of the results of these trials can be delayed for up to two years if the sponsor certifies that it is seeking approval of an unapproved product or that it will file an application for approval of a new indication for an approved product within one year. Competitors may use this publicly available information to gain knowledge regarding the design and progress of the development programs. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. Since the NIH&#39;s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, both NIH and FDA have signaled the government&#39;s willingness to begin enforcing those requirements against clinical trial sponsors who fail to meet those legal obligations, with FDA releasing a guidance document in August 2020 for certain procedural steps it intends to take when determining whether and how to assess civil monetary penalties against a non-compliant party. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Post-Approval Requirements</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">Drugs manufactured, marketed or distributed pursuant to FDA approval decisions are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval before they can be implemented. There also are continuing, annual user fee requirements for any marketed products and related manufacturing facilities, as well as new application fees for supplemental applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In addition, drug manufacturers and other entities involved in the manufacture of approved drugs are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA for compliance with GMP requirements. Prescription drug distribution facilities are also subject to state licensure, including inspections, by the relevant local regulatory authority. Changes to the manufacturing process, specifications or container closure system for an approved drug are strictly regulated and often require prior FDA approval before being </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">implemented. FDA regulations also require investigation and correction of any deviations from GMP and impose reporting and documentation requirements upon the sponsor and others involved in the drug manufacturing process. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain GMP compliance and ensure ongoing compliance with other statutory requirements the FDCA, such as the requirements for making manufacturing changes to an approved NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Thus, even after new drug approval is granted, Regulatory authorities may withdraw that approval or request product recalls if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences of regulatory non-compliance include, among other things:</p><div style="padding-left:3pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:3pt;padding-right:3pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:3.63%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="font-size:1pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:91.47%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:3.63%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.47%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="white-space:pre-wrap;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;   </span></p></td></tr><tr><td style="vertical-align:middle;width:3.63%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span>  </p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.47%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="white-space:pre-wrap;">fines, warning letters or holds on post-approval clinical trials;  </span></p></td></tr><tr><td style="vertical-align:middle;width:3.63%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span>  </p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.47%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="white-space:pre-wrap;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;   </span></p></td></tr><tr><td style="vertical-align:middle;width:3.63%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span>  </p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.47%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="white-space:pre-wrap;">product seizure or detention, or refusal to permit the import or export of products; or  </span></p></td></tr><tr><td style="vertical-align:middle;width:3.63%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.52%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="font-family:'Times New Roman';">&#9679;</span>  </p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:91.47%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;">injunctions or the imposition of civil or criminal penalties.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As described further below, the FDA strictly regulates marketing, labeling, advertising and promotion of prescription drug products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">The Hatch-Waxman Amendments</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Orange Book Listing</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. As part of the marketing application process when seeking approval for a new drug through an NDA, applicants are required to list with the FDA every patent of which claims cover the applicant&#39;s product or an approved method of using the product. Upon approval of a drug, approval information about the drug along with each of the applicant&#39;s listed patents is then published in the FDA&#39;s <i style="font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</i>, commonly known as the &quot;Orange Book.&quot; Pursuant to the Hatch-Waxman Amendments, drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the reference license drug (&#8220;RLD&#8221;) and has been shown through bioequivalence testing to be bioequivalent to the RLD. The FDA is responsible for determining that the generic drug is &quot;bioequivalent&quot; to the innovator drug, although under the statute, a generic drug is bioequivalent to a RLD if &quot;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&quot; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are most often considered to be therapeutically equivalent to the RLD, are commonly referred to as &quot;generic equivalents&quot; to the RLD, and can often be substituted by pharmacists under prescriptions written for the original RLD in accordance with state law. Specifically, upon approval of an ANDA, the FDA indicates whether the generic product is &quot;therapeutically equivalent&quot; to the RLD in the Orange Book. By operation of certain state laws and numerous health insurance programs, the FDA&#39;s designation of therapeutic equivalence in the Orange Book often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or the patient.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The Hatch-Waxman Amendments also amended the FDCA to enact Section 505(b)(2) of the FDCA, which permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. A Section 505(b)(2) applicant may eliminate the need to conduct certain preclinical or clinical studies, if it can establish that reliance on studies conducted for a previously-approved product is scientifically appropriate. The FDA may also require companies to perform additional trials or measurements to support the change from the approved product. The FDA may then approve the new product for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. With respect to listed patents, patent certification requirements, and the blocking of follow-on marketing applications for the drug product previously approved under an NDA and listed in the Orange Book&#8212;known as the reference listed drug, or RLD&#8212;505(b)(2) NDA applications and ANDAs are required under the statute and FDA&#39;s implementing regulations to follow similar procedures and are subject to similar conditions. However, only in some cases is a 505(b)(2) NDA-approved drug product determined by FDA to be therapeutically equivalent to the original innovator RLD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">As part of its own marketing application process, the ANDA/505(b)(2) applicant is required to certify to the FDA concerning any patents listed for the relevant RLD in the FDA&#39;s Orange Book. Specifically, the applicant must certify either that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the generic product. The ANDA applicant may also elect to submit a section viii statement, certifying that its proposed ANDA or 505(b)(2) labeling does not contain (or carves out) any language regarding the patented method-of-use, rather than certify to a listed method-of-use patent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">If the ANDA/505(b)(2) applicant does not challenge the innovator&#39;s listed patents, or indicates that it is not seeking approval of a patented method of use, the ANDA/505(b)(2) application will not be approved by the FDA until all the listed patents claiming the referenced product have expired. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">A certification that the new product will not infringe the already approved product&#39;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA/505(b)(2) applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of that Paragraph IV certification to the NDA sponsor and patent holders once FDA accepts the ANDA/505(b)(2) application for filing. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification, as provided for in the statute. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA/505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA/505(b)(2) applicant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Non-Patent Exclusivity</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Under the Hatch-Waxman Amendments, the FDA also may not approve an ANDA or 505(b)(2) NDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by the FDA in any other NDA. During this five years of marketing exclusivity, the FDA cannot receive any ANDA or 505(b)(2) application seeking approval of a drug that references a version of the NCE drug. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or the addition of a new indication. During this three-year period of exclusivity, the FDA cannot approve an ANDA or 505(b)(2) application that includes the change. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">An ANDA or 505(b)(2) application may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">requirement, and in such situations, no ANDA or 505(b)(2) application may be filed before the expiration of the exclusivity period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">For a botanical drug, the FDA may determine that the active moiety is one or more of the principal components, or the complex mixture as a whole. This determination would affect the possibility of any five-year exclusivity as well as the ability of any potential generic competitor to demonstrate that it is the same drug as the original botanical drug. Because the agency has not promulgated specific regulations for botanical drug products and is approaching the development of such products, especially those that are composed of more complex mixtures, on a case-by-case basis, the 2016 Botanical Drug Development guidance for industry represents the best source for the FDA&#39;s current thinking on these drug products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patent Term Extension</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&#39;s testing phase&#8212;the time between IND submission and NDA submission&#8212;and all of the review phase&#8212;the time between NDA submission and approval up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years from market approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the U.S. Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prescription Drug Marketing Act</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act (PDMA) imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">New Legislation and Regulations </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA and relevant regulatory authorities outside the United States. In addition to new legislation, regulations and policies are often revised or interpreted by regulatory authorities in ways that may significantly affect our business and our product candidates. It is impossible to predict whether further legislative changes will be enacted or whether regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;"><i style="font-style:italic;">Other U.S. Healthcare Laws and Compliance Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 7pt 0pt;">If we obtain regulatory approval of our product candidates and launch them commercially in the United States, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. Some of the laws that may affect our future ability to operate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;  </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment interests; and  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Moreover, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#39;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Europe/Rest of World Government Regulation </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">In addition to regulations in the United States, we are and will be subject, either directly or through our distribution partners, to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries prior to the commencement of clinical trials or marketing of the product in those countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">In the European Union, medicinal products are subject to extensive pre- and post-marketing regulation by regulatory authorities at both the European Union and national levels. Additional rules also apply at the national level to the manufacture, import, export, storage, distribution and sale of controlled substances. In many European Union. member states the regulatory authority responsible for medicinal products is also responsible for controlled substances. Responsibility is, however, split in some member states. Generally, any company manufacturing or distributing a medicinal product containing a controlled substance in the European Union will need to hold a controlled substances license from the competent national authority and will be subject to specific record-keeping and security obligations. Separate import or export certificates are required for each shipment into or out of the member state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trials and Marketing Approval </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Certain countries outside of the United States have a process that requires the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application, or CTA, must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">country&#39;s requirements and a company has received favorable ethics committee approval, clinical trial development may proceed in that country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, even though there is already some degree of legal harmonization in the European Union member states resulting from the national implementation of underlying European Union. legislation. In all cases, the clinical trials must be conducted in accordance with the International Conference on Harmonization, or ICH, guidelines on GCP and other applicable regulatory requirements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">To obtain regulatory approval to place a drug on the market in the European Union, we must submit a marketing authorization application. This application is similar to the NDA in the United States, with the exception of, among other things, country-specific document requirements. All application procedures require an application in the common technical document, or CTD, format, which includes the submission of detailed information about the manufacturing and quality of the product, and non-clinical and clinical trial information. Drugs can be authorized in the European Union by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the decentralized procedure or (iv) national authorization procedures. </p><a id="_Hlk35928040"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The European Commission created the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are valid throughout the European Union and, by extension (after national implementing decisions) in Iceland, Liechtenstein and Norway, which, together with European Union member states, comprise the European Economic Area, or EEA. Applicants file marketing authorization applications with the EMA, where they are reviewed by a relevant scientific committee, in most cases the Committee for Medicinal Products for Human Use, or CHMP. The EMA forwards CHMP opinions to the European Commission, which uses them as the basis for deciding whether to grant a marketing authorization. This procedure results in a single marketing authorization granted by the European Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated &quot;orphan drugs&quot; (drugs used for rare human diseases) and (iv) advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may, at the voluntary request of the applicant, also be used for human drugs which do not fall within the above-mentioned categories if the CHMP agrees that (a) the human drug contains a new active substance not yet approved on November 20, 2005; (b) it constitutes a significant therapeutic, scientific or technical innovation or (c) authorization under the centralized procedure is in the interests of patients at the European Union. level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application by the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP), with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: the seriousness of the disease to be treated, the absence of an appropriate alternative therapeutic approach, and anticipation of exceptional high therapeutic benefit. In this circumstance, the EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">For those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization applications to the national medicines regulators through one of three procedures: (i) the mutual recognition procedure (which must be used if the product has already been authorized in at least one other European Union member state, and in which the European Union member states are required to grant an authorization recognizing the existing authorization in the other European Union member state, unless they identify a serious risk to public health), (ii) the decentralized procedure (in which applications are submitted simultaneously in two or more European Union member states) or (iii) national authorization procedures (which results in a marketing authorization in a single European Union member state).</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Mutual Recognition Procedure </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The mutual recognition procedure, or MRP, for the approval of human drugs is an alternative approach to facilitate individual national marketing authorizations within the European Union. Basically, the MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is applicable to the majority of conventional medicinal products and must be used if the product has already been authorized in one or more member states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The characteristic of the MRP is that the procedure builds on an already&#8212;existing marketing authorization in a member state of the European Union that is used as a reference in order to obtain marketing authorizations in other European Union member states. In the MRP, a marketing authorization for a drug already exists in one or more member states of the European Union and subsequently marketing authorization applications are made in other European Union member states by referring to the initial marketing authorization. The member state in which the marketing authorization was first granted will then act as the reference member state. The member states where the marketing authorization is subsequently applied for act as concerned member states. The concerned member states are required to grant an authorization recognizing the existing authorization in the reference member state, unless they identify a serious risk to public health. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The MRP is based on the principle of the mutual recognition by European Union. member states of their respective national marketing authorizations. Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member states. In such case, the reference member state shall update its existing assessment report about the drug in 90 days. After the assessment is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling and package leaflet. The concerned member states then have 90 days to recognize the decision of the reference member state and the summary of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement of the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">If any European Union member state refuses to recognize the marketing authorization by the reference member state, on the grounds of potential serious risk to public health, the issue will be referred to a coordination group. Within a timeframe of 60 days, member states shall, within the coordination group, make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The opinion of this EMA Committee is then forwarded to the European Commission for the start of the decision making process. As in the centralized procedure, this process entails consulting various European Commission Directorates General and the Standing Committee on Human Medicinal Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Data and Market Exclusivity in the European Union</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">In the European Union, NCEs qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#39;s data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator&#39;s data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization (MA) holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a NCE and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company can complete a full MAA with a complete database of pharmaceutical test, preclinical studies and clinical trials and obtain marketing approval of its product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pharmaceutical Coverage, Pricing and Reimbursement</i> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Sales of pharmaceutical products approved for marketing in the United States by the FDA will depend, in part, on the extent to which the costs of the products will be covered by third-party payers, such as government health programs, and commercial insurance and managed health care organizations. These third-party payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment of health care costs has become a </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, utilization management and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our operating results. If these third-party payers do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell its products on a profitable basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposed requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries and included a major expansion of the prescription drug benefit under Medicare Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Part D is available through both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval in the U.S. However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the &#8220;ACA&#8221;), was enacted with the goal of expanding coverage for the uninsured while at the same time containing overall health care costs. With regard to pharmaceutical products, among other things, the ACA expanded and increased industry rebates for drugs covered under Medicaid programs and made changes to the coverage requirements under the Medicare Part D program.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In the United States, Medicare covers certain drug purchases by the elderly and eligible disabled people and introduced a reimbursement methodology based on average sales prices for physician-administered drugs. In addition, Medicare may limit the number of drugs that will be covered in any therapeutic class. Ongoing cost reduction initiatives and future laws could decrease the coverage and price that we will receive for any approved products. While Medicare beneficiaries are limited to most elderly and certain disabled individuals, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Among the provisions of the ACA of importance to our product candidates are the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of manufacturers&#39; Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of eligibility criteria for Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the entities eligible for discounts under the Public Health Service Act&#39;s pharmaceutical pricing program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new requirements to report financial arrangements with physicians and teaching hospitals (i.e., the Federal Physician Payment Sunshine Act, which has since been expanded to cover additional specified healthcare providers);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we will receive for any approved product. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">There remain judicial and political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to health care, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. In addition, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. The likelihood of success of these and other measures initiated by the former Trump administration is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, some European </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Union jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. Such differences in national pricing regimes may create price differentials between European Union member states. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States. In the European Union, the downward pressure on healthcare costs in general, particularly prescription medicines, has become intense. As a result, barriers to entry of new products are becoming increasingly high and patients are unlikely to use a drug product that is not reimbursed by their government. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Human Capital </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 6pt 0pt;">As of December 31, 2022, we had 2 full-time employees, 2 full-time consultants and 2 part-time consultants, all located in the United States. Of these employees and consultants, two were engaged in research and development and four were engaged in general and administrative functions. We have no collective bargaining agreements with our employees and have not experienced any work stoppages. We consider our relationships with our employees to be good. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 6pt 0pt;">Our&#160;human capital&#160;resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate Information </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">NeuroBo was incorporated under the laws of the State of Delaware in July 2017. Our principal executive offices are located at 200 Berkeley Street, 19th Floor, Boston, Massachusetts, 02116. Our website address is www.neurobopharma.com. The information contained on, or that can be accessed through, our website is not a part of this report.</p><a id="_4cd9da5f_6b50_4b1a_b237_bcb91bed59b5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="ITEM1ARISKFACTORS_215230"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-left:217.7pt;text-indent:-217.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">ITEM 1A.        RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Our business, prospects, financial condition or results of operations could be materially adversely affected by any of the risks and uncertainties set forth below, as well as in any amendments or updates reflected in subsequent filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;). In assessing these risks, you should also refer to other information contained in this report, including our financial statements and related notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><b style="font-weight:bold;">Risks Related to our Operations and to Development, Marketing, Commercialization and Regulation of Our Product Candidates &#160;</b></p><a id="_cp_text_1_2"></a><a id="_cp_text_1_4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred losses since inception</span><span style="font-style:italic;font-weight:bold;">, we </span><span style="font-style:italic;font-weight:bold;">anticipate that we will incur continued losses for the foreseeable future</span><span style="font-style:italic;font-weight:bold;">. We require additional financing to accomplish our long-term business plan and failure to obtain necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></p><a id="_cp_text_1_6"></a><a id="_cp_text_1_8"></a><a id="_cp_text_1_10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">We have experienced net losses and negative cash flows from operating activities since our inception and have an accumulated deficit of $95.8 million as of December 31, 2022. It is possible we will never generate revenue or profit.</p><a id="_cp_text_1_12"></a><a id="_cp_text_1_13"></a><a id="_cp_text_4_14"></a><a id="_cp_text_1_15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Although we are exploring financing opportunities and carefully monitoring the capital markets, we do not yet have any commitments for additional financing and may not be successful in our efforts to raise additional funds. There can be no assurances that additional financing will be available to us on satisfactory terms, or at all. If we are unable to raise sufficient additional capital (which is not assured at this time, particularly as a result of recent depressed capital market conditions), our long-term business plan may not be accomplished, and we may be forced to cease, reduce, or delay operations. For more information about our liquidity and capital resources, see Part II, Item 7 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Liquidity and Capital Resources.&#8221;</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights to our technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Existing stockholders could suffer dilution or be negatively affected by fixed payment obligations we may incur if we raise additional funds through the issuance of additional equity securities or debt. Furthermore, these securities may have rights senior to those of our common stock and could contain covenants or protective rights that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we need to secure additional financing, such additional fundraising efforts may divert our management and research efforts from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Worldwide economic and social instability could adversely affect our revenue, financial condition, or results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">The health of the global economy, and the credit markets and the financial services industry in particular, as well as the stability of the social fabric of our society, affects our business and operating results. For example, the credit and financial markets may be adversely affected by the turmoil in the banking section in the wake of the failure of Silicon Valley Bank and measures taken in response thereto. If the credit markets are not favorable, we may be unable to raise additional financing when needed or on favorable terms. Our customers may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability to purchase our products or to pay for our products on a timely basis, if at all. In addition, adverse economic conditions, such as recent supply chain disruptions and labor shortages and persistent inflation, have impacted, and may continue to adversely impact our suppliers&#8217; ability to provide our manufacturer with materials and components, which may negatively impact our business. These economic conditions make it more difficult for us to accurately forecast and plan our future business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are initially developing DA-1241 for the treatment of NASH, an indication for which there are no approved products. This makes it difficult to predict the timing and costs of the clinical development of DA-1241 and, if applicable, DA-1726, for the treatment of NASH.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.4pt;margin:0pt;"><span style="font-size:4.4pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Our research and development efforts will be focused in part on developing DA-1241 for the treatment of NASH, an indication for which there are no approved products. The regulatory approval process for novel product candidates such as DA-1241 for NASH can be more expensive and take longer than for other, better known or extensively studied product candidates. As other companies are in later stages of clinical trials for their potential NASH therapies, we expect that the path for regulatory approval for NASH therapies may continue to evolve in the near term as these other companies refine their regulatory approval strategies and interact with regulatory authorities. Such evolution may impact our future clinical trial designs, including trial size and endpoints, in ways that we cannot predict today. Our anticipated development costs would likely increase if development of DA -1241 or any future product candidate is delayed because we are required by the FDA to perform studies or trials in addition to, or different from, those that we currently anticipate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of any increase in our anticipated development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be required to make significant payments under the 2022 License Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:6.5pt;margin:0pt;"><span style="font-size:6.5pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">We will have acquired exclusive rights (other than in the Republic of Korea) to DA-1241 and DA-1726 for the specific indications provided in the 2022 License Agreement. Under the 2022 License Agreement, in consideration for the license, we made an upfront payment of 2,200 shares of our Series A Convertible Preferred Stock. As additional consideration for the license, we are required to pay Dong-A milestone payments upon the achievement of specified regulatory milestones and milestone payments upon the achievement of specified commercial milestones. Commencing on the first commercial sale of licensed products, we are obligated to pay royalties of single-digit percentages on annual net sales of the products covered by the license. If milestone or other non-royalty obligations become due, we may not have sufficient funds available to meet our obligations, which will materially adversely affect our business operations and financial condition.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain favorable clinical results, we may not be able to obtain regulatory approval for, or successfully commercialize DA-1241 and DA-1726</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">We are not permitted to market DA-1241 or DA-1726 in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. As a condition to submitting an NDA to the FDA for DA-1241 or DA-1726, we must successfully complete several clinical trials demonstrating efficacy and safety.  DA-1241 and DA-1726 may not be successful in clinical trials or receive regulatory approval. Further, DA-1241 and DA-1726 may not receive regulatory approval even if it is successful in clinical trials. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process that typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, the policies or regulations, or the type and amount of clinical data necessary to gain approval, may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. Our development activities could be harmed or delayed by a partial shutdown of the U.S. government, including the FDA. We have not obtained regulatory approval for any product candidate and it is possible that DA-1241 and DA-1726 will never obtain regulatory approval.  The FDA may delay, limit or deny approval of DA-1241 or DA-1726 for many reasons, including, among others:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may not approve the formulation, labeling or specifications of DA-1241 or DA-1726;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may require that we conduct additional clinical trials; </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the contract research organizations (&#8220;CROs&#8221;) or the clinical investigators that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, our CROs or clinical investigators may fail to perform in accordance with the FDA&#8217;s good clinical practice (&#8220;GCP&#8221;) requirements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may disagree with our interpretation of data from our preclinical studies and clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA may find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract; or</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the policies or regulations of the FDA may significantly change in a manner that renders our clinical data insufficient for approval or may require that we amend or submit new clinical protocols.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">In addition, similar reasons may cause the EMA or other regulatory authorities to delay, limit or deny approval of DA-1241 or DA-1726 outside the United States. Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market DA-1241 and DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">Alternatively, even if we obtain regulatory approval, that approval may be for indications or patient populations that are not as broad as we intend or desire or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional, unanticipated clinical trials to obtain approval or be subject to additional post marketing testing requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product or the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) for a product, which could impose restrictions on its distribution. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to successfully obtain regulatory or marketing approval for, or successfully commercialize, any of our product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Although we currently have no drug product for sale and may never be able to develop marketable drug products, our business depends heavily on the successful clinical development (for our pharmaceutical drug products), regulatory approval and commercialization of our drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">The clinical trials of our product candidates are, and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review and regulation by government authorities in the United States and in other countries where we intend to test and, if approved, market any product candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate as a pharmaceutical product, we must successfully meet a number of critical developmental milestones, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:17.65pt;"></span><span style="display:inline-block;width:17.1pt;"></span><span style="display:inline-block;width:6.6pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:16.75pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>developing dosages that will be well-tolerated, safe and effective;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:16.75pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>completing the development and scale-up to permit manufacture of our product candidates in commercial quantities and at acceptable costs;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:16.75pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>demonstrating through pivotal clinical trials that the product candidate is safe and effective in patients for the intended indication;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:16.75pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><span style="display:inline-block;min-width:16.75pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>obtaining and maintaining exclusive rights, including patent and trade secret protection and non-patent exclusivity for our product candidates.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">The time necessary to achieve these developmental milestones for any individual product candidate is long and uncertain, and we may not successfully complete these milestones for any product candidates that we may develop. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="white-space:pre-wrap;">We are continuing to test and develop our product candidates and may explore possible design or formulation changes to address safety, efficacy, manufacturing efficiency and performance issues to the extent any arise. The design of a clinical trial may be able to determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. There is no assurance that we will be able to design and complete a clinical trial to support marketing approval. Moreover, nonclinical and clinical data are often susceptible to multiple interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have experienced significant setbacks in advanced clinical trials, even after promising results in earlier trials.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">We may not be able to complete development of any product candidates that demonstrate safety and efficacy and that will have a commercially reasonable treatment and storage period. If we are unable to complete development of DA-1241, DA-1726 or any other product candidates that we may develop, we will not be able to commercialize and earn revenue from them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The regulatory review and approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, our business will be substantially harmed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Of the large number of drugs in development in the United States, only a small percentage receive FDA regulatory approval and are commercialized in the United States. We are not permitted to market DA-1241, DA-1726 or any other product candidate as a pharmaceutical drug in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries or jurisdictions, such as the marketing authorization application, or MAA, in the European Union from the European Medicines Agency, or EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Successfully completing clinical trials and obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA, or a comparable foreign regulatory authority, may delay, limit or deny approval of an NDA for many reasons, including, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">disagreement with the design or implementation of our clinical trials;  </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement with the sufficiency of our clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to demonstrate the safety and efficacy of the product candidate for the proposed indications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to demonstrate that any clinical and other benefits of the product candidate outweigh their safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">a negative interpretation of the data from our nonclinical studies or clinical trials;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">deficiencies in the manufacturing or control processes or failure of third-party manufacturing facilities with which our contracts for clinical and commercial supplies to comply with current Good Manufacturing Practice requirements, or cGMPs;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">deficiencies in the harvesting and processing of botanical raw materials under Good Agricultural and Collection Processes, or GACPs, or the inability to demonstrate that the final product is capable of being therapeutically consistent, as applicable to botanical drug products, as applicable;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">insufficient data collected from clinical trials or changes in the approval requirements that render our nonclinical and clinical data insufficient to support the filing of an NDA or to obtain regulatory approval; or  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in clinical practice in or approved products available for the treatment of the target patient population that could have an impact on the indications that we are pursuing for our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The FDA or a comparable foreign regulatory authority may also require more information, including additional nonclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or cause us to abandon the development program. Even if we obtain regulatory approval, our product candidates may be approved for fewer or more limited indications than we request, such approval may be contingent on the performance of costly post-marketing clinical trials, or we may not be allowed to include the labeling claims necessary or desirable for the successful commercialization of such product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Undesirable side effects caused by any of our product candidates that we may develop or acquire could cause us or the FDA or other regulatory authorities to interrupt, delay or halt our clinical trials and could result in more restrictive labels or the delay or denial of marketing approval by the FDA or other regulatory authorities of such product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. In addition, any drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw or limit their approval of such product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &quot;boxed&quot; warning or a contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall the product, change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require a Risk Evaluation and Mitigation Strategy (REMS) plan to mitigate risks, which could include medication guides to be distributed to patients, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to regulatory investigations and government enforcement actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may decide to remove such product candidates from the marketplace after they are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may be rendered less competitive and sales may decrease;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for injury caused to individuals exposed to or taking its product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We believe that any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Delays in our clinical trials may lead to a delay in the submission of marketing approval applications and jeopardize our ability to potentially receive approvals and generate revenues from the sale of our products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">We may experience delays in clinical trials. We do not know whether planned clinical trials will begin or enroll subjects on time, need to be redesigned or be completed on schedule, if at all. Clinical trials may be delayed, suspended or terminated for a variety of reasons, such as: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability, delay or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in competing clinical trial programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issues with the manufacture of drug substance for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in recruiting and enrolling suitable subjects to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in having subjects complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure in obtaining institutional review board, or IRB, approval to conduct a clinical trial at each site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays resulting from negative or equivocal findings of the Data Safety Monitoring Board, or DSMB, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ambiguous or negative results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decision by the FDA, a comparable foreign regulatory authority, or recommendation by a DSMB to suspend or terminate clinical trials at any time for safety issues or for any other reason;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conflicts affecting clinical trial sites and regions where clinical trials are being completed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of adequate funding to continue the product development program; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in governmental regulations or requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may develop DA-1241 and DA-1726, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.05pt;margin:0pt;"><span style="font-size:4.05pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">We may develop DA-1241 and DA-1726 and future product candidates in combination with one or more currently approved therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">We may also evaluate DA-1241 and DA-1726 or any other future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">United States. We will not be able to market and sell DA-1241 and DA-1726 or any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with DA-1241 and DA-1726 or any other product candidate we develop, we may be unable to obtain approval of or market DA-1241 and DA-1726 or any other product candidate we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with NASH and significant competition for recruiting such patients in clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:3.5pt;margin:0pt;"><span style="font-size:3.5pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. In particular, as a result of the inherent difficulties in diagnosing NASH and the significant competition for recruiting patients with NASH in clinical trials, there may be delays in enrolling the patients we need to complete clinical trials on a timely basis, or at all. This risk may be more significant for us than other companies conducting clinical trials for the treatment of patients with NASH because we plan to enroll only patients with a biopsy-confirmed diagnosis of NASH in our planned clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Factors that may generally affect patient enrollment include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.6pt;margin:0pt;"><span style="font-size:4.6pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and location of clinical sites we enroll;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition with other companies for clinical sites or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility and exclusion criteria for the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain and maintain patient consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risk that enrolled participants will drop out before completion; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.75pt;margin:0pt;"><span style="font-size:4.75pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">In addition, if any significant adverse events or other side effects are observed in any of our future clinical trials, it may make it more difficult for us to recruit patients to our clinical trials and patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, which would increase our costs and have an adverse effect on our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The development and commercialization of new products is highly competitive. Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of our product candidates. Our objective is to develop and commercialize new products with superior efficacy, convenience, tolerability and safety. In many cases, the products that we commercialize will compete with existing, market-leading products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Many of our potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and in manufacturing pharmaceutical products. In particular, these companies have greater experience and expertise in securing government contracts and grants to support their research and development efforts, conducting testing and clinical trials, obtaining regulatory approvals to market products, manufacturing such products on a broad scale and marketing approved products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and have collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">discovering, developing and commercializing products before, or more effectively than, we do. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition and to be commercially successful. If we are not able to compete effectively against potential competitors, our business will not grow and our financial condition and operations will suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">T2D</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:6.4pt;margin:0pt;"><span style="font-size:6.4pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for T2D. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.8pt;margin:0pt;"><span style="font-size:7.8pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">NASH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5.85pt;margin:0pt;"><span style="font-size:5.85pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">There are currently no medications approved for the treatment of NASH. However, various therapeutics are used off-label for the treatment of NASH, including vitamin E (an antioxidant), insulin sensitizers (e.g., metformin, pioglitazone), antihyperlipidemic agents (e.g., gemfibrozil), pentoxifylline and ursodeoxycholic acid (UDCA). There are several product candidates in Phase 3 or earlier clinical or preclinical development for the treatment of NASH, including Madrigal Pharmaceuticals, Inc.&#8217;s THR beta agonist (resmetirom), Novo Nordisk&#8217;s GLP1 agonist (semaglutide), <span style="letter-spacing:0.2pt;">Akero Therapeutics&#8217;s FGF21 analog (efruxifermin), 89 Bio&#8217;s FGF21 analog (pegaozafermin</span> and Inventiva&#8217;s pan-PPAR agonist (lanifibranor), as well as FXR agonists from Intercept Pharmaceuticals Inc. (obeticholic acid), Novartis AG (tropifexor, nidufexor), Metacrine (MET409, MET642), Terns Pharmaceuticals (TERN-101), Gilead Sciences, Inc. (cilofexor) and Enanta Pharmaceuticals, Inc. (EDP-305).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7.7pt;margin:0pt;"><span style="font-size:7.7pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Obesity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:6.4pt;margin:0pt;"><span style="font-size:6.4pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Due to the growing overweight and obesity epidemic and consumer demand, there are many competitors in the field of obesity treatment. Obesity treatments range from behavioral modification, to drugs and medical devices, and surgery, generally as a last resort. If DA-1726 were approved for obesity, our primary competition in the obesity treatment market would currently be from approved and marketed products, including, liragluitde (SAXENDA&#174;), semaglutide (WEGOVY&#174;), phentermine/topiramate (QSYMIA&#174;), naltrexone/bupropion (CONTRAVE&#174;) and orlistat (XENICAL&#174;/ ALLI&#174;). Further competition could arise from products currently in development, including Lilly&#8217;s GLP-1/GIP receptor dual agonist (tierzepatide),</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among hospitals, physicians, patients and healthcare payors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among hospitals, physicians, health care payors, patients and the medical community. Market acceptance of any of our product candidates for which we receive regulatory approval depends on a number of factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the clinical indications for which the product candidate is approved;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance by major operators of hospitals, physicians and patients of the product candidate as a safe and effective treatment, particularly the ability of our product candidates to establish themselves as a new standard of care in the treatment paradigm for the indications that we are pursuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the potential and perceived advantages of our product candidates over alternative treatments as compared to the relative costs of the product candidates and alternative treatments;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to prescribe, and patients to take, a product candidate that is based on a botanical source;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the prevalence and severity of any side effects with respect to our product candidates, and any elements that may be imposed by the FDA under a REMS program that could discourage market uptake of the products;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the availability of adequate reimbursement and pricing for any approved products by third party payors and government authorities;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability of certain types of patients to take our product;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstrated ability to treat patients and, if required by any applicable regulatory authority in connection with the approval for target indications, to provide patients with incremental cardiovascular disease benefits, as compared with other available therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative convenience and ease of administration of our product candidates, including as compared with other treatments available for approved indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings contained in the labeling approved by the FDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of alternative treatments already approved or expected to be commercially launched in the near future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effectiveness of our sales and marketing strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">guidelines and recommendations of organizations involved in research, treatment and prevention of various diseases that may advocate for alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay out-of-pocket in the absence of third-party coverage; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians or patients may be reluctant to switch from existing therapies even if potentially more effective, safe or convenient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy, safety, and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the ability to offer our product for sale at competitive prices;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our product together with other medications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interactions of our product with other medicines patients are taking; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our products as well as competitive products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">There may be delays in getting our product candidates, if approved, on hospital or insurance formularies or limitations on coverages that may be available in the early stages of commercialization for newly approved drugs. If any of our product candidates are approved but fail to achieve market acceptance among hospitals, physicians, patients or health care payors, we will not be able to generate significant revenues, which would have a material adverse effect on our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><a id="_Hlk31104337"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize a future pharmaceutical drug candidate, the profitability of such product candidate will likely depend in significant part on third-party reimbursement practices, which, if unfavorable, would harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Our ability to commercialize a drug successfully will depend in part on the extent to which coverage and adequate reimbursement will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, whether the level of reimbursement will be adequate. Assuming we obtain coverage for our product candidates, if approved, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use a product candidate, if approved, unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which a product candidate is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers its costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for a new product, if applicable, may also not be sufficient to cover our costs and may not be made </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost medicines and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"> <span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any product that we may develop.  Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with any of our products or future product candidate during product testing, manufacturing, marketing or sale. For example, we may be sued on allegations that a product candidate caused injury or that the product is otherwise unsuitable. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">If we cannot successfully defend against claims that our product caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><a id="_Hlk36045518"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidate that we are developing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased FDA warnings on product labels;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#39;s attention from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidate that we may develop; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the removal of a product from the market; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased insurance costs. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we or our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by us and our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States and abroad governing laboratory procedures and the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#39; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Although we maintain workers&#39; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Compliance with applicable environmental, health and safety laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely and will continue to rely on collaborative partners regarding the development of our research programs and product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">We are and expect to continue to be dependent on collaborations with partners relating to the development and commercialization of our existing and future research programs and product candidates. In particular, we rely on Dong-A to provide services with respect to our development of DA-1241 and DA-1726.  In addition, we had, have and will continue to have discussions on potential partnering opportunities with various pharmaceutical and medical device companies. If we fail to enter into or maintain collaborative agreements on reasonable terms or at all, our ability to develop our existing or future research programs and product candidates could be delayed, the commercial potential of our products could change, and our costs of development and commercialization could increase.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Our dependence on collaborative partners subjects it to a number of risks, including, but not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:2.6pt;margin:0pt;"><span style="font-size:2.6pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to control the amount or timing of resources that collaborative partners devote to our research programs and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be required to relinquish significant rights, including intellectual property, marketing and distribution rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on the information and data received from third parties regarding our research programs and product candidates and will not have control of the process conducted by the third party in gathering and composing such data and information. We may not have formal or appropriate guarantees from our contract parties with respect to the quality and the completeness of such data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A collaborative partner may develop a competing product either by itself or in collaboration with others, including one or more of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our collaborative partners&#8217; willingness or ability to complete their obligations under our collaboration arrangements may be adversely affected by business combinations or significant changes in a collaborative partner&#8217;s business strategy; and/or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may experience delays in, or increases in the costs of, the development of our research programs and product candidates due to the termination or expiration of collaborative research and development arrangements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to establish sales and marketing capabilities to market and sell our product candidates, if they are approved for such marketing, we may be unable to generate any revenue. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">In order to market and sell our product candidates in development, we currently intend to build and develop our own sales, marketing and distribution operations. Although our management team has previous experience with such efforts for pharmaceutical products, there can be no assurance that we will be successful in building these operations. The establishment and development of our own commercial sales and marketing teams to discuss any products we may develop will be expensive and time-consuming and could delay any product launch. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">If we are unable to establish adequate sales, marketing and distribution capabilities, we may not be able to generate product revenue and may not become profitable. We will also be competing with many companies that currently have extensive and well-funded sales and marketing operations. If any of our product candidates are approved, we may be unable to compete successfully against these more established companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell some of our product candidates if and when they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"> <span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future pharmaceutical products; and  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenue may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">Any pharmaceutical product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not market our products for their approved indications, we may be subject to enforcement action for off-label marketing and/or promotion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">restrictions on such products, manufacturers or manufacturing processes;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">restrictions on the labeling, marketing, distribution or use of a product;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">requirements to conduct post-approval clinical trials;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">warning or untitled letters;  </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">withdrawal of the products from the market;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">refusal to approve pending applications or supplements to approved applications that we submit;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">recall of products;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">fines, restitution or disgorgement of profits or revenue;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">suspension or withdrawal of marketing approvals for the drug products;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">refusal to permit the import or export of our products;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">product seizure; and  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We or any potential collaborator may never receive regulatory approval to market our product candidates outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The activities associated with the development and commercialization of pharmaceutical drugs are subject to comprehensive regulation by the FDA, other regulatory agencies in the United States and by comparable authorities in other countries. Failure to obtain regulatory approval for our product candidates will prevent us or any potential collaborator from commercializing our product candidates as pharmaceutical drugs. We have not received regulatory approval to market any of our product candidates in any jurisdiction, and we do not expect to obtain FDA or any other regulatory approvals to market any of our product candidates for the foreseeable future, if at all. The process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"> <span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may seek to avail ourselves of mechanisms to expedite and/or reduce the cost for development or approval of any of our product candidates or product candidates we may pursue in the future, such as fast track designation or orphan drug designation, but such mechanisms may not actually lead to a faster or less expensive development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We may seek fast track designation, priority review, orphan drug designation, or accelerated approval for any product candidate we may pursue in the future. For example, if a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. However, the FDA has broad discretion with regard to these mechanisms, and even if we believe a particular product candidate is eligible for any such mechanism, it cannot assure you that the FDA would decide to grant it. Even if we obtain fast track or priority review designation or pursue an accelerated approval pathway, we may not experience a faster and/or less costly development process, review or approval compared to conventional FDA procedures. The FDA may withdraw a particular designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Current and future legislation may increase the difficulty and cost to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. See the section titled &#8220;Item 1&#8212;Business&#8212;Government Regulation&#8221; above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.  We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our product candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#39;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of its product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with healthcare providers and third-party payors will be subject to applicable </span><span style="font-style:italic;font-weight:bold;">anti-kickback, fraud and abuse and other healthcare laws and regulations</span><span style="font-style:italic;font-weight:bold;">, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties and consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidate for which we obtain marketing approval. Restrictions and obligations under applicable federal and state healthcare laws and regulations are noted in the section &#8220;Item 1&#8212;Business&#8212;Government Regulation&#8221; above.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to it, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><a id="_Hlk31102860"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair its ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations which can harm its business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#39;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States to sell our products abroad and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if it does not explicitly authorize or have actual knowledge of such activities. Our violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk516115"></a><a id="_Hlk35934435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our ability to use our NOLs to offset future taxable income may be subject to certain limitations. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In general, under Section 382 of Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &quot;ownership change&quot; is subject to limitations on its ability to utilize its carryforwards to offset future taxable income. Our existing NOL carryforwards, or NOLs, were subject to limitation arising from an ownership change related to the Dong-A Financing and the Public Offering. Future changes in our stock ownership, some of which are outside of our control, could result in further ownership changes under Section 382 of the Code. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing and any future NOLs could expire or otherwise be unavailable to offset future income tax liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><a id="_Hlk35934410"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Tax matters, including the changes in corporate tax rates, disagreements with taxing authorities and imposition of new taxes could impact our results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">We are subject to income and other taxes in the United States and our operations, plans and results are affected by tax and other initiatives. On December 22, 2017, comprehensive changes to the Code were signed into law, informally titled the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;). The Tax Act included significant changes that could materially impact the taxation of corporations, like us, including among other things, changes to the corporate income tax rate, limitation of the tax deduction for interest expense to business interest income plus 30% of adjusted taxable income (except for certain small businesses), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including changes to the orphan drug tax credit and changes to the deductibility of research and experimental expenditures that will be effective in the future). The Tax Act also included a limitation of the deduction for net operating losses (&#8220;NOLs&#8221;) generated in tax years beginning after December 31, 2017 to 80% of current year taxable income and the general elimination of carrybacks of NOLs generated in taxable years ending after December 31, 2017.  However, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) signed into law on March 27, 2020, provided that NOLs generated in a taxable year beginning in 2018, 2019, or 2020, may now be carried back five years.  In addition, the 80% taxable income limitation is temporarily removed, allowing NOLs to fully offset net taxable income.  Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act and any future tax reform is uncertain and our business and financial condition could be adversely affected. The impact of the Tax Act and any future tax reform on holders of our common stock is likewise uncertain and could be adverse.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We are also subject to regular reviews, examinations, and audits by the IRS and other taxing authorities with respect to our taxes. Although we believe our tax estimates are reasonable, if a taxing authority disagrees with the positions we have taken, we could face additional tax liability, including interest and penalties. There can be no assurance that payment of such additional amounts upon final adjudication of any disputes will not have a material impact on our results of operations and financial position. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We also need to comply with new, evolving or revised tax laws and regulations. The enactment of or increases in tariffs, or other changes in the application or interpretation of the Tax Act, or on specific products that we may ultimately sell or with which our products compete, may have an adverse effect on our business or on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which the combined organization&#39;s operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could adversely affect our operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;min-height:12.0pt;margin:0pt;"><span style="font-size:10pt;">We may face competition for our product candidates, if approved, from cheaper alternatives sourced from foreign countries that have placed price controls on pharmaceutical products. The Medicare Modernization Act contains provisions that may change U.S. importation laws and expand</span> <span style="font-size:10pt;white-space:pre-wrap;">pharmacists&#39; and wholesalers&#39; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary of Health and Human Services certifies that the changes will pose no additional risk to the public&#39;s health and safety and will result in a significant reduction in the cost of products to consumers. In July of 2021 President Biden issued an executive order to bolster health-care industry competition in the interest of lowering drug prices. Among its proposals are a push for the Food and Drug Administration to work with states to import prescription drugs from Canada.  It remains to be seen how this action will affect the Company and the pharmaceutical industry as a whole.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Dependence on Third Parties</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have relied and will rely on third-party </span><span style="font-style:italic;font-weight:bold;">clinical research organizations (CROs) </span><span style="font-style:italic;font-weight:bold;">to conduct our preclinical studies and clinical trials. If these CROs do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We have relied upon and plan to continue to rely upon CROs and clinical data management organizations to monitor and manage data for our ongoing preclinical and clinical programs. Although we control only certain aspects of their activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third parties to conduct our preclinical studies in accordance with Good Laboratory Practice, or GLP, requirements and the Laboratory Animal Welfare Act of 1966 requirements. We, our CROs and our clinical trial sites are required to comply with regulations and current Good Clinical Practices, or GCP, and comparable foreign requirements to ensure that the health, safety and rights of patients are protected in clinical trials, and that data integrity is assured. Regulatory authorities ensure compliance with GCP requirements through periodic inspections of trial sponsors and trial sites. If we, any of our CROs or our clinical trial sites fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials or a specific site may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If CROs do not successfully carry out their contractual obligations or meet expected timelines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to manufacture our product candidates and preclinical and clinical drug supplies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">We have no experience manufacturing our product candidates on a large clinical or commercial scale and have no manufacturing facility.  We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently work exclusively with Dong-A ST as the sole manufacturer for the production of DA-1241 and DA-1726. To meet our projected needs for clinical supplies to support our activities for DA-1241 and DA-1726 through regulatory approval and commercial manufacturing, Dong-A will need to provide sufficient scale of production for these projected needs. If any issues arise in the manufacturing and we are unable to arrange for </span>alternative third-party manufacturing sources, we are unable to find an alternative third party capable of reproducing the existing manufacturing method or we are unable to do so on commercially reasonable terms or in a timely manner, we may not be able to complete development of our product candidates, or market or distribute them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured our product candidates and preclinical and clinical drug supplies, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">reliance on the third party for regulatory compliance and quality assurance;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control (including a failure to synthesize and manufacture our product candidates or any products that we may eventually commercialize in accordance with our specifications); </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of termination or nonrenewal of the agreement by the third party, based on our own business priorities, at a time that is costly or damaging to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay in, or failure to obtain, regulatory approval of any of our product candidates because of the failure by our third-party manufacturer to comply with cGMP or failure to scale up manufacturing processes; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current manufacturer and any future manufacturers may not be able to manufacture our product candidates at a cost or in quantities or in a timely manner necessary to make commercially successful products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">If third-party manufacturers do not successfully carry out their contractual obligations or meet expected timelines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may engage in future acquisitions or in-licenses of technology that could disrupt our business, cause dilution to the organization&#39;s stockholders and harm our financial condition and operating results. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">While we currently have no specific plans to acquire any other businesses or in-license any additional products or technology, we may, in the future, make acquisitions or licenses of, or investments in, companies, products or technologies that we believe are a strategic or commercial fit with its current product candidates and business or otherwise offer opportunities for us. In connection with these acquisitions or investments, the organization may:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">issue stock that would dilute its stockholders&#39; percentage of ownership;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">expend cash;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">incur debt and assume liabilities; and  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We also may be unable to find suitable acquisition or license candidates and we may not be able to complete acquisitions or licenses on favorable terms, if at all. If we do complete an acquisition or license, we cannot assure you that it will ultimately strengthen our competitive position or that it will not be viewed negatively by customers, financial markets or investors. Further, future acquisitions or licenses could also pose numerous additional risks to our operations, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">problems integrating the purchased or licensed business, products or technologies;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">increases to our expenses;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the failure to have discovered undisclosed liabilities of the acquired or licensed asset or company;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">diversion of management&#39;s attention from their day-to-day responsibilities;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">harm to our operating results or financial condition;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">entrance into markets in which we have limited or no prior experience; and  </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential loss of key employees, particularly those of the acquired entity.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We may not be able to complete one or more acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition without a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our products and any future product candidates that we may develop. Any strategic alliance or collaboration may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. Our likely collaborators include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our products or any future product candidate. Our ability to generate revenues from these arrangements will depend on our collaborators&#39; abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Collaborations involving our product candidates or any future product candidate pose the following risks to us:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#39;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of any such product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may lose certain valuable rights under circumstances identified in its collaborations, including if it undergoes a change of control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may learn about our discoveries and use this knowledge to compete with us in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of collaborators&#39; preclinical or clinical studies could harm or impair other development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">there may be conflicts between different collaborators that could negatively affect those collaborations and potentially others;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">collaboration agreements may not lead to development or commercialization of our product candidate in the most efficient manner or at all. If our present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may be unable to obtain the necessary marketing approvals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">If future collaboration partners fail to develop or effectively commercialize our product candidates or any future product candidate for any of these reasons, such product candidate may not be approved for sale and our sales of such product candidate, if approved, may be limited, which would have an adverse effect on our operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are not able to establish new collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">We may selectively seek additional third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#39; abilities to successfully perform the functions assigned to them in these arrangements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We may be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidate or bring it to market and generate product revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, to provide accurate information to the FDA or comparable foreign regulatory authorities, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee or third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity, such as employee training, may not be effective in controlling </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending such action or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related to Intellectual Property</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain sufficient intellectual property rights, our competitive position could be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We depend on our ability to protect our proprietary technology. We rely on trade secret, patent, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary technology and products. Where we have the right to do so under our license agreements, we seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents, including those patent rights licensed to us by third parties, are highly uncertain. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The steps we have taken to police and protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside the United States. The rights already granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the proprietary protection or competitive advantages that we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">With respect to patent rights, we do not know whether any of our pending patent applications for any of our product candidates will result in the issuance of patents that protect our technology or products, or which will effectively prevent others from commercializing competitive technologies and products. Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Further, the examination process may require us or our licensors to narrow the claims, which may limit the scope of patent protection that may be obtained. Although our license agreement with Dong-A ST includes a number of issued patents that are exclusively licensed to us, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and may, in some cases, not be possible. In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Laws and rulings by U.S. courts make it difficult to predict how patents will be issued or enforced in the biotechnology industry. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. There have been numerous changes to the patent laws and to the rules of the United States Patent and Trademark Office, or USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act, which was signed into law in 2011, includes a transition from a &quot;first-to-invent&quot; system to a &quot;first- to-file&quot; system, and changes the way issued patents are challenged. Certain changes, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">such as the institution of inter partes review proceedings, came into effect on September 16, 2012. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and, if obtained, to enforce or defend them in litigation or post-grant proceedings, all of which could harm our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Furthermore, the patent positions of companies engaged in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Two cases involving diagnostic method claims and &quot;gene patents&quot; have been decided by the Supreme Court. On March 20, 2012, the Supreme Court issued a decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., or Prometheus, a case involving patent claims directed to measuring a metabolic product in a patient to optimize a drug dosage amount for the patient. According to the Supreme Court, the addition of well-understood, routine or conventional activity such as &quot;administering&quot; or &quot;determining&quot; steps was not enough to transform an otherwise patent ineligible natural phenomenon into patent eligible subject matter. On July 3, 2012, the USPTO issued guidance indicating that process claims directed to a law of nature, a natural phenomenon or an abstract idea that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to non-statutory subject matter. On June 13, 2013, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that isolated segments of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent eligible. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We cannot assure you that our current patent protection and our efforts to seek patent protection for our technology and products will not be negatively impacted by the decisions described above, rulings in other cases or changes in guidance or procedures issued by the USPTO. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Moreover, although the Supreme Court has held in Myriad that isolated segments of naturally occurring DNA are not patent-eligible subject matter, certain third parties could allege that activities that we may undertake infringe other gene-related patent claims, and we may deem it necessary to defend against these claims by asserting non-infringement and/or invalidity positions, or pay to obtain a license to these claims. In any of the foregoing or in other situations involving third-party intellectual property rights, if we are unsuccessful in defending against claims of patent infringement, we could be forced to pay damages or be subjected to an injunction that would prevent us from utilizing the patented subject matter. Such outcomes could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect or practice </span><span style="font-style:italic;font-weight:bold;">our</span><span style="font-style:italic;font-weight:bold;"> intellectual property rights throughout the world. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In jurisdictions where we have not obtained patent protection, competitors may use our intellectual property to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. competitor products may compete with our product candidates, if approved, or any future product candidate in jurisdictions where we do not have issued or granted patents or where we issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to pharmaceuticals. This could make it difficult for us to prevent the infringement of its patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert its efforts and attention from other aspects of our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we, or our licensors, encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">or any of our licensors, are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In addition to the possibility of litigation relating to infringement claims asserted against us, we may become a party to other patent litigation and other proceedings, including inter partes review proceedings, post-grant review proceedings, derivation proceedings declared by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future technologies or product candidates or products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Competitors may infringe or otherwise violate our intellectual property, including patents that may issue to or be licensed by us. As a result, we may be required to file claims in an effort to stop third-party infringement or unauthorized use. Any such claims could provoke these parties to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. This can be prohibitively expensive, particularly for a company of our size, and time-consuming, and even if we are successful, any award of monetary damages or other remedy we may receive may not be commercially valuable. In addition, in an infringement proceeding, a court may decide that our asserted intellectual property is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our intellectual property does not cover its technology. An adverse determination in any litigation or defense proceedings could put our intellectual property at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">If the breadth or strength of our patent or other intellectual property rights is compromised or threatened, it could allow third parties to commercialize our technology or products or result in our inability to commercialize our technology and products without infringing third-party intellectual property rights. Further, third parties may be dissuaded from collaborating with us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Interference or derivation proceedings brought by the USPTO or its foreign counterparts may be necessary to determine the priority of inventions with respect to our patent applications, and we may also become involved in other proceedings, such as re-examination proceedings, before the USPTO or its foreign counterparts. Due to the substantial competition in the pharmaceutical space, the number of such proceedings may increase. This could delay the prosecution of our pending patent applications or impact the validity and enforceability of any future patents that we may obtain. In addition, any such litigation, submission or proceeding may be resolved adversely to us and, even if successful, may result in substantial costs and distraction to our management. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, intellectual property law relating to the fields in which we operate is still evolving and, consequently, patent and other intellectual property positions in our industry are subject to change and are often uncertain. We may not prevail in any of these suits or other efforts to protect its technology, and the damages or other remedies awarded, if any, may not be commercially valuable. During the course of this type of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the market price for the combined organization&#39;s common stock could be significantly harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates, and to use our proprietary technologies without infringing the proprietary rights of third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference and various post grant proceedings before the USPTO or non-U.S. opposition proceedings. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">As a result of any such infringement claims, or to avoid potential claims, we may choose or be compelled to seek intellectual property licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us likely would be nonexclusive, which would mean that our competitors also could obtain licenses to the same intellectual property. Ultimately, we could be prevented from commercializing a product candidate or technology or be forced to cease some aspect of our business operations if, as a result of actual or threatened infringement claims, we are unable to enter into licenses of the relevant intellectual property on acceptable terms. Further, if we attempt to modify a product candidate or technology or to develop alternative methods or products in response to infringement claims or to avoid potential claims, we could incur substantial costs, encounter delays in product introductions or interruptions in sales. Ultimately, such efforts could be unsuccessful. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock and negatively impact our ability to raise additional funds. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Our employees and consultants have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we are not aware of any claims currently pending against us, we may be subject to claims that these employees, or we have, inadvertently or otherwise used or disclosed trade secrets or other proprietary information or intellectual property of the former employers of our employees. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize product candidates, which would adversely affect our commercial development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In addition to seeking patents for some of our technologies and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality, non-competition, non-solicitation, and invention assignment agreements with our employees and consultants that obligate them to assign to us any inventions developed in the course of their work for us. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to seek patent protection on technology relating to our product candidates or obtain adequate remedies for such breaches. As a result, we may be forced to bring claims against third parties, or defend claims that they bring against us, to determine ownership of what we regard as our intellectual property. Monitoring unauthorized disclosure is difficult and we do not know whether the procedures that we have followed to prevent such disclosure are or will be adequate. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States may be less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.45pt;margin:0pt;"><span style="font-size:11.45pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Furthermore, if any of the technology or information that we protect as trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our competitive position would be harmed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO, and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">others may be able to make product candidates that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">we or our future licensors or collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">we or our future licensors or collaborators might not have been the first to file patent applications covering certain of our inventions;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">it is possible that our pending patent applications will not lead to issued patents;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">we may not develop additional proprietary technologies that are patentable; and  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><b style="font-weight:bold;">Risks Related Operations, Employee Matters and Managing Growth &#160;</b><span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We currently have no employees and a limited number of consultants and our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Because of the specialized scientific nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. We are highly dependent upon current members of our management and scientific team, each of whom serves as a consultant. We intend to increase our technical and management staff as needs arise and supporting resources become available, but the loss of one or more of our senior executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the pharmaceutical field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2022, we had 2 full-time employees, 2 full-time consultants and 2 part-time consultants, all located in the United States.  As of March 24, 2023, we had no full-time employees, 3 full-time consultants and 2 part-time consultants.  As our development and commercialization plans and strategies develop, or as a result of any future acquisitions, we will need additional managerial, operational, development, sales, marketing, financial and other resources. Our management, personnel and systems currently in place will not be adequate to support our future growth. Future growth would impose significant added responsibilities on our employees, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">managing our clinical trials effectively;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">identifying, recruiting, maintaining, motivating and integrating additional employees;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, contractors and other third parties; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our managerial, development, operational and finance systems</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As our operations expand, we will need to manage additional relationships with various CROs, strategic partners, and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative, research and development, and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We intend to market our product candidates outside of the United States, and if we do, we will be subject to the risks of doing business outside of the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Because we intend to market our product candidates, if approved, outside of the United States, our business is subject to risks associated with doing business outside of the United States. Accordingly, our business and financial results in the future could be adversely affected due to a variety of factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">failure to develop an international sales, marketing and distribution system for our products;   </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">changes in a specific country&#39;s or region&#39;s political and cultural climate or economic condition;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">unexpected changes in foreign laws and regulatory requirements;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">difficulty of effective enforcement of contractual provisions in local jurisdictions;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">inadequate intellectual property protection in foreign countries;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">inadequate data protection against unfair commercial use;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">trade-protection measures, import or export licensing requirements such as Export Administration Regulations promulgated by the United States Department of Commerce and fines, penalties or suspension or revocation of export privileges;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">the effects of applicable foreign tax structures and potentially adverse tax consequences; and  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant adverse changes in foreign currency exchange rates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render certain of our products obsolete or uncompetitive. This is particularly true in the development of therapeutics for indications where new products and combinations of products are rapidly being developed that change the treatment paradigm for patients. There is no assurance that our product candidates will be the most effective, have the best safety profile, be the first to market, or be the most economical to make or use. The introduction of competitive therapies as alternatives to our product candidates could dramatically reduce the value of those development projects or chances of successfully commercializing those product candidates, which could have a material adverse effect on our long-term financial success. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We will compete with companies in the United States and internationally, including major pharmaceutical and chemical companies, specialized CROs, research and development firms, universities and other research institutions. Many of our competitors have greater financial resources and selling and marketing capabilities, greater experience in clinical testing and human clinical trials of pharmaceutical products and greater experience in obtaining FDA and other regulatory approvals than we do. In addition, some of our competitors may have lower development and manufacturing costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Common Stock </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &quot;Risk Factors&quot; section, these factors include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">adverse results or delays in preclinical studies, clinical trials, regulatory decisions or the development status of our product candidates or any product candidates we may pursue in the future;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise sufficient additional funds necessary for the continued development of our product candidates whether through potential collaborative, partnering or other strategic arrangements or otherwise;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any future collaborative, licensing or other strategic arrangements that we may establish; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties created by our future management turnover;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">our inability to comply with the minimum listing requirements of the Nasdaq Stock Market LLC;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of achievement of, or failure to achieve, our, or any potential collaborator&#8217;s clinical, regulatory and other milestones, such as the commencement of clinical development, the completion of a clinical trial or the receipt of regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">decisions to initiate a clinical trial, not initiate a clinical trial, or terminate an existing clinical trial;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval for our product candidates or regulatory actions requiring or leading to a delay or stoppage of any clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commercial success of any product approved by the FDA or its foreign counterparts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable laws, rules or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse developments concerning our manufacturers, suppliers, collaborators and other third parties;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">occurrence of health epidemics or contagious diseases, and potential effects on our business, clinical trial sites, supply chain and manufacturing facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">our failure to commercialize our product candidates;   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if our patents covering our product candidates expire or are invalidated or are found to be unenforceable, or if some or all of our patent applications do not result in issued patents or result in patents with narrow, overbroad, or unenforceable claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">additions or departures of key scientific or management personnel;  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated safety concerns related to the use of any product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our announcements or our competitor&#39;s announcements regarding new products, enhancements, significant contracts, acquisitions or strategic partnerships and investments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our target markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our, or companies perceived to be similar to us, failure to meet external expectations or management guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of research reports about us or our industry, recommendations, earning results or estimates or withdrawal of research coverage by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of similar companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in general economic, political and market conditions in any of the regions in which we conduct our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure or dividend policy, future issuances of securities, sales of common stock by officers, directors and significant stockholders or our incurrence of additional debt;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting practices and ineffectiveness of our internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes, litigation or developments relating to proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of milestones and royalty payments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which are beyond our control.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In addition, the stock market in general, Nasdaq, and the stock of biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#39;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#39;s attention and resources, which would harm our business, operating results or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We</span><span style="font-style:italic;font-weight:bold;"> are </span><span style="font-style:italic;font-weight:bold;">not currently in compliance</span><span style="font-style:italic;font-weight:bold;"> with </span><span style="font-style:italic;font-weight:bold;">the</span><span style="font-style:italic;font-weight:bold;"> continued listing requirements</span><span style="font-style:italic;font-weight:bold;"> for Nasdaq. If the price of </span><span style="font-style:italic;font-weight:bold;">our common stock </span><span style="font-style:italic;font-weight:bold;">continues to trade below $1.00 per share for a sustained period or we do not meet other continued listing requirements, our common stock may be delisted from the Nasdaq Capital Market</span><span style="font-style:italic;font-weight:bold;">, which could affect </span><span style="font-style:italic;font-weight:bold;">the </span><span style="font-style:italic;font-weight:bold;">market price and liquidity </span><span style="font-style:italic;font-weight:bold;">for our common stock </span><span style="font-style:italic;font-weight:bold;">and reduce our ability to raise </span><span style="font-style:italic;font-weight:bold;">additional </span><span style="font-style:italic;font-weight:bold;">capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">On February 8, 2023, we received written notice (the &#8220;Notification Letter&#8221;) from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying us that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities maintain a minimum closing bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company&#8217;s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company did not meet the minimum closing bid price requirement. To regain compliance, the closing bid price of the Company&#8217;s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to August 7, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We continue to monitor the closing bid price of our common stock and consider our available options to resolve our noncompliance with the minimum bid price requirement. There can be no assurance that we will be able to regain compliance with the minimum bid price requirement or we will otherwise be in compliance with other Nasdaq listing </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">criteria. If we fail to regain compliance with the minimum bid requirement or to meet the other applicable continued listing requirements for the Nasdaq Capital Market in the future and Nasdaq may delist our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Delisting from the NASDAQ could adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly affect the ability of investors to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer business development opportunities. If our common stock is delisted by the NASDAQ the price of our common stock may decline and our common stock may be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets where an investor may find it more difficult to dispose of their common stock or obtain accurate quotations as to the market value of our common stock. Further, if we are delisted, we would incur additional costs under requirements of state &#8220;blue sky&#8221; laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In addition, if our common stock is delisted from the NASDAQ Capital Market and the trading price remains below $5.00 per share, trading in our common stock might also become subject to the requirements of certain rules promulgated under the Exchange Act, which require additional disclosure by broker-dealers in connection with any trade involving a stock defined as a &#8220;penny stock&#8221; (generally, any equity security not listed on a national securities exchange or quoted on NASDAQ that has a market price of less than $5.00 per share, subject to certain exceptions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">If we seek to implement a reverse stock split to remain listed on the NASDAQ Capital Market, the announcement or implementation of a reverse stock split could significantly negatively affect the price of our common stock.  Additionally, in 2020, the SEC approved a previously proposed NASDAQ rule change to expedite delisting of securities with a closing bid price at or below $0.10 for 10 consecutive trading days during any bid price compliance period and that have had one or more reverse stock splits with a cumulative ratio of 1 for 250 or more shares over the prior two-year period.  In addition, if a company falls out of compliance with the $1.00 minimum bid price after completing reverse stock splits over the immediately preceding two years that cumulatively result in a ratio of 1 for 250 shares, the company will not be able to avail itself of any bid price compliance periods under Rule 5810(c)(3)(A), and NASDAQ will instead require the issuance of a Staff delisting determination. The company could appeal the determination to a hearings panel, which could grant the company a 180-day exception to remain listed if it believes the company would be able to achieve and maintain compliance with the bid price requirement. Following the exception, the company would be subject to the procedures applicable to a company with recurring deficiencies (NASDAQ Rule 5815(d)(4)(B)).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">We continue to actively monitor our performance with respect to the listing standards and are considering available options to resolve the deficiency and regain compliance with the NASDAQ rules.  There can be no assurance that we will be able to regain compliance with any deficiency, or maintain compliance even if we implement an option that regains our compliance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may enter into financing transactions that are dilutive to our stockholders, impose material restrictions on our business and/or require us to relinquish valuable rights.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of current stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our current stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our largest shareholder may use its significant interest to take actions not supported by our other shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">As of March 24, 2023, our largest shareholder, Dong-A beneficially owned 45.7% of our voting rights, and if the warrants held by Dong-A were exercised, Dong-A would hold 60.3% of our voting rights. As a result, Dong-A may be able to exert a significant influence on the outcome of corporate actions requiring shareholder approval, including mergers, share capital increases and other extraordinary items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.65pt;margin:0pt;"><span style="font-size:4.65pt;font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.65pt;margin:0pt;"><span style="font-size:4.65pt;font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.65pt;margin:0pt;"><span style="font-size:4.65pt;line-height:1.19;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In addition, pursuant to the Investor Rights Agreement between us and Dong-A, Dong-A has the right to appoint a number of our directors commensurate with its percentage holding of our common stock, which may result in Dong-A controlling both the determinations of the Board of Directors and the vote of all matters submitted to a vote of our shareholders, which enables them to control all corporate decisions. This concentration of ownership may delay, deter or prevent acts that would be favored by our other shareholders. The interests of Dong-A may not always coincide with our interests or the interests of our other shareholders. For as long as Dong-A owns shares of our common stock and the Investor Rights Agreement is effective, Dong-A will have significant influence on our management, business plans and policies, including the appointment and removal of our officers, decisions on whether to raise future capital and amending our charter and bylaws, which govern the rights attached to our common stock. In particular, if Dong-A owns a significant percentage of our stock, Dong-A will be able to cause or prevent a change of control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of us. The concentration of ownership could deprive you of an opportunity to receive a premium for your shares of common stock as part of a sale of us and ultimately might affect the market price of our common stock. In addition, this concentration of ownership may adversely affect the trading price of our common stock because investors may perceive disadvantages in owning shares in a company with significant stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Dong-A and its affiliates engage in a broad spectrum of activities, including investments in the healthcare industry generally. In the ordinary course of its business activities, Dong-A and its affiliates may engage in activities where their interests conflict with our interests or those of our other shareholders, such as investing in or advising businesses that directly or indirectly compete with certain portions of our business or are suppliers or customers of ours. Our certificate of incorporation provides that neither Dong-A or any of their affiliates or any director who is not employed by us (including any non-employee director who serves as one of our officers in both her or his director and officer capacities) or its affiliates have any duty to refrain from engaging, directly or indirectly, in the same business activities or similar business activities or lines of business in which we operate. Dong-A also may pursue acquisition opportunities that may be complementary to our business, and, as a result, those acquisition opportunities may not be available to us. In addition, Dong-A may have an interest in pursuing acquisitions, divestitures and other transactions that, in their judgment, could enhance its investment, even though such transactions might involve risks to you.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing rules and may follow certain exemptions from certain corporate governance requirements that could adversely affect our public shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of March 24, 2023, our largest shareholder, Dong-A beneficially owned 45.7% of our voting rights<span style="color:#231f20;white-space:pre-wrap;">.  To the extent that Dong-A acquires additional shares of common stock, including through the exercise of the warrants that it currently holds or otherwise, such that Dong-A would own more than 50% of our outstanding common stock, we would meet the definition of a &#8220;controlled company&#8221; under the corporate governance standards for Nasdaq listed companies.  For so long as we would be a &#8220;controlled company&#8221; under this definition, we would be eligible to utilize certain exemptions from the corporate governance requirements of Nasdaq, including the requirements (i)&#160;that a majority of the Board consist of independent directors, (ii)&#160;to have a governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities, (iii)&#160;to have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities, (iv)&#160;that the compensation committee consider certain independence factors when engaging legal counsel and other committee advisors and (v)&#160;for an annual performance evaluation of the governance and compensation committees. Although we do not currently intend to rely on the &#8220;</span><i style="color:#231f20;font-style:italic;">controlled company</i><span style="color:#231f20;">&#8221; exemptions under the Nasdaq listing rules&#160;even if we would be deemed to a &#8220;</span><i style="color:#231f20;font-style:italic;">controlled company</i><span style="color:#231f20;">,&#8221; we could elect to rely on these exemptions in the future. If we were to elect to rely on the &#8220;</span><i style="color:#231f20;font-style:italic;">controlled company</i><span style="color:#231f20;">&#8221; exemptions, a majority of the members of the Board might not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely of independent directors. Accordingly, if we rely on the exemptions, during the period we remain a controlled company and during any transition period following a time when we are no longer a controlled company, stockholders would not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Provisions in our certificate of incorporation and the bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by stockholders to replace or remove their current management by making it more difficult for stockholders to replace members of our board. Among other things, these provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors such that not all members of the board are elected at one time; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit the manner in which our stockholders can remove directors from the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit our stockholders from calling special meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our board to issue preferred stock without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock, and which could be used to institute a shareholder rights plan, or so-called &quot;poison pill,&quot; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the approval of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with it for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are a &quot;smaller reporting company&quot; and we cannot be certain if the reduced reporting requirements applicable to such companies could make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We are a &quot;smaller reporting company&quot;, as defined in the Exchange Act. For as long as we continue to be an smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &quot;emerging growth companies&quot;, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley Act), only being required to provide two years of audited financial statements in annual reports and reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have identified material weaknesses in our internal control over financial reporting that could, if not remediated, result in material misstatements in our financial statements or impair our ability to produce accurate and timely consolidated financial statements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">We concluded that there were material weaknesses relating to our internal control over financial reporting relating to a lack of segregation of duties over certain financial processes, management review over financial reporting and logical access to financial reporting systems.  For more information about these material weaknesses, see Part II, Item 9A (Controls and Procedures) of this report. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company&#39;s annual or interim consolidated financial statements will not be prevented or detected on a timely basis. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Although we have begun to take measures to remediate these material weaknesses, the measures we have taken, and expect to take, to improve our internal controls may not be sufficient to address the issues identified, to ensure that our internal controls are effective or to ensure that the identified material weaknesses will not result in a material misstatement of our annual or interim consolidated financial statements. If we are unable to correct material weaknesses or deficiencies in internal controls in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC will be adversely affected. This failure could negatively affect the market price and trading liquidity of our common stock, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and materially and adversely impact our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">General Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of system failures or unplanned events. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Despite the implementation of security measures, our internal computer systems and those of our current and future contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we are not aware of any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Furthermore, any unplanned event, such as flood, fire, explosion, tornadoes, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize the facilities, may have an adverse effect on our ability to operate the business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cyber security incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and adversely affect our business and reputation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">In the ordinary course of our business, our contract research organizations and other third parties on which we rely collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information, including research and development information and business and financial information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research, development and commercialization activities, process and prepare Company financial information, manage various general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our research, development and commercialization efforts could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for our common stock may not be maintained.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;"> </span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Our common stock is currently traded on the Nasdaq Capital Market, but we can provide no assurance that we will be able to maintain an active trading market for our shares on the Nasdaq Capital Market or any other exchange in the future. If there is no active market for our common stock, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">If one or more analysts cover our business and downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We incur increased costs as a result of operating as a public company and our management is required to devote substantial time to compliance initiatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the stock exchange upon which our common stock is listed and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="white-space:pre-wrap;">We are a &quot;smaller reporting company&quot;, as defined in the Exchange Act. For as long as we continue to be an smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &quot;emerging growth companies&quot;, including exemption from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley Act), only being required to provide two years of audited financial statements in annual reports and reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements  If our public float is above $75 million as of the last business day of our most recently completed second fiscal quarter or, if before such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">To achieve compliance with Section 404, we are required to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we must dedicate internal resources, hire additional finance and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">In addition, as a public company we are required to timely file accurate quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend on CROs to provide timely and accurate notice of their costs to it. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from Nasdaq or other adverse consequences that would materially harm our business. </p><a id="_cp_text_2_1"></a><a id="_cp_text_2_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock and, consequently, the ability of our stockholders to achieve a return on their investment will depend on appreciation in the price of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">We have never declared or paid any cash dividend on our capital stock and do not currently intend to do so in the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which you purchased them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our Bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#39; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will generally be the sole and exclusive forum for any derivative action or proceeding brought on its behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, as amended, the certificate of incorporation or the bylaws or any other action asserting a </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">claim governed by the internal affairs doctrine. This provision does not apply to claims arising under the Securities Act and the Exchange Act or any claim for which the federal courts have exclusive jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of the bylaws described above. This choice of forum provision may limit a stockholder&#39;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find this provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;"><span style="font-style:italic;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt;">The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. We cannot assure you that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require it to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_24242da9_c91f_4db7_b026_0e5912ef3ef6"></a><a id="ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 1B.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">UNRESOLVED STAFF COMMENTS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Not applicable</p><a id="_2148f7d5_3880_4bed_ad8b_cc39cdb19dcd"></a><a id="ITEM2PROPERTIES_644950"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">PROPERTIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">We currently lease space in Boston, Massachusetts. Effective January 2022, we entered into an amendment to our lease agreement for approximately 40 square feet of office space, which, including subsequent amendments, is due to expire in March 2023.  We previously leased approximately 574 square feet of lab and office space in Seoul, South Korea until April 30, 2022.  We believe that our leased properties are adequate for our purposes and to pursue our strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7d86232b_f66f_444f_9337_0dcb6abd6338"></a><a id="ITEM3LEGALPROCEEDINGS_754217"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">LEGAL PROCEEDINGS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><a id="_c2e7d612_36b4_4d4c_8a49_2f26b2031b47"></a><a id="ITEM4MINESAFETYDISCLOSURES_848551"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">MINE SAFETY DISCLOSURES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Not applicable.</p><a id="_678c0f99_2968_4954_99c5_ba56a696fd1a"></a><a id="PARTII_387386"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II</b><b style="font-weight:bold;"> </b></p><a id="_43f9b8d4_4961_44de_93c4_99a481a8cae4"></a><a id="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">ITEM 5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER</b><b style="font-weight:bold;"> MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our common stock is listed on Nasdaq under the symbol &#8220;NRBO.&#8221; </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stockholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, we had 27,176,685 shares of common stock outstanding and 73 holders of record of our common stock. The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividend Policy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We have never declared or paid any dividends on our common stock, and we do not currently intend to pay any dividends on our common stock for the foreseeable future. Any future determination to pay dividends on our common stock will be, subject to applicable law, at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, and contractual restrictions in loan or other agreements. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3532aaa4_4332_4903_8eda_42cfbdced257"></a><a id="ITEM6SELECTEDFINANCIALDATA_394630"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:11pt;margin-top:0pt;"><b style="font-weight:bold;">[Reserved]</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_90a46174_7b4c_4b73_8881_ccceb7a4aacf"></a><a id="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND</b><b style="font-weight:bold;"> RESULTS OF OPERATIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes included in Part II, Item 8 &#8220;Consolidated Financial Statements and Supplementary Data&#8221; of this report.&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">We are a clinical-stage biotechnology company focused on developing and commercializing novel pharmaceuticals to treat cardiometabolic disorders. For more information on our business and product candidates, see &#8220;Business-Overview&#8221; in Part&#160;I, Item&#160;1 of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Developments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dong-A ST License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On September&#160;14, 2022, we entered into the 2022 License Agreement with Dong-A, pursuant to which, we ultimately received an exclusive global license (other than in the Republic of Korea) to two proprietary compounds for specified indications upon meeting certain financing milestones. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. We may also develop DA-1241 for the treatment of T2D. Under the terms of the 2022 License Agreement, we agreed to pay Dong-A an upfront payment to be settled with 2,200 shares of Series&#160;A Preferred Stock upon completion of a private placement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">In addition, Dong-A will be eligible to receive (i) regulatory milestone payments of up to $178 million for DA-1726 and $138 million for DA-1241, dependent upon the achievement of specific regulatory developments; (ii) commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iii)&#160;single digit royalties on net sales received by us from the commercial sale of products covering DA-1241 or DA-1726. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The term of the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either Dong-A or the Company may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within 60 days of notice of such breach; provided that if the breach cannot be cured within the 60-day period and the breaching party started to remedy the breach, if such breach is not cured within 90 days of receipt of written notice, (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a 30-day cure period in the case of a petition for bankruptcy), or (iii)&#160;in the event we had failed to complete the Public Offering as further described below by December&#160;31, 2022 (or January&#160;31, 2023 under specified circumstances set forth in the License Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">None of the milestone or royalty payments under the 2022 License Agreement were triggered as of the issuance of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Shared Services Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">On September&#160;14, 2022, in conjunction with the 2022 License Agreement, we entered into a shared services agreement with Dong-A (the&#160;&#8220;Shared Services Agreement&#8221;). The Shared Services Agreement provides that Dong-A will provide technical support, pre-clinical development, and clinical trials support services in exchange for payment to Dong-A on a cost plus margin basis. In addition, the Shared Services Agreement provides that Dong-A will manufacture all of the Company&#8217;s clinical requirements of DA-1241 and DA-1726 on a cost plus margin basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">Either party may terminate the Shared Services Agreement for the other party&#8217;s material breach that is not cured within 30 days of notice. Dong-A may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by us which is not cured within 30 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">The Company did not incur any research and development expenses under the Shared Services Agreement as of the issuance of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Current Scientific Activity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following consummation of the 2022 License Agreement, we have two primary programs focused on treatment of NASH, obesity and T2D:<span style="display:inline-block;width:31.51pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DA-1241</b> is a novel chemical drug candidate selectively activating G protein-coupled receptor 119 (GPR119) which has shown consistent target-related mechanisms and glucose-lowering effects from nonclinical studies to a Phase 1b exploratory clinical trials in patients with T2D in the US. GPR119 is known to be a regulator of both blood glucose and lipid levels. Non-clinical studies suggest DA-1241 selectively activates GPR119, thus stimulating the secretion of insulin and incretin hormones such as GLP-1, GIP, and PYY. Extensive non-clinical studies have shown DA-1241 has therapeutic potential for the reduction in hepatic steatosis, inflammation, fibrosis, improved lipid metabolism, and glucose control regardless of body weight reduction. Other preclinical tests have suggested these therapeutic effects are augmented when co-treated with other oral anti-diabetic agents such as metformin, SGLT2 inhibitors, and DPP4 inhibitors which are widely used for treating patients with T2D in the clinic. Moreover, impaired insulin action and lipid metabolism which are frequently observed in T2D patients are highly associated with the pathogenesis of steatosis and inflammation in NASH. In Phase 1a and 1b human trials DA-1241 was well tolerated in both healthy volunteers and those with T2D. We intend to initiate a Phase 2a study with the goal of establishing efficacy of DA-1241 in NASH and T2D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">DA-1726</b> is a novel OXM analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. Activation of GLP-1R contributes to central anorexic effect (appetite suppression) and activation of GCGR peripherally enhances basal metabolic rate. Accordingly, non-clinical studies have shown DA-1726 not only reduces food intake but also increases energy expenditure even at the basal resting state, leading to persistent weight loss in diet-induced obese animals. In preclinical mice models administration of DA-1726 resulted in improved weight loss, as well as reduced hepatic steatosis, inflammation, and fibrosis compared to semaglutide as well as another OXM analogue in development. Having stabilized the fragile peptide through several unique modifications, DA-1726 is predicted to be available as a once-weekly regimen to humans. We intend to advance DA-1726 through Investigational New Drug application and initiation of human clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our Board of Directors has determined to focus our financial resources and management attention on development of DA-1241 for NASH and T2D and DA-1726 for NASH and obesity.  We will continue to consider licensing and acquisition opportunities with respect to our legacy programs designed to impact a range of </span><span style="letter-spacing:0.2pt;">indications in viral, neurodegenerative and cardiometabolic diseases:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ANA001</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is a proprietary oral niclosamide formulation being developed as a treatment for patients with moderate COVID-19. Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and well-understood safety in humans..</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">NB-01</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was being developed as a treatment for painful diabetic neuropathy (PDN) as a first-line pain management therapy for PDN. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">NB-02</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> was being developed to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the misfunction of a protein called tau, and with amyloid beta plaque deposition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Gemcabene</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">was </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being developed </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, and was focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG) and we are currently exploring various acute therapeutic indications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">K</i><span style="font-style:italic;font-weight:bold;">ey operating data</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $14.0 million and $15.3 million for the years ended December 31, 2022 and 2021, respectively. To date, we have not generated any revenue from product sales, collaborations with other companies, government grants or any other source, and do not expect to generate any revenue in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">As of December 31, 2022, we had an accumulated deficit of $95.8 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue clinical development for our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate preclinical studies and clinical trials with respect to our current product candidates and indications and any future product candidates or indications that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other product candidates and/or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, scientific and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure and/or enter into partnership arrangements to commercialize any products for which we may obtain regulatory approval; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add administrative, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, and to support our being a public reporting company.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Components of Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">To date, we have not generated any revenue from product sales, collaborations with other companies, government grants or any other source, and do not expect to generate any revenue in the foreseeable future. If our product development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Cost of Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">To date, we have not generated any revenue and thus have no cost of revenue. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;">product sales and have corresponding cost of revenue. We cannot predict if, when, or to what extent we will incur costs from revenue from the commercialization and sale of our product candidates. If we are successful at commercialization, the cost of revenues would include all costs directly related to providing the commercial asset, which would consist primarily of labor, material, facilities, warehousing and other overhead expenses. Cost of revenues would also include depreciation expense related to certain equipment used as part of the commercial asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs to operations as incurred. These expenses include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, including salaries, related benefits and stock-based compensation, for employees engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with the clinical development of our product candidates, including under agreements with third parties, such as consultants and Clinical Research Organizations (&#8220;CROs&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing and storing drug products for use in our preclinical studies and clinical trials, including under agreements with third parties, such as consultants and Clinical Manufacturing Organizations (&#8220;CMOs&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to compliance with regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments made under third-party licensing agreements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">We recognize external development costs based on an evaluation of the progress toward completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense when the goods have been delivered or the services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">Our direct research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our clinical development, quality assurance and quality control processes, manufacturing, and clinical development activities. Our direct research and development expenses also include fees incurred under third-party license agreements. We use our employee and infrastructure resources across multiple research and development projects. We do not allocate employee costs and costs associated with our facilities, including depreciation or other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">Clinical development activities are central to our business model. We do not believe that our historical costs are indicative of the future costs associated with these programs, nor do they represent the costs of other future programs we may initiate. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We have some control over the timing of these expenses, but costs may be difficult to control once clinical trials have commenced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">The successful development and commercialization of our product candidates are highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">preclinical and clinical development of any of our product candidates. Additionally, because of the risks inherent in novel treatment discovery and development, we cannot reasonably estimate or know:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and progress of preclinical and clinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of clinical programs that we decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain our current development programs and to establish new ones;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing an appropriate safety profile with IND-enabling studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful patient enrollment in, and the initiation and completion of, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt of regulatory approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish new licensing or collaboration arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety profile of the product candidates following commercialization; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of competing technological and market developments.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:14pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We include costs to acquire or in-license product candidates in acquired in-process research and development expenses (&#8220;IPR&amp;D&#8221;). When we acquire the right to develop and commercialize a new product candidate, any up-front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as acquired in-process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, or provided that the product candidate has not achieved regulatory approval for marketing and, absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:46.1pt;text-indent:-46.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:46.1pt;text-indent:-46.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, and audit services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">We anticipate that our general and administrative expenses will increase in the future as a result of accounting, audit, legal, regulatory, compliance, and director and officer insurance costs as we pursue the development of our product pipeline, as well as investor and public relations expenses associated with being a public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Interest Income </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;padding-top:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">Interest income consists of bank interest earned on our cash and cash equivalents.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Change in Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">The fair value change in warrant liabilities is attributed to the change in fair value of Series A Warrants and the Series B Warrants (as defined further below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Other Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Other expense primarily reflects losses on sale of fixed assets and translations of foreign currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Since our inception, we have not recorded any income tax benefits for the NOLs we have incurred in each year or for our earned research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOL carryforwards and tax credits will not be realized. As of December 31, 2022, we had federal, state and foreign NOLs carryforwards of $1.4&#160;<span style="white-space:pre-wrap;">million, $0.8 million, and $0.7 million, respectively, which may be available to offset future income tax liabilities and begin to expire, in 2043 for state carryforwards and in 2028 for the foreign carryforwards.   As of December 31, 2022, we also had federal and state research and development tax credit carryforwards of $24,000 and $2,000, respectively, which may be available to offset future tax liabilities and each begin to expire in 2043. We have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Years Ended December 31, 2022 and December 31, 2021 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">The following table summarizes our results of operations for the years ended December 31, 2022 and December 31, 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:37.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the Year Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:37.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:normal;width:37.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,778</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,546</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,768)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,210</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,210</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,640</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,752</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (112)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,628</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,298</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,330</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (19,628)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,298)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,330)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Interest income </p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financing expense</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,191)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,191)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,935</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,935</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other expense</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (83)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (83)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,967)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,284)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,317</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13,967)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,284)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,317</span></p></td><td style="vertical-align:bottom;white-space:normal;width:0.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Research and development expenses were $2.8 million for the year ended December 31, 2022 as compared to $6.5 million for the year ended December 31, 2021. <span style="background:#ffffff;">The $3.8 million decrease was primarily related to reduced clinical trial activity and drug manufacturing costs of approximately $2.7 as we completed our ANA 001 clinical trial and reduced payroll, consulting and overhead costs of approximately $1.1 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">IPR&amp;D for the year ended December 31, 2022 amounted to $8.2 million and was attributable to the acquisition of intellectual property rights under the 2022 License Agreement. Given that <span style="background:#ffffff;">no processes or activities constituting a &#8220;business&#8221; were acquired and since none of the rights underlying the 2022 License Agreement had alternative future uses or had reached a stage of technological feasibility, the acquisition was recorded as IPR&amp;D </span>and was based on the fair value of the 2,200 shares of <span style="background:#ffffff;">Series A Preferred Stock issued to Dong-A pursuant to the terms and conditions of the 2022 License Agreement. </span>There was no IPR&amp;D for the year ended December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:2pt;text-indent:36pt;background:#ffffff;margin:0pt;">General and administrative expenses were $8.6&#160;million for the year ended December 31, 2022, compared to approximately $8.7&#160;million for the year ended December 31, 2021. The decrease of $0.1 million was primarily due to decreases in payroll, insurance and overhead of $0.5 million, $0.4 million and $0.1 million, respectively, offset by increases in legal and professional fees of $0.7 million, attributed mostly to the pursuit of business opportunities, and by an increase in stock compensation of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Interest income for the year ended December 31, 2022 was nominal.  Interest income for the year ended December 31, 2021 was $14,000 related to our cash deposits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We incurred approximately $2.2 million in financing expense during the year ended December 31, 2022 representing the portion of the transaction costs allocated to the issuance of the Series A Warrants and Series B Warrants described further below.  We did not incur financing expense during the year ended December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in fair value of warrant liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background:#ffffff;">The change in fair value of warrant liabilities resulted in a gain of&#160;$7.9 million for the year ended December 31, 2022, primarily resulting from the fluctuation of the underlying stock price of our common stock at issuance compared to December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><i style="font-style:italic;">Other Expense</i></p><a id="ds47101_liquidity_and_capital_resources"></a><a id="toc_ds47101_1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">During year ended December 31, 2022, we recorded approximately $0.1 million of other expense primarily related to the loss on sale of fixed assets and losses on translations of foreign currency. Other expense for the year ended December 31, 2022 was nominal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:14pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">On September 14, 2022, we entered into the Securities Purchase Agreement with Dong-A.  Pursuant to the Securities Purchase Agreement, Dong-A agreed to purchase shares of our Series A Preferred Stock and warrants to purchase shares of our common stock (collectively, the &#8220;Dong-A Financing&#8221;) concurrent to a qualified financing resulting in gross proceeds of at least $15 million exclusive of the Dong-A Financing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On November 8, 2022, we closed on an underwritten public offering (the &#8220;2022 Public Offering&#8221;) of units with gross proceeds of approximately $17.3 million.  The underwritten public offering was comprised of (1) 3,147,003 Class A Units, priced at a public offering price of $3.00 per Class A Unit, with each Class A Unit consisting of one share of common stock, a Series A Warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock for no additional consideration that expires on the one year anniversary following the initial exercise date and a Series B Warrant (the &#8220;Series B Warrants&#8221;) to purchase one share of common stock for no additional consideration that expires on the five year anniversary following the initial exercise date, and (2) 2,602,997 Class B Units, priced at a public offering price of $3.00 </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">per Class B Unit, with each Class B Unit consisting of one share of Series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;), convertible into one share of common stock, one Series A Warrant and one Series B Warrant. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The 2022 Public Offering satisfied the definition of a Qualified Financing as defined by the Securities Purchase Agreement and on November 8, 2022, we closed on the Dong-A Financing, and issued an additional 1,500 shares of Series A Preferred Stock, 5,000,000 Series A Warrants and 5,000,000 Series B Warrants. The Company received gross proceeds in the amount of $15.0 million from Dong-A in connection with the Dong-A Financing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Net proceeds, of the 2022 Public Offering and Dong-A Financing, after deducting underwriter&#8217;s fees and related offering expenses were $28.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">On October&#160;1, 2021, we entered into a securities purchase agreement (the &#8220;October 2021 Securities Purchase Agreement&#8221;) with several institutional investors for the purchase and sale in a registered direct offering (&#8220;Registered Offering&#8221;) of 4,307,693 shares of our common stock, at a purchase price of $3.25 per share for gross proceeds of approximately $14.0 million. &#160;The October 2021 Securities Purchase Agreement also provides for a concurrent private placement of warrants to purchase our common stock (the &#8220;October 2021 Warrants&#8221;) with the purchasers in the October 2021 Registered Offering. Net proceeds, after deducting placement agent fees and expenses, related offering expenses, was $12.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On January 18, 2021, we entered into a Securities Purchase Agreement (the &#8220;2021 Purchase Agreement&#8221;) with certain institutional and accredited investors, pursuant to which we, in a private placement (the &#8220;2021 Private Placement&#8221;), agreed to issue and sell an aggregate of 2,500,000 shares (the &#8220;2021 Shares&#8221;) of our common stock, par value $0.001 per share at a purchase price of $4.00 per share, and warrants to purchase an aggregate of 2,500,000 shares of common stock (the &#8220;2021 Warrants&#8221;), resulting in total gross proceeds to us in the amount of $10.0 million.  Net proceeds, after deducting placement agent fees and relating offering expenses, were $9.1 million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">The following table summarizes our sources and uses of cash for each of the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:24.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:24.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:24.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,712)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,134)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (586)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28,681</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,026</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net increase in cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,977</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;">Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">During the year ended December 31, 2022, cash used from operating activities was approximately $11.7 million, consisting of our net loss of approximately $14.0 million, offset by non-cash expenses in the aggregate of $1.2 million and by $2.2 million in financing expense related to financing costs attributed to the issuance of the Series A and Series B Warrants reclassified to <i style="font-style:italic;">Financing Activities</i>, and consisting of our<i style="font-style:italic;"> </i><span style="white-space:pre-wrap;">working capital cash usage in the amount of approximately $1.1 million. The non-cash expenses related primarily to IPR&amp;D in the amount of $8.2 million from the 2022 License Agreement, and $0.9 million in stock offset by a $7.9 million fair value change in the warrant liabilities.  Lastly, the change in working capital consisted primarily of decreases in our accrued liabilities associated with fluctuations of our operating expenses under the normal course of business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">During the year ended December 31, 2021 operating activities used $15.1 million of cash, primarily consisting of our net loss of $15.3 million and a net decrease of accounts payable and accrued expenses of $1.0 million, offset by stock-based compensation and other non-cash charges of $0.7 million and $0.4 from a decrease in prepaid expenses and other current assets.  </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">Cash provided by investing activities was approximately $8,000 during the year ended December 31, 2022 related to the sale of equipment.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">During the year ended December 31, 2021, net cash used in investing activities was $0.6 million.  Investing activities during the period consisted mainly of cash paid for transaction costs associated with the 2020 merger with ANA. Purchases of property and equipment in the amount of $3,000 comprised the balance of investing activities during the period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">During the year ended December 31, 2022, net cash provided by financing activities was $28.7 million, consisting of gross proceeds from the Dong-A Financing and the 2022 Public Offering of $32.3 million, offset by $3.6 million of issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">During the year ended December 31, 2021, net cash provided by financing activities was $22.0 million, consisting of gross proceeds from our 2021 Private Placement and 2021 Registered Offering of $24.0 million, offset by $2.1 million of issuance costs, and $0.1 million received from the exercise of stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. To date, we have not generated any revenue from product sales, collaborations with other companies, government grants or any other source, and do not expect to generate any revenue in the foreseeable future, and have been dependent on funding operations through the sale of equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">As of December 31, 2022, we had an accumulated deficit of $95.8 million.  Our net losses were $14.0 million and $15.3 million for the years ended December 31, 2022 and 2021, respectively. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue clinical development for any of our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate preclinical studies and clinical trials with respect to any of our current product candidates and indications and any future product candidates or indications that we may pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other product candidates and/or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop, maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, scientific and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure and/or enter into partnership arrangements to commercialize any products for which we may obtain regulatory approval; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add administrative, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, and to support our being a public reporting company</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022, we had cash of $33.4 million. We expect that our cash will be adequate to fund our operations into 2024. &#160;We will need to continue to raise additional funds until we are able to commercialize our products which would generate sufficient revenues to fund our operations. &#160;Our future operating activities, coupled with our plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within our control and we are unable to predict the ultimate outcome of these actions to generate the liquidity ultimately required.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ds47101_contractual_obligations_and_comm"></a><a id="toc_ds47101_2"></a><a id="ds47101_critical_accounting_policies_a__"></a><a id="toc_ds47101_3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contractual and Other Obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Lease Commitments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;">Boston Leases:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On May 14, 2021, we entered into a non-cancelable operating lease for its corporate headquarters located in Boston Massachusetts. The agreement, effective August 1, 2021, had a six month term, and rental costs of approximately $3,000 per month prior to the application of certain rent concessions granted by the landlord in the amount of approximately $2,000 over the term of the lease.  We&#8217;ve since entered into amendments to this lease which reduced the size of our office space and extend the term to expire in March 2023 for rental costs of approximately $1,000-$2,000 per month.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;"><i style="font-style:italic;">License Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">We are party to license agreements with respect to certain of our product candidates that would obligate us to pay royalties with respect to revenue from such product candidates and milestone payments upon achievement of certain development milestones.  As of the date hereof, we do not expect to achieve such milestones in the near term, but we would have to obtain additional capital to pay such milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Other Obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies, and testing, manufacturing, and other services and products for operating purposes. These contracts provide for termination upon notice. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. These payments have not been included separately within these contractual and other obligations disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Critical Accounting Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;"> Our consolidated financial statements are prepared in accordance with U.S.&#160;GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs, and expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. On an on-going basis, our management evaluates its estimates, including those related to accounting for clinical trials, income taxes including the valuation allowance for deferred tax assets, accrued expenses, warrant liabilities, contingencies and stock-based compensation. We base our estimates on historical experience, known trends and events, and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:0pt;">While our significant accounting estimates are described in more detail in Note&#160;2 to our consolidated financial statements included elsewhere in this report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">Research and development costs are charged to expense as incurred. Research and development expenses may comprise of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730, <i style="font-style:italic;">Research and Development</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Certain of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some service providers require advance payments. We make estimates of our accrued and prepaid expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors in connection with preclinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs and investigative sites in connection with preclinical studies and clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CMOs in connection with the production of preclinical and clinical trial materials.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:14pt 0pt 0pt 0pt;">We base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-indent:36pt;margin:0pt;">We include costs to acquire or in-license product candidates in acquired in-process research and development expenses. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;text-indent:36pt;margin:14pt 0pt 0pt 0pt;">We account for stock-based compensation in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#160;&#8212; Stock Compensation</i> (&#8220;ASC 718&#8221;). Accordingly, compensation costs related to equity instruments granted are recognized at the grant-date fair value. We record forfeitures when they occur. Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718 using a grant date fair value approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;text-indent:36pt;background:#ffffff;margin:2pt 0pt 0pt 0pt;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of the common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term of the stock options and the expected dividend yield.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><a id="ds47101_emerging_growth_company_status"></a><a id="toc_ds47101_4"></a><a id="ds47101_off-balance_sheet_arrangements"></a><a id="toc_ds47101_5"></a><a id="ds47101_recently_issued_accounting_prono"></a><a id="toc_ds47101_6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">As part of the Dong-A Financing and the 2022 Public Offering, we issued the Series A Warrants and Series B Warrants. &#160;We accounted for the Series A and Series B warrants as liabilities at fair value as certain provisions excluded equity accounting treatment for these instruments. &#160;Additionally, issuance costs allocated to the Series A Warrants and Series B Warrants classified as liabilities are expensed as incurred and reflected as financing expense in the accompanying consolidated statements of comprehensive loss. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:14pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;background:#ffffff;margin:0pt;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations disclosed in Note&#160;2 to our consolidated financial statements included in Part II, Item 8<i style="font-style:italic;"> &#8220;Consolidated Financial Statements and Supplementary Data&#8221; </i>of this report.<i style="font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b5876278_8502_42e4_8154_3c097db2417d"></a><a id="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 7A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_09669e4f_a46b_4bd0_a9c8_62e38219a14b"></a><a id="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 8.</b></span><b style="font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;background:#ffffff;">INDEX TO FINANCIAL STATEMENTS</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:6.85pt;"><td style="vertical-align:bottom;width:89.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:AuditorName" id="Narr_xEJTaFszLEyeHVltxcPnow">BDO USA, LLP</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:AuditorLocation" id="Narr_IQzN4Xrw1EeFtAVZUeYbhQ">Boston Massachusetts</ix:nonNumeric>, PCAOB ID#<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="dei:AuditorFirmId" id="Narr_S2fyLGn8v0Cj_0tsiQwddw">243</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:bottom;width:89.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#BalanceSheets_736952"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:bottom;width:89.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ComprehensiveLoss_782761"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:bottom;width:89.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#EquityDeficit_89715"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Mezzanine Equity and Stockholders&#39; Equity </span></a></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">87</p></td></tr><tr><td style="vertical-align:bottom;width:89.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#StatementsofCashFlows_804215"><span style="font-style:normal;font-weight:normal;">Consolidated </span><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:bottom;width:89.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements_2"><span style="font-style:normal;font-weight:normal;">Notes to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">89</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2add85ea_0cbc_48e8_925e_908e4eca5f1e"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Shareholders and Board of Directors</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">NeuroBo Pharmaceuticals, Inc.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Opinion on the Consolidated Financial Statements</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We have audited the accompanying consolidated balance sheets of NeuroBo Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, mezzanine equity and stockholders&#8217; equity and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years then ended</span><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,</b><span style="font-family:'Times New Roman','Times','serif';"> in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. </span><span style="font-family:'Times New Roman','Times','serif';">We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Critical Audit Matters</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Accrual for Research and Development Costs Related to Clinical Trial Activities</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">As described in Note 3 to the consolidated financial statements, the Company&#8217;s accrued external research and development expenses balance was $109,000 at December 31, 2022. This accrual includes liabilities for clinical trial activities such as clinical studies and certain manufacturing costs. Clinical studies are primarily managed internally, with the assistance of contract research organizations. The accrual for clinical trial activities is based on an estimate of the percentage of activities completed to date, contractual rates, and amounts invoiced and paid to date. </span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';">We identified the determination of the accrual for research and development costs related to clinical trial activities as a critical audit matter. When estimating clinical trial expenses, the Company considers several factors including clinical trial budgets, contract amendments and the progress toward completion. Auditing these elements involves especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The primary procedures we performed to address the critical audit matter included:</span></p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Obtaining an understanding of management&#8217;s process for estimating the accrual for clinical trial activities. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For certain contract research organizations, testing the completeness and accuracy of the underlying billing information received from the contract research organizations used in determining the clinical trial accrual. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For certain clinical trial studies, assessing the Company&#39;s estimates of the activities completed to date by (i) inspecting original contract terms, change orders and the expected timeline for the related study, (ii) discussing the status of the clinical trials with certain members of management and project teams and (iii) evaluating the payments made and the invoices received after December 31, 2022 for proper application in the determination of the accrual. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:27pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Testing the completeness of the Company&#8217;s clinical trial accruals by evaluating i) publicly available information (such as press releases and public databases that track clinical trials) &#160;ii) board of directors&#8217; materials regarding the status of clinical trials and inquiring of clinical staff to gain an understanding of the status of certain on-going clinical trials. </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Accounting for 2022 Private Placement and Public Offering </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:12pt 0pt 0pt 0pt;">As discussed in Note 7, the Company entered into two financing transactions during the year that included the issuance of equity securities and warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:12pt;background:#ffffff;margin:0pt;">We identified the accounting for the 2022 Private Placement and Public Offering, including the evaluation for potential embedded derivatives, classification of the preferred stock, and the treatment of the warrants as a critical audit matter. The application of the accounting guidance applicable to the 2022 Private Placement and Public Offering transaction are complex, and therefore, applying such guidance to the contract terms requires significant management judgment. Auditing these elements involved especially complex auditor judgment due to the nature of the terms of the financing transactions and the effort required to address these matters, including the extent of specialized skills and knowledge needed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:12pt;background:#ffffff;margin:0pt;">The primary procedures we performed to address this critical audit matter included: </p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 8pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 8pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inspecting the agreements associated with each financing transaction and evaluating the completeness and accuracy of the Company&#8217;s technical accounting analysis and application of the relevant accounting literature. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:4pt 0pt 0pt 0pt;">&#9679;</td><td style="padding:4pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Utilizing personnel with specialized knowledge and skills in technical accounting to assist in assessing management&#8217;s analysis of the financing transactions, including the evaluation for potential embedded derivatives and classification of the related warrants including: (i) evaluating the contracts to identify relevant terms that affect the recognition in the financial statements, and (ii) assessing the appropriateness of conclusions reached by management. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">We have served as the Company&#39;s auditor since 2019.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">/s/ BDO USA, LLP</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:45.35pt;text-align:justify;text-indent:-45.35pt;margin:0pt 0pt 4.69pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">March 30, 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_97462281_ab50_4776_b6d7_4a2cafe402c5"></a><a id="_Hlk130997199"></a><a id="_Hlk128872644"></a><a id="_Hlk3385988"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b></p><a id="BalanceSheets_736952"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts and par value)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_bf3af7da_f034_46bc_8c39_6851e81451f0"></a><a id="Tc_lhXhM1dLn0meEOvOmyukeQ_1_2"></a><a id="Tc_b6GzMbcbbUuzNZaCJysTrA_1_5"></a><a id="Tc_m5qVW2Mx2E6IV7ORbOEFgQ_2_2"></a><a id="Tc_ZNEx5wj6P0G85YjYyhAMMg_2_5"></a><a id="Tc_O0WmZqY810aqRkB-9NcDIw_4_0"></a><a id="Tc_4wgue0f5qkCOjh3ay16u8w_5_0"></a><a id="Tc_-wGQ_38T70-fB_GQPZUuvw_6_0"></a><a id="Tc_Nln6x5WyHkqkN7AdDwUOGw_6_2"></a><a id="Tc_qzfZsSEMT0-M_MoAJga8bQ_6_5"></a><a id="Tc_BUgQ1St2GkG6593FG5s3FQ_7_0"></a><a id="Tc_fMCsKTn84Uyo8fuucbOuqw_8_0"></a><a id="Tc_-cArdXCwiESdMI4KZX796Q_9_0"></a><a id="Tc_vKMNXni9oUS_kE1ZnJWEcg_9_3"></a><a id="Tc_8HaTSEAKNU2lnouPCRQ8rw_10_0"></a><a id="Tc_oPdNMEHKkUOPmBWuaM__2Q_11_0"></a><a id="Tc_kqe8czPs0UCQWveEPl3Ftg_11_2"></a><a id="Tc_PclqSHvBYEeC1MsFw3hzYg_11_5"></a><a id="Tc_8Mw953dTfkmqI6-55D8Ytw_12_0"></a><a id="Tc_cXqXXu7YkkmtzValPNLFGg_13_0"></a><a id="Tc_HywqsaBFRk6sAwJTX7hSlw_14_0"></a><a id="Tc_G7V7RqPP-kisgg700xUscw_14_2"></a><a id="Tc_OhCG2bteTUWPg1PHfkyHFw_14_5"></a><a id="Tc_OfcncWne9Eur41KUE_G-yw_15_0"></a><a id="Tc_bBTPpy-lt0mtCBij3Yh_MQ_16_0"></a><a id="Tc_stPE65r34EGrBdIq-aOdwQ_16_6"></a><a id="Tc_fLYkos6EiU-2S8lCH5AEXA_17_0"></a><a id="Tc_3C7PMai1jkyc5L5gDdk6VA_17_3"></a><a id="Tc_jqRgkK5Uuku3ms3IcqSp_w_18_0"></a><a id="Tc_vazbC1eEPEOsm5zCNB_DAQ_19_0"></a><a id="Tc_THkRMh8q7UexF4G6QTDX5g_19_3"></a><a id="Tc_K76nOPjMnE-hCiPUprOspQ_20_0"></a><a id="Tc_ZMlRdveWtkK9pd3Ny-u0_w_21_0"></a><a id="Tc_zxQ4a87K1UCTF3bEARRXcg_22_0"></a><a id="Tc_kVPSwpwnmkKwjNMtI0DSfw_23_0"></a><a id="_e4527a8c_2e51_46fb_8339_e68b742e401b"></a><a id="_e4527a8c_2e51_46fb_8339_e68b742e401b_2"></a><a id="_e4527a8c_2e51_46fb_8339_e68b742e401b_3"></a><a id="_7144017b_3d76_4344_8d45_5f6b0c3f9e3a"></a><a id="_7144017b_3d76_4344_8d45_5f6b0c3f9e3a_2"></a><a id="_7144017b_3d76_4344_8d45_5f6b0c3f9e3a_3"></a><a id="Tc_VoKGn1EJdUScXYkB3z2XZw_24_0"></a><a id="Tc_IlVe7iKL7Uun-WQnimtX6g_25_0"></a><a id="Tc_nUaMN_QGdEiDtcKYOX8ncA_26_0"></a><a id="Tc_DXJV1LOknEiFM4alNCk6jA_26_3"></a><a id="Tc_7ipC8cLsO0qFospQYZc7_w_27_0"></a><a id="Tc_TS-DluJ3ukytaMVlqcCOgQ_28_0"></a><a id="Tc_V4-UPFet-kqpKSv1O2e3uA_29_0"></a><a id="Tc_V6V7T2M73EyWhSV-PKEYmA_29_2"></a><a id="Tc_8kQvOZAprUGnn1lPmRxd-g_29_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"> Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_JxbmW0KIF0ay73QZoJbv1Q_6_3">33,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_cI9AwBDev0G6C1Ci6_awZg_6_6">16,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"> Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_TIRKsSIprkqeNHz5KPeOjg_7_3">168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_UjRrWHDWd0uR4sbZKDqyfw_7_6">197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_DSHHbkurzEOvSwgvRpCqrg_8_3">33,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Oz0wy-Z27EOtvTD5C4lBJA_8_6">16,584</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Right-of-use assets and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_1WH0t4s7m0yb3SysHTXh2Q_9_6">105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_-MhoPItvAkudNrPig7tWRg_10_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_wF3a83nOxkK_nHnizlEbqw_10_6">110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_OivYu_p7rkO7msZ-oD0FPA_11_3">33,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_61TorBTWWkCONhIcrc1quQ_11_6">16,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_IbxEEvLLRk2vS0R-G2bN3Q_14_3">708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_ueXsxMId50OzsY83Th-o9A_14_6">830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_1bF6GMX8n06Hk1xQFEeQ1g_15_3">280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_m5ZtX6kqcUuKzx3Z_Zv2BA_15_6">1,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" scale="3" id="Tc_gpmX0_yUGUq9WBg14ZOnrQ_16_3">10,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Lease liability, short-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_7-hIdLJ6pkimqY7ORXOKNw_17_6">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_DjcOekdTJkKtUTKkum_QPg_18_3">11,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_xGoh9wg1jkm7HG7t_vemag_18_6">2,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_pnV8d1YQy0qFs33d497ewA_19_6">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Qp-qWSIrPkWGY1NeP9KjXA_20_3">11,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_TI0gkOrW00uGgiJj4l7CFA_20_6">2,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Commitments and contingencies (Note 4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_oN7j2X3ShU6Ssxg_dCec7A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_RqA4i68_SkCxcXk1r8In6A">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_m6qCZkNgpUa0AEKWTyDBhQ"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_aTrfwKw6Gk6avPfkkhdFRQ">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December 31, 2022 and December 31, 2021; no shares issued or outstanding as of December 31, 2022 and December 31, 2021.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_bQq_NMxy_kGeemiwEPt3VA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Gc9J0P6c8kegK2GqhDWwPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_wJrNeq9ArkmCOHQacPx5xw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_4hp97KrAtEyVj8ZNVxOKDQ">0.001</ix:nonFraction></ix:nonFraction> par value per share, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_1busMyzSQEOEmfBEH_CZfQ"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4a27T42vJki9QxV14x4Zng">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized as <br />of December 31, 2022 and December 31, 2021; <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_by_401blaEWMmdD9gK5jrg">25,436,019</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_7BAxXCoK_E612mH5vFWVyw">888,693</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_tD2RTX7JhEiUN69eOj671g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_OuphcIW93km7Lewq_FhozA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> as of December 31, 2022 and December 31, 2021, respectively.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Z65x5YpQuUaqMEw5FUPmBQ_24_3">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc__OIiaL798kaQ2rwq3UItwQ_24_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Additional paid&#8211;in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_fcsOVJPL7Uav3GMjIAKSIA_25_3">117,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_26SipzIgvkyvfujG6lSKtQ_25_6">96,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_sAQJnpPZX0OrvcqPA0klTA_26_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ImsvSMKsek-8aNzPmQIi2A_27_3">95,795</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_nJW0tJCZWkeifP1kQNsSrw_27_6">81,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2agVWnUcAkq_Zj3h5Mlr7Q_28_3">21,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ALEEjcnBiEyMBTbWvZ9GAQ_28_6">14,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities and stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ZAvSW-aGKEu9lqr0P7khxQ_29_3">33,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_c_jUP96GzkaAhaSWa6Qf9w_29_6">16,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">See accompanying notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_26f4123f_cc8d_4c87_9a72_96fec927dea0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;"> NeuroBo Pharmaceuticals, Inc.</b></p><a id="ComprehensiveLoss_782761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_a564c470_3719_4f3b_9f2b_d85b5edf1eba"></a><a id="_55231cb2_f0bd_4611_ba96_2d6d883aa3fd"></a><a id="Tc_f9I-HfVywUi5A1SB1xCIoQ_1_2"></a><a id="Tc_2WZVZZR7zUuhnQMnqxw99Q_2_2"></a><a id="Tc_F5rk4bvjmkyyBkWq8nCuxg_3_2"></a><a id="Tc_a_ilk9RHpk2wqsK030XTXw_3_5"></a><a id="Tc_0cMHykxBg0WriXsk36FuOw_4_0"></a><a id="Tc_M6SAKII0kkSfVGuTvaMjNw_5_0"></a><a id="Tc_CNcMmL0LckeXAx3vAvSS7g_5_2"></a><a id="Tc_pky8LmsXmkydKDh0RyQh3w_5_5"></a><a id="Tc_hfuH5QmSLEa581ECHt7s6w_6_0"></a><a id="Tc_nYcJQt_rEkCce5sa4stb8w_6_6"></a><a id="Tc_PSRhk3I7akybzR5mZ2ScRw_7_0"></a><a id="Tc_VhrWOan3xEegzt6QLHwgtg_8_0"></a><a id="Tc_QAMI8EmlUkKR-qzIwAPOKQ_9_0"></a><a id="Tc_JCbjBpHIN0yXDZnvP4X-iQ_10_0"></a><a id="Tc_G2bBusEWQkqL5xPJxQjGkg_11_0"></a><a id="Tc_UqpKP2i3gk6s1JFETvB26A_11_3"></a><a id="Tc_OMhcw-cz_EGt2xt5VqTgbw_12_0"></a><a id="Tc_uvMGC3etfU62fRTRpVV2aA_12_6"></a><a id="Tc_KCWoM_dvEkexQfczMKN5MQ_13_0"></a><a id="Tc_e-iLv1dLr0OsJrZx9OvW7A_13_6"></a><a id="Tc_ar9Z5eRZ0EuvXi-c34Q-mQ_14_0"></a><a id="Tc_iCZWDvLiBEmlV3RbI76DpA_14_6"></a><a id="Tc_g0hIMFsXR0mkSqX4iNWOHQ_15_0"></a><a id="Tc_wL1A6Q7n2UeVXzr_Xi6l5g_16_0"></a><a id="Tc_s38vereeAkuinMiNz1Xo5Q_17_0"></a><a id="Tc_pbSnB1MKpUe-_S5S65nAng_17_3"></a><a id="Tc_3yO5qaWyMUajiUF1IffS7w_17_6"></a><a id="Tc_cUvAt6snoE-J8datyfGkuA_18_0"></a><a id="Tc_iUPIb1D8gkWTsuGCMQza5g_19_0"></a><a id="Tc_iHtp-WSxpkiwl-z8p7F3Fw_20_0"></a><a id="Tc_H24QYuW-TkGKkX60lTOTFg_20_2"></a><a id="Tc_zF-i9vMoI0asoRuk_yAS8w_20_5"></a><a id="Tc_WDR4FQc6gEqjTZLmebWU_g_21_0"></a><a id="Tc_HzWVBpBZQ0afdmb3d_A1tQ_22_0"></a><a id="Tc_qz_4inIzvEOMm4aVkJzl9A_22_2"></a><a id="Tc_Jff0HGwT3Uik_j1Pg-COFw_22_5"></a><a id="Tc_R_vJ4Q83hUC4ZdE0MEDfBA_23_0"></a><a id="Tc_QPIxfML8jkmLGAjOyWgSEQ_24_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.0508957%;padding-left:0pt;padding-right:0pt;width:102.1%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_Lk_bWl8U8U-JncAtHY6wOg_5_3">2,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_dn9_iZVv5Ey6QqbpwBCkWQ_5_6">6,546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_t_CMIFXZw0GwgUgYcxib5A_6_3">8,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_8ucs3Pn-n0W1S6SMPApi9Q_7_3">8,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_0hVlkxQkCkupO40VozgKNQ_7_6">8,752</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_q74VALLGn0urKlNeOZ1-PA_8_3">19,628</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_rJ7g3Xs00Eev_aSAmGHNCw_8_6">15,298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_p_RjBn93-UO6wwmSveI_QQ_9_3">19,628</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_CZpXxUP3kkuUc8T9a5nYvg_9_6">15,298</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">     Interest income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="Tc_RsvQTKkG80eofFVZLqhQYQ_11_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">     Financing expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancingInterestExpense" scale="3" id="Tc_QK63HlahZUC6bo52SqK9aw_12_3">2,191</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">     Change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_QPPzKX9GQ0a-OkOkVHbMOw_13_3">7,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">     Other expense</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_K0D3zO5HMEWGcMMWfpW0QQ_14_3">83</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_ETOlzcsMpkOC1aaQJU8slw_15_3">5,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_ydomGoJWvke6DQWlghXanw_15_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_4up5ZepJeUiCAQz3gpqiPQ_16_3">13,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_leeTimUZqkGwxawTewDJvg_16_6">15,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision for income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_o97QUKXtKka_VmwFCt1R5g_18_3">13,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fgo0BXoYDk-AbYguYG8gsg_18_6">15,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other comprehensive loss, net of tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_2hW1FVDnYEOUDSaY8hMT0g_19_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" sign="-" scale="3" id="Tc_S5F9sz2ArUie8kb-fFWzcQ_19_6">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc__iXe-dP6pkOSD4AfqrXs7Q_20_3">13,971</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_SbU98wJAS0O_mtly1eDjJw_20_6">15,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss per share:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Net loss per share, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_pPBn0QhlTUaAqYsyn6MvdA_22_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_pPBn0QhlTUaAqYsyn6MvdA_22_3_2">5.43</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_iDzY4InrW0KqOM-oloJc1w_22_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_iDzY4InrW0KqOM-oloJc1w_22_6_2">19.81</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Weighted average shares of common stock outstanding:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_K9YCZIlJQkKCJ1YNiYPZxw_24_3"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_K9YCZIlJQkKCJ1YNiYPZxw_24_3_2">2,573,624</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_VKyMee-UBEa30qQiZwCM5A_24_6"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_VKyMee-UBEa30qQiZwCM5A_24_6_2">771,422</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">See accompanying notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d3248822_298a_44c0_8394_02f7cd8d426b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b></p><a id="EquityDeficit_89715"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Mezzanine Equity and Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_edf2d1b7_0117_4310_b5ca_1a5bf7856f76"></a><a id="Tc_NabERWwrn0iuac1HHzBM2A_1_16"></a><a id="Tc_rJGnRA4ROUqa_HnVUV0MzQ_1_20"></a><a id="Tc_ZiWNnhxbOUSYacuftpXE9w_2_1"></a><a id="Tc_67DsvXl7CESzIgvktQmCyw_2_6"></a><a id="Tc_MST9Esp6ZUimQAODWzMtTw_2_11"></a><a id="Tc_xrb0Acoh00eP985xunFpfw_2_16"></a><a id="Tc_9ZN1G5HBJEacCLmFTrO8EQ_2_20"></a><a id="Tc_Ri7YxR9aXUCdlmPpAcBQDg_2_22"></a><a id="Tc_KW4Afz56OkadQnv3ftxzzw_2_25"></a><a id="Tc_4LWHZysE7EeNWzfQTs8nhg_3_1"></a><a id="Tc_TRxUZ5BJakOF8EvyMz4zvg_3_3"></a><a id="Tc_Q0Lab-yEeEKK1DQdYsXgDQ_3_6"></a><a id="Tc_4kDbjfZ7qkmPUyORymPmQg_3_8"></a><a id="Tc_cQ_PDdO5EkO6jLwSrtnl2A_3_11"></a><a id="Tc_nRmkTTIjXk-Zf0cupE1bCg_3_13"></a><a id="Tc_Eku8YP3t30OnqH5ps7r6dQ_3_16"></a><a id="Tc_MF1IAmg9g0eCbbfK0h3_UQ_3_20"></a><a id="Tc_nD_FaKootESMltoWX4UZSQ_3_22"></a><a id="Tc_biM_mr1shkmw30JoZWDT2Q_3_25"></a><a id="Tc_tGKrGNlwN0KBiR3w4xOZXg_4_0"></a><a id="Tc_WCgb55u_QUSN6VHuiUcosQ_4_1"></a><a id="Tc__K_uUUTfdk2FMArLLTAqqg_4_3"></a><a id="Tc_g-ozZoclMUmNENuE8f-LOA_4_4"></a><a id="Tc_cZXgAgkBWUya498n2v3uJA_4_6"></a><a id="Tc_VPXvgRIKRkmSjb5-D6nQLw_4_8"></a><a id="Tc_u9vnw3M3ZEak6fYPmh2kTA_4_9"></a><a id="Tc_eo51hNDXrUSN41SvY06W7A_4_13"></a><a id="Tc_0WwFPbAf9EmrJUmjQNfBsw_4_16"></a><a id="Tc_9uPuse-giUqH0VzV_wvMmg_4_19"></a><a id="Tc_pVj97fCdA0CX2hUp43BOZA_4_22"></a><a id="Tc_uM76uwBkNEmSOQp_jJo-ww_4_25"></a><a id="Tc_vOWc4EoAPk225Blodqmncw_5_0"></a><a id="Tc_5atRV_WYjE2hPgRYwCmZLQ_5_1"></a><a id="Tc_tNtYnxK5bUqedY0GcnLLHA_5_4"></a><a id="Tc_edcHSE6Gj0OqSKoWeOsf8Q_5_6"></a><a id="Tc_qyMI-0lM5UijBpgW0QEpQg_5_9"></a><a id="Tc_UJ_rgxqzo06bc3YOBLRXgA_5_14"></a><a id="Tc_DgloVbLgxEyvF2a1xFUdbA_5_20"></a><a id="Tc_bMilIbWrl0m3gv0kDPy20g_5_23"></a><a id="Tc_-dNFEjpQo06za1KZdOKFLg_6_0"></a><a id="Tc_L5Ma_REYbUOkul3UhYJ8Ng_6_1"></a><a id="Tc_LjgdNo1CUkqfQL5_p9Zqqw_6_4"></a><a id="Tc_q6eZuO50TE2zs7JsHE72FA_6_6"></a><a id="Tc_CUWOgiRpKkiVNphpJj1GSw_6_9"></a><a id="Tc_BFDGrS4e9kmF72ZXTlmMew_6_11"></a><a id="Tc_7DF9awBVSUurAoHosLM1gw_6_14"></a><a id="Tc_13KPJXMCIUubWUpqcx8FmA_6_20"></a><a id="Tc_dtGsGULfxk2EUvPNwLbwuw_6_23"></a><a id="Tc_uT4aa9yiWk2LiHXjRHNCqQ_7_0"></a><a id="Tc_LTFDVp0be02vd-1ZGZhWhQ_7_1"></a><a id="Tc_mMXcG_pxREGBE3Bu6JEVJQ_7_4"></a><a id="Tc_y2EZLIHZf0muRi9LICGbAA_7_6"></a><a id="Tc_jNC1SuWRhkadLykJK4RJow_7_9"></a><a id="Tc_pQvlnaPXhkGwfmR8-gGSvA_7_14"></a><a id="Tc__uTBLo9wBk2IKu21yFtCgg_7_20"></a><a id="Tc_HpP82l0P8ESgJzp31MC7iQ_7_23"></a><a id="Tc_mHLjN4H3q06SX3lObze2cA_8_0"></a><a id="Tc_lMN1kPeCsEi80eCBFBpqkQ_8_1"></a><a id="Tc_YtqXRGn9Uk2uJf1weXmM6w_8_4"></a><a id="Tc_doneNUylikOCBWGM9H9weA_8_6"></a><a id="Tc_wIPzR1kK906c0sXSjXBaSA_8_9"></a><a id="Tc_VAPPhd743UWu0pkPtElQwg_8_11"></a><a id="Tc_UIjnn9zkfUaBKRZAXBEbUA_8_14"></a><a id="Tc_k49fEdKJcE2lO0sq4ZuMXw_8_20"></a><a id="Tc_adhD0arfBU6yzeBhDeVBJg_8_23"></a><a id="Tc_FLPps1q4I06E_c_EN74iiA_9_0"></a><a id="Tc_viDskP2AJkeq6EN7vNndJA_9_1"></a><a id="Tc_Pns1Ji3gHk2Uz5RoL_PtAA_9_4"></a><a id="Tc_TRAjnmnvoUWHb828ItRgHg_9_6"></a><a id="Tc_RcpNOTJKcE2-CC-hur2W5Q_9_9"></a><a id="Tc_MQcw6qL6K02O2MQq3ln1cA_9_11"></a><a id="Tc_1N_NMRIEqEuaeZDc6b_fwQ_9_14"></a><a id="Tc_eYSFj_W1z0ekx8M9AjLtDA_9_17"></a><a id="Tc_udU-QQL6d0CDVteBJxxYdA_9_23"></a><a id="Tc_tO5-qEyzwEmhQXTR9ZKcMQ_10_0"></a><a id="Tc_nRxlqlomG0OmTuP3y3M2Kg_10_1"></a><a id="Tc_GLFIQZqBVUmK_Z0btd4MBw_10_4"></a><a id="Tc_N7JEF4hvB02_TwPxtihqrQ_10_6"></a><a id="Tc_lqMLg_1EKkOMOrMMcfu-HA_10_9"></a><a id="Tc_sdSUfegDvEC3zACMLGlSjQ_10_11"></a><a id="Tc_bResfjSjCk-72hX0HU9MeQ_10_14"></a><a id="Tc_XFYiKpa59EisNlWOsTP8nw_10_17"></a><a id="Tc_vvtnkYUMfEGuG9_N1ASGkA_10_20"></a><a id="Tc_pSw3_GE7n0imkzoPBAwHlQ_11_0"></a><a id="Tc_hMh0yXM0s0-pbrLA_a7HQw_11_1"></a><a id="Tc_hmDJWWA3HUChRY9qpIS8GA_11_4"></a><a id="Tc__vyyMJfg3UKcFDP5j0WHkw_11_6"></a><a id="Tc_BO5ZGiOQN0SBSqF2gxIcAA_11_9"></a><a id="Tc_cJV_zQHPFkio34OUK46Kqw_12_0"></a><a id="Tc_d16GeBBwBE-u51VkSewZ4Q_12_6"></a><a id="Tc_yRDvxJ6O7EKpgFrH7hjEOw_12_9"></a><a id="Tc_LEDdYAxCAUWHvtSPUC-zIQ_12_11"></a><a id="Tc_tnI-3RhYvkWWtcsjdw0ICQ_12_14"></a><a id="Tc_bEeYw_x8wUiyG9-iieJQ-Q_12_17"></a><a id="Tc_i4pm5NV7BESvk46OyhcstQ_12_20"></a><a id="Tc_3HxxipJW50SyXhOG3Prkjw_12_23"></a><a id="Tc_h4Z2ndFOuEqPLcR6lFRCZQ_12_26"></a><a id="Tc_6hPrI18CjEOuOvuzTXtGDQ_13_0"></a><a id="Tc_BX1p1rjBJ0Sq4pEKUDyAjw_13_1"></a><a id="Tc_VWMX2UWJx0GHKnUggq1suQ_13_4"></a><a id="Tc_D62vHw2QYESO4yMeFy1EdA_13_20"></a><a id="Tc_dSNLT3dEb0W-cga6FwVJyw_13_23"></a><a id="Tc_Xt8uNjoWeEyDg6RDEbwZhQ_14_0"></a><a id="Tc_qWC55xhT0EGeOfmjeFrtXA_14_1"></a><a id="Tc_YrEoGqYrkk2IgDuPDaP5zQ_14_6"></a><a id="Tc_7Cp6J63rGUiUMm5W5QHHeQ_14_9"></a><a id="Tc_CgtAN8HtwEy4Vzo2xWS86w_14_11"></a><a id="Tc_EaGLn75_0EGPc4DhzuMSZQ_14_14"></a><a id="Tc_7fuThg6qpkOjvfVOcea1Aw_14_20"></a><a id="Tc_YkoFoCyzykahwmdfdeXQ_g_14_23"></a><a id="Tc_JKmn0Kwb6EqS6lkBbP76fQ_15_0"></a><a id="Tc_KeZzUMH2ekinv68_hqIX3g_15_6"></a><a id="Tc_Ht4V4NNyg0KaVuE-gNJPnA_15_9"></a><a id="Tc_HfUhm9sTSE6a5dorXpQjkg_15_20"></a><a id="Tc_N3d7NnJ2702ONlgcZnCwtg_15_23"></a><a id="Tc_sb0jozv1cUO2rnzaTR5zdA_16_0"></a><a id="Tc_bYA6l0DnP0SMCW4h0No-BA_16_1"></a><a id="Tc_zkv0gQkg60anLHHlPxRk4g_16_4"></a><a id="Tc_9vugokYgDkap4BtwfNRwXA_16_17"></a><a id="Tc_xhXtWE3y3kORhCt1VTknUg_16_20"></a><a id="Tc_zmQ6mgNwJ0uTHmGGzMR3UQ_16_23"></a><a id="Tc_--lm1tdJwUeOzrD3frzH6w_16_26"></a><a id="Tc_y8T5tdzZqkuFHkZULb1dIw_17_0"></a><a id="Tc_A1Iq8aLvX0WcfkxDjx3zjQ_17_1"></a><a id="Tc_V0C-gy-GTU-x8VQI-umzWg_17_4"></a><a id="Tc_hHMM_Dakykma9myjxEJ3LQ_17_6"></a><a id="Tc_M15f_-8IXUOPSJDgTMB1ww_17_9"></a><a id="Tc_GE5_KesXVEyy22GitqVESQ_17_20"></a><a id="Tc_XIch--SAyEW3ykDMRjbOUw_17_23"></a><a id="Tc_79SLAqeJ80--GulzaxUKGA_18_0"></a><a id="Tc_iVynkEd5zkyl9SAC24F5RQ_18_1"></a><a id="Tc_msXpI4r2EE6niPK4kjVLTw_18_4"></a><a id="Tc_zfjDfcJ9Jk2XmDIyhLAXIQ_18_6"></a><a id="Tc_2cxImZEqeUGzdtQ_gvxicg_18_9"></a><a id="Tc_0gEVbJ0uoUWAkokjJKZDKw_18_11"></a><a id="Tc_WdzK0h3d-keH3kLq-jku-g_18_14"></a><a id="Tc_Tvh9EeTP9Uq3_nttG0pghA_18_20"></a><a id="Tc_uQpoqqiaY0OYe97cdlZsrg_18_23"></a><a id="Tc_Hq8TQ8odHE-weQd9CN4W-g_19_0"></a><a id="Tc_A0cEIfSV7UiO5g82h30hxA_19_1"></a><a id="Tc_LXyIhc2WHU6fhuoZXJXzHw_19_4"></a><a id="Tc_b65yXIxQNkGrdWpybjBoOg_19_6"></a><a id="Tc_R0MLyax5Q0KyWrqzlxPgTQ_19_9"></a><a id="Tc_XrU5eqsK1kCJh6uxf0-q1Q_19_11"></a><a id="Tc__fv4xggzOkWAlhM0Zvg2SQ_19_14"></a><a id="Tc_C7_4GVV1OkuGZqtxd3AbJg_19_17"></a><a id="Tc_PllbfElR5k6lf-li14cvcQ_19_23"></a><a id="Tc_I4E5VC5J2Uq2_M0-iSYcDQ_20_0"></a><a id="Tc_Qwb5yZqtJ0e02Y8r-6lJvA_20_1"></a><a id="Tc_JYXwVpeNDEWJYsLN2_e0jg_20_4"></a><a id="Tc_1OGRzNXd9k-rM7u_JcIZyA_20_6"></a><a id="Tc_dFQ_FGZVhUuzicGlB6fL-A_20_9"></a><a id="Tc_CKVp5llnXEmHFKWsDPdu7w_20_11"></a><a id="Tc_VUNqAiHMJU2tRLQpH8Srtw_20_14"></a><a id="Tc_pgoUazfQVkig7a6o743sxA_20_20"></a><a id="Tc_56P2qYsoOU6Ykb8dcTfR5g_21_0"></a><a id="Tc_NfFreM2cpUiYwpIgFaMfkg_21_1"></a><a id="Tc_aelXPp9P_U2qx9A4BsEjQg_21_3"></a><a id="Tc_cxBGM2j77EKFc4rYiB4TnQ_21_4"></a><a id="Tc_Gy5RpUDBtEaYJtFY4yb7wA_21_6"></a><a id="Tc_VxWHzOMUw0KQldf38o8ZUg_21_8"></a><a id="Tc_ePDEWlQQIkO1_-y80nxXow_21_9"></a><a id="Tc_F--0RMpL60-1pIV2q_fwIw_21_13"></a><a id="Tc_uLuHfLYroEmliaEQdVXzFQ_21_16"></a><a id="Tc_HFNWYohAGUGO7c8H_bwJvA_21_19"></a><a id="Tc_92JJHYENA0yI2MPcRNSf-w_21_20"></a><a id="Tc_73emH23NQUGOXqt2CSbAmw_21_22"></a><a id="Tc_inWNJeTS8EmM9QU4cFAVjA_21_25"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid&#8211;In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.93%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:4.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Income </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Balance at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_oQsxMOsIMEadseCdFODckQ_4_11">655,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MoqIipQGn0um7V_KO5oInw_4_14">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8ETAng3t0SmxgpKoZ05kQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Ouy0EffzG02-qL2LVflNeA_4_17">73,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KMpsO1-fg0q_X-4JOdhaRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_flrxRGKnnEOS9Cucl8nYxA_4_20">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nZhvaiz6j0isSIkyaUH_sQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jxUIECMoEU-zTYHvNw8ljA_4_23">66,544</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2020_oDsSUJDF10mKNONqEZSMiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-wDECjaJTkWuEBgP0fm8pg_4_26">7,203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Issuance of common stock and warrants in connection with public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0frIUJR_I0OOFhGp2TsYXQ" decimals="INF" format="ixt:numdotdecimal" name="nrbo:StockAndWarrantsIssuedDuringPeriodShares" scale="0" id="Tc_6CoKet-RSEO378SDr7bMQA_5_11">226,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:StockAndWarrantsIssuedDuringPeriodValue" scale="3" id="Tc_6zFsYIP2nEW5cN23Agpxkw_5_17">24,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:StockAndWarrantsIssuedDuringPeriodValue" scale="3" id="Tc_N0-Jiu2PlkqWUKz6bGdKZw_5_26">24,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Transaction costs in connection with public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_h3Q9TjFNpUSRpW2XZoteIQ_6_17">2,089</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_x71GyVrgf0qWs7F_PRi0Rg_6_26">2,089</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0frIUJR_I0OOFhGp2TsYXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_zZPT5CC43U65IgdL8R4SWQ_7_11">6,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_D6vaefPEMkiQzS02SYMurA_7_17">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_qaa0fEDApU6lpa7nUZM2vQ_7_26">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Stock&#8211;based compensation&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_B49tyWgl506ej4tEfqgReg_8_17">662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MeZvoo_IyEWfv9Tavv1j4Q_8_26">662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52vJLxsaskuscStB9Hd_ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" sign="-" scale="3" id="Tc_EepdF6ya2kONQYUgJlgOLg_9_20">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" sign="-" scale="3" id="Tc_A8Ipi9qAI0mqV5xv54J8zA_9_26">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PGFeUl1eO06LDtIaMAVaQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oyWRNKYK10eN3gLIGLE2eg_10_23">15,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Ce5o7rqRgE2IP0gKA48rqQ_10_26">15,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Balance at December 31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zoF33XhQuUy-t80UIXPd1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_Vpai8Rht5k2q5w2KM7w9_g_11_11">888,693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zoF33XhQuUy-t80UIXPd1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ei4ZydJXJE-AnZ9yLmpjOQ_11_14">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JkKhTKgT3kS_VWrdj93liA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_oIfVAcCt8UKgV1nqKMdb4A_11_17">96,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UnyFFCsxtkO8kwOnTjAf6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UnhFFsg_8kiMxR2i7pBfww_11_20">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nvhHRqi-vkm9u_BWawKrYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_eown2grM4kufJvet47SZlw_11_23">81,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZoGRA5oDzky5VyoJrwpLLw_11_26">14,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Issuance of Series A Preferred Stock in Private Offering and License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_A4jJNd6yZEi4EpzdUzOidQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_x7TtBdv7-UaJRwGl0lut9A_12_1">3,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_A4jJNd6yZEi4EpzdUzOidQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Dqh30CLA_02UjG8JXiwPtg_12_4">10,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Issuance of common stock and Series B preferred stock in connection with public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FynBgB2tY0y-WXG6tBWeYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_vmmTXOYEjk-FoEx0-dGktg_13_6">2,602,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FynBgB2tY0y-WXG6tBWeYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_9tDUjCeJxESvxb9A9k_zbA_13_9">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6gHep_8RnUanvUH7fsIEMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_pQcN_oaXBkCZvsE6cLCRzA_13_11">3,147,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6gHep_8RnUanvUH7fsIEMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Qwcyyg-SGkSGHDGBaUT5tA_13_14">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vqWx7AJ5EU2oXUiFHiP21g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_DE9lbE4hO0-p68m0VUjEAQ_13_17">5,528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_PH52T1NMSkudkBlRsUiAzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_AvT4RzREQUSWa-G9k3Tasg_13_26">5,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Transaction costs in connection with private offering and public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_wXdU3UuUqkWf2PXspzjCuA_14_4">959</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_XZmJVGcLz0mn-1CzGAfvkg_14_17">499</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_mLVSVbD-KkuFSvXpKEBnmg_14_26">499</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Conversion of Series A preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w" decimals="INF" format="ixt:numdotdecimal" name="nrbo:StockConvertedDuringPeriodShares" sign="-" scale="0" id="Tc_J68AhHsaxEiSpYnb3uOJzw_15_1">3,700</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w" decimals="-3" format="ixt:numdotdecimal" name="nrbo:StockConvertedDuringPeriodValue" sign="-" scale="3" id="Tc_hYwFPopXckGerFmvXKm7mw_15_4">9,671</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVVU8h7siEiH2naixEFcfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_tbvQPqQibEagmuD_JuFThw_15_11">12,333,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVVU8h7siEiH2naixEFcfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_CWOlgbd0JECJ4aIZunqhVw_15_14">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2VyAR7dXg060hMZr4FuJGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_aze1RPo2mk22mgHVkf0XxA_15_17">9,659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ZNoLMPLiW0aszZnLPwlyiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_WEQC8iJSlU-wnFDPNyvIbg_15_26">9,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Conversion of Series B preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ulqJo4r_k0qlDZTa_a_Bxg" decimals="INF" format="ixt:numdotdecimal" name="nrbo:StockConvertedDuringPeriodShares" sign="-" scale="0" id="Tc_6gA3UEzuq0a0HRNXkD6TkQ_16_6">2,602,997</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ulqJo4r_k0qlDZTa_a_Bxg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:StockConvertedDuringPeriodValue" sign="-" scale="3" id="Tc_M78NgQgC_EKsLPa8ZzWT2g_16_9">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yUrtat3dg0uspmB84hfp8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_GvjSfN0UwECvu3rX7Z5oDg_16_11">2,602,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yUrtat3dg0uspmB84hfp8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc__u6akRUsV0adLVj2b9vAwQ_16_14">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Issuance of stock from exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_DFtfFcpfwUmL48PYQDiVYg_17_11">6,463,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_2eWu5DRjPkqK_mDX_RbVLQ_17_14">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_PrwwRM7QI0OE45-x2fJBWg_17_17">5,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_WHGc1k9yFE26icHtbeiBOg_17_26">5,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Stock&#8211;based compensation&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_yfgQyXgIskavOR41iX1u2w_18_17">854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_4JT5k-0WYkO-D0glFmBPSg_18_26">854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdL7c281rEWmqG_VeW3mHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" sign="-" scale="3" id="Tc_70Vk32U8V0WcXP3uGqWSdQ_19_20">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossRealized" sign="-" scale="3" id="Tc_lL4GAht7a0W3dbdSUbK2rw_19_26">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;background:#cceeff;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORlXGbVUk0-D7PGg_EkbSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ngMszh2hrUWgQBE_sIxbNg_20_23">13,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1ovvwmxAiEqT6Uh3tURTAQ_20_26">13,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.16%;border-bottom:3px double #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_UaXApegMn0OatWCqYsD3fg_21_11">25,436,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xxVtKH21EESjbk2jgR4a5Q_21_14">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6fVwVC7cn0mmYOxFysPq3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pt7_-FltxEeQFUaZkZsBDA_21_17">117,520</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wWZsd3T6gka9TSP8iKUvZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gOYHnuhUHkmQU0BT_a2guA_21_23">95,795</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1oGBrw4G3k6dgh8dSCmT6Q_21_26">21,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">See accompanying notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fef000c9_c223_465f_9ccc_6687b7681e64"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b></p><a id="StatementsofCashFlows_804215"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_05d98cad_97de_4cbb_bf77_626e53e4ba86"></a><a id="Tc_UToSaYpvPUu521ab9f1f9A_1_2"></a><a id="Tc_AeA7tRnr2kqW5-udNW4C5g_2_2"></a><a id="Tc_18xxQGELfUC5Rqae0nczHg_3_2"></a><a id="Tc_7LolQ-u220m8iPIZ_1CeQg_3_5"></a><a id="Tc_dPepl-mqDUC3Zq0dEdlzQg_4_0"></a><a id="Tc_bzLdWo3Ho0itn-iCAB-0hQ_5_0"></a><a id="Tc_4zWa8VLCgUmy9EZSvvigzQ_5_2"></a><a id="Tc_3aCUfVVXDE6hOx1lwBEBlg_5_5"></a><a id="Tc_qbzGjaVdAkusRzwuhQNnQg_6_0"></a><a id="Tc_bPbvkGqE2U6A_EE3i_Jz8w_7_0"></a><a id="Tc_n0nWz-D-OEmkycvC9uqiUw_8_0"></a><a id="Tc_4P3kxfmlQEeJM3sVmQU-sg_9_0"></a><a id="Tc_wIAx-6Mkg0i1oi0apUBf-Q_10_0"></a><a id="Tc_akihNRP2tUWLb5-sXVu6VA_10_6"></a><a id="Tc_DMoC2IRyrkeODTlhSUmZxg_11_0"></a><a id="Tc_OA2wJf4_YUGppcZ5VRWJNw_11_6"></a><a id="Tc_w6CcPXXLLE2TMf_fOEnT2Q_12_0"></a><a id="Tc_-R7KCPxwRk-pgrCviJMchA_12_6"></a><a id="Tc_4tG0whujG06DuN8oFn9VjQ_13_0"></a><a id="Tc_bQ-Xcumn5U6-12Zmglvwqg_13_6"></a><a id="Tc_bQ7j8bad00mBCVF6bC7pkA_14_0"></a><a id="Tc_tJLcdKMpI0WTz8mlr6Ps0A_15_0"></a><a id="Tc_p7abq_CgkEKopvYDeg-IZQ_16_0"></a><a id="Tc_3UuUOLjrpkeNB713xpYfug_17_0"></a><a id="Tc_e5DL-2OA-0SHELf6ywdVaw_18_0"></a><a id="Tc_xRc0rtjC3kKnocWEiGo8hg_19_0"></a><a id="Tc_b0uXVXphgEiRYlezumKEbA_20_0"></a><a id="Tc_fbEbkWdGo0amjJNBOqXuIQ_20_3"></a><a id="Tc_5a_pDCQqr0iOACX7djKurA_21_0"></a><a id="Tc_kaDvVsSmO0Ku0W4DvoPPnw_21_3"></a><a id="Tc_cGJ-vPCpHUqfqzvNjgd72w_22_0"></a><a id="Tc_yEqt7zOjakaCeYyGGWU9Yw_22_6"></a><a id="Tc_Vb2j5T7i8E6GdcPq7OhUzQ_23_0"></a><a id="Tc_WAb8g4Vi90i3PDCkBkaQxw_24_0"></a><a id="Tc_6AsDM2suFEKtQ7f3h_0pUw_25_0"></a><a id="Tc_Q1apdqPvKECcFKfDIgbJ0w_26_0"></a><a id="Tc_mJdZGZ7Ic0KWKDwGFp5PIQ_27_0"></a><a id="Tc_JD50ai7Tu02_Wc9zYURjDQ_27_3"></a><a id="Tc_k9yL0RVjL0OVyjPCqfUHKA_28_0"></a><a id="Tc_8EeQ_V5LhkOW4EQMdD0r-w_29_0"></a><a id="Tc_S_cHYk6t-0yRSGZBIV6f_A_30_0"></a><a id="Tc_vPqGQMcm00u2_kPlwyDBGQ_30_3"></a><a id="Tc_INODzV0qIUCxEFUGdOgZ5g_31_0"></a><a id="Tc_uhzYC6vN60CjWtDS5wBL4Q_32_0"></a><a id="Tc_qZCbST-HF0eB5zjDnLOFDQ_32_2"></a><a id="Tc_B5-m-Rwwdkiy6F4LNC5Wsw_32_5"></a><a id="Tc_nNPWuWY-bU2Yhn8JK9d3iQ_33_0"></a><a id="Tc_wkGKAX6a6kS3HXzpcudyvA_34_0"></a><a id="Tc_DYTmStykV0i08lIVEdi3kQ_34_2"></a><a id="Tc_BOzQ-MiXs0GWC0fh39hFMw_34_5"></a><a id="Tc_1D21XwmcSEqE4Np-JwiQyA_34_6"></a><a id="Tc_Pj-Jo71ZYUeDmtmkk-KX3A_35_0"></a><a id="Tc_FZmwUTNbvkSEjab1f0oYcw_35_2"></a><a id="Tc_dmIYyZ9-vUKPQnJNJbIRgQ_35_5"></a><a id="Tc_NPtBM_zgy0uPO7KjHRZeGw_35_6"></a><a id="Tc_oKIA4ZxUG0O9ClCcBRsbGA_36_0"></a><a id="Tc_ZHLSIrPCkUy9fZXddiK5DQ_36_2"></a><a id="Tc_yU47nMg2x0m69iSZSoGeEA_36_5"></a><a id="Tc_ndmtl6Dgp0O4hZGKR1lC-A_36_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:25.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year Ended </b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:25.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8Hnmewc6tkyGL-NNwJP-Hw_5_3">13,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6FV5-pzlxEmCJ7FuH86s8Q_5_6">15,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_19G9Tfnl_EqOZH_MkY_9Cg_7_3">854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_M1KgxkxnPUqWkIolnfrJ6g_7_6">662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:IncreaseDecreaseInNonCashLeaseExpense" scale="3" id="Tc_Vv0YsyTg00m34byx2K4d5w_8_3">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:IncreaseDecreaseInNonCashLeaseExpense" scale="3" id="Tc_blxvvtwk80m6RLVEgBsiMg_8_6">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_9IUCOIkEJkS1V3WDeBbq7A_9_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_79XJPlRBFEqH8d5CbM57hg_9_6">48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Loss on sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_H4qaGbnw8UOV1aEnh-9ILg_10_3">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_KhcCHfem0Eamr8zFCvxKPg_11_3">8,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Transaction costs allocated to issuance of warrants</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancingInterestExpense" scale="3" id="Tc_9HRqoXzn00SDmzSHXsgdhA_12_3">2,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="3" id="Tc_bDJ_qaxPME2eiNnm7nx5uA_13_3">7,935</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Change in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:IncreaseDecreaseInPrepaidExpensesAndDeposits" sign="-" scale="3" id="Tc_oq3odrUhlkGEccUM7Vl3dg_15_3">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:IncreaseDecreaseInPrepaidExpensesAndDeposits" sign="-" scale="3" id="Tc_EogNIXTicEmTZhxm9qiO5g_15_6">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_6TKN5k3MVEGH5fbTzY4IAg_16_3">202</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_5JUljLBygUWUzNLcsK9Dgg_16_6">1,162</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Accrued and other liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_rqxxACtRA0CQ1pT1drlL_Q_17_3">1,030</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_vnkxoIISb0a3Y8Zpo_zWbA_17_6">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_6j58p4n1NUSIY3zYACOopw_18_3">11,712</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_7MC7hVyIkk2VkEdIpFUS4g_18_6">15,134</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction costs in connection with asset acquisitions</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:PaymentsForTransactionCostsInConnectionWithMerger" scale="3" id="Tc_E17anDgBgUWQEaw7UIyFQg_20_6">583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_FtFFhfApD0qvlQ9QmCy_CQ_21_6">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_1mbsICx72Em4EW77n3J5NA_22_3">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_3vOHdUffx0SW-QWEdWlJQQ_23_3">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_IqQNSthVV0OOErRFJQEYAw_23_6">586</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from issuance of common shares, preferred shares and warrants</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="Tc_JnksoL0ALkWHbNxwqMlaZQ_25_3">32,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" id="Tc_pZN-EpiIKUGgqe7gHkqcAg_25_6">24,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payment of issuance costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc_k7dpi1nxD0m2w7WiSrAXuw_26_3">3,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="Tc__D9RKnWfMUOfUjmvYgfG6w_26_6">2,089</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_bRWYaqiVck2P5eS33pMdSw_27_6">115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Tc1TZsZOOU2lHGOSAJ-OWg_28_3">28,681</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_XeRVbvlf-0efyshEaKd9eA_28_6">22,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net increase in cash</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_wkHuj6UB_kan2vtE4YMN5Q_29_3">16,977</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_Qxd-XkvgfE6F6vtRm-qraw_29_6">6,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net foreign exchange difference</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" sign="-" scale="3" id="Tc_5LfEMPhvDE-Dus8OFAJF1w_30_6">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash at beginning of period</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_zJTyFIHE8ka_SmtII9fANQ_31_3">16,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2020_oDsSUJDF10mKNONqEZSMiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_fG6fFiIuaU6zHsbvwt00XA_31_6">10,089</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cash at end of period</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_H8LXjdXgdkeYGIBDfa4FQA_32_3">33,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_GQHgjEHTtkGGos3ltGcKwg_32_6">16,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Supplemental non-cash investing and financing transactions:</i></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Modification of right-of-use asset and associated lease liability</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:ModificationOfRightOfUseAssetAndAssociatedLeaseLiability" scale="3" id="Tc_MLjz68aE8E6AQnU30As4bQ_34_3">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Unpaid issuance costs</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredIssuanceCostsIncurredButNotYetPaid" scale="3" id="Tc_c1K9jSHBw0WoLFjXGpaTdA_35_3">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclass of warrant liabilities upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.94%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_H_WtaO3ghkWyhma6trABiQ_36_3">5,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.52%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">See accompanying notes.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a><span style="color:#0563c1;"> </span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b></p><a id="NotestoConsolidatedFinancialStatements_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_JnvjZytft0CGsZDv8-kPHA" continuedAt="Tb_JnvjZytft0CGsZDv8-kPHA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. The Company and Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">NeuroBo Pharmaceuticals,&#160;Inc. (together with its subsidiaries, the &#8220;Company&#8221; or &#8220;NeuroBo&#8221;), is a clinical-stage biotechnology company with two primary programs focused on treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;) obesity, and type 2 diabetes (&#8220;T2D&#8221;):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">DA-1241</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D. We intend to initiate a Phase 2a study with the goal of establishing efficacy of DA-1241 in NASH and T2D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">DA-1726</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> is a novel oxyntomodulin (&#8220;OXM&#8221;) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity, that is to be administered once weekly subcutaneously. DA-1726 as a dual agonist of GLP-1 receptors (&#8220;GLP1R&#8221;) and glucagon receptors (&#8220;GCGR&#8221;), leading to weight loss through reduced appetite and increased energy expenditure. We intend to advance DA-1726 through Investigational New Drug application and initiation of human clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The Company had previously focused its efforts on four therapeutic programs: ANA001, NB-01, NB-02 and gemcabene.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company&#8217;s operations have consisted principally of performing research and development activities, clinical development and raising capital. The Company&#39;s activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation and consolidation principles</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The consolidated financial statements of the Company include a South Korean subsidiary, NeuroBo Co.,&#160;Ltd., which is fully owned by the Company. All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The Company&#8217;s Board of Directors approved a <span style="-sec-ix-hidden:Hidden_-c2kEXqIKUut8eHDA86q6w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-thirty</span></span> reverse stock split of the Company&#8217;s issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on September 12, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">All issued and outstanding common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result of the Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company&#8217;s common stock as reported on Nasdaq on the last trading day before the Reverse Stock Split becomes effective (on a split-adjusted basis). The authorized shares and par value per share of the common stock and preferred stock were not adjusted as a result of the Reverse Stock Split.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_JnvjZytft0CGsZDv8-kPHA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">From its inception through December 31, 2022, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#39;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#39;s cost structure. The Company has experienced net losses and negative cash flows from operating activities since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_HJX8wfFLakmp5mvjrF_LLg">95.8</ix:nonFraction>&#160;<span style="white-space:pre-wrap;">million as of December 31, 2022.  These conditions previously raised substantial doubt about the Company&#39;s ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">To date, the Company has raised capital principally through private placements and public offerings of convertible preferred stock, common stock and warrants The Company will need to continue to raise a substantial amount of funds until it is able to generate revenues to fund its development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2022, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_XpetaFvCi0WpxQp2clkI9w">33.4</ix:nonFraction><span style="white-space:pre-wrap;"> million in cash.  The Company believes that its existing cash will be sufficient to fund its operations for at least the next 12 months from the date these financial statements are issued.  The Company will need to continue to raise additional funds until it is able to generate sufficient revenues to fund its development activities.  The Company&#8217;s future operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to predict the ultimate outcome of these actions to generate the liquidity ultimately required.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_IizN8pyp_U-f9Z3g8o386w" continuedAt="Tb_IizN8pyp_U-f9Z3g8o386w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b>&#160;</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:UseOfEstimates" id="Tb_IoDxrmBoS0yabipnmawzMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company&#39;s consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_CrjceC8EykSJ_i1eyEr50w" continuedAt="Tb_CrjceC8EykSJ_i1eyEr50w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is principally held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of December 31, 2022, the Company had deposits in excess of federally insured amounts by $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:DepositsInExcessOfFederallyInsuredAmounts" scale="6" id="Narr_8E9g8QnjikGreO_F5BtZUA">32.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Supplier Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">On September 14, 2022, the Company entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) with Dong-A ST Co., Ltd. (&#8220;Dong-A&#8221;), which requires Dong-A to be the sole manufacturer for the production of DA-1241 and DA-1726.  </span>If any issues arise in the manufacturing and the Company is unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, the Company may not be able to complete development of DA-1241 or DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_IizN8pyp_U-f9Z3g8o386w_cont1" continuedAt="Tb_IizN8pyp_U-f9Z3g8o386w_cont2"><ix:continuation id="Tb_CrjceC8EykSJ_i1eyEr50w_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_9pA-B9FN2k-sra9yUEpIYQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. <span style="white-space:pre-wrap;background:#ffffff;">The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.  </span>See Note 10 - <i style="font-style:italic;">Fair Value Measurements</i>.  <span style="white-space:pre-wrap;background:#ffffff;">  </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="nrbo:WarrantLiabilitiesPolicyPolicyTextBlock" id="Tb_bjoSxBc4wU6sPeXdtTkSnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The Company accounts for its warrants as liabilities at fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities are recognized as a fair value change in warrant liabilities in the consolidated statements of operations and comprehensive loss and as an operating item in the statement of cash flows.<span style="font-size:12pt;"> &#160;</span>Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations and comprehensive loss. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Tb_pVn48ZQ-AU2o1nzMuYnNPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_R1rMsvvrdUyg5-uv-iVPMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, <i style="font-style:italic;">Research and Development</i>. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_LG2-JutxDUeaO0wTnGkpiA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company includes costs to acquire or in-license product candidates in acquired in-process research and development expenses (&#8220;IPR&amp;D&#8221;). When the Company acquires the right to develop and commercialize a new product candidate, any up-front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as acquired in-process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_4km4clayQEC-95o8O-rr1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company utilizes the liability method of accounting for income taxes as required by ASC 740, <i style="font-style:italic;">Income Taxes</i>. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_sQaZiQacBkKsl6cMAAcYNw">no</ix:nonFraction> provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_IizN8pyp_U-f9Z3g8o386w_cont2" continuedAt="Tb_IizN8pyp_U-f9Z3g8o386w_cont3"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_jYWkeS6As06vyS2sa-bWTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#160;&#8212; Stock Compensation</i> (&#8220;ASC 718&#8221;). Accordingly, compensation costs related to equity instruments granted are recognized at the grant-date fair value. The Company records forfeitures when they occur. Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718 using a grant date fair value approach. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_6ky9GrjDW0W6LrOPeliHFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company accounts for leases under Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;<i style="font-style:italic;">Leases</i> (Topic 842)&#160;(&#8220;ASU 2016-02&#8221;). The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company has recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company&#8217;s&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, the Company recognizes lease payments as an expense on a straight-line basis over the remaining lease term.&#160;</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_HMK3WSWSgEWZeZlubzHn8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property&#160;and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from <span style="-sec-ix-hidden:Hidden_FyBBTxlXGEGwh1t7bmaxpQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_AmXET-JeS0ut_dApyT2Ijg">five years</ix:nonNumeric>. Tangible assets acquired for research and development activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_Jl79RsaXskGVQ-V24JfElw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Currency Translation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">The foreign subsidiary uses the South Korean Won (KRW) as its functional currency. The Company translates the assets and liabilities of its foreign operation into U.S. dollars based on the rates of exchange in effect as of the transaction date. The resulting adjustments from the translation process are included in accumulated other comprehensive (loss) income in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Certain transactions of the Company are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="nrbo:PatentCostPolicyPolicyTextBlock" id="Tb_aANCcpDWj0iO3kU5eUetWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patent Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:StockholdersEquityPolicyTextBlock" id="Tb_OydeF6YWok2ephOv01DLJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Comprehensive loss is comprised of net loss and other comprehensive income or loss. Comprehensive loss includes net loss as well as other changes in stockholders&#39; equity that result from transactions and economic events other than those with stockholders. Comprehensive loss currently consists of net loss and changes in foreign currency translation adjustments.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_IizN8pyp_U-f9Z3g8o386w_cont3"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_VgBQ9J2gtUeun8NKGNZP0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_vhBxOMRVzkikLm5iLTAdhA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_h9yS8xioLEGHkGVswyDifQ">one</ix:nonFraction> operating segment, which is principally the business of development and commercialization of therapeutics.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_pZPZsTlK_kSOHQfETARt_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&quot;FASB&quot;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background:#ffffff;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="font-style:italic;">&#8220;Financial Instruments &#8211; Credit Losses&#8221;</i>. The ASU sets forth a &#8220;current expected credit loss&#8221; (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for calendar year 2023 for smaller reporting companies. The Company adopted this new guidance on January 1, 2023, and the adoption did not have a material impact on the Company&#39;s consolidated financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_C2stE3lTb0Oq8NXUEk20Lg_2_2"></a><a id="Tc_MiNs6uFGAU2LVkwBUuqOzw_2_6"></a><a id="Tc_HHvgxxspd02VV0-KB12aCQ_3_2"></a><a id="Tc_ee52CJIns0iOP1t0SWadYw_3_6"></a><a id="Tc_3cNM7K6jmUi8HoW-kxbBdQ_4_0"></a><a id="Tc_mJHCm4eCP0u2uUoT33pyEw_4_2"></a><a id="Tc_cOACuaxtJEyzKZ_8z6LpLg_4_3"></a><a id="Tc_4TVT567brkKO6Ln0l9nQdA_4_6"></a><a id="Tc_Fm3n1vC4eESeeyu_Zv2lNg_5_0"></a><a id="Tc_IdyvuNdQVE67tegGkvc3EQ_6_0"></a><a id="Tc_RZcAPTKnJkasvR0Hscp3gQ_7_0"></a><a id="Tc_iqvT5HcjmkapUZDJWSUIJA_8_0"></a><a id="Tc_RI2jNoWTFEerJq2c6HM2tQ_8_2"></a><a id="Tc_XBEtwg_67kOV3xAMfCBRlQ_8_6"></a><a id="Tc_H4QKOe3lzUumgZpFRmR5Vw_1_2"></a><a id="Tc_O9Me8xV_00S-RZEEFnwJYw_1_5"></a><a id="Tc_ztsgf6-OYU-vLpSaW_tAiw_2_2"></a><a id="Tc_Y39GQ_3mWUyJeJ2RMuyfMQ_2_5"></a><a id="Tc_pFar-MULHEOY_CY9qRopGQ_3_0"></a><a id="Tc_zGaAIbajjkW5iseSZEZWYQ_3_2"></a><a id="Tc__bsgKIr97U2JPPOFOOZbiQ_3_5"></a><a id="Tc_KsjYDphIZ0eMGbNiuoAB1w_4_0"></a><a id="Tc_e_HpQL2rqU2EzWLzb47_dQ_5_0"></a><a id="Tc_ZYZ3cYfdU0yrTeACQBEjXg_6_0"></a><a id="Tc_251qDGrBVkG939ndPU9_fg_7_0"></a><a id="Tc_0VZ_Ryu4d0-ipwqGmHteFg_7_2"></a><a id="Tc_p-LW2prVKkOnkq8RH04OHw_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_t_NiDLleyUuAr7HoLgA8Ag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Balance Sheet Detail</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Property and Equipment </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_OqQr55DIYk-aI3FvNjldRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Research and development equipment</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember_Ysy_oDW2ZUuQshWJ1usWfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_tr3gTmUn8kKTXM0y9UxwFA_4_7">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_kj6tzIw4ikOotzAukBfIhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_TkD7P7kLI06I_QH9VZpisw_5_3">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_szvp0G-HgE6LH9q1BEd5Rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_KDu-eL9fskm69i9i4rDK5Q_5_7">63</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_OwiujHtbIEGYwT4L7Th9Iw_6_3">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_46OmWqVikESSK8qJZPq3uw_6_7">221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_QgoKIelLW0Opjv08zTjz3A_7_3">28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_VZVciykDQUamdIQ1pQ6Gpg_7_7">111</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_AaA4V3kwKUG2nkYwh836IA_8_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_14vhtntuLU-AZ1oVRpLeRQ_8_7">110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accrued liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Accrued liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_qUDcTTm5sUKnMshTfJfQZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">External research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="nrbo:AccruedOtherResearchAndDevelopmentExpenses" scale="3" id="Tc_TvTlgllF9k-UIzwkl8nPHg_3_3">109</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:AccruedOtherResearchAndDevelopmentExpenses" scale="3" id="Tc_aKDzBeuCHE2aw_OrAdpVdA_3_6">854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payroll related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_vke0Kyc3tECP-GBAmTt-8A_4_3">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_CLOGV3z-PkmLXVXzxGeG7g_4_6">376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_jhrOPzVamkmn6OtrB_UDjw_5_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_HjgQDq2WgkafioWwWsqwdw_5_6">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_g5hnewTyM0iP8kvYk7UcgA_6_3">48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_HqRaLR2u40KeW6LHXzdShg_6_6">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_5CAg3D3fKEy__OUnvnJ3AQ_7_3">280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_e8ZajqN-B0yGa5WiOQjgzA_7_6">1,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_QD_ZMRqNa0i00DLnbyGboA" continuedAt="Tb_QD_ZMRqNa0i00DLnbyGboA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Boston Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective August 1, 2021, the Company entered into a non-cancelable operating lease for its corporate headquarters located in Boston Massachusetts. This agreement had a <ix:nonNumeric contextRef="As_Of_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_GR9OQ9E5cEGdGSBaKaofsQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_-7d4Iz0WKE6L8YrV5jl0WQ">six month</ix:nonNumeric> term, and rental costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_5_14_2021_To_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_88MmA4GQEU6X2lD11RT57A" decimals="-3" format="ixt:numdotdecimal" name="nrbo:LesseeMonthlyOperatingLeaseCost" scale="3" id="Narr_rSWj5-iV406WyNOhBbM2qw">3</ix:nonFraction> per month prior to the application of certain rent concessions granted by the landlord in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_GR9OQ9E5cEGdGSBaKaofsQ" decimals="-3" format="ixt:numdotdecimal" name="nrbo:LesseeOperatingLeaseIncentiveFromLessor" scale="3" id="Narr_gQalBABSAkyU7YIPXAoq2g">2</ix:nonFraction><span style="white-space:pre-wrap;"> over the term of the lease.  </span>In December 2021, the Company signed an amendment to its corporate headquarters lease to extend the term until March 31, 2022 for rental costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_qsxaSWG__EyTOF1yU2Gswg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:LesseeMonthlyOperatingLeaseCost" scale="3" id="Narr_1CFtV3tDQEOeWfr34q4lJQ">1</ix:nonFraction><span style="white-space:pre-wrap;"> per month.  In February 2022, April 2022, August, 2022 and December, 2022 the Company signed amendments to extend the lease term until June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prior to February 1, 2021, a non-cancelable operating lease was in effect as of February 1, 2020 which had a <ix:nonNumeric contextRef="As_Of_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_HhypM8orekaUV3ZSz7r8gQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_RS24lPKr_EOrhEw6DDMhrQ">one-year</ix:nonNumeric> term and rental costs of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_2_1_2020_To_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_bI49wt-rv06inimFCn-hbg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:LesseeMonthlyOperatingLeaseCost" scale="3" id="Narr_9vjqcl7qoUGtwwUBWvyccw">21</ix:nonFraction> per month prior to the application of certain rent concessions granted by the landlord in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_HhypM8orekaUV3ZSz7r8gQ" decimals="-3" format="ixt:numdotdecimal" name="nrbo:LesseeOperatingLeaseIncentiveFromLessor" scale="3" id="Narr_TNUdwz8a-U2NsigQZOld-A">32</ix:nonFraction>. Effective February 1, 2021, the Company was party to a non-cancelable operating lease for its corporate headquarters which had a <ix:nonNumeric contextRef="As_Of_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_DMIjvwYsPkGpJljUcZUhyA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_h0Pi7nYRs0GV0bHZKCwoLA">six month</ix:nonNumeric> term, and rental costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_-Qb32V34hEG7LHl67hYHEQ" decimals="-3" format="ixt:numdotdecimal" name="nrbo:LesseeMonthlyOperatingLeaseCost" scale="3" id="Narr_PI22TSVt5kCeAu6ZvDXrag">3</ix:nonFraction> per month prior to the application of certain rent concessions granted by the landlord in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_DMIjvwYsPkGpJljUcZUhyA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:LesseeOperatingLeaseIncentiveFromLessor" scale="3" id="Narr_5FBlfzlekU2YU5YF6qhy0Q">1</ix:nonFraction> over the term of the lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_JfiOhNhM4kq-BfVEu0LZXA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Narr_xVxlzYFxUkuC122xUSG49Q">No</ix:nonFraction> assets and liabilities were recognized for the corporate headquarters leases at December 31, 2022 and 2021. Due to the short-term nature of the leases, the Company recognized lease payments as an expense on a straight-line basis over the remaining lease term. For the years ended December 31, 2022 and 2021, expense under the corporate headquarters leases in the aggregate was $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember__f5vapaPiE6z4tp3rFwAtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_mz8Gv3sNOkSTtLAXBwsh0A">16</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_FGRQQlyE-kqOj-HImH6Z9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="Narr_yZHJxB0SVkmEHVZL8y4K3Q">48</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Lease in Korea:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In May 2019, the Company entered into an operating lease for its new facility in Korea (the &#8220;Korea Lease&#8221;). The initial lease term was </span><ix:nonNumeric contextRef="As_Of_5_31_2019_srt_StatementGeographicalAxis_country_KR_HvV-4l0BaEGxJ9yVDcToOA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_sFIz-E_Nk0uk6VLYK28bDw"><span style="font-size:10pt;">five years</span></ix:nonNumeric><span style="font-size:10pt;"> </span><ix:nonNumeric contextRef="Duration_5_1_2019_To_5_31_2019_srt_StatementGeographicalAxis_country_KR_4xOvJGybuEay2f4Kwe1YKA" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_htRqECv_OUuiboB1NRyuFw"><span style="font-size:10pt;">with an option to renew</span></ix:nonNumeric><span style="font-size:10pt;"> for an additional </span><ix:nonNumeric contextRef="As_Of_5_31_2019_srt_StatementGeographicalAxis_country_KR_HvV-4l0BaEGxJ9yVDcToOA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_t0AnfF3mMUGbZHjjYKAL9g"><span style="font-size:10pt;">five-year</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> term. The lease commenced on July 2, 2019 and was to expire on July 1, 2024.  On April 19, 2022, the Company terminated its Korea Lease effective April 30, 2022, at which time, the Company&#8217;s unamortized right-of-use asset and lease liabilities were fully amortized and extinguished with </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_4_30_2022_To_4_30_2022_srt_StatementGeographicalAxis_country_KR_YsKsKamLv0yflBeWRDvO7w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="Narr_mbW6ATt-r0O6Sf6-C4puZA">no</ix:nonFraction></span><span style="font-size:10pt;"> gain or loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The operating lease was subject to a deposit, base rent payments and additional charges for utilities and other common costs. For the years ended December 31, 2022 and 2021, the Company recorded non-cash expense of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_KR_YvToqRmZfUCr2F12W7LUeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Narr_ee-yvAx68UeekGLARBP-0w">8</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_KR_G_Rp8jJUYUWnai9tqLfSSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Narr_JTQnxdgEAkKvlcRNLH5KUA">24</ix:nonFraction>, respectively, related to the Korea Lease. During the year ended December 31, 2022 and 2021, the Company made cash payments of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_KR_YvToqRmZfUCr2F12W7LUeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Narr_1dMHO3cSV02A5-P_0dn0FA">11</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_KR_G_Rp8jJUYUWnai9tqLfSSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Narr_qYc-ezQmCU2ufvddvt-giA">32</ix:nonFraction>, for amounts included in the measurement of lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Dong-A ST</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">On September 14, 2022, the Company and Dong-A, a related party, and greater than 5% shareholder, entered into the 2022 License Agreement, pursuant to which, subject to the conditions set forth therein, the Company ultimately received an exclusive global license (other than in the Republic of Korea) to <ix:nonFraction unitRef="Unit_Standard_item_BbpdEDrZSk2GQqI08hy64Q" contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_LicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_6hrwWyQFkkGHl0B3-Pe0ug" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" scale="0" id="Narr_JeYm0CCyTUOdGRjKiMGIWw">two</ix:nonFraction> proprietary compounds for specified indications. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. Under the 2022 License Agreement, Dong-A will be eligible to receive (i) regulatory milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1726Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_QniKuwjxwU-VAVU5AQO_tA" decimals="-6" format="ixt:numdotdecimal" name="nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" scale="6" id="Narr_qBQu3dkFA0mC5g5hhD2rqg">178</ix:nonFraction> million for DA-1726 and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1241Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_3M2K_Hs1_kGIY2eTUaM2fA" decimals="-6" format="ixt:numdotdecimal" name="nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" scale="6" id="Narr_oCCywoO-r0OqtoWJQT3hRQ">138</ix:nonFraction> million for DA-1241, dependent upon the achievement of specific regulatory developments; (ii) commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iii)&#160;single digit royalties on net sales received by the Company from the commercial sale of products covering DA-1241 or DA-1726. See Note 5, <i style="font-style:italic;">2022 License Agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt-sec:numwordsen" name="nrbo:MilestonesAccrued" scale="3" id="Narr_9TDDgv5xb0Sb-FhzIObQUg">no</ix:nonFraction> milestone or royalty payments had been accrued as there were no potential milestones yet considered probable.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_QD_ZMRqNa0i00DLnbyGboA_cont1" continuedAt="Tb_QD_ZMRqNa0i00DLnbyGboA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gemphire Contingent Value Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">On December 30, 2019, the Company was party to a definitive merger agreement (the &#8220;2019 Merger&#8221;) with Gemphire Therapeutics, Inc. (&#8220;Gemphire&#8221;). In connection with the 2019 Merger, Gemphire entered into the Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with Grand Rapids Holders&#8217; Representative, LLC, as representative of Gemphire&#8217;s stockholders prior to the 2019 Merger (the &#8220;Holders&#8217; Representative&#8221;), and Computershare Inc. and Computershare Trust Company, N.A. as the rights agents (collectively, the &#8220;Rights Agent&#8221;). Under the CVR Agreement, which NeuroBo assumed in connection with the 2019 Merger, the holders of Gemphire shares at the time of the 2019 Merger (collectively, the &#8220;CVR Holders&#8221;) were entitled to receive <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_30_2019_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_oIsPvJwajkGM38Ex40BY6A" decimals="2" format="ixt:numdotdecimal" name="nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights" scale="-2" id="Narr_spXdSk-whU2ZrhHhWobMDQ">80</ix:nonFraction>% of the proceeds from the grant, sale, or transfer of rights to Gemcabene.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">On March 23, 2021, NeuroBo, the Holders&#8217; Representative, and the Rights Agent entered into the First Amendment to Contingent Value Rights Agreement (the &#8220;CVR Amendment&#8221;) to amend the CVR Agreement. Pursuant to the CVR Amendment, (i) the CVR Holders will continue to have the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_30_2019_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_oIsPvJwajkGM38Ex40BY6A" decimals="2" format="ixt:numdotdecimal" name="nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights" scale="-2" id="Narr_gdx7LNn4UUu3CeEJAU-uGw">80</ix:nonFraction>% of the proceeds from the grant, sale, or transfer of rights to Gemcabene as a treatment for cardiovascular conditions and (ii) the CVR Holders will now also receive <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_3_23_2021_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_GAKGJeHh6UuULfG-TYy7pg" decimals="2" format="ixt:numdotdecimal" name="nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights" scale="-2" id="Narr_REv8bO3fA06lzlGPyMVKVw">10</ix:nonFraction>% of the proceeds from the grant, sale, or transfer of rights to Gemcabene as a treatment for any indication outside of treating cardiometabolic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">As of the December 31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_htnX0uXa7kCB-UHSuxbNSA" decimals="-3" format="ixt-sec:numwordsen" name="nrbo:MilestonesAccrued" scale="3" id="Narr_oGj255NLjUK5JH2kNe0KVg">no</ix:nonFraction> milestones had been accrued as there were no potential payments under the CVR Agreement or the CVR Amendment that were yet considered probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pfizer License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Upon the close of the 2019 Merger, the exclusive license agreement with Pfizer&#160;Inc. (&#8220;Pfizer&#8221;) for the clinical product candidate Gemcabene (the &#8220;Pfizer Agreement&#8221;) was assumed by the Company. Under the Pfizer Agreement, in exchange for this worldwide exclusive right and license to certain patent rights to make, use, sell, offer for sale and import the clinical product Gemcabene, the Company has agreed to certain milestone and royalty payments on future sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company agreed to make milestone payments totaling up to $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OkcQ-fcFaECmAneltF__OA" decimals="-6" format="ixt:numdotdecimal" name="nrbo:ContingentLiability" scale="6" id="Narr_8jVBpfzYo0GFx3oLyqJAgw">37</ix:nonFraction>&#160;million upon the achievement of certain milestones, including the first new drug application (or its foreign equivalent) in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of Gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales, as specified in the Pfizer Agreement, until the later of: (a) <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ" name="nrbo:NumberOfYearsAfterFirstSaleOccurs" id="Narr_vU1SOKR1UkC0Z_G19gTP4w">five</ix:nonNumeric> (5) years after the first commercial sale in such country; (b) the expiration of all regulatory or data exclusivity for Gemcabene in such country; and (c) the expiration or abandonment of the last valid claim of the licensed patents, including any patent term extensions or supplemental protection certificates in such country (collectively, the Royalty Term). Under the Pfizer Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize Gemcabene.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Pfizer Agreement will expire upon expiration of the Royalty Term. On expiration (but not earlier termination), the Company will have a perpetual, exclusive, fully paid-up, royalty-free license under the licensed patent rights and related data to make, use, develop, commercialize, import and otherwise exploit the clinical product candidate Gemcabene. Either party may terminate the Pfizer Agreement for the other party&#8217;s material breach following a cure period or immediately upon certain insolvency events relating to the other party. Pfizer may immediately terminate the Pfizer Agreement in the event that (i) the Company or any of its affiliates or sublicenses contests or challenges, or supports or assists any third party to contest or challenge, Pfizer&#8217;s ownership of or rights in, or the validity, enforceability or scope of any of the patents licensed under the Pfizer Agreement or (ii) the Company or any of its affiliates or sublicensees fails to achieve the first commercial sale in at least one country by April 16, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Furthermore, upon termination of the Pfizer Agreement by Pfizer for any of the foregoing reasons, the Company grants Pfizer a non-exclusive, fully paid-up, royalty free, worldwide, transferrable, perpetual and irrevocable license to use any </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_QD_ZMRqNa0i00DLnbyGboA_cont2" continuedAt="Tb_QD_ZMRqNa0i00DLnbyGboA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">intellectual property rights arising from the development or commercialization of Gemcabene by the Company and any trademarks identifying Gemcabene and agrees to transfer regulatory filings and approvals to Pfizer or permit Pfizer to cross-reference and rely on such regulatory filings and approvals for Gemcabene. The Company may terminate the Pfizer Agreement for convenience upon <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ" format="ixt-sec:durday" name="nrbo:LicenseTerminationNoticePeriod" id="Narr_Bq1KCuNSc0SONa67N5Iw6w">90</ix:nonNumeric> days&#8217; written notice and payment of an early termination fee of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_e_U9zOVAtEW8M7Nl3d2N0g" decimals="-5" format="ixt:numdotdecimal" name="nrbo:LicenseAgreementEarlyTerminationFee" scale="6" id="Narr_L7vZ_2l0IEmei4LAlH9RiQ">3.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2022 and 2021, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the license agreement, and as such, <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_JpNwtACeAEisv2eSDupv_g" decimals="-3" format="ixt-sec:numwordsen" name="nrbo:MilestonesOrRoyaltyPaymentsTriggered" scale="3" id="Narr_WADp29oQ00C4GzdMaxgQvQ"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ" decimals="-3" format="ixt-sec:numwordsen" name="nrbo:MilestonesOrRoyaltyPaymentsTriggered" scale="3" id="Narr_VVnj2WTChUO3hk9gEA1WKQ">no</ix:nonFraction></ix:nonFraction> liabilities were recorded related to the Pfizer Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANA Merger Milestone Payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">On December&#160;31, 2020, the Company acquired <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2020_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IG_Y6UouBkm4R_t4WrbvGQ" decimals="INF" format="ixt:numdotdecimal" name="nrbo:AssetAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="Narr_LwGZUu5GdEGBBth1ecWg0Q">100</ix:nonFraction>% of ANA Therapeutics,&#160;Inc., a Delaware corporation (&#8220;ANA&#8221;), pursuant to an Agreement and Plan of Merger, dated December&#160;31, 2020 (the &#8220;2020 Merger Agreement&#8221; or &#8220;2020 Merger&#8221;). Pursuant to the 2020 Merger Agreement, following the closing of the 2020 Merger, the Company is obligated to pay milestone payments (each, a &#8220;Milestone Payment&#8221;) to certain persons identified in the 2020 Merger Agreement (each a &#8220;Stakeholder&#8221; and collectively, the &#8220;Stakeholders&#8221;) in the form, time and manner as set forth in the 2020 Merger Agreement, upon the achievement of the following milestone events set forth below by the Company or any of its affiliates (each, a &#8220;Milestone Event&#8221;):</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IPbMK5DMBU-arb5dHnRBNg" name="nrbo:ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" id="Tb_WSeedaY5LkeNNYw-or8WTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><div style="padding-left:3pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:91.69%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"></td></tr><tr style="height:22.3pt;"><td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0pt 2pt;"><b style="font-weight:bold;">Milestone Event</b></p></td><td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 20.5pt 0pt 0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr style="height:9.55pt;"><td colspan="2" style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:9.55pt;margin:0pt;">First receipt of Marketing Approval (as defined in the 2020 Merger Agreement) from the FDA for any Niclosamide Product (as defined in the 2020 Merger Agreement)</p></td><td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;"> $</span></p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_FirstAmendmentToOriginalCvrAgreementMember_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_XHR9_9HRME-lP7dY7J3wUA" decimals="-5" format="ixt:numdotdecimal" name="nrbo:InitialMilestonePayment" scale="6" id="Narr_hEyGGJp6DUy8CPacvwGhhQ">45.0</ix:nonFraction> million</p></td></tr><tr style="height:21.6pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Sales Milestones:</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 11pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.15pt;"><td colspan="2" style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Milestone Event &#8211; Worldwide Cumulative Net Sales of a Niclosamide Product</b></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.9pt;"><td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">equal to or greater than:</b></p></td><td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 19.5pt 0pt 0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr style="height:10.45pt;"><td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThan500MillionMember_k1KYYL1K_0-HvDnDN7RX9A" decimals="-6" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="6" id="Narr_r2EoYbxQg0-XCe5isXdIVA">500</ix:nonFraction> million</p></td><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThan500MillionMember_k1KYYL1K_0-HvDnDN7RX9A" decimals="-5" format="ixt:numdotdecimal" name="nrbo:InitialMilestonePayment" scale="6" id="Narr_rnlZe9lnfESYQLl_xbSWWw">9.0</ix:nonFraction> million</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanOneBillionMember_UdP-HCvD0E2O-ZPaLupmow" decimals="-9" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="9" id="Narr_K7tsOr11-UmE84EfVh6yFQ">1</ix:nonFraction> billion</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanOneBillionMember_UdP-HCvD0E2O-ZPaLupmow" decimals="-5" format="ixt:numdotdecimal" name="nrbo:InitialMilestonePayment" scale="6" id="Narr_ZlwFy0LrbEKg8z-8cU8Z7A">13.5</ix:nonFraction> million</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanThreeBillionMember_sZhFMyWVrE2W0wp6FIo2LA" decimals="-9" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="9" id="Narr_dWpV-PRPVUqrB4NV56HouA">3</ix:nonFraction> billion</p></td><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanThreeBillionMember_sZhFMyWVrE2W0wp6FIo2LA" decimals="-5" format="ixt:numdotdecimal" name="nrbo:InitialMilestonePayment" scale="6" id="Narr_spWG7ngj9kaaMdYSSrMjgw">36.0</ix:nonFraction> million</p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanFiveBillionMember_Bk3afARaEEa5UtSxvJFFcw" decimals="-9" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="9" id="Narr_Mc_NqkD3xkmwNNs5IiV13Q">5</ix:nonFraction> billion</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanFiveBillionMember_Bk3afARaEEa5UtSxvJFFcw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:InitialMilestonePayment" scale="6" id="Narr_lmnx4d-O3EWRdsm1Pr2o7g">72.0</ix:nonFraction> million</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Additionally, pursuant to the 2020 Merger Agreement, the Company is obligated to pay <span style="color:#231f20;">a royalty of two and a half percent (</span><span style="color:#231f20;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="3" format="ixt:numdotdecimal" name="nrbo:PercentageOfRoyaltyPayments" scale="-2" id="Narr_FjTNyGM0s0eUtnp4druZQA">2.5</ix:nonFraction>%</span><span style="color:#231f20;">) of annual worldwide net sales of each Niclosamide Product (as defined in the Merger Agreement) </span> (each such payment, a &#8220;Royalty Payment&#8221;) to the Stakeholders in the form, time and manner as set forth in the 2020 Merger Agreement, following the first commercial sale of each Niclosamide Product (as defined in the 2020 Merger Agreement) on a country-by-country and Niclosamide Product-by-Niclosamide Product basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">As of the December 31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt-sec:numwordsen" name="nrbo:RoyaltyPaymentAccrued" scale="0" id="Narr_-4YZB8kD_EyCkB7slXwSYg"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt-sec:numwordsen" name="nrbo:RoyaltyPaymentAccrued" scale="0" id="Narr_4y5Nyj10vkWWCamgP5VIsw">no</ix:nonFraction></ix:nonFraction> Royalty Payments had been accrued as there were no potential milestones yet considered probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">YourChoice License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">In connection with the 2020 Merger, the Company assumed the license agreement between ANA and Your Choice Therapeutics, Inc. (the &#8220;YourChoice Agreement&#8221;). Prior to the 2020 Merger, YourChoice Therapeutics, Inc. granted to ANA, during the term of the YourChoice Agreement, an exclusive, worldwide, fee-bearing license derived from the licensed intellectual property throughout the world.  The fees due under the YourChoice Agreement include royalty payments of </span><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OWD6T-tZC06ThXS0xCkQyw" decimals="3" format="ixt:numdotdecimal" name="nrbo:PercentageOfRoyaltyPayments" scale="-2" id="Narr_xnjQWif_9UurOCRPuMs2tA">0.5</ix:nonFraction>% of annual worldwide net sales of each Niclosamide Product (as defined in the 2020 Merger Agreement) and milestone payments in the aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_uh4H-TEI7EyhE2e1wLB-OA" decimals="-5" format="ixt:numdotdecimal" name="nrbo:RoyaltyAndMilestonePaymentsDue" scale="6" id="Narr_ihNouIWkv0W_3XNXhJ597Q">19.5</ix:nonFraction> million. The first milestone payment due is $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_DrCMGt_Bb0m-pV_jNh3q6A" decimals="-6" format="ixt:numdotdecimal" name="nrbo:RoyaltyAndMilestonePaymentsDue" scale="6" id="Narr_KUZ0cL3P9UCREf3mWpHYew">5</ix:nonFraction> million upon first receipt of Marketing Approval (as defined in the 2020 Merger Agreement) for the FDA for any Nicolsamide Product (as defined by the 2020 Merger Agreement), followed by sales milestones of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierOneNetSalesMilestoneMember_SES_rbkbP0eNKOMs2xwA_A" decimals="-6" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="6" id="Narr_HfX6LRPpgEq9VMT4v9gmBw">1</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierTwoNetSalesMilestoneMember_dpzKVlo1ekGtUs9fT1O3mw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="6" id="Narr_ivAYfnuUfUuGgBuSmIaKIw">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierThreeNetSalesMilestoneMember_fzSwTYIVmkeJrh9SwkEpKQ" decimals="-6" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="6" id="Narr_7TnjGCZZUkWvRYjrt8Zn_g">4</ix:nonFraction> million, and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierFourNetSalesMilestoneMember_TxpZFkCQ10C-ExxaRCaBqA" decimals="-6" format="ixt:numdotdecimal" name="nrbo:SalesBasedMilestonePayment" scale="6" id="Narr_rXNSuCvupUS9I-dRkRHdcw">8</ix:nonFraction> million if worldwide cumulative net sales of a Nicolsamide Product are equal or greater than $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierOneNetSalesMilestoneMember_SES_rbkbP0eNKOMs2xwA_A" decimals="-6" format="ixt:numdotdecimal" name="nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones" scale="6" id="Narr_5oBuJt6PSESkFDEV4cuRZg">500</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierTwoNetSalesMilestoneMember_dpzKVlo1ekGtUs9fT1O3mw" decimals="-9" format="ixt:numdotdecimal" name="nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones" scale="9" id="Narr_Rz1VGjozAUy-5nxbNbk1tQ">1</ix:nonFraction> billion, $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierThreeNetSalesMilestoneMember_fzSwTYIVmkeJrh9SwkEpKQ" decimals="-9" format="ixt:numdotdecimal" name="nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones" scale="9" id="Narr_g0LxaDqRGUma6wLJQUQCMw">3</ix:nonFraction> billion, and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierFourNetSalesMilestoneMember_TxpZFkCQ10C-ExxaRCaBqA" decimals="-9" format="ixt:numdotdecimal" name="nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones" scale="9" id="Narr_wQLhcuYgnkqN7X9gJSEyZw">5</ix:nonFraction><span style="white-space:pre-wrap;"> billion, respectively.  The term of the YourChoice Agreement will expire on the </span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_78f4e738_0248_4f82_8f60_c3359178dbca"></a><ix:continuation id="Tb_QD_ZMRqNa0i00DLnbyGboA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">expiration or invalidation of the last of the licensed patents under the YourChoice Agreement.  As of December 31 2022 and 2021, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the YourChoice Agreement, and as such, </span><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_azdNGhPJu0ixmk2GgSSbKA" decimals="-5" format="ixt-sec:numwordsen" name="nrbo:MilestonesOrRoyaltyPaymentsTriggered" scale="6" id="Narr_uTFj5aZKcU24ywpaKw1heg"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_MCgUOrSmAUGyN4xH2iEx5g" decimals="-5" format="ixt-sec:numwordsen" name="nrbo:MilestonesOrRoyaltyPaymentsTriggered" scale="6" id="Narr_ZNvuJdZ-SES85tSdgI_Bzg">no</ix:nonFraction></ix:nonFraction> liabilities were recorded related to the YourChoice Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company does not expect that the resolution of these matters will have a material adverse effect on its financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="nrbo:LicenseAgreementDisclosureTextBlock" id="Tb_wJ1XL_HaZUWhWrQNcsSIxA" continuedAt="Tb_wJ1XL_HaZUWhWrQNcsSIxA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Dong-A License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On September&#160;14, 2022, the Company and Dong-A entered into the&#160;2022 License Agreement, pursuant to which, the Company received an exclusive global license (except for the territory of the Republic of Korea and certain other jurisdictions) to <ix:nonFraction unitRef="Unit_Standard_item_BbpdEDrZSk2GQqI08hy64Q" contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" scale="0" id="Narr_F86bz-SYzEGsR02iundncA">two</ix:nonFraction> proprietary compounds for specified indications upon meeting certain financing milestones. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. The 2022 License Agreement also provides that the Company may develop DA-1241 for the treatment of T2D. Under the terms of the 2022 License Agreement, (i), the Company agreed to pay Dong-A an upfront payment to be settled with <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_7cfaqECBI0mYM0TA6a38MQ" decimals="INF" format="ixt:numdotdecimal" name="nrbo:ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_dDTFoTmL8Ui3Wn0efnRcpA">2,200</ix:nonFraction> shares of a new series of preferred stock designated as &#8220;Series&#160;A Convertible Preferred Stock&#8221;, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_2N6TCpmcHEazJ6gu1eY5yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_5tDHjNaNVku_xLk95tp4EA">0.001</ix:nonFraction> per share (the&#160;&#8220;Series&#160;A Preferred Stock<span style="font-style:italic;font-weight:bold;">&#8221;</span><span style="white-space:pre-wrap;">), upon completion of a financing (see Note 7 &#8211; Stockholder&#8217;s Equity).  </span><span style="background:#ffffff;">The Series A Preferred Stock issued in connection with the 2022 License Agreement was recorded as IPR&amp;D expense in the amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_goh7paQIHkKoksKth-jjfg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="Narr_RSKxCIaYBEWTJCJzmHlZLQ">8.2</ix:nonFraction></span><span style="white-space:pre-wrap;background:#ffffff;"> million based on the fair market value of the Series A Preferred Stock.  The 2022 License Agreement did not include any processes  or activities constituting a &#8220;business&#8221; were acquired and since none of the rights underlying the Dong-A License Agreement had alternative future uses or had reached a stage of technological feasibility.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The term of the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either Dong-A or the Company may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within <ix:nonNumeric contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ" format="ixt-sec:durwordsen" name="nrbo:PeriodForFailToCureBreachMayTerminateAgreement" id="Narr_sM-L2L5V7EiJd5gGVj-mbA">60 days</ix:nonNumeric> of notice of such breach; provided that if the breach cannot be cured within the <span style="-sec-ix-hidden:Hidden_8VHUHzuV5UqZVxVaa0LNCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60-day</span></span> period and the breaching party started to remedy the breach, if such breach is not cured within <ix:nonNumeric contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ" format="ixt-sec:durwordsen" name="nrbo:CurePeriodForBreachingParty" id="Narr_rkzw6GMq1U2Zg3RGNn-DRQ">90 days</ix:nonNumeric> of receipt of written notice, (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a <span style="-sec-ix-hidden:Hidden_KYNGeI_ZfkuzqiJCYGB1Ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30-day</span></span> cure period in the case of a petition for bankruptcy), or (iii)&#160;in the event the Company had failed to complete the public offering as further described in Note 7 -Stockholders&#8217; Equity by December&#160;31, 2022 (or January&#160;31, 2023 under specified circumstances set forth in the 2022 License Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">None of the milestone or royalty payments under the 2022 License Agreement were triggered as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Shared Services Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">On September&#160;14, 2022, in conjunction with the Dong-A License Agreement, the Company entered into a shared services agreement with Dong-A (the&#160;&#8220;Shared Services Agreement&#8221;). The Shared Services Agreement provides that Dong-A may provide technical support, pre-clinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A will manufacture all of the Company&#8217;s clinical requirements of DA-1241 and DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Either party may terminate the Shared Services Agreement for the other party&#8217;s material breach that is not cured within </span><ix:nonNumeric contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_SharedServicesAgreementMember_bK2yJe4yoU2jm_DEGsbO0Q" format="ixt-sec:durwordsen" name="nrbo:PeriodForTerminationNotice" id="Narr_V888Fm1guUuS43FjVlVEbw"><span style="font-size:10pt;">30 days</span></ix:nonNumeric><span style="font-size:10pt;"> of notice. Dong-A may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by the Company which is not cured within </span><ix:nonNumeric contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_SharedServicesAgreementMember_bK2yJe4yoU2jm_DEGsbO0Q" format="ixt-sec:durwordsen" name="nrbo:PeriodForFailToCureBreachMayTerminateAgreement" id="Narr_tC7GmQVFxEGyiPo3sWmj_Q"><span style="font-size:10pt;">30 days</span></ix:nonNumeric><span style="font-size:10pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">As of December 31, 2022, the Company did not incur any research and development expenses under the Shared Services Agreement.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_wJ1XL_HaZUWhWrQNcsSIxA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb__ZMEmeWitEiPn0z6kVKQ0g" continuedAt="Tb__ZMEmeWitEiPn0z6kVKQ0g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Beijing SL License Agreement </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Beijing SL License and Collaboration Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Upon the close of the 2019 Merger, the License and Collaboration Agreement (the &#8220;Beijing SL Agreement&#8221;) with Beijing SL Pharmaceutical Co., Ltd. (&#8220;Beijing SL&#8221;)(the &#8220;Beijing SL Agreement&#8221;) was assumed by the Company, pursuant to which the Company granted Beijing SL an exclusive royalty-bearing license to research, develop, manufacture and commercialize pharmaceutical products comprising, as an active ingredient, Gemcabene in mainland China, Hong Kong, Macau and Taiwan (each, a &#8220;region&#8221;, and collectively, the &#8220;Territory&#8221;). The terms of the Beijing SL Agreement include payments based upon achievement of milestones and royalties on net product sales. Under the Beijing SL Agreement, the Company has variable consideration in the form of milestone payments. As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_kBvkGV4jekagMWbtRHE_aA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="Narr_VEtYDV8GkECTEiLLS8q_tA">no</ix:nonFraction> revenue under the Beijing SL Agreement has been recognized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Under the terms of the Beijing SL Agreement, Beijing SL will be responsible, at its expense, for developing and commercializing products containing Gemcabene (each, a &#8220;Licensed Product&#8221;) in the Territory, with certain assistance from the Company. To the extent mutually agreed to in writing, the Company and Beijing SL will collaborate on the Phase 3 clinical trial for homozygous familial hypercholesterolemia or other clinical trials with the Company as the sponsor designed to enroll patients both inside and outside the Territory (a &#8220;Global Study&#8221;), but Beijing SL will be responsible, at its expense, for the conduct of any Global Study to the extent solely in the Territory, subject to the Company&#8217;s final decision making authority, and the Company will be responsible, at its expense, for the conduct of any Global Study to the extent solely outside of the Territory. Under a territory development plan, the parties shall develop Licensed Products with respect to the Territory. Beijing SL will be responsible for development activities, including non-clinical and clinical studies directed at obtaining regulatory approval of the Licensed Product in the Territory.&#160;Beijing SL has agreed to use commercially reasonable efforts to commercialize the Licensed Products for each indication that receives regulatory approval in the Territory and shall prepare and present a commercialization plan that shall be subject to approval by the joint steering committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;">Pursuant to the Beijing SL Agreement, Beijing SL was to make a non-refundable upfront gross payment of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ" decimals="-5" format="ixt:numdotdecimal" name="nrbo:LicenseAgreementUpfrontPaymentToBeReceived" scale="6" id="Narr_1vlTuFRwf0C935v8J_Y9xQ">2.5</ix:nonFraction></span><span style="font-size:10pt;">&#160;million to the Company within </span><ix:nonNumeric contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember__rH0iwnWGEWGagjRIx77dQ" format="ixt-sec:durwordsen" name="nrbo:PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" id="Narr_asbRqNMcYUSXMS82ZWRYuw"><span style="font-size:10pt;">45 days</span></ix:nonNumeric><span style="font-size:10pt;"> of the effective date of the Beijing SL Agreement; the upfront payment was received in October 2019 and such funds were fully expended prior to the close of 2019 Merger. Additionally, with respect to each Licensed Product, the Company is eligible to receive (i) payments for specified developmental and regulatory milestones (including submission of a new drug application to China&#8217;s National Medical Product Administration, dosing of the first patient in a phase 3 clinical trial in mainland China and regulatory approval for the first and each additional indication of a Licensed Product in the Territory) totaling up to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ" decimals="-6" format="ixt:numdotdecimal" name="nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" scale="6" id="Narr_luvv_5ryMEeVRryzknUrvA">6</ix:nonFraction></span><span style="font-size:10pt;">&#160;million in the aggregate and (ii) payments for specified global net sales milestones of up to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ" decimals="-6" format="ixt:numdotdecimal" name="nrbo:LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" scale="6" id="Narr_GSOULleXz0anl-AxKJAFsQ">20</ix:nonFraction></span><span style="font-size:10pt;"> million in the aggregate multiplied by the ratio of the net sales of a Licensed Product sold by Beijing SL in the Territory divided by the global net sales of a Licensed Product, which net sales milestone payments are payable once, upon the first achievement of such milestone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;">Beijing SL is also obligated to pay the Company tiered royalties ranging from the mid-teens to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_10_1_2019_To_10_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_wzCrD8W_a0KHVlgiyTYKNg" decimals="2" format="ixt-sec:numwordsen" name="nrbo:PercentageOfRoyaltyOnNetSales" scale="-2" id="Narr_tjgVLVO92E6LpOg89nB3Sg">twenty</ix:nonFraction></span><span style="font-size:10pt;"> percent on the net sales of all Licensed Products in the Territory until the latest of (a) the date on which any applicable regulatory exclusivity with respect to such Licensed Product expires in such region, (b) the expiration or abandonment of the last valid patent claim or joint patent claim covering such Licensed Product in each region and (c) the fifth anniversary of the first commercial sale of such Licensed Product in such region (the &#8220;Royalty Term&#8221;). Future milestone payments under the Beijing SL Agreement, if any, are not expected to begin for at least </span><ix:nonNumeric contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember__rH0iwnWGEWGagjRIx77dQ" format="ixt-sec:durwordsen" name="nrbo:MinimumExpectedPeriodToBeginFutureInstallmentPayment" id="Narr_4KhGJ-J5pUeYS7U4nmsDRQ"><span style="font-size:10pt;">one year</span></ix:nonNumeric><span style="font-size:10pt;"> and will extend over a number of subsequent years. The Company cannot determine the date on which Beijing SL&#8217;s potential royalty payment obligations to the Company would expire because Beijing SL has not yet developed any Licensed Products under the Beijing SL Agreement and therefore the Company cannot at this time identify the date of the first commercial sale or the periods of any regulatory exclusivity or patent claims with respect to any Licensed Product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On a Licensed Product-by-Licensed Product and region-by-region basis upon the expiration of the Royalty Term, the license granted to Beijing SL shall be deemed perpetual, fully paid-up and royalty free with respect to such Licensed Product in such region. Either party may terminate the Agreement (x) with written notice in the event of the other party&#8217;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__ZMEmeWitEiPn0z6kVKQ0g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">addition, the Company may terminate the agreement in its entirety if Beijing SL or its affiliates or sublicensees commence a proceeding challenging the validity, enforceability or scope of any of the Company&#8217;s patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">To the extent rights granted to Beijing SL under the Beijing SL Agreement are controlled by the Company pursuant to the Pfizer Agreement, such rights are subject to the terms and conditions of such agreement with Pfizer, and Beijing SL has agreed to comply with such terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Beijing SL Agreement contemplates that Beijing SL and the Company shall, no later than <ix:nonNumeric contextRef="Duration_10_1_2019_To_10_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_wzCrD8W_a0KHVlgiyTYKNg" format="ixt-sec:durwordsen" name="nrbo:ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" id="Narr_kw9DcJNguU-l9y4eEwVpAQ">twelve months</ix:nonNumeric> prior to the anticipated date of the first commercial sale of a Licensed Product, if any, negotiate in good faith and execute a commercial supply agreement, pursuant to which Beijing SL shall purchase from the Company, and the Company shall use commercially reasonable efforts to supply, Gemcabene or Licensed Product for clinical or commercial purposes, as applicable, until manufacturing and regulatory transfers are complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Each of the Company and Beijing SL has agreed to indemnify the other party against certain losses and expenses relating to the development or commercialization of a Licensed Product by the indemnifying party, the negligence or willful misconduct of the indemnifying party or its directors, officers, employees or agents or a breach of the indemnifying party&#8217;s representations, warranties or covenants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_xGO2NIpcgE2aWjFnodyiUA" continuedAt="Tb_xGO2NIpcgE2aWjFnodyiUA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.</b> S<b style="font-weight:bold;">tockholders&#8217; Equity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock when outstanding. The holders of the common stock are entitled to <ix:nonFraction unitRef="Unit_Divide_Vote_shares_q2LbOB3SVUaQQK-N2RnI1g" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:CommonStockVotingRightsPerShare" scale="0" id="Narr_OY0kmSJHu0K3HM4GZ--WTg">one</ix:nonFraction><span style="white-space:pre-wrap;"> vote for each share of common stock held at all meetings of stockholders.  </span>Common stockholders are entitled to receive dividends at the sole discretion of the board of directors of the Company. There have been <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA" decimals="-3" format="ixt-sec:numwordsen" name="nrbo:CumulativeDividendsDeclared" scale="3" id="Narr_nFx1kBLGD02b53ujdCF1Qg">no</ix:nonFraction><span style="white-space:pre-wrap;"> dividends declared on common stock to date as of December 31, 2022.  In the event of any liquidation, dissolution, or winding-up of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution post preferential distributions made to holders of the Company&#8217;s preferred stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;">The rights of the Series A Preferred Stock and Series B Preferred Stock (as defined further below), collectively, the &#8220;Preferred Stock&#8221;, while outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"><i style="font-style:italic;">Dividends.</i><b style="font-weight:bold;letter-spacing:4pt;"> </b>Holders of the Preferred Stock were entitled to<span style="letter-spacing:-0.6pt;"> </span>receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to&#173; common-stock basis) to the amount paid on shares of the common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"><i style="font-style:italic;">Voting Rights.</i><b style="font-weight:bold;"> T</b>he Preferred Stock had no voting rights. However, as long as any shares of Preferred Stock were outstanding, the Company could not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or amend its Certificate of Designation, (b) amend other charter documents in any manner that could have adversely affected any rights of the holders, (c) increase the number of authorized shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. &#160;In addition, the Series A Preferred Stock could have voted on any matter that authorized, created and/or issued any funded indebtedness (other than indebtedness already incurred); &#160;sold or transferred, other than in the ordinary course of its business, mortgaged, assigned, pledged, leased, granted a security interest in, or encumbered any of the Company&#8217;s assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"><i style="font-style:italic;">Liquidation.</i><b style="font-weight:bold;"> </b>The Preferred Stock while outstanding in the event of a liquidation,<span style="letter-spacing:2pt;"> </span>dissolution<span style="letter-spacing:2pt;"> </span>or<span style="letter-spacing:1.75pt;"> </span>winding-up<span style="letter-spacing:2pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>Company, collectively a &#8220;Liquidation&#8221;, had the following rights: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 0pt 36pt;"><i style="font-style:italic;">Series A Preferred Stock</i><b style="font-weight:bold;">: </b>Upon any Liquidation of the Company<span style="letter-spacing:-0.1pt;">,</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:-0.1pt;">whether</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:-0.1pt;">voluntary or</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:-0.1pt;">involuntary</span><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">,</span><span style="font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">after</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">satisfaction</span><span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">full</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">of </span>the<span style="letter-spacing:-0.8pt;"> </span>debts<span style="letter-spacing:-0.8pt;"> </span>of<span style="letter-spacing:-0.8pt;"> </span>the<span style="letter-spacing:-0.75pt;"> </span>Company<span style="letter-spacing:-0.8pt;"> </span>and<span style="letter-spacing:-0.8pt;"> </span>the<span style="letter-spacing:-0.8pt;"> </span>payment<span style="letter-spacing:-0.75pt;"> </span>of<span style="letter-spacing:-0.8pt;"> </span>any<span style="letter-spacing:-0.8pt;"> </span>liquidation<span style="letter-spacing:-0.55pt;"> </span>preference<span style="letter-spacing:-0.4pt;"> </span>owed<span style="letter-spacing:-0.8pt;"> </span>to<span style="letter-spacing:-0.8pt;"> </span>the<span style="letter-spacing:-0.8pt;"> </span>holders of<span style="letter-spacing:-0.5pt;"> </span>shares of capital stock of the<span style="letter-spacing:-0.05pt;"> </span>Company ranking senior to the Series A<span style="letter-spacing:-0.1pt;"> </span>Preferred Stock upon liquidation, but before any<span style="letter-spacing:-0.45pt;"> </span>distribution or<span style="letter-spacing:-0.35pt;"> </span>payment out of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>assets of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>Company shall<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>made to<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>holders<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.5pt;"> any junior </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xGO2NIpcgE2aWjFnodyiUA_cont1" continuedAt="Tb_xGO2NIpcgE2aWjFnodyiUA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 6.25pt 6pt 36pt;"><span style="letter-spacing:-0.5pt;">securities, including common stock,</span><span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.5pt;"> </span>amount in<span style="letter-spacing:-0.5pt;"> </span>cash per share equal to the amount per share in cash payable to the holder if the shares of Series A Preferred Stock<span style="letter-spacing:-0.05pt;"> </span>were<span style="letter-spacing:-0.25pt;"> </span>converted immediately prior<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Liquidation into<span style="letter-spacing:-0.6pt;"> </span>shares<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.15pt;"> common stock</span><span style="letter-spacing:-0.1pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:4.5pt 19.25pt 6pt 36pt;"><i style="font-style:italic;">Series B Preferred Stock:</i> Upon any <span style="letter-spacing:1.35pt;">L</span>iquidation of the Company, whether voluntary or<span style="letter-spacing:-0.3pt;"> </span>involuntary,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> holder</span>s shall be<span style="letter-spacing:-0.05pt;"> </span>entitled to<span style="letter-spacing:-0.25pt;"> </span>receive out<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>assets, whether<span style="letter-spacing:-0.05pt;"> </span>capital or<span style="letter-spacing:-0.65pt;"> </span>surplus, of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>Company the<span style="letter-spacing:-0.25pt;"> </span>same amount that a holder<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.5pt;"> common stock</span> would receive if<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.65pt;"> Series B </span>Preferred Stock were fully<span style="letter-spacing:-0.55pt;"> </span>converted (disregarding for<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>purposes any<span style="letter-spacing:-0.25pt;"> </span>conversion limitations hereunder) to common stock which amounts shall be<span style="letter-spacing:-0.25pt;"> </span>paid pari passu with all holders of<span style="letter-spacing:-0.2pt;"> </span>common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">Conversion.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">  </i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">  Series A Preferred Stock:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Automatic Conversion. On the first Trading Day after the Company obtains the stockholder approval, all outstanding shares of the Series A Preferred Stock would, without any further action by holders and whether or not any certificates representing such shares are surrendered to the Company or the Transfer Agent, automatically be converted into such number of shares of common stock as determined by dividing the stated value of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA" decimals="INF" format="ixt:numdotdecimal" name="nrbo:PreferredStockStatedValuePerShare" scale="0" id="Narr_GjAe1vd350mFxxtJlql9Ag"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA" decimals="INF" format="ixt:numdotdecimal" name="nrbo:PreferredStockStatedValuePerShare" scale="0" id="Narr_EqP6nG20Z02GWSBEgYq0bw">10,000</ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share by the conversion price then in effect (the &#8220;Automatic Conversion&#8221;). The conversion price upon an Automatic Conversion for the Series A Preferred Stock was equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_xXZWFSFwn0KEBNpdo5QLAA">3.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Special Cash Payout Provisions:  Unless and until stockholder approval was obtained, the holder did not have the right to acquire shares of common stock issuable upon conversion of the Series A Preferred Stock, and the Company was not required to issue shares of common stock issuable upon conversion of the Series A Preferred Stock in excess of the Share Cap as defined (the &quot;Conversion Restriction&quot;). Notwithstanding the foregoing, if the Automatic Conversion had not occurred by the nine (9)-month anniversary of the original issuance date, the holder would have been entitled to submit a request to the Company for the conversion of all, but not less than all, of holder&#39;s shares of Series A Preferred Stock that were subject to the Conversion Restriction that would have exceeded the Share Cap; provided, that, in lieu of the Conversion Shares that would have otherwise been deliverable upon conversion but for the Conversion Restriction, the Company would have instead delivered to such holder for each share of common stock that would have been so otherwise delivered an amount of cash equal to the volume weighted average price (&#8220;VWAP&#8221;) per share of common stock on the trading day immediately preceding the date such request is made.  If the Company failed to make any required cash payment by the required deadline on any share of Series A Preferred Stock, then the holder thereof would have been entitled to receive cumulative cash dividends on each such share at a rate per annum of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ZNoLMPLiW0aszZnLPwlyiQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_X_CtToAZqE2c2fpt75cRww">5.00</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> on the stated value ( &quot;Default Cash Dividends&#39;&#39;). Default Cash Dividends, if any, would have accumulated on a daily basis. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">  Series B Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Conversions at Option of Holder. Each share of Series B Preferred Stock was convertible, at any time at the option of the holder thereof, into that number of shares of common stock (subject to certain limitations) determined by dividing the stated value of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Y7ZQpxzhMUm9V49NbXYQOw" decimals="INF" format="ixt:numdotdecimal" name="nrbo:PreferredStockStatedValuePerShare" scale="0" id="Narr_n3iUaQDKJUunpUnNS9ikpw">3.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share by the conversion price in effect. The conversion price for the Series B Preferred Stock was equal </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Y7ZQpxzhMUm9V49NbXYQOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="Narr_bOcTKJpZBU2nk3yuWm8HZg">3.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Fundamental Transaction.</b> If, at any time while shares of the Preferred Stock were outstanding, the Company, directly or indirectly, in one or more related transactions effected any merger or consolidation of the Company, the holder of the Preferred Stock would have had the right to receive, for each conversion share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction as defined, the number of shares of common stock of the successor or acquiring Company or of the Company, if it is the surviving Company, and any additional consideration (the &quot;Alternate Consideration&#39;&#39;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of the common stock for which shares of the Preferred Stock would have been </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk128819419"></a><a id="_Hlk128843134"></a><ix:continuation id="Tb_xGO2NIpcgE2aWjFnodyiUA_cont2" continuedAt="Tb_xGO2NIpcgE2aWjFnodyiUA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">convertible immediately prior to such Fundamental Transaction. If holders of the common stock were given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Preferred Stock would have been given the same choice as to the Alternate Consideration it would have received upon any conversion of shares of the Preferred Stock following such Fundamental Transaction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2022 Private Placement and Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">On September 14, 2022, the Company entered into a Securities Purchase Agreement with Dong-A (the &#8220;Dong-A Securities Purchase Agreement&#8221;). Pursuant to the Dong-A Securities Purchase Agreement, Dong-A agreed to purchase from the Company shares of its Series A Preferred Stock and warrants to purchase shares of its common stock, equivalent to those to be issued in the Qualified Financing (as hereafter defined), (collectively, the &#8220;Dong-A Financing&#8221;) concurrent with and contingent upon a qualified financing resulting in gross proceeds of at least $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XHL-x0fEb0yRGhDBpCdG2A" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="6" id="Narr_IhMU9REVD0aB5ufbKgwR3A">15</ix:nonFraction> million exclusive of the Dong-A Financing (the &#8220;Qualified Financing&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On November 8, 2022, the Company closed on an underwritten public offering (the &#8220;2022 Public Offering&#8221;) of units with gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_mAMpODa2nkKAzLAAMiOi-g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_LmdZ6Clac02qojrmO-3pOA">17.3</ix:nonFraction><span style="white-space:pre-wrap;"> million.  The underwritten public offering was comprised of (1) </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_flmg7ndj70K84Nl5u2HoQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_N6PLCxfw6EyKx1xUt2z0MQ">3,147,003</ix:nonFraction> Class A Units, priced at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_X91Oqmk7XUCm6SQsu_Avpg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_G8e4dqYgBkuJznHqLMOSdw">3.00</ix:nonFraction> per Class A Unit, with each Class A Unit consisting of <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_X91Oqmk7XUCm6SQsu_Avpg" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:NumberOfCommonStockIssuedPerUnit" scale="0" id="Narr_9EJw9-RQcEuDQBRumPdAbQ">one</ix:nonFraction> share of common stock, a Series A Warrant (the &#8220;Series A Warrants&#8221;) to purchase <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:NumberOfCommonStockIssuedPerUnit" scale="0" id="Narr_QOk_e4L0L0en9R030NwUnw">one</ix:nonFraction> share of common stock for a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_R7FdDLyz20mfsou_WHj9Yg">3.00</ix:nonFraction> per share that expires on the <ix:nonNumeric contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_uN3r5FP-UkmcCRg1NRlaBA">one year</ix:nonNumeric> anniversary following the initial exercise date and a Series B Warrant (the &#8220;Series B Warrants&#8221;) to purchase <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:NumberOfCommonStockIssuedPerUnit" scale="0" id="Narr_yWgKmQ0ad0aqtiqG7MCZTg">one</ix:nonFraction> share of common stock, for a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_nzpoi1KJqkqzct-1-HUHPw">3.00</ix:nonFraction> per share that expires on the <ix:nonNumeric contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_zIDYmgXXCE6RpJxfbgUnjA">five year</ix:nonNumeric> anniversary following the initial exercise date, and (2) <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_DNs6bxizX0y5Tfgm4r8p_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ehe7i_R7aEulcO3iI5noIg">2,602,997</ix:nonFraction> Class B Units, priced at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_-wq4edpIt0OJC42AypcZKQ">3.00</ix:nonFraction> per Class B Unit, with each Class B Unit consisting of <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" scale="0" id="Narr_SwpYMJxlj0CvEb620K3azA">one</ix:nonFraction> share of Series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;), convertible into <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:NumberOfCommonStockIssuedPerUnit" scale="0" id="Narr_qn84SJkwYku2FdDdS_lh3A">one</ix:nonFraction> share of common stock, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_vVxVMB4etkuISAzFnY5dCw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_h1eGCfY9i0yp800IqBfu1g">one</ix:nonFraction> Series A Warrant and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_xKdZLeM_RkacOFor73v_Pg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_CpiEHIqS6Eamh2rD3-mmhg">one</ix:nonFraction> Series B Warrant. The Series A Warrants and the Series B Warrants, (collectively, the &#8220; Public Warrants&#8221;) were to only be exercisable upon stockholder approval, and each Warrant was to be exchangeable for <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_pGc5Bqyg-k-f0Up0HEdEHg">one</ix:nonFraction> share of common stock for <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_11_8_2022_To_11_8_2022_b6Tq9XMF9kWXMJVobfHIhw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_qwzNNuhbUUGd3LoycfR1GQ">no</ix:nonFraction><span style="white-space:pre-wrap;"> additional consideration.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The 2022 Public Offering met the definition of a Qualified Financing as defined by the Dong-A Securities Purchase Agreement; therefore, on November 8, 2022, the license under the Dong-A License Agreement became effective, and the Company issued to Dong-A <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_LDYXw0uQCUG-gO_0LLFXuA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_2Nt_0JoQVUKnXcwFURnYMQ">2,200</ix:nonFraction> shares of Series A Preferred Stock<span style="white-space:pre-wrap;">.  In addition, the Company closed on the Dong-A Financing, and issued an additional </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_YwJOb8m61EqDiD7F2y2HpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_6YGWIm1CN0-o-tafCffSaQ">1,500</ix:nonFraction> shares of Series A Preferred Stock, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_37I4EYMzakCIpYA1bW04gA" decimals="INF" format="ixt:numdotdecimal" name="nrbo:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr_KV5gb33KdkiIDWdT_LOhmw">5,000,000</ix:nonFraction> warrants substantially similar to the Series A Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_JsyKwAESkU-fzjhg3wvYgw" decimals="INF" format="ixt:numdotdecimal" name="nrbo:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="0" id="Narr__Va4uiclGEqg1RwYoFG9SA">5,000,000</ix:nonFraction> warrants substantially similar to the Series B Warrants (the &#8220;Dong-A Warrants&#8221;). The Company received gross proceeds in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_9_14_2022_To_9_14_2022_ZstQZeqBzk69SGCuk3r0kg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_wONMO76EFkOEGhwz7Dyx9g">15.0</ix:nonFraction> million in connection with the Dong-A Financing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The Series A Preferred Stock was initially classified outside of stockholders&#8217; equity due to a contingent redemption feature if stockholder approval of the Series A Preferred Stock had not been secured within nine months from the date of issuance.  Stockholder approval was secured on December 22, 2022, at which time, all of the Series A Preferred Stock was automatically converted into </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ljoZFeq7K0W9sSW4K8xV6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_83ZjtNS5h0C-TGroD1pZxQ">12,333,333</ix:nonFraction><span style="white-space:pre-wrap;"> shares of common stock.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The Series B Convertible Preferred Stock was classified in permanent equity upon issuance as there were no other provisions precluding equity treatment.  As of December 31, 2022, all of the </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_12_31_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AETHQHuOI0u7EUpHpFV96w" decimals="INF" format="ixt:numdotdecimal" name="nrbo:StockConvertedDuringPeriodShares" scale="0" id="Narr_CgDeOb6_uUSCDbDQ78aH-w">2,602,997</ix:nonFraction> shares of the Series B Preferred Stock had been converted into <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_12_31_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AETHQHuOI0u7EUpHpFV96w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_6De0FX5Q6023HE39wm_F-g">2,602,997</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The public Warrants and the Dong-A Warrants (together, the &#8220;2022 Warrants&#8221;), upon their issuance were not exercisable unless and until stockholder approval was granted as required under Nasdaq rules.  The Company accounts for these warrants as a liability at fair value as certain provisions precluded equity accounting treatment for these instruments. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As the 2022 License Agreement and Dong-A Financing were both contingent and based on the terms of a Qualified Financing, the Company combined these two transactions along with the 2022 Public Offering (collectively, the &#8220;2022 </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_zgwFcqHodkSqbgvhSv-7DQ_1_2"></a><a id="Tc_wzMcPMOEz0m2kfEyvELvwQ_1_5"></a><a id="Tc_MWyFx09W7E-LBvTSGY0eWA_2_0"></a><a id="Tc_zdd6uLC6CEuoYdzU0hyTTA_2_2"></a><a id="Tc_1_ttwJaPt0aOn9IEVW6rNw_2_5"></a><a id="Tc_WUw9RxmTwkqlHGIGSlcWOA_3_0"></a><a id="Tc_qSyxZhJn2EOubfTHNLG43Q_3_5"></a><a id="Tc_TltOwZdafkG7lPq0sPYLDA_4_0"></a><a id="Tc_DRpAzEu0dkyqBrsGAHn1VQ_4_5"></a><a id="Tc_l9GKZBw2u0aGrKqCHBeTaw_6_0"></a><a id="Tc_gfirV5uko0-pLka5KwwttA_6_2"></a><ix:continuation id="Tb_xGO2NIpcgE2aWjFnodyiUA_cont3" continuedAt="Tb_xGO2NIpcgE2aWjFnodyiUA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction&#8221;) when allocating gross consideration and issuance costs. The table below lists the aggregate consideration received by the Company in the 2022 Transaction:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="nrbo:ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock" id="Tb_IlH8S8RjVUiV1WW9uLeDYg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consideration received</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Dong-A License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_EEmJUdpNf0uElf6g12GrWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Tc_08IQQrqfw0WYCPjk3ZiH5Q_2_3">8,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Acquired in-process research and development</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Dong-A Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_SecuritiesPurchaseAgreementMember_xdPppEpN60y-0j1Cm-TgmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Tc_VLu446dipUyPICHjgUBnrw_3_3">15,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Cash </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">2022 Public Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_WMNL8kmcJU2TTDRxUzPFXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Tc_oehiyjCG3kGGp63hLCmvSA_4_3">17,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Cash </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" id="Tc_-6ptHclNgU6bxwnNFu86xw_6_3">40,460</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The consideration received was first allocated to the 2022 Warrants at their fair value on the date of issuance.  The remainder of the consideration from the 2022 Transaction was allocated to the Series A Preferred Stock and Series B Preferred Stock (collectively the &#8220;Preferred Stock&#8221;), and to the common stock based on their relative fair values on the date of issuance. Issuance costs in connection with 2022 Transaction in the amount of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-5" format="ixt:numdotdecimal" name="nrbo:StockIssuanceCost" scale="6" id="Narr_UD7KJZkY2UWZXh6yj7VPHg">3.6</ix:nonFraction> million were allocated to each instrument based on the amount of consideration allocated to each instrument. Issuance costs attributed to the Warrants in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_HJQHlQ__sE6LZHYJuTQyyw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:WarrantsIssuanceCost" scale="6" id="Narr_azKKbIiRBkKXpvnmjsRGrA">2.2</ix:nonFraction><span style="white-space:pre-wrap;"> million were recorded as financing expense in the accompanying consolidated statements of operations and comprehensive loss.  The remainder of the issuance costs were recorded in additional paid-in capital. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The fair value of the Series A Preferred Stock was probability weighted for stockholder approval to convert to common stock.  In the approval scenario, the fair value was calculated using the underlying stock price multiplied by the number of common shares to be issued on conversion as adjusted for a </span><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gGUrMvv3ZkSmGD_w_TYU0Q" decimals="0" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_AiioR9ZOEkaeEfXxcaj3Vg">90</ix:nonFraction>% probability factor, a volatility rate of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wUjqzfyMzUqaUq1JGxWv1A" decimals="0" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_U2yP-aA-Y0mqNbVmm5mESg">101</ix:nonFraction>%, a discount for a lack of marketability of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EowmUlNgF0ijywAkcdtsEw" decimals="0" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_ikcBuffAgEG9_7H0Y5Kdhw">11</ix:nonFraction>%, a risk free rate of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mjtKTnsE70-ZgJb276XuuA" decimals="1" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_eLaiMn7W302VVQ0Rpd-IyA">3.7</ix:nonFraction>% and a remaining term of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cq7ytvBYmU6naQ7Efn7LIw" decimals="1" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_a7Ak7A9zDEKETe__hnu7oA">0.1</ix:nonFraction><span style="white-space:pre-wrap;"> years.  In the non-approval scenario, the fair value was calculated using the underlying share price as adjusted for a </span><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_jPeszFZjIEqx6fhLN1VR3Q" decimals="0" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_koHtrnqAfEew0TfeZGoMlQ">10</ix:nonFraction>% probability factor, a volatility rate of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_U3QAOXXUOUiR6REQjSJf4g" decimals="0" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_TJDbL1ohLk6k5acMdMPTrw">107</ix:nonFraction>%, a risk free rate of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_IvLn50OmOkCyhBU3LyuqfA" decimals="1" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_tH92wDfq5U-TGYMQWTbE0w">4.6</ix:nonFraction>% and a remaining term of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JiGuQjKiyUmwErH_myawlQ" decimals="1" format="ixt:numdotdecimal" name="nrbo:PreferredStockMeasurementInput" scale="0" id="Narr_myC9MqJskkqmT2Wv6mfZnw">0.8</ix:nonFraction> years. A credit risk factor was also used to discount the future value of the Series A Preferred Stock as applicable. The concluded fair value of the Series A Preferred Stock upon issuance was approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_72IFixvL4kSbmpjM1YSfwQ" decimals="0" format="ixt:numdotdecimal" name="nrbo:PreferredStockFairValuePerShare" scale="0" id="Narr_k3sC9PbDsEeqwvaQtFq9-g">3,732</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The fair value of the Series B Preferred Stock was equal to the underlying common stock fair value as the shares were readily convertible at the time of issuance on a one-for-one basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The fair value of the 2022 Warrants was determined using a Monte Carlo simulation. However, due to the cashless exercise provision of the 2022 Warrants rendering the exercise price effectively at zero, the calculated price per share of the Warrants was equal to that of a share of common stock prior to taking into account the probability factor of stockholder approval factor at <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_z5T8f5E9g0WIA-Y0HVYsRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Narr_DY3e-MHZdEWMlJjmxMsfCA">90</ix:nonFraction>%. The concluded fair value of the 2022 Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_J16HTiOMUUCrNH8sj3WXBw">24.3</ix:nonFraction> million in the aggregate on their issuance date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">October 2021 Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">On October&#160;1, 2021, the Company entered into a Securities Purchase Agreement (the &#8220;October 2021 Securities Purchase Agreement&#8221;) with several institutional investors for the purchase and sale in a registered direct offering of <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_T7SEnP5JN0igEIrchN0G_w">4,307,693</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_60KFvHiBkEyPLJWW0OE2ZA">3.25</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_94t0jrQotk-hmFkai8obAQ">14.0</ix:nonFraction> million (the &#8220;October 2021 Registered Offering&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The October 2021 Securities Purchase Agreement also provides for a concurrent private placement of warrants to purchase the Company&#8217;s common stock (the &#8220;October 2021 Warrants&#8221;) with the purchasers in the October 2021 Registered Offering. The October 2021 Warrants will be exercisable for up to an aggregate of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_3OxgPHlmh0-PKaiKbXXCvQ">4,307,693</ix:nonFraction></span><span style="font-size:10pt;"> shares of common stock. The October 2021 Warrants will have an exercise price of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_sFdWjl0gbk6TXykjIVDf1A">3.75</ix:nonFraction></span><span style="font-size:10pt;"> per share, will be exercisable commencing </span><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" format="ixt-sec:durwordsen" name="nrbo:PeriodFromIssuanceDateWarrantsBecomeExercisable" id="Narr_ugfm7erJsEiSLiR7cGxDWg"><span style="font-size:10pt;">six months</span></ix:nonNumeric><span style="font-size:10pt;"> from the issuance date (the &#8220;Initial Exercise Date&#8221;), and will expire </span><span style="-sec-ix-hidden:Hidden_Inik_Nb_jUm6ajNMDQ5Ppg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-size:10pt;white-space:pre-wrap;"> and one-half years following the Initial Exercise Date.  The fair value of the 2021 Warrants was </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_Rr4v9TJGfEqSyqn52s593A">4.1</ix:nonFraction></span><span style="font-size:10pt;"> million and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_1a7aRssBOEu9LPWKaA9O-Q">0.5</ix:nonFraction>%</span><span style="font-size:10pt;">; expected volatility of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_E5ZV_gLq4UaRi1Bg-YBpHg">80.0</ix:nonFraction>%</span><span style="font-size:10pt;">; expected life of </span><ix:nonNumeric contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_KNO4zKZTDUqa3rCA5PsqTQ"><span style="font-size:10pt;">3.5</span></ix:nonNumeric><span style="font-size:10pt;"> years; expected dividend yield of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_KvrrZz5UQUGQoiOoxNumAw">0</ix:nonFraction>%</span><span style="font-size:10pt;">; and the underlying traded stock price.&#160;The relative fair value attributable to the stock and warrants was </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="-5" format="ixt:numdotdecimal" name="nrbo:StockAndWarrantsIssuedDuringPeriodValueStocksIssued" scale="6" id="Narr_m5kshJRt20OQcRCZVf73Ww">9.8</ix:nonFraction></span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="6" id="Narr_eb-29TRr3UKegJsiUwV4uQ">4.2</ix:nonFraction></span><span style="font-size:10pt;white-space:pre-wrap;"> million, respectively.  The 2021 Warrants were classified in stockholders&#8217; equity as the number of shares were fixed and determinable, no cash settlement required and no other provisions precluding equity treatment. </span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_GakJcsvWOUCyjAKxCLRijw_1_2"></a><a id="Tc_gv2LODhZ20KjEFIhq19CfQ_2_0"></a><a id="Tc_vC9c_-FiSUWoDhnxu7qOpw_2_2"></a><a id="Tc_ybc24tElLUy1vDFy2EeCiQ_2_3"></a><a id="Tc_ah_CjUU73ka5AE47REOkKQ_2_5"></a><a id="Tc_l_uXq6SnSUiM_swFD3sYgQ_2_8"></a><a id="Tc_z5W-gq0Dg0mg4_ne6XqaKw_3_0"></a><a id="Tc_vi92J_9B80iVdMe0HUH5sQ_3_2"></a><a id="Tc_zAZr3CdGREGNo-93lLJ9zQ_3_5"></a><a id="Tc_XBEYroYn6kW3-S_A_Ulabw_3_8"></a><a id="Tc_u6_mycwg-0CbBXwUT0kBVA_4_0"></a><a id="Tc_yLIzIP5aTE-zZtT8SZKZKw_4_5"></a><a id="Tc_lJ_0JnFVo0Smsen_lW5A5Q_4_8"></a><a id="Tc_8W79piDTcUqj3f_beaNOQQ_5_0"></a><a id="Tc_tdx80dnVrEW-qV4dUXie7w_5_5"></a><a id="Tc_HS9EQn3UXkijwayyr9c-6Q_5_8"></a><a id="Tc_xKHAvvLN8E6u7kYl_T18GQ_6_0"></a><a id="Tc_9qXe7nR-YECos92aDFunUA_6_5"></a><a id="Tc_UIBT3P55bEy0PwmB9xUUTg_6_8"></a><a id="Tc_Z9M0JcF80k2aiCn1RAjV3Q_7_0"></a><a id="Tc_Uead-5yGoEWAm3ljF2Gadg_7_5"></a><a id="Tc_hZS0FCHpakeDBaX-7yBbCw_7_8"></a><a id="Tc_GCq1kEzWz0KKaGFOV6uFIA_8_0"></a><a id="Tc_ExF9JEokkkuPaCzN7K1v2w_8_3"></a><a id="Tc_loJdU7jJ6UC-hChh1J3C1Q_8_5"></a><a id="Tc_yYeO82fVMkK1CrOdEVJ8iA_8_8"></a><a id="Tc_f6Zp5KSQPUKes9ILRUZAlQ_9_0"></a><a id="Tc_xjg9AIkNOUCoAcUbeBfcog_9_3"></a><a id="Tc_rROwJGeOi06AOAdX8UJH9Q_9_5"></a><a id="Tc_xHxDU5Pfr0a9_UVMC8UVQQ_9_8"></a><a id="Tc_sFeQqvRlmEKBEXq61j_nPQ_10_0"></a><ix:continuation id="Tb_xGO2NIpcgE2aWjFnodyiUA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance costs in connection with the October 2021 Registered Direct Offering were $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_DWzQYCZoI0iO_tNobgrQCw">1.2</ix:nonFraction> million which included cash commissions equal to $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForCommissions" scale="6" id="Narr_KZYg8NL_RE2pOpYQeOMSzg">1.0</ix:nonFraction> million and legal and other fees of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="Narr_4u1PpNKXE02cGSq7CvHbWw">0.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">2021 Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On January 21, 2021, the Company closed on a Securities Purchase Agreement (the &#8220;2021 Purchase Agreement&#8221;) with certain institutional and accredited investors, pursuant to which the Company, in a private placement (&#8220;2021 Private Placement&#8221;), agreed to issue and sell an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_FVZDEv9Gsk6rdXrg7k0K6Q">2,500,000</ix:nonFraction> shares of the Company&#8217;s common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_6vsIrAk4mESOAWks9PmW-Q">4.00</ix:nonFraction> per share, and warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_gF9tGUkebkq1YtZUiMbAsA">2,500,000</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;2021 Warrants&#8221;), resulting in total gross proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_9wYk8icWo0uHB8NwKmA_vQ">10.0</ix:nonFraction> million, before deducting placement agent fees and offering expenses. The 2021 Warrants have an initial exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_LB8ERNWHvUuK3MtlIslWyQ">6.03</ix:nonFraction> per share. The 2021 Warrants are exercisable beginning six months following the date of issuance and will expire <span style="-sec-ix-hidden:Hidden_STCOS7deHEiR00lPkfq1OA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> and one-half years following such date. The fair value of the 2021 Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" id="Narr_5FPnHgoz30CvsjF8M6NI-g">7.5</ix:nonFraction> million and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_tx1PuD-W2kqqLnfmOOs_tA">0.5</ix:nonFraction>%; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_3KjnrG8Qm0iEoRf9AKGhpQ">76.0</ix:nonFraction>%; expected life of <ix:nonNumeric contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_tztlNvDIAEuXVW4STMIFgw">5.5</ix:nonNumeric> years; expected dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_L_lvFPoGJEmXtdg_WlpciA">0</ix:nonFraction>%; and the underlying traded stock price.&#160;The relative fair value attributable to the stock and warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="-5" format="ixt:numdotdecimal" name="nrbo:StockAndWarrantsIssuedDuringPeriodValueStocksIssued" scale="6" id="Narr_xljfud5DSUynUwSPFiUk-A">6.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="6" id="Narr_mDLE-Kj4zUy5peVzZiqSsw">3.7</ix:nonFraction><span style="white-space:pre-wrap;"> million, respectively.  The 2021 Warrants were classified in stockholders&#8217; equity as the number of shares were fixed and determinable, no cash settlement required and no other provisions precluding equity treatment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance costs in connection with the 2021 Private Placement were $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_03THbm1X00i9JJ1Lkl2LNQ">0.9</ix:nonFraction> million which included cash commissions equal to $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForCommissions" scale="6" id="Narr_4sHDAH3AVUGU6h595CWtqA">0.7</ix:nonFraction> million and legal and other fees of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="Narr_j_6KiXxqIUWVPEWhs62KJQ">0.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;">The following warrants were outstanding as of December 31, 2022 and 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_7p-qvszUP0qiypI04EUtRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:31.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants:</b></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Warrant Issuance</b></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">March 2017</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_R8tpABL6SEiwPZQ-3VvIFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_MX0IsK55VkGiDjKf9o_ghA_3_3">1,315</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_fo5C0eYqVUyTvpl1YK8Utg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_gA37Y08GpkqJtkkvWc3Gmg_3_6">7,800.00</ix:nonFraction> </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 2022</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">July 2018</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_QPGLTkwobEqQWl1-u_J7ng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Eng1JGFS-UO5jxcDVS1rGg_4_2">48</ix:nonFraction></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_jBT2fr5VpUOllcLVtoPKDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_55JPHbHNFUW5b-midsAMVw_4_3">48</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_QPGLTkwobEqQWl1-u_J7ng" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_ABRYFonX-EmP01pJ8o9xIg_4_6">5,602.50</ix:nonFraction> </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2028</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">April 2020</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_vzleW1-QjkCN0FSzQTflBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_xB1s4xITD0mrgZsm4R1SvA_5_2">1,252</ix:nonFraction></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_s3mxPDUhy0OW0_k2L4JVOA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_jQAOyrclPUuYTEJEWb8f5A_5_3">1,252</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_vzleW1-QjkCN0FSzQTflBg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_C6xEXDrVoESpgdGilnMLJg_5_6">375.00</ix:nonFraction> </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">January 2021</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_AK1S2nZAUUyqC_lMS5p_zQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_fYJhXGXo60qh0p_QFhzSqA_6_2">83,338</ix:nonFraction></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_MMU0eNbMe0utmyloJC2nyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_3RNmMtAMG0WcvyVTH9yXUw_6_3">83,338</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_AK1S2nZAUUyqC_lMS5p_zQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_6Q1zVgnMIUSEteK3Ag8N7A_6_6">180.90</ix:nonFraction> </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">October 2021</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_bysVT-b7fUappax39iT8-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_7NFLneOXH02oCrGZE6yAXQ_7_2">143,597</ix:nonFraction></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_zL_FjtCahk2IkDsWNpvOeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_2zYpluY9O0GfVKgphw6bPQ_7_3">143,597</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_bysVT-b7fUappax39iT8-w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_1cHvMYYCTkG6RTphzk48Sw_7_6">112.50</ix:nonFraction> </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">November 2022 Series A</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesWarrantExercisePrice3.00Member_9QLfqPRLn06Fhfn6AE5raA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_YHHTXBOzYkedv6d_GCUTow_8_2">6,768,837</ix:nonFraction></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesWarrantExercisePrice3.00Member_9QLfqPRLn06Fhfn6AE5raA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_g3iGd0I4CEqw1yGzWeIttw_8_6">0.00</ix:nonFraction> </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2023</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">November 2022 Series B</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesBWarrantExercisePrice3.00Member_GsOHy7n8B0W-TCmc86HAcw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_orYnxz8MNEaS49Mf8MM74A_9_2">8,267,170</ix:nonFraction></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesBWarrantExercisePrice3.00Member_GsOHy7n8B0W-TCmc86HAcw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_ObTNpfeCMUGCVFLuM9RiyA_9_6">0.00</ix:nonFraction> </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2027</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_4ogosnkOFkKSbCkpkRBdTA_10_2">15,264,242</ix:nonFraction></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_ODjNqXXHXUqFhLaLSyEwxw_10_3">229,550</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The warrants outstanding as of December 31, 2022 are all exercisable.  In addition, the 2022 Warrants have a cashless exercise provision whereby </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" scale="0" id="Narr_AQnCMbb9vU2DWuEFfXbeAQ">one</ix:nonFraction> warrant can be exchanged for <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A" decimals="INF" format="ixt-sec:numwordsen" name="nrbo:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" scale="0" id="Narr_WmuBGMhnPEqVRJRuWCqfqA">one</ix:nonFraction> share of common stock for <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_fiikoS_YTk-lUL4_n-0faA">no</ix:nonFraction> additional consideration, which renders the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_ZfzL5Dvo60C4s_TLuxoTqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_OK4pLl6LnU-B9EXPnrvHNw">3.00</ix:nonFraction> per share exercise price to be $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_Syw-BUTd2EajoaUuYlNFGA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_m8LvtoMlgk-cHRLUmn3suA">0.00</ix:nonFraction><span style="white-space:pre-wrap;">.  During the year ended December 31, 2022, </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_UA9AdohqXUSoaG3NbfF6OA" decimals="INF" format="ixt:numdotdecimal" name="nrbo:NumberOfWarrantsExercised" scale="0" id="Narr_FF4vJhnUAUmLWxUhtK6f4A">3,981,163</ix:nonFraction> Series A Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_YWNm-7gVqkq3BnovVKJ0Tg" decimals="INF" format="ixt:numdotdecimal" name="nrbo:NumberOfWarrantsExercised" scale="0" id="Narr__En7SEwWG0O6Ca4-UZp2vg">2,482,830</ix:nonFraction><span style="white-space:pre-wrap;"> Series B Warrants were exchanged for shares of the Company&#8217;s common stock.  </span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_68462639_403e_4271_9ada_fabc0b8eaa5e"></a><a id="Tc_x_NAzdeimEOj20gio-kz2Q_1_1"></a><a id="Tc_0Lof9hi8wkC0pi0jxFHiKQ_2_1"></a><a id="Tc_jI3GgbVMiE2sqPPH05AemA_3_2"></a><a id="Tc_9LXMcl8fyEmzwizfQZBCIA_3_5"></a><a id="Tc_jOWNEjj1K0echZww3nSVzw_4_0"></a><a id="Tc_hIOlcOVNXU2p18Lg2rSAEw_4_1"></a><a id="Tc_5jdQzSti1kGM4XGrClF5hA_4_4"></a><a id="page_gw47101_1_79_13147127"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_UYXp0FsrvUmphvXlyu5etQ" continuedAt="Tb_UYXp0FsrvUmphvXlyu5etQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Stock-Based Compensation</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_v6WNT09i-0ay65s4Hrq1Ww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense was included in general and administrative as follows in the accompanying statements of comprehensive loss:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.64%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.53%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.58%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAEVu6CnL02lDdU-rjBNQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_K8bE8j_e6U6vwSaKZM5dRw_4_2">854</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_N6zssHroH06fo8J6U0yHSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fMt-rm2otkWRMsoaYtpdoA_4_5">662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">In December 2019, in connection with the 2019 Merger, the Company assumed a previously adopted stock option plan (the &#8220;2018 Plan&#8221;) and adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;). In addition, in November 2021, the Company adopted the 2021 Inducement Plan, and in December 2022, the Company adopted the 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;). The 2018 Plan, 2019 Plan, 2021 Inducement Plan and 2022 Plan provide for the grant of stock options, restricted stock and other equity awards of the Company&#39;s common stock to employees, officers, consultants, and directors.   On May 11, 2022, the Company terminated the 2018 Plan.  As of the date of termination, there were </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_5_11_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2018Member_ko1jQnLPBEqgk8fnim0vfg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_rQPGYNCrgk6JiR9oZ36Qtg">no</ix:nonFraction> outstanding awards under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Evergreen provision</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Under the 2022 Plan, the shares reserved automatically increase on January 1st&#160;of each year, for a period of not more than <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_Ry1oAKkWqkWxsb6iJ3oDuw" format="ixt-sec:durwordsen" name="nrbo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" id="Narr_KS4G2ADN40WRTlOfxYti7g">five years</ix:nonNumeric> commencing on January 1, 2023 and ending on (and including) January 1, 2027,&#160;to an amount equal to the lesser of <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_Ry1oAKkWqkWxsb6iJ3oDuw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_Sc4W7t3p3Eiwa9WYKfT0Aw">5</ix:nonFraction>% of the common shares outstanding as of January 1, or a lesser amount as determined by the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On January 1, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_05S9u_n9JkucaP69CQY6Eg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr__FgrzefwzEutaZScNyXlEw">35,549</ix:nonFraction><span style="white-space:pre-wrap;"> shares were added to the 2019 Plan as a result of the evergreen provision associated with the 2019 Plan.  With the adoption of the 2022 Plan, </span><ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_TkENndys2Uaf4fqNaeg3Tw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_CpBrIxXwhEWVZOFL1VNCkw">no</ix:nonFraction> additional shares may be added to or grants awarded from the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022Member_eifF-TPUWEunkLiTyY8FpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_AfKbl61GtU6Woq-yBk7NMQ">5,078,721</ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlan2021Member__jN6B4AZyUeQSX5hmnKlUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_a5DHGS-Z7EKvg8lkhX5_lw">33,333</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2019Member_V9kjpRU_B0mAPphmsOIjvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_glS8ZyN0-kmcPpdOE8wt9g">15,938</ix:nonFraction> shares were authorized under the 2022 Plan, the 2021 Inducement Plan, and 2019 Plan, respectively, prior to the issuance of any shares under these plans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options expire within a period of not more than <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_udpCt7xwTkmIOi0v6glSMQ" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_gKyRojaG4kK6uQ94QMfQlA">ten years</ix:nonNumeric> from the date of grant. During the years ended December 31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_F3Tci6Qu-keRSPI02bBtUQ">5,995</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_dxDidFxQnEarx-2W8BGJHQ">22,555</ix:nonFraction> stock options were granted, respectively, to employees and directors with service conditions. The options granted with service conditions vest over a period between <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aWQ-JSgQ7Eyj0sP8jouJIQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_d7F153idHU-OSnOO6bWlHw">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_udpCt7xwTkmIOi0v6glSMQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_hb8qyulYWUmkznHpHKXc5A">three years</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c54fa43a_07ab_4a38_a8bc_dfd70c7e0bea"></a><a id="Tc_FcqDqtm22k229kjWXZeZMw_1_7"></a><a id="Tc_cZCNYbH-akeL8WZPj8PQNQ_2_4"></a><a id="Tc_26q6uITQRE2OHJtXZGfiqg_2_7"></a><a id="Tc_adDP3gO9QEKKp1JoIIZYVg_2_9"></a><a id="Tc_JGzF-ooAakOIZZh4Cjvd3Q_3_4"></a><a id="Tc_jVglXDyscEeffAneBGzIuA_3_7"></a><a id="Tc_0Y7pRFsT9UexJfrV5EqNKg_3_9"></a><a id="Tc_QdK5rsm_bU6BF8Y3LaZAEw_4_2"></a><a id="Tc_ygdz1hzACUuG44dHgCaZfQ_4_4"></a><a id="Tc_PPzjKO7Pa0CnUlux5Kq-Jg_4_7"></a><a id="Tc_HNWesXmYy0OhsPNcqbsH0A_4_9"></a><a id="Tc_C5QY4mIouEmh5cUvPxf2eA_5_2"></a><a id="Tc_wnEpcLn4KUuHWOToDRoMOQ_5_4"></a><a id="Tc_EIbj3mI2oEKFQ58TcQP9zA_5_7"></a><a id="Tc_BcTKQQNNB0qrCHxLR7kENA_5_9"></a><a id="Tc_ChMh54GP3kO1zMj_XmQinA_6_0"></a><a id="Tc_79vUMu6oiUOGKfzvc-zKrg_6_4"></a><a id="Tc_YNQuVrZDt0GDPAjrFhxB1Q_6_9"></a><a id="Tc_kEBROjiTeku86mC7GkrWcA_6_10"></a><a id="Tc_uVph96NTkECLZshoUetGRg_7_0"></a><a id="Tc_XSW2-1SvcE6_UcGmr52XFQ_7_4"></a><a id="Tc_OuQg58HGVUOxZT26xdTgjw_7_7"></a><a id="Tc_ZjYitM8cmUamrhwFgeSW7w_7_9"></a><a id="Tc_qgaulny8QEiTWCeFLFwbcQ_7_10"></a><a id="Tc_0Bca4xJpWkWa0WIVA9r48g_8_0"></a><a id="Tc_Te_pxtKyu0W2OM46XDpgcw_8_4"></a><a id="Tc_q0_vFiIak0uyYDC4Vi8NxQ_8_7"></a><a id="Tc_dcbqbqUyZEK5Zoh2fTF34A_8_9"></a><a id="Tc_IXJVF-fuBkCWhYUX4WB4IQ_9_0"></a><a id="Tc_6ZIpOARzz0qEl08ReEeKtQ_9_4"></a><a id="Tc_tOYoFAs6X0u6gNWvV4nP-Q_9_7"></a><a id="Tc_Oc_U0SCBOkqQ15jvdZN0rA_9_9"></a><a id="Tc_16huZ28w8UO77yldvmVuBQ_9_10"></a><a id="Tc_MElZi178Vk6n4luFh5K2BQ_10_0"></a><a id="Tc_KAKr0wXpBUWSYW1aSkA1Yg_10_4"></a><a id="Tc_CDrIi53Tik-M0CYaZm524Q_10_9"></a><a id="Tc_3bB5irVYRU-ARUe-dcIn4w_10_10"></a><a id="Tc_q0zTVhpLzkWFl4HF8oF4Yg_11_0"></a><a id="Tc_uWOFtjI70keKOpw_P78Yqg_11_4"></a><a id="Tc_haBWnHcQ_k6tcFKJD5pVlg_11_7"></a><a id="Tc_MMBwBQeR3EKNX-3SGNGvMA_11_9"></a><a id="Tc_hZHQ4DT8vUq1nH2Md7o1sA_11_10"></a><a id="Tc_4wYB6GJEK0GzfyvE3y6pjQ_12_0"></a><a id="Tc_aOGaOFSwP0Cr4doqUy8SAA_12_2"></a><a id="Tc_mRsW94SPRE2t7ujWke-j9w_12_4"></a><a id="Tc_AXBWCR5K7kWVrKfN23SJaw_12_5"></a><a id="Tc_ZMlOJbpJP0SvLdfyRD-4jw_12_7"></a><a id="Tc_-faTKCWqtES-IjLziwE2hw_12_9"></a><a id="Tc_LOoczHAFhE2I-GkQch7eJw_12_10"></a><a id="Tc_sNw4cK_XrkSiXwjBI5UTRw_13_0"></a><a id="Tc_-5bfJJE9E0-S9P4MzBJIlQ_13_4"></a><a id="Tc_10kdp3Q8q0W4fAMk5bxThA_13_7"></a><a id="Tc_a6hkCXNcY0Ge7hHZOpcnQg_13_9"></a><a id="Tc_brOjbsR250Kt_HI3KU6yPg_13_10"></a><a id="Tc_RgfnnUiIQUO_YpuDIokgZg_14_0"></a><a id="Tc_uN1qHdzzsUyE-aYlzWZAwg_14_4"></a><a id="Tc_hwQSdGTWx0-U29WLu2UOHA_14_9"></a><a id="Tc_Zwq3265vlECPD0-YE_Cofw_14_10"></a><a id="Tc_d7uNgpCW9k6FAhxv4nRiRg_15_0"></a><a id="Tc_aH74Zeg1bEiLtb6KT0_uxw_15_4"></a><a id="Tc_0a0jiHhM70iJHKDoxo_C7Q_15_9"></a><a id="Tc_QwUN6Z6Gnk62iTfewY_OCg_15_10"></a><a id="Tc_53NYEpwd10KAA0nkWvGUVw_16_0"></a><a id="Tc_Bn4HWhzv4USS7dGlejAhyA_16_4"></a><a id="Tc_SAn4FOqkrkyq0dmvO_436w_16_9"></a><a id="Tc_mh-x_hSiGkeDksyADvSQDA_16_10"></a><a id="_4f62fcd9_2d55_48a3_bbb0_bfd92a6a2570"></a><a id="Tc_qpgX5T17IUW99A97Yswkag_1_4"></a><a id="Tc_6fVv9V8zmU6MyTUPdTw0rg_2_4"></a><a id="Tc_F0oRwb0-PkWeT-VLDZhdHg_3_2"></a><a id="Tc_madmEe3I3Um8rBMIVvMmqw_3_4"></a><a id="Tc_ieq8r9kht06NINNpvp1W8Q_4_2"></a><a id="Tc_47HX3vb79EqUpTmXfPtwOg_4_4"></a><a id="Tc_4kj6R49bLUGk2b1E4PKczg_5_0"></a><a id="Tc_cF5sKWcN0kud4I9Rv6w8Tg_5_4"></a><a id="Tc_ckxs0_-vOkeijr3FCVqt5g_6_0"></a><a id="Tc_EPqoEXqiBU25ImUm8Lq2Mw_6_4"></a><a id="Tc_Quj7jl1ThUa6Apiihuld-w_7_0"></a><a id="Tc_CTGdvNy5NE-0UJrHsC1vKw_7_4"></a><a id="Tc_wF7GZxUvh0OiKHRlGNsN5A_8_0"></a><a id="Tc_5kAIPfSJ6Uiyc2APLsqecQ_8_4"></a><a id="Tc_p2k9KkJMAU-vilWkvMKejA_9_0"></a><a id="Tc_WFvSlNal6UipZzzmGBnouw_9_4"></a><ix:continuation id="Tb_UYXp0FsrvUmphvXlyu5etQ_cont1" continuedAt="Tb_UYXp0FsrvUmphvXlyu5etQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s stock option plan activity for the years ended December 31, 2022 and 2021 as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_e41n9MuUAE-R_TZ9K13ilQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9VXoK8ZQMkmjMvlnr02F6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_b1-LvEgZ6UeAnt5IQUMwbA_6_2">30,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9VXoK8ZQMkmjMvlnr02F6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_zp2Jxw2rSkuCgZIsz0cY_A_6_5">108.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0sehVfaRLESnA7PGQGiYcQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_xGjBIu24_0yEHaSRcxBSpA_6_7"> 8.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_0VSYNCzvzkOfoj0Yp0oamw_7_2">22,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_UGYSrc-dyk2yRNMHMcAgeQ_7_5">67.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_stL7UnB0IEuQFaFmUWY5XA_8_2">6,096</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_w7XuBsN0bEqw6Gpe4Xk4KQ_8_5">17.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_gbSCNmL4zESowWt3pLBd5g_8_10">364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_uImiC4hG_EO7xmyxq6XktA_9_2">14,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_zMNxG89bZ02cVopCveex4A_9_5">57.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9ZvJ9LtzWUOti8VldYpmzA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zrfcqWvUfUeJHhfyvyuLkg_10_2">32,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9ZvJ9LtzWUOti8VldYpmzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_fFUhlktfeUKE_D-iyBAKGQ_10_5">119.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_uQy6vlf6I0qGRHg0P902SA_10_7"> 9.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_QaJVIisQIkq7o5iu3MkbqA_11_2">5,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_bbx1K6Ify0a0ga-1Mcq3RQ_11_5">17.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_L4TNAzu-iUmEdKal8HR-XQ_13_2">2,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_IgyoVYF2LkqC6AmTPO5OaA_13_5">181.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ATe0f83l8024uciJFcr_Gw_14_2">36,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_6yShRZ5TEEWIN6cp95NYqQ_14_5">99.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_YJE3n51yY0SMmzHgBlf13A_14_7"> 8.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and expected to vest at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_ML0BMwzItkmb6LM9IlcIeQ_15_2">36,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_fn79BNw6qE-O5T3e6LQdhA_15_5">99.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_zqBGzqTs4Ea9_4u0UvignA_15_7"> 8.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options exercisable at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_j713LiZ3NE6GvucfCz_hGw_16_2">17,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_24hUqOn5mkyXkSPkkGcfBQ_16_5">146.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_romuHTsp1UCqH0gZeq8o_A_16_7"> 8.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The weighted average fair value per share of options granted during the year ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ufXrKEgaa0a42YckdtJvvg">12.43</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ULAv7ARwpk-Z69v5dJp-Sg">43.55</ix:nonFraction>, respectively. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="Tb_mjpc_d0dwUK0P927fC7C2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s unvested stock options as of and for the year ended December 31, 2022: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nonvested at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_Q0JmQRsWkkajwZxRRmLcQg_5_2">25,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_oKL4i0FjCE-lzekBKt9kvw_5_5">59.09</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_99aym4WifE2rRrpaMQqN1g_6_2">5,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_n01atKxQOUa47zA_xc_9wQ_6_5">12.43</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_5hVCRADYJkW-LVXSzZUHLQ_7_2">12,018</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_vxicC3GnbkqGODjbNy9Vnw_7_5">64.90</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="Tc_XN1tz_fTJ0Syrw_bdOvBOg_8_2">1,112</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_5e5MNZj__kmqIkNcvCbnDw_8_5">117.26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nonvested as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_CXpaeMjfI0yQg-ElYQsaew_9_2">18,590</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_P5iAJCMfIEy7pD3a6bh15Q_9_5">36.81</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, consultants and directors on the date of grant using the Black-Scholes option pricing model. The Company does not have history to support a calculation of volatility and expected term. As such, the Company has used a weighted-average volatility considering the volatilities of several guideline companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The assumed dividend yield was based on the Company&#8217;s expectation of not paying dividends in the foreseeable future. The average expected life of the options was determined based on the mid-point between the vesting date and the end of the contractual term according to the &#8220;simplified method&#8221; as described in SEC Staff Accounting Bulletin 110, or the contractual term in cases where the &#8220;simplified method&#8221; was precluded. The risk-free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant. The Company records forfeitures when they occur. </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_OVaq9NJKI0y6Qpuekw3sUw_1_3"></a><a id="Tc_32k9iQOwekiCdrjMtsJNRA_2_3"></a><a id="Tc_MksR0IX-b0Gi6L9hLn7u3w_3_3"></a><a id="Tc_XFlJZfyr10KXc9G3y8A0Ow_3_7"></a><a id="Tc_czIeG1feRUilus-gg7Cn7w_5_0"></a><a id="Tc_z9EuYHyB7EK_5JGaSbWGog_5_4"></a><a id="Tc_GvplmbH9uk-89bARELngcw_5_5"></a><a id="Tc_Y415Z3kxAk6Ov2jFko-dfg_5_8"></a><a id="Tc_pArg67P43kuPBQgK6GeYlA_5_9"></a><a id="Tc_xeUbd06g7Em0ZVVY-t6tFQ_6_0"></a><a id="Tc_dxgABhbxFkOCzCASNr_ovg_6_4"></a><a id="Tc_2u9p926XKEyprWHE2hJrzA_7_0"></a><a id="Tc__56K4-IEcEyTs9ktIUF6tw_7_4"></a><a id="Tc_1hExanr_nUuEzM3h8F59Gw_7_5"></a><a id="Tc_8mi7DxLd702_FB75KDvhLQ_7_8"></a><a id="Tc_qAy1qLR57Ua32vcltbDUKg_7_9"></a><a id="Tc_UVvYe5E_bUibbF2UMjxoNQ_8_0"></a><a id="Tc_d6ruMamHz0m2e2QD0mlwmw_8_4"></a><a id="Tc_Z-FekaRYoUy13WKBZrOlEQ_8_5"></a><a id="Tc_RF-5EQg10ESvChz1-OOF1Q_8_8"></a><a id="Tc_6baYp7qMwEyY04JFIZ8QFA_8_9"></a><ix:continuation id="Tb_UYXp0FsrvUmphvXlyu5etQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Black-Scholes option-pricing model are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_aO0pCiSsz0aNWxXyQwOYhw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected stock price volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_E1SHuYAGkkqZX7Fk9nunBQ">80.7</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_gnFaEevQEkyte3CyxV38KQ">85.2</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_uq04BWb7AE-iy-oszOsfGA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_JW-_k31eHEOqDK5gZtE8RQ">79.0</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_edJRGY-FvUOBcIWcKUF6eQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_TxESHx2dnEOz22mH2izdgQ">80.4</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected life of options (years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Wn9Zzta1c0aj2GRefykdbQ">5.5</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_5lWXTUZv20W_kUGxt2TJYw">5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_qmu6ra8kKk21XyF9XlAFbA_6_8">5.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk free interest rate </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_qQKXPMIPCkO_FhStwrKVeA">1.72</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_-BWCw6nS60KWdGqxzgzczA">3.08</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_uq04BWb7AE-iy-oszOsfGA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_9Z4XBB5S_kiCJL8aGn4jKg">0.93</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_edJRGY-FvUOBcIWcKUF6eQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_a3VRL9CvTka4-5JAumq_PA">1.33</ix:nonFraction></p></td><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Narr_MX8vwexzOkmQ3vm6cFTidg">12,018</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Narr_3beo5iC9MEmg22yX-1cwyw">3,164</ix:nonFraction> stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_9UtEMW8IX02TIFXrl1h0rg">64.90</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Narr_3E4ULzMRdkaYTa7KGKctUQ">163.64</ix:nonFraction>, respectively During the years ended December 31, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="Narr_jqr0S-mhyka2gt-0MoYUAQ">2,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="Narr_vU6zf2r05k6RmbeaD0m_2g">14,637</ix:nonFraction> stock options were forfeited, respectively. During the year ended December 31, 2021, $364 was recognized in income by option holders as a result of stock option exercises. &#160;As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_7yFz8TeHqkaHnkGtHM5ODQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_XW_zsbXqCEyofyN72gn7fg">5,091,500</ix:nonFraction> shares in the aggregate were available for future issuance under the 2022 Plan and the 2021 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Unrecognized stock-based compensation cost for the stock options issued under the 2019 Plan, the 2021 Inducement Plan, and the 2022 Plan was $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_5Db9ow_iRkWLj51gC7U6Kw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_FWuErivn_0aN0HOeBzU5og">0.5</ix:nonFraction> million as of December 31, 2022. The unrecognized stock-based expense is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_z5Cl07Q17U2ycss95AZxVQ">0.8</ix:nonNumeric><span style="white-space:pre-wrap;"> years.  </span></p></ix:continuation><a id="Tc_hS14c7zyMkSJiYTeIpU-pA_1_2"></a><a id="Tc_7Y3J3F-YlUG-Md9ls07OiA_2_2"></a><a id="Tc_85G-Z578V0Wn8h3KRW4AHQ_3_2"></a><a id="Tc_U8x8YWadjkW-UHVSZNsdVw_3_4"></a><a id="Tc_CQTTrxCjzUqyMbbt0orcxw_4_0"></a><a id="Tc_-bgsmneG2Eer5DJJEfZSVg_5_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_X4vOu4DuU0mAlc8iOHm_Ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Net Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under the Company&#39;s stock option plan and warrants during the periods that these instruments are outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The basic net loss per share calculation includes the 2022 Warrants given that these instruments are exchangeable into common stock for which no additional consideration is required from the holder.  The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive:</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_oBDUGLIaSUWCku9jXkMDsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_6mbAVgdr_kKuEsMIk2u25w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_yq-FAs8-xEicgxgjjkFdhQ_4_2">36,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_wpEzOwDCY02faZHzEsikFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ccYdYFeZaEmFMQsk0FQzCA_4_4">32,498</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_clpDxqqAN0qB38SnsnjsCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_zY9irCT9nUuMbd9tt_JOOg_5_2">228,235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_X0i0kWRTo0Oc2-qhzLlQFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_F5dXOUdSR0Wkw7Vx1fj0sw_5_4">229,550</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_4a6_rkwmEUaMga56KQq0mQ" continuedAt="Tb_4a6_rkwmEUaMga56KQq0mQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity specific measurement. Fair value is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three level hierarchy:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Level&#160;1 inputs:</b><span style="white-space:pre-wrap;">  Unadjusted quoted prices for identical assets or liabilities in active markets;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3b139672_f323_4152_b6b3_4e2bbc512c05"></a><a id="Tc_xJ8jPc2Yz0-4lXOL61hZUw_1_2"></a><a id="Tc_j582t126BUOCp0LnQQJJiQ_2_0"></a><a id="Tc_RDxiGp-6TkWZLJ4YCukMKg_2_2"></a><a id="Tc_lAl7iR4ILUSPKm4nQCmrzA_2_5"></a><a id="Tc_fBWRUj00JU6iPiX_XYrr-A_2_8"></a><a id="Tc_Bk3fk1E8E0Cz7s08I9SevQ_2_11"></a><a id="Tc_xx4qiJm8Fkm816utQtn2Xg_3_0"></a><a id="Tc_OaKvVigsy0ap7KQwNXb7GQ_4_0"></a><a id="Tc__pcsjqjdh0qCCBFOPX1xlw_4_2"></a><a id="Tc_Sg91WXEldkCaY9Fyp2jB3Q_4_5"></a><a id="Tc_MxhIUAzsNUa_s3PT39vkxg_4_6"></a><a id="Tc_QZ5Uy43lzkOU_iK3ByMilQ_4_8"></a><a id="Tc_y6_IJalZMkKSsMN4h5l9zQ_4_9"></a><a id="Tc_Z29E6jTKUkaFizSN-okwIw_4_11"></a><a id="Tc_mHVZkDTt7EmqcxX7Jie0jQ_5_0"></a><a id="Tc_M4PgKafBskqUbAB38oPWIA_5_2"></a><a id="Tc_jb_dr2-_zE-LRX4bCMmrVw_5_5"></a><a id="Tc_DcjcM2a_BkCSMniJ315IVw_5_6"></a><a id="Tc_gptMmgVKJEe85ZqOtb2IQA_5_8"></a><a id="Tc_R6zWQ-4mUk-mstYKh6Vb_g_5_9"></a><a id="Tc_ehSbc-7bZUiFlHDVpKDHHw_5_11"></a><a id="Tc_xeMQUbV51EqweHRGr-PVWA_1_2"></a><a id="Tc_83_ES-VuQUeKb8xZQOng6Q_2_2"></a><a id="Tc_5X7JiTF_nUS5RXSeaA5yhw_3_2"></a><a id="Tc_dMoLMFZvfUCWh0SvLKU3jQ_4_0"></a><a id="Tc_zB8IdU0YX02zY-uOujKQYQ_4_1"></a><a id="Tc_zj73P-Qfv0-PEWUCOBn7mQ_4_2"></a><a id="Tc_H69hanP6qkueRRFoa-n80Q_5_0"></a><a id="Tc_m9EsvS9mD02qpig7eAfRtA_7_0"></a><a id="Tc_LqMjY6lDhE6yoxqDusInBg_8_0"></a><a id="Tc_JcyOIEWtYUerHcBzA_URNQ_8_1"></a><ix:continuation id="Tb_4a6_rkwmEUaMga56KQq0mQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Level&#160;2 inputs:</b><span style="white-space:pre-wrap;">  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Level&#160;3 inputs:</b><span style="white-space:pre-wrap;">  Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nDBdXISMyEWxxvvugoib-w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Narr_zD6WhFNe0E-pgYIm7chT3w">no</ix:nonFraction> financial instruments measured on a recurring basis as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The fair value of financial instruments measured on a recurring basis as of December 31, 2022 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="Tb_sGMEjPGZu0CwiGX1Xo1q4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:39.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount" scale="3" id="Tc_XAqvV_4pk0ydQ5SfhAueaA_4_3">10,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fNzdadyn-0Gw93J5AhwBdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount" scale="3" id="Tc_0lMexBFMFUWyLmsHGhZuwQ_4_12">10,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities at Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc_RfQ-4aA7B0OzDX88C_HEAg_5_3">10,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fNzdadyn-0Gw93J5AhwBdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="Tc__EKnKDXu0kemTvM-BHa91Q_5_12">10,796</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The fair value of the 2022 Warrants was determined using a Monte Carlo simulation.  </span>This valuation technique involves a significant amount of estimation and judgment. In general, the assumptions used in calculating the fair value of the common stock warrant liability represent management&#8217;s best estimate, but the estimate involves inherent uncertainties and the application of significant management judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Input assumptions were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk free interest rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3.9-4.6</p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Volatility </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">94-103</p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Remaining term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.0-5.0</p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Due to the cashless exercise provision of the 2022 Warrants rendering the exercise price effectively at zero, the calculated price per share of the 2022 Warrants was equal to that of a share of common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The following table provides a roll-forward of the warrant liabilities measured at fair value for the year ended December 31, 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="nrbo:ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock" id="Tb_GM1jQtsPrUG5H5jXmIcE_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of 2022 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="Tc_4JLWf3Ylh06f00HwMj56Nw_5_2">24,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ONTN_FfUsEGhQ_nLCwdysw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" sign="-" scale="3" id="Tc_iGwKIkRnykOGjheOhuQevg_6_2">7,935</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclass of warrant liabilities upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw" decimals="-3" format="ixt:numdotdecimal" name="nrbo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" scale="3" id="Tc_KUDqCXM3-kG4KinWms6bJQ_7_2">5,564</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_u97PYsnPakewyhHU5f9QQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount" scale="3" id="Tc_qhEt7a5GoUy_Rf2igpdJqQ_8_2">10,796</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_OZJWgGvFHE-nVoLx8Iakrg_1_2"></a><a id="Tc_7GeT103YgEacfTc6RkKP3A_2_2"></a><a id="Tc_0XTO9lmmTkSO3_-c8f5diQ_2_5"></a><a id="Tc_ClXnl7OxUECXNkL0tKwh8w_3_0"></a><a id="Tc_xYPcbFPx6kyDwpppX49v6g_3_3"></a><a id="Tc_UYB8TXbiBECwyAXoF6ogZw_3_6"></a><a id="Tc_oQQEUBvwck6-R7rPr-vwjg_4_0"></a><a id="Tc_h8zhiLIdBEav_s4CjpjAkQ_5_0"></a><a id="Tc_DklheCMFO0OmtpseR-O4IQ_6_0"></a><a id="Tc_uxxVuj2t-0i51ti-T5qRkA_7_0"></a><a id="Tc_zVhLVMSgpU6Lpems8zxlZQ_7_2"></a><a id="Tc_X7bLC9qQ2UWE2RPIGAg9Jg_8_0"></a><a id="Tc_qjoNjanXOEqtIc74oo0xLw_8_5"></a><a id="Tc_DB2AjwhSG02EqAPHYCzWIA_9_0"></a><a id="Tc_ux3iKOvRCU-Tibt92U9vPQ_9_5"></a><a id="Tc_yjAIsCvF50aKD8y0cLG83Q_10_0"></a><a id="Tc_3ib8l4uDzk-ISG2ewJLz-g_10_5"></a><a id="Tc_1b4oefI2bUiO9KkLUftW-w_11_0"></a><a id="Tc_qTKeWfokLEOAPfyJg60Trw_12_0"></a><a id="Tc_m4hPIhxZ4EGYCshWPcMc9Q_12_2"></a><a id="Tc_iJJFppLexUS48Mbue-BOjg_12_3"></a><a id="Tc_8rSU20cNoEWjW1NhCAgU5Q_12_5"></a><a id="Tc_5y-wka8RckSrLaPpx6OQUA_12_6"></a><a id="_f8c48883_0cea_454c_a95e_6ca8c99437c3"></a><a id="Tc_2gPphPdOEECW74etBIt0Uw_1_2"></a><a id="Tc_NI5RKcDNh0Cnu7gPEjVkug_2_2"></a><a id="Tc_TfYlyJc0DkSXOlrUJ-UOQA_2_5"></a><a id="Tc_qe26Q3klrUKqAfOT20xmDA_4_0"></a><a id="Tc_2J_7EvQZ-EuLm7Zz_QFAdA_5_0"></a><a id="Tc_fWESe_t2N0CK1ghI7FVt-w_5_2"></a><a id="Tc_ZxBLBYvwj0yh9X0otccPFA_5_5"></a><a id="Tc_ueEuOZ5vykmbeUQ4BBnDWw_6_0"></a><a id="Tc_msXp43gebEi4AUHRlp8PJA_7_2"></a><a id="Tc_MvIFEXO5lUSpdrLgS8Wvyw_7_5"></a><a id="_66decfd3_8e40_42da_b59a_3e393a48d261"></a><a id="Tc_T-AD_KKOHUaVMxFSzDbxTg_1_2"></a><a id="Tc_6aD3v9TSKUqgQ-hqwBx9jQ_2_2"></a><a id="Tc_1jyRyo5BkUOsdxp81YrrUw_2_5"></a><a id="Tc_04VbSyadAE-SYkBs0k9_kA_4_0"></a><a id="Tc_DWOT3DNojUSP7__hS_9gaw_5_0"></a><a id="Tc_y4_KUWqjSU2PoXKzPQx-0A_6_0"></a><a id="Tc_Zz2kwfhpf02LPzO8nAfeHg_6_2"></a><a id="Tc_IlN0i25cVU-p3UC2-42F8w_6_3"></a><a id="Tc_4-BTmYahu0iZ1PxTaS00tw_6_5"></a><a id="Tc_FZHdR7v3AEaUD4W2KJYyZQ_6_6"></a><a id="Tc_BJ-srCD8ZESIc32-GjJjVA_7_0"></a><a id="Tc_J0Of29p_CUGGBFjGp_jN6A_7_3"></a><a id="Tc_dqOl2NrtKkiXX-5uxKVXRA_7_6"></a><a id="Tc_c0Ah8YAeq0yAFlf8-W4s_Q_8_0"></a><a id="Tc_STkZ7nLUr0ehruohNdh9ag_8_3"></a><a id="Tc_8GtePv1KfkSHsZv8ohTPSw_8_6"></a><a id="Tc_TqqYK8mLoEmD64MWR9KtKw_10_0"></a><a id="Tc_wGBHV1pURUGWW8KVU_qJQg_11_0"></a><a id="Tc_7KRcUeRkP0SKs8Hb9f4ajg_12_0"></a><a id="Tc_yikfaw7cqUS2hfvFlKiqEg_13_0"></a><a id="Tc_Da_0iGEZPUygwjWkzlribQ_15_0"></a><a id="Tc_je9SeWF6skCvgyeZtOu-8Q_16_0"></a><a id="Tc_JTddLrFNU0u7Ey4272pUAg_18_0"></a><a id="Tc_tyS6MMSTE0GwWJIpQt3O1g_18_2"></a><a id="Tc_7Nwn1UyoPEyl1LQpLdLLbA_18_3"></a><a id="Tc_TdufG80xlkmOT1W8lpLixA_18_5"></a><a id="Tc_ar_tDkYlT0SHwQaGrku5Xw_18_6"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_dClw-K7hS0WCvaZWXJ3Faw" continuedAt="Tb_dClw-K7hS0WCvaZWXJ3Faw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">11. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The effective tax rate for the years ended December 31, 2022 and 2021 was <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr__-2cPOU4bUSvTq41in0NJA"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_qaBnPvpKPkGRjIMFos0vQQ">zero</ix:nonFraction></ix:nonFraction> percent. A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_aPQT-hZ9u0egQbAq_zMItA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income tax (benefit) provision at federal statutory rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_7yoDJklreU-n0kDBR1qZWQ_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_w8CgsoDgcka4LUe8ahScxQ_3_5">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">State income tax, net of federal benefit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_4SNx6-OcFk-HYF2-E8__xQ_4_2">7.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_GG4V9tCJjkOTg8eXh719PA_4_5">3.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_dohCR85BE0OLiUWOMvZL9A_5_2">188.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_U2QPWfBSikKwfOrIrUH39A_5_5">26.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_CUKcS_us-kC5Ate6hz-NrA_6_2">1.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_kQmAJ7GkjEqLayeLLSd1lQ_6_5">2.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision to tax return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_XXTfd8BT8UO0LA_d4-TL1w_7_5">1.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="nrbo:EffectiveIncomeTaxRateReconciliationTransactionCost" sign="-" scale="-2" id="Tc_apW89VyYjEifV1uBC2JlSg_8_2">3.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="nrbo:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" scale="-2" id="Tc_a0m_FJYYLEeCGkwthekTqQ_9_2">11.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Section 382 limitation adjustment attributes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="nrbo:EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent" sign="-" scale="-2" id="Tc_yRwFUzOq30CJY9Dv0vBI0Q_10_2">225.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" sign="-" scale="-2" id="Tc_ibpRuhtyD0uw9HwPSV8oQA_11_2">1.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="Tc_LjnZtve2c0WdCjgb3PDHjQ_11_5">0.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective tax rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_xIg4R9XY7E2yMpT9ocrAjw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Loss before provision for taxes for the years ended December 31, 2022 and 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before Income taxes:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_jqEvPnpx_kSiC5DOELWxww_5_3">14,559</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="3" id="Tc_jld1Ho0-rUaIN_hVQ2XjsA_5_6">14,954</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="Tc_S1PVCnsi90aJ-yzju7qCrg_6_3">592</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="3" id="Tc_Z1e3E85oLEKoXsrlR20UWg_6_6">330</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_82hAGlZ5jUCTjqa-NrKEGQ_7_3">13,967</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_c1qsMltlwEu6BLe45q2aUQ_7_6">15,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_0DbPBHjWME2bWV4XUE-CuA" continuedAt="Tb_0DbPBHjWME2bWV4XUE-CuA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The components of income tax provision (benefit) consisted of the following for the years ended December 31, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax Provision (Benefit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Domestic</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Domestic</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="Tc_THMEk6b1FU-yl5qpXJh5fA_11_3">26,183</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" sign="-" scale="3" id="Tc_bIYmIq2cx0S-CB-2732NJA_11_6">3,932</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="Tc_dTSGwAJVl0eAF4fD1a8dqQ_12_3">148</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc__j0Zpiwmg0u0bQLOCd56nA_12_6">81</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_UMafUvTxb0u0EHC_oUFrZw_13_3">26,331</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_nP23lV34UkmrrKq6-h0goQ_13_6">4,013</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" scale="3" id="Tc_Geb-sv5rQUqpjGoM85ZNLg_15_3">26,183</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_wGA6zCjvmESEzq1Mz9-tqA_15_6">3,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" scale="3" id="Tc_oUdigkzBZU6uZKX07juESA_16_3">148</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt:numdotdecimal" name="nrbo:ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_YqV5txencE-CLyQpO3jL5Q_16_6">81</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_RH1LTbvgs0CuvoKIZSahVw_1_2"></a><a id="Tc_lw10SsaMu0a4QBmmg49VnQ_2_2"></a><a id="Tc_Z-SYRCyrHUm9VVjFa-rkBA_2_5"></a><a id="Tc_DPeS_4_6QUytC4FO0HR63A_4_0"></a><a id="Tc_nbKuwQcjZ0mJUUt0uozwJg_5_0"></a><a id="Tc_aVJ6_TLxMkK5o-1Z3DarGQ_5_2"></a><a id="Tc_nxJ-0QrHUke6lrmalHRFYA_5_5"></a><a id="Tc_xKjh73rK602jIDqey-wWfw_6_0"></a><a id="Tc_t9HtXp_s2k6hMRNT15-w4Q_7_0"></a><a id="Tc_fQzVZIC-LE66hIK8AkM43Q_8_0"></a><a id="Tc_3e869LLhQkiAqWwWy5EA5Q_9_0"></a><a id="Tc_ZXXJKsWoCEG2ILfTQUQPQw_9_3"></a><a id="Tc_BVTRnoMpiUSXDKIZzW8DSA_10_0"></a><a id="Tc_IA9l5t_q80KRnUbRQBBYaQ_11_0"></a><a id="Tc_bvqXDJQDZ0q8wY7hwHbU_g_12_0"></a><a id="Tc_InGWm0acukGtmTDZs-ajGg_14_0"></a><a id="Tc_-tilZSLydE2WwKyFIA_pOA_15_0"></a><a id="Tc_nsSLh77I7UCtZ9x-J1osPA_16_0"></a><a id="Tc_NVfpkDt0xECfAAtH_lPFrw_16_3"></a><a id="Tc_leeAwVcuzkGqDS6nt7uRjw_18_0"></a><a id="Tc_aad9PD0LMEyWzRXwFMx5kw_19_0"></a><a id="Tc_3If-9GGczUqPor2H2gUqmw_19_3"></a><a id="Tc_ksEN5EwhjUeH9LV6IvQVRw_20_0"></a><a id="Tc_e2seye0sbUONGhvpnU4ugw_20_3"></a><a id="Tc_xr0OK8FtG06Sr4Bq-7x7bg_21_0"></a><a id="Tc_Ownij6KnbUCxli4c99W_-g_21_2"></a><a id="Tc_i_BLbJ90fEOEs7G9QO1ssg_21_3"></a><a id="Tc_LNmZHYSpbUqOUgrhbPDUWQ_21_5"></a><a id="Tc_JHD4KdKdf0OG0ROvgmmuCw_21_6"></a><ix:continuation id="Tb_dClw-K7hS0WCvaZWXJ3Faw_cont1" continuedAt="Tb_dClw-K7hS0WCvaZWXJ3Faw_cont2"><ix:continuation id="Tb_0DbPBHjWME2bWV4XUE-CuA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_2tnAo__8UU6pTVSh5Zg2Lw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Federal and state operating loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_QhuKb6duyk6nFk2i-PGtAg_5_3">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Utur1YpgYk6GHXkDjj0LUw_5_6">19,904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Foreign operating loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="Tc_YLvzsBQotUSTohLO0zkEPw_6_3">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="Tc_b3zYOzaJEUqz0nVxIAh-4Q_6_6">324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired intangibles </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredTaxAssetsAcquiredIntangibles" scale="3" id="Tc_89Lg-Vsm4UyXxo2A1l4How_7_3">3,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredTaxAssetsAcquiredIntangibles" scale="3" id="Tc_8gMf-hB3QkOKbFAo1IEaYw_7_6">1,683</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_bz6WlbaLBk6y2cn3tlrvCQ_8_3">467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_fu8nBdc3Z0WBOxwlMNabyA_8_6">276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredTaxAssetsLeaseLiability" scale="3" id="Tc_NE7HvZTKfkKjtdAxd6WvoQ_9_6">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized R&amp;D Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_hgFmHQjPYEaq4U4VBu2ydg_10_3">278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" scale="3" id="Tc_XM_3qA1qt0eGH-rLhLHUSQ_10_6">7,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_F_WMlQF42kKL6UqLTAveng_11_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_vl77HwuC_kibO4BM0pJa9w_11_6">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development credit carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_Ijgv1gKq8EmH9wVXp_0ANg_12_3">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_AfB0TQ8sYECkD1BAUHfEcw_12_6">1,483</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">   <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_r2yaVtAtEk2-SgWiGXDXJQ_13_3">4,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_0YydAVX4IEWhaXPcQAtDwg_13_6">30,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance - Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_FTH-Z5omkUeyKBGjxwaEdA_14_3">4,252</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1pjv2MX8J0-yfwddaY-lNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Ntzgn5qsb0q73KzrdG6Szw_14_6">30,410</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance - Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_l0ZHVOGbuUOzRBb3KR4MiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_8CcBUAH0-kOqDSRW2zYvsQ_15_3">176</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_h4TI82YIYEafQM3AvpLuuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_2OmnoZEqrkqRPZwoo78z5w_15_6">324</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax assets, net of valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_qFDfvtDlVEmvq7XLQBKKNw_16_6">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredTaxLiabilitiesRouAsset" scale="3" id="Tc_asBIbYWad0erXygOPWvp-A_19_6">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt:numdotdecimal" name="nrbo:DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" scale="3" id="Tc_jHVlj9-ngkeIAjMcFZ99Mw_20_6">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net deferred tax assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">As of December 31, 2022 and 2021, the Company had deferred tax assets of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_smq953lKoU-8J6w7l2NqpQ">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_8k-B5xnGYk6Hl0YPHbWnfw">30.8</ix:nonFraction> million, respectively. Realization of the deferred tax assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the deferred tax assets have been fully offset by a valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_UGlDzWT9bkKxQTCJEqo6hQ">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_s43Mzwcar02OztBd2E1rHA">30.8</ix:nonFraction> million as of December 31, 2022 and 2021, respectively. U.S. deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">As of December 31, 2022 and 2021, the Company&#8217;s federal net operating loss carryforwards were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_OGUCrU91skKYDXJeYxFTDA">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_jSUVqfFIO0-5Ufr4OXMgtg">81.8</ix:nonFraction> million, respectively. The Company had federal research credit carryforwards as of December 31, 2022 and 2021 of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:OperatingLossCarryForwardResearchCredit" scale="6" id="Narr_jRD0wXd_RU-0syhR_l9Oiw">24</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-5" format="ixt:numdotdecimal" name="nrbo:OperatingLossCarryForwardResearchCredit" scale="6" id="Narr_RA5tYGi6QUelftbYb2bwSA">1.0</ix:nonFraction> million, respectively.<span style="white-space:pre-wrap;">  The Federal net operating losses were incurred after December 31, 2017 and therefore, will not expire.</span> As of December 31, 2022 and 2021, the Company had state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_jqDo-_w_qE2ozuCmc2Cimg">65</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_rK39GiKi0E-GQ49BN2XJTQ">42.6</ix:nonFraction> million, respectively. The Company had state research credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:DeferredTaxAssetsTaxCreditCarryforwardsState" scale="6" id="Narr_AtNwEJ2K30-Ges682JVQLQ">2</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-5" format="ixt:numdotdecimal" name="nrbo:DeferredTaxAssetsTaxCreditCarryforwardsState" scale="6" id="Narr_jGQ9DXtaYE-kgOPqgSU_Ng">0.6</ix:nonFraction><span style="white-space:pre-wrap;"> million as of December 31, 2022 and 2021, respectively. The state net operating loss carryforwards and state research credit carryforwards will begin to expire in 2043, if not utilized.  Lastly, the Company had foreign net operating loss carryforwards of approximately </span>$<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_l0ZHVOGbuUOzRBb3KR4MiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_ivY9UTo_KkO1Hq6amOb4wg">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_h4TI82YIYEafQM3AvpLuuQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_Gz-QJ1o4NkS8lXPGOTiEKg">1.3</ix:nonFraction> million as of December 31, 2022 and 2021, respectively. The foreign net operating loss carryforwards will begin to expire in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#8220;5-percent shareholders&#8221; increase their ownership, in the aggregate, by more than 50 percentage points over a 36<span style="font-family:'Cambria Math';">-</span>month testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization. As a result of the public stock offering and private placement offering during the fourth quarter of 2022, a Section 382 ownership change occurred with an annual limitation of $0. Because of the 2022 ownership change and corresponding limitation, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow" decimals="-5" format="ixt:numdotdecimal" name="nrbo:NetOperatingLossCarryforwardsWrittenOff" scale="6" id="Narr_8frcrPkZjUO2fkhH--HGQQ">99.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_zzR33TSc_Eq3qTKp-rYpEw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:NetOperatingLossCarryforwardsWrittenOff" scale="6" id="Narr_ENGcpuPQH0umw4veC_bvaQ">48.5</ix:nonFraction> million of federal and state net operating loss carryforwards, respectively, were written off, with a corresponding offset to the Company&#39;s full valuation allowance. Additionally, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow" decimals="-5" format="ixt:numdotdecimal" name="nrbo:ResearchCreditCarryforwardsWrittenOff" scale="6" id="Narr_G2Mfm7X5UEab5t1KrdxmPQ">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_zzR33TSc_Eq3qTKp-rYpEw" decimals="-5" format="ixt:numdotdecimal" name="nrbo:ResearchCreditCarryforwardsWrittenOff" scale="6" id="Narr_f7DEFdwPJ0SjVuNF-jfRug">0.6</ix:nonFraction> million of federal and </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:24pt 0pt 0pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Notes to Consolidated Financial Statements &#8211; continued</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Dollar Amounts in Thousands, Except Per Share Amounts)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dClw-K7hS0WCvaZWXJ3Faw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">state research credit carryforwards, respectively, were written off, with a corresponding offset to the Company&#39;s full valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_kGcVqM8vf0OHYNPQlAf7Tg"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr__eq-KePaVkyPRcGY8WJO-Q">no</ix:nonFraction></ix:nonFraction> uncertain tax positions as of December 31, 2022 and 2021, and as such, <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr_6zGO34Yc7Um-fgPy-g5Z_w"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="Narr__Cur0k8__EOduU7geI91qA">no</ix:nonFraction></ix:nonFraction> interest or penalties were recorded to income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s corporate returns are subject to examination beginning with the 2018 tax year for federal and state jurisdictions, and beginning with the 2019 tax year for one foreign jurisdiction.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="page_ea47101_1_374"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_4g4AspbtyES5iDrhaVte1w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">12. Related Party Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:11pt;text-indent:-11pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Agreements with Dong-A</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On September&#160;28, 2018, NeuroBo entered into a <span style="-sec-ix-hidden:Hidden_F7zo_zW-NUK53QFVdH_Apw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> year manufacturing and supply agreement with Dong-A, a greater than <ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA" decimals="2" format="ixt:numdotdecimal" name="nrbo:PercentageOfSharesHeldByRelatedParty" scale="-2" id="Narr_HTzaj1YLtUewOlEuGcN8Vw">5</ix:nonFraction>% shareholder,&#160;for the manufacturing and supply of NB-01 drug substance and placebos for the purpose of research and development to be used in Phase&#160;3 clinical trials (the &#8220;Manufacturing Agreement&#8221;). There were <ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_LoFCvnOSokiqESf8sPL2dw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RelatedPartyCosts" scale="3" id="Narr_yy6p6UHKwUCYIp_9nuXY6Q"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_jakDXzDB0EqYM_f7RAVDWQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RelatedPartyCosts" scale="3" id="Narr_ynM5UkTOBUSmhE8CKKuRlQ">no</ix:nonFraction></ix:nonFraction> manufacturing related costs under the Manufacturing Agreement for the years ended December 31, 2022 or 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Manufacturing Agreement will automatically terminate in the event that the license agreement with Dong-A is terminated for any reason. In addition, each of Dong-A and NeuroBo may terminate the Manufacturing Agreement (1)&#160;upon the material breach by the other party, if the breach is not cured within a specified number of days after receiving notice from the terminating party, or if the breach cannot reasonably be cured within such period and the breaching party has not started to remedy the breach within such period and diligently endeavored to cure the breach within a reasonable time thereafter, or (2)&#160;in the event that (i)&#160;the other party is the subject of a petition for bankruptcy, reorganization, or arrangement and the same is not dismissed within <span style="-sec-ix-hidden:Hidden_2TEjfFmoakSOFBCUgn6ldg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span></span> days thereof, (ii)&#160;a receiver or trustee is appointed for all or a substantial portion of the assets of the other party, or (iii)&#160;the other party makes an assignment for the benefit of its creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">On June 7, 2020, the Company entered into a manufacturing and supply agreement (the &#8220;Manufacturing and Supply Agreement&#8221;) with Dong-A for the manufacturing and supply of NB-02 drug product and placebo for the purpose of research and development of NB-02, including but not limited to, the use in the first NB-02 human clinical trial to be conducted by the Company. Under the terms of the Manufacturing and Supply Agreement, upon receipt of a purchase order from the Company no later than </span><ix:nonNumeric contextRef="Duration_6_7_2022_To_6_7_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_ManufacturingAndSupplyAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_mrVIOz70GUG2r1JVXDTTRw" format="ixt-sec:durwordsen" name="nrbo:PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" id="Narr_SyR8J9sXnE6JMcUaMthQhA"><span style="font-size:10pt;">270 days</span></ix:nonNumeric><span style="font-size:10pt;"> prior to the requested delivery date, Dong-A has agreed to produce for the Company tablets of the NB-02 drug substance and placebos at a specified supply price. The Company is obligated to manufacture, or have manufactured, and supply to Dong-A the active pharmaceutical ingredients which are necessary to manufacture the NB-02 drug product. The Manufacturing and Supply Agreement has a </span><span style="-sec-ix-hidden:Hidden_Y_VNuVMUj02pKiVqh9023w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-size:10pt;"> year term, subject to earlier termination under certain circumstances.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_MZZPifuYsESndZuF8q9YTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">13. Defined Contribution Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background:#ffffff;">The Company adopted a 401(k) defined contribution plan in November 2018, effective as of January 1, 2019, for all employees over age&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" format="ixt-sec:duryear" name="nrbo:DefinedContributionPlanEmployeeEligibilityAge" id="Narr_MIQInc-reki5ARdhedm31w"><span style="background:#ffffff;">21</span></ix:nonNumeric><span style="background:#ffffff;">. Employees can defer up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg" decimals="2" format="ixt:numdotdecimal" name="nrbo:DefinedContributionPlanEmployeeContributionDeferredPercentage" scale="-2" id="Narr_upL3P6t0c0ydODUyBnWepw">90</ix:nonFraction>%</span><span style="background:#ffffff;"> of their compensation through payroll withholdings into the plan subject to federal law limits. Discretionary employer matches vest over a </span><span style="-sec-ix-hidden:Hidden_DPeIVkG-okWzbfTbv-bZXQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">six</span></span><span style="background:#ffffff;">-year period beginning on the second anniversary of an employee&#8217;s date of hire. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="2" format="ixt:numdotdecimal" name="nrbo:EmployeeCompensationVestingPercentageOnContribution" scale="-2" id="Narr_yrMKknAFJEmtSEg2kXjGzg">100</ix:nonFraction>%</span><span style="background:#ffffff;"> vested upon contribution. </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_l9KA-uMMbUKFZN4uSa0DEw"><ix:nonFraction unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA" contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_43v-8s2KtEqoO7DAi-3ENw">No</ix:nonFraction></ix:nonFraction></span><span style="background:#ffffff;"> matching contributions were made during the years ended December 31, 2022 and 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_lzGk_YAk-EegUHN35VOwVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. Subsequent Events </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Since December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e0tClQh0z0msDPqPsOTVmg" decimals="INF" format="ixt:numdotdecimal" name="nrbo:NumberOfWarrantsExercised" scale="0" id="Narr_uM7YqQhY4k2iop6wgLr4YQ">345,333</ix:nonFraction> Series A Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hjmzNGpAn0213gk2bupY4A" decimals="INF" format="ixt:numdotdecimal" name="nrbo:NumberOfWarrantsExercised" scale="0" id="Narr_9SZbGhZlSEevG891X51ozg">1,395,333</ix:nonFraction><span style="white-space:pre-wrap;"> Series B Warrants were exchanged for shares of the Company&#8217;s common stock.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47803d05_b8d9_417c_935d_072707056bc5"></a><a id="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 9.</b></span><b style="font-weight:bold;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</b><b style="font-weight:bold;"> FINANCIAL DISCLOSURE </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;">None</p><a id="_8ce00e87_88d3_4de3_ba71_f9362a94f5c9"></a><a id="Item9A"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 9A.</b></span><b style="font-weight:bold;">CONTROLS AND PROCEDURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;margin:0pt;">As required by Rules 13a-15(b) and 15d-15(b) under the Exchange Act, our management, with the participation of our principal executive officer (&#8220;PEO&#8221;) and principal financial officer (&#8220;PFO&#8221;), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this annual report for the Company. Based upon that evaluation, our PEO and PFO concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this annual report, as a result of material weaknesses in our internal control over financial reporting, which is discussed further below. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="white-space:pre-wrap;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and Board; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="white-space:pre-wrap;">Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2022.  The scope of management&#8217;s assessment regarding the Company&#8217;s internal control over financial reporting includes the criteria set forth by the Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of The Treadway Commission.  As a result of material weaknesses, management has concluded that our internal control over financial reporting was not effective as of December 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="white-space:pre-wrap;">In connection with the preparation of the audited financial statements included elsewhere in this report, management has identified a material weakness resulting from a lack of segregation of duties over cash disbursements and financial reporting, a material weakness related to logical access over computer applications, and a material weakness due to lack of supervision and review over financial reporting.  A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Specifically, there was a lack of segregation of duties involved in the execution of wire transfers, preparing journal entries, and review over clinical trial accruals, and certain individuals in the accounting department have administrative access to the financial reporting systems.  See &#8220;Remediation Efforts to Address the Material Weaknesses&#8221; below for steps we are taking to correct these material weaknesses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><b style="font-weight:bold;">Remediation Efforts to Address the Material Weaknesses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;">We are in the process of remediating, but have not yet remediated, the material weaknesses related to lack of segregation of duties, logical access and lack of supervision and review over financial reporting as described above. Under the oversight of the audit committee, management is developing a detailed plan and timetable for the implementation of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;">appropriate remedial measures to address the material weaknesses. As of the date of this report, we are taking or intend to take the following actions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will enhance the controls over disbursements, separating the functions of initiating and approving to two separate individuals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will implement enhanced controls relative to the review and oversight of the accounting for review of journal entries, cash disbursements and financial reporting.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.8pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will restrict administrator rights to only those individuals who require access.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;">Management may decide to take additional measures to remediate these material weaknesses as necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background:#ffffff;">This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit us to provide only management&#8217;s report in this Annual Report on Form 10-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Inherent Limitations of Disclosure Controls and Procedures and Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;">Our management, including our PEO and PFO, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.8pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other than the remediation activities listed above, there have been no changes in our internal control over financial reporting during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_66999503_ecc3_46cd_a5f8_f9b6b1d2858f"></a><a id="ITEM9BOTHERINFORMATION_848698"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 9B.</b></span><b style="font-weight:bold;">OTHER INFORMATION </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 29, 2023, Dr. Richard Kang provided notice of his resignation from the Board of Directors of the Company, effective immediately due to time constraints related to his other positions. Dr. Kang&#8217;s resignation was not the result of any disagreement with the Company regarding the Company&#8217;s operations, policies or practices. </p><a id="_beea34bf_55d6_4e76_9623_6976d69dc8ce"></a><a id="ITEM9C_805257"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 9C.</b></span><b style="font-weight:bold;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b74c8abf_9e6b_4c99_a4ad_299bc8dbf51e"></a><a id="PARTIII_373562"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II</b><b style="font-weight:bold;">I</b></p><a id="_c9b51b83_6c4c_46cf_942d_b67f0dea6b18"></a><a id="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 10.</b></span><b style="font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors and Executive Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">The Board is divided into three classes. Members of each class serve staggered three-year terms. The terms of office of directors in Class I, Class II and Class III expire at the annual meetings of stockholders to be held in 2023, 2024 and 2025, respectively. The following table provides information as to each person who is, as of the filing hereof, a director and/or executive officer of the Company.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:61.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:28.58%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:61.22%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position(s)</b></p></td><td style="vertical-align:top;width:10.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td></tr><tr><td style="vertical-align:top;width:28.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">Andrew Koven</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">Class II Director and Chair of the Board</p></td><td style="vertical-align:top;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;background:#cceeff;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:top;width:28.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#ffffff;margin:0pt;">Hyung Heon Kim</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#ffffff;margin:0pt;">Class II Director</p></td><td style="vertical-align:top;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;background:#ffffff;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:28.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">Jason L. Groves</p></td><td style="vertical-align:top;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">Class II Director</p></td><td style="vertical-align:top;width:10.19%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;background:#cceeff;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:28.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#ffffff;margin:0pt;">Na Yeon (Irene) Kim</p></td><td style="vertical-align:top;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#ffffff;margin:0pt;">Class I Director</p></td><td style="vertical-align:top;width:10.19%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;background:#ffffff;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:28.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">D. Gordon Strickland</p></td><td style="vertical-align:top;width:61.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">Class I Director</p></td><td style="vertical-align:top;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;background:#cceeff;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:28.58%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#ffffff;margin:0pt;">Michael Salsbury</p></td><td style="vertical-align:top;width:61.22%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#ffffff;margin:0pt;">Class III Director</p></td><td style="vertical-align:top;width:10.19%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;background:#ffffff;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:28.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">Joseph Hooker</p></td><td style="vertical-align:top;width:61.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;background:#cceeff;margin:0pt;">Interim Chief Executive Officer and President</p></td><td style="vertical-align:top;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;background:#cceeff;margin:0pt;">70</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Business Experience and Background of Directors and Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Andrew Koven-</span><span style="white-space:pre-wrap;">Mr. Koven has served as a member of our Board since July 2021, and Chair of our Board since January 2022.  Mr.&#160;Koven is the Lead Independent Director of Kala Pharmaceuticals,&#160;Inc., a public biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. He has served as the Lead Independent Director of Kala Pharmaceuticals,&#160;Inc. since December&#160;2018 and as a member of the Kala board of directors since September&#160;2017. Mr.&#160;Koven was, until his retirement in January&#160;2019, the President and Chief Business Officer of Aralez Pharmaceuticals&#160;Inc., or Aralez, a public specialty pharmaceutical company, and served in that role with the company&#8217;s predecessor, Pozen&#160;Inc., commencing in June&#160;2015. Prior to joining Pozen, Mr.&#160;Koven served as Executive Vice President, Chief Administrative Officer and General Counsel of Auxilium Pharmaceuticals&#160;Inc., a public specialty biopharmaceutical company, from February&#160;2012 until January&#160;2015, when it was acquired by Endo International&#160;plc.&#160;Mr.&#160;Koven served as President and Chief Administrative Officer and a member of the board of directors of Neurologix,&#160;Inc., a company focused on the development of multiple innovative gene therapy development programs, from September&#160;2011 to November&#160;2011. Before Neurologix, Mr.&#160;Koven served as Executive Vice President and Chief Administrative and Legal Officer of Inspire Pharmaceuticals,&#160;Inc., a public specialty pharmaceutical company, from July&#160;2010 until May&#160;2011 when it was acquired by Merck&#160;&amp; Co.,&#160;Inc. Previously, Mr.&#160;Koven served as Executive Vice President, General Counsel and Corporate Secretary of Sepracor&#160;Inc. (now Sunovion), a public specialty pharmaceutical company, from March&#160;2007 until February&#160;2010 when it was acquired by Dainippon Sumitomo Pharma Co.,&#160;Ltd. Prior to joining Sepracor, Mr.&#160;Koven served as Executive Vice President, General Counsel and Corporate Secretary of Kos Pharmaceuticals,&#160;Inc., a public specialty pharmaceutical company, from August&#160;2003 until its acquisition by Abbott Laboratories (now AbbVie) in December&#160;2006. Mr.&#160;Koven began his career in the pharmaceutical industry first as an Assistant General Counsel and then as Associate General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992 he was a corporate associate at Cahill, Gordon&#160;&amp; Reindel in New York. From 1992 to 1993 he served as Counsel, Corporate and Investment Division, at The Equitable Life Assurance Society of the U.S. Mr.&#160;Koven holds a Master of Laws (LL.M.) Degree from Columbia University School of Law and a Bachelor of Laws (LL.B.) Degree and Bachelor of Arts Degree in Political Science from Dalhousie University. Our Board believes that Mr.&#160;Koven&#8217;s extensive experience in the pharmaceutical industry qualifies him to serve as a director.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0.05pt 5.6pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Hyung Heon Kim-</span><span style="color:#0f0f0f;font-style:italic;font-weight:bold;"> </span>Mr. Kim has served as a member of our Board since July 2021. Mr. Kim is the General Counsel and a Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APis. Mr. Kim has </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 5.6pt 6pt 0pt;">served as General Counsel of Dong-A ST since January 2018 and as a Vice President of Dong-A ST since December 2020. Mr. Kim previously served as Executive Director of Dong-A ST from January 2018 through December 2020. Prior to his roles with Dong-A ST, Mr. Kim was Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. Since April 2021, Mr. Kim has served as a director of AnaPath Services GmbH, a private Swiss-based provider of scientific research and development services, and STP America Research Corp, a private New Jersey-based research and development company. Prior to joining Dong-A Socio Group, Mr. Kim served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. from 2008 to 2011. Mr. Kim received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law. Our Board believes that Mr. Kim&#39;s experiences gained as General Counsel and Head of International Legal Affairs to an established pharmaceutical group of companies qualify him to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Jason L. Groves, Esq.</span> has served a member of our Board since December 2019. Since July 2022, he has served as the Chief Legal Officer and Corporate Secretary of Medifast,&#160;Inc. (NYSE: MED), a publicly held leading manufacturer and distributor of clinically-proven, healthy-living products and programs.&#160; After joining Medifast in 2009, Mr. Groves has held several executive management positions, most recently serving as Executive Vice President and General Counsel of Medifast,&#160;Inc. from 2011 to July 2022. Mr.&#160;Groves was a Medifast,&#160;Inc. director from 2009 to 2015, serving on the Audit Committee from 2009 to 2011. Prior to joining Medifast, Mr.&#160;Groves was Assistant Vice President of Government Affairs for Verizon Maryland, where he was responsible for the company&#8217;s legislative policy and government affairs. A United States Army veteran, Mr.&#160;Groves was a direct-commissioned Judge Advocate in the United States Army Judge Advocate General&#8217;s (JAG) Corps. As a JAG officer, he practiced law and had the distinction of prosecuting criminal cases in the District Court of Maryland as a Special Assistant United States Attorney. Over the course of three years, he received two Army Achievement Medals and one Army Commendation Medal.&#160; Mr.&#160;Groves completed nine years with the Anne Arundel Medical Center Board of Trustees, chairing their international captive insurance company board for eight years. Mr.&#160;Groves received his Bachelor of Science degree, <i style="font-style:italic;">cum laude</i>, in Hospitality Management from Bethune-Cookman University, and obtained his Juris Doctor from North Carolina Central University School of Law. Our Board believes that Mr. Grove&#8217;s experience serving as an independent director, audit committee member, and chief legal officer of a large public corporation while assisting with the initial international introduction of such corporation&#8217;s products qualify him to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Mr. Groves was nominated in accordance with the terms of the Voting Agreement and each of the E&amp;H Funds and Dong-A ST voted their shares in favor of the election of Mr. Groves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ms.&#160;Na Yeon (&#8220;Irene&#8221;) Kim</span> has served as a member of our Board since December 2019 and served as the Chair of our Board from December 2019 to January 2021. Prior to December 2019, she had served on the Board of Private NeuroBo since April 2018. Ms.&#160;Kim also currently serves as the Chief Executive Officer of E&amp;Investment,&#160;Inc., a South Korean venture capital firm specializing in investments in life sciences companies, a position she has held since March 2018. From October 2015 until March 2018, Ms.&#160;Kim was a Representative Director for The SEED Investment&#160;Co.,&#160;Ltd. (formerly known as OST Investment&#160;Co.,&#160;Ltd.), a South Korean investment and fund manager specializing in investments in life sciences companies, and from January 2015 until December 2017, Ms.&#160;Kim served as member of the board of directors of Macrogen,&#160;Inc., a South Korean, publicly-traded biotechnology company specializing in precision medicine and biotechnology. Ms.&#160;Kim also served as an officer of AJUIB Investment,&#160;Inc., a venture capital firm headquartered in South Korea specializing in investments in life-science companies from August 2014 until September 2015. Ms.&#160;Kim focuses on investment opportunities in a number of industries, particularly in the field of BioPharma, and has more than 15&#160;years of accumulated experience of investment in private equity/venture capital markets. As an investor representative, Ms.&#160;Kim has successfully managed more than $400&#160;million in private equity and venture capital funds. Ms.&#160;Kim holds an M.S. and B.S. in biomolecular engineering, as well as an M.B.A. from Yonsei University in Korea. Our Board believes that Ms.&#160;Kim&#8217;s specialized knowledge in building value in life sciences companies and her extensive investment management experience qualify her to serve as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Mr. D. Gordon Strickland-</span><span style="white-space:pre-wrap;"> has served a member of our Board since January 2022.  He served as Chairman of Ampex Corporation, a publicly traded technology company, from March 2012 until June 2019.  He also served as Ampex&#8217;s Chief Executive Officer from February 2007 to March 2012.  Prior to Ampex, he served as President and Chief Executive Officer of Cardiff Holdings, a privately held producer of credit, debit, loyalty and other cards by Brookside </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="white-space:pre-wrap;">Equity Partners from March 2012 to August 2013.  Prior to Cardiff Holdings, Mr. Strickland was the chairman of Medical Resources, a public operator of diagnostic imaging centers.  Mr. Strickland was also president and CEO of&#160;MCSi, Inc, a technical integrator of audio visual products, from&#160;March 2003&#160;until&#160;</span><span style="white-space:pre-wrap;">March 2004.  Prior to MCSi, Mr. Strickland was the president and CEO of&#160;Capitol Wire, Inc, an internet based news and information service provider from&#160;September 1999&#160;until&#160;August 2002&#160;and had leadership roles with&#160;Kerr Group, a manufacturer of glass containers and plastic packaging,&#160;from&#160;June 1986&#160;until&#160;</span><span style="white-space:pre-wrap;">August 1997, including serving as the president and CEO, and as Senior Vice President, Finance and Chief Financial Officer.  Mr. Strickland has over 35 years of experience as a senior executive and board member with public and private companies.  Mr. Strickland received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A from Yale University.  Our Board believes that Mr. Strickland&#8217;s experience serving as Chairman and Chief Executive Officer of a publicly traded company, Ampex, qualifies him to serve as a director.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr.&#160;Michael Salsbury</span><span style="white-space:pre-wrap;"> has served a member of our Board since December 2019. He has served as Counsel to Current Health Inc., a provider of remote care management products and services, since May 2021.  Current Health was acquired by Best Buy Co., Inc. (BBY) in November 2021.  From September 2017 to May 2022, Mr. Salsbury has served as Counsel to Verisma Systems,&#160;Inc., a provider of cloud-based automated disclosure management systems; and from February 2013 to July 2017, he served as Secretary and General Counsel to Best Doctors,&#160;</span><span style="white-space:pre-wrap;">Inc., a provider of expert medical opinions. Best Doctors was acquired by Teladoc Health, Inc. (TDOC) in July 2017.  Mr.&#160;Salsbury has more than 25&#160;years&#8217; experience as a senior executive with public and private companies and private law practice. Mr.&#160;Salsbury received a J.D. and M.B.A. from University of Virginia and a B.A. from Dartmouth College. Our Board believes that Mr.&#160;Salsbury&#8217;s legal expertise and his experience serving as general counsel and secretary of a Fortune 100 corporation qualifies him to serve as a director.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mr. Joseph Hooker </span><span style="white-space:pre-wrap;">has served as our Interim Chief Executive Officer and President since January 2023. Prior to joining NeuroBo, Mr. Hooker was an independent consultant and advised on an ad hoc basis for leading management consultancies and various pharmaceutical companies with respect to clinical trials, CROs and program management. From May 2019 through October 2020, Mr. Hooker was Sr. Director of Clinical Operations/Program Leader Rare Disease, Oncology for X4 Pharmaceuticals, Inc., where he led a cross functional global program team pre-clinical through development and commercialization including strategic planning, oversight, execution of clinical operations and the management of staff. From March 2018 to March 2019, Mr. Hooker served as Director, Program Leadership at Biogen, where he led programs and clinical development for gene therapy, ALS, ophthalmology, rare orphan disease and CNS. From September 2017 through February 2018 he served as Senior Director, Clinical Operations at Pierian Bioscience, where he built, developed and led clinical operations for an oncology device program. He also served as chief operating officer of MedAvante-ProPhase from March 2017 to August 2017. Mr. Hooker served as Head, Clinical Operations for Sandoz Biopharmaceuticals, division of Novartis, from February 2014 to May 2015. Mr. Hooker began his pharmaceutical career as Senior Clinical Trial Manager and project leader at DuPont-Merck Pharmaceuticals, and also served at various times in clinical trial management roles at Shire Pharmaceuticals, Cephalon Pharmaceuticals, Quintiles and Novo Nordisk. Mr. Hooker received a BA from Rutgers University and an MBA from Rider University.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Business Conduct and Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Our Board has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive officers. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of these provisions, on our website, http://www.neurobopharma.com.The full text of our code of conduct is posted on the investor relations section of our website at http://neurobopharma.com/corporate-governance/highlights. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee </b></p><a id="page_de15601_1_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">Our Board has established an audit committee, which is comprised of Mr.&#160;Strickland, Mr.&#160;Koven and Mr. Groves, with Mr. Strickland serving as chair of the committee. Each member of our audit committee meets the requirements for independence under the current Nasdaq and SEC rules and regulations and is financially literate. In addition, our Board has determined that Mr. Strickland qualifies as an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii) of Regulation&#160;S-K promulgated under the Securities Act based on his serving as chief executive officer of multiple </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">companies as described above. This designation does not impose on either of them any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Delinquent Section 16(a) Reports</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Section 16(a) of the Exchange Act requires that the Company&#8217;s directors, executive officers and persons who beneficially own more than 10% of a registered class of its equity securities, file with the SEC reports of ownership and changes in ownership of its common stock and other equity securities. Executive officers, directors and greater than 10% beneficial owners are required by SEC regulation to furnish the Company with copies of all Section 16(a) reports that they file. Based solely on the Company&#39;s review of such filed forms and representations from our directors and executive officers that no other forms were required, to our knowledge, other than a Form 4 filed by D. Gordon Strickland on February 2, 2022, which was filed two days after the required filing date, all of the Company&#39;s Directors and executive officers, and other persons who owned more than 10% of the Company&#39;s outstanding common stock, fully complied with the reporting requirements of Section 16(a) during fiscal year 2022.</p><a id="_7758fd94_4f96_42e7_b8c9_d78769f49829"></a><a id="ITEM11EXECUTIVECOMPENSATION_607490"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 11.</b></span><b style="font-weight:bold;">EXECUTIVE COMPENSATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Executive Officer Compensation </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">The following tables and accompanying narrative disclosure discuss the compensation awarded to, earned by, or paid to:</p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:13.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Ben Gil Price, our former President, and Chief Executive Officer</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Dr. Price was our sole executive officer for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Summary Compensation Table for 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">The following table presents summary information regarding the total compensation for services rendered in all capacities that was earned by our named executive officer during the fiscal years ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:71.16%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">NAME AND PRINCIPAL POSITION</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">SALARY</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">($)&#160;(4)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">BONUS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">AWARDS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">($)(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">TOTAL</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gil Price (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.23%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.23%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">500,000</p></td></tr><tr><td style="vertical-align:bottom;width:40.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">Former President, and Chief Executive Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">66,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">854,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 2.9pt 0pt 0pt;">920,276</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Reflects the aggregate grant date fair value of options granted during the fiscal year ended December 31, 2021, as computed in accordance with ASC 718.  The assumptions applicable to the determination of grant date fair value of the stock options granted to Dr. Price in 2022 can be found in Note 8 of the Notes to Consolidated Financial Statements &#8211; Stock-Based Compensation in this Annual Report on Form 10-K.   </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Dr. Price was appointed as our President and Chief Executive Officer effective November 15, 2021.  Dr. Price resigned as our Chief Executive Officer effective January 12, 2023.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Narrative Disclosure to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Agreements with Our Named Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">We have entered into written agreements with our named executive officer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">On November 3, 2021, the Company and Dr. Price entered into an employment agreement (the &#8220;Price Employment Agreement&#8221;). The Price Employment Agreement has an initial term (the &#8220;Initial Term&#8221;) of one year beginning on </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">November 3, 2021 and automatically renews for an additional one year period at the end of the Initial Term a (a &#8220;Renewal Term&#8221;) provided that at least 60 days prior to the expiration of the Initial Term or any Renewal Term the Board does not notify Dr. Price of its intention not to renew.  Dr. Price resigned from the Company effective January 12, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">In connection with Dr. Price&#8217;s departure, on January 16, 2023, the Company and Dr. Price entered into a Separation and Release Agreement (the &#8220;Separation Agreement&#8221;). Pursuant to the terms and conditions of the Separation Agreement, in exchange for granting and not revoking a release agreement, Dr. Price will be entitled to receive from the Company (i) severance pay in an amount equal to $100,000, payable in substantially equal installments in accordance with the Company&#8217;s payroll practice over three months, beginning on the first payroll date after Dr. Price&#8217;s release of the Company becomes effective and irrevocable and (ii) an amount equal to $100,000 as Dr. Price&#8217;s annual bonus for 2022, payable on the first payroll date after Dr. Price&#8217;s release of the Company becomes effective and irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Pursuant to the terms of the Employment Agreement, and as approved by the independent members of the Board on November 3, 2021, Dr. Price was granted, effective as of his first day of full-time employment with the Company (the &#8220;Grant Date&#8221;), a non-qualified stock option to purchase 20,555 shares of the Company&#8217;s common stock pursuant to the terms of a stock option award agreement (the &#8220;New Hire Option&#8221;) under the Inducement Plan as an inducement material to Dr. Price becoming an employee of the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The New Hire Option has a ten-year term and vests as to 8,888 of the shares underlying the stock option on the first anniversary of the Grant Date and as to the remaining 11,667 of the shares on the second anniversary of the Grant Date. The New Hire Option granted to Dr. Price has an exercise price per share equal to the closing price of the Company&#8217;s common stock on the Grant Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at Fiscal Year-End 2022 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">The following table sets forth information regarding outstanding stock options held by our executive officer as of December 31, 2022:</span> </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:17.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="2" style="vertical-align:bottom;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:21.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="3" style="vertical-align:bottom;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td colspan="3" style="vertical-align:bottom;width:18.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">NAME</b></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;width:19.46%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER OF</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">SECURITIES</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">UNDERLYING</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">UNEXERCISED</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">OPTIONS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">EXERCISABLE</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;width:0.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:23.1%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER OF</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">SECURITIES</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">UNDERLYING</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">UNEXERCISED</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">OPTIONS</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">UNEXERCISABLE</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(#)</b></p></td><td style="vertical-align:bottom;width:0.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="4" style="vertical-align:bottom;width:13.66%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">EXERCISE</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">PRICE</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">($)</b></p></td><td style="vertical-align:bottom;width:0.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:17.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">OPTION</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">EXPIRATION</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">DATE</b></p></td><td style="vertical-align:bottom;width:0.66%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;padding-left:8pt;text-indent:-8pt;margin:0pt;">Dr. Gil Price</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:17.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Times';">8,888</span></p></td><td colspan="2" style="vertical-align:bottom;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:21.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:right;margin:0pt;">11,667 (2)</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:right;margin:0pt;">61.20</p></td><td style="vertical-align:bottom;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;width:18.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:right;margin:0pt;">November 3, 2031</p></td><td style="vertical-align:bottom;width:0.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;background:#ffffff;"><div style="background-color:#000000;height:1.5pt;position:relative;top:0.6em;width:26.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">(1) All of the outstanding stock option awards were granted under the NeuroBo 2021 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">(2) Subject to continued service: options were to vest on the second anniversary of the vesting commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;padding-top:14pt;text-indent:-10pt;margin:0pt;"><b style="font-weight:bold;">Non-Employee Director Compensation </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Our non-employee directors receive a mix of cash and share-based compensation intended to encourage non-employee directors to continue to serve on our Board, further align the interests of the directors and stockholders, and attract new </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">non-employee directors with outstanding qualifications. Directors who are employees or officers of the Company do not receive any additional compensation for Board service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">The following table provides compensation information for the fiscal year ended December 31, 2022 for each member of our Board. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3pt;padding-right:3pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.39%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:13.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:7.96%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:59.96%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.39%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.75%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.75%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.02%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.75%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.96%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.37%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.96%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;border-bottom:1.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">Name </b></p></td><td style="vertical-align:bottom;width:2.39%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:15.51%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees Earned or</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Paid in Cash</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">($) </b></p></td><td style="vertical-align:bottom;width:10.02%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option Awards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> ($) (5)</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.72%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">($) </b></p></td><td style="vertical-align:bottom;width:2.37%;background:#ffffff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:59.96%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.39%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.02%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.37%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">Ms. Na Yeon (Irene) Kim </p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">45,784</p></td><td style="vertical-align:top;width:10.02%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">6,663</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">52,447</p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">Jason Groves </p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">134,131</p></td><td style="vertical-align:top;width:10.02%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">6,663</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">140,794</p></td><td style="vertical-align:bottom;width:2.37%;background:#fefefe;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">Michael Salsbury </p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">136,989</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">6,663</p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">143,652</p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">Andrew Koven </p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">200,267</p></td><td style="vertical-align:top;width:10.02%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">6,663</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">206,930</p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';">D. Gordon Strickland (1)(4)</span></p></td><td style="vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">123,539</p></td><td style="vertical-align:top;width:10.02%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">34,574</p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">158,113</p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">Richard Kang (2)</p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">38,556</p></td><td style="vertical-align:top;width:10.02%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">6,663</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">45,219</p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;">Hyung Heon Kim</p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">54,217</p></td><td style="vertical-align:top;width:10.02%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">6,663</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">60,880</p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:59.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';">Douglas Swirsky (3)</span></p></td><td style="vertical-align:bottom;width:2.39%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Times';font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:13.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">3,611</p></td><td style="vertical-align:top;width:10.02%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;width:1.75%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.96%;background:#cceeff;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">3,611</p></td><td style="vertical-align:bottom;width:2.37%;margin:0pt;padding:0pt 3pt 0pt 3pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:9pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">(1) Mr. Strickland was appointed to the Board effective January 27, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">(2) Dr. Kang resigned from the Board effective March 29, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">(3) Mr. Swirsky resigned from the Board effective January 14, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">(4) Mr. Strickland was granted an option to purchase 1,333 shares at an exercise price of $30.60 in January 2022.  Each option vests, subject to continuing service, in 36 monthly installments beginning February 28, 2022.  The amount reported reflects the aggregate grant date fair value of the option granted to Mr. Strickland during the fiscal year ended December 31, 2022, as computed in accordance with ASC 718.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">(5) All current board members were granted an option to purchase 666 shares at an exercise price of $14.18 per share in June 2022.  Each option vests, subject to continuing service in June 2023.  The amount reported reflects the aggregate grant date fair value of the options granted during the fiscal year ended December 31, 2022, as computed in accordance with ASC 718.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">(6) As of December 31, 2022, Ms. Kim, Mr. Groves, Mr. Salsbury and Mr. Koven have 2,666 options outstanding, Mr. Strickland has 1,999 options outstanding, and Mr. Kim and Dr. Kang have 666 options outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">In January 2022, the compensation committee recommended and our Board approved the Company&#8217;s Amended and Restated Non-Employee Director Compensation Policy (the &#8220;Amended Non-Employee Director Compensation Policy&#8221;).  Under the Amended Non-Employee Director Compensation Policy, </span><span style="white-space:pre-wrap;">all of our non-employee directors receive an annual cash retainer of $40,000 for Board service except for the Chair of the Board who will receive an annual cash retainer of $75,000.  A lead independent director, if applicable, would receive a total of $60,000. In addition, directors receive an additional cash retainer for serving as a committee chair or member as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:98.51%;"><tr style="height:1pt;"><td style="vertical-align:top;width:20.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:23.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:24.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.2%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:26.5pt;"><td style="vertical-align:top;width:20.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:23.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">Audit Committee</p></td><td style="vertical-align:top;width:24.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">Compensation Committee</p></td><td style="vertical-align:top;width:31.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">Nominating and Corporate Governance Committee</p></td></tr><tr><td style="vertical-align:top;width:20.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Committee Chair </p></td><td style="vertical-align:top;width:23.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">$18,000</p></td><td style="vertical-align:top;width:24.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">$12,000</p></td><td style="vertical-align:top;width:31.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">$8,000</p></td></tr><tr><td style="vertical-align:top;width:20.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Committee Member (other than the Chair)</p></td><td style="vertical-align:top;width:23.49%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">9,000</p></td><td style="vertical-align:top;width:24.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">6,000</p></td><td style="vertical-align:top;width:31.2%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;">4,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">In addition, non-employee directors are entitled to an initial grant for a nonstatutory stock option to acquire 1,333 shares of the Company&#8217;s common stock pursuant to the terms and conditions of the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;Plan&#8221;), which will vest in a series of three successive equal annual installments over the three-year period measured from the date of grant, subject to the director&#8217;s service to the Company through each applicable vesting date. In accordance with the Amended Non-Employee Director Compensation Policy, each non-employee director will also be eligible to be granted, immediately following the Company&#8217;s annual meeting of stockholders, a nonstatutory stock option to purchase 666 shares of Company common stock (the &#8220;Annual Grant&#8221;). Each Annual Grant will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Company&#8217;s next annual </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">meeting occurring after the grant date, subject to such non-employee director&#8217;s service to the Company through the vesting date. Vesting will be accelerated upon a Corporate Transaction (as defined in the Plan) The nonstatutory stock options are subject to the terms and conditions of the Plan and its related agreements. Additionally, pursuant to the Restated Non-Employee Director Compensation Policy, non-employee directors may elect to receive a restricted stock unit award in lieu of the cash compensation payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Under the Company&#8217;s prior Non-Employee Director Compensation Policy, which was in effect prior to the amendment, director compensation was as follows:</p><div style="margin-top:14pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Annual cash compensation of $20,000 per year;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$20,000 per year for service on a committee, irrespective of the number of committees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$35,000 additional per year of service for the Chair of the Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$20,000 additional per year for service for each of the Chair of the Nomination Committee and the Compensation Committee; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$40,000 per year additional for service for each of the Chair of the Audit Committee; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:20.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Option to purchase 2,000 shares, vested monthly over 36 months upon election as a director;</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><div style="margin-top:14pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">In September 2021, the Board formed a transaction committee of the Board consisting of 4 members of the Board to review a licensing transaction presented to the Board.&#160; Pursuant to the authorizing resolution, the Board approved the following compensation for the members of the Board serving on such transaction committee: a monthly fee in the amount of $5,000 per month (for each calendar month or portion thereof that such member serves on the transaction committee) and $800 per meeting of the transaction committee attended by such member.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_51674572_210f_4fee_aa59_fb39f448af6c"></a><a id="ITEM12SECURITYOWNERSHIPOFCERTAIN_50405"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;padding-bottom:12pt;"><b style="font-weight:bold;">ITEM 12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:10.0pt;padding-bottom:12pt;"><b style="font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b><b style="font-weight:bold;">&#160;AND RELATED STOCKHOLDER MATTERS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">The following table sets forth information regarding beneficial ownership of our common stock, as of March 25, 2023 by: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our named executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of our current executive officers and directors as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The table lists applicable&#160;percentage ownership based on 27,176,685 shares of common stock outstanding as of March 25, 2023. In addition, the rules include shares of our common stock issuable pursuant to the exercise of stock options and warrants that are either immediately exercisable or exercisable within 60&#160;days of March 25, 2023. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the&#160;percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">property laws. Except as otherwise noted below, the address for each person or entity listed in the table is c/o&#160;NeuroBo Pharmaceuticals, Inc., 200 Berkeley Street, 19th Floor, Boston, Massachusetts, 02116.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SHARES</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">BENEFICIALLY</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">OWNED</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">NAME OF BENEFICIAL OWNER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">NUMBER</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">PERCENT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Greater than 5% stockholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dong-A ST Co., Ltd. (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">12,429,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;">&#8199;&#8199;&#8199;45.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Directors and Named Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Andrew Koven, Chair of the Board of Directors (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Na Yeon (Irene) Kim, Director (2)(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">204,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;">   * </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jason Groves, Director (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> *</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Michael Salsbury, Director (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Hyung Heon Kim, Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 36pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 36pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Richard Kang, Former Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">D. Gordon Strickland, Director (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Joseph Hooker, Interim Chief Executive Officer and President</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Gil Price, Former President and Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">8,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 36pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 3pt 0pt 36pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">All current executive officers and directors as a group (7 persons)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">218,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:26.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">*<span style="font-size:13.5pt;">&#160;&#160;&#160;&#160;</span>Represents beneficial ownership of less than one percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based solely on the Company&#39;s review of a filing made on an amendment to Schedule&#160;13D on December 30, 2022 with the SEC. Dong-A ST&#160;Co.,&#160;Ltd. is a South Korean corporation. The address of Dong-A ST&#160;Co.,&#160;Ltd. Is 64, Cheonho-daero, Dongdaemun-gu, Seoul, Republic of Korea.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">(2)</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based solely on the Company&#8217;s review of a filing made on an amendment to Schedule&#160;13D on July 25, 2022 with the SEC. The amendment to the Schedule&#160;13D was filed by The E&amp;Healthcare Investment Fund&#160;II (&#8220;Fund&#160;II&#8221;), The E&amp;Healthcare Investment Fund&#160;No. 6 (&#8220;Fund 6&#8221;), The E&amp;Healthcare Investment Fund&#160;No. 7 (&#8220;Fund 7&#8221;), E&amp;Investment, Inc. (&#8220;GP&#8221;), and Na Yeon Kim. Fund&#160;II beneficially owns 96,351 shares of common stock, Fund 6 beneficially owns 37,373 shares of common stock, Fund 7 beneficially owns 62,159 shares of common stock and GP, as the general partner of each of Fund II, Fund 6 and Fund 7, owns 1,459 shares of common stock and may be deemed to beneficially own 200,554 shares of common stock. Ms. Kim has been granted stock options to purchase up to 2,000 shares of common stock in respect of her service on the Board, all of which are exercisable of March 25, 2023. Ms.&#160;Kim, as the Chief Executive Officer of GP, may be deemed to hold shared voting and dispositive power over a total of 204,013 shares of Common Stock. The business address of Ms.&#160;Kim and the address of the principal office of the person and entities noted in this footnote is 16th floor, Yeoksam I-Tower, 326,&#160;Teheran-ro, Gangnam-gu, Seoul, Republic of Korea 06211.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents shares underlying outstanding stock options that are vested or will become vested within 60&#160;days of March 25, 2023.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:15.52pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-top:12pt;margin:0pt 0pt 12pt 0pt;">The following table presents information as of December&#160;31, 2022 with respect to compensation plans under which shares of our common stock may be issued. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Plan Category </b></p></td><td style="vertical-align:bottom;width:1.54%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:9.77%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number of</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">securities</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">to be issued</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">upon exercise</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">of outstanding</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">options,</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">warrants and</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">rights</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">(#)(a) </b></p></td><td style="vertical-align:bottom;width:1.54%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:11.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Weighted-average</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">exercise</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">price of</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">outstanding</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">options,</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">warrants and</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">rights</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">($) (b)</b></p></td><td style="vertical-align:bottom;width:1.54%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:10.07%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">Number of</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">securities</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">remaining</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">available</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">for future</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">issuance</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">under equity</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">compensation</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">plans</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;">(excluding securities reflected in column (a))</b><b style="font-size:7.5pt;font-weight:bold;"><br /></b><b style="font-size:7.5pt;font-weight:bold;white-space:pre-wrap;">(#)(c)  </b></p></td><td style="vertical-align:bottom;width:4.8%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.21%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#cceeff;margin:0pt;">Equity compensation plans approved by security holders</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">15,938</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">149.16</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;"><span style="font-family:'Times';">5,078,721</span></p></td><td style="vertical-align:bottom;width:4.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">(1)(2)</p></td></tr><tr><td style="vertical-align:bottom;width:59.21%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.75%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.02%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#ffffff;margin:0pt;">20,555</p></td><td style="vertical-align:bottom;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.34%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.15%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#ffffff;margin:0pt;">61.20</p></td><td style="vertical-align:bottom;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.59%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.47%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#ffffff;margin:0pt;">12,778&#160;</p></td><td style="vertical-align:bottom;width:4.8%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;(3)</p></td></tr><tr><td style="vertical-align:bottom;width:59.21%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.54%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.75%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203; </span></p></td><td style="vertical-align:bottom;width:9.02%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:right;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203; </span></p></td><td style="vertical-align:bottom;width:1.54%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203; </span></p></td><td style="vertical-align:bottom;width:10.15%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:right;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203; </span></p></td><td style="vertical-align:bottom;width:1.54%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.59%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203; </span></p></td><td style="vertical-align:bottom;width:9.47%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;text-align:right;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203; </span></p></td><td style="vertical-align:bottom;width:4.8%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;min-height:0.0pt;background:#ffffff;margin:0pt;"><span style="font-size:1.5pt;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#cceeff;margin:0pt;">Total</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">36,493</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;"><span style="font-family:'Times';line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">99.62</p></td><td style="vertical-align:bottom;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">5,091,500</p></td><td style="vertical-align:bottom;width:4.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:13.5pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">The number of shares of common stock remaining available for future issuance represent shares available for issuance under the 2022 Plan.  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The 2022 Plan provides that the number of shares that may be issued under the 2022 Plan shall be increased on the first day of each fiscal year by an amount equal to the lesser of (i) 5% of the number of outstanding shares of Common Stock on such date and (ii) an amount determined by the Administrator.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Our only equity compensation plan not approved by our security holders is our 2021 Inducement Plan.  A total of 33,333 shares of common stock of the Company have been reserved for issuance under the Inducement Plan, subject to adjustment for stock dividends, stock splits, or other changes in the Company&#8217;s common stock or capital structure. The Inducement Plan was approved by the Compensation Committee without stockholder approval pursuant to Nasdaq Stock Market Listing Rule 5635(c)(4), and is to be utilized exclusively for the grant of stock awards to individuals who were not previously an employee or non-employee director of the Company (or following a bona fide period of non-employment with the Company) as an inducement material to such individual&#8217;s entry into employment with the Company, within the meaning of Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is administered by the Board. Stock awards under the Inducement Plan may only be granted by: (i) the Compensation Committee or (ii) another committee of the Board composed solely of at least two members of the Board who meet the requirements for independence under the Nasdaq Stock Market Listing Rules (the foregoing subsections (i) and (ii) are collectively referred to as the &#8220;Committee&#8221;). Under the 2021 Inducement Plan, the Committee may choose to grant (i) nonstatutory stock options, (ii) stock appreciation rights, (iii) restricted stock awards, (iv) restricted stock unit awards, (v) performance stock awards, (vi) performance cash awards, and (vii) other stock awards to eligible recipients, with each grant to be evidenced by an award agreement setting forth the terms and conditions of the grant as determined by the Committee in accordance with the terms of the Inducement Plan.</span></td></tr></table><a id="_78304553_8ba6_46f6_b4a2_6ae2fcfc6823"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:72pt;text-indent:-72pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><a id="ITEM13CERTAINRELATIONSHIPSANDRE_750177"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 13. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR</b><b style="font-weight:bold;"> INDEPENDENCE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certain Relationships and Related Party Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">The following includes a summary of transactions since January&#160;1, 2021 to which we have been a party, in which the amount involved in the transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Transactions with Dong-A ST Co., Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On September 14, 2022, we entered into a License Agreement with Dong-A pursuant to which, subject to the conditions set forth therein, we would receive an exclusive global license (other than in the Republic of Korea) to two proprietary compounds for specified indications (the &#8220;2022 License Agreement&#8221;). The 2022 License Agreement covers the rights to a compound referred to as DA-1241 for treatment of NASH and a compound referred to as DA-1726 for treatment of obesity and NASH. We may also develop DA-1241 for the treatment of T2D. The 2022 License Agreement became effective on November 8, 2022.  </span>As of March 24, 2023, Dong-A ST was the beneficial owner of more than 5% of our capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the 2022 License Agreement, Dong-A (i) received an upfront payment of 2,200 shares of Series A Preferred Stock under the terms of the Securities Purchase Agreement (as defined below); (ii) is eligible to receive single digit royalties on net sales received by us from the commercial sale of products covering DA-1241 or DA-1726; (iii) is eligible to receive commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iv) is eligible to receive regulatory milestone payments of up to $178 million for DA-1726 and $138 million for DA-1241, dependent upon the achievement of specific regulatory developments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Securities Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">On September 14, 2022, in connection with the 2022 License Agreement, we entered into the Securities Purchase Agreement with Dong-A. Pursuant to the Securities Purchase Agreement, upon the consummation of the 2022 License Agreement and a Qualified Financing (as defined in the Securities Purchase Agreement), which occurred on November 8, 2022, (i) Dong-A received the Upfront License Payment and (ii) Dong-A purchased 1,500 shares of Series A Preferred Stock and the Dong-A Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">On December 22, 2022, our stockholders approved the conversion of the Series A Preferred Stock and the exercise of the Dong-A Warrants and all of the Series A Preferred Stock converted into 12,333,333 shares of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Shared Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">On September&#160;14, 2022, in connection with the 2022 License Agreement, we and Dong-A entered into the Shared Services Agreement. The Shared Services Agreement provides that Dong-A will provide technical support, pre-clinical development, and clinical trials support services in exchange for payment to Dong-A as set forth therein. In addition, the Shared Services Agreement provides that Dong-A will manufacture all of our clinical requirements of DA-1241 and DA-1726 under the terms provided in the Shared Services Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;<span style="color:#231f20;">Either party may terminate the Shared Services Agreement for the other party&#8217;s material breach that is not cured within 30 days of notice. Dong-A may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by us which is not cured within 30 days.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Registration Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#231f20;">In connection with the Securities Purchase Agreement, on September&#160;14, 2022, we entered into a registration rights agreement with Dong-A and the other selling stockholders (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Registration Rights Agreement</span><span style="color:#231f20;">&#8221;). The Registration Rights Agreement provides Dong-A with demand and piggyback registration rights, including the right to two long-form registration statements. In addition, we agreed to file, within 30 days following the stockholder approval of the conversion of the Series&#160;A Preferred Stock (&#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Stockholder Approval</span><span style="color:#231f20;">&#8221;), which occurred on December&#160;22, 2022, a registration statement to (i)&#160;register the shares of common stock issuable upon the conversion of the Series&#160;A Preferred Stock; (ii)&#160;shares of our common stock issuable upon the exercise of the warrants; and (iii)&#160;any other common stock held by the parties to the Registration Rights Agreement (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Registrable Securities</span><span style="color:#231f20;">&#8221;); and to use commercially reasonable efforts to cause each registration statement to be declared effective under the Securities Act of 1933, as amended (the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#231f20;">&#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Securities Act</span><span style="color:#231f20;">&#8221;), as promptly as possible after the filing thereof, but in any event no later than the 60th day after Stockholder Approval (or in case the SEC reviews the registration statement, the 90th date after Stockholder Approval); provided that if we are notified that the registration statement is not being reviewed or is no longer subject to comment, we are required to make the registration statement effective by the fourth trading day after such date. We agreed to use our commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such registration statement have been sold or are otherwise able to be sold pursuant to Rule&#160;144.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Investor Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#231f20;">On September&#160;14, 2022, we entered into an investor rights agreement with Dong-A (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">Investor Rights Agreement</span><span style="color:#231f20;">&#8221;) pursuant to which, following the conversion of the Series&#160;A Preferred Stock into common stock, Dong-A will have the right, subject to the terms thereof, to designate for appointment to our Board that number of directors commensurate with Dong-A&#8217;s and its affiliates&#8217; beneficial ownership of our common stock, with the number of directors that Dong-A is entitled to designate rounded up to the nearest whole number (the &#8220;</span><span style="color:#231f20;font-style:italic;font-weight:bold;">DA Designees</span><span style="color:#231f20;">&#8221;). To the extent necessary to permit the designation of the DA Designees, the size of our Board of Directors shall be increased to that number of directors that would permit Dong-A to designate a number of directors to fill the vacancies created thereby that is commensurate with Dong-A&#8217;s and its affiliates&#8217; collective beneficial ownership of the common stock outstanding at such time (taking into account any DA Designees already serving on our Board of Directors at such time). The compensation (including equity-based compensation) and rights to indemnity of, and reimbursement of expenses incurred by, the DA Designees that are members of our Board will be the same as those provided to other non-employee directors generally. When evaluating a prospective DA Designee for membership on our Board, our Board and the Nominating and Corporate Governance Committee shall apply the same review processes and standards as each of them, respectively, applies to other prospective non-employee directors generally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="color:#231f20;">In addition, the Investor Rights Agreement provides for a customary standstill for nine months following the conversion of the Series&#160;A Preferred Stock to common stock. Furthermore, for so long as Dong-A has the right to designate any DA Designee to our Board of Directors, Dong-A will vote their shares of our common stock in favor of any Company Director (as defined in the Investor Rights Agreement) or any nominee designated by the Nominating and Corporate Governance Committee of the Board and against the removal of any Director, in each case, at any meeting of the stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Manufacturing Agreement with Dong-A ST</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">On September&#160;28, 2018, our predecessor entered into a five year manufacturing and supply agreement with Dong-A ST for manufacturing and supply of NB-01 drug substance and placebos for the purpose of research and development to be used in Phase&#160;<span style="white-space:pre-wrap;">3 clinical trials (the &#8220;Manufacturing Agreement&#8221;).  Under the terms of the Manufacturing Agreement, Dong-A ST has agreed to produce for NeuroBo a specified number of tablets of the NB-01 drug substance and placebos at a supply price to be determined at the time of each individual order. In addition, prices were set for stability testing of the NB-01 drug substance and placebo. The Company incurred no such expenses for the years ended December&#160;31, 2022 and 2021. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">The Manufacturing Agreement will automatically terminate in the event that the license agreement with Dong-A ST is terminated for any reason. In addition, each of Dong-A ST and NeuroBo may terminate the Manufacturing Agreement (1)&#160;upon the material breach by the other party, if the breach is not cured within a specified number of days after receiving notice from the terminating party, or if the breach cannot reasonably be cured within such period and the breaching party has not started to remedy the breach within such period and diligently endeavored to cure the breach within a reasonable time thereafter, or (2)&#160;in the event that (i)&#160;the other party is the subject of a petition for bankruptcy, reorganization, or arrangement and the same is not dismissed within thirty days thereof, (ii)&#160;a receiver or trustee is appointed for all or a substantial portion of the assets of the other party, or (iii)&#160;the other party makes an assignment for the benefit of its creditors. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Our common stock is listed on Nasdaq. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#8217;s board of directors. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Additionally, compensation committee members must not have a relationship with us that is material to the director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Audit committee members must also satisfy the independence criteria set forth in Rule&#160;10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board of directors committee: (i)&#160;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (ii)&#160;be an affiliated person of the listed company or any of its subsidiaries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Our Board has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our Board affirmatively determined that Na Yeon (Irene)&#160;Kim, Jason Groves, Michael Salsbury, Andrew Koven Hyung Heon Kim, D. Gordon Strickland and Douglas Swirsky, who was a member of the board through January 2022, are &#8220;independent directors&#8221; as defined under the applicable rules and regulations of the SEC and the listing requirements and rules of Nasdaq. The Board determined that Richard Kang, our former Chief Executive Officer, President, Interim Chief Financial Officer, Secretary and Treasurer, who served as a director until his resignation on March 29, 2023, was not independent. In making this determination, our Board considered the current and prior relationships that each non-employee director has with us and all other facts and circumstances that our Board deemed relevant in determining each non-employee director&#8217;s independence, including the participation by our non-employee directors, or their affiliates, in certain financing transactions by the Company and the beneficial ownership of our common stock by each non-employee director. </p><a id="_27b04140_c574_49fe_9c27_04f7a82d4b90"></a><a id="ITEM14PRINCIPALACCOUNTINGFEESANDSERVICES"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">ITEM 14. </b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Service Fees Paid to the Independent Registered Public Accounting Firms </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">The Audit Committee has considered the scope and fee arrangements for all services provided by BDO USA,&#160;LLP, taking into account whether the provision of non-audit-related services is compatible with maintaining BDO USA,&#160;LLP independence. The following table presents fees for professional audit services rendered by BDO USA,&#160;LLP for the audit of the annual financial statements for the years ended December&#160;31, 2022 and 2021. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">FEE CATEGORY </b></p></td><td style="vertical-align:bottom;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:27.94%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">FISCAL YEAR</b><b style="font-size:7.5pt;font-weight:bold;"><br /><br /></b><b style="font-size:7.5pt;font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.37%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:27.94%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">FISCAL YEAR</b><b style="font-size:7.5pt;font-weight:bold;"><br /><br /></b><b style="font-size:7.5pt;font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:1.37%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#cceeff;margin:0pt;">Audit fees</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;"><span style="font-family:'Times';">571,037</span></p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">343,034</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;">Audit-related fees</p></td><td style="vertical-align:bottom;width:1.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.21%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#ffffff;margin:0pt;">-&#160;</p></td><td style="vertical-align:bottom;width:1.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.11%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#ffffff;margin:0pt;">-&#160;</p></td><td style="vertical-align:bottom;width:1.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#cceeff;margin:0pt;">Tax fees</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">-&#160;</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">-&#160;</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#ffffff;margin:0pt;">All other fees</p></td><td style="vertical-align:bottom;width:1.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.72%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.21%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#ffffff;margin:0pt;">-&#160;</p></td><td style="vertical-align:bottom;width:1.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.11%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#ffffff;margin:0pt;">-&#160;</p></td><td style="vertical-align:bottom;width:1.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#ffffff;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:39.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:10pt;text-indent:-10pt;background:#cceeff;margin:0pt;">Total fees</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">571,037</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:24.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;background:#cceeff;margin:0pt;">343,034</p></td><td style="vertical-align:bottom;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;background:#cceeff;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Audit fees consist of fees billed for services relating to the audit of our annual financial statement and review of our quarterly financial statements, services that are normally provided in connection with statutory and regulatory filings or engagements, comfort letters, reports on an issuer&#39;s internal controls, and review of documents to be filed with the SEC (e.g.&#160;periodic filings, registration statements, and company responses to SEC comment letters). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Audit-related fees are related to other assurance and related services that are traditionally performed by an independent accountant such as employee benefit plan audits, due diligence related to mergers and acquisitions, accounting assistance and audits in connection with proposed or consummated acquisitions, attest services that are not required by statute or regulation, and consultations concerning proposed accounting and reporting standards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;">Tax fees relate to permissible services for technical tax advice related to federal and state income tax matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Our audit committee generally pre-approves all audit and permitted non-audit and tax services provided by the independent registered public accounting firm. Pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent registered public accounting firm and management are required to periodically report to the audit committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this pre-approval, and the fees for the services performed to date. Our audit committee may also pre-approve particular services on a case-by-case basis. All of the services relating to the fees described in the table above were approved by our audit committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d0e72d5e_2792_4a1e_a0a9_c6b79e4cc708"></a><a id="PARTIV_836208"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:72pt;text-indent:-72pt;margin:0pt;"><b style="font-weight:bold;">PART IV</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a051c1c9_8298_417a_95b8_94d701c1c413"></a><a id="ITEM15_562720"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"><b style="font-weight:bold;">ITEM 15.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;padding-bottom:12pt;"><b style="font-weight:bold;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">(a) The following documents are filed as part of this report:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">1. Financial Statements: The information required by this item is contained in Item 8 of this Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">2. Financial Statement Schedules:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;background:#ffffff;margin:0pt;">3. The exhibits to this Annual Report are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_99c7c57b_d08b_4909_9187_f238392cfbce"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:83.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:-53.07pt;"></span><b style="font-weight:bold;">EXHIBIT</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">NUMBER</b></p></td><td style="vertical-align:bottom;width:4.34%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:83.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF DOCUMENT</b></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000051/tmb-20201231xex2d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Agreement and Plan of Merger, dated as of December 31, 2020, by and among the Registrant, Shelby Merger Sub 1, Inc., Shelby Merger Sub 2, LLC, ANA Therapeutics, Inc. and Akash Bakshi (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on January 6, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.1 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465916138639/a16-16524_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amended and Restated Certificate of Incorporation of Registrant (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#39;s Current Report on Form&#160;8-K, filed on August&#160;10, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.2 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465919076916/a19-28294_1ex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Registrant&#39;s Current Report on Form 8-K, filed on December 31, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.3 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465919076916/a19-28294_1ex3d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment (Name Change) to the Third Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.2 to the Registrant&#39;s Current Report on Form 8-K, filed on December 31, 2019).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837022014321/nrbo-20220912xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment (Reverse Stock Split) to the Third Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Registrant&#39;s Current Report on Form 8-K, filed on September 12, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.5 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231ex34ff53fc5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.4 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922114732/tm2229700d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Second Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on November 4, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations, filed with the Delaware Secretary of State on November 4, 2022, with respect to the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations, filed with the Delaware Secretary of State on November 4, 2022, with respect to the Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.1 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000104746916013774/a2228362zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#39;s Amendment No.&#160;1 to Registration Statement on Form&#160;S-1, filed on June&#160;13, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.2 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465917016147/a17-7290_3ex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed on March&#160;13, 2017).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.3 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837018006443/gemp-20180731ex416ef151f.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant to Purchase Stock, dated July&#160;31, 2018, by and between the Registrant and Silicon Valley Bank (incorporated by reference to Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form&#160;8- K, filed on August&#160;6, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003927/nrbo-20200413xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Placement Agent&#8217;s Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on April 15, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000329/tmb-20210118xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on January 21, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465921122546/tm2129080d2_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant to Purchase shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.7 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series A Warrant to purchase shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2022).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Series B Warrant to purchase shares of common stock (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Agency Agreement, dated as of November 8, 2022, by and between the Registrant and American Stock Transfer and Trust Company LLC (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.10</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Dong-A Series A Warrant to purchase shares of common stock (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2022)</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.11</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922116023/tm2225873d12_ex4-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Dong-A Series B Warrant to purchase shares of common stock (incorporated by reference to Exhibit 4.5 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4.12 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20221231xex4d12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Description of Securities</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> , filed herewith</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.1 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000104746916012305/a2228243zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#39;s Registration Statement on Form&#160;S-1, filed on April&#160;18, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.9 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">+</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837018006442/gemp-20180802ex1012c91f0.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated License Agreement, effective as of August&#160;2, 2018, by and between the Registrant and Pfizer&#160;Inc. (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed on August&#160;6, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.10 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465919076916/a19-28294_1ex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on December 31, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.11 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">+++</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837019006287/ex-10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License and Collaboration Agreement, dated as of July&#160;23, 2019, by and between the Registrant and Beijing SL Pharmaceutical&#160;Co.,&#160;Ltd. (incorporated by reference to Exhibit&#160;10.6 to the Registrant&#8217;s Current Report on Form&#160;8-K, filed on July&#160;25, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.12 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231ex1015a1f45.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Membership Agreement, dated as of November 11, 2020, by and between WeWork and the Registrant (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.13 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">+++</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000104746919004919/a2239535zex-10_36.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Manufacturing and Supply Agreement, dated as of September&#160;28, 2018, between Dong-A ST&#160;Co., Lt. and the Registrant (incorporated by reference to Exhibit 10.36 to the Registrant&#8217;s Registration Statement on Form S-4, filed on September 3, 2019).</span></a>&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.14 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000104746919004919/a2239535zex-10_40.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated as of May&#160;2, 2019, by and between Gyeonggi Urban Innovation Corporation and NeuroBo&#160;Co.,&#160;Ltd. (incorporated by reference to Exhibit 10.40 to the Registrant&#39;s Registration Statement on Form S-4, filed on September 3, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.15 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">+++</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000104746919004919/a2239535zex-10_42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated as of January&#160;18, 2018, as amended on April&#160;18, 2018 and July&#160;24, 2019, by and between Dong-A ST&#160;Co.,&#160;Ltd. and the Registrant (incorporated by reference to Exhibit 10.42 to the Registrant&#8217;s Registration Statement on Form S-4, filed on September 3, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.16 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">+++</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000104746919004919/a2239535zex-10_43.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Acquisition Agreement, dated January&#160;18, 2018, as amended on April&#160;18, 2018 and July&#160;24, 2019, by and between Dong-A ST&#160;Co.,&#160;Ltd. and the Registrant (incorporated by reference to Exhibit 10.43 to the Registrant&#8217;s Registration Statement on Form S-4, filed on September 3, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.17 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">++</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465919076916/a19-28294_1ex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Contingent Value Rights Agreement, dated as of December&#160;30, 2019, by and among the Registrant, Grand Rapids Holders Representative, LLC, Computershare Inc. and Computershare Trust Company, N.A. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on December 31, 2019).</span></a>&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021003397/tmb-20210323xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Contingent Value Rights Agreement, dated as of December&#160;30, 2019, by and among the Registrant, Grand Rapids Holders Representative, LLC, Computershare Inc. and Computershare Trust Company, N.A., dated as of March 23, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on March 24, 2021).</span></a>&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.19 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231ex1031f7a64.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Agreement for 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.31 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 30, 2020).</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.20 </p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231ex1032e2dfc.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement for 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.32 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003385/nrbo-20191231ex1033b8a5e.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Non-Qualified Stock Option Agreement for 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.33 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 30, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020003927/nrbo-20200413xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 15, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837020010309/nrbo-20200630ex102564787.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Manufacturing and Supply Agreement (NB-02 formerly DA-9803), dated as of June 7, 2020, by and between Dong-A ST Co., Ltd. and the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 11, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000051/tmb-20201231xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Support Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on January 6, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837021000051/tmb-20201231xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on January 6, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465921122546/tm2129080d2_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Securities Purchase Agreement, dated as of October 1, 2021, by and among NeuroBo Pharmaceuticals, Inc. and the purchasers identified on the signature pages thereto. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.27</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465921134050/tm2131812d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NeuroBo Pharmaceuticals, Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.28</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465921134050/tm2131812d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the NeuroBo Pharmaceuticals, Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.29</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465921134050/tm2131812d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement entered into on November 3, 2021 by and between NeuroBo Pharmaceuticals, Inc. and Ben Gil Price (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.30</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">#</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837022000589/nrbo-20220127xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Non-Employee Director Compensation Policy, dated January 14, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, as filed on January 28, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.31</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837022004958/nrbo-20211231xex10d47.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Membership Agreement, dated December 23, 2021, by and between WeWork and the Registrant (incorporated by reference to Exhibit 10.47 to the Registrant&#8217;s Annual Report on Form 10-K, as filed on March 30, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.32</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837022004958/nrbo-20211231xex10d48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Membership Agreement, dated February 9, 2022, by and between WeWork and the Registrant (incorporated by reference to Exhibit 10.48 to the Registrant&#8217;s Annual Report on Form 10-K, as filed on March 30, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.33</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837022013500/nrbo-20220630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Membership Agreement, dated April 19, 2022, by and between WeWork and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, as filed on May 13, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.34</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000155837022017864/nrbo-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Membership Agreement, dated August 30, 2022, by and between WeWork and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, as filed on November 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.35</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated September 14, 2022, by and between Dong-A ST Co., Ltd. and the Registrant (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, as filed on September 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.36</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shared Services Agreement, , dated September 14, 2022, by and between Dong-A ST Co., Ltd. and the Registrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, as filed on September 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.37</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement, dated September 14, 2022, by and between Dong-A ST Co., Ltd. and the Registrant (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, as filed on September 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.38</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated September 14, 2022, by and among Dong-A ST Co., Ltd., The E&amp;Healthcare Investment Fund II, The E&amp;Healthcare Investment Fund No. 6, The E&amp;Healthcare Investment Fund No. 7 and the Registrant (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K, as filed on September 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.39</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922100082/tm2225847d1_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Investor Rights Agreement, , dated September 14, 2022, by and between Dong-A ST Co. Ltd. and the Registrant (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K, as filed on September 14, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.40</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922129589/tm2233293d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NeuroBo Pharmaceuticals, Inc. 2022 Equity Incentive Plan, effective as of December 22, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, as filed on December 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.41</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465922129589/tm2233293d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NeuroBo Pharmaceuticals, Inc. 2022 Equity Incentive Plan Forms of Restricted Stock Unit Agreement and Option Grant Agreements (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, as filed on December 22, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.42</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20221231xex10d42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Membership Agreement, dated December 14, 2022 by and between WeWork and the Registrant, filed herewith.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">10.43</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1638287/000110465923004461/tm233671d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Separation and Release Agreement, dated January 16, 2023, by and between the Registrant and Gil Price (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, as filed on January 18, 2023.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">*</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Registrant</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">*</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of BDO USA, LLP</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">*</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">**</p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 6pt 0pt;">101.INS*</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Inline XBRL Instance Document</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 6pt 0pt;">101.SCH*</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 6pt 0pt;">101.CAL*</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 6pt 0pt;">101.DEF*</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 6pt 0pt;">101.LAB*</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">101.PRE*</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">104</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">__________</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">#</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Indicates management contract or compensatory plan</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Filed herewith</p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">**</p></td><td style="vertical-align:middle;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Furnished herewith</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">+</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to a confidential treatment request under Rule&#160;406 promulgated under the Securities Act.</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">++</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Certain schedules and exhibits have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">+++</p></td><td style="vertical-align:top;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Certain schedules and exhibits have been omitted pursuant to Item&#160;601(a)(5) of Regulation&#160;S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. Certain portions of the exhibits that are not material and would be competitively harmful if publicly disclosed have been redacted pursuant to Item&#160;601(b)(10)(iv) of Regulation&#160;S-K. Copies of the unredacted exhibits will be furnished to the SEC upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_94a15984_a296_4870_a589_c8afc22e0037"></a><a id="ITEM16_822338"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">ITEM 16.</b></span><b style="font-weight:bold;">FORM 10-K SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="margin-top:21.6pt;min-height:41.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#Toc"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_06af05c1_7f64_49f4_bc93_f809aac95915"></a><a id="SIGNATURES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Date: March 30, 2023</p></td><td colspan="2" style="vertical-align:top;width:49.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><b style="font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Joseph Hooker</p></td></tr><tr><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.89%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">Joseph Hooker</p></td></tr><tr><td style="vertical-align:top;width:50.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.6pt;margin:0pt;"><i style="font-style:italic;">Interim President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">3</p></div></div></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:47.67%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TITLE</b></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:14.7%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DATE</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Joseph Hooker</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.5pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.5pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.5pt;text-align:center;margin:0pt;">Joseph Hooker</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.5pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.5pt;margin:0pt;">Interim President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) </p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.5pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.5pt;text-align:center;margin:0pt;">&#160;March 30, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">/s/ Andrew Koven</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">Andrew Koven</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Chair of the Board of Directors</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;March 30, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">/s/ Jason L. Groves</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">Jason L. Groves</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">March 30, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">/s/ Hyung Heon Kim</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:47.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">Hyung Heon Kim</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">March 30. 2023</p></td></tr><tr><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">/s/ Na Yeon (Irene) Kim</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">Na Yeon (Irene) Kim</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;March 30, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">/s/ Michael Salsbury</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">Michael Salsbury</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">March 30, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">/s/ D. Gordon Strickland</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">D. Gordon Strickland</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;">&#160;March 30, 2023</p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>2
<FILENAME>nrbo-20221231xex4d12.htm
<DESCRIPTION>EX-4.12
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/30/2023 07:48:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 4.12</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following summary describes the securities of NeuroBo Pharmaceuticals, Inc. (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Exchange Act</font>&#8221;), certain provisions of the Company&#8217;s certificate of incorporation and bylaws, and certain provisions of Delaware law. Because it is only a summary, it does not contain all of the information that may be important to you.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has one class of securities registered under Section 12 of the Exchange Act, the Company&#8217;s common stock, par value $0.001 per share (&#8220;<font style="font-style:italic;font-weight:bold;">Common Stock</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s authorized capital stock consists of 100,000,000 shares of Common Stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share (&#8220;<font style="font-style:italic;font-weight:bold;">Preferred Stock</font>&#8220;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 12, 2022, the Company completed a 30-for-1 reverse stock split of its Common Stock. As a result of the foregoing, every thirty (30) shares of Common Stock outstanding was automatically changed and reclassified into one (1) share of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, the Company&#8217;s board of directors (the &#8220;<font style="font-style:italic;font-weight:bold;">Board</font>&#8221;) designated 3,700&#160;<font style="white-space:pre-wrap;"> shares of  Preferred Stock as Series A Convertible Preferred Stock, pursuant to a License Agreement with Dong-A ST Co. Ltd. (&#8220;</font><font style="font-style:italic;font-weight:bold;">Dong-A</font><font style="white-space:pre-wrap;">&#8221;), dated September 14, 2022 and a Securities Purchase Agreement with Dong-A, dated September 14, 2022.  On November 8, 2022, the Company issued 3,700 shares of Series A Convertible Stock to Dong-A. On December 22, 2022, the Company&#8217;s stockholders approved the conversion of the Series A Preferred Stock and all of the Series A Preferred Stock converted into 12,333,333 shares of Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, the Board designated 2,602,997 shares of Preferred Stock as Series B Convertible Preferred Stock, all of which were issued and outstanding in accordance with an Underwriting Agreement between the Company and Ladenburg Thalmann &amp; Co. Inc., as part of an underwritten public offering by the Company. As of March 29, 2023, all of the shares of Series B Preferred Stock had been converted into shares of our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Description of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Third Amended and Restated Certificate of Incorporation, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Certificate of Incorporation</font>&#8221;) and our Second Amended and Restated Bylaws (the &#8220;<font style="font-style:italic;font-weight:bold;">Bylaws</font>&#8221;), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Description of Registrant&#8217;s Securities is a part. We encourage you to read our Certificate of Incorporation, Bylaws, and the applicable provisions of the Delaware General Corporation Law for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights. </i>Holders of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors. The Company&#8217;s Certificate of Incorporation and Bylaws do not provide for cumulative voting in the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividend Rights. </i>Holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by the Board in its discretion out of funds legally available for the payment of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights. </i>In the event of the Company&#8217;s liquidation, the holders of the Company&#8217;s Common Stock will be entitled to share ratably in any distribution of the Company&#8217;s assets after payment of all debts and other liabilities and the preferences payable to holders of shares of Preferred Stock then outstanding, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Applicable Anti-Takeover Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Set forth below is a summary of the provisions of the Certificate of Incorporation and the Bylaws that could have the effect of delaying or preventing a change in control of the Company. The following description is only a summary and it is qualified by reference to the Certificate of Incorporation, the Bylaws and relevant provisions of the Delaware General Corporation Law (&#8220;<font style="font-style:italic;font-weight:bold;">DGCL</font>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Delaware Anti-Takeover Law</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation such as us from engaging in a &quot;business combination&quot; with an &quot;interested stockholder&quot; for a period of three years following the time that the stockholder became an interested stockholder, unless:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prior to the time the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers and (b) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at or subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section 203 defines a business combination to include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any merger or consolidation involving the corporation and the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority-owned subsidiary);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section 203, provided by or through the corporation.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Charter Documents</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Certificate of Incorporation and Bylaws provide that the Board be divided into three classes of directors, as nearly equal in number as possible, with each class serving a staggered three-year term. The classification system of electing directors may tend to discourage a third-party from making a tender offer or otherwise attempting to obtain control of us since the classification of the board of directors generally increases the difficulty of replacing a majority of directors. In addition, our Certificate of Incorporation and Bylaws:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to our Board or for proposing matters that can be acted upon at a stockholder meeting;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by resolution of the board of directors; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that special meetings of our stockholders may be called only by the chairman of the Board, the chief executive officer or the Board pursuant to a resolution adopted by a majority of the total number of authorized directors.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote is required to amend a corporation&#39;s bylaws, unless a corporation&#39;s certificate of incorporation requires a greater percentage or also confers the power upon the corporation&#39;s directors. The Company&#8217;s Bylaws may be amended or repealed by:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the affirmative vote of a majority of our directors then in office; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18.25pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the affirmative vote of the holders of at least 66-2/3% of the voting power of all then-outstanding shares of our capital stock entitled to vote generally in the election of directors.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The foregoing provisions of the Certificate of Incorporation may only be amended or repealed by the affirmative vote of a majority of directors and the affirmative vote of the holders of at least 66-2/3% of the voting power of all then-outstanding shares of our capital stock entitled to vote generally in the election of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These and other provisions contained in the Certificate of Incorporation or Bylaws could delay or discourage some types of transactions involving an actual or potential change in control or change in management, including transactions in which stockholders might otherwise receive a premium for their shares over then current prices, and may limit the ability of stockholders to remove current management or approve transactions that stockholders may deem to be in their best interests and, therefore, could adversely affect the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exclusive Forum Provision</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with an exclusive forum provision set forth in the Bylaws, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (a) any derivative action or proceeding brought on behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#8217;s stockholders, (c) any action asserting a claim arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws or (d) any action asserting a claim governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. The exclusive forum provision does not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">apply to actions brought to enforce a duty or liability created by the Exchange Act, or the Securities Act of 1933, as amended, or any claim for which the federal courts have exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Common Stock trade on NASDAQ Capital Market under the trading symbol &#8220;NRBO&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer Agent</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s transfer agent is American Stock Transfer and Trust Company, LLC.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>3
<FILENAME>nrbo-20221231xex10d42.htm
<DESCRIPTION>EX-10.42
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/30/2023 07:48:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="color:#181818;font-size:10.5pt;font-weight:bold;background:#ffffff;">Exhibit 10.42</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="nrbo-20221231xex10d42002.jpg" alt="Graphic" style="display:inline-block;height:16.8pt;width:73.8pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="4" width="7.0%" style="background-color:#000000;color:#000000;height:4pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.44pt 0pt;"><font style="font-size:18pt;">AMENDMENT TO MEMBERSHIP AGREEMENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 0pt;"><font style="font-size:12pt;">HI ADAM PERLISH</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="4" style="background-color:#000000;color:#000000;height:4pt;position:relative;top:0.6em;width:100%;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.2pt 0pt;">Please review the Amendment to your Membership Agreement below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.25pt 0pt;">If you have any questions or concerns, please don&#39;t hesitate to reach out to us at we-us-39470@wework.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Reference is hereby made to the Membership Agreement between 200 Berkeley Street Tenant LLC (&quot;WeWork&quot;) and dated January 29, 2020, including the accompanying Membership Details Form and any other amendments thereto (the &quot;Agreement&quot;). The parties agree that the following terms shall be considered binding amendments to the Agreement (the &quot;Amendment&quot;). Capitalized terms not defined herein shall have the meaning ascribed to them in the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 0pt;"><font style="font-size:12pt;">MEMBER INFORMATION</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="4" style="background-color:#000000;color:#000000;height:4pt;position:relative;top:0.6em;width:100%;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">Primary member:</font><font style="font-size:10pt;"> </font><font style="font-size:9.5pt;">Adam Perlish </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">adam.perlish@neurobopharma.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><font style="font-size:9.5pt;">+17034070449</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.15pt 0pt;"><font style="font-size:12pt;">AMENDED MEMBERSHIP DETAILS</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="4" width="50.0%" style="background-color:#000000;color:#000000;height:4pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WeWork 200 Berkeley</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Current Office(s)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 5.75pt;"><b style="font-size:9.5pt;font-weight:bold;">19-120</b><font style="font-size:10pt;"> </font><font style="font-size:10pt;letter-spacing:-1.2pt;"> </font><font style="font-size:10pt;">&#8226;</font><font style="font-size:10pt;"> </font><font style="font-size:10pt;letter-spacing:0.5pt;"> </font><b style="font-size:9.5pt;font-weight:bold;white-space:pre-wrap;">2 person  office</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 2.15pt 5.05pt;"><b style="font-size:9.5pt;font-weight:bold;">Membership Fee:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 5.05pt;"><font style="font-size:9.5pt;">$1,750.00/mo from January 1, 2023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.75pt 5.05pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 5pt 5.05pt;"><b style="font-size:9.5pt;font-weight:bold;">Commitment term</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 2.2pt 5.05pt;"><font style="font-size:9.5pt;">Start date: January 1, 2023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 5.05pt;"><font style="font-size:9.5pt;">End date: March 31, 2023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="4" style="background-color:#000000;color:#000000;height:4pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;" align="center"></div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Amendment to Membership Agreement</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">1</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 12.25pt;"><font style="font-size:12pt;">MEMBERSHIP FEE SUMMARY</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:12.25pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="4" width="50.0%" style="background-color:#000000;color:#000000;height:4pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:12.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:50%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:17.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:18.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:13.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:17.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">NET</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">MEMBERSHIP</b></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">DISCOUNTED</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.7%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">OFFICE</b></p></td><td style="vertical-align:top;width:2.59%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:17.79%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">DATES</b></p></td><td style="vertical-align:top;width:2.59%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:18.01%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">FEE</b></p></td><td style="vertical-align:top;width:2.59%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:13.81%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">DISCOUNT</b></p></td><td style="vertical-align:top;width:2.59%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:17.29%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">FEE</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.7%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">19-120</p></td><td style="vertical-align:top;width:2.59%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.79%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">01/01/2023 -</p></td><td style="vertical-align:top;width:2.59%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.01%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$1,750.00</p></td><td style="vertical-align:top;width:2.59%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.81%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$87.50</p></td><td style="vertical-align:top;width:2.59%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.29%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$1,662.50</p></td></tr><tr><td style="vertical-align:bottom;width:22.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 48pt;"><font style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">03/31/2023</p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:18.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:13.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:17.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 12.25pt;"><font style="font-size:12pt;">ANNUAL ESCALATION</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:12.25pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="4" style="background-color:#000000;color:#000000;height:4pt;position:relative;top:0.6em;width:97.73%;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12.25pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.1pt 12.25pt;">On each anniversary of the start date for the office, the Membership Fee will be subject to an automatic three and a half percent (3.5%) increase over the then current Membership Fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.1pt 12.25pt;"><font style="font-size:8.5pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.1pt 12.25pt;">This amendment may alter the date upon which Member Company&#39;s annual increase of the Membership Fee occurs, but in no event shall it occur on a date earlier than the next anniversary of the Start Date of the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 5.94pt 0pt;"><font style="font-size:8.5pt;">In the event of any inconsistency between the Agreement and this Amendment, the terms of this Amendment shall prevail. The parties further agree that other than the terms modified by this Amendment, the Agreement remains otherwise unchanged, including the annual Membership Fee increases set forth in the Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:8.5pt;">By electronically signing this Amendment you represent that you have the proper authority to execute this Amendment on behalf of and incur the obligations described in this Amendment on behalf of </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Community Manager&#39;s signature</b></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:48.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Electronic Signature</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:48.22%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Molly McLaughlin</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.86%;border-bottom:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gil Price</p></td></tr><tr><td style="vertical-align:bottom;width:48.22%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">200 Berkeley Street Tenant LLC</p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.86%;border-top:1.0pt solid #dcdcdc;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Signed on December 14, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:48.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">WeWork</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><font style="font-size:7.5pt;">200 Berkeley Street</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 38.9pt 0pt 0pt;"><font style="font-size:7.5pt;">(646) 491-9060</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><font style="font-size:7.5pt;">Boston, MA, 02116, USA</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><font style="font-size:7.5pt;">we-us-39470@wework.com</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><font style="font-size:7.5pt;">VAT: 834152702</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:3pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Amendment to Membership Agreement</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">2</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>nrbo-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/30/2023 07:48:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">SUBSIDIARIES OF NEUROBO PHARMACEUTICALS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:76.29%;" align="center"><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.9pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction of Organization</b></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.9pt;">NeuroBo Therapeutics, Inc.</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.9pt;">NeuroBo Co., Ltd.</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">A Korean limited company</p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2.9pt;">ANA Therapeutics, LLC</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>nrbo-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/30/2023 07:48:00 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Trebuchet MS';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Trebuchet MS';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Trebuchet MS';font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">NeuroBo Pharmaceuticals, Inc.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-bottom:4.7pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-252412, 333-220315, 333-217296, 333-256135 and 333-269365), Form S-1 (No. 333-267482) and Form S-8 (No. 333-237535, 333-232667, 333-225435, 333-222675, 333-213946 and 333-213014) of NeuroBo Pharmaceuticals, Inc. of our report dated March 30, 2023, relating to the consolidated financial statements which appear in this Annual Report on Form 10-K. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';margin-bottom:4.7pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';text-decoration-line:none;">/s/ BDO USA, LLP</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Boston, Massachusetts</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">March 30, 2023</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>nrbo-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/30/2023 07:48:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">I, Joseph Hooker, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of NeuroBo Pharmaceuticals, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit<font style="letter-spacing:-1.4pt;"> </font>to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this<font style="letter-spacing:-1.4pt;"> </font>report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly<font style="letter-spacing:-0.3pt;"> </font>present<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.15pt;"> </font>all<font style="letter-spacing:-0.05pt;"> </font>material<font style="letter-spacing:-0.1pt;"> </font>respects<font style="letter-spacing:-0.15pt;"> </font>the financial<font style="letter-spacing:-0.1pt;"> </font>condition, results<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>operations<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>cash<font style="letter-spacing:-0.1pt;"> </font>flows<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>registrant<font style="letter-spacing:-0.15pt;"> </font>as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I<font style="letter-spacing:-0.15pt;"> </font>am<font style="letter-spacing:-0.15pt;"> </font>responsible<font style="letter-spacing:-0.15pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font>establishing<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>maintaining<font style="letter-spacing:-0.2pt;"> </font>disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant<font style="letter-spacing:-1.75pt;"> </font>and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being<font style="letter-spacing:-0.75pt;"> </font>prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial<font style="letter-spacing:-0.2pt;"> </font>reporting<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>be<font style="letter-spacing:-0.15pt;"> </font>designed<font style="letter-spacing:-0.1pt;"> </font>under<font style="letter-spacing:-0.1pt;"> </font>my<font style="letter-spacing:-0.15pt;"> </font>supervision,<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>provide<font style="letter-spacing:-0.15pt;"> </font>reasonable<font style="letter-spacing:-0.15pt;"> </font>assurance regarding<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>reliability<font style="letter-spacing:-0.2pt;"> </font>of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting<font style="letter-spacing:-0.55pt;"> </font>principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented<font style="letter-spacing:-1.7pt;"> </font>in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;<font style="letter-spacing:-1.05pt;"> </font>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.5pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual<font style="letter-spacing:-0.15pt;"> </font>report)<font style="letter-spacing:-0.15pt;"> </font>that<font style="letter-spacing:-0.15pt;"> </font>has<font style="letter-spacing:-0.05pt;"> </font>materially<font style="letter-spacing:-0.15pt;"> </font>affected,<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>is<font style="letter-spacing:-0.2pt;"> </font>reasonably<font style="letter-spacing:-0.2pt;"> </font>likely<font style="letter-spacing:-0.3pt;"> </font>to materially<font style="letter-spacing:-0.2pt;"> </font>affect,<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>registrant&#8217;s<font style="letter-spacing:-0.2pt;"> </font>internal<font style="letter-spacing:-0.2pt;"> </font>control over financial reporting;<font style="letter-spacing:-0.8pt;"> </font>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.5pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; I have disclosed, based on my most recent evaluation of internal<font style="letter-spacing:-0.2pt;"> </font>control<font style="letter-spacing:-0.2pt;"> </font>over<font style="letter-spacing:-0.1pt;"> </font>financial<font style="letter-spacing:-0.05pt;"> </font>reporting,<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>registrant&#8217;s<font style="letter-spacing:-0.2pt;"> </font>auditors<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>audit<font style="letter-spacing:-0.2pt;"> </font>committee<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>registrant&#8217;s<font style="letter-spacing:-0.2pt;"> </font>board of directors (or persons performing the equivalent<font style="letter-spacing:-1.1pt;"> </font>functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.55pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control<font style="letter-spacing:-1.7pt;"> </font>over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information;<font style="letter-spacing:-0.8pt;"> </font>and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.5pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have<font style="letter-spacing:-1.5pt;"> </font>a significant role in the registrant&#8217;s internal control over financial<font style="letter-spacing:-1.45pt;"> </font>reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:39.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">March 30, 2023</p></td><td style="vertical-align:top;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/</p></td><td colspan="2" style="vertical-align:top;width:47.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Joseph Hooker</p></td></tr><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Joseph Hooker</p></td></tr><tr><td style="vertical-align:top;width:50.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Interim President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>nrbo-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/30/2023 07:48:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:9.35pt;text-align:right;margin:0pt 113.95pt 0pt 118.1pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.35pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350, </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">AS ADOPTED PURSUANT TO </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;min-height:10.0pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-indent:24.7pt;margin:0pt 18.1pt 0pt 15pt;"><font style="white-space:pre-wrap;">                                                                                            </font><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-indent:24.7pt;margin:0pt 18.1pt 0pt 15pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-indent:24.7pt;margin:0pt 18.1pt 0pt 15pt;">In connection with the Annual Report of NeuroBo Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Joseph Hooker, Interim President and Chief Executive Officer, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:102.36%;"><tr style="height:23.05pt;"><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><div style="height:23.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt 0pt 0pt 10pt;">(1)</p></div></div></td><td style="vertical-align:top;width:92.93%;margin:0pt;padding:0pt;"><div style="height:23.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 2.5pt 0pt 12.15pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:5pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:103.26%;"><tr style="height:23.05pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt;"><div style="height:23.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt 0pt 0pt 10pt;">(2)</p></div></div></td><td style="vertical-align:top;width:92.99%;margin:0pt;padding:0pt;"><div style="height:23.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;margin:0pt 0pt 0pt 12.15pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:68pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:87.5%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;">April </p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"></td></tr><tr style="height:20.05pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11.05pt;margin:0pt 0pt 0pt 10pt;"><font style="display:inline-block;text-indent:0pt;width:69.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">March 30,</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023</font></font><font style="white-space:pre-wrap;">                                                                         </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Joseph Hooker</u></p></td></tr><tr style="height:21.8pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:8.55pt 0pt 0pt 270.2pt;">Joseph Hooker</p></td></tr><tr style="height:24.3pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:3.6pt;margin:1.25pt 0pt 0pt 196.6pt;"><i style="font-style:italic;">Interim President, and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)</i></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>nrbo-20221231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20221231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &^ F # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ1>3:=X:U:[MW\NX
M@M)I8WP#M94)!P>#R.]?(WPL_:>\<:_^QIXVU3Q/>06/Q=\/^ I/%$-_!;QB
M.\MY]/DN;"_CC*^6>5,<B[=@E@D&W:5!^N?%%G-J/AK5K2W3S+B>TFBC3(&Y
MF0@#)X')[U\D_%']F#QMXB_8R\$Z5X:M(=/^+OA[P%'X9DL9[E!'=P3Z?';7
M^GR2!O+.=H>-MVT301'<$+$@'UMX7O)M1\-:3=W#^9<3VD,LCX W,R DX' Y
M/:M.LSPO9S:=X:TFTN$\NX@M(8I$R#M94 (R.#R.U:= !1110 4444 %>'?M
MA?$GQ_\ #'X*>)]6^'NCP3:K::/?7\NNWT\:VVDQP1;R_E,&::9@3Y2;#'N0
MF1E  ?W&O-_VDO".K>/_ -GSXD^&M!M/M^MZOX=O[&RM?,2/S9I('1$W.0JY
M8@98@#N10!RWQS^,,_A*_P# /A.UUX^'=4\5I>7,FI6]B;V^2UM(%><6-L(Y
M!/=,\L 2/RY/E,C;'V;3T/P#\5:EXIT37OMGBB#Q;9V.I?9;*^FLVL=5CC^S
MPNT6I6IAA$%TKNYVK&@,;0ML4DYI_$GP1JT?BSX>>/=&T)?$>J^%(;VSGTI;
MB.&XDM;J&,2FV:1EB,PDMX !(Z*4:3YP<9M?!KPIKEIXE\?^,=>TI?#MQXLU
M"VN8-$,T<LUM#!:10*URT3-&9V*-N\MF4(L2[FVYH ]2HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#[PO\,7^'/Q#&C^-_!EMJ%K/J^KZ8+NVU=;]_.NS+!O!0^?B1-KG;C:=_4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE7]H?
M_D^S]D;_ +F[_P!-<=?55?*O[0__ "?9^R-_W-W_ *:XZ /JJBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF2LR1.RIYC $A
M<;CZ5^7D?[</CHIKFMW?QIT?3M?O/"6HZE;^!I]!BC_L36[74+18M(,3XN)9
MIHQ<P[G.?G:100BX /U&HK-\-7]YJOAS2KW4;,Z=J%S:137-F3GR)60%X\]]
MI)'X5I4 %%%% !1110 5\J_M#_\ )]G[(W_<W?\ IKCKZJKY5_:'_P"3[/V1
MO^YN_P#37'0!]54444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF#]I_P#Y'ZP_[!D?_HV6FMP.@_X:L_ZE?_RH?_:J/^&K/^I7_P#*A_\ :J\
MHJ[(#W__ (:L_P"I7_\ *A_]JH_X:L_ZE?\ \J'_ -JKP"BBR ]__P"&K/\
MJ5__ "H?_:J/^&K/^I7_ /*A_P#:J\ HHL@/M[P%XK_X3?PG8ZW]E^Q?:O,_
M<>9YFW;(R?>P,YVYZ=ZZ"O/_ ("_\DGT+_MO_P"CY*] J& 4444@"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC2] HHHKPCUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (K
MD*;:4.K.FPY5,Y(QT&.]? G[)EO\8;3X!>%D\+?!CX?7?A0I*VCS:WK M]1>
MS,K^4;L16SHTY'+L-NYB245LBOORX"&WE$C;(RIW-G&!CDY[5^66G>&M'TSP
M5J'Q%\+_  8^)3? ^*2XU!M>M/B9<VFH7-FN]IM173FD4E&96;#.'92'Z'@
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M'ZP_[!D?_HV6JCN!Y!1115@%%%% !1110!]?? 7_ ))/H7_;?_T?)7H%>?\
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MOI[1]8L/$.DV6J:7>V^I:9>PI<VMY:2K+#/$ZADD1U)#*P(((."#7S#^T/\
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M\O;'][[WF<8VFOO31]'L/#VDV6EZ796^FZ990I;6MG:1+%#!$BA4C1% "JH
M  & !7S#^T/_ ,GV?LC?]S=_Z:XZ /I+3K_69_$6L6UYI,%IH]NL!T_4$O/,
MDNV96,H>+8/*V$* =S;MQ/RXYR8M=\8MX'TW4)/"EDGBB:6W6[T4:N##;(TR
MK,PN/*^<I&6<#8-Q7;D9S7744 ?*G_#0_P"T]G_DT?C_ +*5IG_QNC_AH?\
M:>P?^,1QGM_Q<G3/_C=?5=% 'RH?VA_VGN,?LC_7_BY6F?\ QNO,?BAKG[3O
MQ(U^WU/_ (9?_L[RK5;;RO\ A8&ERYP[MNSA?[^,8[5]\T4 ?FM_PC7[3O\
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M0^+NT?\ &,XSW/\ PGEI_P#&*Y2BOUO_ %.P'\\_OC_\B?G/^LV,_EC]S_\
MDCK/^'B'Q<S_ ,FS\?\ 8^VG_P CTG_#Q#XN[3_QC.,]C_PGEI_\8KE**/\
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M6F?_ !NOJNBO!/8/A7_AX#\8\G_C&/C_ +'ZS_\ C%)_P\!^,F!_QC(,^O\
MPGUG_P#&*S3UI*OE0&I_P\!^,>?^38^/^Q^L_P#XQ2?\/ ?C)S_QC(/;_BOK
M/_XQ6911RH#4_P"'@/QCX_XQC'O_ ,5]9_\ QBC_ (> _&//_)L?'_8_6?\
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M<8)!'51VK;HK2G4E2FJD'9IW7JB)PC4BX25T]&>*?\,F>$/^@CK?_?\ A_\
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MJJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1_:F/_Z")_\ @4O\P_L_!_\ /F/_ ("O\CS?_AG;X>_]"_\ ^3MQ_P#'*/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]&C?^9*TO_XW1_PT/^T[_P!&C?\ F2M+_P#C=?55% 'RK_PT/^T[_P!&C?\
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MC\::U^T1?KX,^+?CW5-+\>^(K+2]2\*>+Y+*SLEC8-#;B'SPVY&;=\L3\.H
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MZVEO;B>STO*-&WV*UDD:&TRC,A\A$RK$'()H ^8_"^G>))/A3\'O%G_"P_&
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M +N<W-W<W=U-=W5W-M5?,GN)G>69]J(H9V8A451P   =)1110 4444 %%%%
M#)X([F&2&:-98I%*/&Z@JRD8((/4&L^'PQH]OX;C\/1:38QZ!%:K8II26R"U
M2W";!"(L;1&% 4+C&.,8K3HH YS2?AMX1T#P?/X3TOPMHNF^%;B.6&;0[33H
M8K&2.4$2HT"J$*ON;<",-DYSFF>+/ACX.\>V-A9>)O">A^([.P<26=OJVFPW
M4=LP& T:R*0A XR,<5TU% %2_P!)L=5TNXTR]LK>\TVXA:WFL[B)7AEB8;61
MD(P5()!!&"*S_$O@?PYXT?37\0>']+UU],N5O;%M3LH[@VEPOW98MZG8X[,N
M"/6MNB@ HHHH **** "BBB@#G=4^'/A/6_%.G^)M1\+Z-?\ B33@5LM8NM/B
MDO+4'.1',RET')^Z1U-:B:%IL>M3:PNGVBZO-;I9RZ@(%%Q) C.Z1-)C<45I
M)&"DX!=B!R:O44 <WX5^&OA#P+>ZE>>&_"NB>'KS4Y#-?7&E:=#;27;Y)+2L
MB@N<DG+9.2:VX],LX=1GU".T@2_N(HX)KI8P)9(T+F-&;&2JF20@'@%VQU-6
M:* ,3POX&\-^"$OT\.>']+T!-0N6O;Q=+LH[87-PV-TLFQ1O<X&6.2<=:VZ*
M* "BBB@ KFO''PR\'_$VTMK7QAX3T/Q9;6KF6"'7-.AO$B<C!9%E5@I(XR*Z
M6B@#C/#_ ,%OA[X2T74-'T/P)X9T;2=0=)+RPT_1[>""Y9#E&DC1 KE2!@D'
M&*T_%?P^\+>.VT]O$OAK2/$+:=.+FR.JV$5T;64=)(_,4[&&!\RX-=!10!!>
M6-MJ%N;>ZMXKF E6,4R!U)4AE.#QP0"/0@5FZWX+\/>)=3TK4=7T'3-5U#29
M3/I]W>V<<TMG(1@O"[ F-O=2#6S10 4444 %%%% !1110!EZ?X6T72?#L6@6
M.D6%EH,,'V6/2[>V2.U2'&/+$0&T)CC:!C%4_"OP]\*^!=#DT7PUX:T?P]H\
MA8OI^E6$5M;L6^\3'&H4Y[\<UT%% ',ZS\,/!OB/PG:>%M6\):%JGABTCBBM
M]%O=-AFLH4C $:I"RE%"@ * . !C%;<>DV,6EC34LK=-.$7D"S6)1#Y>,;-F
M,;<<8QC%6Z* ,3Q)X'\.>,M.MM/U_P /Z7KEA;2I/!:ZE91W$44B?<=5=2%9
M>Q R.U;0&!@=*6B@ HHHH **** (;RSM]0M)K6Z@CN;:9#'+#,@=)%(P593P
M01V-9'A?P%X9\$: ="\.>'=)T#1"7)TW2[&*VMLO]_\ =HH7YLG/'-;M% ',
MZS\,?!WB+PC:^%=6\)Z'J?A>T2**WT2\TV&:RA2, 1*D#*44(  H X XQ6Z-
M,LQIO]GBT@%AY7D?9?+'E>7C;LV8QMQQC&,59HH Q/$G@?PYXQTZVT_7_#^E
MZY86TJ3P6NI64=Q%%(GW'574A67L0,CM6T!@8' I:* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>nrbo-20221231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20221231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N CT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7X[?]CG;?^H]HU 'JM%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_AI-JR-XSU6RFU"#38E+LD$?5Y".$!YV[L;MK8Z&NXKXUUSX6^%_AU_P4/\
MA??>'])CL;_Q%I7B/5-5O"[237=PYB;+NY)VKN(5 =J#A0!0!]'^//C=X/\
MAMXO\'>%M>U46VO^+KMK+2+%(VD>=U +,<#Y4&5!8X&2!7(W7[8GPHLOBL/A
MY+XCD&O_ -IIHAF%C.;%=1==RV9N]GD^<1QLW9W97[P(KX/^,&J^/[#]I'P#
M\0O&?PA\12^+[GQ^D.DR1S6WE/I,$<RVFG6O[XX=M[SR,X0,[-T"J!J:MXJT
MI/"_CGX.12-IWQ:U+X[?;[;1S;$W<T4FH0W4=_A028?LZ[O-; VH.VTD _46
MO*O@W_R47X[?]CG;?^H]HU<I\4O^&I_^$[U/_A7'_"G_ /A#/W7V#_A*?[5_
MM'_5)YOF^1^[_P!;YFW;_#MSSFC]DG_A./M7QC_X6/\ \(__ ,)G_P )G']O
M_P"$6\_^SO\ D!Z3Y7E>?^\_U7E[MW\6['&* /H"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **X?QE\=/AM\.=7&E>+/B%X5\,:HT2SBQU
MG6K:TG,9) ?9(ZMM)!P<8X/I6%_PUC\$/^BR?#__ ,*BQ_\ CM 'JM%5-)U:
MQU_2K/4],O;?4=-O84N;6\M)5EAGB=0R2(ZDAE92"&!((((JW0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,EFC@0O*ZQH.K.<"
MECD65 Z,'0\AE.0:^=;S]@SX8^+]6;6/B(=?^*&LM/+<+<>*-:N)88-^<QPV
MT;I"D:@X5=AP .21FN0^'?[/GPFT#X^>)/#?PPC\5_#+Q#X0;3-7U,:)J\JZ
M5JD=P'*PR6TDDB.I6%E;Y$(RI5L\@ ^NZ@>QMI;N.Z>WB>YB!5)F0%T!Z@-U
M -3T4 07%C;7;PO/;Q3/"V^)I$#&-O5<]#[BD.GVK7HO#;0F[5=@N#&/,"^F
M[KCVJQ10 5Y5\&_^2B_';_L<[;_U'M&KU6O*O@W_ ,E%^.W_ &.=M_ZCVC4
M>JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.56T/V3@6K4JX:NZDF_>6[OT%HHHKY@_3@HHHH ***0,"2 02.H]* %HHHH
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M[.W@;Q5HWB31/AY]BUK1[V'4+&Y_MO49/)GB<21OM>X*MAE!PP(..017TK0
M4444 %%%% !1110!\_\ QI_:IMOA+XQT;0;S2K^Q:;4XDFFNK%YH[VQ,;EY+
M1HV.763RT*MS\WW2#D>T^$]>E\3^';'5)M*OM$DNH_,-AJ2*EQ#R<!U4D XY
MQGO7FWQ%_9@\'?$3Q/8Z]=V%LVH#4XK[4)+V%KLWD*0O']F&]_W2'<K848RN
M=N>1Z3X2\*:;X'\.6&A:/"]OI=C'Y5O#),\Q1,Y"[G)8@9P,G@<5Q45B%5FZ
MK7+T[_U_6NY]3F%3)I9=AXX*,EB%_$;6GRU[^M]_<^$UZ***[3Y8**** "BB
MB@ HHHH **** "O(OC%\)_B'X^U^SO?"'QDU/X<V$-L(9=.L=&M+U9Y-['S2
M\RE@<%5P./ESWKD/VK/VK-<_9Y\5?#OPWX;^'?\ PL/6O&7]H_9[7^VX],\K
M[)'#(WS/$ZME96/)7&SN3QYC_P -Q?''_HUS_P R%8__ !FNBGAZU5<U.#:\
MDV8SK4J;M.23\V4?@YX)^/'Q0\1?$W39_P!I36[!/"/B6308I(_#.FN;E5MX
M9?,8%/E/[[&!G[OO7V;X*T74_#OA/2M,UK79O$VJVL"QW.KSP) ]VXZR-&GR
MJ3Z+Q7Y]?"3]H+XX_"W7_B-J7_#.7]I_\)AXBDU_RO\ A.;&'[)N@AB\K/EM
MOQY.=V%^]C'&3V_B#_@H!\8_"V@ZEK6J?LQ?9=-TZVEO+J?_ (3^S?RXHU+N
MVU8"3A03@ D]A6CP>)2NZ4ON9"Q-!Z*:^]'W37/_ !"\:V/PU\ ^)?%VIQ7$
M^FZ!IESJMU%:*K3/%!$TKJ@9E!8JA !(&<9(ZU4^$WCK_A:'PL\&^,OL/]F?
M\)%HUGJ_V+S?-^S_ &B!)?+W[5W;=^-VT9QG Z5RO[6'_)K/QD_[$S6?_2&:
MN,Z3YVM?^"LOP\OK:&YMOA=\6;BWF021S1>'[=D=2,AE(NL$$<@BO(_VD?V^
MO#?QAM_AI'HWPR^)UL?#7CK2/$]Y]OT"-/,MK61FD2/;.V9"&&T' /=A7COP
MO_Y)IX2_[!%I_P"B4KIJ^SIY%3G!2YWJC\;K\=8FE5G35".C:W?1GT[_ ,/6
M_ 7_ $2GXN_^$Y;_ /R57H_[._[=O@S]I'XD7O@C1O"GC/PWK5KI+ZRW_"3Z
M=#:H\"S1PG;MG=B2THQ\N/E;G(P?ANN__85_Y/RU;_LFTW_ITMZX<?E,,'1]
MK&3>I[>1<5ULWQJPLZ2BFF[IOH?IO7YD_MU_\GXZ/_V3:+_TZ7%?IM7YD_MU
M_P#)^.C_ /9-HO\ TZ7%>9EO^]T_4^EXC_Y%.(_PGG]%%%?IQ_,QS/Q/_P"2
M:>+?^P1=_P#HEZ_9L=!7XR?$_P#Y)IXM_P"P1=_^B7K]FQT%?$Y__%I^A^U<
M _[M7_Q+\A:Q/&GC31/AWX5U+Q)XCU"/2M#TV(SW=Y*&*Q)D#<0H)[CH*VZ*
M^5/U,^<O^'B?[.7_ $572?\ OS<?_&Z[OX2?M0_"WX[:O>Z7X"\8V7B2_LH/
MM-Q!;1RJ8X]P7<=Z =2!7#?M3_\ )5/V</\ L>6_]-UW7T70 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% &/XQ\1_\ "'^$]8UW^R]2UO\ LVTE
MN_[-T>W^T7MUL4MY4$>1OD;&%7(R2!7YN6?BO6O&7Q)FUOQ#:?MG:7>ZEKLD
M]O8Z1IW]G:-;VS3DP0FWW-L1(MB28)W;6?C<0/TD\7>'(_&'A75]"EOK_3(]
M2M);1KW2[@V]U;AU*^9#(.4=<Y5NQ -?!-I^Q3XL\.?M"_#32-=^*GB+Q7I-
MO>ZCJ\6JW/C6Y@U86R6\B*BV3[@2LDT$;SPR ,DC*T2!LD _0VBBB@ HKS*'
M]IGX57'Q+;X>Q>/M"?QFLIMSI"W:F7SAP8<_=\P'CR\[L@\<5-J_[1WPOT#X
ME6WP^U'QWH=EXTN)(X8]&FO%6<RR!3'&1T5WW+M0D,VY< Y% 'H]>5?!O_DH
MOQV_['.V_P#4>T:O5:\J^#?_ "47X[?]CG;?^H]HU 'JM%%% !1110 4444
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MK*^5/U,**** /U3_ ."&/7XV?]P3_P!OZ_56ORJ_X(8]?C9_W!/_ &_K]5:
M"L?4/!V@:M=O=7VAZ;>W+X#37%I'([8&!EB,]*V** /E?]@OP3X=O_V>8);G
M0-+N)?\ A(-<7?+9QLV!JER ,E>@  'L*^IHXUB1410B*,*JC  ]!7SG^P#_
M ,FYP?\ 8Q:]_P"G6ZKZ.H **** "BBB@ HHHH **** "BBB@#\P_C#X'^,H
MU[Q7)^T-I7Q*^(/@>22==(A^&&H0G2!#)NV)>6,*Q7#+'A?WCD\9'S<EO?\
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M $A@K<K#_;C_ .3J?V7/^YI_](8*W*^KR#_=9?XG^2/GLW_CQ]/U85P7Q_\
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M -B9K/\ Z0S5_-97]*?[6'_)K7QC_P"Q,UG_ -(9J_FLKY4_4PHHHH _5/\
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M7XV?]P3_ -OZ_56ORJ_X(8]?C9_W!/\ V_K]5: /Q6_X+5_\G2^%?^Q,M?\
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M35O!/_;]_P"EUQ7=D'^]2_PO\T<N;_P(^OZ,]ZHHHK[X^0.,^!/_ "D>N_\
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M2A__ $\1U]XU^7YE_OE3U/O<#_NT/0^)?VX_^3J?V7/^YI_](8*W*P_VX_\
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MUP%=_P#L*_\ )^6K?]DVF_\ 3I;UX^=_[H_5'V'!?_(VC_AD?IO7YD_MU_\
M)^.C_P#9-HO_ $Z7%?IM7YD_MU_\GXZ/_P!DVB_].EQ7Q^6_[W3]3]>XC_Y%
M.(_PGG]%%%?IQ_,QS/Q/_P"2:>+?^P1=_P#HEZ_9L=!7XR?$_P#Y)IXM_P"P
M1=_^B7K]FQT%?$Y__%I^A^U< _[M7_Q+\CRO]K#_ )-:^,?_ &)FL_\ I#-7
M\UE?TI_M8?\ )K7QC_[$S6?_ $AFK^:ROE3]3"BBB@#]4_\ @ACU^-G_ '!/
M_;^OU5K\JO\ @ACU^-G_ '!/_;^OU5H _%;_ (+5_P#)TOA7_L3+7_TNOJ^
M*^__ /@M7_R=+X5_[$RU_P#2Z^KX H **** /ZIU^Z/I2TB_='TI: "BBB@
MHHHH **** "BBB@#X%_:=FL?V==2C.L?&KX_:Y>WUO<ZN^E>#VLKLZ?8QL!)
M<R[X5$4"LZIN9NI'H37I7[#_ (W?Q7K?CVRDU3XM75SI:V27-A\6OL=O>6C2
M"5E,5M#B1%=1G?( K;0$SM?&+\:_'_P"\=_M&P:-X@^*.FZ->+X.UG0=>(UC
M3TTVZLIY$AET^>9Y-\%VDNV954*V(GR< BMK]C<^'F^)7Q)%O\8Y?C=XHAT_
M2(+G7[>*S6QM[!3=_9+:-K9V#S*3.978@MN0X!+9 /K"BBB@ HHHH *\J^#?
M_)1?CM_V.=M_ZCVC5ZK7E7P;_P"2B_';_L<[;_U'M&H ]5KY5_8%_P";C?\
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MV?\ INAK["KX]_:V_P"3ROV4?^YL_P#3=#7AT?XD?5'K5?@EZ,]BHHHKZ<\
M*M_LG?\ )K/P;_[$S1O_ $AAJI5O]D[_ )-9^#?_ &)FC?\ I##7DX_[/S_0
M]'!_:^1ZK7YC_L)_\FK>"?\ M^_]+KBOTXK\Q_V$_P#DU;P3_P!OW_I=<5W9
M!_O4O\+_ #1RYO\ P(^OZ,]ZHHHK[X^0.,^!/_*1Z[_[)0__ *>(Z^\:^#O@
M3_RD>N_^R4/_ .GB.OO&OR_,O]\J>I][@?\ =H>A\2_MQ_\ )U/[+G_<T_\
MI#!6Y6'^W'_R=3^RY_W-/_I#!6Y7U>0?[K+_ !/\D?/9O_'CZ?JPK@OC_P#\
MD'^)'_8M:E_Z2R5WM<%\?_\ D@_Q(_[%K4O_ $EDKWZW\*7HSR*7\2/JCZE_
M9-_Y-8^#?_8F:-_Z0PTO[6'_ ":S\9/^Q,UG_P!(9J3]DW_DUCX-_P#8F:-_
MZ0PTO[6'_)K/QD_[$S6?_2&:OR(_1C\N/A?_ ,DT\)?]@BT_]$I735S/PO\
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MS:-\$_#.E:WIOP=U_0?$#27"WNLW6F:\NKW<LS@A9+F;S9').QMNXXX; ZT
M>U4444 <\_Q%\*1^,4\(OXGT9?%;P_:%T)M0B%\8O[X@W;]O!YQBEN_B#X6T
M_P 6VGA:Z\2Z/;>)[N,S6VBS7\27LR#.62$MO8<'D#'!KXB\8? ;P)XZ_:2M
M_"7P[T.34_%6E^-[?QWXU^(5Z%FET<JPE33(;C 8M(57;""5B'S$$@[?(_B)
MHMO?_"W]HWX@_P!CZ?J'QAT;XX+:>'-6NX$&H1K#>6"64$4AVN(_+W *" 5!
M/;( /U9KRKX-_P#)1?CM_P!CG;?^H]HU<I\4OC-\=O"GCO4]*\&_LZ?\)WX;
MM_*^R>(/^$XL-.^U;HD9_P#1Y4+IM=G3D\[-PX(H_9)\1>)_%=U\8]5\9>$?
M^$$\27'C./[7X?\ [3BU'[+MT/253_2(@$?<BH_ XW[3R#0!] 5\J_L"_P#-
MQO\ V6;Q'_[;U]55\J_L"_\ -QO_ &6;Q'_[;T ?55%%% 'RK^T/_P GV?LC
M?]S=_P"FN.OJJOE7]H?_ )/L_9&_[F[_ --<=?55 'RK^WU_S;E_V6;PY_[<
M5]55\J_M]?\ -N7_ &6;PY_[<5]54 %%%% 'RK_P2X_Y,3^&7_<3_P#3I=U]
M55\J_P#!+C_DQ/X9?]Q/_P!.EW7U50!\Q?!?_D6_$7_8Y^*O_3_?UWM<%\%_
M^1;\1?\ 8Y^*O_3_ ']=[7U%'^''T1X-7XY>K"O!?B-_R?9^RM_W-7_IK6O>
MJ\%^(W_)]G[*W_<U?^FM:QQ?\&7R_,TP_P#%7]=#[:KX]_:V_P"3ROV4?^YL
M_P#3=#7V%7Q[^UM_R>5^RC_W-G_INAKPZ/\ $CZH]:K\$O1GL5%%%?3G@!5O
M]D[_ )-9^#?_ &)FC?\ I##52K?[)W_)K/P;_P"Q,T;_ -(8:\G'_9^?Z'HX
M/[7R/5:_,?\ 83_Y-6\$_P#;]_Z77%?IQ7YC_L)_\FK>"?\ M^_]+KBN[(/]
MZE_A?YHY<W_@1]?T9[U1117WQ\@<9\"?^4CUW_V2A_\ T\1U]XU\'? G_E(]
M=_\ 9*'_ /3Q'7WC7Y?F7^^5/4^]P/\ NT/0^)?VX_\ DZG]ES_N:?\ TA@K
M<K#_ &X_^3J?V7/^YI_](8*W*^KR#_=9?XG^2/GLW_CQ]/U85P7Q_P#^2#_$
MC_L6M2_])9*[VN"^/_\ R0?XD?\ 8M:E_P"DLE>_6_A2]&>12_B1]4?4O[)O
M_)K'P;_[$S1O_2&&E_:P_P"36?C)_P!B9K/_ *0S4G[)O_)K'P;_ .Q,T;_T
MAAI?VL/^36?C)_V)FL_^D,U?D1^C'Y<?"_\ Y)IX2_[!%I_Z)2NFKF?A?_R3
M3PE_V"+3_P!$I735^M4?X4?1'\FXS_>:O^)_F%=_^PK_ ,GY:M_V3:;_ -.E
MO7 5W_["O_)^6K?]DVF_].EO7CYW_NC]4?8<%_\ (VC_ (9'Z;U^9/[=?_)^
M.C_]DVB_].EQ7Z;5^9/[=?\ R?CH_P#V3:+_ -.EQ7Q^6_[W3]3]>XC_ .13
MB/\ ">?T445^G'\S',_$_P#Y)IXM_P"P1=_^B7K]FQT%?C)\3_\ DFGBW_L$
M7?\ Z)>OV;'05\3G_P#%I^A^U< _[M7_ ,2_(\K_ &L/^36OC'_V)FL_^D,U
M?S65_2G^UA_R:U\8_P#L3-9_](9J_FLKY4_4PHHHH _5/_@ACU^-G_<$_P#;
M^OU5K\JO^"&/7XV?]P3_ -OZ_56@#\5O^"U?_)TOA7_L3+7_ -+KZO@"OO\
M_P""U?\ R=+X5_[$RU_]+KZO@"@ HHHH _JG7[H^E+2+]T?2EH **** "BBB
M@ HHHH **** /F;X"?L1>!?!?PYBT[XA?#[P'XL\5-J.H7=QJLNBP7KRI-=R
MRP@RS0AV*QNBX(P-N!D &O;? WPD\#?#![UO!O@OP]X2:]""Z;0M*@LC.$SL
MW^4B[MNYL9SC<<=:ZRB@ HHHH ^=9?\ @GM\ )_'[^-I/ ;2>*'U,ZRVH-K6
MH$M=F7SC*4^T;/\ 6?-C&.V,<5V>N?LJ_";Q+\7;+XGZGX'TV[\=6;QRQ:L^
M\'S(P!'*T8;RWD3:NV1E++M7!&T8]7HH *\J^#?_ "47X[?]CG;?^H]HU>JU
MY5\&_P#DHOQV_P"QSMO_ %'M&H ]5KY5_8%_YN-_[+-XC_\ ;>OJJOE7]@7_
M )N-_P"RS>(__;>@#ZJHHHH ^5?VA_\ D^S]D;_N;O\ TUQU]55\J_M#_P#)
M]G[(W_<W?^FN.OJJ@#Y5_;Z_YMR_[+-X<_\ ;BOJJOE7]OK_ )MR_P"RS>'/
M_;BOJJ@ HHHH ^5?^"7'_)B?PR_[B?\ Z=+NOJJOE7_@EQ_R8G\,O^XG_P"G
M2[KZJH ^8O@O_P BWXB_['/Q5_Z?[^N]K@O@O_R+?B+_ +'/Q5_Z?[^N]KZB
MC_#CZ(\&K\<O5A7@OQ&_Y/L_96_[FK_TUK7O5>"_$;_D^S]E;_N:O_36M8XO
M^#+Y?F:8?^*OZZ'VU7Q[^UM_R>5^RC_W-G_INAK["KX]_:V_Y/*_91_[FS_T
MW0UX='^)'U1ZU7X)>C/8J***^G/ "K?[)W_)K/P;_P"Q,T;_ -(8:J5;_9._
MY-9^#?\ V)FC?^D,->3C_L_/]#T<']KY'JM?F/\ L)_\FK>"?^W[_P!+KBOT
MXK\Q_P!A/_DU;P3_ -OW_I=<5W9!_O4O\+_-'+F_\"/K^C/>J***^^/D#C/@
M3_RD>N_^R4/_ .GB.OO&O@[X$_\ *1Z[_P"R4/\ ^GB.OO&OR_,O]\J>I][@
M?]VAZ'Q+^W'_ ,G4_LN?]S3_ .D,%;E8?[<?_)U/[+G_ '-/_I#!6Y7U>0?[
MK+_$_P D?/9O_'CZ?JPK@OC_ /\ )!_B1_V+6I?^DLE=[7!?'_\ Y(/\2/\
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M^PK_ ,GY:M_V3:;_ -.EO7CYW_NC]4?8<%_\C:/^&1^F]?F3^W7_ ,GXZ/\
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M1UO3;G3A=#QQIDGD^;"R;RN1G&[."1G&,C-?7_[,?P4USX+'XL?VW=:?=?\
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M8)/,CZ^?C: <;>O.!\_#_@E_^TV8T?\ X5B^U\8']MZ;GGU'VG(_'I7] 5%
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M[<WQC^*/AOPMHNH?#F33-/\  37VDO?>,+;4Q)<W;37QA:SM8D4@ !8V>5F
M99=J\AJ]'^&G[)EAIT?C+4?BKJ\'Q@\3^,&MAJ]UJ^EQ16)@MB3;6\-GEDC2
M,G=U)9_F/-;/QL_9MTOXE_!>S^'/AV2R\%Z39:A8WEM'9V(,$*6]RL_EI$K(
M%#%2.#QG.#TH ]E%+110 5\;Z#X \;?'/XR_&TQ?&CQQX,@\.>(8M.TNPT6X
M@-G$IL;>;+Q21,6&^0DJ& (XK[(KY=U?]F;XNZ7\1/B'K_P_^-&G^#--\8Z@
MFHS6<WA./4)K61;>.#<DCS@$XC!P5Q[4 <+=_'KXWZC^PIK?B32$T6^^(.A)
MKEAKGB:5_L\%O%IS7"R7D, 4[YW2$!$PJ"1MQ 0;*^C?V7O$6I>+OV;_ (7Z
MWK-[+J.K:CX:T^[N[R=MTDTKVZ,[L>Y))-8VE?LRZ5X7_9>U[X-Z)JMTL6JZ
M+J.FRZYJ.;FXEN+Q)1+=2\C>Q>9G(R/0$5VWP:^'[?"?X2^#?!;WPU-O#VD6
MNEF]6+RA.88ECW[,G;G;G&3C/4T =E1110!\E?$C0/%7Q9_;+U3P3:?$_P 7
M^!?#^G>"+/5UM_#%U%#YEP][<1,S>9&X^ZJ] .@KH_V<?BGK7AV_^*7@;XF>
M,K369? FN06%MXIU/RK)[RVN;9+B!)^0AE0.5+ #=@'&<DV/BC^SM\1=;^/<
MWQ-^'WQ.L/!5S<^'H/#]S8WWAU=261([B682!C,FTYDQ@#L>N1C5^&?[)?AS
M0/!NO:;\0I;?XLZYXEU-=8U_5O$&FP^7>W2H(XRMO@I$D:* B#.W)P>: /+/
MVR?C'\4/"WC7X+MX0N=/TKX::UXTT33;O6[.]$MYJQN)'8P1JH*I;B.)M[;M
MSET"X4-N^R*\4^./[-5E\5/#?PPT+1;VU\):7X&\5Z9XBMK2VL0\+PV:R*MJ
MB*R",$2 !AD*%^Z:]KH **** /A#X/>"?B3^T)JOQTUBV^.?C;PGJ7A[XBZY
MX?T2SM)+>;3;>*!D: 2021$NJF7:5#@%5 XZU5\5_M2_&;XB_P#!/[0_B3X*
MTG3--U2^T'4KGQ!XFFO?)_LTV<WD,;:!5+/-<;)F0\+%LY.2M=[IO[(7Q>\'
M:K\1H_!'QUM/"6@^-/%%_P")KB"/PE'<W=L]TZETCFDGQD(BINVCH6 !Z>HW
M_P"R_HMC^RA?? WPQ>MH^DR:'+H\&H7$0F=6D!+SR*NP.[.SNV-H+,>E 'H7
MPJU&YUCX7^#[^]G>YO+K1[.>>:0Y:1V@1F8GU))-=36+X)\/'PCX-T'0FG%T
MVF6$%D9PFP2>7&J;L9.,[<XR:VJ "OD'6O"OBWXU_M:_%/PS%\5_&G@?1/#>
MDZ+<6=GX:NX8HVDN8Y_,+B2)\\Q*>,=37U]7S9XY_9P^)TGQM\7?$'X=_%;3
MO!1\2V%C97=G>>&DU)E^S(ZHZNTR@',CG&WTSF@!_P"S#\:-43PKXUT+XJ>+
M=+N-9\&>++SPPOB*\DBLAJL<:1S12LAVJLFR8*RKD?)G)Y-<A^T)\5/BWHW[
M2'PBTNQBLO#GPMO_ !9;::M[;7_G7GB#?:><Q:-5Q%;HQDCVLVYFC#8VD5Z/
M\-_V.O WAGX>S^'_ !I8V7Q0U/4=7G\1ZQJ_B33XI?MNJ3 ++<+"P9(1M 54
M3A5&,DDD]#\7_@8/B=X@^%NH6VJ1Z/!X(U^/6A;"V\P7*)"\8A4AEV??SG!Z
M8Q0!ZO1110 5\'_#WP%\4/BI\,?'7Q TKX[^-="\2V.N:[#IFG/);3Z3&+6[
MFCAC>%X69D*Q@'YCCK@XP?O"OD"R_8\^+FDZ%XD\):1\>(=!\#Z]JE_>W%G8
M>%8_M\4-Y.\L\,5TTY*L1(RB3;E<Y X H X3]J#]I;XRW'[!WAGXF>"X--\.
MOJ.AZ?J7B'Q!%<%)[62:6"+R;&$AN7DER7=L)&& RY4C[PTN1I=-M'=BSM$A
M+'J3@5XG\:OV5M-^)'[*%U\#?#VI?\(OI7V*PL+.]E@-V8([6>&5=R[U+EA#
M@G<.6SSTKW"SM_LEI!!NW>6BINQC.!B@":BBB@ HHHH **** "BBB@ HHHH
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MX?T5KV6.WMKCQ%\+I](MIII&"1Q+/=V,49D=F553=N8G"@UG21?LE1-J3O\
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M;V:2]TEC;);?V:GVB2[>XE2*W2%0?G:1Y8PN#SN':@#P+_AZ/^S%_P!%-_\
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M!T=%%% !1110!X9^S+KFF>&/V6-%U?6KN"PTBPMK^YO+JZ8+%%"ES.SLY/
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K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>nrbo-20221231xex10d42002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20221231xex10d42002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  < 'P# 2(  A$! Q$!_\0
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M_P %!=<_9]\;3>'/%OPEF@E8&:SNH=<1XKNW+%5D4B'C.TY4\@C'H3T?BO\
M:_\ B#X-^%EO\1+_ ."ZR>$IX(;G[79^*89VCCEV['=5AR 2RC(S@L,T ?5U
M%?+_ .S=^UWXB_:7L=<U'1/AY;6&G:;&\8EN/$"F26Z"!HX?+$.55L_ZPY P
M>#SCG/#O[?MS/:Z_K'B7X>KX<\*>'[I[#4=877$N=UT =L%M&(E\]R0.C  '
M).!0!]AT5\AWG[7GQ/G^&T_Q.TWX3V"> HHQ<*+W7@FH36^X#S1$(RJCG.,D
M_P ZGU7]NZ:\^#MO\3/"'@&7Q-X<@S%K*/JBVUQIDV<;63RWWIT.\'N.* /K
M6BOCSX+?MQ^,?V@XM4?P5\([:]_LW;]HCNO%4=NXW=-H:#GZ\"N<T7_@HWXA
MU_XI1?#V#X1I9^*GNS9&VOO$B1(DHZJ7^SD?3'6@#[FHKYH^,7[4GC/X5?$?
MP]X0MOAC;^(;[7XE-C]G\0)&Q<#]X'4PG:BG^(G!Z\=*Y.?]O*_\5^/;'X??
M#SP/'XJ\:-E;YO[3":=:.O\ K )MF9%7NVU>G&: /L.BOC6[_;YU'X5?$]/!
M'QE\##PK--L:/5M)O?M=L48X#[2H)3/4@DC'W:S_ -H[_@HT/A'XD_X1S0?!
M5Y>7\BQRPZGJC!+6XA<96:%4),J$="66@#Z7^/B>(E^$OB6X\+>(&\,:W:VC
MW,&HK;QS[=@W%2K@@;@"-W49S7PG_P $ROB+XI^)7QV\8ZCXJ\0ZGK]X-";#
MZA<O)M_TB'@*3A?H ,9KNO$?[>6M^-?&%_\ #X_#'5M*T_4M*F!NM15HKL*T
M!83^21@1=_O$XR<\8KR'_@DJ6'Q?\9%<G&A' SW^T0]Z?0#]4ATI:^23^UM\
M3]?^+^L_#OPK\([#6-2TF4I=ZC%XCWV5LIY4RRB !&QC,?+9RHY%?3/A277I
MO#UD_B:'3K772A^U0Z5(\ULK9. CNJL1C'4#G-(#YK_X*,_ D?%GX(7&O:?!
MYGB#PIOOX2JY:2V('VB/\% D_P"V>.]?)7[-7C_Q)^T=\*M&_9Q4W=M8I>M=
M:CK28;R=)CQ((1G^+SF4 G@#:.@-?J]=6\=Q;RPRQK+$ZE'C<95E(P01W&*^
M:/V-/@;X6^%6K_$^XT.WF$[^(I].$EPX9DMX<-&BD 8&9&SZ\9Z4 ? 'PH^(
MOB[]C'XO>/\ P0MG<7U_J$,NC0V\'&Z[)Q:W"@GD?/D#N'%>@_MR?";4/@Q\
M!?A)X=0.]HK7-QJEP@^66_D".[,?Q.W/88[5]@_%'X%^%/$G[8'P]\67MM(V
MII9RS.BLHBFDAXB=QMR2NX8.?X%]*]L^*'PK\-?&+PC>>&/%6GKJ.E7&&VDX
M>)QG#HW56'J/4CH<4 ?&G[,?[)/[/_QT^#VA:Y'97E]JAMDBU2%-8G5H;@#Y
MU9 _R@GD< $<CBOH[X6? [X3^"_"?B_P!X.BADL;ES#K%F+QKIXY'C  <L3M
M(7! [5\,2_LB^%_"/QO'AG2/$/BC3[&67RWFM[^..8KGIN6(?RK]'OA3\)_#
M7P;\*6WA_P ,61M;-<R2RRN9)KB0]9)'/+,?7\L"@#\G/!OC#7OV#OVH-?T[
M['-?VRF2S-I'Q]JB;)@9?7G'7U-6OVF/@?XO^"Q\%_%VZNYY=9UZ;^T=08XQ
M9WA;S%C!7!V[<#GZ5][_ !Y^ /A'Q_\ M"_#3Q%JUM,]_%(ZND;*(YQ%\R>8
M"I)P?0CH*[O]J/X?:/\ $CX'^)]'UB)FMDA$\3Q$*\<BG*LI((!'TH ^9_A-
M>Z]^TCIWCWXVS6,UG=P: ^BZ!;MR5D$7^D2KZ%CD?B*\$_X)<WUM8_M&7]M?
M$)>SZ=,D2RGYMX.6Z]\ U^F/P*\$Z5\/OA'X9T+1X3%86]DA42$%F+#+%C@9
M))KYJ_:3_9-\%^$=;'Q/\*7.K^#_ !2EQY^_1;E(H3*>2^QD;!/?:0#Z4 >,
M?\%<HK1?&/@*1"#>M9W =1UV[TQFO!_VB[34;#3O@A#JBR+?+X=A9A+]_8;A
MS'_XZ5Q[5]I_!K]FWP_\>=?C\?\ Q(UC7/&VN6:*L,6J3PBU4+RO[J.)!@'G
M'0]P:H?$K]D'0/C)XMEUWQ5XO\5W^H0'[/ 4FLXD@B5CM1$6V  &>._O5 ?5
M?CJ&,_!#69"B[_\ A'Y%W@<X\CUK\H/V(O#GQ!\3:M\0X?AMXE_X1WQ%%X>D
MD5?LZ2&[7S8OW*NW,3'.0XZ'';I^AA\!:MK_ ,&I/"]Y\0O%3VK7)M'O5>S6
MZ>V\G;Y)D%M]WOG&[_:KC/A%^Q?X:^!/C:WU[PAXO\7V%XS+!<(]U:O'=1%U
M)CD7[-RIP.F#Z$5('AG_  3@_:7_ .$#\6ZG\*?&9^Q/JU^\MI=W:;)$OR=L
MD,Q/.7*@#=SO&/XN/T\'2OB;QM_P3^\!?$CQUKWBO6/$7BHZQ?7<ES(]M<VD
M2JV_ V@6W   ]^,DD\U[Y\+O ^I>&?#CZ=)XZ\3ZZL,^V.YUF:VN)PNQ,+O\
+@$@<GG)R3S0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>nrbo-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2023 7:48:19 PM-->
<!--Modified on: 3/30/2023 7:48:19 PM-->
<xsd:schema targetNamespace="http://www.gemphire.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:nrbo="http://www.gemphire.com/20221231" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2" id="StatementCondensedStatementsOfComprehensiveLossCalc2">
        <link:definition>00205 - Statement - Condensed Statements of Comprehensive Loss (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" id="DisclosureBalanceSheetDetailPropertyAndEquipmentDetails">
        <link:definition>40301 - Disclosure - Balance Sheet Detail - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails" id="DisclosureBalanceSheetDetailAccruedLiabilitiesDetails">
        <link:definition>40302 - Disclosure - Balance Sheet Detail - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails">
        <link:definition>41102 - Disclosure - Income Taxes - Reconciliation of income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesTaxProvisionBenefitDetails">
        <link:definition>41103 - Disclosure - Income Taxes - Tax provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>41104 - Disclosure - Income Taxes - Significant components of deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity" id="StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Preferred Stock and Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation" id="DisclosureCompanyAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10401 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreement" id="DisclosureBeijingSlLicenseAgreement">
        <link:definition>10601 - Disclosure - Beijing SL License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10701 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10801 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShare" id="DisclosureNetLossPerCommonShare">
        <link:definition>10901 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>11001 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11101 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11201 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureDefinedContributionPlan" id="DisclosureDefinedContributionPlan">
        <link:definition>11301 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30403 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30603 - Disclosure - Stockholders Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30703 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>30803 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>31003 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31103 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails" id="DisclosureCompanyAndBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeasesDetails">
        <link:definition>40401 - Disclosure - Commitments and Contingencies - Operating Leases - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails" id="DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails">
        <link:definition>40403 - Disclosure - Commitments and Contingencies - ANA Merger Milestone Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails" id="DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails">
        <link:definition>40404 - Disclosure - Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails" id="DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails">
        <link:definition>40405 - Disclosure - Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails" id="DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails">
        <link:definition>40406 - Disclosure - Commitments and Contingencies - License Agreement with Dong-A ST (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails" id="DisclosureDongStLicenseAgreementDetails">
        <link:definition>40501 - Disclosure - Dong-A ST License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails" id="DisclosureBeijingSlLicenseAgreementBeijingDetails">
        <link:definition>40601 - Disclosure - Beijing SL License Agreement - Beijing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40701 - Disclosure - Stockholders Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails" id="DisclosureStockholdersEquityAggregateConsiderationReceivedDetails">
        <link:definition>40702 - Disclosure - Stockholders Equity - Aggregate Consideration Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails" id="DisclosureStockholdersEquityWarrantsDetails">
        <link:definition>40703 - Disclosure - Stockholders Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" id="DisclosureStockholdersEquityWarrantsNarrativeDetails">
        <link:definition>40704 - Disclosure - Stockholders Equity - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationExpenseDetails">
        <link:definition>40801 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails" id="DisclosureStockBasedCompensationStockOptionsDetails">
        <link:definition>40802 - Disclosure - Stock-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails" id="DisclosureStockBasedCompensationUnvestedStockOptionsDetails">
        <link:definition>40803 - Disclosure - Stock-Based Compensation - Unvested stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>40804 - Disclosure - Stock Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails" id="DisclosureStockBasedCompensationEvergreenProvisionDetails">
        <link:definition>40805 - Disclosure - Stock-Based Compensation - Evergreen provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails">
        <link:definition>40901 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" id="DisclosureFairValueMeasurementsRecurringBasisDetails">
        <link:definition>41001 - Disclosure - Fair Value Measurements - Recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" id="DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails">
        <link:definition>41002 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41101 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41201 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails" id="DisclosureDefinedContributionPlanDetails">
        <link:definition>41301 - Disclosure - Defined Contribution Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetail" id="DisclosureBalanceSheetDetail">
        <link:definition>10301 - Disclosure - Balance Sheet Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureDongStLicenseAgreement" id="DisclosureDongStLicenseAgreement">
        <link:definition>10501 - Disclosure - Dong-A ST License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailTables" id="DisclosureBalanceSheetDetailTables">
        <link:definition>30303 - Disclosure - Balance Sheet Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20221231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:element name="EmployeeConsultantsAndDirectorsStockOptionsMember" id="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInPrepaidExpensesAndDeposits" id="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PfizerInc.Member" id="nrbo_PfizerInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementMember" id="nrbo_LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentsMember" id="nrbo_MilestonePaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentLiability" id="nrbo_ContingentLiability" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CumulativeDividendsDeclared" id="nrbo_CumulativeDividendsDeclared" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementDisclosureAbstract" id="nrbo_LicenseAgreementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InducementPlanMember" id="nrbo_InducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsAcquiredIntangibles" id="nrbo_DeferredTaxAssetsAcquiredIntangibles" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxAssetsTaxCreditCarryforwardsState" id="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DefinedContributionPlanEmployeeEligibilityAge" id="nrbo_DefinedContributionPlanEmployeeEligibilityAge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanEmployeeContributionDeferredPercentage" id="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeCompensationVestingPercentageOnContribution" id="nrbo_EmployeeCompensationVestingPercentageOnContribution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanEmployerMatchingContributionVestingPercentage" id="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedOtherResearchAndDevelopmentExpenses" id="nrbo_AccruedOtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CommonStockVotingRightsPerShare" id="nrbo_CommonStockVotingRightsPerShare" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfYearsAfterFirstSaleOccurs" id="nrbo_NumberOfYearsAfterFirstSaleOccurs" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseTerminationNoticePeriod" id="nrbo_LicenseTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonesOrRoyaltyPaymentsTriggered" id="nrbo_MilestonesOrRoyaltyPaymentsTriggered" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PaymentsForSpecifiedGlobalNetSalesMilestones" id="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementWithBeijingSLMember" id="nrbo_LicenseAgreementWithBeijingSLMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementUpfrontPaymentToBeReceived" id="nrbo_LicenseAgreementUpfrontPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" id="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" id="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" id="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DepositsInExcessOfFederallyInsuredAmounts" id="nrbo_DepositsInExcessOfFederallyInsuredAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LesseeMonthlyOperatingLeaseCost" id="nrbo_LesseeMonthlyOperatingLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="HeadquartersInBostonLeaseMember" id="nrbo_HeadquartersInBostonLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" id="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesaRedeemableConvertiblePreferredStockMember" id="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" id="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPlan2018Member" id="nrbo_StockPlan2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockPlan2019Member" id="nrbo_StockPlan2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" id="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" id="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" id="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DongStMember" id="nrbo_DongStMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManufacturingAgreementMember" id="nrbo_ManufacturingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractTerm" id="nrbo_ContractTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" id="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseIncentiveFromLessor" id="nrbo_LesseeOperatingLeaseIncentiveFromLessor" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfRoyaltyOnNetSales" id="nrbo_PercentageOfRoyaltyOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" id="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaymentsForTransactionCostsInConnectionWithMerger" id="nrbo_PaymentsForTransactionCostsInConnectionWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="MinimumExpectedPeriodToBeginFutureInstallmentPayment" id="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementEarlyTerminationFee" id="nrbo_LicenseAgreementEarlyTerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PatentCostPolicyPolicyTextBlock" id="nrbo_PatentCostPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInNonCashLeaseExpense" id="nrbo_IncreaseDecreaseInNonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DeferredTaxAssetsLeaseLiability" id="nrbo_DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DeferredTaxLiabilitiesRouAsset" id="nrbo_DeferredTaxLiabilitiesRouAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AnaTherapeuticsInc.AssetAcquisitionMember" id="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsIssued" id="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAndMilestonePaymentsDue" id="nrbo_RoyaltyAndMilestonePaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="YourchoiceTherapeuticsInc.Member" id="nrbo_YourchoiceTherapeuticsInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" id="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CumulativeNetSalesMoreThan500MillionMember" id="nrbo_CumulativeNetSalesMoreThan500MillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CumulativeNetSalesMoreThanOneBillionMember" id="nrbo_CumulativeNetSalesMoreThanOneBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CumulativeNetSalesMoreThanThreeBillionMember" id="nrbo_CumulativeNetSalesMoreThanThreeBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CumulativeNetSalesMoreThanFiveBillionMember" id="nrbo_CumulativeNetSalesMoreThanFiveBillionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SalesBasedMilestonePayment" id="nrbo_SalesBasedMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="InitialMilestonePayment" id="nrbo_InitialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfRoyaltyPayments" id="nrbo_PercentageOfRoyaltyPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="OriginalCvrAgreementMember" id="nrbo_OriginalCvrAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FirstAmendmentToOriginalCvrAgreementMember" id="nrbo_FirstAmendmentToOriginalCvrAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TierOneNetSalesMilestoneMember" id="nrbo_TierOneNetSalesMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TierTwoNetSalesMilestoneMember" id="nrbo_TierTwoNetSalesMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TierThreeNetSalesMilestoneMember" id="nrbo_TierThreeNetSalesMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TierFourNetSalesMilestoneMember" id="nrbo_TierFourNetSalesMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPaymentAccrued" id="nrbo_RoyaltyPaymentAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MilestonesAccrued" id="nrbo_MilestonesAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfProceedsFromGrantSaleOrTransferOfRights" id="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ManufacturingAndSupplyAgreementMember" id="nrbo_ManufacturingAndSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeferredIssuanceCostsIncurredButNotYetPaid" id="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PeriodFromIssuanceDateWarrantsBecomeExercisable" id="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RegisteredDirectOfferingMember" id="nrbo_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryForwardResearchCredit" id="nrbo_OperatingLossCarryForwardResearchCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="StockAndWarrantsIssuedDuringPeriodValue" id="nrbo_StockAndWarrantsIssuedDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockAndWarrantsIssuedDuringPeriodShares" id="nrbo_StockAndWarrantsIssuedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfSharesHeldByRelatedParty" id="nrbo_PercentageOfSharesHeldByRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockAndWarrantsIssuedDuringPeriodValueStocksIssued" id="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetAcquisitionPercentageOfVotingInterestsAcquired" id="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ModificationOfRightOfUseAssetAndAssociatedLeaseLiability" id="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsExercisePrice7800.00Member" id="nrbo_WarrantsExercisePrice7800.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisePrice5602.50Member" id="nrbo_WarrantsExercisePrice5602.50Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisePrice375.00Member" id="nrbo_WarrantsExercisePrice375.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisePrice180.90Member" id="nrbo_WarrantsExercisePrice180.90Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsExercisePrice112.50Member" id="nrbo_WarrantsExercisePrice112.50Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" id="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SecuritiesPurchaseAgreementMember" id="nrbo_SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" id="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="Da1726Member" id="nrbo_Da1726Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Da1241Member" id="nrbo_Da1241Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodForFailToCureBreachMayTerminateAgreement" id="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CurePeriodForPetitionForBankruptcy" id="nrbo_CurePeriodForPetitionForBankruptcy" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CurePeriodForBreachingParty" id="nrbo_CurePeriodForBreachingParty" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassUnitsMember" id="nrbo_ClassUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassBUnitsMember" id="nrbo_ClassBUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesWarrantMember" id="nrbo_SeriesWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesBWarrantMember" id="nrbo_SeriesBWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfCommonStockIssuedPerUnit" id="nrbo_NumberOfCommonStockIssuedPerUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" id="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PublicOfferingMember" id="nrbo_PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" id="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UndesignatedPreferredStockMember" id="nrbo_UndesignatedPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAgreementDisclosureTextBlock" id="nrbo_LicenseAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PrivateInvestmentInPublicEquityAndLicenseMember" id="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPlan2022201And2019PlansMember" id="nrbo_StockPlan2022201And2019PlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DongaStCoLtdLicenseAgreementMember" id="nrbo_DongaStCoLtdLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" id="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LicenseAgreementAbstract" id="nrbo_LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockConvertedDuringPeriodValue" id="nrbo_StockConvertedDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockConvertedDuringPeriodShares" id="nrbo_StockConvertedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationTransactionCost" id="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" id="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreferredStockStatedValuePerShare" id="nrbo_PreferredStockStatedValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="November2022SeriesWarrantExercisePrice3.00Member" id="nrbo_November2022SeriesWarrantExercisePrice3.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="November2022SeriesBWarrantExercisePrice3.00Member" id="nrbo_November2022SeriesBWarrantExercisePrice3.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="November2022SeriesAndSeriesBWarrantsMember" id="nrbo_November2022SeriesAndSeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" id="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfWarrantsExercised" id="nrbo_NumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock" id="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuanceCost" id="nrbo_StockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WarrantsIssuanceCost" id="nrbo_WarrantsIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PreferredStockMeasurementInput" id="nrbo_PreferredStockMeasurementInput" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MeasurementInputProbabilityFactorMember" id="nrbo_MeasurementInputProbabilityFactorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScenarioStockholderApprovalToConvertCommonStockMember" id="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScenarioStockholderNonApprovalToConvertCommonStockMember" id="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreferredStockFairValuePerShare" id="nrbo_PreferredStockFairValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="WarrantLiabilityRollForward" id="nrbo_WarrantLiabilityRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" id="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock" id="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantLiabilitiesPolicyPolicyTextBlock" id="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockPlan2022Member" id="nrbo_StockPlan2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InducementPlan2021Member" id="nrbo_InducementPlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent" id="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ResearchCreditCarryforwardsWrittenOff" id="nrbo_ResearchCreditCarryforwardsWrittenOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NetOperatingLossCarryforwardsWrittenOff" id="nrbo_NetOperatingLossCarryforwardsWrittenOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PeriodForTerminationNotice" id="nrbo_PeriodForTerminationNotice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharedServicesAgreementMember" id="nrbo_SharedServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>nrbo-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2023 7:48:19 PM-->
<!--Modified on: 3/30/2023 7:48:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.gemphire.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementCondensedStatementsOfComprehensiveLossCalc2" roleURI="http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBalanceSheetDetailAccruedLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesTaxProvisionBenefitDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638158024964656111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638158024964656111" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158024964656111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638158024964656111" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158024964656111" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638158024964656111" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638158024964656111" xlink:to="us-gaap_PrepaidExpenseCurrent_638158024964656111" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638158024964666100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638158024964666100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638158024964666100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638158024964666100" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638158024964666100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638158024964666100" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638158024964666100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638158024964666100" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638158024964666100" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638158024964666100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638158024964666100" xlink:to="us-gaap_LiabilitiesCurrent_638158024964666100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638158024964666100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158024964666100" xlink:to="us-gaap_AccountsPayableCurrent_638158024964666100" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638158024964666100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158024964666100" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638158024964666100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_638158024964676100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158024964666100" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_638158024964676100" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638158024964676100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638158024964666100" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638158024964676100" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638158024964676100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638158024964676100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158024964676100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638158024964676100" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638158024964676100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158024964676100" xlink:to="us-gaap_AdditionalPaidInCapital_638158024964676100" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638158024964676100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158024964676100" xlink:to="us-gaap_PreferredStockValue_638158024964676100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638158024964676100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158024964676100" xlink:to="us-gaap_CommonStockValue_638158024964676100" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638158024964686101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158024964676100" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638158024964686101" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158024964686101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638158024964676100" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158024964686101" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024964686101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024964686101" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638158024964686101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024964686101" xlink:to="us-gaap_OperatingIncomeLoss_638158024964686101" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638158024964686101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638158024964686101" xlink:to="us-gaap_CostsAndExpenses_638158024964686101" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638158024964686101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638158024964686101" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638158024964686101" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638158024964686101" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638158024964696101" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638158024964686101" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024964696101" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024964686101" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638158024964696101" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638158024964696101" xlink:to="us-gaap_InterestIncomeExpenseNet_638158024964696101" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingInterestExpense" xlink:label="us-gaap_FinancingInterestExpense_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638158024964696101" xlink:to="us-gaap_FinancingInterestExpense_638158024964696101" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638158024964696101" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638158024964696101" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638158024964696101" xlink:to="us-gaap_OtherNonoperatingExpense_638158024964696101" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158024964696101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158024964696101" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2" xlink:type="extended" xlink:title="00205 - Statement - Condensed Statements of Comprehensive Loss (Calc 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158024964706100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638158024964706100" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638158024964706100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638158024964706100" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158024964706100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_NetIncomeLoss_638158024964706100" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638158024964706100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_ShareBasedCompensation_638158024964706100" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_Depreciation_638158024964716102" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638158024964716102" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024964716102" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingInterestExpense" xlink:label="us-gaap_FinancingInterestExpense_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_FinancingInterestExpense_638158024964716102" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638158024964716102" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_IncreaseDecreaseInNonCashLeaseExpense" xlink:label="nrbo_IncreaseDecreaseInNonCashLeaseExpense_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="nrbo_IncreaseDecreaseInNonCashLeaseExpense_638158024964716102" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_GainLossOnTerminationOfLease_638158024964716102" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:label="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_638158024964716102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_638158024964716102" order="10" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638158024964726100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638158024964726100" order="11" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158024964726100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024964706100" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158024964726100" order="12" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158024964726100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158024964726100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PaymentsForTransactionCostsInConnectionWithMerger" xlink:label="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_638158024964726100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158024964726100" xlink:to="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_638158024964726100" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638158024964726100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158024964726100" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638158024964726100" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638158024964726100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158024964726100" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638158024964726100" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158024964736099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158024964736099" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638158024964736099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158024964736099" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638158024964736099" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638158024964736099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158024964736099" xlink:to="us-gaap_PaymentsOfFinancingCosts_638158024964736099" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638158024964736099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158024964736099" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638158024964736099" order="3" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Balance Sheet Detail - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638158024964736099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638158024964736099" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638158024964736099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638158024964736099" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Balance Sheet Detail - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AccruedOtherResearchAndDevelopmentExpenses" xlink:label="nrbo_AccruedOtherResearchAndDevelopmentExpenses_638158024964746100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="nrbo_AccruedOtherResearchAndDevelopmentExpenses_638158024964746100" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158024964746100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158024964746100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638158024964746100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638158024964746100" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638158024964746100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638158024964746100" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes - Reconciliation of income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158024964746100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158024964746100" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158024964746100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158024964746100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638158024964756102" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158024964756102" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638158024964756102" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_638158024964756102" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_638158024964756102" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638158024964756102" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes - Tax provision (Benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638158024964756102" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638158024964756102" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638158024964756102" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" xlink:label="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_638158024964766101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_638158024964766101" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" xlink:label="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_638158024964766101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_638158024964766101" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638158024964766101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638158024964766101" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_638158024964766101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638158024964766101" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_638158024964766101" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_638158024964766101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638158024964766101" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_638158024964766101" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Income Taxes - Significant components of deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" xlink:label="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_638158024964766101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_638158024964766101" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesRouAsset" xlink:label="nrbo_DeferredTaxLiabilitiesRouAsset_638158024964766101" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="nrbo_DeferredTaxLiabilitiesRouAsset_638158024964766101" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638158024964776100" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638158024964776100" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638158024964776100" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638158024964776100" xlink:to="us-gaap_DeferredTaxAssetsGross_638158024964776100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158024964776100" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsAcquiredIntangibles" xlink:label="nrbo_DeferredTaxAssetsAcquiredIntangibles_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="nrbo_DeferredTaxAssetsAcquiredIntangibles_638158024964776100" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158024964776100" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsLeaseLiability" xlink:label="nrbo_DeferredTaxAssetsLeaseLiability_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="nrbo_DeferredTaxAssetsLeaseLiability_638158024964776100" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638158024964776100" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638158024964776100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="us-gaap_DeferredTaxAssetsOther_638158024964776100" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638158024964786100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638158024964786100" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158024964786100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638158024964776100" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158024964786100" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>nrbo-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2023 7:48:19 PM-->
<!--Modified on: 3/30/2023 7:48:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity" roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureDongStLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBeijingSlLicenseAgreementBeijingDetails" roleURI="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityAggregateConsiderationReceivedDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityWarrantsNarrativeDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationEvergreenProvisionDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureDefinedContributionPlanDetails" roleURI="http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.gemphire.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_IncomeStatementAbstract To us-gaap_FairValueAdjustmentOfWarrants_2" order="1" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.gemphire.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="ConversionOfStockByUniqueDescriptionAxis" xlink:title="ConversionOfStockByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="ConversionOfStockNameDomain" xlink:title="ConversionOfStockNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConversionOfStockByUniqueDescriptionAxis" xlink:to="ConversionOfStockNameDomain" xlink:title="definition: ConversionOfStockByUniqueDescriptionAxis to ConversionOfStockNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="DebtConversionByUniqueDescriptionAxis" xlink:title="DebtConversionByUniqueDescriptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionNameDomain" xlink:label="DebtConversionNameDomain" xlink:title="DebtConversionNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtConversionByUniqueDescriptionAxis" xlink:to="DebtConversionNameDomain" xlink:title="definition: DebtConversionByUniqueDescriptionAxis to DebtConversionNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AircraftTypeAxis" xlink:label="AircraftTypeAxis" xlink:title="AircraftTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AircraftTypeMember" xlink:label="AircraftTypeMember" xlink:title="AircraftTypeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AircraftTypeAxis" xlink:to="AircraftTypeMember" xlink:title="definition: AircraftTypeAxis to AircraftTypeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="OtherCommitmentsAxis" xlink:title="OtherCommitmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="OtherCommitmentsDomain" xlink:title="OtherCommitmentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OtherCommitmentsAxis" xlink:to="OtherCommitmentsDomain" xlink:title="definition: OtherCommitmentsAxis to OtherCommitmentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="definition: ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="LongtermDebtTypeAxis" xlink:title="LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="LongtermDebtTypeDomain" xlink:title="LongtermDebtTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongtermDebtTypeAxis" xlink:to="LongtermDebtTypeDomain" xlink:title="definition: LongtermDebtTypeAxis to LongtermDebtTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationDocumentAxis" xlink:label="DocumentInformationDocumentAxis" xlink:title="DocumentInformationDocumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentDomain" xlink:label="DocumentDomain" xlink:title="DocumentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DocumentInformationDocumentAxis" xlink:to="DocumentDomain" xlink:title="definition: DocumentInformationDocumentAxis to DocumentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_UndesignatedPreferredStockMember" xlink:label="nrbo_UndesignatedPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrbo_UndesignatedPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockStatedValuePerShare" xlink:label="nrbo_PreferredStockStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_PreferredStockStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Preferred Stock and Stockholders Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" xlink:label="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_StockAndWarrantsIssuedDuringPeriodValue" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodValue" xlink:label="nrbo_StockConvertedDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="nrbo_StockConvertedDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodShares" xlink:label="nrbo_StockConvertedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_StockConvertedDuringPeriodValue" xlink:to="nrbo_StockConvertedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" xlink:label="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" xlink:label="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DepositsInExcessOfFederallyInsuredAmounts" xlink:label="nrbo_DepositsInExcessOfFederallyInsuredAmounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="nrbo_DepositsInExcessOfFederallyInsuredAmounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Balance Sheet Detail - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Commitments and Contingencies - Operating Leases - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_HeadquartersInBostonLeaseMember" xlink:label="nrbo_HeadquartersInBostonLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nrbo_HeadquartersInBostonLeaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="country_KR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrbo_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1726Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1241Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongStMember" xlink:label="nrbo_DongStMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nrbo_DongStMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LesseeMonthlyOperatingLeaseCost" xlink:label="nrbo_LesseeMonthlyOperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_LesseeMonthlyOperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LesseeOperatingLeaseIncentiveFromLessor" xlink:label="nrbo_LesseeOperatingLeaseIncentiveFromLessor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_LesseeOperatingLeaseIncentiveFromLessor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForBreachingParty" xlink:label="nrbo_CurePeriodForBreachingParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_CurePeriodForBreachingParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForPetitionForBankruptcy" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_CurePeriodForPetitionForBankruptcy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Commitments and Contingencies - ANA Merger Milestone Payment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThan500MillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThan500MillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nrbo_CumulativeNetSalesMoreThan500MillionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanOneBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanOneBillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nrbo_CumulativeNetSalesMoreThanOneBillionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanThreeBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanThreeBillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nrbo_CumulativeNetSalesMoreThanThreeBillionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanFiveBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanFiveBillionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nrbo_CumulativeNetSalesMoreThanFiveBillionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_FirstAmendmentToOriginalCvrAgreementMember" xlink:label="nrbo_FirstAmendmentToOriginalCvrAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nrbo_FirstAmendmentToOriginalCvrAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" xlink:label="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InitialMilestonePayment" xlink:label="nrbo_InitialMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="nrbo_InitialMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SalesBasedMilestonePayment" xlink:label="nrbo_SalesBasedMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="nrbo_SalesBasedMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyPayments" xlink:label="nrbo_PercentageOfRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="nrbo_PercentageOfRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyPaymentAccrued" xlink:label="nrbo_RoyaltyPaymentAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="nrbo_RoyaltyPaymentAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PfizerInc.Member" xlink:label="nrbo_PfizerInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nrbo_PfizerInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_YourchoiceTherapeuticsInc.Member" xlink:label="nrbo_YourchoiceTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="nrbo_YourchoiceTherapeuticsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonePaymentsMember" xlink:label="nrbo_MilestonePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="nrbo_MilestonePaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierOneNetSalesMilestoneMember" xlink:label="nrbo_TierOneNetSalesMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="nrbo_TierOneNetSalesMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierTwoNetSalesMilestoneMember" xlink:label="nrbo_TierTwoNetSalesMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="nrbo_TierTwoNetSalesMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierThreeNetSalesMilestoneMember" xlink:label="nrbo_TierThreeNetSalesMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="nrbo_TierThreeNetSalesMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierFourNetSalesMilestoneMember" xlink:label="nrbo_TierFourNetSalesMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="nrbo_TierFourNetSalesMilestoneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ContingentLiability" xlink:label="nrbo_ContingentLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_ContingentLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfYearsAfterFirstSaleOccurs" xlink:label="nrbo_NumberOfYearsAfterFirstSaleOccurs" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_NumberOfYearsAfterFirstSaleOccurs" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesOrRoyaltyPaymentsTriggered" xlink:label="nrbo_MilestonesOrRoyaltyPaymentsTriggered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_MilestonesOrRoyaltyPaymentsTriggered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseTerminationNoticePeriod" xlink:label="nrbo_LicenseTerminationNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_LicenseTerminationNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementEarlyTerminationFee" xlink:label="nrbo_LicenseAgreementEarlyTerminationFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_LicenseAgreementEarlyTerminationFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyAndMilestonePaymentsDue" xlink:label="nrbo_RoyaltyAndMilestonePaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_RoyaltyAndMilestonePaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyPayments" xlink:label="nrbo_PercentageOfRoyaltyPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_PercentageOfRoyaltyPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SalesBasedMilestonePayment" xlink:label="nrbo_SalesBasedMilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_SalesBasedMilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" xlink:label="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_OriginalCvrAgreementMember" xlink:label="nrbo_OriginalCvrAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_OriginalCvrAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" xlink:label="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesAccrued" xlink:label="nrbo_MilestonesAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="nrbo_MilestonesAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Commitments and Contingencies - License Agreement with Dong-A ST (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrbo_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1726Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1241Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongStMember" xlink:label="nrbo_DongStMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nrbo_DongStMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyPaymentAccrued" xlink:label="nrbo_RoyaltyPaymentAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrbo_RoyaltyPaymentAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Dong-A ST License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrbo_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1726Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1241Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongaStCoLtdLicenseAgreementMember" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_DongaStCoLtdLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SharedServicesAgreementMember" xlink:label="nrbo_SharedServicesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_SharedServicesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForBreachingParty" xlink:label="nrbo_CurePeriodForBreachingParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_CurePeriodForBreachingParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForPetitionForBankruptcy" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_CurePeriodForPetitionForBankruptcy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForTerminationNotice" xlink:label="nrbo_PeriodForTerminationNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_PeriodForTerminationNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesAccrued" xlink:label="nrbo_MilestonesAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_MilestonesAccrued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Beijing SL License Agreement - Beijing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementWithBeijingSLMember" xlink:label="nrbo_LicenseAgreementWithBeijingSLMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_LicenseAgreementWithBeijingSLMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementUpfrontPaymentToBeReceived" xlink:label="nrbo_LicenseAgreementUpfrontPaymentToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_LicenseAgreementUpfrontPaymentToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" xlink:label="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" xlink:label="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyOnNetSales" xlink:label="nrbo_PercentageOfRoyaltyOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_PercentageOfRoyaltyOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" xlink:label="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" xlink:label="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RegisteredDirectOfferingMember" xlink:label="nrbo_RegisteredDirectOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrbo_RegisteredDirectOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PublicOfferingMember" xlink:label="nrbo_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrbo_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassUnitsMember" xlink:label="nrbo_ClassUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrbo_ClassUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassBUnitsMember" xlink:label="nrbo_ClassBUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrbo_ClassBUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesWarrantMember" xlink:label="nrbo_SeriesWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_SeriesWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesBWarrantMember" xlink:label="nrbo_SeriesBWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_SeriesBWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CommonStockVotingRightsPerShare" xlink:label="nrbo_CommonStockVotingRightsPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="nrbo_CommonStockVotingRightsPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockAbstract" xlink:label="us-gaap_DividendsCommonStockAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsCommonStockAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeDividendsDeclared" xlink:label="nrbo_CumulativeDividendsDeclared" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DividendsCommonStockAbstract" xlink:to="nrbo_CumulativeDividendsDeclared" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockStatedValuePerShare" xlink:label="nrbo_PreferredStockStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_PreferredStockStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfCommonStockIssuedPerUnit" xlink:label="nrbo_NumberOfCommonStockIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_NumberOfCommonStockIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" xlink:label="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodShares" xlink:label="nrbo_StockConvertedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_StockConvertedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForCommissions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stockholders Equity - Aggregate Consideration Received (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PublicOfferingMember" xlink:label="nrbo_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrbo_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongaStCoLtdLicenseAgreementMember" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_DongaStCoLtdLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SecuritiesPurchaseAgreementMember" xlink:label="nrbo_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MeasurementInputProbabilityFactorMember" xlink:label="nrbo_MeasurementInputProbabilityFactorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="nrbo_MeasurementInputProbabilityFactorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" xlink:label="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" xlink:label="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockIssuanceCost" xlink:label="nrbo_StockIssuanceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_StockIssuanceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsIssuanceCost" xlink:label="nrbo_WarrantsIssuanceCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_WarrantsIssuanceCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockMeasurementInput" xlink:label="nrbo_PreferredStockMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_PreferredStockMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockFairValuePerShare" xlink:label="nrbo_PreferredStockFairValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_PreferredStockFairValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stockholders Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice7800.00Member" xlink:label="nrbo_WarrantsExercisePrice7800.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_WarrantsExercisePrice7800.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice5602.50Member" xlink:label="nrbo_WarrantsExercisePrice5602.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_WarrantsExercisePrice5602.50Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice375.00Member" xlink:label="nrbo_WarrantsExercisePrice375.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_WarrantsExercisePrice375.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice180.90Member" xlink:label="nrbo_WarrantsExercisePrice180.90Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_WarrantsExercisePrice180.90Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice112.50Member" xlink:label="nrbo_WarrantsExercisePrice112.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_WarrantsExercisePrice112.50Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesWarrantExercisePrice3.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_November2022SeriesWarrantExercisePrice3.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesBWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_November2022SeriesBWarrantExercisePrice3.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:label="nrbo_November2022SeriesAndSeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_November2022SeriesAndSeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stockholders Equity - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:label="nrbo_November2022SeriesAndSeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_November2022SeriesAndSeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesWarrantMember" xlink:label="nrbo_SeriesWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:to="nrbo_SeriesWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesBWarrantMember" xlink:label="nrbo_SeriesBWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:to="nrbo_SeriesBWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesBWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_November2022SeriesBWarrantExercisePrice3.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" xlink:label="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfWarrantsExercised" xlink:label="nrbo_NumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="nrbo_NumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stock-Based Compensation - Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2018Member" xlink:label="nrbo_StockPlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrbo_StockPlan2018Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2019Member" xlink:label="nrbo_StockPlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrbo_StockPlan2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Stock Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Stock-Based Compensation - Evergreen provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InducementPlanMember" xlink:label="nrbo_InducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrbo_InducementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2022201And2019PlansMember" xlink:label="nrbo_StockPlan2022201And2019PlansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrbo_StockPlan2022201And2019PlansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2022Member" xlink:label="nrbo_StockPlan2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrbo_StockPlan2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InducementPlan2021Member" xlink:label="nrbo_InducementPlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrbo_InducementPlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2019Member" xlink:label="nrbo_StockPlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrbo_StockPlan2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:label="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Fair Value Measurements - Recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantLiabilityRollForward" xlink:label="nrbo_WarrantLiabilityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="nrbo_WarrantLiabilityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_WarrantLiabilityRollForward" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="nrbo_WarrantLiabilityRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="nrbo_WarrantLiabilityRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" xlink:label="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="nrbo_WarrantLiabilityRollForward" xlink:to="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_OperatingLossCarryForwardResearchCredit" xlink:label="nrbo_OperatingLossCarryForwardResearchCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="nrbo_OperatingLossCarryForwardResearchCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NetOperatingLossCarryforwardsWrittenOff" xlink:label="nrbo_NetOperatingLossCarryforwardsWrittenOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="nrbo_NetOperatingLossCarryforwardsWrittenOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ResearchCreditCarryforwardsWrittenOff" xlink:label="nrbo_ResearchCreditCarryforwardsWrittenOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="nrbo_ResearchCreditCarryforwardsWrittenOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" xlink:label="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Income Taxes - Significant components of deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsAcquiredIntangibles" xlink:label="nrbo_DeferredTaxAssetsAcquiredIntangibles" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nrbo_DeferredTaxAssetsAcquiredIntangibles" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsLeaseLiability" xlink:label="nrbo_DeferredTaxAssetsLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nrbo_DeferredTaxAssetsLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesRouAsset" xlink:label="nrbo_DeferredTaxLiabilitiesRouAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="nrbo_DeferredTaxLiabilitiesRouAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" xlink:label="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongStMember" xlink:label="nrbo_DongStMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nrbo_DongStMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ManufacturingAgreementMember" xlink:label="nrbo_ManufacturingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="nrbo_ManufacturingAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ManufacturingAndSupplyAgreementMember" xlink:label="nrbo_ManufacturingAndSupplyAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrbo_ManufacturingAndSupplyAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrbo_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1726Member" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_Da1241Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SecuritiesPurchaseAgreementMember" xlink:label="nrbo_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrbo_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ContractTerm" xlink:label="nrbo_ContractTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_ContractTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfSharesHeldByRelatedParty" xlink:label="nrbo_PercentageOfSharesHeldByRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_PercentageOfSharesHeldByRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="us-gaap_RelatedPartyCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" xlink:label="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForBreachingParty" xlink:label="nrbo_CurePeriodForBreachingParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_CurePeriodForBreachingParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForPetitionForBankruptcy" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_CurePeriodForPetitionForBankruptcy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" xlink:label="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesAccrued" xlink:label="nrbo_MilestonesAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_MilestonesAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Defined Contribution Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="nrbo_DefinedContributionPlanEmployeeEligibilityAge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="nrbo_DefinedContributionPlanEmployeeEligibilityAge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:label="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:label="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EmployeeCompensationVestingPercentageOnContribution" xlink:label="nrbo_EmployeeCompensationVestingPercentageOnContribution" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="nrbo_EmployeeCompensationVestingPercentageOnContribution" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesWarrantMember" xlink:label="nrbo_SeriesWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_SeriesWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesBWarrantMember" xlink:label="nrbo_SeriesBWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrbo_SeriesBWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RegisteredDirectOfferingMember" xlink:label="nrbo_RegisteredDirectOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="nrbo_RegisteredDirectOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfWarrantsExercised" xlink:label="nrbo_NumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nrbo_NumberOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>nrbo-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2023 7:48:19 PM-->
<!--Modified on: 3/30/2023 7:48:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability, short-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, short-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, long-term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 5)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021; no shares issued or outstanding as of December 31, 2022 and December 31, 2021.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 25,436,019 and 888,693 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred stock</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_UndesignatedPreferredStockMember" xlink:label="nrbo_UndesignatedPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_UndesignatedPreferredStockMember" xlink:to="nrbo_UndesignatedPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to undesignated preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undesignated Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_UndesignatedPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undesignated Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockStatedValuePerShare" xlink:label="nrbo_PreferredStockStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PreferredStockStatedValuePerShare" xlink:to="nrbo_PreferredStockStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PreferredStockStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PreferredStockStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PreferredStockStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stated value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrbo_PreferredStockStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, stated value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Asset Acquired Other than Through Business Combination, Written-off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPR&amp;D expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingInterestExpense" xlink:label="us-gaap_FinancingInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingInterestExpense" xlink:to="us-gaap_FinancingInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinancingInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancingInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs allocated to issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total tax provision (benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive loss, net of tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares of common stock outstanding:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Preferred Stock and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:to="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to series A and series B redeemable convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A and Series B Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to series A redeemable convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" xlink:label="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" xlink:to="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to private investment in public equity and license.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Investment in Public Equity and License [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PIPE and license</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockAndWarrantsIssuedDuringPeriodValue" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock and warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and Warrants Issued During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and warrants in connection with public offering</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockAndWarrantsIssuedDuringPeriodShares" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock and warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and Warrants Issued During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock and warrants in connection with public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodValue" xlink:label="nrbo_StockConvertedDuringPeriodValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockConvertedDuringPeriodValue" xlink:to="nrbo_StockConvertedDuringPeriodValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockConvertedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares converted into common stock during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockConvertedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Converted During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_StockConvertedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodShares" xlink:label="nrbo_StockConvertedDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockConvertedDuringPeriodShares" xlink:to="nrbo_StockConvertedDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockConvertedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares converted into common stock during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockConvertedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Converted During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_StockConvertedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_StockConvertedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares converted into common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible notes to common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclass of warrant liabilities upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock from exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), Realized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_IncreaseDecreaseInNonCashLeaseExpense" xlink:label="nrbo_IncreaseDecreaseInNonCashLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_IncreaseDecreaseInNonCashLeaseExpense" xlink:to="nrbo_IncreaseDecreaseInNonCashLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_IncreaseDecreaseInNonCashLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to increase or decrease in non cash lease expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_IncreaseDecreaseInNonCashLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Lease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_IncreaseDecreaseInNonCashLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Termination of Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability extinguishment gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain or loss of extinguished unamortized right-of-use asset and lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:label="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:to="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) of consideration paid in advance that provide economic benefits in future periods and deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Expenses And Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PaymentsForTransactionCostsInConnectionWithMerger" xlink:label="nrbo_PaymentsForTransactionCostsInConnectionWithMerger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PaymentsForTransactionCostsInConnectionWithMerger" xlink:to="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow related to transaction cost in connection with the merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments For Transaction Costs In Connection With Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs in connection with asset acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common shares, preferred shares and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net foreign exchange difference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental non-cash investing and financing transactions:</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability" xlink:label="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability" xlink:to="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of modification of right-of-use asset and associated lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Modification of Right-of-use Asset and Associated Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Modification of right-of-use asset and associated lease liability</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredIssuanceCostsIncurredButNotYetPaid" xlink:label="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid" xlink:to="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future cash outflow to pay for deferred issuance costs that have occurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Issuance Costs Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unpaid issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Company and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Company and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Detail</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Detail</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementAbstract" xlink:label="nrbo_LicenseAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementAbstract" xlink:to="nrbo_LicenseAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A ST License Agreement.</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDisclosureTextBlock" xlink:label="nrbo_LicenseAgreementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementDisclosureTextBlock" xlink:to="nrbo_LicenseAgreementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LicenseAgreementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A ST License Agreement.</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDisclosureAbstract" xlink:label="nrbo_LicenseAgreementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementDisclosureAbstract" xlink:to="nrbo_LicenseAgreementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License and Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:label="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:to="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for determining the warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired In-Process Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PatentCostPolicyPolicyTextBlock" xlink:label="nrbo_PatentCostPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PatentCostPolicyPolicyTextBlock" xlink:to="nrbo_PatentCostPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PatentCostPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PatentCostPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Cost Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PatentCostPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" xlink:label="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" xlink:to="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to ANA Therapeutics, Inc., merger asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ANA Merger</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" xlink:label="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" xlink:to="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of future milestone payments to be paid up on achieving of milestone events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Milestone Payment Up On Achievement of Milestone Events [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of milestone events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock" xlink:label="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock" xlink:to="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of consideration received for issue of equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Consideration Received for Issuance of Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of consideration Received for issuance of equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option plan activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Options Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unvested stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used in the Black Scholes option-pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potential common shares not considered in computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of financial instruments measured on recurring basis</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock" xlink:label="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock" xlink:to="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of a roll-forward of the warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Roll-forward of Warrant Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of a roll-forward of the warrant liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of statutory federal income tax rate to the provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Loss before provision for taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split, ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risks, Types, No Concentration Percentage [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DepositsInExcessOfFederallyInsuredAmounts" xlink:label="nrbo_DepositsInExcessOfFederallyInsuredAmounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DepositsInExcessOfFederallyInsuredAmounts" xlink:to="nrbo_DepositsInExcessOfFederallyInsuredAmounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DepositsInExcessOfFederallyInsuredAmounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to deposits in excess of federally insured amounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DepositsInExcessOfFederallyInsuredAmounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits In Excess Of Federally Insured Amounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DepositsInExcessOfFederallyInsuredAmounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits in excess of federally insured amounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Provision (Benefit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information, Additional Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Detail</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AccruedOtherResearchAndDevelopmentExpenses" xlink:label="nrbo_AccruedOtherResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_AccruedOtherResearchAndDevelopmentExpenses" xlink:to="nrbo_AccruedOtherResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_AccruedOtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_AccruedOtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll related</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_HeadquartersInBostonLeaseMember" xlink:label="nrbo_HeadquartersInBostonLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_HeadquartersInBostonLeaseMember" xlink:to="nrbo_HeadquartersInBostonLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_HeadquartersInBostonLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to new Boston lease agreement for head quarters.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_HeadquartersInBostonLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Head Quarters in Boston Lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="country_KR" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Korea</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementMember" xlink:to="nrbo_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exclusive worldwide license to certain patent rights to make, use, sell, offer for sale and import product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong A ST License Agreement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_Da1726Member" xlink:to="nrbo_Da1726Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_Da1726Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The License Agreement covers the rights to DA-1726 for treatment of obesity and NASH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_Da1726Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1726 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_Da1726Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1726</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_Da1241Member" xlink:to="nrbo_Da1241Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_Da1241Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The License Agreement covers the rights to DA-1241 for treatment of NASH .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_Da1241Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1241 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_Da1241Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DA-1241</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongStMember" xlink:label="nrbo_DongStMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DongStMember" xlink:to="nrbo_DongStMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DongStMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Dong-A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DongStMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DongStMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of contract</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LesseeMonthlyOperatingLeaseCost" xlink:label="nrbo_LesseeMonthlyOperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LesseeMonthlyOperatingLeaseCost" xlink:to="nrbo_LesseeMonthlyOperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LesseeMonthlyOperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of monthly operating lease cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LesseeMonthlyOperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Monthly Operating Lease Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LesseeMonthlyOperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monthly rental cost</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LesseeOperatingLeaseIncentiveFromLessor" xlink:label="nrbo_LesseeOperatingLeaseIncentiveFromLessor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LesseeOperatingLeaseIncentiveFromLessor" xlink:to="nrbo_LesseeOperatingLeaseIncentiveFromLessor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LesseeOperatingLeaseIncentiveFromLessor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the operating lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LesseeOperatingLeaseIncentiveFromLessor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Incentive From Lessor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LesseeOperatingLeaseIncentiveFromLessor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent concessions granted by the landlord</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to renew</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash expense related to Korea lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cash payments</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Developmental And Regulatory Milestone To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Developmental and regulatory milestone payment eligible to be received</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:to="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for failing to cure the beach, the agreement may get terminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for Fail to Cure the Breach, May Terminate Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for failing to cure the beach, the agreement may get terminated</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForBreachingParty" xlink:label="nrbo_CurePeriodForBreachingParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CurePeriodForBreachingParty" xlink:to="nrbo_CurePeriodForBreachingParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CurePeriodForBreachingParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cure period for beaching party if cannot be cured within the 60-day period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CurePeriodForBreachingParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure Period for Breaching Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_CurePeriodForBreachingParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure period for beaching party if cannot be cured within the 60-day period</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForPetitionForBankruptcy" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CurePeriodForPetitionForBankruptcy" xlink:to="nrbo_CurePeriodForPetitionForBankruptcy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cure period for petition for bankruptcy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure Period for Petition for Bankruptcy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cure period for petition for bankruptcy</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Relative fair value attributable to the warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares and warrants issued to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThan500MillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThan500MillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CumulativeNetSalesMoreThan500MillionMember" xlink:to="nrbo_CumulativeNetSalesMoreThan500MillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CumulativeNetSalesMoreThan500MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to cumulative net sales more than 500 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CumulativeNetSalesMoreThan500MillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">500 million</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanOneBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanOneBillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CumulativeNetSalesMoreThanOneBillionMember" xlink:to="nrbo_CumulativeNetSalesMoreThanOneBillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CumulativeNetSalesMoreThanOneBillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to cumulative net sales more than one billion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CumulativeNetSalesMoreThanOneBillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">1 billion</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanThreeBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanThreeBillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CumulativeNetSalesMoreThanThreeBillionMember" xlink:to="nrbo_CumulativeNetSalesMoreThanThreeBillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CumulativeNetSalesMoreThanThreeBillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to cumulative net sales more than three billion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CumulativeNetSalesMoreThanThreeBillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">3 billion</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanFiveBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanFiveBillionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CumulativeNetSalesMoreThanFiveBillionMember" xlink:to="nrbo_CumulativeNetSalesMoreThanFiveBillionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CumulativeNetSalesMoreThanFiveBillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to cumulative net sales more than five billion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CumulativeNetSalesMoreThanFiveBillionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">5 billion</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_FirstAmendmentToOriginalCvrAgreementMember" xlink:label="nrbo_FirstAmendmentToOriginalCvrAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_FirstAmendmentToOriginalCvrAgreementMember" xlink:to="nrbo_FirstAmendmentToOriginalCvrAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_FirstAmendmentToOriginalCvrAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to the First Amendment to the Original CVR Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_FirstAmendmentToOriginalCvrAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Amendment to Original CVR Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mergers</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of voting equity interests acquired at the acquisition date in the asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Percentage of Voting Interests Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership acquired</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InitialMilestonePayment" xlink:label="nrbo_InitialMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_InitialMilestonePayment" xlink:to="nrbo_InitialMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_InitialMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of initial milestone payment to be made.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_InitialMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_InitialMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SalesBasedMilestonePayment" xlink:label="nrbo_SalesBasedMilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_SalesBasedMilestonePayment" xlink:to="nrbo_SalesBasedMilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_SalesBasedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of mile stone payments to be made based on sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_SalesBasedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Based Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_SalesBasedMilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales based milestone payment</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyPayments" xlink:label="nrbo_PercentageOfRoyaltyPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PercentageOfRoyaltyPayments" xlink:to="nrbo_PercentageOfRoyaltyPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PercentageOfRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty percent of annual worldwide income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PercentageOfRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Royalty Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PercentageOfRoyaltyPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty payments</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyPaymentAccrued" xlink:label="nrbo_RoyaltyPaymentAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_RoyaltyPaymentAccrued" xlink:to="nrbo_RoyaltyPaymentAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_RoyaltyPaymentAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to royalty payments accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_RoyaltyPaymentAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Payment Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_RoyaltyPaymentAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of royalty payments accrued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_YourchoiceTherapeuticsInc.Member" xlink:label="nrbo_YourchoiceTherapeuticsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_YourchoiceTherapeuticsInc.Member" xlink:to="nrbo_YourchoiceTherapeuticsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_YourchoiceTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to YourChoice Therapeutics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_YourchoiceTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">YourChoice</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PfizerInc.Member" xlink:label="nrbo_PfizerInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PfizerInc.Member" xlink:to="nrbo_PfizerInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PfizerInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Pfizer Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PfizerInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pfizer, Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonePaymentsMember" xlink:label="nrbo_MilestonePaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_MilestonePaymentsMember" xlink:to="nrbo_MilestonePaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment to make milestone payments contingent upon achieving specified goals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierOneNetSalesMilestoneMember" xlink:label="nrbo_TierOneNetSalesMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_TierOneNetSalesMilestoneMember" xlink:to="nrbo_TierOneNetSalesMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_TierOneNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_TierOneNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tier One Net Sales Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierTwoNetSalesMilestoneMember" xlink:label="nrbo_TierTwoNetSalesMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_TierTwoNetSalesMilestoneMember" xlink:to="nrbo_TierTwoNetSalesMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_TierTwoNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_TierTwoNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tier Two Net Sales Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierThreeNetSalesMilestoneMember" xlink:label="nrbo_TierThreeNetSalesMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_TierThreeNetSalesMilestoneMember" xlink:to="nrbo_TierThreeNetSalesMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_TierThreeNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_TierThreeNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tier Three Net Sales Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierFourNetSalesMilestoneMember" xlink:label="nrbo_TierFourNetSalesMilestoneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_TierFourNetSalesMilestoneMember" xlink:to="nrbo_TierFourNetSalesMilestoneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_TierFourNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_TierFourNetSalesMilestoneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tier Four Net Sales Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ContingentLiability" xlink:label="nrbo_ContingentLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ContingentLiability" xlink:to="nrbo_ContingentLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a contingent liability to make payments if certain conditions are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential payments upon achievement of certain milestones</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfYearsAfterFirstSaleOccurs" xlink:label="nrbo_NumberOfYearsAfterFirstSaleOccurs" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_NumberOfYearsAfterFirstSaleOccurs" xlink:to="nrbo_NumberOfYearsAfterFirstSaleOccurs_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_NumberOfYearsAfterFirstSaleOccurs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to number of years after the first sale occurs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_NumberOfYearsAfterFirstSaleOccurs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Years After The First Sale Occurs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_NumberOfYearsAfterFirstSaleOccurs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of years after the first commercial sale</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesOrRoyaltyPaymentsTriggered" xlink:label="nrbo_MilestonesOrRoyaltyPaymentsTriggered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_MilestonesOrRoyaltyPaymentsTriggered" xlink:to="nrbo_MilestonesOrRoyaltyPaymentsTriggered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_MilestonesOrRoyaltyPaymentsTriggered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to milestone or royalty payments triggered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_MilestonesOrRoyaltyPaymentsTriggered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Or Royalty Payments Triggered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_MilestonesOrRoyaltyPaymentsTriggered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones or royalty payments triggered</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseTerminationNoticePeriod" xlink:label="nrbo_LicenseTerminationNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseTerminationNoticePeriod" xlink:to="nrbo_LicenseTerminationNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseTerminationNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for which the entity inform for the termination of license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseTerminationNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Termination, Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LicenseTerminationNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementEarlyTerminationFee" xlink:label="nrbo_LicenseAgreementEarlyTerminationFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementEarlyTerminationFee" xlink:to="nrbo_LicenseAgreementEarlyTerminationFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementEarlyTerminationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of early termination fee payable on termination of license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementEarlyTerminationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Early Termination Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LicenseAgreementEarlyTerminationFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination fee</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyAndMilestonePaymentsDue" xlink:label="nrbo_RoyaltyAndMilestonePaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_RoyaltyAndMilestonePaymentsDue" xlink:to="nrbo_RoyaltyAndMilestonePaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_RoyaltyAndMilestonePaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of royalty and milestone payment due under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_RoyaltyAndMilestonePaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Milestone Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_RoyaltyAndMilestonePaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and milestone payment due</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" xlink:label="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" xlink:to="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to payments for specified global net sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments For Specified Global Net Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for specified global net sales milestones</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_OriginalCvrAgreementMember" xlink:label="nrbo_OriginalCvrAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_OriginalCvrAgreementMember" xlink:to="nrbo_OriginalCvrAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_OriginalCvrAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to the Original CVR Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_OriginalCvrAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original CVR Agreement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" xlink:label="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" xlink:to="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to percentage of proceeds from grant sale or transfer of rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Proceeds From Grant Sale Or Transfer Of Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of proceeds from the grant, sale, or transfer of rights</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesAccrued" xlink:label="nrbo_MilestonesAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_MilestonesAccrued" xlink:to="nrbo_MilestonesAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_MilestonesAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to milestones accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_MilestonesAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_MilestonesAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestones accrued</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:to="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of Proprietary compounds to be received by the company in a license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Proprietary Compounds to Be Received Through License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of proprietary compounds in a license</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongaStCoLtdLicenseAgreementMember" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DongaStCoLtdLicenseAgreementMember" xlink:to="nrbo_DongaStCoLtdLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Dong-A ST Co., LTD  license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DongA ST Co LTD License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DongA ST Co LTD License agreement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SharedServicesAgreementMember" xlink:label="nrbo_SharedServicesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_SharedServicesAgreementMember" xlink:to="nrbo_SharedServicesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_SharedServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Shared Services Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_SharedServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shared Services Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_SharedServicesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shared Services Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForTerminationNotice" xlink:label="nrbo_PeriodForTerminationNotice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PeriodForTerminationNotice" xlink:to="nrbo_PeriodForTerminationNotice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PeriodForTerminationNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for petition for termination notice for the other party's material breach that is not cured.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PeriodForTerminationNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for Termination Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PeriodForTerminationNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for termination notice when material breach not cured</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" xlink:to="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible preferred stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares to be issued for upfront payment made to a related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible Preferred Stock, Par Value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementWithBeijingSLMember" xlink:label="nrbo_LicenseAgreementWithBeijingSLMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementWithBeijingSLMember" xlink:to="nrbo_LicenseAgreementWithBeijingSLMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementWithBeijingSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to merger agreement with Beijing SL.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementWithBeijingSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement with Beijing SL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from the agreement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementUpfrontPaymentToBeReceived" xlink:label="nrbo_LicenseAgreementUpfrontPaymentToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementUpfrontPaymentToBeReceived" xlink:to="nrbo_LicenseAgreementUpfrontPaymentToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementUpfrontPaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payment to be received under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementUpfrontPaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Upfront Payment To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LicenseAgreementUpfrontPaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment to be received</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" xlink:label="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" xlink:to="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from effective date within which upfront gross payment to be paid under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period From Effective Date Within Which Upfront Gross Payment To Be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from effective date within which upfront gross payment to be paid</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" xlink:label="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" xlink:to="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of threshold global net sales milestone payments eligible to be received under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Threshold Global Net Sales Milestone Payment To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Global net sales milestone payment to be received</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyOnNetSales" xlink:label="nrbo_PercentageOfRoyaltyOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PercentageOfRoyaltyOnNetSales" xlink:to="nrbo_PercentageOfRoyaltyOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of royalty to be paid on net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Royalty on Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PercentageOfRoyaltyOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on net sales</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" xlink:label="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" xlink:to="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected period to begin future milestone payments as decided in the terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Expected Period To Begin Future Installment Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum expected period to begin future installment payment</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" xlink:label="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" xlink:to="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period over which the entity will execute the clinical supply from effective date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Supply Agreement Execution Period From Effective date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical supply agreement execution period from effective date</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RegisteredDirectOfferingMember" xlink:label="nrbo_RegisteredDirectOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_RegisteredDirectOfferingMember" xlink:to="nrbo_RegisteredDirectOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to registered direct offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">October 2021 Registered Direct Offering</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PublicOfferingMember" xlink:label="nrbo_PublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PublicOfferingMember" xlink:to="nrbo_PublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrbo_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Public Offering</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassUnitsMember" xlink:label="nrbo_ClassUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ClassUnitsMember" xlink:to="nrbo_ClassUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ClassUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Class A Units, each consisting of one share of Class A Common Stock and one Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ClassUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class A Units [Member]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassBUnitsMember" xlink:label="nrbo_ClassBUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ClassBUnitsMember" xlink:to="nrbo_ClassBUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ClassBUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Class B Units, each Class B Unit consisting of one share of Series B Convertible Preferred Stock, convertible into one share of common stock, one Series A Warrant and one Series B Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ClassBUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class B Units [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesWarrantMember" xlink:label="nrbo_SeriesWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_SeriesWarrantMember" xlink:to="nrbo_SeriesWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_SeriesWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series A Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_SeriesWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesBWarrantMember" xlink:label="nrbo_SeriesBWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_SeriesBWarrantMember" xlink:to="nrbo_SeriesBWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_SeriesBWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Series B Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_SeriesBWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CommonStockVotingRightsPerShare" xlink:label="nrbo_CommonStockVotingRightsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CommonStockVotingRightsPerShare" xlink:to="nrbo_CommonStockVotingRightsPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the voting rights per share for common stock of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Voting Rights Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, vote per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockAbstract" xlink:label="us-gaap_DividendsCommonStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockAbstract" xlink:to="us-gaap_DividendsCommonStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsCommonStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Common Stock [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsCommonStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Rights</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeDividendsDeclared" xlink:label="nrbo_CumulativeDividendsDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_CumulativeDividendsDeclared" xlink:to="nrbo_CumulativeDividendsDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_CumulativeDividendsDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cumulative cash dividends declared.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_CumulativeDividendsDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Dividends Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_CumulativeDividendsDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stocks, Including Additional Paid in Capital, Net of Discount [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfCommonStockIssuedPerUnit" xlink:label="nrbo_NumberOfCommonStockIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_NumberOfCommonStockIssuedPerUnit" xlink:to="nrbo_NumberOfCommonStockIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_NumberOfCommonStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of common stock per units issued under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_NumberOfCommonStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Common Stock Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_NumberOfCommonStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock per Unit</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" xlink:label="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" xlink:to="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of Series B Convertible Preferred Stock per units issued under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Series B Convertible Preferred Stock Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Series B Convertible Preferred Stock per Unit</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:to="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants per unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering shares (Per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase shares of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" xlink:to="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period from issuance date from which the warrants become exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period From Issuance Date The Warrants Become Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from issuance date the warrants become exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Warrant Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair market value of warrant</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of common stock issued along with warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and Warrants Issued During Period, Value, Stocks Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Relative fair value attributable to the stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life of options (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash commissions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Legal Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and other fees</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SecuritiesPurchaseAgreementMember" xlink:label="nrbo_SecuritiesPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_SecuritiesPurchaseAgreementMember" xlink:to="nrbo_SecuritiesPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Securities Purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrbo_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dong-A Financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MeasurementInputProbabilityFactorMember" xlink:label="nrbo_MeasurementInputProbabilityFactorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_MeasurementInputProbabilityFactorMember" xlink:to="nrbo_MeasurementInputProbabilityFactorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_MeasurementInputProbabilityFactorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input using probability factor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_MeasurementInputProbabilityFactorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Probability Factor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_MeasurementInputProbabilityFactorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Probability factor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Discount for Lack of Marketability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount for a lack of marketability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining term</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" xlink:label="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" xlink:to="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to scenario of stockholder approving conversion to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Stockholder Approval to Convert Common Stock</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" xlink:label="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" xlink:to="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to scenario of stockholder not approving conversion to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Stockholder Non Approval to Convert Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Stockholder Non Approval to Convert Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockIssuanceCost" xlink:label="nrbo_StockIssuanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockIssuanceCost" xlink:to="nrbo_StockIssuanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of stock issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance Cost</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsIssuanceCost" xlink:label="nrbo_WarrantsIssuanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantsIssuanceCost" xlink:to="nrbo_WarrantsIssuanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantsIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of warrants issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantsIssuanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issuance Cost</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockMeasurementInput" xlink:label="nrbo_PreferredStockMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PreferredStockMeasurementInput" xlink:to="nrbo_PreferredStockMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PreferredStockMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of input used to measure outstanding preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PreferredStockMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockFairValuePerShare" xlink:label="nrbo_PreferredStockFairValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PreferredStockFairValuePerShare" xlink:to="nrbo_PreferredStockFairValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PreferredStockFairValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value per share of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PreferredStockFairValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Fair Value per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PreferredStockFairValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value per share of preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant measurement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice7800.00Member" xlink:label="nrbo_WarrantsExercisePrice7800.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantsExercisePrice7800.00Member" xlink:to="nrbo_WarrantsExercisePrice7800.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantsExercisePrice7800.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price $260.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantsExercisePrice7800.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 7,800.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_WarrantsExercisePrice7800.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$7800.00</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice5602.50Member" xlink:label="nrbo_WarrantsExercisePrice5602.50Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantsExercisePrice5602.50Member" xlink:to="nrbo_WarrantsExercisePrice5602.50Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantsExercisePrice5602.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price $5,602.50.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantsExercisePrice5602.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 5,602.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_WarrantsExercisePrice5602.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$5,602.50</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice375.00Member" xlink:label="nrbo_WarrantsExercisePrice375.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantsExercisePrice375.00Member" xlink:to="nrbo_WarrantsExercisePrice375.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantsExercisePrice375.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price of $375.00</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantsExercisePrice375.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 375.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_WarrantsExercisePrice375.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$375.00</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice180.90Member" xlink:label="nrbo_WarrantsExercisePrice180.90Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantsExercisePrice180.90Member" xlink:to="nrbo_WarrantsExercisePrice180.90Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantsExercisePrice180.90Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price of $180.90</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantsExercisePrice180.90Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 180.90 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_WarrantsExercisePrice180.90Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$180.90</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice112.50Member" xlink:label="nrbo_WarrantsExercisePrice112.50Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantsExercisePrice112.50Member" xlink:to="nrbo_WarrantsExercisePrice112.50Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantsExercisePrice112.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants with exercise price of $112.50</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantsExercisePrice112.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Exercise Price 112.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_WarrantsExercisePrice112.50Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$112.50</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesWarrantExercisePrice3.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_November2022SeriesWarrantExercisePrice3.00Member" xlink:to="nrbo_November2022SeriesWarrantExercisePrice3.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_November2022SeriesWarrantExercisePrice3.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to November 2022 Series A warrants with exercise price of $ 3.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_November2022SeriesWarrantExercisePrice3.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series A Warrant Exercise Price 3.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_November2022SeriesWarrantExercisePrice3.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$3.00</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesBWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_November2022SeriesBWarrantExercisePrice3.00Member" xlink:to="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to November 2022 Series B warrants with exercise price of $ 3.00.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series B Warrant Exercise Price 3.00 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">$3.00</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:label="nrbo_November2022SeriesAndSeriesBWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:to="nrbo_November2022SeriesAndSeriesBWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_November2022SeriesAndSeriesBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to series A and series B warrants issued in November 2022.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_November2022SeriesAndSeriesBWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2022 Series A and B</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" xlink:label="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" xlink:to="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exchanged for each of securities called by warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Securities Called by Each Warrant or Right, Number of Warrants Exchanged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exchanged</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfWarrantsExercised" xlink:label="nrbo_NumberOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_NumberOfWarrantsExercised" xlink:to="nrbo_NumberOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_NumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_NumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_NumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exchanged for common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining nonvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2018Member" xlink:label="nrbo_StockPlan2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockPlan2018Member" xlink:to="nrbo_StockPlan2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockPlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2018 stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockPlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2019Member" xlink:label="nrbo_StockPlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockPlan2019Member" xlink:to="nrbo_StockPlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2019 stock plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockPlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options, Additional Disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Number, Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Number, Beginning Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable (in share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Outstanding, Weighted Average Remaining Contractual Term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options Exercisable (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Outstanding, Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value per share of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited, nonvested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested, Weighted Average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value per share of options vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value per share of options forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InducementPlanMember" xlink:label="nrbo_InducementPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_InducementPlanMember" xlink:to="nrbo_InducementPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_InducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the Inducement Plan, an equity incentive plan used by the reporting entity targeted at individuals not previously employees or directors as an inducement into employment with the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_InducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrbo_InducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Plan</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2022201And2019PlansMember" xlink:label="nrbo_StockPlan2022201And2019PlansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockPlan2022201And2019PlansMember" xlink:to="nrbo_StockPlan2022201And2019PlansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockPlan2022201And2019PlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2022,201 And 2019 plans..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockPlan2022201And2019PlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Plan 2022,201 And 2019 Plans</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2022Member" xlink:label="nrbo_StockPlan2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_StockPlan2022Member" xlink:to="nrbo_StockPlan2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_StockPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2022 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_StockPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Plan 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_StockPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Plan</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InducementPlan2021Member" xlink:label="nrbo_InducementPlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_InducementPlan2021Member" xlink:to="nrbo_InducementPlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_InducementPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to 2021 Inducement Plan..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_InducementPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Plan 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_InducementPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:label="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:to="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period over which the shares reserved for further issuance under share based compensation will increase annually.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Period Number of shares reserved for further issuance Increase Annually</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of automatic increase in shares reserved</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the common shares outstanding (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares added (In shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation - Weighted average period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities at Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantLiabilityRollForward" xlink:label="nrbo_WarrantLiabilityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_WarrantLiabilityRollForward" xlink:to="nrbo_WarrantLiabilityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_WarrantLiabilityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_WarrantLiabilityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liability [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of 2022 warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" xlink:label="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" xlink:to="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of extinguishment of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability extinguishment on exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance, Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_OperatingLossCarryForwardResearchCredit" xlink:label="nrbo_OperatingLossCarryForwardResearchCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_OperatingLossCarryForwardResearchCredit" xlink:to="nrbo_OperatingLossCarryForwardResearchCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_OperatingLossCarryForwardResearchCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net operating loss carry forward relating to research activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_OperatingLossCarryForwardResearchCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry Forward Research Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_OperatingLossCarryForwardResearchCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal research credit carry forward</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NetOperatingLossCarryforwardsWrittenOff" xlink:label="nrbo_NetOperatingLossCarryforwardsWrittenOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_NetOperatingLossCarryforwardsWrittenOff" xlink:to="nrbo_NetOperatingLossCarryforwardsWrittenOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_NetOperatingLossCarryforwardsWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net operating loss carryforward written off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_NetOperatingLossCarryforwardsWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carryforwards, Written Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_NetOperatingLossCarryforwardsWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards written off</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ResearchCreditCarryforwardsWrittenOff" xlink:label="nrbo_ResearchCreditCarryforwardsWrittenOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ResearchCreditCarryforwardsWrittenOff" xlink:to="nrbo_ResearchCreditCarryforwardsWrittenOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ResearchCreditCarryforwardsWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net operating loss carryforward relating to research credit written off.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ResearchCreditCarryforwardsWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Credit Carryforwards, Written Off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ResearchCreditCarryforwardsWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credit carryforwards written off</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" xlink:label="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" xlink:to="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state tax credit carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Credit Carryforwards State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State research credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (benefit) provision at federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income tax, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credits (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision to tax return (as a percent)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to transaction cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Transaction Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs (as percentage)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to change in fair value of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Fair Value of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liability (as percent)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Section 382 limitation adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Section 382 limitation Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Section 382 limitation adjustment attributes (as percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant components of deferred tax assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before Income taxes:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal, State and Local, Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Foreign Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" xlink:label="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" xlink:to="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of valuation allowance of domestic income tax expense (benefit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance of Domestic Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance - Domestic</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" xlink:label="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" xlink:to="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of valuation allowance of foreign income tax expense (benefit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance of Foreign Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance - Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsAcquiredIntangibles" xlink:label="nrbo_DeferredTaxAssetsAcquiredIntangibles" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DeferredTaxAssetsAcquiredIntangibles" xlink:to="nrbo_DeferredTaxAssetsAcquiredIntangibles_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DeferredTaxAssetsAcquiredIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from acquired intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DeferredTaxAssetsAcquiredIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Acquired Intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrbo_DeferredTaxAssetsAcquiredIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired intangibles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsLeaseLiability" xlink:label="nrbo_DeferredTaxAssetsLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DeferredTaxAssetsLeaseLiability" xlink:to="nrbo_DeferredTaxAssetsLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Lease Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets, net of valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesRouAsset" xlink:label="nrbo_DeferredTaxLiabilitiesRouAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DeferredTaxLiabilitiesRouAsset" xlink:to="nrbo_DeferredTaxLiabilitiesRouAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DeferredTaxLiabilitiesRouAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences classified as ROU Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DeferredTaxLiabilitiesRouAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, ROU Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_DeferredTaxLiabilitiesRouAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ROU Asset</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" xlink:label="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" xlink:to="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from lease liabilities and other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Lease Liabilities and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ManufacturingAgreementMember" xlink:label="nrbo_ManufacturingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ManufacturingAgreementMember" xlink:to="nrbo_ManufacturingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ManufacturingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Manufacturing Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ManufacturingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing Agreement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ManufacturingAndSupplyAgreementMember" xlink:label="nrbo_ManufacturingAndSupplyAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ManufacturingAndSupplyAgreementMember" xlink:to="nrbo_ManufacturingAndSupplyAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ManufacturingAndSupplyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers to Manufacturing and Supply Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ManufacturingAndSupplyAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing and Supply Agreement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ContractTerm" xlink:label="nrbo_ContractTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ContractTerm" xlink:to="nrbo_ContractTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ContractTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for which the entity entered in to the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ContractTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ContractTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of agreement</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfSharesHeldByRelatedParty" xlink:label="nrbo_PercentageOfSharesHeldByRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PercentageOfSharesHeldByRelatedParty" xlink:to="nrbo_PercentageOfSharesHeldByRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PercentageOfSharesHeldByRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of shares held by related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PercentageOfSharesHeldByRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Shares Held by Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PercentageOfSharesHeldByRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares held</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="us-gaap_RelatedPartyCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyCosts" xlink:to="us-gaap_RelatedPartyCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party costs</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" xlink:label="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" xlink:to="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The notice period for purchase order prior to the requested delivery date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for Receipts of Purchase Order Prior to Requested Delivery Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for purchase order prior to requested delivery date</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" xlink:label="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" xlink:to="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The notice period for dismission of bankruptcy and other disputes other wise the agreement gets terminated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condition For Termination of Agreement, Either Party Not Dismissed Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for dismission of allegations.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="nrbo_DefinedContributionPlanEmployeeEligibilityAge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DefinedContributionPlanEmployeeEligibilityAge" xlink:to="nrbo_DefinedContributionPlanEmployeeEligibilityAge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee eligibility age criteria under defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employee Eligibility Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age of employee to cover under the plan</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:label="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:to="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which the employer contribution will be vested under defined contribution plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer matches vesting period</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:label="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:to="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employee contributions may be deferred to a defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employee Contribution Deferred, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation deferred percentage</label>
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EmployeeCompensationVestingPercentageOnContribution" xlink:label="nrbo_EmployeeCompensationVestingPercentageOnContribution" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrbo_EmployeeCompensationVestingPercentageOnContribution" xlink:to="nrbo_EmployeeCompensationVestingPercentageOnContribution_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrbo_EmployeeCompensationVestingPercentageOnContribution_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employee contribution vested on contribution made by employee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrbo_EmployeeCompensationVestingPercentageOnContribution_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Compensation Vesting Percentage on Contribution</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrbo_EmployeeCompensationVestingPercentageOnContribution_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of employee contribution vested on their contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of discretionary matching contributions on employee deferrals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>nrbo-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/30/2023 7:48:19 PM-->
<!--Modified on: 3/30/2023 7:48:19 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.gemphire.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.gemphire.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity" roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCompanyAndBasisOfPresentation" roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBalanceSheetDetail" roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetail" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureDongStLicenseAgreement" roleURI="http://www.gemphire.com/role/DisclosureDongStLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBeijingSlLicenseAgreement" roleURI="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureNetLossPerCommonShare" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureDefinedContributionPlan" roleURI="http://www.gemphire.com/role/DisclosureDefinedContributionPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://www.gemphire.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBalanceSheetDetailTables" roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureNetLossPerCommonShareTables" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCompanyAndBasisOfPresentationDetails" roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBalanceSheetDetailAccruedLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureDongStLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureBeijingSlLicenseAgreementBeijingDetails" roleURI="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityAggregateConsiderationReceivedDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockholdersEquityWarrantsNarrativeDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationUnvestedStockOptionsDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureStockBasedCompensationEvergreenProvisionDetails" roleURI="http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesTaxProvisionBenefitDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureDefinedContributionPlanDetails" roleURI="http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nrbo-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://www.gemphire.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638158024965986109" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_638158024965986109" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638158024965986109" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638158024965986109" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638158024965986109" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638158024965986109" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638158024965986109" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638158024965986109" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638158024965986109" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638158024965986109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638158024965986109" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638158024965996105" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638158024965996105" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638158024965996105" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638158024965996105" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638158024965996105" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638158024965996105" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638158024965996105" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638158024965996105" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638158024965996105" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638158024965996105" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638158024965996105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638158024965996105" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638158024966006106" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638158024966006106" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638158024966006106" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638158024966006106" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638158024966006106" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_638158024966006106" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638158024966006106" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_638158024966006106" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638158024966006106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_638158024966006106" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638158024966016104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_638158024966016104" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638158024966016104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638158024966016104" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638158024966016104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638158024966016104" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638158024966016104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638158024966016104" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638158024966016104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638158024966016104" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638158024966016104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638158024966016104" order="36" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638158024966026107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158024966026107" xlink:to="us-gaap_AssetsCurrentAbstract_638158024966026107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158024966026107" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158024966026107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158024966026107" xlink:to="us-gaap_PrepaidExpenseCurrent_638158024966026107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638158024966026107" xlink:to="us-gaap_AssetsCurrent_638158024966026107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158024966026107" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638158024966026107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158024966026107" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638158024966026107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638158024966026107" xlink:to="us-gaap_Assets_638158024966026107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158024966026107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158024966026107" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" xlink:to="us-gaap_AccountsPayableCurrent_638158024966026107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638158024966026107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638158024966026107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_638158024966036107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638158024966036107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" xlink:to="us-gaap_LiabilitiesCurrent_638158024966036107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638158024966036107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638158024966026107" xlink:to="us-gaap_Liabilities_638158024966036107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158024966026107" xlink:to="us-gaap_CommitmentsAndContingencies_638158024966036107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158024966026107" xlink:to="us-gaap_StockholdersEquityAbstract_638158024966036107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158024966036107" xlink:to="us-gaap_PreferredStockValue_638158024966036107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158024966036107" xlink:to="us-gaap_CommonStockValue_638158024966036107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638158024966036107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158024966036107" xlink:to="us-gaap_AdditionalPaidInCapital_638158024966036107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158024966036107" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638158024966046105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158024966036107" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158024966046105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638158024966036107" xlink:to="us-gaap_StockholdersEquity_638158024966046105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638158024966026107" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638158024966046105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638158024966046105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966046105" xlink:to="us-gaap_StatementClassOfStockAxis_638158024966046105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966046105" xlink:to="us-gaap_ClassOfStockDomain_638158024966046105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966046105" xlink:to="us-gaap_SeriesAPreferredStockMember_638158024966046105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638158024966046105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966046105" xlink:to="us-gaap_SeriesBPreferredStockMember_638158024966046105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_UndesignatedPreferredStockMember" xlink:label="nrbo_UndesignatedPreferredStockMember_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966046105" xlink:to="nrbo_UndesignatedPreferredStockMember_638158024966056106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966046105" xlink:to="us-gaap_StatementLineItems_638158024966056106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638158024966056106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockStatedValuePerShare" xlink:label="nrbo_PreferredStockStatedValuePerShare_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="nrbo_PreferredStockStatedValuePerShare_638158024966056106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_PreferredStockSharesAuthorized_638158024966056106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_PreferredStockSharesIssued_638158024966056106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_PreferredStockSharesOutstanding_638158024966056106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638158024966056106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_CommonStockSharesAuthorized_638158024966056106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_CommonStockSharesIssued_638158024966056106" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638158024966056106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966056106" xlink:to="us-gaap_CommonStockSharesOutstanding_638158024966056106" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638158024966066107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158024966066107" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638158024966066107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158024966066107" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024966066107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158024966066107" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638158024966066107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638158024966066107" xlink:to="us-gaap_CostsAndExpenses_638158024966066107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638158024966066107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638158024966066107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638158024966066107" xlink:to="us-gaap_InterestIncomeExpenseNet_638158024966066107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingInterestExpense" xlink:label="us-gaap_FinancingInterestExpense_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638158024966066107" xlink:to="us-gaap_FinancingInterestExpense_638158024966066107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638158024966066107" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638158024966066107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_638158024966066107" xlink:to="us-gaap_OtherNonoperatingExpense_638158024966066107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638158024966066107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638158024966066107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024966076104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158024966076104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638158024966076104" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_638158024966076104" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638158024966076104" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_638158024966076104" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638158024966076104" xlink:to="us-gaap_EarningsPerShareBasic_638158024966076104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638158024966076104" xlink:to="us-gaap_EarningsPerShareDiluted_638158024966076104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_638158024966076104" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158024966076104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_638158024966076104" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638158024966076104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_638158024966076104" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638158024966086106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Preferred Stock and Stockholders Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638158024966086106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966086106" xlink:to="us-gaap_StatementClassOfStockAxis_638158024966086106" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966086106" xlink:to="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966086106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966086106" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966086106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966086106" xlink:to="us-gaap_SeriesAPreferredStockMember_638158024966086106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966086106" xlink:to="us-gaap_SeriesBPreferredStockMember_638158024966086106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966086106" xlink:to="us-gaap_ClassOfStockDomain_638158024966086106" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966086106" xlink:to="us-gaap_StatementEquityComponentsAxis_638158024966086106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638158024966086106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158024966086106" xlink:to="us-gaap_PreferredStockMember_638158024966086106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158024966086106" xlink:to="us-gaap_CommonStockMember_638158024966096106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158024966086106" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638158024966096106" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158024966086106" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638158024966096106" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158024966086106" xlink:to="us-gaap_RetainedEarningsMember_638158024966096106" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158024966086106" xlink:to="us-gaap_EquityComponentDomain_638158024966096106" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966086106" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638158024966096106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158024966096106" xlink:to="us-gaap_PrivatePlacementMember_638158024966096106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PrivateInvestmentInPublicEquityAndLicenseMember" xlink:label="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158024966096106" xlink:to="nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_638158024966096106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158024966096106" xlink:to="us-gaap_IPOMember_638158024966096106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158024966096106" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966096106" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966096106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966086106" xlink:to="us-gaap_StatementLineItems_638158024966096106" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966096106" xlink:to="us-gaap_StockholdersEquity_638158024966106107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966096106" xlink:to="us-gaap_SharesIssued_638158024966106107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966096106" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodValue" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValue_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodValue_638158024966106107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodShares" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodShares_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_StockAndWarrantsIssuedDuringPeriodValue_638158024966106107" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodShares_638158024966106107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158024966106107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158024966106107" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966106107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodValue" xlink:label="nrbo_StockConvertedDuringPeriodValue_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="nrbo_StockConvertedDuringPeriodValue_638158024966106107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodShares" xlink:label="nrbo_StockConvertedDuringPeriodShares_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_StockConvertedDuringPeriodValue_638158024966106107" xlink:to="nrbo_StockConvertedDuringPeriodShares_638158024966106107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638158024966106107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638158024966106107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638158024966116105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638158024966106107" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638158024966116105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638158024966116105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638158024966116105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638158024966116105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638158024966116105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158024966116105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158024966116105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158024966116105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158024966116105" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158024966116105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossRealized_638158024966116105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossRealized_638158024966116105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158024966116105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638158024966106107" xlink:to="us-gaap_NetIncomeLoss_638158024966116105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966096106" xlink:to="us-gaap_StockholdersEquity_638158024966126107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966096106" xlink:to="us-gaap_SharesIssued_638158024966126107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638158024966126107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638158024966126107" xlink:to="us-gaap_NetIncomeLoss_638158024966126107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638158024966126107" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_ShareBasedCompensation_638158024966126107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_IncreaseDecreaseInNonCashLeaseExpense" xlink:label="nrbo_IncreaseDecreaseInNonCashLeaseExpense_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="nrbo_IncreaseDecreaseInNonCashLeaseExpense_638158024966126107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638158024966126107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_Depreciation_638158024966126107" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638158024966136106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024966136106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingInterestExpense" xlink:label="us-gaap_FinancingInterestExpense_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_FinancingInterestExpense_638158024966136106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638158024966136106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_GainLossOnTerminationOfLease_638158024966136106" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638158024966126107" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158024966136106" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:label="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158024966136106" xlink:to="nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits_638158024966136106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158024966136106" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638158024966136106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638158024966136106" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638158024966136106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638158024966126107" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638158024966136106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638158024966136106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PaymentsForTransactionCostsInConnectionWithMerger" xlink:label="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_638158024966136106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638158024966136106" xlink:to="nrbo_PaymentsForTransactionCostsInConnectionWithMerger_638158024966136106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638158024966136106" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638158024966146105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638158024966136106" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638158024966146105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638158024966136106" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638158024966146105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638158024966146105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638158024966146105" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638158024966146105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638158024966146105" xlink:to="us-gaap_PaymentsOfFinancingCosts_638158024966146105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638158024966146105" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638158024966146105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638158024966146105" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638158024966146105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638158024966146105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638158024966146105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158024966156105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158024966156105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158024966156105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638158024966156105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381580249661561051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381580249661561051" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638158024966156105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638158024966156105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability" xlink:label="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability_638158024966156105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638158024966156105" xlink:to="nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability_638158024966156105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredIssuanceCostsIncurredButNotYetPaid" xlink:label="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid_638158024966156105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638158024966156105" xlink:to="nrbo_DeferredIssuanceCostsIncurredButNotYetPaid_638158024966156105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158024966156105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638158024966156105" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638158024966156105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - The Company and Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638158024966166103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638158024966166103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638158024966166103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638158024966166103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureBalanceSheetDetail" xlink:type="extended" xlink:title="10301 - Disclosure - Balance Sheet Detail" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638158024966166103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638158024966166103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10401 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638158024966166103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638158024966166103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureDongStLicenseAgreement" xlink:type="extended" xlink:title="10501 - Disclosure - Dong-A ST License Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementAbstract" xlink:label="nrbo_LicenseAgreementAbstract" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDisclosureTextBlock" xlink:label="nrbo_LicenseAgreementDisclosureTextBlock_638158024966176105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementAbstract" xlink:to="nrbo_LicenseAgreementDisclosureTextBlock_638158024966176105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreement" xlink:type="extended" xlink:title="10601 - Disclosure - Beijing SL License Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDisclosureAbstract" xlink:label="LicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638158024966176105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638158024966176105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10701 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638158024966176105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638158024966176105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10801 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638158024966176105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638158024966176105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShare" xlink:type="extended" xlink:title="10901 - Disclosure - Net Loss Per Common Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638158024966176105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638158024966176105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="11001 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638158024966186106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638158024966186106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11101 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638158024966186106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638158024966186106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11201 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638158024966186106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638158024966186106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureDefinedContributionPlan" xlink:type="extended" xlink:title="11301 - Disclosure - Defined Contribution Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638158024966186106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638158024966186106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11401 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638158024966186106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638158024966186106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638158024966186106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638158024966186106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638158024966196105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638158024966196105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantLiabilitiesPolicyPolicyTextBlock" xlink:label="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="nrbo_WarrantLiabilitiesPolicyPolicyTextBlock_638158024966196105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_638158024966196105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638158024966196105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_638158024966196105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638158024966196105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638158024966196105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638158024966196105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638158024966196105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638158024966196105" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PatentCostPolicyPolicyTextBlock" xlink:label="nrbo_PatentCostPolicyPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="nrbo_PatentCostPolicyPolicyTextBlock_638158024966196105" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_638158024966196105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_638158024966196105" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638158024966206106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638158024966206106" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638158024966206106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638158024966206106" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureBalanceSheetDetailTables" xlink:type="extended" xlink:title="30303 - Disclosure - Balance Sheet Detail (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638158024966206106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638158024966206106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638158024966206106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638158024966206106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966206106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable_638158024966206106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638158024966206106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966206106" xlink:to="us-gaap_AssetAcquisitionAxis_638158024966206106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638158024966206106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638158024966206106" xlink:to="us-gaap_AssetAcquisitionDomain_638158024966206106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" xlink:label="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638158024966206106" xlink:to="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_638158024966216134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966206106" xlink:to="us-gaap_StatementLineItems_638158024966216134" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock" xlink:label="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966216134" xlink:to="nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock_638158024966216134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30603 - Disclosure - Stockholders Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638158024966216134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock" xlink:label="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock_638158024966216134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638158024966216134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638158024966216134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_638158024966216134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638158024966216134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638158024966216134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables" xlink:type="extended" xlink:title="30803 - Disclosure - Net Loss Per Common Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638158024966226107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31003 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_638158024966226107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock" xlink:label="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock_638158024966226107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31103 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638158024966226107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638158024966226107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638158024966226107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638158024966226107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - The Company and Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638158024966226107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638158024966226107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638158024966236105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638158024966236105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638158024966236105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966236105" xlink:to="srt_RangeAxis_638158024966236105" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638158024966236105" xlink:to="srt_RangeMember_638158024966236105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966236105" xlink:to="srt_MinimumMember_638158024966236105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966236105" xlink:to="srt_MaximumMember_638158024966236105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966236105" xlink:to="us-gaap_StatementLineItems_638158024966236105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966236105" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638158024966236105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966236105" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_638158024966236105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DepositsInExcessOfFederallyInsuredAmounts" xlink:label="nrbo_DepositsInExcessOfFederallyInsuredAmounts_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_638158024966236105" xlink:to="nrbo_DepositsInExcessOfFederallyInsuredAmounts_638158024966236105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966236105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966236105" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966236105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966236105" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158024966246107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966236105" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638158024966246107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_638158024966246107" xlink:to="us-gaap_NumberOfOperatingSegments_638158024966246107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Balance Sheet Detail - Property and Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638158024966246107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638158024966246107" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638158024966246107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638158024966246107" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638158024966246107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638158024966246107" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_638158024966246107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638158024966246107" xlink:to="us-gaap_OfficeEquipmentMember_638158024966246107" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638158024966246107" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638158024966246107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638158024966246107" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638158024966246107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638158024966246107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638158024966246107" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638158024966246107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638158024966246107" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638158024966256105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Balance Sheet Detail - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AccruedOtherResearchAndDevelopmentExpenses" xlink:label="nrbo_AccruedOtherResearchAndDevelopmentExpenses_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="nrbo_AccruedOtherResearchAndDevelopmentExpenses_638158024966256105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638158024966256105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638158024966256105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638158024966256105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638158024966256105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Commitments and Contingencies - Operating Leases - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638158024966256105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966256105" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638158024966256105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638158024966256105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638158024966256105" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638158024966256105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_HeadquartersInBostonLeaseMember" xlink:label="nrbo_HeadquartersInBostonLeaseMember_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638158024966256105" xlink:to="nrbo_HeadquartersInBostonLeaseMember_638158024966266107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966256105" xlink:to="srt_StatementGeographicalAxis_638158024966266107" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638158024966266107" xlink:to="srt_SegmentGeographicalDomain_638158024966266107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR" xlink:label="country_KR_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638158024966266107" xlink:to="country_KR_638158024966266107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966256105" xlink:to="us-gaap_RelatedPartyTransactionAxis_638158024966266107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638158024966266107" xlink:to="us-gaap_RelatedPartyTransactionDomain_638158024966266107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638158024966266107" xlink:to="nrbo_LicenseAgreementMember_638158024966266107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966266107" xlink:to="nrbo_Da1726Member_638158024966266107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966266107" xlink:to="nrbo_Da1241Member_638158024966266107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966256105" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966266107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966266107" xlink:to="us-gaap_RelatedPartyDomain_638158024966266107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongStMember" xlink:label="nrbo_DongStMember_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638158024966266107" xlink:to="nrbo_DongStMember_638158024966266107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966256105" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638158024966276106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LesseeMonthlyOperatingLeaseCost" xlink:label="nrbo_LesseeMonthlyOperatingLeaseCost_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="nrbo_LesseeMonthlyOperatingLeaseCost_638158024966276106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LesseeOperatingLeaseIncentiveFromLessor" xlink:label="nrbo_LesseeOperatingLeaseIncentiveFromLessor_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="nrbo_LesseeOperatingLeaseIncentiveFromLessor_638158024966276106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_OperatingLeaseExpense_638158024966276106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638158024966276106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638158024966276106" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638158024966276106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_GainLossOnTerminationOfLease_638158024966276106" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638158024966276106" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638158024966276106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_OperatingLeasePayments_638158024966276106" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966286106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966286106" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_638158024966286106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_638158024966286106" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForBreachingParty" xlink:label="nrbo_CurePeriodForBreachingParty_638158024966286106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="nrbo_CurePeriodForBreachingParty_638158024966286106" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForPetitionForBankruptcy" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy_638158024966286106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="nrbo_CurePeriodForPetitionForBankruptcy_638158024966286106" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966286106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966266107" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966286106" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Commitments and Contingencies - ANA Merger Milestone Payment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638158024966286106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AssetAcquisitionTable_638158024966286106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638158024966286106" xlink:to="srt_StatementScenarioAxis_638158024966296106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638158024966296106" xlink:to="srt_ScenarioUnspecifiedDomain_638158024966296106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThan500MillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThan500MillionMember_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638158024966296106" xlink:to="nrbo_CumulativeNetSalesMoreThan500MillionMember_638158024966296106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanOneBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanOneBillionMember_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638158024966296106" xlink:to="nrbo_CumulativeNetSalesMoreThanOneBillionMember_638158024966296106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanThreeBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanThreeBillionMember_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638158024966296106" xlink:to="nrbo_CumulativeNetSalesMoreThanThreeBillionMember_638158024966296106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeNetSalesMoreThanFiveBillionMember" xlink:label="nrbo_CumulativeNetSalesMoreThanFiveBillionMember_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638158024966296106" xlink:to="nrbo_CumulativeNetSalesMoreThanFiveBillionMember_638158024966296106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_FirstAmendmentToOriginalCvrAgreementMember" xlink:label="nrbo_FirstAmendmentToOriginalCvrAgreementMember_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638158024966296106" xlink:to="nrbo_FirstAmendmentToOriginalCvrAgreementMember_638158024966296106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638158024966286106" xlink:to="us-gaap_AssetAcquisitionAxis_638158024966296106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638158024966296106" xlink:to="us-gaap_AssetAcquisitionDomain_638158024966296106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AnaTherapeuticsInc.AssetAcquisitionMember" xlink:label="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638158024966296106" xlink:to="nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_638158024966296106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638158024966286106" xlink:to="us-gaap_AssetAcquisitionLineItems_638158024966296106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638158024966296106" xlink:to="nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired_638158024966296106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InitialMilestonePayment" xlink:label="nrbo_InitialMilestonePayment_638158024966296106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638158024966296106" xlink:to="nrbo_InitialMilestonePayment_638158024966296106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SalesBasedMilestonePayment" xlink:label="nrbo_SalesBasedMilestonePayment_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638158024966296106" xlink:to="nrbo_SalesBasedMilestonePayment_638158024966306106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyPayments" xlink:label="nrbo_PercentageOfRoyaltyPayments_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638158024966296106" xlink:to="nrbo_PercentageOfRoyaltyPayments_638158024966306106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyPaymentAccrued" xlink:label="nrbo_RoyaltyPaymentAccrued_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638158024966296106" xlink:to="nrbo_RoyaltyPaymentAccrued_638158024966306106" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966306106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966306106" xlink:to="srt_CounterpartyNameAxis_638158024966306106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638158024966306106" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638158024966306106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_YourchoiceTherapeuticsInc.Member" xlink:label="nrbo_YourchoiceTherapeuticsInc.Member_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638158024966306106" xlink:to="nrbo_YourchoiceTherapeuticsInc.Member_638158024966306106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PfizerInc.Member" xlink:label="nrbo_PfizerInc.Member_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638158024966306106" xlink:to="nrbo_PfizerInc.Member_638158024966306106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966306106" xlink:to="us-gaap_TypeOfArrangementAxis_638158024966306106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966306106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638158024966306106" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966306106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966306106" xlink:to="nrbo_LicenseAgreementMember_638158024966316107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966306106" xlink:to="us-gaap_OtherCommitmentsAxis_638158024966316107" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_638158024966316107" xlink:to="us-gaap_OtherCommitmentsDomain_638158024966316107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonePaymentsMember" xlink:label="nrbo_MilestonePaymentsMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638158024966316107" xlink:to="nrbo_MilestonePaymentsMember_638158024966316107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierOneNetSalesMilestoneMember" xlink:label="nrbo_TierOneNetSalesMilestoneMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638158024966316107" xlink:to="nrbo_TierOneNetSalesMilestoneMember_638158024966316107" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierTwoNetSalesMilestoneMember" xlink:label="nrbo_TierTwoNetSalesMilestoneMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638158024966316107" xlink:to="nrbo_TierTwoNetSalesMilestoneMember_638158024966316107" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierThreeNetSalesMilestoneMember" xlink:label="nrbo_TierThreeNetSalesMilestoneMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638158024966316107" xlink:to="nrbo_TierThreeNetSalesMilestoneMember_638158024966316107" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_TierFourNetSalesMilestoneMember" xlink:label="nrbo_TierFourNetSalesMilestoneMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638158024966316107" xlink:to="nrbo_TierFourNetSalesMilestoneMember_638158024966316107" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966306106" xlink:to="srt_RangeAxis_638158024966316107" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638158024966316107" xlink:to="srt_RangeMember_638158024966316107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966316107" xlink:to="srt_MaximumMember_638158024966316107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966306106" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ContingentLiability" xlink:label="nrbo_ContingentLiability_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_ContingentLiability_638158024966326107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfYearsAfterFirstSaleOccurs" xlink:label="nrbo_NumberOfYearsAfterFirstSaleOccurs_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_NumberOfYearsAfterFirstSaleOccurs_638158024966326107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesOrRoyaltyPaymentsTriggered" xlink:label="nrbo_MilestonesOrRoyaltyPaymentsTriggered_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_MilestonesOrRoyaltyPaymentsTriggered_638158024966326107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseTerminationNoticePeriod" xlink:label="nrbo_LicenseTerminationNoticePeriod_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_LicenseTerminationNoticePeriod_638158024966326107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementEarlyTerminationFee" xlink:label="nrbo_LicenseAgreementEarlyTerminationFee_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_LicenseAgreementEarlyTerminationFee_638158024966326107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyAndMilestonePaymentsDue" xlink:label="nrbo_RoyaltyAndMilestonePaymentsDue_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_RoyaltyAndMilestonePaymentsDue_638158024966326107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyPayments" xlink:label="nrbo_PercentageOfRoyaltyPayments_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_PercentageOfRoyaltyPayments_638158024966326107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SalesBasedMilestonePayment" xlink:label="nrbo_SalesBasedMilestonePayment_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_SalesBasedMilestonePayment_638158024966326107" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones" xlink:label="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones_638158024966326107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966316107" xlink:to="nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones_638158024966326107" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_AssetAcquisitionTable_638158024966336106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638158024966336106" xlink:to="us-gaap_TypeOfArrangementAxis_638158024966336106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638158024966336106" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966336106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_OriginalCvrAgreementMember" xlink:label="nrbo_OriginalCvrAgreementMember_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966336106" xlink:to="nrbo_OriginalCvrAgreementMember_638158024966336106" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638158024966336106" xlink:to="us-gaap_AssetAcquisitionLineItems_638158024966336106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights" xlink:label="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638158024966336106" xlink:to="nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights_638158024966336106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesAccrued" xlink:label="nrbo_MilestonesAccrued_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638158024966336106" xlink:to="nrbo_MilestonesAccrued_638158024966336106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Commitments and Contingencies - License Agreement with Dong-A ST (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638158024966336106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638158024966336106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966336106" xlink:to="us-gaap_RelatedPartyTransactionAxis_638158024966346103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638158024966346103" xlink:to="us-gaap_RelatedPartyTransactionDomain_638158024966346103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638158024966346103" xlink:to="nrbo_LicenseAgreementMember_638158024966346103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966346103" xlink:to="nrbo_Da1726Member_638158024966346103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966346103" xlink:to="nrbo_Da1241Member_638158024966346103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966336106" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966346103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966346103" xlink:to="us-gaap_RelatedPartyDomain_638158024966346103" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongStMember" xlink:label="nrbo_DongStMember_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638158024966346103" xlink:to="nrbo_DongStMember_638158024966346103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638158024966336106" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638158024966346103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966346103" xlink:to="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_638158024966346103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966346103" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966346103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RoyaltyPaymentAccrued" xlink:label="nrbo_RoyaltyPaymentAccrued_638158024966346103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638158024966346103" xlink:to="nrbo_RoyaltyPaymentAccrued_638158024966346103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Dong-A ST License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract_1" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966356107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966356107" xlink:to="us-gaap_RelatedPartyTransactionAxis_638158024966356107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638158024966356107" xlink:to="us-gaap_RelatedPartyTransactionDomain_638158024966356107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638158024966356107" xlink:to="nrbo_LicenseAgreementMember_638158024966356107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966356107" xlink:to="nrbo_Da1726Member_638158024966356107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966356107" xlink:to="nrbo_Da1241Member_638158024966356107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966356107" xlink:to="us-gaap_StatementClassOfStockAxis_638158024966356107" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966356107" xlink:to="us-gaap_ClassOfStockDomain_638158024966356107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966356107" xlink:to="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966356107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966356107" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966356107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966356107" xlink:to="us-gaap_SeriesAPreferredStockMember_638158024966356107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638158024966356107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966356107" xlink:to="us-gaap_TypeOfArrangementAxis_638158024966356107" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966366104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638158024966356107" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966366104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongaStCoLtdLicenseAgreementMember" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember_638158024966366104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966366104" xlink:to="nrbo_DongaStCoLtdLicenseAgreementMember_638158024966366104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SharedServicesAgreementMember" xlink:label="nrbo_SharedServicesAgreementMember_638158024966366104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966366104" xlink:to="nrbo_SharedServicesAgreementMember_638158024966366104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966356107" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966406107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966406107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_638158024966406107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForBreachingParty" xlink:label="nrbo_CurePeriodForBreachingParty_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_CurePeriodForBreachingParty_638158024966406107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForPetitionForBankruptcy" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_CurePeriodForPetitionForBankruptcy_638158024966406107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForTerminationNotice" xlink:label="nrbo_PeriodForTerminationNotice_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_PeriodForTerminationNotice_638158024966406107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_638158024966406107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_638158024966406107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_638158024966416105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638158024966416105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638158024966416105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesAccrued" xlink:label="nrbo_MilestonesAccrued_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966406107" xlink:to="nrbo_MilestonesAccrued_638158024966416105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Beijing SL License Agreement - Beijing (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDisclosureAbstract" xlink:label="LicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966416105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966416105" xlink:to="us-gaap_TypeOfArrangementAxis_638158024966416105" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638158024966416105" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966416105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementWithBeijingSLMember" xlink:label="nrbo_LicenseAgreementWithBeijingSLMember_638158024966416105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966416105" xlink:to="nrbo_LicenseAgreementWithBeijingSLMember_638158024966416105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966416105" xlink:to="srt_RangeAxis_638158024966426112" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638158024966426112" xlink:to="srt_RangeMember_638158024966426112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966426112" xlink:to="srt_MaximumMember_638158024966426112" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638158024966416105" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638158024966426112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementUpfrontPaymentToBeReceived" xlink:label="nrbo_LicenseAgreementUpfrontPaymentToBeReceived_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="nrbo_LicenseAgreementUpfrontPaymentToBeReceived_638158024966426112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid" xlink:label="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid_638158024966426112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966426112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived" xlink:label="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived_638158024966426112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfRoyaltyOnNetSales" xlink:label="nrbo_PercentageOfRoyaltyOnNetSales_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="nrbo_PercentageOfRoyaltyOnNetSales_638158024966426112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment" xlink:label="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment_638158024966426112" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate" xlink:label="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate_638158024966426112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638158024966426112" xlink:to="nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate_638158024966426112" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StatementTable_638158024966436106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966436106" xlink:to="srt_RangeAxis_638158024966436106" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638158024966436106" xlink:to="srt_RangeMember_638158024966436106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966436106" xlink:to="srt_MinimumMember_638158024966436106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966436106" xlink:to="srt_MaximumMember_638158024966436106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966436106" xlink:to="us-gaap_StatementEquityComponentsAxis_638158024966436106" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638158024966436106" xlink:to="us-gaap_EquityComponentDomain_638158024966436106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638158024966436106" xlink:to="us-gaap_CommonStockMember_638158024966436106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966436106" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638158024966436106" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966436106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158024966436106" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966436106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RegisteredDirectOfferingMember" xlink:label="nrbo_RegisteredDirectOfferingMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966436106" xlink:to="nrbo_RegisteredDirectOfferingMember_638158024966446105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966436106" xlink:to="us-gaap_PrivatePlacementMember_638158024966446105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PublicOfferingMember" xlink:label="nrbo_PublicOfferingMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966436106" xlink:to="nrbo_PublicOfferingMember_638158024966446105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966436106" xlink:to="us-gaap_StatementClassOfStockAxis_638158024966446105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966446105" xlink:to="us-gaap_ClassOfStockDomain_638158024966446105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassUnitsMember" xlink:label="nrbo_ClassUnitsMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966446105" xlink:to="nrbo_ClassUnitsMember_638158024966446105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassBUnitsMember" xlink:label="nrbo_ClassBUnitsMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966446105" xlink:to="nrbo_ClassBUnitsMember_638158024966446105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966446105" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966446105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966446105" xlink:to="us-gaap_SeriesAPreferredStockMember_638158024966446105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966446105" xlink:to="us-gaap_SeriesBPreferredStockMember_638158024966446105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638158024966446105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966436106" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638158024966446105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638158024966446105" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638158024966456108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesWarrantMember" xlink:label="nrbo_SeriesWarrantMember_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966456108" xlink:to="nrbo_SeriesWarrantMember_638158024966456108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesBWarrantMember" xlink:label="nrbo_SeriesBWarrantMember_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966456108" xlink:to="nrbo_SeriesBWarrantMember_638158024966456108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966436106" xlink:to="us-gaap_StatementLineItems_638158024966456108" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638158024966456108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CommonStockVotingRightsPerShare" xlink:label="nrbo_CommonStockVotingRightsPerShare_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_638158024966456108" xlink:to="nrbo_CommonStockVotingRightsPerShare_638158024966456108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockAbstract" xlink:label="us-gaap_DividendsCommonStockAbstract_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_DividendsCommonStockAbstract_638158024966456108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CumulativeDividendsDeclared" xlink:label="nrbo_CumulativeDividendsDeclared_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsCommonStockAbstract_638158024966456108" xlink:to="nrbo_CumulativeDividendsDeclared_638158024966456108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract" xlink:label="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_638158024966456108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_638158024966456108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CommonStockVotingRightsPerShare" xlink:label="nrbo_CommonStockVotingRightsPerShare_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract_638158024966456108" xlink:to="nrbo_CommonStockVotingRightsPerShare_638158024966466107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockStatedValuePerShare" xlink:label="nrbo_PreferredStockStatedValuePerShare_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="nrbo_PreferredStockStatedValuePerShare_638158024966466107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966466107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_638158024966466107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638158024966466107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_SharePrice_638158024966466107" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfCommonStockIssuedPerUnit" xlink:label="nrbo_NumberOfCommonStockIssuedPerUnit_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="nrbo_NumberOfCommonStockIssuedPerUnit_638158024966466107" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit" xlink:label="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit_638158024966466107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit_638158024966466107" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966476105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966476105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_638158024966476105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_638158024966476105" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638158024966476105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638158024966476105" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638158024966476105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_SharesIssuedPricePerShare_638158024966476105" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638158024966476105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638158024966476105" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158024966476105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158024966476105" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966486107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966486107" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_638158024966486107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_638158024966486107" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638158024966486107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638158024966486107" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638158024966486107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638158024966486107" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued" xlink:label="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued_638158024966486107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued_638158024966486107" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966486107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966486107" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638158024966486107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638158024966486107" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockConvertedDuringPeriodShares" xlink:label="nrbo_StockConvertedDuringPeriodShares_638158024966496108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="nrbo_StockConvertedDuringPeriodShares_638158024966496108" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638158024966496108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638158024966496108" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638158024966496108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638158024966496108" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638158024966496108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638158024966496108" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638158024966496108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638158024966496108" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638158024966506105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638158024966506105" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions_638158024966506105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_PaymentsForCommissions_638158024966506105" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements_638158024966506105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966456108" xlink:to="us-gaap_PaymentsForLegalSettlements_638158024966506105" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stockholders Equity - Aggregate Consideration Received (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_1" xlink:to="us-gaap_StatementTable_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158024966516106" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PublicOfferingMember" xlink:label="nrbo_PublicOfferingMember_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966516106" xlink:to="nrbo_PublicOfferingMember_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="us-gaap_TypeOfArrangementAxis_638158024966516106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638158024966516106" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongaStCoLtdLicenseAgreementMember" xlink:label="nrbo_DongaStCoLtdLicenseAgreementMember_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966516106" xlink:to="nrbo_DongaStCoLtdLicenseAgreementMember_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SecuritiesPurchaseAgreementMember" xlink:label="nrbo_SecuritiesPurchaseAgreementMember_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966516106" xlink:to="nrbo_SecuritiesPurchaseAgreementMember_638158024966516106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="us-gaap_StatementClassOfStockAxis_638158024966516106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966516106" xlink:to="us-gaap_ClassOfStockDomain_638158024966516106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966516106" xlink:to="us-gaap_SeriesAPreferredStockMember_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="us-gaap_IncomeStatementLocationAxis_638158024966516106" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638158024966516106" xlink:to="us-gaap_IncomeStatementLocationDomain_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember_638158024966516106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638158024966516106" xlink:to="us-gaap_InterestExpenseMember_638158024966516106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="us-gaap_MeasurementInputTypeAxis_638158024966526105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638158024966526105" xlink:to="us-gaap_MeasurementInputTypeDomain_638158024966526105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MeasurementInputProbabilityFactorMember" xlink:label="nrbo_MeasurementInputProbabilityFactorMember_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638158024966526105" xlink:to="nrbo_MeasurementInputProbabilityFactorMember_638158024966526105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638158024966526105" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638158024966526105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:label="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638158024966526105" xlink:to="us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_638158024966526105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638158024966526105" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638158024966526105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638158024966526105" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638158024966526105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="srt_StatementScenarioAxis_638158024966526105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638158024966526105" xlink:to="srt_ScenarioUnspecifiedDomain_638158024966526105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScenarioStockholderApprovalToConvertCommonStockMember" xlink:label="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_638158024966526105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638158024966526105" xlink:to="nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_638158024966526105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember" xlink:label="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638158024966526105" xlink:to="nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_638158024966536106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="us-gaap_FinancialInstrumentAxis_638158024966536106" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638158024966536106" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638158024966536106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638158024966536106" xlink:to="us-gaap_WarrantMember_638158024966536106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966516106" xlink:to="us-gaap_StatementLineItems_638158024966536106" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966536106" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966536106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockIssuanceCost" xlink:label="nrbo_StockIssuanceCost_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966536106" xlink:to="nrbo_StockIssuanceCost_638158024966536106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsIssuanceCost" xlink:label="nrbo_WarrantsIssuanceCost_638158024966536106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966536106" xlink:to="nrbo_WarrantsIssuanceCost_638158024966536106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockMeasurementInput" xlink:label="nrbo_PreferredStockMeasurementInput_638158024966546108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966536106" xlink:to="nrbo_PreferredStockMeasurementInput_638158024966546108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PreferredStockFairValuePerShare" xlink:label="nrbo_PreferredStockFairValuePerShare_638158024966546108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966536106" xlink:to="nrbo_PreferredStockFairValuePerShare_638158024966546108" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638158024966546108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966536106" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638158024966546108" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_638158024966546108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966536106" xlink:to="us-gaap_WarrantsAndRightsOutstanding_638158024966546108" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stockholders Equity - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966546108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="us-gaap_StatementTable_638158024966546108" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638158024966546108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966546108" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638158024966546108" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638158024966546108" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice7800.00Member" xlink:label="nrbo_WarrantsExercisePrice7800.00Member_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_WarrantsExercisePrice7800.00Member_638158024966556107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice5602.50Member" xlink:label="nrbo_WarrantsExercisePrice5602.50Member_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_WarrantsExercisePrice5602.50Member_638158024966556107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice375.00Member" xlink:label="nrbo_WarrantsExercisePrice375.00Member_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_WarrantsExercisePrice375.00Member_638158024966556107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice180.90Member" xlink:label="nrbo_WarrantsExercisePrice180.90Member_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_WarrantsExercisePrice180.90Member_638158024966556107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantsExercisePrice112.50Member" xlink:label="nrbo_WarrantsExercisePrice112.50Member_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_WarrantsExercisePrice112.50Member_638158024966556107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesWarrantExercisePrice3.00Member_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_November2022SeriesWarrantExercisePrice3.00Member_638158024966556107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesBWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_638158024966556107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:label="nrbo_November2022SeriesAndSeriesBWarrantsMember_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966546108" xlink:to="nrbo_November2022SeriesAndSeriesBWarrantsMember_638158024966556107" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966546108" xlink:to="us-gaap_StatementLineItems_638158024966556107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966556107" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638158024966556107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638158024966556107" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638158024966556107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966556107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_638158024966556107" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966556107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stockholders Equity - Warrants - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable_638158024966566105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966566105" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638158024966566105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638158024966566105" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638158024966566105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesAndSeriesBWarrantsMember" xlink:label="nrbo_November2022SeriesAndSeriesBWarrantsMember_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966566105" xlink:to="nrbo_November2022SeriesAndSeriesBWarrantsMember_638158024966566105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesWarrantMember" xlink:label="nrbo_SeriesWarrantMember_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_November2022SeriesAndSeriesBWarrantsMember_638158024966566105" xlink:to="nrbo_SeriesWarrantMember_638158024966566105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesBWarrantMember" xlink:label="nrbo_SeriesBWarrantMember_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_November2022SeriesAndSeriesBWarrantsMember_638158024966566105" xlink:to="nrbo_SeriesBWarrantMember_638158024966566105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_November2022SeriesBWarrantExercisePrice3.00Member" xlink:label="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966566105" xlink:to="nrbo_November2022SeriesBWarrantExercisePrice3.00Member_638158024966566105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966566105" xlink:to="us-gaap_StatementLineItems_638158024966566105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged" xlink:label="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966566105" xlink:to="nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged_638158024966566105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966566105" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638158024966566105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966566105" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966566105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfWarrantsExercised" xlink:label="nrbo_NumberOfWarrantsExercised_638158024966566105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966566105" xlink:to="nrbo_NumberOfWarrantsExercised_638158024966566105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966566105" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966576105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stock-Based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966576105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966576105" xlink:to="us-gaap_IncomeStatementLocationAxis_638158024966576105" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638158024966576105" xlink:to="us-gaap_IncomeStatementLocationDomain_638158024966576105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638158024966576105" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638158024966576105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966576105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966576105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966576105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966576105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966576105" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638158024966576105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638158024966576105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966576105" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638158024966576105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stock-Based Compensation - Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966586105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966586105" xlink:to="srt_RangeAxis_638158024966586105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638158024966586105" xlink:to="srt_RangeMember_638158024966586105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966586105" xlink:to="srt_MinimumMember_638158024966586105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966586105" xlink:to="srt_MaximumMember_638158024966586105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966586105" xlink:to="us-gaap_AwardTypeAxis_638158024966586105" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638158024966586105" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158024966586105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158024966586105" xlink:to="us-gaap_EmployeeStockOptionMember_638158024966586105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966586105" xlink:to="us-gaap_PlanNameAxis_638158024966586105" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638158024966586105" xlink:to="us-gaap_PlanNameDomain_638158024966586105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2018Member" xlink:label="nrbo_StockPlan2018Member_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158024966586105" xlink:to="nrbo_StockPlan2018Member_638158024966586105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2019Member" xlink:label="nrbo_StockPlan2019Member_638158024966586105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158024966586105" xlink:to="nrbo_StockPlan2019Member_638158024966586105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966586105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966596107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638158024966596107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638158024966596107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638158024966596107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381580249665961071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381580249665961071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158024966596107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638158024966596107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638158024966596107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638158024966596107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63815802496659610712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63815802496659610712" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638158024966606106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638158024966606106" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638158024966606106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638158024966606106" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638158024966606106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638158024966606106" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638158024966606106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638158024966606106" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638158024966606106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638158024966606106" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638158024966606106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638158024966606106" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381580249666061061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381580249666061061" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638158024966606106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638158024966606106" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638158024966616107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638158024966616107" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638158024966616107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638158024966616107" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638158024966616107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638158024966616107" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638158024966616107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638158024966616107" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638158024966616107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638158024966616107" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638158024966616107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638158024966616107" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638158024966616107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638158024966596107" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638158024966616107" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Stock-Based Compensation - Unvested stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638158024966626104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638158024966626104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638158024966626104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638158024966626104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638158024966626104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638158024966626104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_6381580249666261041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_6381580249666261041" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638158024966626104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638158024966626104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638158024966626104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638158024966626104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638158024966626104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638158024966626104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638158024966636104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638158024966626104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638158024966636104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Stock Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966636104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966636104" xlink:to="srt_RangeAxis_638158024966636104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638158024966636104" xlink:to="srt_RangeMember_638158024966636104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966636104" xlink:to="srt_MinimumMember_638158024966636104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966636104" xlink:to="srt_MaximumMember_638158024966636104" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638158024966636104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638158024966636104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638158024966636104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638158024966646105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638158024966646105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638158024966646105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638158024966646105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638158024966646105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966636104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638158024966646105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Stock-Based Compensation - Evergreen provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966646105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966646105" xlink:to="us-gaap_PlanNameAxis_638158024966646105" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638158024966646105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638158024966646105" xlink:to="us-gaap_PlanNameDomain_638158024966646105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InducementPlanMember" xlink:label="nrbo_InducementPlanMember_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158024966646105" xlink:to="nrbo_InducementPlanMember_638158024966656104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2022201And2019PlansMember" xlink:label="nrbo_StockPlan2022201And2019PlansMember_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158024966646105" xlink:to="nrbo_StockPlan2022201And2019PlansMember_638158024966656104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2022Member" xlink:label="nrbo_StockPlan2022Member_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158024966646105" xlink:to="nrbo_StockPlan2022Member_638158024966656104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_InducementPlan2021Member" xlink:label="nrbo_InducementPlan2021Member_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158024966646105" xlink:to="nrbo_InducementPlan2021Member_638158024966656104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_StockPlan2019Member" xlink:label="nrbo_StockPlan2019Member_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638158024966646105" xlink:to="nrbo_StockPlan2019Member_638158024966656104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966646105" xlink:to="us-gaap_AwardTypeAxis_638158024966656104" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638158024966656104" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158024966656104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638158024966656104" xlink:to="us-gaap_EmployeeStockOptionMember_638158024966656104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638158024966646105" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966656104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966656104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually" xlink:label="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually_638158024966656104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_638158024966656104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638158024966656104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638158024966656104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638158024966666105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638158024966666105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638158024966666105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638158024966666105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638158024966666105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638158024966656104" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638158024966666105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638158024966656104" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638158024966666105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638158024966666105" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638158024966666105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638158024966666105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_638158024966666105" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638158024966666105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158024966676106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158024966676106" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638158024966676106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638158024966676106" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638158024966676106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638158024966676106" xlink:to="nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_638158024966676106" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638158024966676106" xlink:to="us-gaap_WarrantMember_638158024966676106" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638158024966676106" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638158024966676106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638158024966676106" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638158024966676106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Fair Value Measurements - Recurring basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638158024966676106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638158024966676106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638158024966676106" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638158024966686105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638158024966686105" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638158024966686105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638158024966686105" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638158024966686105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638158024966676106" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638158024966686105" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638158024966686105" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638158024966686105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638158024966686105" xlink:to="us-gaap_FairValueInputsLevel3Member_638158024966686105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638158024966676106" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638158024966686105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638158024966686105" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_638158024966686105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638158024966686105" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_638158024966686105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638158024966686105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_638158024966686105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638158024966686105" xlink:to="us-gaap_FairValueByLiabilityClassAxis_638158024966686105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_638158024966686105" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638158024966696105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_638158024966696105" xlink:to="us-gaap_WarrantMember_638158024966696105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_638158024966686105" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638158024966696105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_WarrantLiabilityRollForward" xlink:label="nrbo_WarrantLiabilityRollForward_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_638158024966696105" xlink:to="nrbo_WarrantLiabilityRollForward_638158024966696105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_WarrantLiabilityRollForward_638158024966696105" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_638158024966696105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_WarrantLiabilityRollForward_638158024966696105" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_638158024966696105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_WarrantLiabilityRollForward_638158024966696105" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638158024966696105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_638158024966696105" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_638158024966696105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment" xlink:label="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment_638158024966696105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_WarrantLiabilityRollForward_638158024966696105" xlink:to="nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment_638158024966696105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_6381580249666961051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_WarrantLiabilityRollForward_638158024966696105" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount_6381580249666961051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_638158024966706107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966706107" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638158024966706107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638158024966706107" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638158024966706107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638158024966706107" xlink:to="us-gaap_DomesticCountryMember_638158024966706107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638158024966706107" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638158024966706107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638158024966706107" xlink:to="us-gaap_ForeignCountryMember_638158024966706107" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966706107" xlink:to="us-gaap_StatementLineItems_638158024966706107" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966706107" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638158024966706107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158024966706107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_DeferredTaxAssetsGross_638158024966706107" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638158024966706107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638158024966706107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638158024966706107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_OperatingLossCarryForwardResearchCredit" xlink:label="nrbo_OperatingLossCarryForwardResearchCredit_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="nrbo_OperatingLossCarryForwardResearchCredit_638158024966716108" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NetOperatingLossCarryforwardsWrittenOff" xlink:label="nrbo_NetOperatingLossCarryforwardsWrittenOff_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="nrbo_NetOperatingLossCarryforwardsWrittenOff_638158024966716108" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ResearchCreditCarryforwardsWrittenOff" xlink:label="nrbo_ResearchCreditCarryforwardsWrittenOff_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="nrbo_ResearchCreditCarryforwardsWrittenOff_638158024966716108" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158024966716108" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638158024966716108" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState" xlink:label="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState_638158024966716108" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_638158024966706107" xlink:to="us-gaap_OperatingLossCarryforwards_638158024966716108" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966706107" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_638158024966716108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_638158024966716108" xlink:to="us-gaap_UnrecognizedTaxBenefits_638158024966716108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638158024966716108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_638158024966716108" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638158024966716108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Income Taxes - Reconciliation of income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638158024966726112" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638158024966726112" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638158024966726112" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638158024966726112" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638158024966726112" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="7" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost_638158024966726112" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants_638158024966726112" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent" xlink:label="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent_638158024966726112" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638158024966726112" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638158024966726112" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638158024966736105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638158024966726112" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158024966736105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Income Taxes - Tax provision (Benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966736105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966736105" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_638158024966736105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_638158024966736105" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638158024966736105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_638158024966736105" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638158024966736105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_638158024966736105" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638158024966736105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966736105" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_638158024966736105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_638158024966736105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_638158024966736105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638158024966746107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit" xlink:label="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" xlink:to="nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit_638158024966746107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit" xlink:label="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" xlink:to="nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit_638158024966746107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_638158024966736105" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638158024966746107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Income Taxes - Significant components of deferred tax assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StatementTable_638158024966746107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966746107" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638158024966746107" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638158024966746107" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638158024966746107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638158024966746107" xlink:to="us-gaap_DomesticCountryMember_638158024966746107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638158024966746107" xlink:to="us-gaap_ForeignCountryMember_638158024966746107" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638158024966746107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638158024966746107" xlink:to="us-gaap_StatementLineItems_638158024966746107" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638158024966746107" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966756108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966756108" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638158024966756108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_638158024966756108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsAcquiredIntangibles" xlink:label="nrbo_DeferredTaxAssetsAcquiredIntangibles_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="nrbo_DeferredTaxAssetsAcquiredIntangibles_638158024966756108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638158024966756108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsLeaseLiability" xlink:label="nrbo_DeferredTaxAssetsLeaseLiability_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="nrbo_DeferredTaxAssetsLeaseLiability_638158024966756108" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_638158024966756108" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsOther_638158024966756108" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638158024966756108" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsGross_638158024966756108" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638158024966756108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638158024966756108" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638158024966766106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_638158024966756108" xlink:to="us-gaap_DeferredTaxAssetsNet_638158024966766106" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638158024966766106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638158024966756108" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638158024966766106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesRouAsset" xlink:label="nrbo_DeferredTaxLiabilitiesRouAsset_638158024966766106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638158024966766106" xlink:to="nrbo_DeferredTaxLiabilitiesRouAsset_638158024966766106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther" xlink:label="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_638158024966766106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638158024966766106" xlink:to="nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther_638158024966766106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638158024966766106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_638158024966766106" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638158024966766106" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Related Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966766106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966766106" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638158024966766106" xlink:to="us-gaap_RelatedPartyDomain_638158024966776104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DongStMember" xlink:label="nrbo_DongStMember_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638158024966776104" xlink:to="nrbo_DongStMember_638158024966776104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" xlink:to="srt_ProductOrServiceAxis_638158024966776104" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638158024966776104" xlink:to="srt_ProductsAndServicesDomain_638158024966776104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ManufacturingAgreementMember" xlink:label="nrbo_ManufacturingAgreementMember_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638158024966776104" xlink:to="nrbo_ManufacturingAgreementMember_638158024966776104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" xlink:to="us-gaap_RelatedPartyTransactionAxis_638158024966776104" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638158024966776104" xlink:to="us-gaap_RelatedPartyTransactionDomain_638158024966776104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ManufacturingAndSupplyAgreementMember" xlink:label="nrbo_ManufacturingAndSupplyAgreementMember_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638158024966776104" xlink:to="nrbo_ManufacturingAndSupplyAgreementMember_638158024966776104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementMember" xlink:label="nrbo_LicenseAgreementMember_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638158024966776104" xlink:to="nrbo_LicenseAgreementMember_638158024966776104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1726Member" xlink:label="nrbo_Da1726Member_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966776104" xlink:to="nrbo_Da1726Member_638158024966776104" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_Da1241Member" xlink:label="nrbo_Da1241Member_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_LicenseAgreementMember_638158024966776104" xlink:to="nrbo_Da1241Member_638158024966776104" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" xlink:to="us-gaap_StatementClassOfStockAxis_638158024966776104" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638158024966776104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638158024966776104" xlink:to="us-gaap_ClassOfStockDomain_638158024966776104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966776104" xlink:to="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966786105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember_638158024966786105" xlink:to="nrbo_SeriesaRedeemableConvertiblePreferredStockMember_638158024966786105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638158024966776104" xlink:to="us-gaap_SeriesAPreferredStockMember_638158024966786105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" xlink:to="us-gaap_TypeOfArrangementAxis_638158024966786105" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638158024966786105" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966786105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SecuritiesPurchaseAgreementMember" xlink:label="nrbo_SecuritiesPurchaseAgreementMember_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638158024966786105" xlink:to="nrbo_SecuritiesPurchaseAgreementMember_638158024966786105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638158024966766106" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ContractTerm" xlink:label="nrbo_ContractTerm_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_ContractTerm_638158024966786105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PercentageOfSharesHeldByRelatedParty" xlink:label="nrbo_PercentageOfSharesHeldByRelatedParty_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_PercentageOfSharesHeldByRelatedParty_638158024966786105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyCosts" xlink:label="us-gaap_RelatedPartyCosts_638158024966786105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="us-gaap_RelatedPartyCosts_638158024966786105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate" xlink:label="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate_638158024966796105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived" xlink:label="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived_638158024966796105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_638158024966796105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodForFailToCureBreachMayTerminateAgreement" xlink:label="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_PeriodForFailToCureBreachMayTerminateAgreement_638158024966796105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForBreachingParty" xlink:label="nrbo_CurePeriodForBreachingParty_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_CurePeriodForBreachingParty_638158024966796105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_CurePeriodForPetitionForBankruptcy" xlink:label="nrbo_CurePeriodForPetitionForBankruptcy_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_CurePeriodForPetitionForBankruptcy_638158024966796105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod" xlink:label="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod_638158024966796105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement" xlink:label="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_638158024966796105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement_638158024966796105" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_638158024966806104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues_638158024966806104" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638158024966806104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638158024966806104" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_MilestonesAccrued" xlink:label="nrbo_MilestonesAccrued_638158024966806104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_MilestonesAccrued_638158024966806104" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158024966806104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638158024966806104" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966806104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638158024966806104" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966806104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966806104" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:label="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_638158024966806104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638158024966786105" xlink:to="nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued_638158024966806104" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Defined Contribution Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638158024966816105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638158024966816105" xlink:to="srt_RangeAxis_638158024966816105" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638158024966816105" xlink:to="srt_RangeMember_638158024966816105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638158024966816105" xlink:to="srt_MaximumMember_638158024966816105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638158024966816105" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638158024966816105" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="nrbo_DefinedContributionPlanEmployeeEligibilityAge_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638158024966816105" xlink:to="nrbo_DefinedContributionPlanEmployeeEligibilityAge_638158024966816105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage" xlink:label="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638158024966816105" xlink:to="nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage_638158024966816105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage" xlink:label="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage_638158024966816105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638158024966816105" xlink:to="nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage_638158024966816105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_EmployeeCompensationVestingPercentageOnContribution" xlink:label="nrbo_EmployeeCompensationVestingPercentageOnContribution_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638158024966816105" xlink:to="nrbo_EmployeeCompensationVestingPercentageOnContribution_638158024966826110" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638158024966816105" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638158024966826110" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638158024966826110" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638158024966826110" xlink:to="us-gaap_SubsequentEventTypeAxis_638158024966826110" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638158024966826110" xlink:to="us-gaap_SubsequentEventTypeDomain_638158024966826110" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638158024966826110" xlink:to="us-gaap_SubsequentEventMember_638158024966826110" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638158024966826110" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638158024966826110" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638158024966826110" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638158024966826110" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesWarrantMember" xlink:label="nrbo_SeriesWarrantMember_638158024966826110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966826110" xlink:to="nrbo_SeriesWarrantMember_638158024966826110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_SeriesBWarrantMember" xlink:label="nrbo_SeriesBWarrantMember_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638158024966826110" xlink:to="nrbo_SeriesBWarrantMember_638158024966836108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638158024966826110" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638158024966836108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638158024966836108" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966836108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_RegisteredDirectOfferingMember" xlink:label="nrbo_RegisteredDirectOfferingMember_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638158024966836108" xlink:to="nrbo_RegisteredDirectOfferingMember_638158024966836108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638158024966826110" xlink:to="us-gaap_SubsequentEventLineItems_638158024966836108" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_NumberOfWarrantsExercised" xlink:label="nrbo_NumberOfWarrantsExercised_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="nrbo_NumberOfWarrantsExercised_638158024966836108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638158024966836108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="us-gaap_SharesIssuedPricePerShare_638158024966836108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638158024966836108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638158024966836108" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966836108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638158024966836108" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nrbo-20221231.xsd#nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable" xlink:label="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_638158024966846105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable_638158024966846105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638158024966846105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638158024966836108" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638158024966846105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209889712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NeuroBo Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Berkeley Street, Office 19th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRBO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,176,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073208086608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 33,364<span></span>
</td>
<td class="nump">$ 16,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">33,532<span></span>
</td>
<td class="nump">16,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">33,534<span></span>
</td>
<td class="nump">16,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Warrant liability, short-term</a></td>
<td class="nump">10,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, short-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,784<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,784<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021; no shares issued or outstanding as of December 31, 2022 and December 31, 2021.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 25,436,019 and 888,693 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively.</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">117,520<span></span>
</td>
<td class="nump">96,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(95,795)<span></span>
</td>
<td class="num">(81,828)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">21,750<span></span>
</td>
<td class="nump">14,597<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 33,534<span></span>
</td>
<td class="nump">$ 16,799<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209239744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,436,019<span></span>
</td>
<td class="nump">25,436,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">888,693<span></span>
</td>
<td class="nump">888,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockStatedValuePerShare', window );">Preferred stock, stated value (in dollar per share)</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockStatedValuePerShare', window );">Preferred stock, stated value (in dollar per share)</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_UndesignatedPreferredStockMember', window );">Undesignated Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollar per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrbo_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrbo_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209013168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">$ 6,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">8,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,640<span></span>
</td>
<td class="nump">8,752<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,628<span></span>
</td>
<td class="nump">15,298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,628)<span></span>
</td>
<td class="num">(15,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingInterestExpense', window );">Financing expense</a></td>
<td class="num">(2,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(7,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">5,661<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(13,967)<span></span>
</td>
<td class="num">(15,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,967)<span></span>
</td>
<td class="num">(15,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss, net of tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (13,971)<span></span>
</td>
<td class="num">$ (15,294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (5.43)<span></span>
</td>
<td class="num">$ (19.81)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (5.43)<span></span>
</td>
<td class="num">$ (19.81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average shares of common stock outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">2,573,624<span></span>
</td>
<td class="nump">771,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">2,573,624<span></span>
</td>
<td class="nump">771,422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents interest incurred for borrowed money which was used to produce goods or render services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073205020160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Preferred Stock and Stockholders Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Series A Preferred stock </div>
<div>Preferred Stock </div>
<div>PIPE and license</div>
</th>
<th class="th">
<div>Series A Preferred stock </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series A Preferred stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Series A Preferred stock </div>
<div>Additional Paid-in Capital</div>
</th>
<th class="th"><div>Series A Preferred stock</div></th>
<th class="th">
<div>Series B Preferred stock </div>
<div>Preferred Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Series B Preferred stock </div>
<div>Preferred Stock</div>
</th>
<th class="th">
<div>Series B Preferred stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,732<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">$ (66,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,203<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at beginning of period (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockAndWarrantsIssuedDuringPeriodValue', window );">Issuance of common stock and warrants in connection with public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockAndWarrantsIssuedDuringPeriodShares', window );">Issuance of common stock and warrants in connection with public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of stock from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of stock from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,284)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,420<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(81,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,597<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at end of period (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 10,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,147,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockConvertedDuringPeriodValue', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockConvertedDuringPeriodShares', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 9,659<span></span>
</td>
<td class="nump">$ 9,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of stock from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of stock from exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,463,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,967)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (95,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,750<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at end of period (shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,436,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_StockAndWarrantsIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_StockAndWarrantsIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_StockAndWarrantsIssuedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_StockAndWarrantsIssuedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_StockConvertedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted into common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_StockConvertedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_StockConvertedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares converted into common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_StockConvertedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073304471360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,967)<span></span>
</td>
<td class="num">$ (15,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_IncreaseDecreaseInNonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of property and equipment</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">8,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingInterestExpense', window );">Transaction costs allocated to issuance of warrants</a></td>
<td class="nump">2,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(7,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits', window );">Prepaid expenses and other assets</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(1,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,712)<span></span>
</td>
<td class="num">(15,134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PaymentsForTransactionCostsInConnectionWithMerger', window );">Transaction costs in connection with asset acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sale of property and equipment</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common shares, preferred shares and warrants</a></td>
<td class="nump">32,250<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of issuance costs</a></td>
<td class="num">(3,569)<span></span>
</td>
<td class="num">(2,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">28,681<span></span>
</td>
<td class="nump">22,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash</a></td>
<td class="nump">16,977<span></span>
</td>
<td class="nump">6,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Net foreign exchange difference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="nump">16,387<span></span>
</td>
<td class="nump">10,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at end of period</a></td>
<td class="nump">33,364<span></span>
</td>
<td class="nump">16,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability', window );">Modification of right-of-use asset and associated lease liability</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DeferredIssuanceCostsIncurredButNotYetPaid', window );">Unpaid issuance costs</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Reclass of warrant liabilities upon exercise of warrants</a></td>
<td class="nump">$ 5,564<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DeferredIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for deferred issuance costs that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DeferredIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_IncreaseDecreaseInNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to increase or decrease in non cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_IncreaseDecreaseInNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance that provide economic benefits in future periods and deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of modification of right-of-use asset and associated lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PaymentsForTransactionCostsInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow related to transaction cost in connection with the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PaymentsForTransactionCostsInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents interest incurred for borrowed money which was used to produce goods or render services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213508928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. The Company and Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">NeuroBo Pharmaceuticals,&#160;Inc. (together with its subsidiaries, the &#8220;Company&#8221; or &#8220;NeuroBo&#8221;), is a clinical-stage biotechnology company with two primary programs focused on treatment of nonalcoholic steatohepatitis (&#8220;NASH&#8221;) obesity, and type 2 diabetes (&#8220;T2D&#8221;):</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">DA-1241</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D. We intend to initiate a Phase 2a study with the goal of establishing efficacy of DA-1241 in NASH and T2D.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">DA-1726</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> is a novel oxyntomodulin (&#8220;OXM&#8221;) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity, that is to be administered once weekly subcutaneously. DA-1726 as a dual agonist of GLP-1 receptors (&#8220;GLP1R&#8221;) and glucagon receptors (&#8220;GCGR&#8221;), leading to weight loss through reduced appetite and increased energy expenditure. We intend to advance DA-1726 through Investigational New Drug application and initiation of human clinical trials.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;">The Company had previously focused its efforts on four therapeutic programs: ANA001, NB-01, NB-02 and gemcabene.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company&#8217;s operations have consisted principally of performing research and development activities, clinical development and raising capital. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Basis of presentation and consolidation principles</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The consolidated financial statements of the Company include a South Korean subsidiary, NeuroBo Co.,&#160;Ltd., which is fully owned by the Company. All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The Company&#8217;s Board of Directors approved a <span style="-sec-ix-hidden:Hidden_-c2kEXqIKUut8eHDA86q6w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-thirty</span></span> reverse stock split of the Company&#8217;s issued and outstanding shares of common stock (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on September 12, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">All issued and outstanding common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result of the Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company&#8217;s common stock as reported on Nasdaq on the last trading day before the Reverse Stock Split becomes effective (on a split-adjusted basis). The authorized shares and par value per share of the common stock and preferred stock were not adjusted as a result of the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">From its inception through December 31, 2022, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials. The Company has a limited operating history and the sales and income potential of the Company's business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company's cost structure. The Company has experienced net losses and negative cash flows from operating activities since its inception and had an accumulated deficit of $95.8&#160;<span style="white-space:pre-wrap;">million as of December 31, 2022.  These conditions previously raised substantial doubt about the Company's ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">To date, the Company has raised capital principally through private placements and public offerings of convertible preferred stock, common stock and warrants The Company will need to continue to raise a substantial amount of funds until it is able to generate revenues to fund its development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2022, the Company had $33.4<span style="white-space:pre-wrap;"> million in cash.  The Company believes that its existing cash will be sufficient to fund its operations for at least the next 12 months from the date these financial statements are issued.  The Company will need to continue to raise additional funds until it is able to generate sufficient revenues to fund its development activities.  The Company&#8217;s future operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to predict the ultimate outcome of these actions to generate the liquidity ultimately required.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213683696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is principally held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of December 31, 2022, the Company had deposits in excess of federally insured amounts by $32.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Supplier Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">On September 14, 2022, the Company entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) with Dong-A ST Co., Ltd. (&#8220;Dong-A&#8221;), which requires Dong-A to be the sole manufacturer for the production of DA-1241 and DA-1726.  </span>If any issues arise in the manufacturing and the Company is unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, the Company may not be able to complete development of DA-1241 or DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. <span style="white-space:pre-wrap;background:#ffffff;">The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.  </span>See Note 10 - <i style="font-style:italic;">Fair Value Measurements</i>.  <span style="white-space:pre-wrap;background:#ffffff;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The Company accounts for its warrants as liabilities at fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities are recognized as a fair value change in warrant liabilities in the consolidated statements of operations and comprehensive loss and as an operating item in the statement of cash flows.<span style="font-size:12pt;"> &#160;</span>Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, <i style="font-style:italic;">Research and Development</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company includes costs to acquire or in-license product candidates in acquired in-process research and development expenses (&#8220;IPR&amp;D&#8221;). When the Company acquires the right to develop and commercialize a new product candidate, any up-front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as acquired in-process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company utilizes the liability method of accounting for income taxes as required by ASC 740, <i style="font-style:italic;">Income Taxes</i>. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#160;&#8212; Stock Compensation</i> (&#8220;ASC 718&#8221;). Accordingly, compensation costs related to equity instruments granted are recognized at the grant-date fair value. The Company records forfeitures when they occur. Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718 using a grant date fair value approach. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company accounts for leases under Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;<i style="font-style:italic;">Leases</i> (Topic 842)&#160;(&#8220;ASU 2016-02&#8221;). The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company has recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company&#8217;s&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, the Company recognizes lease payments as an expense on a straight-line basis over the remaining lease term.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property&#160;and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from <span style="-sec-ix-hidden:Hidden_FyBBTxlXGEGwh1t7bmaxpQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to five years. Tangible assets acquired for research and development activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Currency Translation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">The foreign subsidiary uses the South Korean Won (KRW) as its functional currency. The Company translates the assets and liabilities of its foreign operation into U.S. dollars based on the rates of exchange in effect as of the transaction date. The resulting adjustments from the translation process are included in accumulated other comprehensive (loss) income in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Certain transactions of the Company are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patent Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Comprehensive loss is comprised of net loss and other comprehensive income or loss. Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. Comprehensive loss currently consists of net loss and changes in foreign currency translation adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its business in one operating segment, which is principally the business of development and commercialization of therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background:#ffffff;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="font-style:italic;">&#8220;Financial Instruments &#8211; Credit Losses&#8221;</i>. The ASU sets forth a &#8220;current expected credit loss&#8221; (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for calendar year 2023 for smaller reporting companies. The Company adopted this new guidance on January 1, 2023, and the adoption did not have a material impact on the Company's consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073297565088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Balance Sheet Detail</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Balance Sheet Detail</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Property and Equipment </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Research and development equipment</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (111)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accrued liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Accrued liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">External research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payroll related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213619424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Boston Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective August 1, 2021, the Company entered into a non-cancelable operating lease for its corporate headquarters located in Boston Massachusetts. This agreement had a six month term, and rental costs of approximately $3 per month prior to the application of certain rent concessions granted by the landlord in the amount of approximately $2<span style="white-space:pre-wrap;"> over the term of the lease.  </span>In December 2021, the Company signed an amendment to its corporate headquarters lease to extend the term until March 31, 2022 for rental costs of approximately $1<span style="white-space:pre-wrap;"> per month.  In February 2022, April 2022, August, 2022 and December, 2022 the Company signed amendments to extend the lease term until June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Prior to February 1, 2021, a non-cancelable operating lease was in effect as of February 1, 2020 which had a one-year term and rental costs of $21 per month prior to the application of certain rent concessions granted by the landlord in the amount of $32. Effective February 1, 2021, the Company was party to a non-cancelable operating lease for its corporate headquarters which had a six month term, and rental costs of approximately $3 per month prior to the application of certain rent concessions granted by the landlord in the amount of approximately $1 over the term of the lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">No assets and liabilities were recognized for the corporate headquarters leases at December 31, 2022 and 2021. Due to the short-term nature of the leases, the Company recognized lease payments as an expense on a straight-line basis over the remaining lease term. For the years ended December 31, 2022 and 2021, expense under the corporate headquarters leases in the aggregate was $16 and $48, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Lease in Korea:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">In May 2019, the Company entered into an operating lease for its new facility in Korea (the &#8220;Korea Lease&#8221;). The initial lease term was </span><span style="font-size:10pt;">five years</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">with an option to renew</span><span style="font-size:10pt;"> for an additional </span><span style="font-size:10pt;">five-year</span><span style="font-size:10pt;white-space:pre-wrap;"> term. The lease commenced on July 2, 2019 and was to expire on July 1, 2024.  On April 19, 2022, the Company terminated its Korea Lease effective April 30, 2022, at which time, the Company&#8217;s unamortized right-of-use asset and lease liabilities were fully amortized and extinguished with </span><span style="font-size:10pt;">no</span><span style="font-size:10pt;"> gain or loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The operating lease was subject to a deposit, base rent payments and additional charges for utilities and other common costs. For the years ended December 31, 2022 and 2021, the Company recorded non-cash expense of $8 and $24, respectively, related to the Korea Lease. During the year ended December 31, 2022 and 2021, the Company made cash payments of $11 and $32, for amounts included in the measurement of lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">License Agreement with Dong-A ST</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">On September 14, 2022, the Company and Dong-A, a related party, and greater than 5% shareholder, entered into the 2022 License Agreement, pursuant to which, subject to the conditions set forth therein, the Company ultimately received an exclusive global license (other than in the Republic of Korea) to two proprietary compounds for specified indications. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. Under the 2022 License Agreement, Dong-A will be eligible to receive (i) regulatory milestone payments of up to $178 million for DA-1726 and $138 million for DA-1241, dependent upon the achievement of specific regulatory developments; (ii) commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iii)&#160;single digit royalties on net sales received by the Company from the commercial sale of products covering DA-1241 or DA-1726. See Note 5, <i style="font-style:italic;">2022 License Agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, no milestone or royalty payments had been accrued as there were no potential milestones yet considered probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gemphire Contingent Value Rights Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">On December 30, 2019, the Company was party to a definitive merger agreement (the &#8220;2019 Merger&#8221;) with Gemphire Therapeutics, Inc. (&#8220;Gemphire&#8221;). In connection with the 2019 Merger, Gemphire entered into the Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with Grand Rapids Holders&#8217; Representative, LLC, as representative of Gemphire&#8217;s stockholders prior to the 2019 Merger (the &#8220;Holders&#8217; Representative&#8221;), and Computershare Inc. and Computershare Trust Company, N.A. as the rights agents (collectively, the &#8220;Rights Agent&#8221;). Under the CVR Agreement, which NeuroBo assumed in connection with the 2019 Merger, the holders of Gemphire shares at the time of the 2019 Merger (collectively, the &#8220;CVR Holders&#8221;) were entitled to receive 80% of the proceeds from the grant, sale, or transfer of rights to Gemcabene.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">On March 23, 2021, NeuroBo, the Holders&#8217; Representative, and the Rights Agent entered into the First Amendment to Contingent Value Rights Agreement (the &#8220;CVR Amendment&#8221;) to amend the CVR Agreement. Pursuant to the CVR Amendment, (i) the CVR Holders will continue to have the right to receive 80% of the proceeds from the grant, sale, or transfer of rights to Gemcabene as a treatment for cardiovascular conditions and (ii) the CVR Holders will now also receive 10% of the proceeds from the grant, sale, or transfer of rights to Gemcabene as a treatment for any indication outside of treating cardiometabolic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">As of the December 31, 2022 and 2021, no milestones had been accrued as there were no potential payments under the CVR Agreement or the CVR Amendment that were yet considered probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Pfizer License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Upon the close of the 2019 Merger, the exclusive license agreement with Pfizer&#160;Inc. (&#8220;Pfizer&#8221;) for the clinical product candidate Gemcabene (the &#8220;Pfizer Agreement&#8221;) was assumed by the Company. Under the Pfizer Agreement, in exchange for this worldwide exclusive right and license to certain patent rights to make, use, sell, offer for sale and import the clinical product Gemcabene, the Company has agreed to certain milestone and royalty payments on future sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company agreed to make milestone payments totaling up to $37&#160;million upon the achievement of certain milestones, including the first new drug application (or its foreign equivalent) in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of Gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales, as specified in the Pfizer Agreement, until the later of: (a) five (5) years after the first commercial sale in such country; (b) the expiration of all regulatory or data exclusivity for Gemcabene in such country; and (c) the expiration or abandonment of the last valid claim of the licensed patents, including any patent term extensions or supplemental protection certificates in such country (collectively, the Royalty Term). Under the Pfizer Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize Gemcabene.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Pfizer Agreement will expire upon expiration of the Royalty Term. On expiration (but not earlier termination), the Company will have a perpetual, exclusive, fully paid-up, royalty-free license under the licensed patent rights and related data to make, use, develop, commercialize, import and otherwise exploit the clinical product candidate Gemcabene. Either party may terminate the Pfizer Agreement for the other party&#8217;s material breach following a cure period or immediately upon certain insolvency events relating to the other party. Pfizer may immediately terminate the Pfizer Agreement in the event that (i) the Company or any of its affiliates or sublicenses contests or challenges, or supports or assists any third party to contest or challenge, Pfizer&#8217;s ownership of or rights in, or the validity, enforceability or scope of any of the patents licensed under the Pfizer Agreement or (ii) the Company or any of its affiliates or sublicensees fails to achieve the first commercial sale in at least one country by April 16, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Furthermore, upon termination of the Pfizer Agreement by Pfizer for any of the foregoing reasons, the Company grants Pfizer a non-exclusive, fully paid-up, royalty free, worldwide, transferrable, perpetual and irrevocable license to use any </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">intellectual property rights arising from the development or commercialization of Gemcabene by the Company and any trademarks identifying Gemcabene and agrees to transfer regulatory filings and approvals to Pfizer or permit Pfizer to cross-reference and rely on such regulatory filings and approvals for Gemcabene. The Company may terminate the Pfizer Agreement for convenience upon 90 days&#8217; written notice and payment of an early termination fee of $3.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As of December 31, 2022 and 2021, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the license agreement, and as such, no liabilities were recorded related to the Pfizer Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANA Merger Milestone Payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">On December&#160;31, 2020, the Company acquired 100% of ANA Therapeutics,&#160;Inc., a Delaware corporation (&#8220;ANA&#8221;), pursuant to an Agreement and Plan of Merger, dated December&#160;31, 2020 (the &#8220;2020 Merger Agreement&#8221; or &#8220;2020 Merger&#8221;). Pursuant to the 2020 Merger Agreement, following the closing of the 2020 Merger, the Company is obligated to pay milestone payments (each, a &#8220;Milestone Payment&#8221;) to certain persons identified in the 2020 Merger Agreement (each a &#8220;Stakeholder&#8221; and collectively, the &#8220;Stakeholders&#8221;) in the form, time and manner as set forth in the 2020 Merger Agreement, upon the achievement of the following milestone events set forth below by the Company or any of its affiliates (each, a &#8220;Milestone Event&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><div style="padding-left:3pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:91.69%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"/></tr><tr style="height:22.3pt;"><td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0pt 2pt;"><b style="font-weight:bold;">Milestone Event</b></p></td><td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 20.5pt 0pt 0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr style="height:9.55pt;"><td colspan="2" style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:9.55pt;margin:0pt;">First receipt of Marketing Approval (as defined in the 2020 Merger Agreement) from the FDA for any Niclosamide Product (as defined in the 2020 Merger Agreement)</p></td><td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;"> $</span></p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">45.0 million</p></td></tr><tr style="height:21.6pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Sales Milestones:</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 11pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.15pt;"><td colspan="2" style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Milestone Event &#8211; Worldwide Cumulative Net Sales of a Niclosamide Product</b></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.9pt;"><td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">equal to or greater than:</b></p></td><td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 19.5pt 0pt 0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr style="height:10.45pt;"><td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$500 million</p></td><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">9.0 million</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$1 billion</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">13.5 million</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$3 billion</p></td><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">36.0 million</p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$5 billion</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">72.0 million</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Additionally, pursuant to the 2020 Merger Agreement, the Company is obligated to pay <span style="color:#231f20;">a royalty of two and a half percent (</span><span style="color:#231f20;">2.5%</span><span style="color:#231f20;">) of annual worldwide net sales of each Niclosamide Product (as defined in the Merger Agreement) </span> (each such payment, a &#8220;Royalty Payment&#8221;) to the Stakeholders in the form, time and manner as set forth in the 2020 Merger Agreement, following the first commercial sale of each Niclosamide Product (as defined in the 2020 Merger Agreement) on a country-by-country and Niclosamide Product-by-Niclosamide Product basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">As of the December 31, 2022 and 2021, no Royalty Payments had been accrued as there were no potential milestones yet considered probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">YourChoice License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">In connection with the 2020 Merger, the Company assumed the license agreement between ANA and Your Choice Therapeutics, Inc. (the &#8220;YourChoice Agreement&#8221;). Prior to the 2020 Merger, YourChoice Therapeutics, Inc. granted to ANA, during the term of the YourChoice Agreement, an exclusive, worldwide, fee-bearing license derived from the licensed intellectual property throughout the world.  The fees due under the YourChoice Agreement include royalty payments of </span>0.5% of annual worldwide net sales of each Niclosamide Product (as defined in the 2020 Merger Agreement) and milestone payments in the aggregate of $19.5 million. The first milestone payment due is $5 million upon first receipt of Marketing Approval (as defined in the 2020 Merger Agreement) for the FDA for any Nicolsamide Product (as defined by the 2020 Merger Agreement), followed by sales milestones of $1 million, $1.5 million, $4 million, and $8 million if worldwide cumulative net sales of a Nicolsamide Product are equal or greater than $500 million, $1 billion, $3 billion, and $5<span style="white-space:pre-wrap;"> billion, respectively.  The term of the YourChoice Agreement will expire on the </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">expiration or invalidation of the last of the licensed patents under the YourChoice Agreement.  As of December 31 2022 and 2021, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the YourChoice Agreement, and as such, </span>no liabilities were recorded related to the YourChoice Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company does not expect that the resolution of these matters will have a material adverse effect on its financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213547856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dong-A ST License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementAbstract', window );"><strong>Dong-A ST License Agreement.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDisclosureTextBlock', window );">Dong-A ST License Agreement.</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Dong-A License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On September&#160;14, 2022, the Company and Dong-A entered into the&#160;2022 License Agreement, pursuant to which, the Company received an exclusive global license (except for the territory of the Republic of Korea and certain other jurisdictions) to two proprietary compounds for specified indications upon meeting certain financing milestones. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. The 2022 License Agreement also provides that the Company may develop DA-1241 for the treatment of T2D. Under the terms of the 2022 License Agreement, (i), the Company agreed to pay Dong-A an upfront payment to be settled with 2,200 shares of a new series of preferred stock designated as &#8220;Series&#160;A Convertible Preferred Stock&#8221;, par value $0.001 per share (the&#160;&#8220;Series&#160;A Preferred Stock<span style="font-style:italic;font-weight:bold;">&#8221;</span><span style="white-space:pre-wrap;">), upon completion of a financing (see Note 7 &#8211; Stockholder&#8217;s Equity).  </span><span style="background:#ffffff;">The Series A Preferred Stock issued in connection with the 2022 License Agreement was recorded as IPR&amp;D expense in the amount of </span><span style="background:#ffffff;">$8.2</span><span style="white-space:pre-wrap;background:#ffffff;"> million based on the fair market value of the Series A Preferred Stock.  The 2022 License Agreement did not include any processes  or activities constituting a &#8220;business&#8221; were acquired and since none of the rights underlying the Dong-A License Agreement had alternative future uses or had reached a stage of technological feasibility.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The term of the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either Dong-A or the Company may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within 60 days of notice of such breach; provided that if the breach cannot be cured within the <span style="-sec-ix-hidden:Hidden_8VHUHzuV5UqZVxVaa0LNCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60-day</span></span> period and the breaching party started to remedy the breach, if such breach is not cured within 90 days of receipt of written notice, (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a <span style="-sec-ix-hidden:Hidden_KYNGeI_ZfkuzqiJCYGB1Ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30-day</span></span> cure period in the case of a petition for bankruptcy), or (iii)&#160;in the event the Company had failed to complete the public offering as further described in Note 7 -Stockholders&#8217; Equity by December&#160;31, 2022 (or January&#160;31, 2023 under specified circumstances set forth in the 2022 License Agreement).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">None of the milestone or royalty payments under the 2022 License Agreement were triggered as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Shared Services Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">On September&#160;14, 2022, in conjunction with the Dong-A License Agreement, the Company entered into a shared services agreement with Dong-A (the&#160;&#8220;Shared Services Agreement&#8221;). The Shared Services Agreement provides that Dong-A may provide technical support, pre-clinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A will manufacture all of the Company&#8217;s clinical requirements of DA-1241 and DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Either party may terminate the Shared Services Agreement for the other party&#8217;s material breach that is not cured within </span><span style="font-size:10pt;">30 days</span><span style="font-size:10pt;"> of notice. Dong-A may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by the Company which is not cured within </span><span style="font-size:10pt;">30 days</span><span style="font-size:10pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;">As of December 31, 2022, the Company did not incur any research and development expenses under the Shared Services Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213787920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Beijing SL License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDisclosureAbstract', window );"><strong>License and Collaboration Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Beijing SL License Agreement </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Beijing SL License and Collaboration Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Upon the close of the 2019 Merger, the License and Collaboration Agreement (the &#8220;Beijing SL Agreement&#8221;) with Beijing SL Pharmaceutical Co., Ltd. (&#8220;Beijing SL&#8221;)(the &#8220;Beijing SL Agreement&#8221;) was assumed by the Company, pursuant to which the Company granted Beijing SL an exclusive royalty-bearing license to research, develop, manufacture and commercialize pharmaceutical products comprising, as an active ingredient, Gemcabene in mainland China, Hong Kong, Macau and Taiwan (each, a &#8220;region&#8221;, and collectively, the &#8220;Territory&#8221;). The terms of the Beijing SL Agreement include payments based upon achievement of milestones and royalties on net product sales. Under the Beijing SL Agreement, the Company has variable consideration in the form of milestone payments. As of December 31, 2022, no revenue under the Beijing SL Agreement has been recognized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Under the terms of the Beijing SL Agreement, Beijing SL will be responsible, at its expense, for developing and commercializing products containing Gemcabene (each, a &#8220;Licensed Product&#8221;) in the Territory, with certain assistance from the Company. To the extent mutually agreed to in writing, the Company and Beijing SL will collaborate on the Phase 3 clinical trial for homozygous familial hypercholesterolemia or other clinical trials with the Company as the sponsor designed to enroll patients both inside and outside the Territory (a &#8220;Global Study&#8221;), but Beijing SL will be responsible, at its expense, for the conduct of any Global Study to the extent solely in the Territory, subject to the Company&#8217;s final decision making authority, and the Company will be responsible, at its expense, for the conduct of any Global Study to the extent solely outside of the Territory. Under a territory development plan, the parties shall develop Licensed Products with respect to the Territory. Beijing SL will be responsible for development activities, including non-clinical and clinical studies directed at obtaining regulatory approval of the Licensed Product in the Territory.&#160;Beijing SL has agreed to use commercially reasonable efforts to commercialize the Licensed Products for each indication that receives regulatory approval in the Territory and shall prepare and present a commercialization plan that shall be subject to approval by the joint steering committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"><span style="line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;">Pursuant to the Beijing SL Agreement, Beijing SL was to make a non-refundable upfront gross payment of </span><span style="font-size:10pt;">$2.5</span><span style="font-size:10pt;">&#160;million to the Company within </span><span style="font-size:10pt;">45 days</span><span style="font-size:10pt;"> of the effective date of the Beijing SL Agreement; the upfront payment was received in October 2019 and such funds were fully expended prior to the close of 2019 Merger. Additionally, with respect to each Licensed Product, the Company is eligible to receive (i) payments for specified developmental and regulatory milestones (including submission of a new drug application to China&#8217;s National Medical Product Administration, dosing of the first patient in a phase 3 clinical trial in mainland China and regulatory approval for the first and each additional indication of a Licensed Product in the Territory) totaling up to </span><span style="font-size:10pt;">$6</span><span style="font-size:10pt;">&#160;million in the aggregate and (ii) payments for specified global net sales milestones of up to </span><span style="font-size:10pt;">$20</span><span style="font-size:10pt;"> million in the aggregate multiplied by the ratio of the net sales of a Licensed Product sold by Beijing SL in the Territory divided by the global net sales of a Licensed Product, which net sales milestone payments are payable once, upon the first achievement of such milestone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;">Beijing SL is also obligated to pay the Company tiered royalties ranging from the mid-teens to </span><span style="font-size:10pt;">twenty</span><span style="font-size:10pt;"> percent on the net sales of all Licensed Products in the Territory until the latest of (a) the date on which any applicable regulatory exclusivity with respect to such Licensed Product expires in such region, (b) the expiration or abandonment of the last valid patent claim or joint patent claim covering such Licensed Product in each region and (c) the fifth anniversary of the first commercial sale of such Licensed Product in such region (the &#8220;Royalty Term&#8221;). Future milestone payments under the Beijing SL Agreement, if any, are not expected to begin for at least </span><span style="font-size:10pt;">one year</span><span style="font-size:10pt;"> and will extend over a number of subsequent years. The Company cannot determine the date on which Beijing SL&#8217;s potential royalty payment obligations to the Company would expire because Beijing SL has not yet developed any Licensed Products under the Beijing SL Agreement and therefore the Company cannot at this time identify the date of the first commercial sale or the periods of any regulatory exclusivity or patent claims with respect to any Licensed Product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On a Licensed Product-by-Licensed Product and region-by-region basis upon the expiration of the Royalty Term, the license granted to Beijing SL shall be deemed perpetual, fully paid-up and royalty free with respect to such Licensed Product in such region. Either party may terminate the Agreement (x) with written notice in the event of the other party&#8217;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">addition, the Company may terminate the agreement in its entirety if Beijing SL or its affiliates or sublicensees commence a proceeding challenging the validity, enforceability or scope of any of the Company&#8217;s patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">To the extent rights granted to Beijing SL under the Beijing SL Agreement are controlled by the Company pursuant to the Pfizer Agreement, such rights are subject to the terms and conditions of such agreement with Pfizer, and Beijing SL has agreed to comply with such terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Beijing SL Agreement contemplates that Beijing SL and the Company shall, no later than twelve months prior to the anticipated date of the first commercial sale of a Licensed Product, if any, negotiate in good faith and execute a commercial supply agreement, pursuant to which Beijing SL shall purchase from the Company, and the Company shall use commercially reasonable efforts to supply, Gemcabene or Licensed Product for clinical or commercial purposes, as applicable, until manufacturing and regulatory transfers are complete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Each of the Company and Beijing SL has agreed to indemnify the other party against certain losses and expenses relating to the development or commercialization of a Licensed Product by the indemnifying party, the negligence or willful misconduct of the indemnifying party or its directors, officers, employees or agents or a breach of the indemnifying party&#8217;s representations, warranties or covenants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213619424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7.</b> S<b style="font-weight:bold;">tockholders&#8217; Equity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock when outstanding. The holders of the common stock are entitled to one<span style="white-space:pre-wrap;"> vote for each share of common stock held at all meetings of stockholders.  </span>Common stockholders are entitled to receive dividends at the sole discretion of the board of directors of the Company. There have been no<span style="white-space:pre-wrap;"> dividends declared on common stock to date as of December 31, 2022.  In the event of any liquidation, dissolution, or winding-up of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution post preferential distributions made to holders of the Company&#8217;s preferred stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;">The rights of the Series A Preferred Stock and Series B Preferred Stock (as defined further below), collectively, the &#8220;Preferred Stock&#8221;, while outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"><i style="font-style:italic;">Dividends.</i><b style="font-weight:bold;letter-spacing:4pt;"> </b>Holders of the Preferred Stock were entitled to<span style="letter-spacing:-0.6pt;"> </span>receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to&#173; common-stock basis) to the amount paid on shares of the common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"><i style="font-style:italic;">Voting Rights.</i><b style="font-weight:bold;"> T</b>he Preferred Stock had no voting rights. However, as long as any shares of Preferred Stock were outstanding, the Company could not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or amend its Certificate of Designation, (b) amend other charter documents in any manner that could have adversely affected any rights of the holders, (c) increase the number of authorized shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. &#160;In addition, the Series A Preferred Stock could have voted on any matter that authorized, created and/or issued any funded indebtedness (other than indebtedness already incurred); &#160;sold or transferred, other than in the ordinary course of its business, mortgaged, assigned, pledged, leased, granted a security interest in, or encumbered any of the Company&#8217;s assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"><i style="font-style:italic;">Liquidation.</i><b style="font-weight:bold;"> </b>The Preferred Stock while outstanding in the event of a liquidation,<span style="letter-spacing:2pt;"> </span>dissolution<span style="letter-spacing:2pt;"> </span>or<span style="letter-spacing:1.75pt;"> </span>winding-up<span style="letter-spacing:2pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>Company, collectively a &#8220;Liquidation&#8221;, had the following rights: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 0pt 36pt;"><i style="font-style:italic;">Series A Preferred Stock</i><b style="font-weight:bold;">: </b>Upon any Liquidation of the Company<span style="letter-spacing:-0.1pt;">,</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:-0.1pt;">whether</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:-0.1pt;">voluntary or</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:-0.1pt;">involuntary</span><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">,</span><span style="font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">after</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">the</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.1pt;">satisfaction</span><span style="letter-spacing:0.35pt;"> </span><span style="letter-spacing:-0.1pt;">in</span><span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">full</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.1pt;">of </span>the<span style="letter-spacing:-0.8pt;"> </span>debts<span style="letter-spacing:-0.8pt;"> </span>of<span style="letter-spacing:-0.8pt;"> </span>the<span style="letter-spacing:-0.75pt;"> </span>Company<span style="letter-spacing:-0.8pt;"> </span>and<span style="letter-spacing:-0.8pt;"> </span>the<span style="letter-spacing:-0.8pt;"> </span>payment<span style="letter-spacing:-0.75pt;"> </span>of<span style="letter-spacing:-0.8pt;"> </span>any<span style="letter-spacing:-0.8pt;"> </span>liquidation<span style="letter-spacing:-0.55pt;"> </span>preference<span style="letter-spacing:-0.4pt;"> </span>owed<span style="letter-spacing:-0.8pt;"> </span>to<span style="letter-spacing:-0.8pt;"> </span>the<span style="letter-spacing:-0.8pt;"> </span>holders of<span style="letter-spacing:-0.5pt;"> </span>shares of capital stock of the<span style="letter-spacing:-0.05pt;"> </span>Company ranking senior to the Series A<span style="letter-spacing:-0.1pt;"> </span>Preferred Stock upon liquidation, but before any<span style="letter-spacing:-0.45pt;"> </span>distribution or<span style="letter-spacing:-0.35pt;"> </span>payment out of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>assets of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>Company shall<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.25pt;"> </span>made to<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.65pt;"> </span>holders<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.5pt;"> any junior </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 6.25pt 6pt 36pt;"><span style="letter-spacing:-0.5pt;">securities, including common stock,</span><span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.5pt;"> </span>amount in<span style="letter-spacing:-0.5pt;"> </span>cash per share equal to the amount per share in cash payable to the holder if the shares of Series A Preferred Stock<span style="letter-spacing:-0.05pt;"> </span>were<span style="letter-spacing:-0.25pt;"> </span>converted immediately prior<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Liquidation into<span style="letter-spacing:-0.6pt;"> </span>shares<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.15pt;"> common stock</span><span style="letter-spacing:-0.1pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:4.5pt 19.25pt 6pt 36pt;"><i style="font-style:italic;">Series B Preferred Stock:</i> Upon any <span style="letter-spacing:1.35pt;">L</span>iquidation of the Company, whether voluntary or<span style="letter-spacing:-0.3pt;"> </span>involuntary,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> holder</span>s shall be<span style="letter-spacing:-0.05pt;"> </span>entitled to<span style="letter-spacing:-0.25pt;"> </span>receive out<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>assets, whether<span style="letter-spacing:-0.05pt;"> </span>capital or<span style="letter-spacing:-0.65pt;"> </span>surplus, of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.45pt;"> </span>Company the<span style="letter-spacing:-0.25pt;"> </span>same amount that a holder<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.5pt;"> common stock</span> would receive if<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.65pt;"> Series B </span>Preferred Stock were fully<span style="letter-spacing:-0.55pt;"> </span>converted (disregarding for<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>purposes any<span style="letter-spacing:-0.25pt;"> </span>conversion limitations hereunder) to common stock which amounts shall be<span style="letter-spacing:-0.25pt;"> </span>paid pari passu with all holders of<span style="letter-spacing:-0.2pt;"> </span>common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">Conversion.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">  </i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">  Series A Preferred Stock:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Automatic Conversion. On the first Trading Day after the Company obtains the stockholder approval, all outstanding shares of the Series A Preferred Stock would, without any further action by holders and whether or not any certificates representing such shares are surrendered to the Company or the Transfer Agent, automatically be converted into such number of shares of common stock as determined by dividing the stated value of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share by the conversion price then in effect (the &#8220;Automatic Conversion&#8221;). The conversion price upon an Automatic Conversion for the Series A Preferred Stock was equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Special Cash Payout Provisions:  Unless and until stockholder approval was obtained, the holder did not have the right to acquire shares of common stock issuable upon conversion of the Series A Preferred Stock, and the Company was not required to issue shares of common stock issuable upon conversion of the Series A Preferred Stock in excess of the Share Cap as defined (the "Conversion Restriction"). Notwithstanding the foregoing, if the Automatic Conversion had not occurred by the nine (9)-month anniversary of the original issuance date, the holder would have been entitled to submit a request to the Company for the conversion of all, but not less than all, of holder's shares of Series A Preferred Stock that were subject to the Conversion Restriction that would have exceeded the Share Cap; provided, that, in lieu of the Conversion Shares that would have otherwise been deliverable upon conversion but for the Conversion Restriction, the Company would have instead delivered to such holder for each share of common stock that would have been so otherwise delivered an amount of cash equal to the volume weighted average price (&#8220;VWAP&#8221;) per share of common stock on the trading day immediately preceding the date such request is made.  If the Company failed to make any required cash payment by the required deadline on any share of Series A Preferred Stock, then the holder thereof would have been entitled to receive cumulative cash dividends on each such share at a rate per annum of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.00%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> on the stated value ( "Default Cash Dividends''). Default Cash Dividends, if any, would have accumulated on a daily basis. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;">  Series B Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Conversions at Option of Holder. Each share of Series B Preferred Stock was convertible, at any time at the option of the holder thereof, into that number of shares of common stock (subject to certain limitations) determined by dividing the stated value of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share by the conversion price in effect. The conversion price for the Series B Preferred Stock was equal </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Fundamental Transaction.</b> If, at any time while shares of the Preferred Stock were outstanding, the Company, directly or indirectly, in one or more related transactions effected any merger or consolidation of the Company, the holder of the Preferred Stock would have had the right to receive, for each conversion share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction as defined, the number of shares of common stock of the successor or acquiring Company or of the Company, if it is the surviving Company, and any additional consideration (the "Alternate Consideration'') receivable as a result of such Fundamental Transaction by a holder of the number of shares of the common stock for which shares of the Preferred Stock would have been </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">convertible immediately prior to such Fundamental Transaction. If holders of the common stock were given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Preferred Stock would have been given the same choice as to the Alternate Consideration it would have received upon any conversion of shares of the Preferred Stock following such Fundamental Transaction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2022 Private Placement and Public Offering</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;">On September 14, 2022, the Company entered into a Securities Purchase Agreement with Dong-A (the &#8220;Dong-A Securities Purchase Agreement&#8221;). Pursuant to the Dong-A Securities Purchase Agreement, Dong-A agreed to purchase from the Company shares of its Series A Preferred Stock and warrants to purchase shares of its common stock, equivalent to those to be issued in the Qualified Financing (as hereafter defined), (collectively, the &#8220;Dong-A Financing&#8221;) concurrent with and contingent upon a qualified financing resulting in gross proceeds of at least $15 million exclusive of the Dong-A Financing (the &#8220;Qualified Financing&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On November 8, 2022, the Company closed on an underwritten public offering (the &#8220;2022 Public Offering&#8221;) of units with gross proceeds of approximately $17.3<span style="white-space:pre-wrap;"> million.  The underwritten public offering was comprised of (1) </span>3,147,003 Class A Units, priced at a public offering price of $3.00 per Class A Unit, with each Class A Unit consisting of one share of common stock, a Series A Warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock for a purchase price of $3.00 per share that expires on the one year anniversary following the initial exercise date and a Series B Warrant (the &#8220;Series B Warrants&#8221;) to purchase one share of common stock, for a purchase price of $3.00 per share that expires on the five year anniversary following the initial exercise date, and (2) 2,602,997 Class B Units, priced at a public offering price of $3.00 per Class B Unit, with each Class B Unit consisting of one share of Series B convertible preferred stock (the &#8220;Series B Preferred Stock&#8221;), convertible into one share of common stock, one Series A Warrant and one Series B Warrant. The Series A Warrants and the Series B Warrants, (collectively, the &#8220; Public Warrants&#8221;) were to only be exercisable upon stockholder approval, and each Warrant was to be exchangeable for one share of common stock for no<span style="white-space:pre-wrap;"> additional consideration.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The 2022 Public Offering met the definition of a Qualified Financing as defined by the Dong-A Securities Purchase Agreement; therefore, on November 8, 2022, the license under the Dong-A License Agreement became effective, and the Company issued to Dong-A 2,200 shares of Series A Preferred Stock<span style="white-space:pre-wrap;">.  In addition, the Company closed on the Dong-A Financing, and issued an additional </span>1,500 shares of Series A Preferred Stock, 5,000,000 warrants substantially similar to the Series A Warrants and 5,000,000 warrants substantially similar to the Series B Warrants (the &#8220;Dong-A Warrants&#8221;). The Company received gross proceeds in the amount of $15.0 million in connection with the Dong-A Financing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The Series A Preferred Stock was initially classified outside of stockholders&#8217; equity due to a contingent redemption feature if stockholder approval of the Series A Preferred Stock had not been secured within nine months from the date of issuance.  Stockholder approval was secured on December 22, 2022, at which time, all of the Series A Preferred Stock was automatically converted into </span>12,333,333<span style="white-space:pre-wrap;"> shares of common stock.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The Series B Convertible Preferred Stock was classified in permanent equity upon issuance as there were no other provisions precluding equity treatment.  As of December 31, 2022, all of the </span>2,602,997 shares of the Series B Preferred Stock had been converted into 2,602,997 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The public Warrants and the Dong-A Warrants (together, the &#8220;2022 Warrants&#8221;), upon their issuance were not exercisable unless and until stockholder approval was granted as required under Nasdaq rules.  The Company accounts for these warrants as a liability at fair value as certain provisions precluded equity accounting treatment for these instruments. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As the 2022 License Agreement and Dong-A Financing were both contingent and based on the terms of a Qualified Financing, the Company combined these two transactions along with the 2022 Public Offering (collectively, the &#8220;2022 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction&#8221;) when allocating gross consideration and issuance costs. The table below lists the aggregate consideration received by the Company in the 2022 Transaction:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consideration received</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Dong-A License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Acquired in-process research and development</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Dong-A Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Cash </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">2022 Public Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 17,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Cash </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">40,460 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The consideration received was first allocated to the 2022 Warrants at their fair value on the date of issuance.  The remainder of the consideration from the 2022 Transaction was allocated to the Series A Preferred Stock and Series B Preferred Stock (collectively the &#8220;Preferred Stock&#8221;), and to the common stock based on their relative fair values on the date of issuance. Issuance costs in connection with 2022 Transaction in the amount of </span>$3.6 million were allocated to each instrument based on the amount of consideration allocated to each instrument. Issuance costs attributed to the Warrants in the amount of $2.2<span style="white-space:pre-wrap;"> million were recorded as financing expense in the accompanying consolidated statements of operations and comprehensive loss.  The remainder of the issuance costs were recorded in additional paid-in capital. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The fair value of the Series A Preferred Stock was probability weighted for stockholder approval to convert to common stock.  In the approval scenario, the fair value was calculated using the underlying stock price multiplied by the number of common shares to be issued on conversion as adjusted for a </span>90% probability factor, a volatility rate of 101%, a discount for a lack of marketability of 11%, a risk free rate of 3.7% and a remaining term of 0.1<span style="white-space:pre-wrap;"> years.  In the non-approval scenario, the fair value was calculated using the underlying share price as adjusted for a </span>10% probability factor, a volatility rate of 107%, a risk free rate of 4.6% and a remaining term of 0.8 years. A credit risk factor was also used to discount the future value of the Series A Preferred Stock as applicable. The concluded fair value of the Series A Preferred Stock upon issuance was approximately $3,732 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The fair value of the Series B Preferred Stock was equal to the underlying common stock fair value as the shares were readily convertible at the time of issuance on a one-for-one basis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The fair value of the 2022 Warrants was determined using a Monte Carlo simulation. However, due to the cashless exercise provision of the 2022 Warrants rendering the exercise price effectively at zero, the calculated price per share of the Warrants was equal to that of a share of common stock prior to taking into account the probability factor of stockholder approval factor at 90%. The concluded fair value of the 2022 Warrants was $24.3 million in the aggregate on their issuance date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">October 2021 Registered Direct Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">On October&#160;1, 2021, the Company entered into a Securities Purchase Agreement (the &#8220;October 2021 Securities Purchase Agreement&#8221;) with several institutional investors for the purchase and sale in a registered direct offering of 4,307,693 shares of the Company&#8217;s common stock, at a purchase price of $3.25 per share for gross proceeds of approximately $14.0 million (the &#8220;October 2021 Registered Offering&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">The October 2021 Securities Purchase Agreement also provides for a concurrent private placement of warrants to purchase the Company&#8217;s common stock (the &#8220;October 2021 Warrants&#8221;) with the purchasers in the October 2021 Registered Offering. The October 2021 Warrants will be exercisable for up to an aggregate of </span><span style="font-size:10pt;">4,307,693</span><span style="font-size:10pt;"> shares of common stock. The October 2021 Warrants will have an exercise price of </span><span style="font-size:10pt;">$3.75</span><span style="font-size:10pt;"> per share, will be exercisable commencing </span><span style="font-size:10pt;">six months</span><span style="font-size:10pt;"> from the issuance date (the &#8220;Initial Exercise Date&#8221;), and will expire </span><span style="-sec-ix-hidden:Hidden_Inik_Nb_jUm6ajNMDQ5Ppg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span><span style="font-size:10pt;white-space:pre-wrap;"> and one-half years following the Initial Exercise Date.  The fair value of the 2021 Warrants was </span><span style="font-size:10pt;">$4.1</span><span style="font-size:10pt;"> million and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of </span><span style="font-size:10pt;">0.5%</span><span style="font-size:10pt;">; expected volatility of </span><span style="font-size:10pt;">80.0%</span><span style="font-size:10pt;">; expected life of </span><span style="font-size:10pt;">3.5</span><span style="font-size:10pt;"> years; expected dividend yield of </span><span style="font-size:10pt;">0%</span><span style="font-size:10pt;">; and the underlying traded stock price.&#160;The relative fair value attributable to the stock and warrants was </span><span style="font-size:10pt;">$9.8</span><span style="font-size:10pt;"> million and </span><span style="font-size:10pt;">$4.2</span><span style="font-size:10pt;white-space:pre-wrap;"> million, respectively.  The 2021 Warrants were classified in stockholders&#8217; equity as the number of shares were fixed and determinable, no cash settlement required and no other provisions precluding equity treatment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance costs in connection with the October 2021 Registered Direct Offering were $1.2 million which included cash commissions equal to $1.0 million and legal and other fees of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">2021 Private Placement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On January 21, 2021, the Company closed on a Securities Purchase Agreement (the &#8220;2021 Purchase Agreement&#8221;) with certain institutional and accredited investors, pursuant to which the Company, in a private placement (&#8220;2021 Private Placement&#8221;), agreed to issue and sell an aggregate of 2,500,000 shares of the Company&#8217;s common stock at a purchase price of $4.00 per share, and warrants to purchase an aggregate of 2,500,000 shares of the Company&#8217;s common stock (the &#8220;2021 Warrants&#8221;), resulting in total gross proceeds to the Company of $10.0 million, before deducting placement agent fees and offering expenses. The 2021 Warrants have an initial exercise price of $6.03 per share. The 2021 Warrants are exercisable beginning six months following the date of issuance and will expire <span style="-sec-ix-hidden:Hidden_STCOS7deHEiR00lPkfq1OA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> and one-half years following such date. The fair value of the 2021 Warrants was $7.5 million and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of 0.5%; expected volatility of 76.0%; expected life of 5.5 years; expected dividend yield of 0%; and the underlying traded stock price.&#160;The relative fair value attributable to the stock and warrants was $6.3 million and $3.7<span style="white-space:pre-wrap;"> million, respectively.  The 2021 Warrants were classified in stockholders&#8217; equity as the number of shares were fixed and determinable, no cash settlement required and no other provisions precluding equity treatment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance costs in connection with the 2021 Private Placement were $0.9 million which included cash commissions equal to $0.7 million and legal and other fees of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;">The following warrants were outstanding as of December 31, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:31.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants:</b></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Warrant Issuance</b></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">March 2017</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,800.00 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 2022</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">July 2018</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,602.50 </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2028</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">April 2020</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">375.00 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">January 2021</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,338</p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,338</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">180.90 </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">October 2021</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,597</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,597</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">112.50 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">November 2022 Series A</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,768,837</p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00 </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2023</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">November 2022 Series B</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">8,267,170</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2027</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15,264,242</p></td><td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">229,550</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The warrants outstanding as of December 31, 2022 are all exercisable.  In addition, the 2022 Warrants have a cashless exercise provision whereby </span>one warrant can be exchanged for one share of common stock for no additional consideration, which renders the $3.00 per share exercise price to be $0.00<span style="white-space:pre-wrap;">.  During the year ended December 31, 2022, </span>3,981,163 Series A Warrants and 2,482,830<span style="white-space:pre-wrap;"> Series B Warrants were exchanged for shares of the Company&#8217;s common stock.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213666624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Stock-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense was included in general and administrative as follows in the accompanying statements of comprehensive loss:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.64%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.53%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.58%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">In December 2019, in connection with the 2019 Merger, the Company assumed a previously adopted stock option plan (the &#8220;2018 Plan&#8221;) and adopted the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;). In addition, in November 2021, the Company adopted the 2021 Inducement Plan, and in December 2022, the Company adopted the 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;). The 2018 Plan, 2019 Plan, 2021 Inducement Plan and 2022 Plan provide for the grant of stock options, restricted stock and other equity awards of the Company's common stock to employees, officers, consultants, and directors.   On May 11, 2022, the Company terminated the 2018 Plan.  As of the date of termination, there were </span>no outstanding awards under the 2018 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Evergreen provision</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Under the 2022 Plan, the shares reserved automatically increase on January 1st&#160;of each year, for a period of not more than five years commencing on January 1, 2023 and ending on (and including) January 1, 2027,&#160;to an amount equal to the lesser of 5% of the common shares outstanding as of January 1, or a lesser amount as determined by the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On January 1, 2022, 35,549<span style="white-space:pre-wrap;"> shares were added to the 2019 Plan as a result of the evergreen provision associated with the 2019 Plan.  With the adoption of the 2022 Plan, </span>no additional shares may be added to or grants awarded from the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">As of December 31, 2022, 5,078,721, 33,333 and 15,938 shares were authorized under the 2022 Plan, the 2021 Inducement Plan, and 2019 Plan, respectively, prior to the issuance of any shares under these plans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options expire within a period of not more than ten years from the date of grant. During the years ended December 31, 2022 and 2021, 5,995 and 22,555 stock options were granted, respectively, to employees and directors with service conditions. The options granted with service conditions vest over a period between one year and three years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s stock option plan activity for the years ended December 31, 2022 and 2021 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (6,096)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (14,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and expected to vest at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options exercisable at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The weighted average fair value per share of options granted during the year ended December 31, 2022 and 2021 was $12.43 and $43.55, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s unvested stock options as of and for the year ended December 31, 2022: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nonvested at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.09</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.43</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64.90</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,112)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117.26</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nonvested as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.81</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, consultants and directors on the date of grant using the Black-Scholes option pricing model. The Company does not have history to support a calculation of volatility and expected term. As such, the Company has used a weighted-average volatility considering the volatilities of several guideline companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The assumed dividend yield was based on the Company&#8217;s expectation of not paying dividends in the foreseeable future. The average expected life of the options was determined based on the mid-point between the vesting date and the end of the contractual term according to the &#8220;simplified method&#8221; as described in SEC Staff Accounting Bulletin 110, or the contractual term in cases where the &#8220;simplified method&#8221; was precluded. The risk-free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant. The Company records forfeitures when they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Black-Scholes option-pricing model are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected stock price volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">80.7-85.2</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">79.0-80.4</p></td><td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected life of options (years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5.8</p></td><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk free interest rate </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.72-3.08</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.93-1.33</p></td><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2022 and 2021, 12,018 and 3,164 stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended December 31, 2022 and 2021 was $64.90 and $163.64, respectively During the years ended December 31, 2022 and 2021, 2,000 and 14,637 stock options were forfeited, respectively. During the year ended December 31, 2021, $364 was recognized in income by option holders as a result of stock option exercises. &#160;As of December 31, 2022, 5,091,500 shares in the aggregate were available for future issuance under the 2022 Plan and the 2021 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Unrecognized stock-based compensation cost for the stock options issued under the 2019 Plan, the 2021 Inducement Plan, and the 2022 Plan was $0.5 million as of December 31, 2022. The unrecognized stock-based expense is expected to be recognized over a weighted average period of 0.8<span style="white-space:pre-wrap;"> years.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213668288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Net Loss Per Share of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under the Company's stock option plan and warrants during the periods that these instruments are outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The basic net loss per share calculation includes the 2022 Warrants given that these instruments are exchangeable into common stock for which no additional consideration is required from the holder.  The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,498</p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 228,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229,550</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213666624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">10. Fair Value Measurements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity specific measurement. Fair value is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three level hierarchy:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Level&#160;1 inputs:</b><span style="white-space:pre-wrap;">  Unadjusted quoted prices for identical assets or liabilities in active markets;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Level&#160;2 inputs:</b><span style="white-space:pre-wrap;">  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Level&#160;3 inputs:</b><span style="white-space:pre-wrap;">  Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">There were no financial instruments measured on a recurring basis as of December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The fair value of financial instruments measured on a recurring basis as of December 31, 2022 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:39.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities at Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">The fair value of the 2022 Warrants was determined using a Monte Carlo simulation.  </span>This valuation technique involves a significant amount of estimation and judgment. In general, the assumptions used in calculating the fair value of the common stock warrant liability represent management&#8217;s best estimate, but the estimate involves inherent uncertainties and the application of significant management judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Input assumptions were as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of</b></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk free interest rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">3.9-4.6</p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Volatility </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">94-103</p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Remaining term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.0-5.0</p></td><td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Due to the cashless exercise provision of the 2022 Warrants rendering the exercise price effectively at zero, the calculated price per share of the 2022 Warrants was equal to that of a share of common stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The following table provides a roll-forward of the warrant liabilities measured at fair value for the year ended December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of 2022 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,295</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ONTN_FfUsEGhQ_nLCwdysw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,935)</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclass of warrant liabilities upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(5,564)</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213741296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">11. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The effective tax rate for the years ended December 31, 2022 and 2021 was zero percent. A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income tax (benefit) provision at federal statutory rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">State income tax, net of federal benefit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (26.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision to tax return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Section 382 limitation adjustment attributes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (225.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective tax rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Loss before provision for taxes for the years ended December 31, 2022 and 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before Income taxes:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (14,559)</p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (14,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 592</p></td><td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,967)</p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (15,284)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The components of income tax provision (benefit) consisted of the following for the years ended December 31, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax Provision (Benefit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Domestic</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Domestic</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,183</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,932)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (81)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,331</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (4,013)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (26,183)</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (148)</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Federal and state operating loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Foreign operating loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired intangibles </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized R&amp;D Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development credit carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">   <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance - Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (4,252)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (30,410)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance - Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (324)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax assets, net of valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net deferred tax assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">As of December 31, 2022 and 2021, the Company had deferred tax assets of approximately $4.4 million and $30.8 million, respectively. Realization of the deferred tax assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the deferred tax assets have been fully offset by a valuation allowance of $4.4 million and $30.8 million as of December 31, 2022 and 2021, respectively. U.S. deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">As of December 31, 2022 and 2021, the Company&#8217;s federal net operating loss carryforwards were approximately $1.5 million and $81.8 million, respectively. The Company had federal research credit carryforwards as of December 31, 2022 and 2021 of approximately $24 thousand and $1.0 million, respectively.<span style="white-space:pre-wrap;">  The Federal net operating losses were incurred after December 31, 2017 and therefore, will not expire.</span> As of December 31, 2022 and 2021, the Company had state net operating loss carryforwards of approximately $65 thousand and $42.6 million, respectively. The Company had state research credit carryforwards of $2 thousand and $0.6<span style="white-space:pre-wrap;"> million as of December 31, 2022 and 2021, respectively. The state net operating loss carryforwards and state research credit carryforwards will begin to expire in 2043, if not utilized.  Lastly, the Company had foreign net operating loss carryforwards of approximately </span>$0.7 million and $1.3 million as of December 31, 2022 and 2021, respectively. The foreign net operating loss carryforwards will begin to expire in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#8220;5-percent shareholders&#8221; increase their ownership, in the aggregate, by more than 50 percentage points over a 36<span style="font-family:'Cambria Math';">-</span>month testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization. As a result of the public stock offering and private placement offering during the fourth quarter of 2022, a Section 382 ownership change occurred with an annual limitation of $0. Because of the 2022 ownership change and corresponding limitation, approximately $99.0 million and $48.5 million of federal and state net operating loss carryforwards, respectively, were written off, with a corresponding offset to the Company's full valuation allowance. Additionally, approximately $1.2 million and $0.6 million of federal and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">state research credit carryforwards, respectively, were written off, with a corresponding offset to the Company's full valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December 31, 2022 and 2021, and as such, no interest or penalties were recorded to income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The Company&#8217;s corporate returns are subject to examination beginning with the 2018 tax year for federal and state jurisdictions, and beginning with the 2019 tax year for one foreign jurisdiction.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213763520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">12. Related Party Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:11pt;text-indent:-11pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Agreements with Dong-A</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">On September&#160;28, 2018, NeuroBo entered into a <span style="-sec-ix-hidden:Hidden_F7zo_zW-NUK53QFVdH_Apw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> year manufacturing and supply agreement with Dong-A, a greater than 5% shareholder,&#160;for the manufacturing and supply of NB-01 drug substance and placebos for the purpose of research and development to be used in Phase&#160;3 clinical trials (the &#8220;Manufacturing Agreement&#8221;). There were no manufacturing related costs under the Manufacturing Agreement for the years ended December 31, 2022 or 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Manufacturing Agreement will automatically terminate in the event that the license agreement with Dong-A is terminated for any reason. In addition, each of Dong-A and NeuroBo may terminate the Manufacturing Agreement (1)&#160;upon the material breach by the other party, if the breach is not cured within a specified number of days after receiving notice from the terminating party, or if the breach cannot reasonably be cured within such period and the breaching party has not started to remedy the breach within such period and diligently endeavored to cure the breach within a reasonable time thereafter, or (2)&#160;in the event that (i)&#160;the other party is the subject of a petition for bankruptcy, reorganization, or arrangement and the same is not dismissed within <span style="-sec-ix-hidden:Hidden_2TEjfFmoakSOFBCUgn6ldg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span></span> days thereof, (ii)&#160;a receiver or trustee is appointed for all or a substantial portion of the assets of the other party, or (iii)&#160;the other party makes an assignment for the benefit of its creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;margin:14pt 0pt 0pt 0pt;"><span style="font-size:10pt;">On June 7, 2020, the Company entered into a manufacturing and supply agreement (the &#8220;Manufacturing and Supply Agreement&#8221;) with Dong-A for the manufacturing and supply of NB-02 drug product and placebo for the purpose of research and development of NB-02, including but not limited to, the use in the first NB-02 human clinical trial to be conducted by the Company. Under the terms of the Manufacturing and Supply Agreement, upon receipt of a purchase order from the Company no later than </span><span style="font-size:10pt;">270 days</span><span style="font-size:10pt;"> prior to the requested delivery date, Dong-A has agreed to produce for the Company tablets of the NB-02 drug substance and placebos at a specified supply price. The Company is obligated to manufacture, or have manufactured, and supply to Dong-A the active pharmaceutical ingredients which are necessary to manufacture the NB-02 drug product. The Manufacturing and Supply Agreement has a </span><span style="-sec-ix-hidden:Hidden_Y_VNuVMUj02pKiVqh9023w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-size:10pt;"> year term, subject to earlier termination under certain circumstances.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213612128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Defined Contribution Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-weight:bold;">13. Defined Contribution Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background:#ffffff;">The Company adopted a 401(k) defined contribution plan in November 2018, effective as of January 1, 2019, for all employees over age&#160;</span><span style="background:#ffffff;">21</span><span style="background:#ffffff;">. Employees can defer up to </span><span style="background:#ffffff;">90%</span><span style="background:#ffffff;"> of their compensation through payroll withholdings into the plan subject to federal law limits. Discretionary employer matches vest over a </span><span style="-sec-ix-hidden:Hidden_DPeIVkG-okWzbfTbv-bZXQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">six</span></span><span style="background:#ffffff;">-year period beginning on the second anniversary of an employee&#8217;s date of hire. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are </span><span style="background:#ffffff;">100%</span><span style="background:#ffffff;"> vested upon contribution. </span><span style="background:#ffffff;">No</span><span style="background:#ffffff;"> matching contributions were made during the years ended December 31, 2022 and 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213556032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. Subsequent Events </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Since December 31, 2022, 345,333 Series A Warrants and 1,395,333<span style="white-space:pre-wrap;"> Series B Warrants were exchanged for shares of the Company&#8217;s common stock.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210019920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is principally held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of December 31, 2022, the Company had deposits in excess of federally insured amounts by $32.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Supplier Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">On September 14, 2022, the Company entered into an exclusive license agreement (the &#8220;2022 License Agreement&#8221;) with Dong-A ST Co., Ltd. (&#8220;Dong-A&#8221;), which requires Dong-A to be the sole manufacturer for the production of DA-1241 and DA-1726.  </span>If any issues arise in the manufacturing and the Company is unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, the Company may not be able to complete development of DA-1241 or DA-1726.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. <span style="white-space:pre-wrap;background:#ffffff;">The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.  </span>See Note 10 - <i style="font-style:italic;">Fair Value Measurements</i>.  <span style="white-space:pre-wrap;background:#ffffff;">  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_WarrantLiabilitiesPolicyPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Warrant Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">The Company accounts for its warrants as liabilities at fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities are recognized as a fair value change in warrant liabilities in the consolidated statements of operations and comprehensive loss and as an operating item in the statement of cash flows.<span style="font-size:12pt;"> &#160;</span>Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations and comprehensive loss. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, <i style="font-style:italic;">Research and Development</i>. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company includes costs to acquire or in-license product candidates in acquired in-process research and development expenses (&#8220;IPR&amp;D&#8221;). When the Company acquires the right to develop and commercialize a new product candidate, any up-front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as acquired in-process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">The Company utilizes the liability method of accounting for income taxes as required by ASC 740, <i style="font-style:italic;">Income Taxes</i>. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, <i style="font-style:italic;">Compensation&#160;&#8212; Stock Compensation</i> (&#8220;ASC 718&#8221;). Accordingly, compensation costs related to equity instruments granted are recognized at the grant-date fair value. The Company records forfeitures when they occur. Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718 using a grant date fair value approach. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">The Company accounts for leases under Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02,&#160;<i style="font-style:italic;">Leases</i> (Topic 842)&#160;(&#8220;ASU 2016-02&#8221;). The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company has recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company&#8217;s&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, the Company recognizes lease payments as an expense on a straight-line basis over the remaining lease term.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Property&#160;and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from <span style="-sec-ix-hidden:Hidden_FyBBTxlXGEGwh1t7bmaxpQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>&#160;to five years. Tangible assets acquired for research and development activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Foreign Currency Translation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">The foreign subsidiary uses the South Korean Won (KRW) as its functional currency. The Company translates the assets and liabilities of its foreign operation into U.S. dollars based on the rates of exchange in effect as of the transaction date. The resulting adjustments from the translation process are included in accumulated other comprehensive (loss) income in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Certain transactions of the Company are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PatentCostPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Patent Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;">Comprehensive loss is comprised of net loss and other comprehensive income or loss. Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. Comprehensive loss currently consists of net loss and changes in foreign currency translation adjustments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its business in one operating segment, which is principally the business of development and commercialization of therapeutics.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background:#ffffff;">In June 2016, the FASB issued ASU 2016-13,&#160;</span><i style="font-style:italic;">&#8220;Financial Instruments &#8211; Credit Losses&#8221;</i>. The ASU sets forth a &#8220;current expected credit loss&#8221; (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for calendar year 2023 for smaller reporting companies. The Company adopted this new guidance on January 1, 2023, and the adoption did not have a material impact on the Company's consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PatentCostPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PatentCostPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_WarrantLiabilitiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_WarrantLiabilitiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213565664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td><td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Research and development equipment</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Office equipment</p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 63</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (111)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">External research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Payroll related</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,301</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073297630608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nrbo_AnaTherapeuticsInc.AssetAcquisitionMember', window );">ANA Merger</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock', window );">Schedule of milestone events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><div style="padding-left:3pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:91.69%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"/></tr><tr style="height:22.3pt;"><td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0pt 2pt;"><b style="font-weight:bold;">Milestone Event</b></p></td><td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 20.5pt 0pt 0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr style="height:9.55pt;"><td colspan="2" style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:9.55pt;margin:0pt;">First receipt of Marketing Approval (as defined in the 2020 Merger Agreement) from the FDA for any Niclosamide Product (as defined in the 2020 Merger Agreement)</p></td><td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;"> $</span></p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">45.0 million</p></td></tr><tr style="height:21.6pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Sales Milestones:</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 11pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.15pt;"><td colspan="2" style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Milestone Event &#8211; Worldwide Cumulative Net Sales of a Niclosamide Product</b></p></td><td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.9pt;"><td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">equal to or greater than:</b></p></td><td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 19.5pt 0pt 0pt;"><b style="font-weight:bold;">Milestone Payment</b></p></td></tr><tr style="height:10.45pt;"><td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$500 million</p></td><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"><span style="font-size:8.5pt;">$</span></p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">9.0 million</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$1 billion</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">13.5 million</p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$3 billion</p></td><td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">36.0 million</p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">$5 billion</p></td><td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;">$</p></td><td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;">72.0 million</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future milestone payments to be paid up on achieving of milestone events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nrbo_AnaTherapeuticsInc.AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nrbo_AnaTherapeuticsInc.AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213804160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:31.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Warrants:</b></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Warrant Issuance</b></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">March 2017</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">7,800.00 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 2022</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">July 2018</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5,602.50 </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2028</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">April 2020</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,252</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">375.00 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">January 2021</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,338</p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,338</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">180.90 </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">July 2026</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">October 2021</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,597</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,597</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">112.50 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">April 2025</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">November 2022 Series A</p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">6,768,837</p></td><td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00 </p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2023</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">November 2022 Series B</p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">8,267,170</p></td><td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00 </p></td><td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2027</p></td></tr><tr><td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">15,264,242</p></td><td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">229,550</p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock', window );">Schedule of consideration Received for issuance of equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Consideration received</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Dong-A License Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 8,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Acquired in-process research and development</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Dong-A Financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 15,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Cash </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">2022 Public Offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"> 17,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;">Cash </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;">40,460 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of consideration received for issue of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073214377632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense was included in general and administrative as follows in the accompanying statements of comprehensive loss:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.64%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.53%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.58%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:66.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 854</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 662</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option plan activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (6,096)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (14,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Exercised </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested and expected to vest at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Options exercisable at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 146.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of unvested stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The following table summarizes the Company&#8217;s unvested stock options as of and for the year ended December 31, 2022: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nonvested at January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.09</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Granted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.43</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64.90</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited/Cancelled </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,112)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 117.26</p></td></tr><tr><td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Nonvested as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.81</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black Scholes option-pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected stock price volatility </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">80.7-85.2</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">79.0-80.4</p></td><td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected life of options (years)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5-5.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">5.8</p></td><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Expected dividend yield </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Risk free interest rate </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">1.72-3.08</p></td><td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">0.93-1.33</p></td><td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073213573584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential common shares not considered in computation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,493</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,498</p></td></tr><tr><td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 228,235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 229,550</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209131808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of financial instruments measured on recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;width:39.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total liabilities at Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"><span style="margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock', window );">Schedule of a roll-forward of the warrant liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of 2022 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,295</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="-sec-ix-hidden:Hidden_ONTN_FfUsEGhQ_nLCwdysw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in fair value of warrant liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,935)</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reclass of warrant liabilities upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(5,564)</p></td></tr><tr><td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Balance at end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,796</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a roll-forward of the warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209930512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of statutory federal income tax rate to the provision (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Income tax (benefit) provision at federal statutory rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">State income tax, net of federal benefit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (26.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Provision to tax return</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Transaction costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Section 382 limitation adjustment attributes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (225.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Effective tax rate </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss before provision for taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">Loss before provision for taxes for the years ended December 31, 2022 and 2021 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Loss before Income taxes:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (14,559)</p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (14,954)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 592</p></td><td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,967)</p></td><td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (15,284)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax provision (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;">The components of income tax provision (benefit) consisted of the following for the years ended December 31, 2022 and 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Tax Provision (Benefit):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Domestic</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total current tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Domestic</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,183</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,932)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">   Foreign</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 148</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (81)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,331</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (4,013)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (26,183)</p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Change in valuation allowance - Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (148)</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total tax provision (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Federal and state operating loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,904</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Foreign operating loss carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Acquired intangibles </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,683</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Capitalized R&amp;D Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Research and development credit carryforwards </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,483</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">   <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance - Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (4,252)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (30,410)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Valuation allowance - Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (176)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (324)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Total deferred tax assets, net of valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">ROU asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (18)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Net deferred tax assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209217920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, ratio</a></td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,364<span></span>
</td>
<td class="nump">$ 16,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (95,795)<span></span>
</td>
<td class="num">$ (81,828)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209262288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Concentration of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DepositsInExcessOfFederallyInsuredAmounts', window );">Deposits in excess of federally insured amounts</a></td>
<td class="nump">$ 32,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DepositsInExcessOfFederallyInsuredAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to deposits in excess of federally insured amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DepositsInExcessOfFederallyInsuredAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210234512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Detail - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and development equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210672048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Detail - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Balance Sheet Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_AccruedOtherResearchAndDevelopmentExpenses', window );">External research and development expenses</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll related</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">$ 1,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_AccruedOtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_AccruedOtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073205383648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Leases - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>Feb. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member', window );">DA-1726 | Dong-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member', window );">DA-1241 | Dong-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to renew</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain or loss of extinguished unamortized right-of-use asset and lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Non-cash expense related to Korea lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nrbo_HeadquartersInBostonLeaseMember', window );">Head Quarters in Boston Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LesseeMonthlyOperatingLeaseCost', window );">Monthly rental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LesseeOperatingLeaseIncentiveFromLessor', window );">Rent concessions granted by the landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LesseeMonthlyOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LesseeMonthlyOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LesseeOperatingLeaseIncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the operating lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LesseeOperatingLeaseIncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nrbo_HeadquartersInBostonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nrbo_HeadquartersInBostonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073205251760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - ANA Merger Milestone Payment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PercentageOfRoyaltyPayments', window );">Percentage of royalty payments</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_RoyaltyPaymentAccrued', window );">Amount of royalty payments accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=nrbo_AnaTherapeuticsInc.AssetAcquisitionMember', window );">ANA Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired', window );">Ownership acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThan500MillionMember', window );">500 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_InitialMilestonePayment', window );">Milestone Payment</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanOneBillionMember', window );">1 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_InitialMilestonePayment', window );">Milestone Payment</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanThreeBillionMember', window );">3 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_InitialMilestonePayment', window );">Milestone Payment</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanFiveBillionMember', window );">5 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_InitialMilestonePayment', window );">Milestone Payment</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=nrbo_FirstAmendmentToOriginalCvrAgreementMember', window );">First Amendment to Original CVR Agreement | ANA Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_InitialMilestonePayment', window );">Milestone Payment</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_InitialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of initial milestone payment to be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_InitialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PercentageOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percent of annual worldwide income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PercentageOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_RoyaltyPaymentAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to royalty payments accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_RoyaltyPaymentAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_SalesBasedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of mile stone payments to be made based on sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_SalesBasedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=nrbo_AnaTherapeuticsInc.AssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=nrbo_AnaTherapeuticsInc.AssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThan500MillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThan500MillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanOneBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanOneBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanThreeBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanThreeBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanFiveBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nrbo_CumulativeNetSalesMoreThanFiveBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nrbo_FirstAmendmentToOriginalCvrAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nrbo_FirstAmendmentToOriginalCvrAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210174672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PercentageOfRoyaltyPayments', window );">Percentage of royalty payments</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=nrbo_TierOneNetSalesMilestoneMember', window );">Tier One Net Sales Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones', window );">Payments for specified global net sales milestones</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=nrbo_TierTwoNetSalesMilestoneMember', window );">Tier Two Net Sales Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones', window );">Payments for specified global net sales milestones</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=nrbo_TierThreeNetSalesMilestoneMember', window );">Tier Three Net Sales Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones', window );">Payments for specified global net sales milestones</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=nrbo_TierFourNetSalesMilestoneMember', window );">Tier Four Net Sales Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_SalesBasedMilestonePayment', window );">Sales based milestone payment</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones', window );">Payments for specified global net sales milestones</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nrbo_YourchoiceTherapeuticsInc.Member', window );">YourChoice | License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_MilestonesOrRoyaltyPaymentsTriggered', window );">Milestones or royalty payments triggered</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_RoyaltyAndMilestonePaymentsDue', window );">Royalty and milestone payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PercentageOfRoyaltyPayments', window );">Percentage of royalty payments</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nrbo_YourchoiceTherapeuticsInc.Member', window );">YourChoice | License Agreements | Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_RoyaltyAndMilestonePaymentsDue', window );">Royalty and milestone payment due</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nrbo_PfizerInc.Member', window );">Pfizer, Inc. | License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfYearsAfterFirstSaleOccurs', window );">Number of years after the first commercial sale</a></td>
<td class="text">five<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_MilestonesOrRoyaltyPaymentsTriggered', window );">Milestones or royalty payments triggered</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseTerminationNoticePeriod', window );">Notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementEarlyTerminationFee', window );">Termination fee</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nrbo_PfizerInc.Member', window );">Pfizer, Inc. | License Agreements | Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ContingentLiability', window );">Potential payments upon achievement of certain milestones</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents a contingent liability to make payments if certain conditions are achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementEarlyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of early termination fee payable on termination of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementEarlyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for which the entity inform for the termination of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_MilestonesOrRoyaltyPaymentsTriggered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to milestone or royalty payments triggered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_MilestonesOrRoyaltyPaymentsTriggered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfYearsAfterFirstSaleOccurs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to number of years after the first sale occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfYearsAfterFirstSaleOccurs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to payments for specified global net sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PercentageOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percent of annual worldwide income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PercentageOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_RoyaltyAndMilestonePaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty and milestone payment due under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_RoyaltyAndMilestonePaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_SalesBasedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of mile stone payments to be made based on sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_SalesBasedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=nrbo_TierOneNetSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=nrbo_TierOneNetSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=nrbo_TierTwoNetSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=nrbo_TierTwoNetSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=nrbo_TierThreeNetSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=nrbo_TierThreeNetSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=nrbo_TierFourNetSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=nrbo_TierFourNetSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nrbo_YourchoiceTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nrbo_YourchoiceTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=nrbo_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=nrbo_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nrbo_PfizerInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nrbo_PfizerInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073205388240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 23, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Mergers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_MilestonesAccrued', window );">Amount of milestones accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrbo_OriginalCvrAgreementMember', window );">Original CVR Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Mergers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights', window );">Percentage of proceeds from the grant, sale, or transfer of rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_MilestonesAccrued', window );">Amount of milestones accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_MilestonesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to milestones accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_MilestonesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to percentage of proceeds from grant sale or transfer of rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_OriginalCvrAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_OriginalCvrAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210236240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - License Agreement with Dong-A ST (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_RoyaltyPaymentAccrued', window );">Amount of royalty payments accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrbo_LicenseAgreementMember', window );">Dong A ST License Agreement | Dong-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement', window );">Number of proprietary compounds in a license | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member', window );">DA-1726 | Dong-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member', window );">DA-1241 | Dong-A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of Proprietary compounds to be received by the company in a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_RoyaltyPaymentAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to royalty payments accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_RoyaltyPaymentAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073204649296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dong-A ST License Agreement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">IPR&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_MilestonesAccrued', window );">Amount of milestones accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrbo_DongaStCoLtdLicenseAgreementMember', window );">DongA ST Co LTD License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PeriodForFailToCureBreachMayTerminateAgreement', window );">Period for failing to cure the beach, the agreement may get terminated</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_CurePeriodForBreachingParty', window );">Cure period for beaching party if cannot be cured within the 60-day period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_CurePeriodForPetitionForBankruptcy', window );">Cure period for petition for bankruptcy</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement', window );">Number of proprietary compounds in a license | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrbo_SharedServicesAgreementMember', window );">Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PeriodForFailToCureBreachMayTerminateAgreement', window );">Period for failing to cure the beach, the agreement may get terminated</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PeriodForTerminationNotice', window );">Period for termination notice when material breach not cured</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock | DongA ST Co LTD License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues', window );">Shares to be issued for upfront payment made to a related party | shares</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible Preferred Stock, Par Value (in dollar per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Value of shares and warrants issued to purchase common stock</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | DongA ST Co LTD License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">IPR&amp;D expense</a></td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of convertible preferred stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_CurePeriodForBreachingParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cure period for beaching party if cannot be cured within the 60-day period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_CurePeriodForBreachingParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_CurePeriodForPetitionForBankruptcy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cure period for petition for bankruptcy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_CurePeriodForPetitionForBankruptcy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_MilestonesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to milestones accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_MilestonesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of Proprietary compounds to be received by the company in a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PeriodForFailToCureBreachMayTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for failing to cure the beach, the agreement may get terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PeriodForFailToCureBreachMayTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PeriodForTerminationNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for petition for termination notice for the other party's material breach that is not cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PeriodForTerminationNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_DongaStCoLtdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_DongaStCoLtdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_SharedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_SharedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209264400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Beijing SL License Agreement - Beijing (Details) - License Agreement with Beijing SL - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementUpfrontPaymentToBeReceived', window );">Upfront payment to be received</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid', window );">Period from effective date within which upfront gross payment to be paid</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived', window );">Global net sales milestone payment to be received</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment', window );">Minimum expected period to begin future installment payment</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrbo_LicenseAgreementWithBeijingSLMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate', window );">Clinical supply agreement execution period from effective date</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period over which the entity will execute the clinical supply from effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of threshold global net sales milestone payments eligible to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementUpfrontPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementUpfrontPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected period to begin future milestone payments as decided in the terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PercentageOfRoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty to be paid on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PercentageOfRoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from effective date within which upfront gross payment to be paid under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_LicenseAgreementWithBeijingSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_LicenseAgreementWithBeijingSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073200934784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 21, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Vote / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair market value of warrant | $</a></td>
<td class="nump">$ 24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember', window );">Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfCommonStockIssuedPerUnit', window );">Number of common stock per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember', window );">Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfCommonStockIssuedPerUnit', window );">Number of common stock per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_ClassUnitsMember', window );">Class A Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfCommonStockIssuedPerUnit', window );">Number of common stock per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,147,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_ClassBUnitsMember', window );">Class B Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfCommonStockIssuedPerUnit', window );">Number of common stock per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit', window );">Number of Series B Convertible Preferred Stock per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_ClassBUnitsMember', window );">Class B Units [Member] | Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_ClassBUnitsMember', window );">Class B Units [Member] | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockStatedValuePerShare', window );">Stated value per share | $ / shares</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Relative fair value attributable to the warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockStatedValuePerShare', window );">Stated value per share | $ / shares</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock (in shares)</a></td>
<td class="nump">2,602,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockConvertedDuringPeriodShares', window );">Shares converted into common stock</a></td>
<td class="nump">2,602,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_RegisteredDirectOfferingMember', window );">October 2021 Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,307,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering shares (Per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,307,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable', window );">Period from issuance date the warrants become exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair market value of warrant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued', window );">Relative fair value attributable to the stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Relative fair value attributable to the warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Cash commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Legal and other fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering shares (Per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair market value of warrant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued', window );">Relative fair value attributable to the stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Relative fair value attributable to the warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Cash commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Legal and other fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_PublicOfferingMember', window );">Public Offering | Series A Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_CommonStockVotingRightsPerShare', window );">Common stock, vote per share | Vote / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockAbstract', window );"><strong>Dividends Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_CumulativeDividendsDeclared', window );">Dividends declared | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_CommonStockVotingRightsPerShare', window );">Common stock, vote per share | Vote / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,602,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract', window );"><strong>Voting Rights</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_CommonStockVotingRightsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the voting rights per share for common stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_CommonStockVotingRightsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_CumulativeDividendsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends declared.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_CumulativeDividendsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfCommonStockIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common stock per units issued under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfCommonStockIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of Series B Convertible Preferred Stock per units issued under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period from issuance date from which the warrants become exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock issued along with warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_StockConvertedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted into common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_StockConvertedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrbo_ClassUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrbo_ClassUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrbo_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrbo_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrbo_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrbo_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073200925456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity - Aggregate Consideration Received (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 40,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_StockIssuanceCost', window );">Stock Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair market value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_WarrantsIssuanceCost', window );">Warrants Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Scenario, Stockholder Non Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockFairValuePerShare', window );">Fair value per share of preferred stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Probability factor | Scenario, Stockholder Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Probability factor | Scenario, Stockholder Non Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Volatility rate | Scenario, Stockholder Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Volatility rate | Scenario, Stockholder Non Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Discount for a lack of marketability | Scenario, Stockholder Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Risk free rate | Scenario, Stockholder Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Risk free rate | Scenario, Stockholder Non Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Remaining term | Scenario, Stockholder Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock | Remaining term | Scenario, Stockholder Non Approval to Convert Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PreferredStockMeasurementInput', window );">Preferred Stock, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrbo_DongaStCoLtdLicenseAgreementMember', window );">DongA ST Co LTD License agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrbo_SecuritiesPurchaseAgreementMember', window );">Dong-A Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_PublicOfferingMember', window );">2022 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PreferredStockFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value per share of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PreferredStockFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PreferredStockMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PreferredStockMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_StockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_StockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_WarrantsIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_WarrantsIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=nrbo_MeasurementInputProbabilityFactorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=nrbo_MeasurementInputProbabilityFactorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=nrbo_ScenarioStockholderApprovalToConvertCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=nrbo_ScenarioStockholderApprovalToConvertCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_DongaStCoLtdLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_DongaStCoLtdLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrbo_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073205271840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">15,264,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice7800.00Member', window );">$7800.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 7,800.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice5602.50Member', window );">$5,602.50</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 5,602.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice375.00Member', window );">$375.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 375.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice180.90Member', window );">$180.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">83,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 180.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice112.50Member', window );">$112.50</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">143,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 112.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesWarrantExercisePrice3.00Member', window );">$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">6,768,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesBWarrantExercisePrice3.00Member', window );">$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">8,267,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesAndSeriesBWarrantsMember', window );">November 2022 Series A and B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice7800.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice7800.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice5602.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice5602.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice375.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice375.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice180.90Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice180.90Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice112.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_WarrantsExercisePrice112.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesWarrantExercisePrice3.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesWarrantExercisePrice3.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesBWarrantExercisePrice3.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesBWarrantExercisePrice3.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesAndSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesAndSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073204618000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity - Warrants - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 08, 2022</div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Consideration received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesAndSeriesBWarrantsMember', window );">November 2022 Series A and B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged', window );">Number of warrants exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember', window );">Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfWarrantsExercised', window );">Number of warrants exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,981,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember', window );">Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants per unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfWarrantsExercised', window );">Number of warrants exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,482,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesBWarrantExercisePrice3.00Member', window );">November 2022 Series B Warrant Exercise Price 3.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exchanged for each of securities called by warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesAndSeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesAndSeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesBWarrantExercisePrice3.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_November2022SeriesBWarrantExercisePrice3.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073205235424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Remaining nonvested options</a></td>
<td class="nump">18,590<span></span>
</td>
<td class="nump">25,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073208430544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">5,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options granted</a></td>
<td class="nump">$ 12.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_StockPlan2018Member', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_StockPlan2019Member', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">15,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">36,493<span></span>
</td>
<td class="nump">32,498<span></span>
</td>
<td class="nump">30,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Number, Beginning Balance (in shares)</a></td>
<td class="nump">32,498<span></span>
</td>
<td class="nump">30,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">5,995<span></span>
</td>
<td class="nump">22,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,096)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(14,637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="nump">36,493<span></span>
</td>
<td class="nump">32,498<span></span>
</td>
<td class="nump">30,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">36,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable (in share)</a></td>
<td class="nump">17,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 119.72<span></span>
</td>
<td class="nump">$ 108.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">17.83<span></span>
</td>
<td class="nump">67.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in dollars per share)</a></td>
<td class="nump">181.20<span></span>
</td>
<td class="nump">57.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</a></td>
<td class="nump">99.62<span></span>
</td>
<td class="nump">$ 119.72<span></span>
</td>
<td class="nump">$ 108.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">99.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable (in dollars per share)</a></td>
<td class="nump">$ 146.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term (years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable (years)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options granted</a></td>
<td class="nump">$ 12.43<span></span>
</td>
<td class="nump">$ 43.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrbo_StockPlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrbo_StockPlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrbo_StockPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrbo_StockPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073204642048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Unvested stock options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Nonvested Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested, Beginning Balance | shares</a></td>
<td class="nump">25,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">5,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested | shares</a></td>
<td class="num">(12,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited/Cancelled | shares</a></td>
<td class="num">(1,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested, Ending Balance | shares</a></td>
<td class="nump">18,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Nonvested, Weighted Average</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 59.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options granted | $ / shares</a></td>
<td class="nump">12.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options vested | $ / shares</a></td>
<td class="nump">64.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options forfeited | $ / shares</a></td>
<td class="nump">117.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, Ending Balance | $ / shares</a></td>
<td class="nump">$ 36.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209998448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">80.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">85.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">3.08%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073205345360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Evergreen provision (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Remaining nonvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,590<span></span>
</td>
<td class="nump">25,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited, nonvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_InducementPlanMember', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually', window );">Period of automatic increase in shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of the common shares outstanding (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of shares added (In shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_InducementPlanMember', window );">2022 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,018<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.90<span></span>
</td>
<td class="nump">$ 163.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited, nonvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">14,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation - Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_StockPlan2022201And2019PlansMember', window );">Stock Plan 2022,201 And 2019 Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_StockPlan2022201And2019PlansMember', window );">Stock Plan 2022,201 And 2019 Plans | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,091,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_StockPlan2022Member', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,078,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_InducementPlan2021Member', window );">2021 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrbo_StockPlan2019Member', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period over which the shares reserved for further issuance under share based compensation will increase annually.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrbo_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrbo_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrbo_StockPlan2022201And2019PlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrbo_StockPlan2022201And2019PlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrbo_StockPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrbo_StockPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrbo_InducementPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrbo_InducementPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrbo_StockPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrbo_StockPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210649136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share of Common Stock - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">36,493<span></span>
</td>
<td class="nump">32,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">228,235<span></span>
</td>
<td class="nump">229,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209895840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount', window );">Warrant liabilities</a></td>
<td class="nump">$ 10,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at Fair Value</a></td>
<td class="nump">10,796<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount', window );">Warrant liabilities</a></td>
<td class="nump">10,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at Fair Value</a></td>
<td class="nump">$ 10,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount that would be paid, determined under the conditions specified in the contract, if the holder of the share has the right to redeem the shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073214650688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details) - Warrants<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_WarrantLiabilityRollForward', window );"><strong>Warrant Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of 2022 warrants</a></td>
<td class="nump">$ 24,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of warrant liability</a></td>
<td class="num">$ (7,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment', window );">Warrant liability extinguishment on exercise of warrants</a></td>
<td class="num">$ (5,564)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 10,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of extinguishment of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_WarrantLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_WarrantLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount that would be paid, determined under the conditions specified in the contract, if the holder of the share has the right to redeem the shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073208277920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Assets, Gross</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">$ 30,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance, Total</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">30,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">81,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_OperatingLossCarryForwardResearchCredit', window );">Federal research credit carry forward</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">42,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState', window );">State research credit carryforwards</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance, Total</a></td>
<td class="nump">4,252<span></span>
</td>
<td class="nump">30,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NetOperatingLossCarryforwardsWrittenOff', window );">Net operating loss carryforwards written off</a></td>
<td class="nump">99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ResearchCreditCarryforwardsWrittenOff', window );">Research credit carryforwards written off</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NetOperatingLossCarryforwardsWrittenOff', window );">Net operating loss carryforwards written off</a></td>
<td class="nump">48,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ResearchCreditCarryforwardsWrittenOff', window );">Research credit carryforwards written off</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance, Total</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NetOperatingLossCarryforwardsWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NetOperatingLossCarryforwardsWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_OperatingLossCarryForwardResearchCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carry forward relating to research activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_OperatingLossCarryForwardResearchCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ResearchCreditCarryforwardsWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward relating to research credit written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ResearchCreditCarryforwardsWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073209181584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax (benefit) provision at federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit (as a percent)</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance (as a percent)</a></td>
<td class="nump">188.60%<span></span>
</td>
<td class="num">(26.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research credits (as a percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Provision to tax return (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost', window );">Transaction costs (as percentage)</a></td>
<td class="num">(3.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants', window );">Change in fair value of warrant liability (as percent)</a></td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent', window );">Section 382 limitation adjustment attributes (as percent)</a></td>
<td class="num">(225.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as a percent)</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to change in fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Section 382 limitation adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to transaction cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210125120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before Income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (14,559)<span></span>
</td>
<td class="num">$ (14,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">592<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(13,967)<span></span>
</td>
<td class="num">(15,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Domestic</a></td>
<td class="nump">26,183<span></span>
</td>
<td class="num">(3,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">148<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax provision (benefit)</a></td>
<td class="nump">26,331<span></span>
</td>
<td class="num">(4,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit', window );">Change in valuation allowance - Domestic</a></td>
<td class="num">(26,183)<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit', window );">Change in valuation allowance - Foreign</a></td>
<td class="num">(148)<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of valuation allowance of domestic income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of valuation allowance of foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210258144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant components of deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state operating loss carryforwards</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 19,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign operating loss carryforwards</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DeferredTaxAssetsAcquiredIntangibles', window );">Acquired intangibles</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DeferredTaxAssetsLeaseLiability', window );">Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D Costs</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">7,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">30,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(4,400)<span></span>
</td>
<td class="num">(30,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DeferredTaxLiabilitiesRouAsset', window );">ROU Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(4,252)<span></span>
</td>
<td class="num">(30,410)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (176)<span></span>
</td>
<td class="num">$ (324)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DeferredTaxAssetsAcquiredIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DeferredTaxAssetsAcquiredIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from lease liabilities and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DeferredTaxLiabilitiesRouAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as ROU Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DeferredTaxLiabilitiesRouAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073208601904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 08, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 14, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th"><div>Jun. 07, 2022</div></th>
<th class="th"><div>Jun. 07, 2020</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_MilestonesAccrued', window );">Amount of milestones accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrbo_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Value of shares and warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember', window );">Dong-A | Manufacturing and Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate', window );">Notice period for purchase order prior to requested delivery date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">270 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember', window );">Dong-A | Dong A ST License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement', window );">Number of proprietary compounds in a license | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember', window );">Dong-A | DA-1726</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember', window );">Dong-A | DA-1241</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived', window );">Developmental and regulatory milestone payment eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember', window );">Dong-A | Manufacturing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ContractTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PercentageOfSharesHeldByRelatedParty', window );">Percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod', window );">Period for dismission of allegations.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The notice period for dismission of bankruptcy and other disputes other wise the agreement gets terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for which the entity entered in to the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_MilestonesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers to milestones accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_MilestonesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of Proprietary compounds to be received by the company in a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PercentageOfSharesHeldByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares held by related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PercentageOfSharesHeldByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The notice period for purchase order prior to the requested delivery date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrbo_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrbo_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrbo_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nrbo_DongStMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_ManufacturingAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_ManufacturingAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_Da1726Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrbo_Da1241Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nrbo_ManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nrbo_ManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073210228560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DefinedContributionPlanEmployeeEligibilityAge', window );">Minimum age of employee to cover under the plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage', window );">Employer matches vesting period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_EmployeeCompensationVestingPercentageOnContribution', window );">Percentage of employee contribution vested on their contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Amount of discretionary matching contributions on employee deferrals</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage', window );">Employee compensation deferred percentage</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employee contributions may be deferred to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DefinedContributionPlanEmployeeEligibilityAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee eligibility age criteria under defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DefinedContributionPlanEmployeeEligibilityAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which the employer contribution will be vested under defined contribution plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_EmployeeCompensationVestingPercentageOnContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employee contribution vested on contribution made by employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_EmployeeCompensationVestingPercentageOnContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140073200906432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 08, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_RegisteredDirectOfferingMember', window );">October 2021 Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="nump">4,307,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering shares (Per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">4,307,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable', window );">Period from issuance date the warrants become exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember', window );">Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfWarrantsExercised', window );">Number of warrants exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,981,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember', window );">Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfWarrantsExercised', window );">Number of warrants exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,482,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfWarrantsExercised', window );">Number of warrants exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrbo_NumberOfWarrantsExercised', window );">Number of warrants exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,395,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period from issuance date from which the warrants become exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrbo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nrbo_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nrbo_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrbo_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>nrbo-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nrbo="http://www.gemphire.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nrbo-20221231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_z5T8f5E9g0WIA-Y0HVYsRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_2N6TCpmcHEazJ6gu1eY5yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vqWx7AJ5EU2oXUiFHiP21g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_PH52T1NMSkudkBlRsUiAzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2VyAR7dXg060hMZr4FuJGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_LDYXw0uQCUG-gO_0LLFXuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_flmg7ndj70K84Nl5u2HoQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_DNs6bxizX0y5Tfgm4r8p_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FynBgB2tY0y-WXG6tBWeYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_A4jJNd6yZEi4EpzdUzOidQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PrivateInvestmentInPublicEquityAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_YwJOb8m61EqDiD7F2y2HpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6gHep_8RnUanvUH7fsIEMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_22_2022_To_12_22_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ljoZFeq7K0W9sSW4K8xV6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yUrtat3dg0uspmB84hfp8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVVU8h7siEiH2naixEFcfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_12_2022_To_9_12_2022_kJ01-s11pEi5GhaVIbxoAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wWZsd3T6gka9TSP8iKUvZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6fVwVC7cn0mmYOxFysPq3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nvhHRqi-vkm9u_BWawKrYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JkKhTKgT3kS_VWrdj93liA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UnyFFCsxtkO8kwOnTjAf6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nZhvaiz6j0isSIkyaUH_sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8ETAng3t0SmxgpKoZ05kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KMpsO1-fg0q_X-4JOdhaRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XHL-x0fEb0yRGhDBpCdG2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_u97PYsnPakewyhHU5f9QQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zoF33XhQuUy-t80UIXPd1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0sehVfaRLESnA7PGQGiYcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_11_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2018Member_ko1jQnLPBEqgk8fnim0vfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-11</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9ZvJ9LtzWUOti8VldYpmzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9VXoK8ZQMkmjMvlnr02F6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_7yFz8TeHqkaHnkGtHM5ODQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2022201And2019PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022Member_eifF-TPUWEunkLiTyY8FpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2019Member_V9kjpRU_B0mAPphmsOIjvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlan2021Member__jN6B4AZyUeQSX5hmnKlUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_TkENndys2Uaf4fqNaeg3Tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_05S9u_n9JkucaP69CQY6Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_uq04BWb7AE-iy-oszOsfGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_edJRGY-FvUOBcIWcKUF6eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_21_2021_To_1_21_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CsdGhmL_B0m66NunxNjvUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aWQ-JSgQ7Eyj0sP8jouJIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_udpCt7xwTkmIOi0v6glSMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_goh7paQIHkKoksKth-jjfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_jakDXzDB0EqYM_f7RAVDWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_LoFCvnOSokiqESf8sPL2dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_kj6tzIw4ikOotzAukBfIhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember_Ysy_oDW2ZUuQshWJ1usWfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_szvp0G-HgE6LH9q1BEd5Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_mAMpODa2nkKAzLAAMiOi-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_b6Tq9XMF9kWXMJVobfHIhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2022_To_9_14_2022_ZstQZeqBzk69SGCuk3r0kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_SecuritiesPurchaseAgreementMember_xdPppEpN60y-0j1Cm-TgmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_WMNL8kmcJU2TTDRxUzPFXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_EEmJUdpNf0uElf6g12GrWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ZNoLMPLiW0aszZnLPwlyiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_JfiOhNhM4kq-BfVEu0LZXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_KR_YvToqRmZfUCr2F12W7LUeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_KR_G_Rp8jJUYUWnai9tqLfSSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember__f5vapaPiE6z4tp3rFwAtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_FGRQQlyE-kqOj-HImH6Z9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORlXGbVUk0-D7PGg_EkbSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PGFeUl1eO06LDtIaMAVaQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2019_srt_StatementGeographicalAxis_country_KR_HvV-4l0BaEGxJ9yVDcToOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2019_To_5_31_2019_srt_StatementGeographicalAxis_country_KR_4xOvJGybuEay2f4Kwe1YKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="Duration_4_30_2022_To_4_30_2022_srt_StatementGeographicalAxis_country_KR_YsKsKamLv0yflBeWRDvO7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdL7c281rEWmqG_VeW3mHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52vJLxsaskuscStB9Hd_ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fNzdadyn-0Gw93J5AhwBdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nDBdXISMyEWxxvvugoib-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_5Db9ow_iRkWLj51gC7U6Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:StockPlan2022201And2019PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_l0ZHVOGbuUOzRBb3KR4MiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_h4TI82YIYEafQM3AvpLuuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1pjv2MX8J0-yfwddaY-lNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_kBvkGV4jekagMWbtRHE_aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_R8tpABL6SEiwPZQ-3VvIFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice7800.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_jBT2fr5VpUOllcLVtoPKDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice5602.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_s3mxPDUhy0OW0_k2L4JVOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice375.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_MMU0eNbMe0utmyloJC2nyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice180.90Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_zL_FjtCahk2IkDsWNpvOeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice112.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_vVxVMB4etkuISAzFnY5dCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_xKdZLeM_RkacOFor73v_Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_fo5C0eYqVUyTvpl1YK8Utg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice7800.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_QPGLTkwobEqQWl1-u_J7ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice5602.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_vzleW1-QjkCN0FSzQTflBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice375.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_AK1S2nZAUUyqC_lMS5p_zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice180.90Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_bysVT-b7fUappax39iT8-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:WarrantsExercisePrice112.50Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesWarrantExercisePrice3.00Member_9QLfqPRLn06Fhfn6AE5raA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesWarrantExercisePrice3.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesBWarrantExercisePrice3.00Member_GsOHy7n8B0W-TCmc86HAcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesBWarrantExercisePrice3.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_Syw-BUTd2EajoaUuYlNFGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_ZfzL5Dvo60C4s_TLuxoTqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-21</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_oDsSUJDF10mKNONqEZSMiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_clpDxqqAN0qB38SnsnjsCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_6mbAVgdr_kKuEsMIk2u25w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrbo:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_X0i0kWRTo0Oc2-qhzLlQFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_wpEzOwDCY02faZHzEsikFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nrbo:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAEVu6CnL02lDdU-rjBNQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_N6zssHroH06fo8J6U0yHSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_HJQHlQ__sE6LZHYJuTQyyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_31_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AETHQHuOI0u7EUpHpFV96w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ulqJo4r_k0qlDZTa_a_Bxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-21</startDate>
            <endDate>2021-01-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0frIUJR_I0OOFhGp2TsYXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_Ry1oAKkWqkWxsb6iJ3oDuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrbo:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IPbMK5DMBU-arb5dHnRBNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nrbo:AnaTherapeuticsInc.AssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_DrCMGt_Bb0m-pV_jNh3q6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_uh4H-TEI7EyhE2e1wLB-OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Y7ZQpxzhMUm9V49NbXYQOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_IvLn50OmOkCyhBU3LyuqfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_U3QAOXXUOUiR6REQjSJf4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JiGuQjKiyUmwErH_myawlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_jPeszFZjIEqx6fhLN1VR3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrbo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mjtKTnsE70-ZgJb276XuuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wUjqzfyMzUqaUq1JGxWv1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cq7ytvBYmU6naQ7Efn7LIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EowmUlNgF0ijywAkcdtsEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gGUrMvv3ZkSmGD_w_TYU0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">nrbo:MeasurementInputProbabilityFactorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_72IFixvL4kSbmpjM1YSfwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:ScenarioStockholderNonApprovalToConvertCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nrbo:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="Duration_6_7_2022_To_6_7_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_ManufacturingAndSupplyAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_mrVIOz70GUG2r1JVXDTTRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-07</startDate>
            <endDate>2022-06-07</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_SharedServicesAgreementMember_bK2yJe4yoU2jm_DEGsbO0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OWD6T-tZC06ThXS0xCkQyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_23_2021_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_GAKGJeHh6UuULfG-TYy7pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:OriginalCvrAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-23</instant>
        </period>
    </context>
    <context id="As_Of_12_30_2019_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_oIsPvJwajkGM38Ex40BY6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:OriginalCvrAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierTwoNetSalesMilestoneMember_dpzKVlo1ekGtUs9fT1O3mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierTwoNetSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierThreeNetSalesMilestoneMember_fzSwTYIVmkeJrh9SwkEpKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierThreeNetSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierOneNetSalesMilestoneMember_SES_rbkbP0eNKOMs2xwA_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierOneNetSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierFourNetSalesMilestoneMember_TxpZFkCQ10C-ExxaRCaBqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:TierFourNetSalesMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e0tClQh0z0msDPqPsOTVmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hjmzNGpAn0213gk2bupY4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_UA9AdohqXUSoaG3NbfF6OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_YWNm-7gVqkq3BnovVKJ0Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2022_To_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_LicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_6hrwWyQFkkGHl0B3-Pe0ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_X91Oqmk7XUCm6SQsu_Avpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:ClassBUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-08</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_zzR33TSc_Eq3qTKp-rYpEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember__rH0iwnWGEWGagjRIx77dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_MCgUOrSmAUGyN4xH2iEx5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_azdNGhPJu0ixmk2GgSSbKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:YourchoiceTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_JpNwtACeAEisv2eSDupv_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_htnX0uXa7kCB-UHSuxbNSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:OriginalCvrAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_e_U9zOVAtEW8M7Nl3d2N0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1726Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_QniKuwjxwU-VAVU5AQO_tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:Da1726Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1241Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_3M2K_Hs1_kGIY2eTUaM2fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrbo:Da1241Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="As_Of_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_GR9OQ9E5cEGdGSBaKaofsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_DMIjvwYsPkGpJljUcZUhyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="As_Of_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_HhypM8orekaUV3ZSz7r8gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-01</instant>
        </period>
    </context>
    <context id="Duration_12_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_qsxaSWG__EyTOF1yU2Gswg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_14_2021_To_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_88MmA4GQEU6X2lD11RT57A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-14</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_-Qb32V34hEG7LHl67hYHEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2020_To_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_bI49wt-rv06inimFCn-hbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nrbo:HeadquartersInBostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_FirstAmendmentToOriginalCvrAgreementMember_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_XHR9_9HRME-lP7dY7J3wUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:FirstAmendmentToOriginalCvrAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nrbo:AnaTherapeuticsInc.AssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanThreeBillionMember_sZhFMyWVrE2W0wp6FIo2LA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThanThreeBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanOneBillionMember_UdP-HCvD0E2O-ZPaLupmow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThanOneBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanFiveBillionMember_Bk3afARaEEa5UtSxvJFFcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThanFiveBillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThan500MillionMember_k1KYYL1K_0-HvDnDN7RX9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">nrbo:CumulativeNetSalesMoreThan500MillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_7cfaqECBI0mYM0TA6a38MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrbo:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:DongaStCoLtdLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="Duration_6_7_2020_To_6_7_2020_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_KAwevGFCTkiubmzYUmtJdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-07</startDate>
            <endDate>2020-06-07</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OkcQ-fcFaECmAneltF__OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nrbo:PfizerInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">nrbo:MilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nrbo:ManufacturingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nrbo:DongStMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-28</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_wzCrD8W_a0KHVlgiyTYKNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrbo:LicenseAgreementWithBeijingSLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:November2022SeriesAndSeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_37I4EYMzakCIpYA1bW04gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_JsyKwAESkU-fzjhg3wvYgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrbo:SeriesBWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IG_Y6UouBkm4R_t4WrbvGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">nrbo:AnaTherapeuticsInc.AssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_xJD90V2mhku1eTe__WHVCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2023_shKXoRPAsEWqXet8afQ58A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_Vote_shares_q2LbOB3SVUaQQK-N2RnI1g">
        <divide>
            <unitNumerator>
                <measure>nrbo:Vote</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_item_BbpdEDrZSk2GQqI08hy64Q">
        <measure>nrbo:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_vhBxOMRVzkikLm5iLTAdhA">
        <measure>nrbo:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      id="Hidden_r5YIjCyGvEK3yHB4n1BpVg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      id="Hidden_Zmo1ORFQGUyxA6SSbXkV7Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      id="Hidden_bQq_NMxy_kGeemiwEPt3VA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      id="Hidden_Gc9J0P6c8kegK2GqhDWwPw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_T5Gmm1J_cEeEoTz2t4fs2A_2_1">0001638287</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_gSxZQIhmHU6J8OfFHxqGSA_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_tS4MdZqYcEmPBkbE5KRJeQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_ShYqrFnj_EqW9YAucBBL3g">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA"
      decimals="INF"
      id="Hidden_fP5EDXxBPka1AU3Q6LoP_Q"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA"
      decimals="INF"
      id="Hidden_bb_q-QCsp0yUzMAewPYP5Q"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA"
      decimals="INF"
      id="Hidden_Mn5738ISFkmHUd9Ofy-Zkw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA"
      decimals="INF"
      id="Hidden_Df2pWX79BkWs2KdKZLAPcA"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="INF"
      id="Hidden_tD2RTX7JhEiUN69eOj671g"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">25436019</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="INF"
      id="Hidden_OuphcIW93km7Lewq_FhozA"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">888693</us-gaap:CommonStockSharesOutstanding>
    <nrbo:DefinedContributionPlanEmployerMatchingContributionVestingPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Hidden_DPeIVkG-okWzbfTbv-bZXQ">P6Y</nrbo:DefinedContributionPlanEmployerMatchingContributionVestingPercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ"
      id="Hidden_FyBBTxlXGEGwh1t7bmaxpQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <nrbo:ContractTerm
      contextRef="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA"
      id="Hidden_F7zo_zW-NUK53QFVdH_Apw">P5Y</nrbo:ContractTerm>
    <nrbo:ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod
      contextRef="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA"
      id="Hidden_2TEjfFmoakSOFBCUgn6ldg">P30D</nrbo:ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod>
    <nrbo:ContractTerm
      contextRef="Duration_6_7_2020_To_6_7_2020_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_KAwevGFCTkiubmzYUmtJdQ"
      id="Hidden_Y_VNuVMUj02pKiVqh9023w">P5Y</nrbo:ContractTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_21_2021_To_1_21_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CsdGhmL_B0m66NunxNjvUQ"
      id="Hidden_STCOS7deHEiR00lPkfq1OA">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg"
      id="Hidden_Inik_Nb_jUm6ajNMDQ5Ppg">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw"
      id="Hidden_ONTN_FfUsEGhQ_nLCwdysw">http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_9_12_2022_To_9_12_2022_kJ01-s11pEi5GhaVIbxoAg"
      decimals="2"
      id="Hidden_-c2kEXqIKUut8eHDA86q6w"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <nrbo:CurePeriodForPetitionForBankruptcy
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ"
      id="Hidden_KYNGeI_ZfkuzqiJCYGB1Ww">P30D</nrbo:CurePeriodForPetitionForBankruptcy>
    <nrbo:PeriodForFailToCureBreachMayTerminateAgreement
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ"
      id="Hidden_8VHUHzuV5UqZVxVaa0LNCA">P60D</nrbo:PeriodForFailToCureBreachMayTerminateAgreement>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_mHJlKcmS9UKKMieYtJc1HQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_VxLgoPgDeUOgQbTzsRTQJA_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_wvTMLhkimkWer8BeSjgrgw">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_69Gh4z6co0i1_YgNp0oG0w">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_3iNBj3FkZE-yMAGA_j-8yg_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_CBdq8oNAGk-JzX2XfTyz0w">001-37809</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_6Iw-K_uKL0excIkdsFSvyw">NeuroBo Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_883AyHmG602ze4bogiVjuA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_m8JT-hze7ke1VExUGUwL3g_1_2">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_RhQ3PblpGUut1b5YpQiBzQ">200 Berkeley Street, Office 19th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_xkPjB2dAwUiWFlmuUh5DUQ">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_PKpNj1SdkkqUYid8g_fFXg">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_VDbzLTkM70q1F9IM4-PxLQ_4_2">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_6W7vAbPTLU2YSblK6GEqYg">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_aUuwVHnRn02ynZ1lm5berA">702-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_vdnlOXn8n0OcNjCgmjnERw_3_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tc_UwA2xbusFkCbp5XgDaHQog_3_2">NRBO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_e__4DgZOFkCu8-CQtuNFgQ">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_15cA8HebWkajnm24XMemRg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_xgDFLKWV90qFLu8zP6hWFQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_eadODY4BXUmFhz1Cqb9bUw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_AmUJjj5kCUmtxoQpbEShMg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_-_OdpztBs0eUpum-d-wwew">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_q7Fh_yKidE6ghqcKZ7RwEA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_r7qwrGP4RE-YGueKS_syYw">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_L4vG_7hvNECvGGBzwi0gIA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_hLFPFL0zsUeIWvqYKwec9Q">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_xJD90V2mhku1eTe__WHVCg"
      decimals="-5"
      id="Narr_ghAZoyJmjkO14KztBoYavg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">7000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_24_2023_shKXoRPAsEWqXet8afQ58A"
      decimals="INF"
      id="Narr_d4U9ouOuOEmDXV1z1qJa0Q"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">27176685</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_xEJTaFszLEyeHVltxcPnow">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_IQzN4Xrw1EeFtAVZUeYbhQ">Boston Massachusetts</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_S2fyLGn8v0Cj_0tsiQwddw">243</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_JxbmW0KIF0ay73QZoJbv1Q_6_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">33364000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_cI9AwBDev0G6C1Ci6_awZg_6_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16387000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_TIRKsSIprkqeNHz5KPeOjg_7_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">168000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_UjRrWHDWd0uR4sbZKDqyfw_7_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">197000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_DSHHbkurzEOvSwgvRpCqrg_8_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">33532000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_Oz0wy-Z27EOtvTD5C4lBJA_8_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16584000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_1WH0t4s7m0yb3SysHTXh2Q_9_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">105000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_-MhoPItvAkudNrPig7tWRg_10_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_wF3a83nOxkK_nHnizlEbqw_10_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">110000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_OivYu_p7rkO7msZ-oD0FPA_11_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">33534000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_61TorBTWWkCONhIcrc1quQ_11_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16799000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_IbxEEvLLRk2vS0R-G2bN3Q_14_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">708000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_ueXsxMId50OzsY83Th-o9A_14_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">830000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_1bF6GMX8n06Hk1xQFEeQ1g_15_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">280000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_m5ZtX6kqcUuKzx3Z_Zv2BA_15_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1301000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_gpmX0_yUGUq9WBg14ZOnrQ_16_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10796000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_7-hIdLJ6pkimqY7ORXOKNw_17_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">26000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_DjcOekdTJkKtUTKkum_QPg_18_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">11784000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_xGoh9wg1jkm7HG7t_vemag_18_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2157000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_pnV8d1YQy0qFs33d497ewA_19_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">45000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_Qp-qWSIrPkWGY1NeP9KjXA_20_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">11784000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_TI0gkOrW00uGgiJj4l7CFA_20_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2202000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA"
      decimals="INF"
      id="Narr_oN7j2X3ShU6Ssxg_dCec7A"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA"
      decimals="INF"
      id="Narr_RqA4i68_SkCxcXk1r8In6A"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_plvJfPEz8kyF6cNcNaB0nA"
      decimals="INF"
      id="Narr_m6qCZkNgpUa0AEKWTyDBhQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_nrbo_UndesignatedPreferredStockMember_FTe1B7w9yU63K-MGeJ9hHA"
      decimals="INF"
      id="Narr_aTrfwKw6Gk6avPfkkhdFRQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="INF"
      id="Narr_wJrNeq9ArkmCOHQacPx5xw"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="INF"
      id="Narr_4hp97KrAtEyVj8ZNVxOKDQ"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="INF"
      id="Narr_1busMyzSQEOEmfBEH_CZfQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="INF"
      id="Narr_4a27T42vJki9QxV14x4Zng"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="INF"
      id="Narr_by_401blaEWMmdD9gK5jrg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">25436019</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="INF"
      id="Narr_7BAxXCoK_E612mH5vFWVyw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">888693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_Z65x5YpQuUaqMEw5FUPmBQ_24_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">25000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc__OIiaL798kaQ2rwq3UItwQ_24_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_fcsOVJPL7Uav3GMjIAKSIA_25_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">117520000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_26SipzIgvkyvfujG6lSKtQ_25_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">96420000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_sAQJnpPZX0OrvcqPA0klTA_26_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_ImsvSMKsek-8aNzPmQIi2A_27_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-95795000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_nJW0tJCZWkeifP1kQNsSrw_27_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-81828000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_2agVWnUcAkq_Zj3h5Mlr7Q_28_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">21750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_ALEEjcnBiEyMBTbWvZ9GAQ_28_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">14597000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_ZAvSW-aGKEu9lqr0P7khxQ_29_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">33534000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_c_jUP96GzkaAhaSWa6Qf9w_29_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16799000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_Lk_bWl8U8U-JncAtHY6wOg_5_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2778000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_dn9_iZVv5Ey6QqbpwBCkWQ_5_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">6546000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_t_CMIFXZw0GwgUgYcxib5A_6_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8210000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_8ucs3Pn-n0W1S6SMPApi9Q_7_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8640000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_0hVlkxQkCkupO40VozgKNQ_7_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8752000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_q74VALLGn0urKlNeOZ1-PA_8_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">19628000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_rJ7g3Xs00Eev_aSAmGHNCw_8_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">15298000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_p_RjBn93-UO6wwmSveI_QQ_9_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-19628000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_CZpXxUP3kkuUc8T9a5nYvg_9_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15298000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_RsvQTKkG80eofFVZLqhQYQ_11_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">14000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:FinancingInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_QK63HlahZUC6bo52SqK9aw_12_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2191000</us-gaap:FinancingInterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_QPPzKX9GQ0a-OkOkVHbMOw_13_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-7935000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_K0D3zO5HMEWGcMMWfpW0QQ_14_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">83000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_ETOlzcsMpkOC1aaQJU8slw_15_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5661000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_ydomGoJWvke6DQWlghXanw_15_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_4up5ZepJeUiCAQz3gpqiPQ_16_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-13967000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_leeTimUZqkGwxawTewDJvg_16_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15284000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_o97QUKXtKka_VmwFCt1R5g_18_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-13967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_fgo0BXoYDk-AbYguYG8gsg_18_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15284000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_2hW1FVDnYEOUDSaY8hMT0g_19_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-4000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_S5F9sz2ArUie8kb-fFWzcQ_19_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-10000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc__iXe-dP6pkOSD4AfqrXs7Q_20_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-13971000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_SbU98wJAS0O_mtly1eDjJw_20_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15294000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="2"
      id="Tc_pPBn0QhlTUaAqYsyn6MvdA_22_3"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">-5.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="2"
      id="Tc_pPBn0QhlTUaAqYsyn6MvdA_22_3_2"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">-5.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="2"
      id="Tc_iDzY4InrW0KqOM-oloJc1w_22_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">-19.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="2"
      id="Tc_iDzY4InrW0KqOM-oloJc1w_22_6_2"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">-19.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="0"
      id="Tc_K9YCZIlJQkKCJ1YNiYPZxw_24_3"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2573624</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="0"
      id="Tc_K9YCZIlJQkKCJ1YNiYPZxw_24_3_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2573624</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="0"
      id="Tc_VKyMee-UBEa30qQiZwCM5A_24_6"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">771422</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="0"
      id="Tc_VKyMee-UBEa30qQiZwCM5A_24_6_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">771422</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ"
      decimals="INF"
      id="Tc_oQsxMOsIMEadseCdFODckQ_4_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">655662</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ"
      decimals="-3"
      id="Tc_MoqIipQGn0um7V_KO5oInw_4_14"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8ETAng3t0SmxgpKoZ05kQ"
      decimals="-3"
      id="Tc_Ouy0EffzG02-qL2LVflNeA_4_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">73732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KMpsO1-fg0q_X-4JOdhaRQ"
      decimals="-3"
      id="Tc_flrxRGKnnEOS9Cucl8nYxA_4_20"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nZhvaiz6j0isSIkyaUH_sQ"
      decimals="-3"
      id="Tc_jxUIECMoEU-zTYHvNw8ljA_4_23"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-66544000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_oDsSUJDF10mKNONqEZSMiw"
      decimals="-3"
      id="Tc_-wDECjaJTkWuEBgP0fm8pg_4_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">7203000</us-gaap:StockholdersEquity>
    <nrbo:StockAndWarrantsIssuedDuringPeriodShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0frIUJR_I0OOFhGp2TsYXQ"
      decimals="INF"
      id="Tc_6CoKet-RSEO378SDr7bMQA_5_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">226935</nrbo:StockAndWarrantsIssuedDuringPeriodShares>
    <nrbo:StockAndWarrantsIssuedDuringPeriodValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA"
      decimals="-3"
      id="Tc_6zFsYIP2nEW5cN23Agpxkw_5_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24000000</nrbo:StockAndWarrantsIssuedDuringPeriodValue>
    <nrbo:StockAndWarrantsIssuedDuringPeriodValue
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_N0-Jiu2PlkqWUKz6bGdKZw_5_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24000000</nrbo:StockAndWarrantsIssuedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA"
      decimals="-3"
      id="Tc_h3Q9TjFNpUSRpW2XZoteIQ_6_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_x71GyVrgf0qWs7F_PRi0Rg_6_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0frIUJR_I0OOFhGp2TsYXQ"
      decimals="INF"
      id="Tc_zZPT5CC43U65IgdL8R4SWQ_7_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">6096</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA"
      decimals="-3"
      id="Tc_D6vaefPEMkiQzS02SYMurA_7_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">115000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_qaa0fEDApU6lpa7nUZM2vQ_7_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">115000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtLHw9_F2E25lSdfJQoMuA"
      decimals="-3"
      id="Tc_B49tyWgl506ej4tEfqgReg_8_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">662000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_MeZvoo_IyEWfv9Tavv1j4Q_8_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">662000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_52vJLxsaskuscStB9Hd_ag"
      decimals="-3"
      id="Tc_EepdF6ya2kONQYUgJlgOLg_9_20"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-10000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_A8Ipi9qAI0mqV5xv54J8zA_9_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-10000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PGFeUl1eO06LDtIaMAVaQQ"
      decimals="-3"
      id="Tc_oyWRNKYK10eN3gLIGLE2eg_10_23"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_Ce5o7rqRgE2IP0gKA48rqQ_10_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15284000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zoF33XhQuUy-t80UIXPd1g"
      decimals="INF"
      id="Tc_Vpai8Rht5k2q5w2KM7w9_g_11_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">888693</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zoF33XhQuUy-t80UIXPd1g"
      decimals="-3"
      id="Tc_ei4ZydJXJE-AnZ9yLmpjOQ_11_14"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JkKhTKgT3kS_VWrdj93liA"
      decimals="-3"
      id="Tc_oIfVAcCt8UKgV1nqKMdb4A_11_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">96420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UnyFFCsxtkO8kwOnTjAf6w"
      decimals="-3"
      id="Tc_UnhFFsg_8kiMxR2i7pBfww_11_20"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nvhHRqi-vkm9u_BWawKrYQ"
      decimals="-3"
      id="Tc_eown2grM4kufJvet47SZlw_11_23"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-81828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_ZoGRA5oDzky5VyoJrwpLLw_11_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">14597000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_A4jJNd6yZEi4EpzdUzOidQ"
      decimals="INF"
      id="Tc_x7TtBdv7-UaJRwGl0lut9A_12_1"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">3700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PrivateInvestmentInPublicEquityAndLicenseMember_A4jJNd6yZEi4EpzdUzOidQ"
      decimals="-3"
      id="Tc_Dqh30CLA_02UjG8JXiwPtg_12_4"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10630000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FynBgB2tY0y-WXG6tBWeYA"
      decimals="INF"
      id="Tc_vmmTXOYEjk-FoEx0-dGktg_13_6"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2602997</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FynBgB2tY0y-WXG6tBWeYA"
      decimals="-3"
      id="Tc_9tDUjCeJxESvxb9A9k_zbA_13_9"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6gHep_8RnUanvUH7fsIEMg"
      decimals="INF"
      id="Tc_pQcN_oaXBkCZvsE6cLCRzA_13_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">3147003</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_6gHep_8RnUanvUH7fsIEMg"
      decimals="-3"
      id="Tc_Qwcyyg-SGkSGHDGBaUT5tA_13_14"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_vqWx7AJ5EU2oXUiFHiP21g"
      decimals="-3"
      id="Tc_DE9lbE4hO0-p68m0VUjEAQ_13_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5528000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_PH52T1NMSkudkBlRsUiAzw"
      decimals="-3"
      id="Tc_AvT4RzREQUSWa-G9k3Tasg_13_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5534000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w"
      decimals="-3"
      id="Tc_wXdU3UuUqkWf2PXspzjCuA_14_4"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">959000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ"
      decimals="-3"
      id="Tc_XZmJVGcLz0mn-1CzGAfvkg_14_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">499000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_mLVSVbD-KkuFSvXpKEBnmg_14_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">499000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <nrbo:StockConvertedDuringPeriodShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w"
      decimals="INF"
      id="Tc_J68AhHsaxEiSpYnb3uOJzw_15_1"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">-3700</nrbo:StockConvertedDuringPeriodShares>
    <nrbo:StockConvertedDuringPeriodValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VymKCpDv_ECT2-g7qv4Z7w"
      decimals="-3"
      id="Tc_hYwFPopXckGerFmvXKm7mw_15_4"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-9671000</nrbo:StockConvertedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVVU8h7siEiH2naixEFcfg"
      decimals="INF"
      id="Tc_tbvQPqQibEagmuD_JuFThw_15_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">12333333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hVVU8h7siEiH2naixEFcfg"
      decimals="-3"
      id="Tc_CWOlgbd0JECJ4aIZunqhVw_15_14"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">12000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2VyAR7dXg060hMZr4FuJGw"
      decimals="-3"
      id="Tc_aze1RPo2mk22mgHVkf0XxA_15_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">9659000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ZNoLMPLiW0aszZnLPwlyiQ"
      decimals="-3"
      id="Tc_WEQC8iJSlU-wnFDPNyvIbg_15_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">9671000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <nrbo:StockConvertedDuringPeriodShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ulqJo4r_k0qlDZTa_a_Bxg"
      decimals="INF"
      id="Tc_6gA3UEzuq0a0HRNXkD6TkQ_16_6"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">-2602997</nrbo:StockConvertedDuringPeriodShares>
    <nrbo:StockConvertedDuringPeriodValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ulqJo4r_k0qlDZTa_a_Bxg"
      decimals="-3"
      id="Tc_M78NgQgC_EKsLPa8ZzWT2g_16_9"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-3000</nrbo:StockConvertedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yUrtat3dg0uspmB84hfp8A"
      decimals="INF"
      id="Tc_GvjSfN0UwECvu3rX7Z5oDg_16_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2602997</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yUrtat3dg0uspmB84hfp8A"
      decimals="-3"
      id="Tc__u6akRUsV0adLVj2b9vAwQ_16_14"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg"
      decimals="INF"
      id="Tc_DFtfFcpfwUmL48PYQDiVYg_17_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">6463993</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg"
      decimals="-3"
      id="Tc_2eWu5DRjPkqK_mDX_RbVLQ_17_14"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ"
      decimals="-3"
      id="Tc_PrwwRM7QI0OE45-x2fJBWg_17_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5558000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_WHGc1k9yFE26icHtbeiBOg_17_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5564000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_A5lK6FBOd0qWUbYQKcQfqQ"
      decimals="-3"
      id="Tc_yfgQyXgIskavOR41iX1u2w_18_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">854000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_4JT5k-0WYkO-D0glFmBPSg_18_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">854000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cdL7c281rEWmqG_VeW3mHg"
      decimals="-3"
      id="Tc_70Vk32U8V0WcXP3uGqWSdQ_19_20"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-4000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:ForeignCurrencyTransactionGainLossRealized
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_lL4GAht7a0W3dbdSUbK2rw_19_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-4000</us-gaap:ForeignCurrencyTransactionGainLossRealized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ORlXGbVUk0-D7PGg_EkbSA"
      decimals="-3"
      id="Tc_ngMszh2hrUWgQBE_sIxbNg_20_23"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-13967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_1ovvwmxAiEqT6Uh3tURTAQ_20_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-13967000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA"
      decimals="INF"
      id="Tc_UaXApegMn0OatWCqYsD3fg_21_11"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">25436019</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA"
      decimals="-3"
      id="Tc_xxVtKH21EESjbk2jgR4a5Q_21_14"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6fVwVC7cn0mmYOxFysPq3g"
      decimals="-3"
      id="Tc_pt7_-FltxEeQFUaZkZsBDA_21_17"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">117520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wWZsd3T6gka9TSP8iKUvZg"
      decimals="-3"
      id="Tc_gOYHnuhUHkmQU0BT_a2guA_21_23"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-95795000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_1oGBrw4G3k6dgh8dSCmT6Q_21_26"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">21750000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_8Hnmewc6tkyGL-NNwJP-Hw_5_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-13967000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_6FV5-pzlxEmCJ7FuH86s8Q_5_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15284000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_19G9Tfnl_EqOZH_MkY_9Cg_7_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">854000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_M1KgxkxnPUqWkIolnfrJ6g_7_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">662000</us-gaap:ShareBasedCompensation>
    <nrbo:IncreaseDecreaseInNonCashLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_Vv0YsyTg00m34byx2K4d5w_8_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8000</nrbo:IncreaseDecreaseInNonCashLeaseExpense>
    <nrbo:IncreaseDecreaseInNonCashLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_blxvvtwk80m6RLVEgBsiMg_8_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24000</nrbo:IncreaseDecreaseInNonCashLeaseExpense>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_9IUCOIkEJkS1V3WDeBbq7A_9_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">20000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_79XJPlRBFEqH8d5CbM57hg_9_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">48000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_H4qaGbnw8UOV1aEnh-9ILg_10_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-75000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_KhcCHfem0Eamr8zFCvxKPg_11_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8210000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:FinancingInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_9HRqoXzn00SDmzSHXsgdhA_12_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2191000</us-gaap:FinancingInterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_bDJ_qaxPME2eiNnm7nx5uA_13_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-7935000</us-gaap:FairValueAdjustmentOfWarrants>
    <nrbo:IncreaseDecreaseInPrepaidExpensesAndDeposits
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_oq3odrUhlkGEccUM7Vl3dg_15_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-64000</nrbo:IncreaseDecreaseInPrepaidExpensesAndDeposits>
    <nrbo:IncreaseDecreaseInPrepaidExpensesAndDeposits
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_EogNIXTicEmTZhxm9qiO5g_15_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-396000</nrbo:IncreaseDecreaseInPrepaidExpensesAndDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_6TKN5k3MVEGH5fbTzY4IAg_16_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-202000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_5JUljLBygUWUzNLcsK9Dgg_16_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-1162000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_rqxxACtRA0CQ1pT1drlL_Q_17_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-1030000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_vnkxoIISb0a3Y8Zpo_zWbA_17_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">182000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_6j58p4n1NUSIY3zYACOopw_18_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-11712000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_7MC7hVyIkk2VkEdIpFUS4g_18_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15134000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <nrbo:PaymentsForTransactionCostsInConnectionWithMerger
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_E17anDgBgUWQEaw7UIyFQg_20_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">583000</nrbo:PaymentsForTransactionCostsInConnectionWithMerger>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_FtFFhfApD0qvlQ9QmCy_CQ_21_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_1mbsICx72Em4EW77n3J5NA_22_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_3vOHdUffx0SW-QWEdWlJQQ_23_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_IqQNSthVV0OOErRFJQEYAw_23_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-586000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_JnksoL0ALkWHbNxwqMlaZQ_25_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">32250000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_pZN-EpiIKUGgqe7gHkqcAg_25_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_k7dpi1nxD0m2w7WiSrAXuw_26_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3569000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc__D9RKnWfMUOfUjmvYgfG6w_26_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2089000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_bRWYaqiVck2P5eS33pMdSw_27_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">115000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_Tc1TZsZOOU2lHGOSAJ-OWg_28_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">28681000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_XeRVbvlf-0efyshEaKd9eA_28_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">22026000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_wkHuj6UB_kan2vtE4YMN5Q_29_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_Qxd-XkvgfE6F6vtRm-qraw_29_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">6306000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_5LfEMPhvDE-Dus8OFAJF1w_30_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_zJTyFIHE8ka_SmtII9fANQ_31_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_oDsSUJDF10mKNONqEZSMiw"
      decimals="-3"
      id="Tc_fG6fFiIuaU6zHsbvwt00XA_31_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10089000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_H8LXjdXgdkeYGIBDfa4FQA_32_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">33364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_GQHgjEHTtkGGos3ltGcKwg_32_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nrbo:ModificationOfRightOfUseAssetAndAssociatedLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_MLjz68aE8E6AQnU30As4bQ_34_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">62000</nrbo:ModificationOfRightOfUseAssetAndAssociatedLeaseLiability>
    <nrbo:DeferredIssuanceCostsIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_c1K9jSHBw0WoLFjXGpaTdA_35_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">80000</nrbo:DeferredIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_H_WtaO3ghkWyhma6trABiQ_36_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5564000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_JnvjZytft0CGsZDv8-kPHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. The Company and Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"&gt;NeuroBo Pharmaceuticals,&#160;Inc. (together with its subsidiaries, the &#x201c;Company&#x201d; or &#x201c;NeuroBo&#x201d;), is a clinical-stage biotechnology company with two primary programs focused on treatment of nonalcoholic steatohepatitis (&#x201c;NASH&#x201d;) obesity, and type 2 diabetes (&#x201c;T2D&#x201d;):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;DA-1241&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D. We intend to initiate a Phase 2a study with the goal of establishing efficacy of DA-1241 in NASH and T2D.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;DA-1726&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; is a novel oxyntomodulin (&#x201c;OXM&#x201d;) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity, that is to be administered once weekly subcutaneously. DA-1726 as a dual agonist of GLP-1 receptors (&#x201c;GLP1R&#x201d;) and glucagon receptors (&#x201c;GCGR&#x201d;), leading to weight loss through reduced appetite and increased energy expenditure. We intend to advance DA-1726 through Investigational New Drug application and initiation of human clinical trials.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company had previously focused its efforts on four therapeutic programs: ANA001, NB-01, NB-02 and gemcabene.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company&#x2019;s operations have consisted principally of performing research and development activities, clinical development and raising capital. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding before sustainable revenues and profit from operations are achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Basis of presentation and consolidation principles&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The accompanying financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The consolidated financial statements of the Company include a South Korean subsidiary, NeuroBo Co.,&#160;Ltd., which is fully owned by the Company. All significant intercompany accounts and transactions have been eliminated in the preparation of the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s Board of Directors approved a &lt;span style="-sec-ix-hidden:Hidden_-c2kEXqIKUut8eHDA86q6w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-for-thirty&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock (the &#x201c;Reverse Stock Split&#x201d;). The Reverse Stock Split became effective as of 5:00 p.m. Eastern Time on September 12, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;All issued and outstanding common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company&#x2019;s equity incentive compensation plans to reflect the Reverse Stock Split. Any fraction of a share of common stock that was created as a result of the Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company&#x2019;s common stock as reported on Nasdaq on the last trading day before the Reverse Stock Split becomes effective (on a split-adjusted basis). The authorized shares and par value per share of the common stock and preferred stock were not adjusted as a result of the Reverse Stock Split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;From its inception through December 31, 2022, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials. The Company has a limited operating history and the sales and income potential of the Company's business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company's cost structure. The Company has experienced net losses and negative cash flows from operating activities since its inception and had an accumulated deficit of $95.8&#160;&lt;span style="white-space:pre-wrap;"&gt;million as of December 31, 2022.  These conditions previously raised substantial doubt about the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;To date, the Company has raised capital principally through private placements and public offerings of convertible preferred stock, common stock and warrants The Company will need to continue to raise a substantial amount of funds until it is able to generate revenues to fund its development activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2022, the Company had $33.4&lt;span style="white-space:pre-wrap;"&gt; million in cash.  The Company believes that its existing cash will be sufficient to fund its operations for at least the next 12 months from the date these financial statements are issued.  The Company will need to continue to raise additional funds until it is able to generate sufficient revenues to fund its development activities.  The Company&#x2019;s future operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to predict the ultimate outcome of these actions to generate the liquidity ultimately required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_HJX8wfFLakmp5mvjrF_LLg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-95800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_XpetaFvCi0WpxQp2clkI9w"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">33400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_IizN8pyp_U-f9Z3g8o386w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentrations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#x2019;s cash is principally held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of December 31, 2022, the Company had deposits in excess of federally insured amounts by $32.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Supplier Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On September 14, 2022, the Company entered into an exclusive license agreement (the &#x201c;2022 License Agreement&#x201d;) with Dong-A ST Co., Ltd. (&#x201c;Dong-A&#x201d;), which requires Dong-A to be the sole manufacturer for the production of DA-1241 and DA-1726.  &lt;/span&gt;If any issues arise in the manufacturing and the Company is unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, the Company may not be able to complete development of DA-1241 or DA-1726.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. &lt;span style="white-space:pre-wrap;background:#ffffff;"&gt;The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.  &lt;/span&gt;See Note 10 - &lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;.  &lt;span style="white-space:pre-wrap;background:#ffffff;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;The Company accounts for its warrants as liabilities at fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities are recognized as a fair value change in warrant liabilities in the consolidated statements of operations and comprehensive loss and as an operating item in the statement of cash flows.&lt;span style="font-size:12pt;"&gt; &#160;&lt;/span&gt;Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company includes costs to acquire or in-license product candidates in acquired in-process research and development expenses (&#x201c;IPR&amp;amp;D&#x201d;). When the Company acquires the right to develop and commercialize a new product candidate, any up-front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as acquired in-process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#x201c;business&#x201d; as defined under GAAP, or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes the liability method of accounting for income taxes as required by ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation&#160;&#x2014; Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). Accordingly, compensation costs related to equity instruments granted are recognized at the grant-date fair value. The Company records forfeitures when they occur. Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718 using a grant date fair value approach. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company accounts for leases under Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842)&#160;(&#x201c;ASU 2016-02&#x201d;). The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company has recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company&#x2019;s&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, the Company recognizes lease payments as an expense on a straight-line basis over the remaining lease term.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property&#160;and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from &lt;span style="-sec-ix-hidden:Hidden_FyBBTxlXGEGwh1t7bmaxpQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&#160;to five years. Tangible assets acquired for research and development activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;The foreign subsidiary uses the South Korean Won (KRW) as its functional currency. The Company translates the assets and liabilities of its foreign operation into U.S. dollars based on the rates of exchange in effect as of the transaction date. The resulting adjustments from the translation process are included in accumulated other comprehensive (loss) income in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;Certain transactions of the Company are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;Comprehensive loss is comprised of net loss and other comprehensive income or loss. Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. Comprehensive loss currently consists of net loss and changes in foreign currency translation adjustments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its business in one operating segment, which is principally the business of development and commercialization of therapeutics.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;&#x201c;Financial Instruments &#x2013; Credit Losses&#x201d;&lt;/i&gt;. The ASU sets forth a &#x201c;current expected credit loss&#x201d; (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for calendar year 2023 for smaller reporting companies. The Company adopted this new guidance on January 1, 2023, and the adoption did not have a material impact on the Company's consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_IoDxrmBoS0yabipnmawzMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company's consolidated financial statements relate to accrued expenses and the fair value of stock-based compensation and warrant issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_CrjceC8EykSJ_i1eyEr50w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Concentrations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#x2019;s cash is principally held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of December 31, 2022, the Company had deposits in excess of federally insured amounts by $32.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Supplier Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On September 14, 2022, the Company entered into an exclusive license agreement (the &#x201c;2022 License Agreement&#x201d;) with Dong-A ST Co., Ltd. (&#x201c;Dong-A&#x201d;), which requires Dong-A to be the sole manufacturer for the production of DA-1241 and DA-1726.  &lt;/span&gt;If any issues arise in the manufacturing and the Company is unable to arrange for alternative third-party manufacturing sources, or unable to find an alternative third party capable of reproducing the existing manufacturing method or unable to do so on commercially reasonable terms or in a timely manner, the Company may not be able to complete development of DA-1241 or DA-1726.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <nrbo:DepositsInExcessOfFederallyInsuredAmounts
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_8E9g8QnjikGreO_F5BtZUA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">32900000</nrbo:DepositsInExcessOfFederallyInsuredAmounts>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_9pA-B9FN2k-sra9yUEpIYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments principally include cash, prepaid expenses, right of use assets, accounts payable, accrued liabilities, lease liabilities and warrant liabilities. &lt;span style="white-space:pre-wrap;background:#ffffff;"&gt;The carrying amounts of cash, prepaid expenses and other current assets, accounts payable, and accrued liabilities are reasonable estimates of their fair value because of the short maturity of these items.  &lt;/span&gt;See Note 10 - &lt;i style="font-style:italic;"&gt;Fair Value Measurements&lt;/i&gt;.  &lt;span style="white-space:pre-wrap;background:#ffffff;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <nrbo:WarrantLiabilitiesPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_bjoSxBc4wU6sPeXdtTkSnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrant Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;The Company accounts for its warrants as liabilities at fair value if equity accounting treatment is precluded due to provisions existing within the warrant agreements. The change in fair value of the warrant liabilities are recognized as a fair value change in warrant liabilities in the consolidated statements of operations and comprehensive loss and as an operating item in the statement of cash flows.&lt;span style="font-size:12pt;"&gt; &#160;&lt;/span&gt;Additionally, issuance costs associated with warrants initially classified as liabilities are expensed as incurred and reflected as financing costs in the accompanying consolidated statements of operations and comprehensive loss. &lt;/p&gt;</nrbo:WarrantLiabilitiesPolicyPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_pVn48ZQ-AU2o1nzMuYnNPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative expenses consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_R1rMsvvrdUyg5-uv-iVPMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt;. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_LG2-JutxDUeaO0wTnGkpiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Acquired In-Process Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company includes costs to acquire or in-license product candidates in acquired in-process research and development expenses (&#x201c;IPR&amp;amp;D&#x201d;). When the Company acquires the right to develop and commercialize a new product candidate, any up-front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as acquired in-process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#x201c;business&#x201d; as defined under GAAP, or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_4km4clayQEC-95o8O-rr1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes the liability method of accounting for income taxes as required by ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Narr_sQaZiQacBkKsl6cMAAcYNw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_jYWkeS6As06vyS2sa-bWTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company accounts for stock-based compensation in accordance with the provisions of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation&#160;&#x2014; Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). Accordingly, compensation costs related to equity instruments granted are recognized at the grant-date fair value. The Company records forfeitures when they occur. Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718 using a grant date fair value approach. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_6ky9GrjDW0W6LrOPeliHFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company accounts for leases under Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02,&#160;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842)&#160;(&#x201c;ASU 2016-02&#x201d;). The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company has recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company&#x2019;s&#160;incremental borrowing rate and amortized over the remaining terms of the leases. For operating leases of a short-term nature, i.e., those with a term of less than twelve months, the Company recognizes lease payments as an expense on a straight-line basis over the remaining lease term.&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_HMK3WSWSgEWZeZlubzHn8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Property&#160;and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:27pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Property and equipment is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the assets using the straight-line method. The estimated useful life for property and equipment ranges from &lt;span style="-sec-ix-hidden:Hidden_FyBBTxlXGEGwh1t7bmaxpQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&#160;to five years. Tangible assets acquired for research and development activities and that have an alternative use are capitalized over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged directly to expense as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg"
      id="Narr_AmXET-JeS0ut_dApyT2Ijg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_Jl79RsaXskGVQ-V24JfElw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;The foreign subsidiary uses the South Korean Won (KRW) as its functional currency. The Company translates the assets and liabilities of its foreign operation into U.S. dollars based on the rates of exchange in effect as of the transaction date. The resulting adjustments from the translation process are included in accumulated other comprehensive (loss) income in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;Certain transactions of the Company are settled in foreign currency and are thus translated to U.S. dollars at the rate of exchange in effect at the end of each month. Gains and losses resulting from the translation are included in other income or expense in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <nrbo:PatentCostPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_aANCcpDWj0iO3kU5eUetWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses.&lt;/p&gt;</nrbo:PatentCostPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_OydeF6YWok2ephOv01DLJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:10.1pt;text-indent:-10.1pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;Comprehensive loss is comprised of net loss and other comprehensive income or loss. Comprehensive loss includes net loss as well as other changes in stockholders' equity that result from transactions and economic events other than those with stockholders. Comprehensive loss currently consists of net loss and changes in foreign currency translation adjustments.&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_VgBQ9J2gtUeun8NKGNZP0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its business in one operating segment, which is principally the business of development and commercialization of therapeutics.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="INF"
      id="Narr_h9yS8xioLEGHkGVswyDifQ"
      unitRef="Unit_Standard_segment_vhBxOMRVzkikLm5iLTAdhA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_pZPZsTlK_kSOHQfETARt_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;In June 2016, the FASB issued ASU 2016-13,&#160;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;&#x201c;Financial Instruments &#x2013; Credit Losses&#x201d;&lt;/i&gt;. The ASU sets forth a &#x201c;current expected credit loss&#x201d; (CECL) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some off-balance sheet credit exposures. This ASU is effective for calendar year 2023 for smaller reporting companies. The Company adopted this new guidance on January 1, 2023, and the adoption did not have a material impact on the Company's consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_t_NiDLleyUuAr7HoLgA8Ag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Balance Sheet Detail&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property and Equipment &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Research and development equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (111)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accrued liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Accrued liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;External research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Payroll related&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_OqQr55DIYk-aI3FvNjldRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Research and development equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 63&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (111)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember_Ysy_oDW2ZUuQshWJ1usWfw"
      decimals="-3"
      id="Tc_tr3gTmUn8kKTXM0y9UxwFA_4_7"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">158000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_kj6tzIw4ikOotzAukBfIhw"
      decimals="-3"
      id="Tc_TkD7P7kLI06I_QH9VZpisw_5_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_szvp0G-HgE6LH9q1BEd5Rg"
      decimals="-3"
      id="Tc_KDu-eL9fskm69i9i4rDK5Q_5_7"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">63000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_OwiujHtbIEGYwT4L7Th9Iw_6_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">30000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_46OmWqVikESSK8qJZPq3uw_6_7"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">221000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_QgoKIelLW0Opjv08zTjz3A_7_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">28000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_VZVciykDQUamdIQ1pQ6Gpg_7_7"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">111000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_AaA4V3kwKUG2nkYwh836IA_8_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_14vhtntuLU-AZ1oVRpLeRQ_8_7"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">110000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_qUDcTTm5sUKnMshTfJfQZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;External research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 109&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Payroll related&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,301&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <nrbo:AccruedOtherResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_TvTlgllF9k-UIzwkl8nPHg_3_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">109000</nrbo:AccruedOtherResearchAndDevelopmentExpenses>
    <nrbo:AccruedOtherResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_aKDzBeuCHE2aw_OrAdpVdA_3_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">854000</nrbo:AccruedOtherResearchAndDevelopmentExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_vke0Kyc3tECP-GBAmTt-8A_4_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_CLOGV3z-PkmLXVXzxGeG7g_4_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">376000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_jhrOPzVamkmn6OtrB_UDjw_5_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">23000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_HjgQDq2WgkafioWwWsqwdw_5_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">59000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_g5hnewTyM0iP8kvYk7UcgA_6_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">48000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_HqRaLR2u40KeW6LHXzdShg_6_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">12000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_5CAg3D3fKEy__OUnvnJ3AQ_7_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">280000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_e8ZajqN-B0yGa5WiOQjgzA_7_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1301000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_QD_ZMRqNa0i00DLnbyGboA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Boston Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Effective August 1, 2021, the Company entered into a non-cancelable operating lease for its corporate headquarters located in Boston Massachusetts. This agreement had a six month term, and rental costs of approximately $3 per month prior to the application of certain rent concessions granted by the landlord in the amount of approximately $2&lt;span style="white-space:pre-wrap;"&gt; over the term of the lease.  &lt;/span&gt;In December 2021, the Company signed an amendment to its corporate headquarters lease to extend the term until March 31, 2022 for rental costs of approximately $1&lt;span style="white-space:pre-wrap;"&gt; per month.  In February 2022, April 2022, August, 2022 and December, 2022 the Company signed amendments to extend the lease term until June 30, 2022, September 30, 2022, December 31, 2022 and March 31, 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Prior to February 1, 2021, a non-cancelable operating lease was in effect as of February 1, 2020 which had a one-year term and rental costs of $21 per month prior to the application of certain rent concessions granted by the landlord in the amount of $32. Effective February 1, 2021, the Company was party to a non-cancelable operating lease for its corporate headquarters which had a six month term, and rental costs of approximately $3 per month prior to the application of certain rent concessions granted by the landlord in the amount of approximately $1 over the term of the lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;No assets and liabilities were recognized for the corporate headquarters leases at December 31, 2022 and 2021. Due to the short-term nature of the leases, the Company recognized lease payments as an expense on a straight-line basis over the remaining lease term. For the years ended December 31, 2022 and 2021, expense under the corporate headquarters leases in the aggregate was $16 and $48, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Lease in Korea:&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;In May 2019, the Company entered into an operating lease for its new facility in Korea (the &#x201c;Korea Lease&#x201d;). The initial lease term was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;five years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;with an option to renew&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; for an additional &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;five-year&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; term. The lease commenced on July 2, 2019 and was to expire on July 1, 2024.  On April 19, 2022, the Company terminated its Korea Lease effective April 30, 2022, at which time, the Company&#x2019;s unamortized right-of-use asset and lease liabilities were fully amortized and extinguished with &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; gain or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The operating lease was subject to a deposit, base rent payments and additional charges for utilities and other common costs. For the years ended December 31, 2022 and 2021, the Company recorded non-cash expense of $8 and $24, respectively, related to the Korea Lease. During the year ended December 31, 2022 and 2021, the Company made cash payments of $11 and $32, for amounts included in the measurement of lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;License Agreement with Dong-A ST&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;On September 14, 2022, the Company and Dong-A, a related party, and greater than 5% shareholder, entered into the 2022 License Agreement, pursuant to which, subject to the conditions set forth therein, the Company ultimately received an exclusive global license (other than in the Republic of Korea) to two proprietary compounds for specified indications. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. Under the 2022 License Agreement, Dong-A will be eligible to receive (i) regulatory milestone payments of up to $178 million for DA-1726 and $138 million for DA-1241, dependent upon the achievement of specific regulatory developments; (ii) commercial-based milestone payments, dependent upon the achievement of specific commercial developments; and (iii)&#160;single digit royalties on net sales received by the Company from the commercial sale of products covering DA-1241 or DA-1726. See Note 5, &lt;i style="font-style:italic;"&gt;2022 License Agreement.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, no milestone or royalty payments had been accrued as there were no potential milestones yet considered probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Gemphire Contingent Value Rights Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;On December 30, 2019, the Company was party to a definitive merger agreement (the &#x201c;2019 Merger&#x201d;) with Gemphire Therapeutics, Inc. (&#x201c;Gemphire&#x201d;). In connection with the 2019 Merger, Gemphire entered into the Contingent Value Rights Agreement (the &#x201c;CVR Agreement&#x201d;) with Grand Rapids Holders&#x2019; Representative, LLC, as representative of Gemphire&#x2019;s stockholders prior to the 2019 Merger (the &#x201c;Holders&#x2019; Representative&#x201d;), and Computershare Inc. and Computershare Trust Company, N.A. as the rights agents (collectively, the &#x201c;Rights Agent&#x201d;). Under the CVR Agreement, which NeuroBo assumed in connection with the 2019 Merger, the holders of Gemphire shares at the time of the 2019 Merger (collectively, the &#x201c;CVR Holders&#x201d;) were entitled to receive 80% of the proceeds from the grant, sale, or transfer of rights to Gemcabene.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;On March 23, 2021, NeuroBo, the Holders&#x2019; Representative, and the Rights Agent entered into the First Amendment to Contingent Value Rights Agreement (the &#x201c;CVR Amendment&#x201d;) to amend the CVR Agreement. Pursuant to the CVR Amendment, (i) the CVR Holders will continue to have the right to receive 80% of the proceeds from the grant, sale, or transfer of rights to Gemcabene as a treatment for cardiovascular conditions and (ii) the CVR Holders will now also receive 10% of the proceeds from the grant, sale, or transfer of rights to Gemcabene as a treatment for any indication outside of treating cardiometabolic diseases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;As of the December 31, 2022 and 2021, no milestones had been accrued as there were no potential payments under the CVR Agreement or the CVR Amendment that were yet considered probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Pfizer License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Upon the close of the 2019 Merger, the exclusive license agreement with Pfizer&#160;Inc. (&#x201c;Pfizer&#x201d;) for the clinical product candidate Gemcabene (the &#x201c;Pfizer Agreement&#x201d;) was assumed by the Company. Under the Pfizer Agreement, in exchange for this worldwide exclusive right and license to certain patent rights to make, use, sell, offer for sale and import the clinical product Gemcabene, the Company has agreed to certain milestone and royalty payments on future sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company agreed to make milestone payments totaling up to $37&#160;million upon the achievement of certain milestones, including the first new drug application (or its foreign equivalent) in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of Gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Company also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales, as specified in the Pfizer Agreement, until the later of: (a) five (5) years after the first commercial sale in such country; (b) the expiration of all regulatory or data exclusivity for Gemcabene in such country; and (c) the expiration or abandonment of the last valid claim of the licensed patents, including any patent term extensions or supplemental protection certificates in such country (collectively, the Royalty Term). Under the Pfizer Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize Gemcabene.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Pfizer Agreement will expire upon expiration of the Royalty Term. On expiration (but not earlier termination), the Company will have a perpetual, exclusive, fully paid-up, royalty-free license under the licensed patent rights and related data to make, use, develop, commercialize, import and otherwise exploit the clinical product candidate Gemcabene. Either party may terminate the Pfizer Agreement for the other party&#x2019;s material breach following a cure period or immediately upon certain insolvency events relating to the other party. Pfizer may immediately terminate the Pfizer Agreement in the event that (i) the Company or any of its affiliates or sublicenses contests or challenges, or supports or assists any third party to contest or challenge, Pfizer&#x2019;s ownership of or rights in, or the validity, enforceability or scope of any of the patents licensed under the Pfizer Agreement or (ii) the Company or any of its affiliates or sublicensees fails to achieve the first commercial sale in at least one country by April 16, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Furthermore, upon termination of the Pfizer Agreement by Pfizer for any of the foregoing reasons, the Company grants Pfizer a non-exclusive, fully paid-up, royalty free, worldwide, transferrable, perpetual and irrevocable license to use any &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;intellectual property rights arising from the development or commercialization of Gemcabene by the Company and any trademarks identifying Gemcabene and agrees to transfer regulatory filings and approvals to Pfizer or permit Pfizer to cross-reference and rely on such regulatory filings and approvals for Gemcabene. The Company may terminate the Pfizer Agreement for convenience upon 90 days&#x2019; written notice and payment of an early termination fee of $3.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As of December 31, 2022 and 2021, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the license agreement, and as such, no liabilities were recorded related to the Pfizer Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;ANA Merger Milestone Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;On December&#160;31, 2020, the Company acquired 100% of ANA Therapeutics,&#160;Inc., a Delaware corporation (&#x201c;ANA&#x201d;), pursuant to an Agreement and Plan of Merger, dated December&#160;31, 2020 (the &#x201c;2020 Merger Agreement&#x201d; or &#x201c;2020 Merger&#x201d;). Pursuant to the 2020 Merger Agreement, following the closing of the 2020 Merger, the Company is obligated to pay milestone payments (each, a &#x201c;Milestone Payment&#x201d;) to certain persons identified in the 2020 Merger Agreement (each a &#x201c;Stakeholder&#x201d; and collectively, the &#x201c;Stakeholders&#x201d;) in the form, time and manner as set forth in the 2020 Merger Agreement, upon the achievement of the following milestone events set forth below by the Company or any of its affiliates (each, a &#x201c;Milestone Event&#x201d;):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:3pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:91.69%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr style="height:22.3pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0pt 2pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Event&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 20.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.55pt;"&gt;&lt;td colspan="2" style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:9.55pt;margin:0pt;"&gt;First receipt of Marketing Approval (as defined in the 2020 Merger Agreement) from the FDA for any Niclosamide Product (as defined in the 2020 Merger Agreement)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; $&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;45.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21.6pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;Sales Milestones:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 11pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21.15pt;"&gt;&lt;td colspan="2" style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Event &#x2013; Worldwide Cumulative Net Sales of a Niclosamide Product&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.9pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equal to or greater than:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 19.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.45pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$500 million&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;9.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.8pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$1 billion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;13.5 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.8pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$3 billion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;36.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.7pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$5 billion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;72.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, pursuant to the 2020 Merger Agreement, the Company is obligated to pay &lt;span style="color:#231f20;"&gt;a royalty of two and a half percent (&lt;/span&gt;&lt;span style="color:#231f20;"&gt;2.5%&lt;/span&gt;&lt;span style="color:#231f20;"&gt;) of annual worldwide net sales of each Niclosamide Product (as defined in the Merger Agreement) &lt;/span&gt; (each such payment, a &#x201c;Royalty Payment&#x201d;) to the Stakeholders in the form, time and manner as set forth in the 2020 Merger Agreement, following the first commercial sale of each Niclosamide Product (as defined in the 2020 Merger Agreement) on a country-by-country and Niclosamide Product-by-Niclosamide Product basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;As of the December 31, 2022 and 2021, no Royalty Payments had been accrued as there were no potential milestones yet considered probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;YourChoice License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In connection with the 2020 Merger, the Company assumed the license agreement between ANA and Your Choice Therapeutics, Inc. (the &#x201c;YourChoice Agreement&#x201d;). Prior to the 2020 Merger, YourChoice Therapeutics, Inc. granted to ANA, during the term of the YourChoice Agreement, an exclusive, worldwide, fee-bearing license derived from the licensed intellectual property throughout the world.  The fees due under the YourChoice Agreement include royalty payments of &lt;/span&gt;0.5% of annual worldwide net sales of each Niclosamide Product (as defined in the 2020 Merger Agreement) and milestone payments in the aggregate of $19.5 million. The first milestone payment due is $5 million upon first receipt of Marketing Approval (as defined in the 2020 Merger Agreement) for the FDA for any Nicolsamide Product (as defined by the 2020 Merger Agreement), followed by sales milestones of $1 million, $1.5 million, $4 million, and $8 million if worldwide cumulative net sales of a Nicolsamide Product are equal or greater than $500 million, $1 billion, $3 billion, and $5&lt;span style="white-space:pre-wrap;"&gt; billion, respectively.  The term of the YourChoice Agreement will expire on the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;expiration or invalidation of the last of the licensed patents under the YourChoice Agreement.  As of December 31 2022 and 2021, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the YourChoice Agreement, and as such, &lt;/span&gt;no liabilities were recorded related to the YourChoice Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;From time to time, the Company may be subject to various claims and suits arising in the ordinary course of business. The Company does not expect that the resolution of these matters will have a material adverse effect on its financial position or results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_GR9OQ9E5cEGdGSBaKaofsQ"
      id="Narr_-7d4Iz0WKE6L8YrV5jl0WQ">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <nrbo:LesseeMonthlyOperatingLeaseCost
      contextRef="Duration_5_14_2021_To_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_88MmA4GQEU6X2lD11RT57A"
      decimals="-3"
      id="Narr_rSWj5-iV406WyNOhBbM2qw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000</nrbo:LesseeMonthlyOperatingLeaseCost>
    <nrbo:LesseeOperatingLeaseIncentiveFromLessor
      contextRef="As_Of_5_14_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_GR9OQ9E5cEGdGSBaKaofsQ"
      decimals="-3"
      id="Narr_gQalBABSAkyU7YIPXAoq2g"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2000</nrbo:LesseeOperatingLeaseIncentiveFromLessor>
    <nrbo:LesseeMonthlyOperatingLeaseCost
      contextRef="Duration_12_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_qsxaSWG__EyTOF1yU2Gswg"
      decimals="-3"
      id="Narr_1CFtV3tDQEOeWfr34q4lJQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000</nrbo:LesseeMonthlyOperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_HhypM8orekaUV3ZSz7r8gQ"
      id="Narr_RS24lPKr_EOrhEw6DDMhrQ">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <nrbo:LesseeMonthlyOperatingLeaseCost
      contextRef="Duration_2_1_2020_To_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_bI49wt-rv06inimFCn-hbg"
      decimals="-3"
      id="Narr_9vjqcl7qoUGtwwUBWvyccw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">21000</nrbo:LesseeMonthlyOperatingLeaseCost>
    <nrbo:LesseeOperatingLeaseIncentiveFromLessor
      contextRef="As_Of_2_1_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_HhypM8orekaUV3ZSz7r8gQ"
      decimals="-3"
      id="Narr_TNUdwz8a-U2NsigQZOld-A"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">32000</nrbo:LesseeOperatingLeaseIncentiveFromLessor>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_DMIjvwYsPkGpJljUcZUhyA"
      id="Narr_h0Pi7nYRs0GV0bHZKCwoLA">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <nrbo:LesseeMonthlyOperatingLeaseCost
      contextRef="Duration_2_1_2021_To_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_-Qb32V34hEG7LHl67hYHEQ"
      decimals="-3"
      id="Narr_PI22TSVt5kCeAu6ZvDXrag"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000</nrbo:LesseeMonthlyOperatingLeaseCost>
    <nrbo:LesseeOperatingLeaseIncentiveFromLessor
      contextRef="As_Of_2_1_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_DMIjvwYsPkGpJljUcZUhyA"
      decimals="-3"
      id="Narr_5FBlfzlekU2YU5YF6qhy0Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000</nrbo:LesseeOperatingLeaseIncentiveFromLessor>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_JfiOhNhM4kq-BfVEu0LZXA"
      decimals="-3"
      id="Narr_xVxlzYFxUkuC122xUSG49Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember__f5vapaPiE6z4tp3rFwAtg"
      decimals="-3"
      id="Narr_mz8Gv3sNOkSTtLAXBwsh0A"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nrbo_HeadquartersInBostonLeaseMember_FGRQQlyE-kqOj-HImH6Z9A"
      decimals="-3"
      id="Narr_yZHJxB0SVkmEHVZL8y4K3Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">48000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_5_31_2019_srt_StatementGeographicalAxis_country_KR_HvV-4l0BaEGxJ9yVDcToOA"
      id="Narr_sFIz-E_Nk0uk6VLYK28bDw">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_5_1_2019_To_5_31_2019_srt_StatementGeographicalAxis_country_KR_4xOvJGybuEay2f4Kwe1YKA"
      id="Narr_htRqECv_OUuiboB1NRyuFw">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_5_31_2019_srt_StatementGeographicalAxis_country_KR_HvV-4l0BaEGxJ9yVDcToOA"
      id="Narr_t0AnfF3mMUGbZHjjYKAL9g">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="Duration_4_30_2022_To_4_30_2022_srt_StatementGeographicalAxis_country_KR_YsKsKamLv0yflBeWRDvO7w"
      decimals="-3"
      id="Narr_mbW6ATt-r0O6Sf6-C4puZA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_KR_YvToqRmZfUCr2F12W7LUeA"
      decimals="-3"
      id="Narr_ee-yvAx68UeekGLARBP-0w"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_KR_G_Rp8jJUYUWnai9tqLfSSA"
      decimals="-3"
      id="Narr_JTQnxdgEAkKvlcRNLH5KUA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_KR_YvToqRmZfUCr2F12W7LUeA"
      decimals="-3"
      id="Narr_1dMHO3cSV02A5-P_0dn0FA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">11000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_KR_G_Rp8jJUYUWnai9tqLfSSA"
      decimals="-3"
      id="Narr_qYc-ezQmCU2ufvddvt-giA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">32000</us-gaap:OperatingLeasePayments>
    <nrbo:NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_LicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_6hrwWyQFkkGHl0B3-Pe0ug"
      decimals="INF"
      id="Narr_JeYm0CCyTUOdGRjKiMGIWw"
      unitRef="Unit_Standard_item_BbpdEDrZSk2GQqI08hy64Q">2</nrbo:NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement>
    <nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived
      contextRef="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1726Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_QniKuwjxwU-VAVU5AQO_tA"
      decimals="-6"
      id="Narr_qBQu3dkFA0mC5g5hhD2rqg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">178000000</nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived>
    <nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived
      contextRef="As_Of_9_14_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_Da1241Member_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_3M2K_Hs1_kGIY2eTUaM2fA"
      decimals="-6"
      id="Narr_oCCywoO-r0OqtoWJQT3hRQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">138000000</nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived>
    <nrbo:MilestonesAccrued
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Narr_9TDDgv5xb0Sb-FhzIObQUg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:MilestonesAccrued>
    <nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights
      contextRef="As_Of_12_30_2019_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_oIsPvJwajkGM38Ex40BY6A"
      decimals="2"
      id="Narr_spXdSk-whU2ZrhHhWobMDQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.80</nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights>
    <nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights
      contextRef="As_Of_12_30_2019_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_oIsPvJwajkGM38Ex40BY6A"
      decimals="2"
      id="Narr_gdx7LNn4UUu3CeEJAU-uGw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.80</nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights>
    <nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights
      contextRef="As_Of_3_23_2021_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_GAKGJeHh6UuULfG-TYy7pg"
      decimals="2"
      id="Narr_REv8bO3fA06lzlGPyMVKVw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.10</nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights>
    <nrbo:MilestonesAccrued
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_htnX0uXa7kCB-UHSuxbNSA"
      decimals="-3"
      id="Narr_oGj255NLjUK5JH2kNe0KVg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:MilestonesAccrued>
    <nrbo:ContingentLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_srt_RangeAxis_srt_MaximumMember_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OkcQ-fcFaECmAneltF__OA"
      decimals="-6"
      id="Narr_8jVBpfzYo0GFx3oLyqJAgw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">37000000</nrbo:ContingentLiability>
    <nrbo:NumberOfYearsAfterFirstSaleOccurs
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ"
      id="Narr_vU1SOKR1UkC0Z_G19gTP4w">five</nrbo:NumberOfYearsAfterFirstSaleOccurs>
    <nrbo:LicenseTerminationNoticePeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ"
      id="Narr_Bq1KCuNSc0SONa67N5Iw6w">P90D</nrbo:LicenseTerminationNoticePeriod>
    <nrbo:LicenseAgreementEarlyTerminationFee
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_e_U9zOVAtEW8M7Nl3d2N0g"
      decimals="-5"
      id="Narr_L7vZ_2l0IEmei4LAlH9RiQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000000.0</nrbo:LicenseAgreementEarlyTerminationFee>
    <nrbo:MilestonesOrRoyaltyPaymentsTriggered
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_JpNwtACeAEisv2eSDupv_g"
      decimals="-3"
      id="Narr_WADp29oQ00C4GzdMaxgQvQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:MilestonesOrRoyaltyPaymentsTriggered>
    <nrbo:MilestonesOrRoyaltyPaymentsTriggered
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_mjMk3AND9EGHArh1vyRDSQ"
      decimals="-3"
      id="Narr_VVnj2WTChUO3hk9gEA1WKQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:MilestonesOrRoyaltyPaymentsTriggered>
    <nrbo:AssetAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="As_Of_12_31_2020_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IG_Y6UouBkm4R_t4WrbvGQ"
      decimals="INF"
      id="Narr_LwGZUu5GdEGBBth1ecWg0Q"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">1</nrbo:AssetAcquisitionPercentageOfVotingInterestsAcquired>
    <nrbo:ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IPbMK5DMBU-arb5dHnRBNg"
      id="Tb_WSeedaY5LkeNNYw-or8WTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:3pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:91.69%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr style="height:22.3pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0pt 2pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Event&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 20.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9.55pt;"&gt;&lt;td colspan="2" style="vertical-align:bottom;width:70.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:9.55pt;margin:0pt;"&gt;First receipt of Marketing Approval (as defined in the 2020 Merger Agreement) from the FDA for any Niclosamide Product (as defined in the 2020 Merger Agreement)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; $&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;45.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21.6pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;Sales Milestones:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 11pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21.15pt;"&gt;&lt;td colspan="2" style="vertical-align:bottom;width:70.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Event &#x2013; Worldwide Cumulative Net Sales of a Niclosamide Product&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.9pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equal to or greater than:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.68%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.89%;border-bottom:1.0pt solid #cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 19.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Payment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.45pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$500 million&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;9.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.8pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$1 billion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;13.5 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:10.8pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$3 billion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;36.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.7pt;"&gt;&lt;td style="vertical-align:bottom;width:27.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;"&gt;$5 billion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:42.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:5.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 4.8pt 0pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:24.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"&gt;72.0 million&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</nrbo:ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock>
    <nrbo:InitialMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_FirstAmendmentToOriginalCvrAgreementMember_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_XHR9_9HRME-lP7dY7J3wUA"
      decimals="-5"
      id="Narr_hEyGGJp6DUy8CPacvwGhhQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">45000000.0</nrbo:InitialMilestonePayment>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThan500MillionMember_k1KYYL1K_0-HvDnDN7RX9A"
      decimals="-6"
      id="Narr_r2EoYbxQg0-XCe5isXdIVA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">500000000</nrbo:SalesBasedMilestonePayment>
    <nrbo:InitialMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThan500MillionMember_k1KYYL1K_0-HvDnDN7RX9A"
      decimals="-5"
      id="Narr_rnlZe9lnfESYQLl_xbSWWw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">9000000.0</nrbo:InitialMilestonePayment>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanOneBillionMember_UdP-HCvD0E2O-ZPaLupmow"
      decimals="-9"
      id="Narr_K7tsOr11-UmE84EfVh6yFQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000000000</nrbo:SalesBasedMilestonePayment>
    <nrbo:InitialMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanOneBillionMember_UdP-HCvD0E2O-ZPaLupmow"
      decimals="-5"
      id="Narr_ZlwFy0LrbEKg8z-8cU8Z7A"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">13500000</nrbo:InitialMilestonePayment>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanThreeBillionMember_sZhFMyWVrE2W0wp6FIo2LA"
      decimals="-9"
      id="Narr_dWpV-PRPVUqrB4NV56HouA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000000000</nrbo:SalesBasedMilestonePayment>
    <nrbo:InitialMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanThreeBillionMember_sZhFMyWVrE2W0wp6FIo2LA"
      decimals="-5"
      id="Narr_spWG7ngj9kaaMdYSSrMjgw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">36000000.0</nrbo:InitialMilestonePayment>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanFiveBillionMember_Bk3afARaEEa5UtSxvJFFcw"
      decimals="-9"
      id="Narr_Mc_NqkD3xkmwNNs5IiV13Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5000000000</nrbo:SalesBasedMilestonePayment>
    <nrbo:InitialMilestonePayment
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_CumulativeNetSalesMoreThanFiveBillionMember_Bk3afARaEEa5UtSxvJFFcw"
      decimals="-5"
      id="Narr_lmnx4d-O3EWRdsm1Pr2o7g"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">72000000.0</nrbo:InitialMilestonePayment>
    <nrbo:PercentageOfRoyaltyPayments
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="3"
      id="Narr_FjTNyGM0s0eUtnp4druZQA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.025</nrbo:PercentageOfRoyaltyPayments>
    <nrbo:RoyaltyPaymentAccrued
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Narr_-4YZB8kD_EyCkB7slXwSYg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:RoyaltyPaymentAccrued>
    <nrbo:RoyaltyPaymentAccrued
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Narr_4y5Nyj10vkWWCamgP5VIsw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:RoyaltyPaymentAccrued>
    <nrbo:PercentageOfRoyaltyPayments
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_OWD6T-tZC06ThXS0xCkQyw"
      decimals="3"
      id="Narr_xnjQWif_9UurOCRPuMs2tA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.005</nrbo:PercentageOfRoyaltyPayments>
    <nrbo:RoyaltyAndMilestonePaymentsDue
      contextRef="As_Of_12_31_2020_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_uh4H-TEI7EyhE2e1wLB-OA"
      decimals="-5"
      id="Narr_ihNouIWkv0W_3XNXhJ597Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">19500000</nrbo:RoyaltyAndMilestonePaymentsDue>
    <nrbo:RoyaltyAndMilestonePaymentsDue
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_OtherCommitmentsAxis_nrbo_MilestonePaymentsMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_DrCMGt_Bb0m-pV_jNh3q6A"
      decimals="-6"
      id="Narr_KUZ0cL3P9UCREf3mWpHYew"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5000000</nrbo:RoyaltyAndMilestonePaymentsDue>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierOneNetSalesMilestoneMember_SES_rbkbP0eNKOMs2xwA_A"
      decimals="-6"
      id="Narr_HfX6LRPpgEq9VMT4v9gmBw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000000</nrbo:SalesBasedMilestonePayment>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierTwoNetSalesMilestoneMember_dpzKVlo1ekGtUs9fT1O3mw"
      decimals="-5"
      id="Narr_ivAYfnuUfUuGgBuSmIaKIw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1500000</nrbo:SalesBasedMilestonePayment>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierThreeNetSalesMilestoneMember_fzSwTYIVmkeJrh9SwkEpKQ"
      decimals="-6"
      id="Narr_7TnjGCZZUkWvRYjrt8Zn_g"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4000000</nrbo:SalesBasedMilestonePayment>
    <nrbo:SalesBasedMilestonePayment
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierFourNetSalesMilestoneMember_TxpZFkCQ10C-ExxaRCaBqA"
      decimals="-6"
      id="Narr_rXNSuCvupUS9I-dRkRHdcw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8000000</nrbo:SalesBasedMilestonePayment>
    <nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierOneNetSalesMilestoneMember_SES_rbkbP0eNKOMs2xwA_A"
      decimals="-6"
      id="Narr_5oBuJt6PSESkFDEV4cuRZg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">500000000</nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones>
    <nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierTwoNetSalesMilestoneMember_dpzKVlo1ekGtUs9fT1O3mw"
      decimals="-9"
      id="Narr_Rz1VGjozAUy-5nxbNbk1tQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000000000</nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones>
    <nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierThreeNetSalesMilestoneMember_fzSwTYIVmkeJrh9SwkEpKQ"
      decimals="-9"
      id="Narr_g0LxaDqRGUma6wLJQUQCMw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3000000000</nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones>
    <nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones
      contextRef="As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierFourNetSalesMilestoneMember_TxpZFkCQ10C-ExxaRCaBqA"
      decimals="-9"
      id="Narr_wQLhcuYgnkqN7X9gJSEyZw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5000000000</nrbo:PaymentsForSpecifiedGlobalNetSalesMilestones>
    <nrbo:MilestonesOrRoyaltyPaymentsTriggered
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_azdNGhPJu0ixmk2GgSSbKA"
      decimals="-5"
      id="Narr_uTFj5aZKcU24ywpaKw1heg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:MilestonesOrRoyaltyPaymentsTriggered>
    <nrbo:MilestonesOrRoyaltyPaymentsTriggered
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_nrbo_YourchoiceTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementMember_MCgUOrSmAUGyN4xH2iEx5g"
      decimals="-5"
      id="Narr_ZNvuJdZ-SES85tSdgI_Bzg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:MilestonesOrRoyaltyPaymentsTriggered>
    <nrbo:LicenseAgreementDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_wJ1XL_HaZUWhWrQNcsSIxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Dong-A License Agreement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;On September&#160;14, 2022, the Company and Dong-A entered into the&#160;2022 License Agreement, pursuant to which, the Company received an exclusive global license (except for the territory of the Republic of Korea and certain other jurisdictions) to two proprietary compounds for specified indications upon meeting certain financing milestones. The 2022 License Agreement covers the rights to DA-1241 for treatment of NASH and DA-1726 for treatment of obesity and NASH. The 2022 License Agreement also provides that the Company may develop DA-1241 for the treatment of T2D. Under the terms of the 2022 License Agreement, (i), the Company agreed to pay Dong-A an upfront payment to be settled with 2,200 shares of a new series of preferred stock designated as &#x201c;Series&#160;A Convertible Preferred Stock&#x201d;, par value $0.001 per share (the&#160;&#x201c;Series&#160;A Preferred Stock&lt;span style="font-style:italic;font-weight:bold;"&gt;&#x201d;&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;), upon completion of a financing (see Note 7 &#x2013; Stockholder&#x2019;s Equity).  &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;The Series A Preferred Stock issued in connection with the 2022 License Agreement was recorded as IPR&amp;amp;D expense in the amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$8.2&lt;/span&gt;&lt;span style="white-space:pre-wrap;background:#ffffff;"&gt; million based on the fair market value of the Series A Preferred Stock.  The 2022 License Agreement did not include any processes  or activities constituting a &#x201c;business&#x201d; were acquired and since none of the rights underlying the Dong-A License Agreement had alternative future uses or had reached a stage of technological feasibility.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The term of the 2022 License Agreement continues on a product-by-product and country-by country basis until the later of (i)&#160;the fifth anniversary of the first commercial sale of such product in such country, (ii)&#160;the expiration or termination of the last valid patent claim that covers a product in such country and (iii)&#160;the loss of regulatory exclusivity for such product in such jurisdiction. Either Dong-A or the Company may terminate the 2022 License Agreement (i)&#160;if the other party is in material breach of the agreement and has not cured or started to cure the breach within 60 days of notice of such breach; provided that if the breach cannot be cured within the &lt;span style="-sec-ix-hidden:Hidden_8VHUHzuV5UqZVxVaa0LNCA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;60-day&lt;/span&gt;&lt;/span&gt; period and the breaching party started to remedy the breach, if such breach is not cured within 90 days of receipt of written notice, (ii)&#160;if the other party is subject to a bankruptcy or insolvency event (subject to a &lt;span style="-sec-ix-hidden:Hidden_KYNGeI_ZfkuzqiJCYGB1Ww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;30-day&lt;/span&gt;&lt;/span&gt; cure period in the case of a petition for bankruptcy), or (iii)&#160;in the event the Company had failed to complete the public offering as further described in Note 7 -Stockholders&#x2019; Equity by December&#160;31, 2022 (or January&#160;31, 2023 under specified circumstances set forth in the 2022 License Agreement).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;None of the milestone or royalty payments under the 2022 License Agreement were triggered as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Shared Services Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;On September&#160;14, 2022, in conjunction with the Dong-A License Agreement, the Company entered into a shared services agreement with Dong-A (the&#160;&#x201c;Shared Services Agreement&#x201d;). The Shared Services Agreement provides that Dong-A may provide technical support, pre-clinical development, and clinical trial support services on terms and conditions acceptable to both parties. In addition, the Shared Services Agreement provides that Dong-A will manufacture all of the Company&#x2019;s clinical requirements of DA-1241 and DA-1726.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Either party may terminate the Shared Services Agreement for the other party&#x2019;s material breach that is not cured within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of notice. Dong-A may also terminate the Shared Services Agreement in part on a service-by-service or product-by-product basis upon a breach by the Company which is not cured within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;30 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;As of December 31, 2022, the Company did not incur any research and development expenses under the Shared Services Agreement.&lt;/p&gt;</nrbo:LicenseAgreementDisclosureTextBlock>
    <nrbo:NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ"
      decimals="INF"
      id="Narr_F86bz-SYzEGsR02iundncA"
      unitRef="Unit_Standard_item_BbpdEDrZSk2GQqI08hy64Q">2</nrbo:NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement>
    <nrbo:ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_7cfaqECBI0mYM0TA6a38MQ"
      decimals="INF"
      id="Narr_dDTFoTmL8Ui3Wn0efnRcpA"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2200</nrbo:ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_9_14_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_2N6TCpmcHEazJ6gu1eY5yA"
      decimals="INF"
      id="Narr_5tDHjNaNVku_xLk95tp4EA"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_goh7paQIHkKoksKth-jjfg"
      decimals="-5"
      id="Narr_RSKxCIaYBEWTJCJzmHlZLQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8200000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <nrbo:PeriodForFailToCureBreachMayTerminateAgreement
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ"
      id="Narr_sM-L2L5V7EiJd5gGVj-mbA">P60D</nrbo:PeriodForFailToCureBreachMayTerminateAgreement>
    <nrbo:CurePeriodForBreachingParty
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ"
      id="Narr_rkzw6GMq1U2Zg3RGNn-DRQ">P90D</nrbo:CurePeriodForBreachingParty>
    <nrbo:PeriodForTerminationNotice
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_SharedServicesAgreementMember_bK2yJe4yoU2jm_DEGsbO0Q"
      id="Narr_V888Fm1guUuS43FjVlVEbw">P30D</nrbo:PeriodForTerminationNotice>
    <nrbo:PeriodForFailToCureBreachMayTerminateAgreement
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_SharedServicesAgreementMember_bK2yJe4yoU2jm_DEGsbO0Q"
      id="Narr_tC7GmQVFxEGyiPo3sWmj_Q">P30D</nrbo:PeriodForFailToCureBreachMayTerminateAgreement>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb__ZMEmeWitEiPn0z6kVKQ0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Beijing SL License Agreement &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Beijing SL License and Collaboration Agreement &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Upon the close of the 2019 Merger, the License and Collaboration Agreement (the &#x201c;Beijing SL Agreement&#x201d;) with Beijing SL Pharmaceutical Co., Ltd. (&#x201c;Beijing SL&#x201d;)(the &#x201c;Beijing SL Agreement&#x201d;) was assumed by the Company, pursuant to which the Company granted Beijing SL an exclusive royalty-bearing license to research, develop, manufacture and commercialize pharmaceutical products comprising, as an active ingredient, Gemcabene in mainland China, Hong Kong, Macau and Taiwan (each, a &#x201c;region&#x201d;, and collectively, the &#x201c;Territory&#x201d;). The terms of the Beijing SL Agreement include payments based upon achievement of milestones and royalties on net product sales. Under the Beijing SL Agreement, the Company has variable consideration in the form of milestone payments. As of December 31, 2022, no revenue under the Beijing SL Agreement has been recognized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Under the terms of the Beijing SL Agreement, Beijing SL will be responsible, at its expense, for developing and commercializing products containing Gemcabene (each, a &#x201c;Licensed Product&#x201d;) in the Territory, with certain assistance from the Company. To the extent mutually agreed to in writing, the Company and Beijing SL will collaborate on the Phase 3 clinical trial for homozygous familial hypercholesterolemia or other clinical trials with the Company as the sponsor designed to enroll patients both inside and outside the Territory (a &#x201c;Global Study&#x201d;), but Beijing SL will be responsible, at its expense, for the conduct of any Global Study to the extent solely in the Territory, subject to the Company&#x2019;s final decision making authority, and the Company will be responsible, at its expense, for the conduct of any Global Study to the extent solely outside of the Territory. Under a territory development plan, the parties shall develop Licensed Products with respect to the Territory. Beijing SL will be responsible for development activities, including non-clinical and clinical studies directed at obtaining regulatory approval of the Licensed Product in the Territory.&#160;Beijing SL has agreed to use commercially reasonable efforts to commercialize the Licensed Products for each indication that receives regulatory approval in the Territory and shall prepare and present a commercialization plan that shall be subject to approval by the joint steering committee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Pursuant to the Beijing SL Agreement, Beijing SL was to make a non-refundable upfront gross payment of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million to the Company within &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;45 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; of the effective date of the Beijing SL Agreement; the upfront payment was received in October 2019 and such funds were fully expended prior to the close of 2019 Merger. Additionally, with respect to each Licensed Product, the Company is eligible to receive (i) payments for specified developmental and regulatory milestones (including submission of a new drug application to China&#x2019;s National Medical Product Administration, dosing of the first patient in a phase 3 clinical trial in mainland China and regulatory approval for the first and each additional indication of a Licensed Product in the Territory) totaling up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$6&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;million in the aggregate and (ii) payments for specified global net sales milestones of up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$20&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million in the aggregate multiplied by the ratio of the net sales of a Licensed Product sold by Beijing SL in the Territory divided by the global net sales of a Licensed Product, which net sales milestone payments are payable once, upon the first achievement of such milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;Beijing SL is also obligated to pay the Company tiered royalties ranging from the mid-teens to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;twenty&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; percent on the net sales of all Licensed Products in the Territory until the latest of (a) the date on which any applicable regulatory exclusivity with respect to such Licensed Product expires in such region, (b) the expiration or abandonment of the last valid patent claim or joint patent claim covering such Licensed Product in each region and (c) the fifth anniversary of the first commercial sale of such Licensed Product in such region (the &#x201c;Royalty Term&#x201d;). Future milestone payments under the Beijing SL Agreement, if any, are not expected to begin for at least &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;one year&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and will extend over a number of subsequent years. The Company cannot determine the date on which Beijing SL&#x2019;s potential royalty payment obligations to the Company would expire because Beijing SL has not yet developed any Licensed Products under the Beijing SL Agreement and therefore the Company cannot at this time identify the date of the first commercial sale or the periods of any regulatory exclusivity or patent claims with respect to any Licensed Product.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;On a Licensed Product-by-Licensed Product and region-by-region basis upon the expiration of the Royalty Term, the license granted to Beijing SL shall be deemed perpetual, fully paid-up and royalty free with respect to such Licensed Product in such region. Either party may terminate the Agreement (x) with written notice in the event of the other party&#x2019;s material breach following a cure period or (y) if the other party becomes subject to certain insolvency proceedings. In &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;addition, the Company may terminate the agreement in its entirety if Beijing SL or its affiliates or sublicensees commence a proceeding challenging the validity, enforceability or scope of any of the Company&#x2019;s patents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;To the extent rights granted to Beijing SL under the Beijing SL Agreement are controlled by the Company pursuant to the Pfizer Agreement, such rights are subject to the terms and conditions of such agreement with Pfizer, and Beijing SL has agreed to comply with such terms and conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Beijing SL Agreement contemplates that Beijing SL and the Company shall, no later than twelve months prior to the anticipated date of the first commercial sale of a Licensed Product, if any, negotiate in good faith and execute a commercial supply agreement, pursuant to which Beijing SL shall purchase from the Company, and the Company shall use commercially reasonable efforts to supply, Gemcabene or Licensed Product for clinical or commercial purposes, as applicable, until manufacturing and regulatory transfers are complete.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Each of the Company and Beijing SL has agreed to indemnify the other party against certain losses and expenses relating to the development or commercialization of a Licensed Product by the indemnifying party, the negligence or willful misconduct of the indemnifying party or its directors, officers, employees or agents or a breach of the indemnifying party&#x2019;s representations, warranties or covenants. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_kBvkGV4jekagMWbtRHE_aA"
      decimals="-3"
      id="Narr_VEtYDV8GkECTEiLLS8q_tA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nrbo:LicenseAgreementUpfrontPaymentToBeReceived
      contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ"
      decimals="-5"
      id="Narr_1vlTuFRwf0C935v8J_Y9xQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2500000</nrbo:LicenseAgreementUpfrontPaymentToBeReceived>
    <nrbo:PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember__rH0iwnWGEWGagjRIx77dQ"
      id="Narr_asbRqNMcYUSXMS82ZWRYuw">P45D</nrbo:PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid>
    <nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived
      contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ"
      decimals="-6"
      id="Narr_luvv_5ryMEeVRryzknUrvA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">6000000</nrbo:LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived>
    <nrbo:LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived
      contextRef="As_Of_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_90Lwqnec50el-MHwzeAkKQ"
      decimals="-6"
      id="Narr_GSOULleXz0anl-AxKJAFsQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">20000000</nrbo:LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived>
    <nrbo:PercentageOfRoyaltyOnNetSales
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_wzCrD8W_a0KHVlgiyTYKNg"
      decimals="2"
      id="Narr_tjgVLVO92E6LpOg89nB3Sg"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.20</nrbo:PercentageOfRoyaltyOnNetSales>
    <nrbo:MinimumExpectedPeriodToBeginFutureInstallmentPayment
      contextRef="Duration_10_1_2019_To_10_31_2019_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember__rH0iwnWGEWGagjRIx77dQ"
      id="Narr_4KhGJ-J5pUeYS7U4nmsDRQ">P1Y</nrbo:MinimumExpectedPeriodToBeginFutureInstallmentPayment>
    <nrbo:ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_wzCrD8W_a0KHVlgiyTYKNg"
      id="Narr_kw9DcJNguU-l9y4eEwVpAQ">P12M</nrbo:ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_xGO2NIpcgE2aWjFnodyiUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7.&lt;/b&gt; S&lt;b style="font-weight:bold;"&gt;tockholders&#x2019; Equity &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock when outstanding. The holders of the common stock are entitled to one&lt;span style="white-space:pre-wrap;"&gt; vote for each share of common stock held at all meetings of stockholders.  &lt;/span&gt;Common stockholders are entitled to receive dividends at the sole discretion of the board of directors of the Company. There have been no&lt;span style="white-space:pre-wrap;"&gt; dividends declared on common stock to date as of December 31, 2022.  In the event of any liquidation, dissolution, or winding-up of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution post preferential distributions made to holders of the Company&#x2019;s preferred stock. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"&gt;The rights of the Series A Preferred Stock and Series B Preferred Stock (as defined further below), collectively, the &#x201c;Preferred Stock&#x201d;, while outstanding were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends.&lt;/i&gt;&lt;b style="font-weight:bold;letter-spacing:4pt;"&gt; &lt;/b&gt;Holders of the Preferred Stock were entitled to&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to&#173; common-stock basis) to the amount paid on shares of the common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights.&lt;/i&gt;&lt;b style="font-weight:bold;"&gt; T&lt;/b&gt;he Preferred Stock had no voting rights. However, as long as any shares of Preferred Stock were outstanding, the Company could not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Preferred Stock or amend its Certificate of Designation, (b) amend other charter documents in any manner that could have adversely affected any rights of the holders, (c) increase the number of authorized shares of Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing. &#160;In addition, the Series A Preferred Stock could have voted on any matter that authorized, created and/or issued any funded indebtedness (other than indebtedness already incurred); &#160;sold or transferred, other than in the ordinary course of its business, mortgaged, assigned, pledged, leased, granted a security interest in, or encumbered any of the Company&#x2019;s assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 6pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation.&lt;/i&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;The Preferred Stock while outstanding in the event of a liquidation,&lt;span style="letter-spacing:2pt;"&gt; &lt;/span&gt;dissolution&lt;span style="letter-spacing:2pt;"&gt; &lt;/span&gt;or&lt;span style="letter-spacing:1.75pt;"&gt; &lt;/span&gt;winding-up&lt;span style="letter-spacing:2pt;"&gt; &lt;/span&gt;of the&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Company, collectively a &#x201c;Liquidation&#x201d;, had the following rights: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0.05pt 6.25pt 0pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Series A Preferred Stock&lt;/i&gt;&lt;b style="font-weight:bold;"&gt;: &lt;/b&gt;Upon any Liquidation of the Company&lt;span style="letter-spacing:-0.1pt;"&gt;,&lt;/span&gt;&lt;span style="letter-spacing:-0.7pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;whether&lt;/span&gt;&lt;span style="letter-spacing:-0.7pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;voluntary or&lt;/span&gt;&lt;span style="letter-spacing:-0.7pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;involuntary&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;"&gt;,&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:-0.65pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;after&lt;/span&gt;&lt;span style="letter-spacing:-0.55pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.55pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;satisfaction&lt;/span&gt;&lt;span style="letter-spacing:0.35pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;in&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;full&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;of &lt;/span&gt;the&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;debts&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.75pt;"&gt; &lt;/span&gt;Company&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;payment&lt;span style="letter-spacing:-0.75pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;any&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;liquidation&lt;span style="letter-spacing:-0.55pt;"&gt; &lt;/span&gt;preference&lt;span style="letter-spacing:-0.4pt;"&gt; &lt;/span&gt;owed&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.8pt;"&gt; &lt;/span&gt;holders of&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;shares of capital stock of the&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;Company ranking senior to the Series A&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;Preferred Stock upon liquidation, but before any&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;distribution or&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;payment out of&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;assets of&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;Company shall&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;be&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;made to&lt;span style="letter-spacing:-0.55pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;holders&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.5pt;"&gt; any junior &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 6.25pt 6pt 36pt;"&gt;&lt;span style="letter-spacing:-0.5pt;"&gt;securities, including common stock,&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;an&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;amount in&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;cash per share equal to the amount per share in cash payable to the holder if the shares of Series A Preferred Stock&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;were&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;converted immediately prior&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;Liquidation into&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;shares&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; common stock&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:4.5pt 19.25pt 6pt 36pt;"&gt;&lt;i style="font-style:italic;"&gt;Series B Preferred Stock:&lt;/i&gt; Upon any &lt;span style="letter-spacing:1.35pt;"&gt;L&lt;/span&gt;iquidation of the Company, whether voluntary or&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;involuntary,&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.05pt;"&gt; holder&lt;/span&gt;s shall be&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;entitled to&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;receive out&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;assets, whether&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;capital or&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;surplus, of&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;Company the&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;same amount that a holder&lt;span style="letter-spacing:-0.05pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.5pt;"&gt; common stock&lt;/span&gt; would receive if&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.65pt;"&gt; Series B &lt;/span&gt;Preferred Stock were fully&lt;span style="letter-spacing:-0.55pt;"&gt; &lt;/span&gt;converted (disregarding for&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;such&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;purposes any&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;conversion limitations hereunder) to common stock which amounts shall be&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;paid pari passu with all holders of&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Conversion.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;white-space:pre-wrap;"&gt;  &lt;/i&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;white-space:pre-wrap;"&gt;  Series A Preferred Stock:&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Automatic Conversion. On the first Trading Day after the Company obtains the stockholder approval, all outstanding shares of the Series A Preferred Stock would, without any further action by holders and whether or not any certificates representing such shares are surrendered to the Company or the Transfer Agent, automatically be converted into such number of shares of common stock as determined by dividing the stated value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share by the conversion price then in effect (the &#x201c;Automatic Conversion&#x201d;). The conversion price upon an Automatic Conversion for the Series A Preferred Stock was equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;Special Cash Payout Provisions:  Unless and until stockholder approval was obtained, the holder did not have the right to acquire shares of common stock issuable upon conversion of the Series A Preferred Stock, and the Company was not required to issue shares of common stock issuable upon conversion of the Series A Preferred Stock in excess of the Share Cap as defined (the "Conversion Restriction"). Notwithstanding the foregoing, if the Automatic Conversion had not occurred by the nine (9)-month anniversary of the original issuance date, the holder would have been entitled to submit a request to the Company for the conversion of all, but not less than all, of holder's shares of Series A Preferred Stock that were subject to the Conversion Restriction that would have exceeded the Share Cap; provided, that, in lieu of the Conversion Shares that would have otherwise been deliverable upon conversion but for the Conversion Restriction, the Company would have instead delivered to such holder for each share of common stock that would have been so otherwise delivered an amount of cash equal to the volume weighted average price (&#x201c;VWAP&#x201d;) per share of common stock on the trading day immediately preceding the date such request is made.  If the Company failed to make any required cash payment by the required deadline on any share of Series A Preferred Stock, then the holder thereof would have been entitled to receive cumulative cash dividends on each such share at a rate per annum of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5.00%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; on the stated value ( "Default Cash Dividends''). Default Cash Dividends, if any, would have accumulated on a daily basis. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;white-space:pre-wrap;"&gt;  Series B Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Conversions at Option of Holder. Each share of Series B Preferred Stock was convertible, at any time at the option of the holder thereof, into that number of shares of common stock (subject to certain limitations) determined by dividing the stated value of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share by the conversion price in effect. The conversion price for the Series B Preferred Stock was equal &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fundamental Transaction.&lt;/b&gt; If, at any time while shares of the Preferred Stock were outstanding, the Company, directly or indirectly, in one or more related transactions effected any merger or consolidation of the Company, the holder of the Preferred Stock would have had the right to receive, for each conversion share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction as defined, the number of shares of common stock of the successor or acquiring Company or of the Company, if it is the surviving Company, and any additional consideration (the "Alternate Consideration'') receivable as a result of such Fundamental Transaction by a holder of the number of shares of the common stock for which shares of the Preferred Stock would have been &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;convertible immediately prior to such Fundamental Transaction. If holders of the common stock were given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder of the Preferred Stock would have been given the same choice as to the Alternate Consideration it would have received upon any conversion of shares of the Preferred Stock following such Fundamental Transaction. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022 Private Placement and Public Offering&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:12pt 0pt 0pt 0pt;"&gt;On September 14, 2022, the Company entered into a Securities Purchase Agreement with Dong-A (the &#x201c;Dong-A Securities Purchase Agreement&#x201d;). Pursuant to the Dong-A Securities Purchase Agreement, Dong-A agreed to purchase from the Company shares of its Series A Preferred Stock and warrants to purchase shares of its common stock, equivalent to those to be issued in the Qualified Financing (as hereafter defined), (collectively, the &#x201c;Dong-A Financing&#x201d;) concurrent with and contingent upon a qualified financing resulting in gross proceeds of at least $15 million exclusive of the Dong-A Financing (the &#x201c;Qualified Financing&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;On November 8, 2022, the Company closed on an underwritten public offering (the &#x201c;2022 Public Offering&#x201d;) of units with gross proceeds of approximately $17.3&lt;span style="white-space:pre-wrap;"&gt; million.  The underwritten public offering was comprised of (1) &lt;/span&gt;3,147,003 Class A Units, priced at a public offering price of $3.00 per Class A Unit, with each Class A Unit consisting of one share of common stock, a Series A Warrant (the &#x201c;Series A Warrants&#x201d;) to purchase one share of common stock for a purchase price of $3.00 per share that expires on the one year anniversary following the initial exercise date and a Series B Warrant (the &#x201c;Series B Warrants&#x201d;) to purchase one share of common stock, for a purchase price of $3.00 per share that expires on the five year anniversary following the initial exercise date, and (2) 2,602,997 Class B Units, priced at a public offering price of $3.00 per Class B Unit, with each Class B Unit consisting of one share of Series B convertible preferred stock (the &#x201c;Series B Preferred Stock&#x201d;), convertible into one share of common stock, one Series A Warrant and one Series B Warrant. The Series A Warrants and the Series B Warrants, (collectively, the &#x201c; Public Warrants&#x201d;) were to only be exercisable upon stockholder approval, and each Warrant was to be exchangeable for one share of common stock for no&lt;span style="white-space:pre-wrap;"&gt; additional consideration.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The 2022 Public Offering met the definition of a Qualified Financing as defined by the Dong-A Securities Purchase Agreement; therefore, on November 8, 2022, the license under the Dong-A License Agreement became effective, and the Company issued to Dong-A 2,200 shares of Series A Preferred Stock&lt;span style="white-space:pre-wrap;"&gt;.  In addition, the Company closed on the Dong-A Financing, and issued an additional &lt;/span&gt;1,500 shares of Series A Preferred Stock, 5,000,000 warrants substantially similar to the Series A Warrants and 5,000,000 warrants substantially similar to the Series B Warrants (the &#x201c;Dong-A Warrants&#x201d;). The Company received gross proceeds in the amount of $15.0 million in connection with the Dong-A Financing. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Series A Preferred Stock was initially classified outside of stockholders&#x2019; equity due to a contingent redemption feature if stockholder approval of the Series A Preferred Stock had not been secured within nine months from the date of issuance.  Stockholder approval was secured on December 22, 2022, at which time, all of the Series A Preferred Stock was automatically converted into &lt;/span&gt;12,333,333&lt;span style="white-space:pre-wrap;"&gt; shares of common stock.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Series B Convertible Preferred Stock was classified in permanent equity upon issuance as there were no other provisions precluding equity treatment.  As of December 31, 2022, all of the &lt;/span&gt;2,602,997 shares of the Series B Preferred Stock had been converted into 2,602,997 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The public Warrants and the Dong-A Warrants (together, the &#x201c;2022 Warrants&#x201d;), upon their issuance were not exercisable unless and until stockholder approval was granted as required under Nasdaq rules.  The Company accounts for these warrants as a liability at fair value as certain provisions precluded equity accounting treatment for these instruments. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;As the 2022 License Agreement and Dong-A Financing were both contingent and based on the terms of a Qualified Financing, the Company combined these two transactions along with the 2022 Public Offering (collectively, the &#x201c;2022 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Transaction&#x201d;) when allocating gross consideration and issuance costs. The table below lists the aggregate consideration received by the Company in the 2022 Transaction:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consideration received&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Dong-A License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 8,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Acquired in-process research and development&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Dong-A Financing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cash &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;2022 Public Offering&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 17,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cash &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;40,460 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The consideration received was first allocated to the 2022 Warrants at their fair value on the date of issuance.  The remainder of the consideration from the 2022 Transaction was allocated to the Series A Preferred Stock and Series B Preferred Stock (collectively the &#x201c;Preferred Stock&#x201d;), and to the common stock based on their relative fair values on the date of issuance. Issuance costs in connection with 2022 Transaction in the amount of &lt;/span&gt;$3.6 million were allocated to each instrument based on the amount of consideration allocated to each instrument. Issuance costs attributed to the Warrants in the amount of $2.2&lt;span style="white-space:pre-wrap;"&gt; million were recorded as financing expense in the accompanying consolidated statements of operations and comprehensive loss.  The remainder of the issuance costs were recorded in additional paid-in capital. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The fair value of the Series A Preferred Stock was probability weighted for stockholder approval to convert to common stock.  In the approval scenario, the fair value was calculated using the underlying stock price multiplied by the number of common shares to be issued on conversion as adjusted for a &lt;/span&gt;90% probability factor, a volatility rate of 101%, a discount for a lack of marketability of 11%, a risk free rate of 3.7% and a remaining term of 0.1&lt;span style="white-space:pre-wrap;"&gt; years.  In the non-approval scenario, the fair value was calculated using the underlying share price as adjusted for a &lt;/span&gt;10% probability factor, a volatility rate of 107%, a risk free rate of 4.6% and a remaining term of 0.8 years. A credit risk factor was also used to discount the future value of the Series A Preferred Stock as applicable. The concluded fair value of the Series A Preferred Stock upon issuance was approximately $3,732 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The fair value of the Series B Preferred Stock was equal to the underlying common stock fair value as the shares were readily convertible at the time of issuance on a one-for-one basis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The fair value of the 2022 Warrants was determined using a Monte Carlo simulation. However, due to the cashless exercise provision of the 2022 Warrants rendering the exercise price effectively at zero, the calculated price per share of the Warrants was equal to that of a share of common stock prior to taking into account the probability factor of stockholder approval factor at 90%. The concluded fair value of the 2022 Warrants was $24.3 million in the aggregate on their issuance date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;October 2021 Registered Direct Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;On October&#160;1, 2021, the Company entered into a Securities Purchase Agreement (the &#x201c;October 2021 Securities Purchase Agreement&#x201d;) with several institutional investors for the purchase and sale in a registered direct offering of 4,307,693 shares of the Company&#x2019;s common stock, at a purchase price of $3.25 per share for gross proceeds of approximately $14.0 million (the &#x201c;October 2021 Registered Offering&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The October 2021 Securities Purchase Agreement also provides for a concurrent private placement of warrants to purchase the Company&#x2019;s common stock (the &#x201c;October 2021 Warrants&#x201d;) with the purchasers in the October 2021 Registered Offering. The October 2021 Warrants will be exercisable for up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;4,307,693&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shares of common stock. The October 2021 Warrants will have an exercise price of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3.75&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; per share, will be exercisable commencing &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;six months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; from the issuance date (the &#x201c;Initial Exercise Date&#x201d;), and will expire &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Inik_Nb_jUm6ajNMDQ5Ppg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; and one-half years following the Initial Exercise Date.  The fair value of the 2021 Warrants was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.1&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;0.5%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;; expected volatility of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;80.0%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;; expected life of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;3.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; years; expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;0%&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;; and the underlying traded stock price.&#160;The relative fair value attributable to the stock and warrants was &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$9.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$4.2&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; million, respectively.  The 2021 Warrants were classified in stockholders&#x2019; equity as the number of shares were fixed and determinable, no cash settlement required and no other provisions precluding equity treatment. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issuance costs in connection with the October 2021 Registered Direct Offering were $1.2 million which included cash commissions equal to $1.0 million and legal and other fees of $0.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021 Private Placement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;On January 21, 2021, the Company closed on a Securities Purchase Agreement (the &#x201c;2021 Purchase Agreement&#x201d;) with certain institutional and accredited investors, pursuant to which the Company, in a private placement (&#x201c;2021 Private Placement&#x201d;), agreed to issue and sell an aggregate of 2,500,000 shares of the Company&#x2019;s common stock at a purchase price of $4.00 per share, and warrants to purchase an aggregate of 2,500,000 shares of the Company&#x2019;s common stock (the &#x201c;2021 Warrants&#x201d;), resulting in total gross proceeds to the Company of $10.0 million, before deducting placement agent fees and offering expenses. The 2021 Warrants have an initial exercise price of $6.03 per share. The 2021 Warrants are exercisable beginning six months following the date of issuance and will expire &lt;span style="-sec-ix-hidden:Hidden_STCOS7deHEiR00lPkfq1OA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; and one-half years following such date. The fair value of the 2021 Warrants was $7.5 million and was based on the Black-Scholes pricing model. Input assumptions used were as follows: a risk-free interest rate of 0.5%; expected volatility of 76.0%; expected life of 5.5 years; expected dividend yield of 0%; and the underlying traded stock price.&#160;The relative fair value attributable to the stock and warrants was $6.3 million and $3.7&lt;span style="white-space:pre-wrap;"&gt; million, respectively.  The 2021 Warrants were classified in stockholders&#x2019; equity as the number of shares were fixed and determinable, no cash settlement required and no other provisions precluding equity treatment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issuance costs in connection with the 2021 Private Placement were $0.9 million which included cash commissions equal to $0.7 million and legal and other fees of $0.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"&gt;The following warrants were outstanding as of December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:31.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;March 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,800.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;March 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;July 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5,602.50 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;April 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;375.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;January 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;180.90 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;October 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;112.50 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;November 2022 Series A&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,768,837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;November 2022 Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,267,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;December 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15,264,242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;229,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The warrants outstanding as of December 31, 2022 are all exercisable.  In addition, the 2022 Warrants have a cashless exercise provision whereby &lt;/span&gt;one warrant can be exchanged for one share of common stock for no additional consideration, which renders the $3.00 per share exercise price to be $0.00&lt;span style="white-space:pre-wrap;"&gt;.  During the year ended December 31, 2022, &lt;/span&gt;3,981,163 Series A Warrants and 2,482,830&lt;span style="white-space:pre-wrap;"&gt; Series B Warrants were exchanged for shares of the Company&#x2019;s common stock.  &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <nrbo:CommonStockVotingRightsPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_So7KMVKDvUCsP2KQ3cuIrg"
      decimals="INF"
      id="Narr_OY0kmSJHu0K3HM4GZ--WTg"
      unitRef="Unit_Divide_Vote_shares_q2LbOB3SVUaQQK-N2RnI1g">1</nrbo:CommonStockVotingRightsPerShare>
    <nrbo:CumulativeDividendsDeclared
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q3-mJMBicE61mfQGtilTDA"
      decimals="-3"
      id="Narr_nFx1kBLGD02b53ujdCF1Qg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</nrbo:CumulativeDividendsDeclared>
    <nrbo:PreferredStockStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA"
      decimals="INF"
      id="Narr_GjAe1vd350mFxxtJlql9Ag"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">10000</nrbo:PreferredStockStatedValuePerShare>
    <nrbo:PreferredStockStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA"
      decimals="INF"
      id="Narr_EqP6nG20Z02GWSBEgYq0bw"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">10000</nrbo:PreferredStockStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XN-rjhRAiE-9_iqVqgbcAA"
      decimals="2"
      id="Narr_xXZWFSFwn0KEBNpdo5QLAA"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ZNoLMPLiW0aszZnLPwlyiQ"
      decimals="4"
      id="Narr_X_CtToAZqE2c2fpt75cRww"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.0500</us-gaap:PreferredStockDividendRatePercentage>
    <nrbo:PreferredStockStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Y7ZQpxzhMUm9V49NbXYQOw"
      decimals="INF"
      id="Narr_n3iUaQDKJUunpUnNS9ikpw"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</nrbo:PreferredStockStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Y7ZQpxzhMUm9V49NbXYQOw"
      decimals="2"
      id="Narr_bOcTKJpZBU2nk3yuWm8HZg"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="Duration_9_14_2022_To_9_14_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XHL-x0fEb0yRGhDBpCdG2A"
      decimals="-6"
      id="Narr_IhMU9REVD0aB5ufbKgwR3A"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">15000000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_mAMpODa2nkKAzLAAMiOi-g"
      decimals="-5"
      id="Narr_LmdZ6Clac02qojrmO-3pOA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">17300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_flmg7ndj70K84Nl5u2HoQg"
      decimals="INF"
      id="Narr_N6PLCxfw6EyKx1xUt2z0MQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">3147003</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_X91Oqmk7XUCm6SQsu_Avpg"
      decimals="2"
      id="Narr_G8e4dqYgBkuJznHqLMOSdw"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</us-gaap:SharePrice>
    <nrbo:NumberOfCommonStockIssuedPerUnit
      contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassUnitsMember_X91Oqmk7XUCm6SQsu_Avpg"
      decimals="INF"
      id="Narr_9EJw9-RQcEuDQBRumPdAbQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</nrbo:NumberOfCommonStockIssuedPerUnit>
    <nrbo:NumberOfCommonStockIssuedPerUnit
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ"
      decimals="INF"
      id="Narr_QOk_e4L0L0en9R030NwUnw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</nrbo:NumberOfCommonStockIssuedPerUnit>
    <us-gaap:SharePrice
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ"
      decimals="2"
      id="Narr_R7FdDLyz20mfsou_WHj9Yg"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ"
      id="Narr_uN3r5FP-UkmcCRg1NRlaBA">P1Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <nrbo:NumberOfCommonStockIssuedPerUnit
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ"
      decimals="INF"
      id="Narr_yWgKmQ0ad0aqtiqG7MCZTg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</nrbo:NumberOfCommonStockIssuedPerUnit>
    <us-gaap:SharePrice
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ"
      decimals="2"
      id="Narr_nzpoi1KJqkqzct-1-HUHPw"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ"
      id="Narr_zIDYmgXXCE6RpJxfbgUnjA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_DNs6bxizX0y5Tfgm4r8p_Q"
      decimals="INF"
      id="Narr_ehe7i_R7aEulcO3iI5noIg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2602997</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww"
      decimals="2"
      id="Narr_-wq4edpIt0OJC42AypcZKQ"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</us-gaap:SharePrice>
    <nrbo:NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit
      contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww"
      decimals="INF"
      id="Narr_SwpYMJxlj0CvEb620K3azA"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</nrbo:NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit>
    <nrbo:NumberOfCommonStockIssuedPerUnit
      contextRef="As_Of_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_yccuUby-0EWt--VYgYebww"
      decimals="INF"
      id="Narr_qn84SJkwYku2FdDdS_lh3A"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</nrbo:NumberOfCommonStockIssuedPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_vVxVMB4etkuISAzFnY5dCw"
      decimals="INF"
      id="Narr_h1eGCfY9i0yp800IqBfu1g"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_StatementClassOfStockAxis_nrbo_ClassBUnitsMember_xKdZLeM_RkacOFor73v_Pg"
      decimals="INF"
      id="Narr_CpiEHIqS6Eamh2rD3-mmhg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_Z5jcQtyp30eqx-cCA3OCtQ"
      decimals="INF"
      id="Narr_pGc5Bqyg-k-f0Up0HEdEHg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_11_8_2022_To_11_8_2022_b6Tq9XMF9kWXMJVobfHIhw"
      decimals="-5"
      id="Narr_qwzNNuhbUUGd3LoycfR1GQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_StatementClassOfStockAxis_nrbo_SeriesaRedeemableConvertiblePreferredStockMember_LDYXw0uQCUG-gO_0LLFXuA"
      decimals="INF"
      id="Narr_2Nt_0JoQVUKnXcwFURnYMQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_YwJOb8m61EqDiD7F2y2HpQ"
      decimals="INF"
      id="Narr_6YGWIm1CN0-o-tafCffSaQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nrbo:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_37I4EYMzakCIpYA1bW04gA"
      decimals="INF"
      id="Narr_KV5gb33KdkiIDWdT_LOhmw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">5000000</nrbo:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <nrbo:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="Duration_11_8_2022_To_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_JsyKwAESkU-fzjhg3wvYgw"
      decimals="INF"
      id="Narr__Va4uiclGEqg1RwYoFG9SA"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">5000000</nrbo:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_9_14_2022_To_9_14_2022_ZstQZeqBzk69SGCuk3r0kg"
      decimals="-5"
      id="Narr_wONMO76EFkOEGhwz7Dyx9g"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">15000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_12_22_2022_To_12_22_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ljoZFeq7K0W9sSW4K8xV6A"
      decimals="INF"
      id="Narr_83ZjtNS5h0C-TGroD1pZxQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">12333333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <nrbo:StockConvertedDuringPeriodShares
      contextRef="Duration_12_31_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AETHQHuOI0u7EUpHpFV96w"
      decimals="INF"
      id="Narr_CgDeOb6_uUSCDbDQ78aH-w"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2602997</nrbo:StockConvertedDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_12_31_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_AETHQHuOI0u7EUpHpFV96w"
      decimals="INF"
      id="Narr_6De0FX5Q6023HE39wm_F-g"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2602997</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <nrbo:ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_IlH8S8RjVUiV1WW9uLeDYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:22.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Consideration received&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Dong-A License Agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 8,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Acquired in-process research and development&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Dong-A Financing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 15,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cash &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;2022 Public Offering&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt; 17,250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 6pt;"&gt;Cash &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:33.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3pt 0.05pt 0pt;"&gt;40,460 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:10pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</nrbo:ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_EEmJUdpNf0uElf6g12GrWw"
      decimals="-3"
      id="Tc_08IQQrqfw0WYCPjk3ZiH5Q_2_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">8210000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_SecuritiesPurchaseAgreementMember_xdPppEpN60y-0j1Cm-TgmQ"
      decimals="-3"
      id="Tc_VLu446dipUyPICHjgUBnrw_3_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">15000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_nrbo_PublicOfferingMember_WMNL8kmcJU2TTDRxUzPFXw"
      decimals="-3"
      id="Tc_oehiyjCG3kGGp63hLCmvSA_4_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">17250000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_-6ptHclNgU6bxwnNFu86xw_6_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">40460000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <nrbo:StockIssuanceCost
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-5"
      id="Narr_UD7KJZkY2UWZXh6yj7VPHg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3600000</nrbo:StockIssuanceCost>
    <nrbo:WarrantsIssuanceCost
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_HJQHlQ__sE6LZHYJuTQyyw"
      decimals="-5"
      id="Narr_azKKbIiRBkKXpvnmjsRGrA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2200000</nrbo:WarrantsIssuanceCost>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gGUrMvv3ZkSmGD_w_TYU0Q"
      decimals="0"
      id="Narr_AiioR9ZOEkaeEfXxcaj3Vg"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">90</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wUjqzfyMzUqaUq1JGxWv1A"
      decimals="0"
      id="Narr_U2yP-aA-Y0mqNbVmm5mESg"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">101</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EowmUlNgF0ijywAkcdtsEw"
      decimals="0"
      id="Narr_ikcBuffAgEG9_7H0Y5Kdhw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">11</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mjtKTnsE70-ZgJb276XuuA"
      decimals="1"
      id="Narr_eLaiMn7W302VVQ0Rpd-IyA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">3.7</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_cq7ytvBYmU6naQ7Efn7LIw"
      decimals="1"
      id="Narr_a7Ak7A9zDEKETe__hnu7oA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.1</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_nrbo_MeasurementInputProbabilityFactorMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_jPeszFZjIEqx6fhLN1VR3Q"
      decimals="0"
      id="Narr_koHtrnqAfEew0TfeZGoMlQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">10</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_U3QAOXXUOUiR6REQjSJf4g"
      decimals="0"
      id="Narr_TJDbL1ohLk6k5acMdMPTrw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">107</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_IvLn50OmOkCyhBU3LyuqfA"
      decimals="1"
      id="Narr_tH92wDfq5U-TGYMQWTbE0w"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">4.6</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockMeasurementInput
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JiGuQjKiyUmwErH_myawlQ"
      decimals="1"
      id="Narr_myC9MqJskkqmT2Wv6mfZnw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.8</nrbo:PreferredStockMeasurementInput>
    <nrbo:PreferredStockFairValuePerShare
      contextRef="As_Of_12_31_2022_srt_StatementScenarioAxis_nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_72IFixvL4kSbmpjM1YSfwQ"
      decimals="0"
      id="Narr_k3sC9PbDsEeqwvaQtFq9-g"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3732</nrbo:PreferredStockFairValuePerShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_z5T8f5E9g0WIA-Y0HVYsRg"
      decimals="0"
      id="Narr_DY3e-MHZdEWMlJjmxMsfCA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_J16HTiOMUUCrNH8sj3WXBw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24300000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="INF"
      id="Narr_T7SEnP5JN0igEIrchN0G_w"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">4307693</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg"
      decimals="2"
      id="Narr_60KFvHiBkEyPLJWW0OE2ZA"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="-5"
      id="Narr_94t0jrQotk-hmFkai8obAQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">14000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg"
      decimals="INF"
      id="Narr_3OxgPHlmh0-PKaiKbXXCvQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">4307693</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg"
      decimals="2"
      id="Narr_sFdWjl0gbk6TXykjIVDf1A"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nrbo:PeriodFromIssuanceDateWarrantsBecomeExercisable
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      id="Narr_ugfm7erJsEiSLiR7cGxDWg">P6M</nrbo:PeriodFromIssuanceDateWarrantsBecomeExercisable>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_6ZluvfUWt0SoBxJiMoVVdg"
      decimals="-5"
      id="Narr_Rr4v9TJGfEqSyqn52s593A"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4100000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="3"
      id="Narr_1a7aRssBOEu9LPWKaA9O-Q"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="3"
      id="Narr_E5ZV_gLq4UaRi1Bg-YBpHg"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      id="Narr_KNO4zKZTDUqa3rCA5PsqTQ">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="INF"
      id="Narr_KvrrZz5UQUGQoiOoxNumAw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <nrbo:StockAndWarrantsIssuedDuringPeriodValueStocksIssued
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="-5"
      id="Narr_m5kshJRt20OQcRCZVf73Ww"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">9800000</nrbo:StockAndWarrantsIssuedDuringPeriodValueStocksIssued>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="-5"
      id="Narr_eb-29TRr3UKegJsiUwV4uQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4200000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="-5"
      id="Narr_DWzQYCZoI0iO_tNobgrQCw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForCommissions
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="-5"
      id="Narr_KZYg8NL_RE2pOpYQeOMSzg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000000.0</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng"
      decimals="-5"
      id="Narr_4u1PpNKXE02cGSq7CvHbWw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">200000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="INF"
      id="Narr_FVZDEv9Gsk6rdXrg7k0K6Q"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg"
      decimals="2"
      id="Narr_6vsIrAk4mESOAWks9PmW-Q"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg"
      decimals="INF"
      id="Narr_gF9tGUkebkq1YtZUiMbAsA"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="-5"
      id="Narr_9wYk8icWo0uHB8NwKmA_vQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg"
      decimals="2"
      id="Narr_LB8ERNWHvUuK3MtlIslWyQ"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">6.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="As_Of_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xUfWT1fBpkWkrLnOindKJg"
      decimals="-5"
      id="Narr_5FPnHgoz30CvsjF8M6NI-g"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">7500000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="3"
      id="Narr_tx1PuD-W2kqqLnfmOOs_tA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="3"
      id="Narr_3KjnrG8Qm0iEoRf9AKGhpQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      id="Narr_tztlNvDIAEuXVW4STMIFgw">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="INF"
      id="Narr_L_lvFPoGJEmXtdg_WlpciA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <nrbo:StockAndWarrantsIssuedDuringPeriodValueStocksIssued
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="-5"
      id="Narr_xljfud5DSUynUwSPFiUk-A"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">6300000</nrbo:StockAndWarrantsIssuedDuringPeriodValueStocksIssued>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="-5"
      id="Narr_mDLE-Kj4zUy5peVzZiqSsw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3700000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="-5"
      id="Narr_03THbm1X00i9JJ1Lkl2LNQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForCommissions
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="-5"
      id="Narr_4sHDAH3AVUGU6h595CWtqA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">700000</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="Duration_1_21_2021_To_1_21_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_LgKhj78-RECe9eyA90a8sA"
      decimals="-5"
      id="Narr_j_6KiXxqIUWVPEWhs62KJQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">200000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_7p-qvszUP0qiypI04EUtRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:31.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of Warrants:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;March 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,800.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;March 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;July 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5,602.50 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;April 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;375.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;January 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;180.90 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;July 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;October 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 143,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;112.50 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;April 2025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;November 2022 Series A&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6,768,837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;December 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;November 2022 Series B&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,267,170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;December 2027&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;15,264,242&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;229,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_R8tpABL6SEiwPZQ-3VvIFg"
      decimals="INF"
      id="Tc_MX0IsK55VkGiDjKf9o_ghA_3_3"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1315</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice7800.00Member_fo5C0eYqVUyTvpl1YK8Utg"
      decimals="2"
      id="Tc_gA37Y08GpkqJtkkvWc3Gmg_3_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">7800.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_QPGLTkwobEqQWl1-u_J7ng"
      decimals="INF"
      id="Tc_Eng1JGFS-UO5jxcDVS1rGg_4_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">48</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_jBT2fr5VpUOllcLVtoPKDA"
      decimals="INF"
      id="Tc_55JPHbHNFUW5b-midsAMVw_4_3"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">48</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice5602.50Member_QPGLTkwobEqQWl1-u_J7ng"
      decimals="2"
      id="Tc_ABRYFonX-EmP01pJ8o9xIg_4_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">5602.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_vzleW1-QjkCN0FSzQTflBg"
      decimals="INF"
      id="Tc_xB1s4xITD0mrgZsm4R1SvA_5_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1252</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_s3mxPDUhy0OW0_k2L4JVOA"
      decimals="INF"
      id="Tc_jQAOyrclPUuYTEJEWb8f5A_5_3"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1252</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice375.00Member_vzleW1-QjkCN0FSzQTflBg"
      decimals="2"
      id="Tc_C6xEXDrVoESpgdGilnMLJg_5_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">375.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_AK1S2nZAUUyqC_lMS5p_zQ"
      decimals="INF"
      id="Tc_fYJhXGXo60qh0p_QFhzSqA_6_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">83338</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_MMU0eNbMe0utmyloJC2nyg"
      decimals="INF"
      id="Tc_3RNmMtAMG0WcvyVTH9yXUw_6_3"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">83338</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice180.90Member_AK1S2nZAUUyqC_lMS5p_zQ"
      decimals="2"
      id="Tc_6Q1zVgnMIUSEteK3Ag8N7A_6_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">180.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_bysVT-b7fUappax39iT8-w"
      decimals="INF"
      id="Tc_7NFLneOXH02oCrGZE6yAXQ_7_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">143597</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_zL_FjtCahk2IkDsWNpvOeg"
      decimals="INF"
      id="Tc_2zYpluY9O0GfVKgphw6bPQ_7_3"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">143597</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_WarrantsExercisePrice112.50Member_bysVT-b7fUappax39iT8-w"
      decimals="2"
      id="Tc_1cHvMYYCTkG6RTphzk48Sw_7_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">112.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesWarrantExercisePrice3.00Member_9QLfqPRLn06Fhfn6AE5raA"
      decimals="INF"
      id="Tc_YHHTXBOzYkedv6d_GCUTow_8_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">6768837</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesWarrantExercisePrice3.00Member_9QLfqPRLn06Fhfn6AE5raA"
      decimals="2"
      id="Tc_g3iGd0I4CEqw1yGzWeIttw_8_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesBWarrantExercisePrice3.00Member_GsOHy7n8B0W-TCmc86HAcw"
      decimals="INF"
      id="Tc_orYnxz8MNEaS49Mf8MM74A_9_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">8267170</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesBWarrantExercisePrice3.00Member_GsOHy7n8B0W-TCmc86HAcw"
      decimals="2"
      id="Tc_ObTNpfeCMUGCVFLuM9RiyA_9_6"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="INF"
      id="Tc_4ogosnkOFkKSbCkpkRBdTA_10_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">15264242</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="INF"
      id="Tc_ODjNqXXHXUqFhLaLSyEwxw_10_3"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">229550</us-gaap:ClassOfWarrantOrRightOutstanding>
    <nrbo:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A"
      decimals="INF"
      id="Narr_AQnCMbb9vU2DWuEFfXbeAQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</nrbo:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged>
    <nrbo:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A"
      decimals="INF"
      id="Narr_WmuBGMhnPEqVRJRuWCqfqA"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1</nrbo:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A"
      decimals="-5"
      id="Narr_fiikoS_YTk-lUL4_n-0faA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_ZfzL5Dvo60C4s_TLuxoTqg"
      decimals="2"
      id="Narr_OK4pLl6LnU-B9EXPnrvHNw"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_Syw-BUTd2EajoaUuYlNFGA"
      decimals="2"
      id="Narr_m8LvtoMlgk-cHRLUmn3suA"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nrbo:NumberOfWarrantsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_UA9AdohqXUSoaG3NbfF6OA"
      decimals="INF"
      id="Narr_FF4vJhnUAUmLWxUhtK6f4A"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">3981163</nrbo:NumberOfWarrantsExercised>
    <nrbo:NumberOfWarrantsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_YWNm-7gVqkq3BnovVKJ0Tg"
      decimals="INF"
      id="Narr__En7SEwWG0O6Ca4-UZp2vg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2482830</nrbo:NumberOfWarrantsExercised>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_UYXp0FsrvUmphvXlyu5etQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense was included in general and administrative as follows in the accompanying statements of comprehensive loss:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.64%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.53%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.58%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In December 2019, in connection with the 2019 Merger, the Company assumed a previously adopted stock option plan (the &#x201c;2018 Plan&#x201d;) and adopted the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;). In addition, in November 2021, the Company adopted the 2021 Inducement Plan, and in December 2022, the Company adopted the 2022 Equity Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2018 Plan, 2019 Plan, 2021 Inducement Plan and 2022 Plan provide for the grant of stock options, restricted stock and other equity awards of the Company's common stock to employees, officers, consultants, and directors.   On May 11, 2022, the Company terminated the 2018 Plan.  As of the date of termination, there were &lt;/span&gt;no outstanding awards under the 2018 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Evergreen provision&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Under the 2022 Plan, the shares reserved automatically increase on January 1st&#160;of each year, for a period of not more than five years commencing on January 1, 2023 and ending on (and including) January 1, 2027,&#160;to an amount equal to the lesser of 5% of the common shares outstanding as of January 1, or a lesser amount as determined by the Board. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;On January 1, 2022, 35,549&lt;span style="white-space:pre-wrap;"&gt; shares were added to the 2019 Plan as a result of the evergreen provision associated with the 2019 Plan.  With the adoption of the 2022 Plan, &lt;/span&gt;no additional shares may be added to or grants awarded from the 2019 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;As of December 31, 2022, 5,078,721, 33,333 and 15,938 shares were authorized under the 2022 Plan, the 2021 Inducement Plan, and 2019 Plan, respectively, prior to the issuance of any shares under these plans. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Options expire within a period of not more than ten years from the date of grant. During the years ended December 31, 2022 and 2021, 5,995 and 22,555 stock options were granted, respectively, to employees and directors with service conditions. The options granted with service conditions vest over a period between one year and three years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s stock option plan activity for the years ended December 31, 2022 and 2021 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (6,096)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/Cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (14,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/Cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and expected to vest at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Options exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average fair value per share of options granted during the year ended December 31, 2022 and 2021 was $12.43 and $43.55, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s unvested stock options as of and for the year ended December 31, 2022: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Nonvested at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.43&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,018)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64.90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/Cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,112)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Nonvested as of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.81&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures the fair value of stock options with service-based and performance-based vesting criteria to employees, consultants and directors on the date of grant using the Black-Scholes option pricing model. The Company does not have history to support a calculation of volatility and expected term. As such, the Company has used a weighted-average volatility considering the volatilities of several guideline companies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The assumed dividend yield was based on the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The average expected life of the options was determined based on the mid-point between the vesting date and the end of the contractual term according to the &#x201c;simplified method&#x201d; as described in SEC Staff Accounting Bulletin 110, or the contractual term in cases where the &#x201c;simplified method&#x201d; was precluded. The risk-free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant. The Company records forfeitures when they occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in the Black-Scholes option-pricing model are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected stock price volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;80.7-85.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;79.0-80.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected life of options (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk free interest rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.72-3.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.93-1.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December 31, 2022 and 2021, 12,018 and 3,164 stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended December 31, 2022 and 2021 was $64.90 and $163.64, respectively During the years ended December 31, 2022 and 2021, 2,000 and 14,637 stock options were forfeited, respectively. During the year ended December 31, 2021, $364 was recognized in income by option holders as a result of stock option exercises. &#160;As of December 31, 2022, 5,091,500 shares in the aggregate were available for future issuance under the 2022 Plan and the 2021 Inducement Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Unrecognized stock-based compensation cost for the stock options issued under the 2019 Plan, the 2021 Inducement Plan, and the 2022 Plan was $0.5 million as of December 31, 2022. The unrecognized stock-based expense is expected to be recognized over a weighted average period of 0.8&lt;span style="white-space:pre-wrap;"&gt; years.  &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_v6WNT09i-0ay65s4Hrq1Ww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense was included in general and administrative as follows in the accompanying statements of comprehensive loss:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;white-space:nowrap;width:30.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.64%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.53%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:3.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.58%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 854&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 662&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAEVu6CnL02lDdU-rjBNQQ"
      decimals="-3"
      id="Tc_K8bE8j_e6U6vwSaKZM5dRw_4_2"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">854000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_N6zssHroH06fo8J6U0yHSg"
      decimals="-3"
      id="Tc_fMt-rm2otkWRMsoaYtpdoA_4_5"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">662000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_5_11_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2018Member_ko1jQnLPBEqgk8fnim0vfg"
      decimals="INF"
      id="Narr_rQPGYNCrgk6JiR9oZ36Qtg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <nrbo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_Ry1oAKkWqkWxsb6iJ3oDuw"
      id="Narr_KS4G2ADN40WRTlOfxYti7g">P5Y</nrbo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_Ry1oAKkWqkWxsb6iJ3oDuw"
      decimals="2"
      id="Narr_Sc4W7t3p3Eiwa9WYKfT0Aw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_05S9u_n9JkucaP69CQY6Eg"
      decimals="INF"
      id="Narr__FgrzefwzEutaZScNyXlEw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">35549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_TkENndys2Uaf4fqNaeg3Tw"
      decimals="INF"
      id="Narr_CpBrIxXwhEWVZOFL1VNCkw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022Member_eifF-TPUWEunkLiTyY8FpA"
      decimals="INF"
      id="Narr_AfKbl61GtU6Woq-yBk7NMQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">5078721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlan2021Member__jN6B4AZyUeQSX5hmnKlUg"
      decimals="INF"
      id="Narr_a5DHGS-Z7EKvg8lkhX5_lw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">33333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2019Member_V9kjpRU_B0mAPphmsOIjvw"
      decimals="INF"
      id="Narr_glS8ZyN0-kmcPpdOE8wt9g"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">15938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_udpCt7xwTkmIOi0v6glSMQ"
      id="Narr_gKyRojaG4kK6uQ94QMfQlA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      decimals="INF"
      id="Narr_F3Tci6Qu-keRSPI02bBtUQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">5995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="INF"
      id="Narr_dxDidFxQnEarx-2W8BGJHQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">22555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_aWQ-JSgQ7Eyj0sP8jouJIQ"
      id="Narr_d7F153idHU-OSnOO6bWlHw">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_udpCt7xwTkmIOi0v6glSMQ"
      id="Narr_hb8qyulYWUmkznHpHKXc5A">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_e41n9MuUAE-R_TZ9K13ilQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 108.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (6,096)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/Cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (14,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Exercised &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/Cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested and expected to vest at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Options exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 146.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:35.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9VXoK8ZQMkmjMvlnr02F6g"
      decimals="INF"
      id="Tc_b1-LvEgZ6UeAnt5IQUMwbA_6_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">30676</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9VXoK8ZQMkmjMvlnr02F6g"
      decimals="2"
      id="Tc_zp2Jxw2rSkuCgZIsz0cY_A_6_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">108.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0sehVfaRLESnA7PGQGiYcQ"
      id="Tc_xGjBIu24_0yEHaSRcxBSpA_6_7">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="INF"
      id="Tc_0VSYNCzvzkOfoj0Yp0oamw_7_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">22555</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="2"
      id="Tc_UGYSrc-dyk2yRNMHMcAgeQ_7_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">67.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="INF"
      id="Tc_stL7UnB0IEuQFaFmUWY5XA_8_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">6096</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="2"
      id="Tc_w7XuBsN0bEqw6Gpe4Xk4KQ_8_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">17.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_gbSCNmL4zESowWt3pLBd5g_8_10"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">364000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="INF"
      id="Tc_uImiC4hG_EO7xmyxq6XktA_9_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">14637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="2"
      id="Tc_zMNxG89bZ02cVopCveex4A_9_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">57.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9ZvJ9LtzWUOti8VldYpmzA"
      decimals="INF"
      id="Tc_zrfcqWvUfUeJHhfyvyuLkg_10_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">32498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9ZvJ9LtzWUOti8VldYpmzA"
      decimals="2"
      id="Tc_fFUhlktfeUKE_D-iyBAKGQ_10_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">119.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      id="Tc_uQy6vlf6I0qGRHg0P902SA_10_7">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      decimals="INF"
      id="Tc_QaJVIisQIkq7o5iu3MkbqA_11_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">5995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      decimals="2"
      id="Tc_bbx1K6Ify0a0ga-1Mcq3RQ_11_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">17.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      decimals="INF"
      id="Tc_L4TNAzu-iUmEdKal8HR-XQ_13_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      decimals="2"
      id="Tc_IgyoVYF2LkqC6AmTPO5OaA_13_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">181.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg"
      decimals="INF"
      id="Tc_ATe0f83l8024uciJFcr_Gw_14_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">36493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg"
      decimals="2"
      id="Tc_6yShRZ5TEEWIN6cp95NYqQ_14_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">99.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      id="Tc_YJE3n51yY0SMmzHgBlf13A_14_7">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg"
      decimals="INF"
      id="Tc_ML0BMwzItkmb6LM9IlcIeQ_15_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">36493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg"
      decimals="2"
      id="Tc_fn79BNw6qE-O5T3e6LQdhA_15_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">99.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      id="Tc_zqBGzqTs4Ea9_4u0UvignA_15_7">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg"
      decimals="INF"
      id="Tc_j713LiZ3NE6GvucfCz_hGw_16_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">17903</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_YefwLu_Rr0WSsNVauhQUPg"
      decimals="2"
      id="Tc_24hUqOn5mkyXkSPkkGcfBQ_16_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">146.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      id="Tc_romuHTsp1UCqH0gZeq8o_A_16_7">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ihkvPbd2V0ORA1221FgO0w"
      decimals="2"
      id="Narr_ufXrKEgaa0a42YckdtJvvg"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">12.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2JHEne2saU-HPyMzinVwAA"
      decimals="2"
      id="Narr_ULAv7ARwpk-Z69v5dJp-Sg"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">43.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_mjpc_d0dwUK0P927fC7C2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;The following table summarizes the Company&#x2019;s unvested stock options as of and for the year ended December 31, 2022: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Nonvested at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Granted &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.43&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (12,018)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64.90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited/Cancelled &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,112)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 117.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Nonvested as of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,590&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.81&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="INF"
      id="Tc_Q0JmQRsWkkajwZxRRmLcQg_5_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">25725</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="2"
      id="Tc_oKL4i0FjCE-lzekBKt9kvw_5_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">59.09</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="INF"
      id="Tc_99aym4WifE2rRrpaMQqN1g_6_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">5995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="2"
      id="Tc_n01atKxQOUa47zA_xc_9wQ_6_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">12.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="INF"
      id="Tc_5hVCRADYJkW-LVXSzZUHLQ_7_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">12018</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="2"
      id="Tc_vxicC3GnbkqGODjbNy9Vnw_7_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">64.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="INF"
      id="Tc_XN1tz_fTJ0Syrw_bdOvBOg_8_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1112</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="2"
      id="Tc_5e5MNZj__kmqIkNcvCbnDw_8_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">117.26</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="INF"
      id="Tc_CXpaeMjfI0yQg-ElYQsaew_9_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">18590</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="2"
      id="Tc_P5iAJCMfIEy7pD3a6bh15Q_9_5"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">36.81</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_aO0pCiSsz0aNWxXyQwOYhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:35.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:16.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected stock price volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;80.7-85.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;79.0-80.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected life of options (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5-5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Expected dividend yield &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:60.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk free interest rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.72-3.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.93-1.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ"
      decimals="4"
      id="Narr_E1SHuYAGkkqZX7Fk9nunBQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg"
      decimals="4"
      id="Narr_gnFaEevQEkyte3CyxV38KQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_uq04BWb7AE-iy-oszOsfGA"
      decimals="4"
      id="Narr_JW-_k31eHEOqDK5gZtE8RQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_edJRGY-FvUOBcIWcKUF6eQ"
      decimals="4"
      id="Narr_TxESHx2dnEOz22mH2izdgQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ"
      id="Narr_Wn9Zzta1c0aj2GRefykdbQ">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg"
      id="Narr_5lWXTUZv20W_kUGxt2TJYw">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      id="Tc_qmu6ra8kKk21XyF9XlAFbA_6_8">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ"
      decimals="4"
      id="Narr_qQKXPMIPCkO_FhStwrKVeA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg"
      decimals="4"
      id="Narr_-BWCw6nS60KWdGqxzgzczA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.0308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_uq04BWb7AE-iy-oszOsfGA"
      decimals="4"
      id="Narr_9Z4XBB5S_kiCJL8aGn4jKg"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_edJRGY-FvUOBcIWcKUF6eQ"
      decimals="4"
      id="Narr_a3VRL9CvTka4-5JAumq_PA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA"
      decimals="INF"
      id="Narr_MX8vwexzOkmQ3vm6cFTidg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">12018</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ"
      decimals="INF"
      id="Narr_3beo5iC9MEmg22yX-1cwyw"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">3164</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA"
      decimals="2"
      id="Narr_9UtEMW8IX02TIFXrl1h0rg"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">64.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ"
      decimals="2"
      id="Narr_3E4ULzMRdkaYTa7KGKctUQ"
      unitRef="Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg">163.64</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA"
      decimals="INF"
      id="Narr_jqr0S-mhyka2gt-0MoYUAQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">2000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_pDaArbEpY0KdJXM9PqUAzQ"
      decimals="INF"
      id="Narr_vU6zf2r05k6RmbeaD0m_2g"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">14637</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_7yFz8TeHqkaHnkGtHM5ODQ"
      decimals="INF"
      id="Narr_XW_zsbXqCEyofyN72gn7fg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">5091500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nrbo_StockPlan2022201And2019PlansMember_5Db9ow_iRkWLj51gC7U6Kw"
      decimals="-5"
      id="Narr_FWuErivn_0aN0HOeBzU5og"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_z0wxz13-f0W8MenhGuDdtA"
      id="Narr_z5Cl07Q17U2ycss95AZxVQ">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_X4vOu4DuU0mAlc8iOHm_Ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Net Loss Per Share of Common Stock&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, options outstanding under the Company's stock option plan and warrants during the periods that these instruments are outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The basic net loss per share calculation includes the 2022 Warrants given that these instruments are exchangeable into common stock for which no additional consideration is required from the holder.  The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 228,235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 229,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_oBDUGLIaSUWCku9jXkMDsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,493&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 228,235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 229,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_6mbAVgdr_kKuEsMIk2u25w"
      decimals="0"
      id="Tc_yq-FAs8-xEicgxgjjkFdhQ_4_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">36493</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_wpEzOwDCY02faZHzEsikFQ"
      decimals="0"
      id="Tc_ccYdYFeZaEmFMQsk0FQzCA_4_4"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">32498</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_clpDxqqAN0qB38SnsnjsCA"
      decimals="0"
      id="Tc_zY9irCT9nUuMbd9tt_JOOg_5_2"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">228235</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_X0i0kWRTo0Oc2-qhzLlQFQ"
      decimals="0"
      id="Tc_F5dXOUdSR0Wkw7Vx1fj0sw_5_4"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">229550</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_4a6_rkwmEUaMga56KQq0mQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity specific measurement. Fair value is defined as &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three level hierarchy:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1 inputs:&lt;/b&gt;&lt;span style="white-space:pre-wrap;"&gt;  Unadjusted quoted prices for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2 inputs:&lt;/b&gt;&lt;span style="white-space:pre-wrap;"&gt;  Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the asset or liability;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3 inputs:&lt;/b&gt;&lt;span style="white-space:pre-wrap;"&gt;  Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;There were no financial instruments measured on a recurring basis as of December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The fair value of financial instruments measured on a recurring basis as of December 31, 2022 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:39.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total liabilities at Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The fair value of the 2022 Warrants was determined using a Monte Carlo simulation.  &lt;/span&gt;This valuation technique involves a significant amount of estimation and judgment. In general, the assumptions used in calculating the fair value of the common stock warrant liability represent management&#x2019;s best estimate, but the estimate involves inherent uncertainties and the application of significant management judgment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;Input assumptions were as follows: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Risk free interest rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3.9-4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Volatility &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;94-103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Remaining term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.0-5.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;Due to the cashless exercise provision of the 2022 Warrants rendering the exercise price effectively at zero, the calculated price per share of the 2022 Warrants was equal to that of a share of common stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The following table provides a roll-forward of the warrant liabilities measured at fair value for the year ended December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issuance of 2022 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ONTN_FfUsEGhQ_nLCwdysw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,935)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Reclass of warrant liabilities upon exercise of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(5,564)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_nDBdXISMyEWxxvvugoib-w"
      decimals="-3"
      id="Narr_zD6WhFNe0E-pgYIm7chT3w"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_sGMEjPGZu0CwiGX1Xo1q4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;width:39.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total liabilities at Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;span style="margin-bottom:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw"
      decimals="-3"
      id="Tc_XAqvV_4pk0ydQ5SfhAueaA_4_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10796000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fNzdadyn-0Gw93J5AhwBdg"
      decimals="-3"
      id="Tc_0lMexBFMFUWyLmsHGhZuwQ_4_12"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10796000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw"
      decimals="-3"
      id="Tc_RfQ-4aA7B0OzDX88C_HEAg_5_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10796000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_fNzdadyn-0Gw93J5AhwBdg"
      decimals="-3"
      id="Tc__EKnKDXu0kemTvM-BHa91Q_5_12"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10796000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <nrbo:ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_GM1jQtsPrUG5H5jXmIcE_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at beginning of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issuance of 2022 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ONTN_FfUsEGhQ_nLCwdysw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,935)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Reclass of warrant liabilities upon exercise of warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;(5,564)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Balance at end of period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nrbo:ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw"
      decimals="-3"
      id="Tc_4JLWf3Ylh06f00HwMj56Nw_5_2"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24295000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw"
      decimals="-3"
      id="Tc_iGwKIkRnykOGjheOhuQevg_6_2"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-7935000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <nrbo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw"
      decimals="-3"
      id="Tc_KUDqCXM3-kG4KinWms6bJQ_7_2"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">5564000</nrbo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_u97PYsnPakewyhHU5f9QQw"
      decimals="-3"
      id="Tc_qhEt7a5GoUy_Rf2igpdJqQ_8_2"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">10796000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_dClw-K7hS0WCvaZWXJ3Faw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The effective tax rate for the years ended December 31, 2022 and 2021 was zero percent. A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Income tax (benefit) provision at federal statutory rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;State income tax, net of federal benefit &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (26.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Provision to tax return&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Section 382 limitation adjustment attributes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (225.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Effective tax rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;Loss before provision for taxes for the years ended December 31, 2022 and 2021 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss before Income taxes:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (14,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (14,954)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (330)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,967)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (15,284)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The components of income tax provision (benefit) consisted of the following for the years ended December 31, 2022 and 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Tax Provision (Benefit):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total current tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,932)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (81)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (4,013)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (26,183)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (148)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Federal and state operating loss carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,904&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Foreign operating loss carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Acquired intangibles &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized R&amp;amp;D Costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development credit carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,483&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;   &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance - Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (4,252)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (30,410)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (176)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (324)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred tax assets, net of valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net deferred tax assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;As of December 31, 2022 and 2021, the Company had deferred tax assets of approximately $4.4 million and $30.8 million, respectively. Realization of the deferred tax assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre-tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the deferred tax assets have been fully offset by a valuation allowance of $4.4 million and $30.8 million as of December 31, 2022 and 2021, respectively. U.S. deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;As of December 31, 2022 and 2021, the Company&#x2019;s federal net operating loss carryforwards were approximately $1.5 million and $81.8 million, respectively. The Company had federal research credit carryforwards as of December 31, 2022 and 2021 of approximately $24 thousand and $1.0 million, respectively.&lt;span style="white-space:pre-wrap;"&gt;  The Federal net operating losses were incurred after December 31, 2017 and therefore, will not expire.&lt;/span&gt; As of December 31, 2022 and 2021, the Company had state net operating loss carryforwards of approximately $65 thousand and $42.6 million, respectively. The Company had state research credit carryforwards of $2 thousand and $0.6&lt;span style="white-space:pre-wrap;"&gt; million as of December 31, 2022 and 2021, respectively. The state net operating loss carryforwards and state research credit carryforwards will begin to expire in 2043, if not utilized.  Lastly, the Company had foreign net operating loss carryforwards of approximately &lt;/span&gt;$0.7 million and $1.3 million as of December 31, 2022 and 2021, respectively. The foreign net operating loss carryforwards will begin to expire in 2028.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#x201c;5-percent shareholders&#x201d; increase their ownership, in the aggregate, by more than 50 percentage points over a 36&lt;span style="font-family:'Cambria Math';"&gt;-&lt;/span&gt;month testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization. As a result of the public stock offering and private placement offering during the fourth quarter of 2022, a Section 382 ownership change occurred with an annual limitation of $0. Because of the 2022 ownership change and corresponding limitation, approximately $99.0 million and $48.5 million of federal and state net operating loss carryforwards, respectively, were written off, with a corresponding offset to the Company's full valuation allowance. Additionally, approximately $1.2 million and $0.6 million of federal and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;state research credit carryforwards, respectively, were written off, with a corresponding offset to the Company's full valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December 31, 2022 and 2021, and as such, no interest or penalties were recorded to income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The Company&#x2019;s corporate returns are subject to examination beginning with the 2018 tax year for federal and state jurisdictions, and beginning with the 2019 tax year for one foreign jurisdiction.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="2"
      id="Narr__-2cPOU4bUSvTq41in0NJA"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="2"
      id="Narr_qaBnPvpKPkGRjIMFos0vQQ"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_aPQT-hZ9u0egQbAq_zMItA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Income tax (benefit) provision at federal statutory rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;State income tax, net of federal benefit &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (26.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Provision to tax return&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Section 382 limitation adjustment attributes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (225.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Effective tax rate &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_7yoDJklreU-n0kDBR1qZWQ_3_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="3"
      id="Tc_w8CgsoDgcka4LUe8ahScxQ_3_5"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_4SNx6-OcFk-HYF2-E8__xQ_4_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.072</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="3"
      id="Tc_GG4V9tCJjkOTg8eXh719PA_4_5"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_dohCR85BE0OLiUWOMvZL9A_5_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">1.886</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="3"
      id="Tc_U2QPWfBSikKwfOrIrUH39A_5_5"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">-0.262</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_CUKcS_us-kC5Ate6hz-NrA_6_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="3"
      id="Tc_kQmAJ7GkjEqLayeLLSd1lQ_6_5"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="3"
      id="Tc_XXTfd8BT8UO0LA_d4-TL1w_7_5"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <nrbo:EffectiveIncomeTaxRateReconciliationTransactionCost
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_apW89VyYjEifV1uBC2JlSg_8_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">-0.033</nrbo:EffectiveIncomeTaxRateReconciliationTransactionCost>
    <nrbo:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_a0m_FJYYLEeCGkwthekTqQ_9_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.119</nrbo:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants>
    <nrbo:EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_yRwFUzOq30CJY9Dv0vBI0Q_10_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">-2.251</nrbo:EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="3"
      id="Tc_ibpRuhtyD0uw9HwPSV8oQA_11_2"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="3"
      id="Tc_LjnZtve2c0WdCjgb3PDHjQ_11_5"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_xIg4R9XY7E2yMpT9ocrAjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;Loss before provision for taxes for the years ended December 31, 2022 and 2021 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Loss before Income taxes:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (14,559)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (14,954)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (330)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,967)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (15,284)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_jqEvPnpx_kSiC5DOELWxww_5_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-14559000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_jld1Ho0-rUaIN_hVQ2XjsA_5_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-14954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_S1PVCnsi90aJ-yzju7qCrg_6_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">592000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_Z1e3E85oLEKoXsrlR20UWg_6_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-330000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_82hAGlZ5jUCTjqa-NrKEGQ_7_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-13967000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_c1qsMltlwEu6BLe45q2aUQ_7_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-15284000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_0DbPBHjWME2bWV4XUE-CuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 6pt 0pt;"&gt;The components of income tax provision (benefit) consisted of the following for the years ended December 31, 2022 and 2021:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Tax Provision (Benefit):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total current tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,932)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 148&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (81)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (4,013)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (26,183)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Change in valuation allowance - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (148)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total tax provision (benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_THMEk6b1FU-yl5qpXJh5fA_11_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">26183000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_bIYmIq2cx0S-CB-2732NJA_11_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-3932000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_dTSGwAJVl0eAF4fD1a8dqQ_12_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">148000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc__j0Zpiwmg0u0bQLOCd56nA_12_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-81000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_UMafUvTxb0u0EHC_oUFrZw_13_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">26331000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_nP23lV34UkmrrKq6-h0goQ_13_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-4013000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <nrbo:ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_Geb-sv5rQUqpjGoM85ZNLg_15_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">26183000</nrbo:ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit>
    <nrbo:ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_wGA6zCjvmESEzq1Mz9-tqA_15_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-3932000</nrbo:ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit>
    <nrbo:ValuationAllowanceOfForeignIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Tc_oUdigkzBZU6uZKX07juESA_16_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">148000</nrbo:ValuationAllowanceOfForeignIncomeTaxExpenseBenefit>
    <nrbo:ValuationAllowanceOfForeignIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Tc_YqV5txencE-CLyQpO3jL5Q_16_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">-81000</nrbo:ValuationAllowanceOfForeignIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_2tnAo__8UU6pTVSh5Zg2Lw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.02%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:14.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Federal and state operating loss carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,904&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Foreign operating loss carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Acquired intangibles &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,683&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Capitalized R&amp;amp;D Costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development credit carryforwards &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,483&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;   &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance - Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (4,252)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (30,410)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Valuation allowance - Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (176)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (324)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total deferred tax assets, net of valuation allowance &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;ROU asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (18)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Net deferred tax assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:6pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_QhuKb6duyk6nFk2i-PGtAg_5_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">370000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_Utur1YpgYk6GHXkDjj0LUw_5_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">19904000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_YLvzsBQotUSTohLO0zkEPw_6_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">176000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_b3zYOzaJEUqz0nVxIAh-4Q_6_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">324000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <nrbo:DeferredTaxAssetsAcquiredIntangibles
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_89Lg-Vsm4UyXxo2A1l4How_7_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">3095000</nrbo:DeferredTaxAssetsAcquiredIntangibles>
    <nrbo:DeferredTaxAssetsAcquiredIntangibles
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_8gMf-hB3QkOKbFAo1IEaYw_7_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1683000</nrbo:DeferredTaxAssetsAcquiredIntangibles>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_bz6WlbaLBk6y2cn3tlrvCQ_8_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">467000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_fu8nBdc3Z0WBOxwlMNabyA_8_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">276000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <nrbo:DeferredTaxAssetsLeaseLiability
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_NE7HvZTKfkKjtdAxd6WvoQ_9_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">17000</nrbo:DeferredTaxAssetsLeaseLiability>
    <nrbo:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_hgFmHQjPYEaq4U4VBu2ydg_10_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">278000</nrbo:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <nrbo:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_XM_3qA1qt0eGH-rLhLHUSQ_10_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">7023000</nrbo:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_F_WMlQF42kKL6UqLTAveng_11_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">16000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_vl77HwuC_kibO4BM0pJa9w_11_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">44000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_Ijgv1gKq8EmH9wVXp_0ANg_12_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">26000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_AfB0TQ8sYECkD1BAUHfEcw_12_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1483000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Tc_r2yaVtAtEk2-SgWiGXDXJQ_13_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4428000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_0YydAVX4IEWhaXPcQAtDwg_13_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">30754000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow"
      decimals="-3"
      id="Tc_FTH-Z5omkUeyKBGjxwaEdA_14_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4252000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1pjv2MX8J0-yfwddaY-lNA"
      decimals="-3"
      id="Tc_Ntzgn5qsb0q73KzrdG6Szw_14_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">30410000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_l0ZHVOGbuUOzRBb3KR4MiQ"
      decimals="-3"
      id="Tc_8CcBUAH0-kOqDSRW2zYvsQ_15_3"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">176000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_h4TI82YIYEafQM3AvpLuuQ"
      decimals="-3"
      id="Tc_2OmnoZEqrkqRPZwoo78z5w_15_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">324000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_qFDfvtDlVEmvq7XLQBKKNw_16_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">20000</us-gaap:DeferredTaxAssetsNet>
    <nrbo:DeferredTaxLiabilitiesRouAsset
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_asBIbYWad0erXygOPWvp-A_19_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">18000</nrbo:DeferredTaxLiabilitiesRouAsset>
    <nrbo:DeferredTaxLiabilitiesLeaseLiabilitiesAndOther
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Tc_jHVlj9-ngkeIAjMcFZ99Mw_20_6"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2000</nrbo:DeferredTaxLiabilitiesLeaseLiabilitiesAndOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_smq953lKoU-8J6w7l2NqpQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-5"
      id="Narr_8k-B5xnGYk6Hl0YPHbWnfw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">30800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_UGlDzWT9bkKxQTCJEqo6hQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">4400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-5"
      id="Narr_s43Mzwcar02OztBd2E1rHA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">30800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_OGUCrU91skKYDXJeYxFTDA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-5"
      id="Narr_jSUVqfFIO0-5Ufr4OXMgtg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">81800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <nrbo:OperatingLossCarryForwardResearchCredit
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_jRD0wXd_RU-0syhR_l9Oiw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">24000000</nrbo:OperatingLossCarryForwardResearchCredit>
    <nrbo:OperatingLossCarryForwardResearchCredit
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-5"
      id="Narr_RA5tYGi6QUelftbYb2bwSA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1000000.0</nrbo:OperatingLossCarryForwardResearchCredit>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_jqDo-_w_qE2ozuCmc2Cimg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">65000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-5"
      id="Narr_rK39GiKi0E-GQ49BN2XJTQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">42600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <nrbo:DeferredTaxAssetsTaxCreditCarryforwardsState
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-5"
      id="Narr_AtNwEJ2K30-Ges682JVQLQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">2000000</nrbo:DeferredTaxAssetsTaxCreditCarryforwardsState>
    <nrbo:DeferredTaxAssetsTaxCreditCarryforwardsState
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-5"
      id="Narr_jGQ9DXtaYE-kgOPqgSU_Ng"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">600000</nrbo:DeferredTaxAssetsTaxCreditCarryforwardsState>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_l0ZHVOGbuUOzRBb3KR4MiQ"
      decimals="-5"
      id="Narr_ivY9UTo_KkO1Hq6amOb4wg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_h4TI82YIYEafQM3AvpLuuQ"
      decimals="-5"
      id="Narr_Gz-QJ1o4NkS8lXPGOTiEKg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1300000</us-gaap:OperatingLossCarryforwards>
    <nrbo:NetOperatingLossCarryforwardsWrittenOff
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow"
      decimals="-5"
      id="Narr_8frcrPkZjUO2fkhH--HGQQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">99000000.0</nrbo:NetOperatingLossCarryforwardsWrittenOff>
    <nrbo:NetOperatingLossCarryforwardsWrittenOff
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_zzR33TSc_Eq3qTKp-rYpEw"
      decimals="-5"
      id="Narr_ENGcpuPQH0umw4veC_bvaQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">48500000</nrbo:NetOperatingLossCarryforwardsWrittenOff>
    <nrbo:ResearchCreditCarryforwardsWrittenOff
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_w7ef3RzSNEOfh4Y97Tu2ow"
      decimals="-5"
      id="Narr_G2Mfm7X5UEab5t1KrdxmPQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">1200000</nrbo:ResearchCreditCarryforwardsWrittenOff>
    <nrbo:ResearchCreditCarryforwardsWrittenOff
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_zzR33TSc_Eq3qTKp-rYpEw"
      decimals="-5"
      id="Narr_f7DEFdwPJ0SjVuNF-jfRug"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">600000</nrbo:ResearchCreditCarryforwardsWrittenOff>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA"
      decimals="-3"
      id="Narr_kGcVqM8vf0OHYNPQlAf7Tg"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw"
      decimals="-3"
      id="Narr__eq-KePaVkyPRcGY8WJO-Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-3"
      id="Narr_6zGO34Yc7Um-fgPy-g5Z_w"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-3"
      id="Narr__Cur0k8__EOduU7geI91qA"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_4g4AspbtyES5iDrhaVte1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 5pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Related Party Transactions &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:11pt;text-indent:-11pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Agreements with Dong-A&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;On September&#160;28, 2018, NeuroBo entered into a &lt;span style="-sec-ix-hidden:Hidden_F7zo_zW-NUK53QFVdH_Apw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; year manufacturing and supply agreement with Dong-A, a greater than 5% shareholder,&#160;for the manufacturing and supply of NB-01 drug substance and placebos for the purpose of research and development to be used in Phase&#160;3 clinical trials (the &#x201c;Manufacturing Agreement&#x201d;). There were no manufacturing related costs under the Manufacturing Agreement for the years ended December 31, 2022 or 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;The Manufacturing Agreement will automatically terminate in the event that the license agreement with Dong-A is terminated for any reason. In addition, each of Dong-A and NeuroBo may terminate the Manufacturing Agreement (1)&#160;upon the material breach by the other party, if the breach is not cured within a specified number of days after receiving notice from the terminating party, or if the breach cannot reasonably be cured within such period and the breaching party has not started to remedy the breach within such period and diligently endeavored to cure the breach within a reasonable time thereafter, or (2)&#160;in the event that (i)&#160;the other party is the subject of a petition for bankruptcy, reorganization, or arrangement and the same is not dismissed within &lt;span style="-sec-ix-hidden:Hidden_2TEjfFmoakSOFBCUgn6ldg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty&lt;/span&gt;&lt;/span&gt; days thereof, (ii)&#160;a receiver or trustee is appointed for all or a substantial portion of the assets of the other party, or (iii)&#160;the other party makes an assignment for the benefit of its creditors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:10.0pt;margin:14pt 0pt 0pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On June 7, 2020, the Company entered into a manufacturing and supply agreement (the &#x201c;Manufacturing and Supply Agreement&#x201d;) with Dong-A for the manufacturing and supply of NB-02 drug product and placebo for the purpose of research and development of NB-02, including but not limited to, the use in the first NB-02 human clinical trial to be conducted by the Company. Under the terms of the Manufacturing and Supply Agreement, upon receipt of a purchase order from the Company no later than &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;270 days&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; prior to the requested delivery date, Dong-A has agreed to produce for the Company tablets of the NB-02 drug substance and placebos at a specified supply price. The Company is obligated to manufacture, or have manufactured, and supply to Dong-A the active pharmaceutical ingredients which are necessary to manufacture the NB-02 drug product. The Manufacturing and Supply Agreement has a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Y_VNuVMUj02pKiVqh9023w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; year term, subject to earlier termination under certain circumstances.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <nrbo:PercentageOfSharesHeldByRelatedParty
      contextRef="Duration_9_28_2018_To_9_28_2018_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_C0OWpWGxFkaoyVUi5CLhYA"
      decimals="2"
      id="Narr_HTzaj1YLtUewOlEuGcN8Vw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.05</nrbo:PercentageOfSharesHeldByRelatedParty>
    <us-gaap:RelatedPartyCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_LoFCvnOSokiqESf8sPL2dw"
      decimals="-3"
      id="Narr_yy6p6UHKwUCYIp_9nuXY6Q"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_nrbo_ManufacturingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_jakDXzDB0EqYM_f7RAVDWQ"
      decimals="-3"
      id="Narr_ynM5UkTOBUSmhE8CKKuRlQ"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:RelatedPartyCosts>
    <nrbo:PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate
      contextRef="Duration_6_7_2022_To_6_7_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_ManufacturingAndSupplyAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_mrVIOz70GUG2r1JVXDTTRw"
      id="Narr_SyR8J9sXnE6JMcUaMthQhA">P270D</nrbo:PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_MZZPifuYsESndZuF8q9YTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13. Defined Contribution Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company adopted a 401(k) defined contribution plan in November 2018, effective as of January 1, 2019, for all employees over age&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;21&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. Employees can defer up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;90%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of their compensation through payroll withholdings into the plan subject to federal law limits. Discretionary employer matches vest over a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_DPeIVkG-okWzbfTbv-bZXQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;-year period beginning on the second anniversary of an employee&#x2019;s date of hire. Employee contributions and any employer matching contributions made to satisfy certain non-discrimination tests required by the Internal Revenue Code are &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;100%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; vested upon contribution. &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;No&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; matching contributions were made during the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <nrbo:DefinedContributionPlanEmployeeEligibilityAge
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Narr_MIQInc-reki5ARdhedm31w">P21Y</nrbo:DefinedContributionPlanEmployeeEligibilityAge>
    <nrbo:DefinedContributionPlanEmployeeContributionDeferredPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_6gFw4DluH0CPluUhAa94mg"
      decimals="2"
      id="Narr_upL3P6t0c0ydODUyBnWepw"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">0.90</nrbo:DefinedContributionPlanEmployeeContributionDeferredPercentage>
    <nrbo:EmployeeCompensationVestingPercentageOnContribution
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="2"
      id="Narr_yrMKknAFJEmtSEg2kXjGzg"
      unitRef="Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw">1</nrbo:EmployeeCompensationVestingPercentageOnContribution>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg"
      decimals="-5"
      id="Narr_l9KA-uMMbUKFZN4uSa0DEw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      decimals="-5"
      id="Narr_43v-8s2KtEqoO7DAi-3ENw"
      unitRef="Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg"
      id="Tb_lzGk_YAk-EegUHN35VOwVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14. Subsequent Events &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Since December 31, 2022, 345,333 Series A Warrants and 1,395,333&lt;span style="white-space:pre-wrap;"&gt; Series B Warrants were exchanged for shares of the Company&#x2019;s common stock.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <nrbo:NumberOfWarrantsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e0tClQh0z0msDPqPsOTVmg"
      decimals="INF"
      id="Narr_uM7YqQhY4k2iop6wgLr4YQ"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">345333</nrbo:NumberOfWarrantsExercised>
    <nrbo:NumberOfWarrantsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesBWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hjmzNGpAn0213gk2bupY4A"
      decimals="INF"
      id="Narr_9SZbGhZlSEevG891X51ozg"
      unitRef="Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA">1395333</nrbo:NumberOfWarrantsExercised>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MF<\V!-NDB\@?F1 L2#^N*7$I3WX WR\9$]N-Y "[_[@P^A=02P,$%     @
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MZ 3DN 8Y=H*\B;YM4P&%GQ:7&\$C!C4M?@)X&3TXPC0AV&\!=T)XY2@$-<'
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M&FRB>/\S_%'OB),!XJQC@% /$*@!$[YCP+@>,*8&C+LJ3.H!$WJ5A(X!8CU
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M49-B7:3+2).CD8JC<6LTNV4F$^(>RFD-<>J?8Z(8VE'*&,!$[,& 9"Z TR[
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M=A;A>(+9PW#8Z>&#QUW>#[9A,5?((4J6!GP?&\\.]I2)9Y"@I"]X9U;30;$
MA4Z1\Z-@$NN2!(T#58V+_+@4>?_989.XR_VEW$UDKGX\/AZ?] A@@0RT;>-T
M#K&'[4)[Q&6R>$#_II,(H"FAS_DHP*=W0VG<]JX.^DMT3>0S:(B;^36=J2J]
M]A-X\_5<FDI0MU=E<;\G63?^2U78/L;\0>('\?RE&NP3KXN&^W]OZS+"TON;
M_L771GB(VQW*6V6#]!#ZJTV,71Z !>5UU;W)MV(L^^'1RM?DQ8$JW(J'3IOA
M3MWK=EA!X;)B96\VLA=:=I>+>_;N#RR<T"Z-Z*/<M)J)%4/%*04C"+TG0X.]
MAWF7<=^[WJUEJF&YY@?GQGTO1R>#U]HXFBWEY3T3,6J=WG#W5_O_#URFU^*;
MQ],_%SYKOS1PKJ0%EAZ-7[T8X?@L+^S3C^AJ>4D^=S&Z2KX6A*'@^0'<7SB,
ML?8';]#_U^3BOU!+ P04    "  RB'Y61 6NTY -   ^)0  &    'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;+5:;7/;-A+^*QCUIDUF9-F2W217)Y[Q2]++
M-6D\<=)\ADA(0DT1+ !:UOWZ>W8!D)!-)>G<W!=;(H%]WV=W ;W<&'OK5DIY
M<;^N:O=JM/*^^>7PT!4KM99N8AI5X\W"V+7T^&J7AZZQ2I:\:5T=SHZ.GAVN
MI:Y'9R_YV;4]>VE:7^E:75OAVO5:VNV%JLSFU6@Z2@\^ZN7*TX/#LY>-7*H;
MY3\WUQ;?#CLJI5ZKVFE3"ZL6KT;GTU\N3F@]+_A#JXW+/@O29&[,+7UY6[X:
M'9% JE*%)PH2_^[4I:HJ(@0Q_HHT1QU+VIA_3M3?L.[092Z=NC35%UWZU:O1
MBY$HU4*VE?]H-O]249^?B5YA*L=_Q2:L/3D>B:)UWJSC9DBPUG7X+^^C';(-
M+X[V;)C%#3.6.S!B*:^DEV<OK=D(2ZM!C3ZPJKP;PNF:G'+C+=YJ[/-G-\$9
MPBS$C5[6>J$+67MQ7A2FK;VNE^+:5+K0RKT\].!'NPZ+2/LBT)[MH3V=B?>F
M]BLG7M>E*G<)'$+03MI9DO9B]E6*5ZJ8B./I6,R.9K.OT#ONM#]F>L?_%^T#
M[9-AVI1-O[A&%NK5".GBE+U3H[,??Y@^.SK]BN0GG>0G7Z/^/TK^==JSB?A^
M\N+32@DHV$@K.<^P9:%K61=:5L)YZ15RV#NA:U&8FF!$^RVBW*_$K^?GU\CL
MOUH- R&J:\  +1;>X-NM$LIYC<S#2UF70CI 1T-,G/ KZ85<+)#<^*Q I3'6
M*RQ:DX2.Q,!ZY=U85%K.=:4]I!T+=0\\<_2)2%I52=I5:E=4QK56T4;(23J2
M)($&K\W("!FXEMA,&^@S-CG8I&1Z@Q8@(OMD36*)LK5DWGX=?6N4U::<L*W7
MQGGA,J?T1H*):=^E63>RWO[DOD.F8  RN"P*VV)9)TD2=R&U%7>R:EE5(%)Q
M>T! 6(+\FM8&O]/RC;261-+P%'@I%T2. C%\0DJP[67&SI4&40ME*F9NM<)6
MIH>7=Q*JMU@'4>Q ",!C<U5I=0=YH,6<S":=J>6\4N-H1@>(9BMO5KI8"8I!
M?@-YM*.O%&UDYS_;<AE]-4<%"WZ%3EMZR2;( NMA4$R0'KZ%$HDA<J6BT$*4
M6K&PAI@:ET7U1%RN).*,/9?%NB6A%U2XH)2N^X!)E*.C0UC0MZ 8GL'("FY1
MXK8VFWHB?OSAQ>SH^!0N@$UK'W+4]8^M*K47'[6[[9Z]Z>)$U\[;-AB$K=T8
MCR]X56U1QN=_INQ+#J8PHJ#K67$Z!2:6F%!$PMW\6+K53GR0 -/GIX[?((8
M*QJ"-,QNI6#+.1"I5EDDDX3:M\PI&N5SK<E4-SY8^#SE6(UBW1@'0=9RRPF,
MY@*1>%\H2@Y5*LN,0!(P0)X%4(' ^QZ68J!%8W!N#$OB^A=D*4A0!KQ!DAE;
M(IJJ[9C*.3Q>[=A'W<,Z+L CO-VPA<U^7E"00Q*54:WGB+-4'<<[CEG),JD?
M@@U:.][X6/&$2C#V/XYGDW]"SJIB5BE";MJF@27L;MQ\J,6-:GP08WHR) :,
MJ"S'-$4*BU&U#FT9K%T0Z@BYM"H8^PEM)-JSHU.B)-[%)>=I";^<GCX-UKHR
M]?+@7-Q\ K?)6+SSP,LG<7]XE]:/8[ITE2=N#?!!; &:BNI1NT#7"*-8!@E.
M.6O*MDB1?75^,)V=3-FU]/GY[%EOI2Z?"#__2/C99]?;++O2VJ%L6 SF8YX;
M^%2UI>*\&8=BK,NLTEEJ38EY2Q:.55&&6@Y*<AO ,E6 G7I9 4W5;NW+@'X'
M_C[E:)G5MF&Q L SJA>MM7VQ'10MY,Y#\2)4)KS/RPH791@^JUY 1DD6B 7;
MK0"J\#(<3!U)>(K7@(\UM,G<]AX<$ 7!\%^BZN\R,?(BUPE/(4/I%FT%8=W#
M'B(33J,'0#CZC@!W =#-<S8P&BIV,S*YY8J-6+S3CO&<88-V4"I$($P^ZE(J
MN8AK#J' ;F7/]SRV<6'0<?R'X %/\IT]N:'-49:=1B1K/\ 6\V6J2N1EZBFL
M6M'81[!@7.K]""_B6NA)3DK$.WHIV,0"LZ;K,_%751/&,:'SDF#7<7D"@]<I
M&H?6RMVU7>2F(H8<1)>L*PX>B(8PK%5UD)K* IT:HCED)PGM9(7E,?3W-E)Q
M&X5/1Y.]U=9%L%-M/-H*^,2#-9+& !V(8:H:2EK &S$I4:XJT[!Q> ".J?J!
M\R[O(IEKAR256L(&"Z5<UR(CX #;&)]5Z'(0?1"/XI6]9M&B4">)? +&!Q6Q
M9($R YD3,5(JB^\> F@^TMPP)D=\S/6XRO2X9$D'E^7J!H4H>!&A=ADTB"ZD
M<(*J!#NH$GM)]%!%5"@P-7F+)X1H+29!WH$M>+:!5M_A@3PJ"LQ?W/QZ2R ?
MW=]7'U[#_,AZ<]BKWQ*LK ZZ!X1^1(;19@-OT?^(LH::,NXID[7'7=TE[XPS
M?ZA[T*F3.!/QNZG1DJ*/89R5Y1VU]X3/(8])LJ4Q90SM2#[T21NT#U186Q<L
MM6BII'Z/E=CNT0F(;H "YWM<L&50#&8GK]A^11!E)>\(]!4UT(5"!J,)0XR2
M>A"L#LNC"D1K+4M%CHE=&FO(*96-O6@K80,+ZI>FY-SAG$V-QOG-9=>5/#\^
M&N^/XA2_YP4W(27:@8-K:[@M^^:FO-[$E'4Q1GB28Y)D$5T?) _'S@4 69<,
MQ"ZH&MEC91/9[_5,EP])W;?7'W^4Z^;T*BD]$5^2#_IZ&+LLGL6X$X&,D6R"
M_+6RU.&@P*"XU&KS6%H*SJUHFP,,4A E1=Z8M*0W,:K0JZ()H"&ABTT.PG[.
M#1$$F= +<QMG8Q*0>VG ;4GS*"D%H(9T)0$LP+8+1JI'?\=T7YO8F$F'1I^X
M">G1:Y ]EWYJ!;I)I%.W-%P?  &&!D>2B.P5!*3.R.89%C*4!U6J:CQ6D ^B
M@^?HSFOLB_XEM4N%AA2<@05()#K"81\,2/30A4C(4+MDL0H#NU7+%GXQ%D9H
MB +5"1['[:WJ*H2<LPIF[B50CNHHNRAN&$>RT)@ABTMUC 9 #N#=;/&*E#4;
MQ6<*\2W*<9SG$3\Q3<I.[ 1;G<UW71A.%D)IM%"F;A^U2GTM>UOS3/Y)WJO!
M7E]@EJ/@#TF2^J>M6"N_,EQPLJ+)?64@Z)F@=&F4X0D9&"2>GP![=KC><+MQ
MP>W&9=YN#(FST\/N;50&D#+Z/;6E$)REF;X8/V8ZG9T&J8;E>:>DVV.M'?&J
ML"Z$XR!2?VXX^GJ,_MQA].]F@C%U^NS@")/J X[7>8/S&O8-F;SS6'6/M6//
M6TH!&;J/>,*(: J.@=CMNHT'CI29U+;Q8'V5?>MZE$@QMMWF3H4)-,TX)47W
MHJT0+G?=P)..IEJ7#A&I>R4H.Z!3WAA080X8(+10H>T<5M&&LZIXDH6AHA]Q
MC57H)<4E#W+%5GS"6E<]#K!%7.C:N=- -21^ZV+8WY@6$?0;5J V?Z&B^MO'
M+T^Y52-7Q^Z76I+(9?=PT4>6D=J>@UN828? 83FZX2,<27R>W$P H!7:="="
MQ)N0]39-E>J^'WA4.'^6G?59!AF.!RCF@H3AU([1K/RS=3ZV3,&,JA.<-J4Z
M$DM"&/="GG6AD[JY?$YZ0H/2TP0+.O5)1;!-Z""S"6R.081REN^-LI[[$EZ7
MM+O7H].M2SY"3N5]%;NY:,GDE(#8ELY16M<[A;OO'?/&*F'C$?J07<,*53,"
M*E0-L:;[I(GX%4)&WQHN:KV)!\WZT)S!A-%:QO8I]RW#_<W1M;?LM?2/9Y?P
M+1NP%@C36/2:UKJ6S_[#3DE';D7BEO?%V2PS#K6@(+!(-22U-+R^U%3Y'&$+
M\BEX>Z#ER$RU_/8\G)\RYQ9X1\/[\"N>Z[7;':IJY?N!?RC*>X<%XP[13-UP
M3^S1'-2?N7-I6YD*I</]E,Y?8K]( 16C*<\&AD3$A%GK0E#=]XDNSQ3AA)]K
M84Y\4-9X[(6^+AXHN$=6R&1]E&@[ =X#2W9,J_@R WU N+S/P?A#=Y+B5+KR
MB$,NFN=T@5:'$UMV$5>&T+6Z<-NW>R3=\X!?Y9W451@5H04>*#HLBLT2]7P6
M6L^W.;#TI_]H#A?944^)RLB_ : K0<I:?L*C\\IL>."I*E.0//"::6W1WQ?2
MZ4.X/V/Q$/)[;AR^P3/4H$M>]?I>%2TGP(<%!D!EATGN62SNZ(<%@XH_@)-P
M'QHXISZ<P0MUW#QT7SK3?G!KPK=<:2\\NC-G/QB]NOL:BF;9*(A=[)S'T*W.
MSA4P)C%#,!+BY[PT#3GX#>>,7H=I"__'/-%E'6RSNY$AQ[DV=$DD<G](/MC0
M71C\$T]&;\YO+D9/"0_B(5)<P?6)MLPQHZOLIE!&$7<C+RO@=.&"J9ZN0;D&
MD>-"(?]<5VQ#8K2A=* KXQ815NY><3R^(])X4?#9I&43TH%]T-9U&G42TGBT
M!0+T['D.H<=\G"&[$YZ.;LT1LN>JEZ]\XIB;781FH=8VC!^F\3MW/&]K\>\6
MD4;=<="0K)TD1P\=^N;I\3C-BOMO-J;3[J;Q'=?K-$Y&9D._ASC,?M."$%WR
M+W?X3K7VX><MW=/NQT'GX3<Q_?+PRZ+WTBZI7ZC4 EN/)L]_'H7Q/GWQIN%?
MR,R-]V;-'U=* K=I =XOC/'I"S'H?C)U]E]02P,$%     @ ,HA^5G6%J>(;
M P  !0H  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6S-5FU/VS 0_BM6
MAA"36//6EJZTE2@P;=(0%>SELYM<&@O'#K9#X=_O[+1I6%^T"6G:E]AWYWMR
M=W[.]F@IU8/. 0QY+KC08R\WIASZODYR**CNR!($6C*I"FI05 M?EPIHZIP*
M[D=!T/<+RH0W&3G=3$U&LC*<"9@IHJNBH.IE"EPNQU[HK15W;)$;J_ GHY(N
MX![,]W*F4/(;E)05(#23@BC(QMY%.)QV[7JWX >#I6[-B<UD+N6#%;ZD8R^P
M 0&'Q%@$BL,37 +G%@C#>%QA>LTOK6-[OD;_Y'+'7.94PZ7D/UEJ\K$W\$@*
M&:VXN9/+S[#*IV?Q$LFU^Y)EO3;"/R:5-K)8.:-<,%&/]'E5AY;#(-CC$*T<
M(A=W_2,7Y14U=#)2<DF478UH=N)2==X8'!-V4^Z-0BM#/S.94DY% N3>,> *
M#&5\Y!M$MG8_6:%,:Y1H#TH8D1LI3*[)M4@A?0W@8TA-7-$ZKFET$/$*D@Z)
MPU,2!5%T "]N\HP=7OS&/&N4[FX4VR%#7=($QAZV@ ;U!-[D^%W8#\X/Q-AM
M8NP>0O_C& ^CQ!VR"XC,%':R,B^$BI1</U:LQ-XRY/C=( KB\]=F:,R)Q/[3
MALB,F!Q()CFV,1.+8>/XOX_()"CFH)!-AVRG>P$L W<I-W!W2 6JDMS5+H4G
M/.KJZL%6F8_(ARVL(Q+V!HUTFV4,]V[;=3W&P=Y0^W$S_28-Y:3<O:M_ 1FU
M\OP*6N,YFE1%Q:D!FRNV0<*H.V!_]SR)!N_WPIZ$8;BQ[B;?*1'0KMSV+F#E
MPOVAOW6\2!)589:<T3GCS##0.W7_KD=V\O4@B5^1UY'V^MF $L@-M9>USWCE
M:TRL5>;@8TL:]+J;K:,O"A-&M)H2:WT8;#8F/NNWMSI#&B%A, 1[@B+9]7;8
M\9:JMXG@%LNL&JF[Z9UPDVO-_Q9Y!D$[G],XV#X.WCCNN@+\UM5<@%JX!XBE
M3"5,?4LWVN:-<U%?[9OE]0/IAJH%$YIPR- UZ)SU/*+J1T<M&%FZBWXN#3X;
MW#3'=QHHNP#MF91F+=@?-"^_R2]02P,$%     @ ,HA^5@!^Z(0<$0  /#8
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M247'&>$\U29 OJ0+JZ@DZZQ/#(S$NR <.;P#,B-'WR%'ELYKL?(A:HG&6@"
M%[2(7/1X_(A)'E\^.13QG%AH]_\8E)9/T_/WA.\$;^,?[THJU4%GKU 7SF5.
MQMXD^N*$2-$9DXMG_@DSP$_&STXIBQ W<!!X? _]2)HYQ:77WUK#V?EP]FYP
M J^F W$X'LNBT/0%:-"F#F4\?4\W1T)&]H4HH/!S"X^>9"POJXP.9"RNM55I
MA;<3LOG?JX#YI!Z/NWTET5FZ\OD2NNA)&O"14S<3Z( ;GNVAH$'Q/:!'ZAD_
M?N;@#8A&V[";6O9 ,S]# O8AYB.,3]F)LWE;@O]N-RU%HH'=6HTBMO JK8Q8
M$$9 C:5QKG,34ML^P'?M[%\$]PR#A:J-TTA]5*U[G.FB".?US)(OI5V -S)8
MVT1.:9&!W):- Z4SYGU_\&P'MJ4-'J3=L@ME@/X3'Q^3RV%\T%\EFR]@2<^"
MA#&6M! Y^DZ&5K* \Q$C23G$R7CL69G"$]B-&78IL/.R+52"XQ5X )9QC85]
M.^;NA;;.6<[K5).QC=^8:G%V+3Y_(2?N"HCQY3Y'YOJ%-U %$)7"J<\G)]#&
M(S(/XN[J!X"NM&IIRH+JG0%6$%E6RPY?F:A;ZUID(5(WQT#6]RR/?I5W'O@<
M/!T:HAP)5U&Z&K*,KC"F*-A>P9Z%!W#HT5'<+4HS(W0);)QXCV,!@HX_J;J=
MX7M2,%O^E-E8&R18@ZA5#54&\-$:-BJ\%Y/SZ+EF:8N0=IW'F_U28_\M 3CG
M#(IE!IPWUV?CR>78)T/2;33TQ^O//WES8,7CR:/=%6:F'($M+:+5(_%K2AZ'
M%!^<8:W+4LP 3J5>:"IA&%%9>>)$G^+SHH7I#:1>Z5)1^:\&[MO6M.5X_/@)
M+2@)E(F_R"M[]GBZ^R5$S0@W*(0@15N;D,?RI5:WR<N#<O,^(P6^+TW-+#P#
MEV"3(=WFR!UG!$'%'F:_Z[2.WM9I) ].Q)$.2 !]%=!;(ZS9R)*1#(0KN*F3
M.+]SPU!A14^=6[,*SIW.H1W$ QRM:',N&N$E!#?1,SJUCA"^"@46LOU5=L#$
M'1Q<LZ%V4"HCT._T!.I>BDUG7RI-9TK1)">W+863\Z'G4POVU^"AXIR=*#E@
M(]>93A<, I!H1N7Q2/Q-K>HEI=74 S?B-UFB<OODXZ"+$4!4Q_%%MJ<>V2K%
M"S7G\N&6D!(IQO9:TG[QP8G^ Z^(Q8>'Q\0<(M?*6B$[Y?":]U4^$B=A<US3
ME2WO*5=559AX,2$?=NF4K*.\ XOWZZ'/^NO?/G7?;#%OR3,_R5H#E7YB%':A
M>"!0HSD)>@G23B9^^>5U1I:T@^?D(WWQN.R 0?.O'M3=L,?H"3C@\<ZS(\]9
M&(2LZI9*6<H<7L^[C[]8FG($FV?BX^AZ%+PP8J=<L*^>Y*8LNS3>8RGIM*>U
M/D0.U)J%4NRC:JUYQ2U,N_))^%X[TX.HK)XV?6KD!H9;)A1YL2$9:/&@ ,1@
M3Z_>ZLK[DVY*7ZQ$U'YR\4.DCL#+E:(T%?&&.[Z,L283G$9DY>8X'#NZ5 3&
M<SE#7<WEKA\@T.C ES1!,Y[#>UQ-AG%&WP2[4?!.6]CX.LY"B(5_(S#B]J0B
M@H55'*@,C#P2-[VZ(WT=*62<^N+C(*)/E3GSY5O-I82ZDR/^63;@-K27[RF!
MYM(6VMQ*ER,GVGZ)%/+3 >XKLQ:R=!VCXS^94<+IKBH2IFTH*?"1M(ZRFY=E
MA<IJ9JCR*K3CQG84\A9Q<E>%W4]BWY>Q4IIK]T.!,';7-ZA<;#RQ@VGN9HY.
MR^XI_'Z-=4>.)FL?"/B@ZBK66*K*824?#ABD)O\L.7^:J93(BCE)Z^L*Z!OV
M*&A0T%FN'TN!]IX\0_8-:#BL9_I@NKT]X]'@-[1]B.; E79T<506:_*%3E@?
M1GY8Y,6&>\7A52W);#V_6\FO<$NTP/!059;PT#GY)E?D5$H1'8TZW3;[]9"D
M'U852QEFV47_]*Y,XKG<=IU$=6W+@R:N^X;=<^JH$E5B?5\YW9A&EA03H:B>
M/DYE\Z&*=8=!EX7&,3:J<P97FI$4MET,9H,G86(#G2F]@)E^;_4M!*B:4[(:
M,9U3+VJY+4[U-T\#L8XM"WZB'_^*\@L"?@;X$QMOD29JK["?)320]=B15:6I
M!Z)N*NSV7QPX9L *461]>%TPB 0U=%,P7X"75+S'9!QSVCMOJCT&:.]RX[G@
M"D0RC#0\3,C#H&"F%MJW-L &:LS1 .!D"^;]Y"(,72@9\;A0BJIE0*.FHYTY
M:)X,RHL/> _!=N="8#GRB+:#X&?0@LBHK;/9YBQ\#.-*WQ]U_E15+=CL9KVI
M>^$:L=_<'E",OY_P ^2&17HJ3M X\]3NY.HTJF#>!-UZ2V^W/J#O6CA3X!:-
MW>PTH&&M;1IF2Z2QGI- Y< RF5"$VF"R0X=M.W0Y1>:[M&&5&;XS58PM+Q)8
MA1/J @@B=3?K]@A5!%P:1!V9*\ 5CS#9\'[B3N#4(@)9=1Z,FE!2D@M3[TG!
ML\WTOMKP4P"A+SCB]&X$[N,;#:QG:/;CC*MU_2Z41R?2F8JO,]2<IBV,MJ$+
M9N5URW%0/[#Z?KO-A2] PE25O6]HUVV1N/3L+3F9M8V/.VE+K6R:M.++TZW&
MD$[BXDS2#4FM&GAXUB6:+,Q$:ZF+L[;.(IZ?S<%KRCT=%FS9.O4=?$/CYV+L
M@\.D%#26#=65Q9R4)IYK[=@/2Z,/9*H]&7LDWFH>7OD&>"5[D^>]3I#J =-M
M2UT>#<TL!>+,,I[/X6QFS:XL<H)*:%&;@KQ70Y9"^R$;6S$BKZZ<*6]5E6\$
M!"<P9=UP%C+;)Z<2B1COD[Q'B(!!?( OQ%*A'FP?:DXX%"4V.9_K4G-$<>3-
M@BD=U_&*K]4LC:017"A/7!8#E-V>:#E )MN:"AYMBV[B$"@,"&2BJ\)8LV9=
M42.K:Q[3V>@Z-+D,]F!LT314515LE"L_SV5)7$X)U,RC2%RF>[SIG/)PSB(2
M72_P70JB ;W4)8=^J#CNANZ4]RB?IH2SB7<EC^+U282(=ZTE=UBA\LA",NKB
M.<JZ(] L);UY)P?S!3H+0\[FX6OKCH\[&1?W^FO;>^% $!QD7:6:I0;($CIF
M';;X6M-:=6MR!LY>_<IW--P%P<$)PEL?V=B,(R*46$WCQ*[UZ@T=V<%Z$)(T
MU*6XK>DBW[B0PUI9J)6T7^%P-/;4\PT=TFO8:"$IE^V<VKM>>B7OJ!;A$B?4
M8[PXJ!*\U62W)A4C" QKG#NS"J3HEBWBY(;J$DYJ]](?)/#1H QZ(-(A.($1
MFL]G[_KQ AB]27.*M=4-XH@2B@XLAB+0AQMGF<W )^?*7QQ-1Q>Q*K]WQ#J\
M"++QY@Q!EVN>0U<!/IN-;^RH>+6^I#1APH2>&>9/S6+*#@TAMDL3E@@;V&IF
MC,B]<^8 B8#$ =WZP<-74G=6PSMMJ"_"61BZLD%;O?=^GZ_?MB[4MNW54^+'
MZS@+^Y"XN8G<# ;"X:V2K2NK'/T+E<+C"S_6((*[PURZSWH#GM94R<>[=2XQ
M0@>,;=V@LG]!!;_HW(P4<%-*#L78O!<LZ Z;6_-G/ AB;C?9%$^[R[J9Y?;4
M:B^MK)>_XZR!/J=I0]IS=V5(+<8>KSBA$H%T&!C=,55__I:Z=V1!JG\##O7Z
MB;TB^$.Z,]!2?@UWBU%3OA ],##MK>\FIN% >JLV\T-8HK%" T0YH7^[>!=K
MV<%6W!./FN\T%\JACOR,WLO=!NV#>?FPOM_>]K3=O<#QT/^W"/T;^X+!P_R6
M9XHUJ^(#DH[BVN\Z-O$GT#!?T=QC^M,N";Y[<YWR_$=-;BQ7-#&Z"77QPTEN
MBW"</EU>=7 N/O/,(,GG_AB=CN&M_TCCKM?MBI(?]<8?X1'^2,HY>T5\Z+GJ
M=RHK"/OMX&+^X1+L6O7XZJ)3S:%MQ^+'G@*/QV*VM>%8C*>CJV[%=,^*Z:,^
MC:L]*QY/1H=YN4YOEQ ,U _#R/N03Z8RD$)[;7S"0UM9S@G-<D8I,1E=_2!.
M?<W <Y1NKMG= N-;AK,'^O"N^SYX$!X;Z)L_ZP+WGZ:UKY>&:J;=Z?;!J] #
M"2<.D_=6&&"[61/GE,1)2#I:A+/WW=#VX+_'Y<X8>]2]ZKK#7&_?GA/BVY+8
M"9Z0[+N7@?IO0>X[/!N\AS+H*5!6GLU0;?+;54$)T#J_-9"0,#5[^[N(9FE-
MNUBB4N353-V7S7.J[8NV/\W8QU]\UVC/9'L>HW'[/<(O#Y![,/0)67,X<M,5
M-\"#MH]G;@?F;/<(,MJMQ/^K"O%#SM6KQ8<_+WC'+D3%#CG\]NN%W$[-5/^5
MJUNXHFF=GW9ZJ5RK>SUJ0"G4]NB,^&4H "YK90;O!GJX8<=6&+#1#<S]V(9O
M394S9=LS/*BL9-.DV\HPPDO3*5G0E4%\D9+\B2\OP$;%LPA^!S'X%8BWI???
M\/8BOY054L:^WXF<]W[1PR^0T.^6G)]E^!_WI*?IIU'7_A=!W7+_NRJ4/PM=
MT>W#'%LO1H^OCGRG'_]H3,V_#X)O-6;%'^G57F5I ;Z?&Z!R^(,.2#\8>_E_
M4$L#!!0    ( #*(?E:TX/N<QP8  (T1   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$Q+GAM;)58VW(3.1#]%96A**A*?)F$P))+52!L0>W"I@CL/LLSLD>@
MD09)$^._W],MS<0.L7=Y2>;25W6?TST^6SG_+=1*1?&C,3:<C^H8VU>322AK
MU<@P=JVR>+-POI$1MWXY":U7LF*EQDR*Z?1DTDAM1Q=G_.S:7YRY+AIMU;47
MH6L:Z=>OE7&K\]%LU#_XI)=UI >3B[-6+M6-BE_::X^[R6"ETHVR03LKO%J<
MCRYGKUX?DSP+_*W5*FQ<"\ID[MPWNGE?G8^F%) RJHQD0>+?K7JCC"%#".-[
MMCD:7)+BYG5O_7?.';G,95!OG/E'5[$^'[T<B4HM9&?B)[=ZIW(^S\E>Z4S@
MOV*59(O?1J+L0G1-5D8$C;;IO_R1SV%#X>5TAT*1%0J..SGB**]DE!=GWJV$
M)VE8HPM.E;41G+94E)OH\59#+UY<.;L\O!0WG\6?NL19*W&Y]$KAV./9),(!
MB4W*;.QU,E;L,#8KQ =G8QW$6UNI:MO !)$-X15]>*^+O1:O5#D61[,#44R+
M8H^]HR'=([9W].OICA_*-UD[?M@: >95:&6ISD= 1%#^5HTNGCR:G4Q/]\1Z
M/,1ZO,_Z+\>ZW]KSL<@&?[(F_K+B1K51-7/EQ>PXG?:!B+42;US32KL6TE:]
M/C245Y70-CJ6(>F?K1Z(MO.AD[ /N56MRWK;I%>E B(KV!;J1VFZ@#NQ-&XN
MC3#9W%.\06@"],/*<.UU='XMW((??%)M-X<TW?_AP$L<:JE\!",)!Q$OOG9>
MATHS#X1G%$Y<.=%ZUWJM(KA(E(C)=;8*["BTJM0+S3E"3;*>Z%JP2 .@:;L<
M'"RTE;:D)XTV"G"U*HS%YYVG D^WR@<.W1-C! KGZO)P5AS/4I;((;(H,OIX
M>?,NG3TD7A0G/TNXN0HZI@*1]%[GT@3.^U97BF*0<:LBC5R#T6[!U.UV2'3P
MFTX_%U=C\048'XK2A+X@N[KAJ7YVKZ7H747IM_";FPN]T+4+#Q:AI^P/ G,E
M@HK10'RE8RV* PP=$6H)U)%?*2SX'P#4Z1YH7*!1((Z*E-^05-!+*R,U6Q!/
M'KTLBNGI31*_1$ 6-8EZ;I2X'C1O2)-%9Z?H9>G%K32=$H^GX^ET)EKDS@&(
MIY34?9OW[(AL2. ,N(^HX8SBP<3QW_71TZ"4^.BB$B]8:P8MME$[@P/G1R].
M0;'?.]3]6:KW3K\ZA([[&!ZMS:.0SW!WK<0*AP1T.E^E WM__>F);-K3*^"T
M95G8(WW9 #3<$8]?C@N"@"'[-"8KX9+,0FJ/SO+?L&&D$\R-LBOFO1U<Z4I8
M%Q$ "*-"!&@D-'2I0J#2^S3F=23+R#A$'3L&K.Q+- ?/ *2AK\@*9 8MG*9G
M+D+/P+B"%SN$FI':4<>;-9FCISOYM)8P9( *M!QQVJ*+'9QT.41Z#31AOX(8
M.A3+#SM296V=<4LPCA$+)8.>:X,:IP,AD.W'&"6,7#OR@GV'SJ7JRG@X7Q_F
MR\2-5#._QN/^D@JF*;VH#=LW@(HG9P!M*J)>H&6DM9K82][1[T+[0(Z;1OE2
M(^X@#6<3NK+N(Z!VX?OLC\@@&T9#:2\3#CSGJ*WL89%""=PWJ'N+J"A+(W63
MR"N3J=SEB/.%K^S,N,#TX-6R0XHT1?K!0Q3*U/]0V)OS8RS>:AXJN?J9'C<I
MM,]"[:L5G:Q.*:8A!89!#"@#O#9T_G2:<^Z3_BSD'9$CKQK()"B4'34NQ8Y1
M%A.CTC-6R08(\;![,A657/,90!,Q#95*<J?]<*C2^>8 LY$2]8<_D'%RF8V2
MQ,GT$(;%4?I'T)H>G8+%[B TC$>*U+LU\+'N*3XC:R\E$4HC<+CDW4-R#M@.
MT\[2;XCCP?4-47-%'',+6^&_EYW$D%\[>X\B=X%\>Y9M[40R#8:*!E+R?E<X
MMIMM;@V.7?%FFNIY?F=:VU,]>Z!NS"\2O3"UA*YMG:<%S:O#$HLB/\V#/^7&
M/-&_B=R*6>LN*>)W'OR)5+ II3U)EK2Q29JF-+K1W=S;FA:C]^"E*@FF _S%
MA%:8,,C*=@OP//6XQ'WNL%R+84 .\7O%Y)XZC=HFKS8;>]6 ZH3"GU&\.\Y^
M0=I \1#"?1PG4&W"-F/HZ#XPQYLEY+7M_\8#:Q1$&@&Y6#0"\B7![X'!D"=
MRUHY6@R(S1[G%7YO]'?PNWP8G]N@V9CEG1?IDR HZ<N:2[/1D/W>L4D4.T]@
M_-"WUV3C$QFC:LD_!(0T)]+7\O!T^*WA,GUBWXFG'RH^2+_4Z'.C%E"=CE\\
M'Z4%H;^)KN4/;K0^/M_YLE82<9, WB\<MKM\0PZ&7V N_@502P,$%     @
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MZ<ITU*/3RB:56!9R:(?,40_9338KB.*H\M@U.8.='@UPHO+)&ZTG;]*LME:
MH6CCIXW)5 &/Z4IWW.A\ P4>[M"&&F;4$ME'4@#6I47:+*3F@DS\KZJ>.MF)
MT+[KAF.L&*3]0^@]%L*2BOOYW6.R_8.2^,(WSMQ1F?P &6[:8RJJQN,80;^W
MUD"Q#C.:CX?38^]5I*YM>^8]'#1FM0.SC/$+-"T)YH@W2O,6'3\3.4US[CCZ
M,(^HU@S5+2<LN00W47 32V&N].E,.1T>T=0*O9@3(DSR<Y:)T<.9P.&I(.7H
MJ N?II(21>J E^@:F)0@E+H9%!,T43X[LSK\_L!W\>S&.OC<@OI@$GY1LMB-
MBAPHE]R&T:^!XQ^4.K*84^G\(W8TF$&D(\K2428UJ$;F-'?H,]E9]E6SI7&=
MOMT2#P,.\0/G>'?\//PR?A7=+H_?EM]*!X;VZ $7>/7\],>GL\ADPT6P'7\C
M+6T(MN6?*R5!I[0 SQ<6G5NZH W&C^:W_P-02P,$%     @ ,HA^5F"ZZU.'
M$0  BCH  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL[5OI<]NV$O]7
M,*[;.C.TK,/R$2>9<>)VFDX/OSIM/T,D)*$A"94 +?O]]6]W<1"@*-L]/KZ9
M3"R1Q&+/WQZ@WFQ5\UFOA3#LH2IK_?9@;<SF]<F)SM>BXGJD-J*&.TO55-S
MUV9UHC>-X 4MJLJ3Z7A\=E)Q61^\>T/7;IMW;U1K2EF+VX;IMJIX\_A>E&K[
M]F!RX"_\(E=K@Q=.WKW9\)6X$^;7S6T#WTX"E4)6HM92U:P1R[<'UY/7[T_Q
M>7K@-RFV.OK,4)*%4I_QR\?B[<$8&1*ER U2X/#G7GP098F$@(T_'<V#L"4N
MC#][ZM^2["#+@FOQ096_R\*LWQY<'+!"+'E;FE_4]COAY)DCO5R5FOYG6_OL
M%';,6VU4Y1;#]TK6]B]_<'J(%ER,]RR8N@53XMMN1%S><,/?O6G4EC7X-%##
M#R0JK0;F9(U&N3,-W)6PSKR[,RK_O%9E(1K]-?OFSU::QS<G!BCC_9/<47EO
MJ4SW4)E,V8^J-FO-OJD+4:0$3H"EP-?4\_5^^B3%&Y&/V&R2L>EX.GV"WBS(
M.2-ZLW\HIZ5R.DP%(^2UWO!<O#V $-"BN1<'[[[Z8G(VOGJ"Q]/ X^E3U%_,
MXY-4AGD\'[&(^%=?7$PGYU=N"_9!514$"&W/\-YX=L4^K06[5T;6JXP5\EX6
MHBXRQNN"E1*6%9R"JD&GUTPMF8'G'7G_-;=T-='EC8#(7_P!T0BL$*$_6U[*
MI10%6SS2 DLM8QNU!3)V-Y!A*1I1YV+?-O:)!LC8G;9K43/ 'VU@/? _(EF>
MXTW41IH2B !SJB;9!0/08X+G:Z;7^ RL3=:M15DP;A@O2U9!!,)FM(&.=#T*
MVM. %GG)D5&@D!""/4&A@G%:#KXOJH5H@O^/V,>:N!;WP"8^PNO'V YH(JU5
MV=HOP/56DNS'[<9+#%;>P+*LK\*$$9 39%FDZK#"2\M"(Q#J@30PJT5G>T>>
M\7LN2[XHK?* +=/(!?$%9M4FV--(7B:W-<!:(7"_GJD<9>>TNF_O$;L-%W9=
M.'70.]%(\*/KG27H:>[F^YV;1QQ-MX0X*]BR;8 09 ),9Z\RT%Y)">9>E$ZU
MN/MT?-4C0E<G5QEXIP3=1.[)P-?)\DL@I;;Z-;OQ#C-BOU$$,LJ5\/43^Z$S
M^FB_.*\9;B2(TWMPB]I PD6WD'7W%>)K:> !9%H#1;WD-E."I9<MN('SLS_:
M6L)2+?*VD08VS.")O&R)^=A[LM271GLU^IK]X(R<K@C/?U#U/7@ ">FMN4_8
MU^&)K[ZX/#N_O&+7+61-$"A/Z/QL_7<I&_#"3PTG]F_X8Z0%[\-J8<#'M=5,
M%\N,;S:-NN=E1A$?VY!"Y'DWVZJV!!3=2K.&U:1=[U!.]X"$WOW1)[T10?^U
ML@MRT1A S1SP0D,T$L;7Y"6Z]4BE'=S"UI"/&QO&B8168%!#K8%#=KT"&B"6
MUQS(]X@PD),"#1"0-2(![E"W!$Z(<T'J%$XQ7$"G%44,2$0(B!Q:A7*D!VIL
M"5$/V62<C<=CM@&B%FI<.LB#]2#F92[P(GFG6"XQC1Q%X39D<Q=SKVP"V*'6
M;K JK ?=A<#K:5."E (S&*KV<#:*!1CMN.3=1N0(>!^X7K-;_HC6OP5?DK@9
MA/RO=2FT-3E$IRP'W8[VM+XIBAC'0<$%^<>:WXLNDU*>S0$OT!>&3059HR6P
M)F5$*GK&DVUNCCT*>4,6&D$;DL<A]7]]:W* AQS5Y9\DI_G -RP":G*.@\BB
MOPC,-11E!^ 2/RF#81@BF+!!-6*EJ.21EO2@;ZRYU;;*\Y;X<OX*65&PH\M7
MQQ76PJ"A6N(2@EY+3H%=9 V6).&AIJ&TGYB2(,(:<B' W9-$W"XJ"2A 2@9Q
M^E'MG395)L1RQB#'$L_D9F8-;D^7X;;=]VL=V6FOZF&AL?DJ*N4L!T-Z=L]W
M$J'=1"&*U&Q7#/T;4AXY-3>87Z"Z$6U7 03J=Y;)/F&%*+F5VBFM$"6J?M"]
M4!->4<-L9ZEC=[M 3C#0^'KRWBB B<YXS]2+?:Z)5ZTB[CO*:*%*M;;<RQ$V
M MH8*LW+MA)@"PQT?!S%70D';4<.%7_[_?K6HV"$KWV^E$V-QB7% I*BK"I1
M2'!.R .08G(1@H0*51+:>Z&TI1M4J6DIN(1*T.JHXI\%):^ #B31AC]66-#Z
M\M_?+$#)V-8P NC'CNO]<$2I(0HCU*B %4^%$XH%VH8VNVI+;N@CLM45[+"_
M-6?(K%3NLP9U@/J$&&\KY&P.">!+K\@DQ1VQ@QL[);#H'ZJ[K[\&&!J^1?A#
MQ7K$/\\=H[:!X& )B5F::ZEWRJ3=*K:?DCK?URC4SQOC\.([TN"(?9,X\EZZ
M"/RN3) 0;QEI"(QF9$7:(MP+Q'=-E-G2@F+CV=+B*,(=+(0X(06 (E7$^M5?
M*CS2I+VWZ@@%QYXZHE<J#&O(!N_>.N';MBXXQ@(\1$69+0='L69[,8DUN8>?
MO<L_+I]L? G*5^#X-L[RM4*!@%V',G'-3Z$!>P)6@P#F$9]9"!]$6"""2^YA
M9#<^'3>#!7(4KI8WVZ& .^TP>%V"N6N,1G!G#<'3V+F$3' V\.A*OL=>ADRK
M]SY/MB\+!?9>77M;8L<.1.0]LG5;<FCF$>2P8+IM%R74$C^#.S5($'J2.[$Q
MMMN?G-IN/TT_L)3R 04)A\>]18!8DZ\Y)(WK52/L'EC1L!L%??]U4AV[2T\N
M[JIEN(?524CN+UF=^:<X7B%XW?B'EHVJ$IDZ?4OHS9]LRK>\ 1T;G1!,UZ<M
M*.80"''AV5=:.$^E:K3P<XS_A.'3MU"1U3F: QM]!"7;$;I*$IK\H[U=OA,Z
MD C)%AR,BD-O%)0%KF&?AM>L(T83L&5@ B2#A("?@--5HS1./!36320QQQJ.
M0]8]G,Q9)<L2?1CJJK+5F,"<#_?Y2KQA0/3.^-Z+P35_4O?6,R^&'#,O0;4V
M$]70M$#H;<$[#(3KQGJY\EX>[VV#(PV#H#1@OJW1I*2R =FQ$7J0E87 P\GY
M:.958+'Y239LHJH .8GO)3N:O&*\*"2&+P1S'B/(*)DB#7'-*F&3&_F)] F.
M#WI6U)BX-/.2H+JR.1+;D@P5/6P08$K4V@D?T_[!W>CP82%RA%&;SL!==MLX
M%R00,8[(-)M"RGI!;T!#2J_.?:XRY)N6";<QKV.3Q#9XLA,G ]#0(B^YUE;]
M.* !@_8GLG[Z+>STNV@)('@<GD!<5+9F60IN6AQ_+H=[\N>Z5=\LVEH?K0VW
MT+\ANJEAK.S!20!)JJ\1VER+.&)W^V8!GARP&6;&Z!76-[#76$O(6%B)N9'5
M<_,I()K.@/H#H,&R;#1D*#_%L[7+8-78F0J4 45%Q6O4OC,,861HE+FVP6!K
MEMHU3;9SM$4LMBEN*NDH&(!R@XX_8M?#D_5$+;$0#CQ^]^G'QXESWG#]R*@5
MC>B2M$!XX9_Q\)99B> QV71R.7% Z@?1Y%+;GO7%XZ 5;H%QH[OVR0+!3UP7
M_$_6M$#*HF,8T><Y-I;:5ZX $2'-H@, HO"%+%&#X$/0Q36N:$:;N:)[5^^P
ML5.[HT]UM[= M!=VT4V+%Z.VY=I.6TEQN[B%BMA)::2Y!;A!'+GX))[2!K3!
M=D#O!>8>3JEJ01AM&35;A3VQK_! ,Z7"?3$YF7U987^M0(]'%6-(>W1@!7ZH
M<DY*LXDO24<!(LEG<J6-LZDA?Z'3"#";-E:-? 6J6R&0I%1"(>R24$#]NA,H
MXC >K?^]OQ^&M__@(C^WU_?F*T_F$#+>=#+NO"5WKB[K8RH0-+J_%APR**FJ
M$*!^M2$B.X[39W(RI_ESX!D;G4';[BP\SZ;SWL*_JJ%/RD2)[I"=CK/3L_'^
MQ]=[;8IP8$\WG"]U8_\$CUQ3#E$=A;:+EMWD\RF<^45M6\I!2%U]_['YI,_,
MWSR$B^/J^8.V5ZZT4;M-;PP/('\CW.RGTX;>KXZ/20QBX( N:O>*"2'#CA)<
M<'73/%^U$X"!^5136 3OF@#QL*%0\&OSW$:J/7*KM2KQ$)".0.$/82E2QLZ<
M.ZRBA@.J7;'&5VA /BC"]!Y[ILC28TPF)=F&R^(8Q>8;"9Z;IO[8H5Y0:D#H
M+GRF"9-,3!2#Z0Y'/K:BL!_C^L.=CX=G-2 );Z2R !RQ174'+W,W1X.FR4V'
M*&F6I&#K)G:X4V$OMBFCEQ2Z&95GP8VDXR8S'3EC%!1_M-J+Q]DC0)4.;->J
M/OZ76*=)EF5]=]<7F>JI^94+IVC#)++24H&F-E8WSJ%X(;N2DLI"-Q^D66$4
M9W:^J6IQ#(P?X^L8O2GGL 0IS&W3<TBK+TXO*N&Q0U-".2OMY!?[O>_4%I(&
MU'&N(2#< $2G2LP59Z*K>X;WM.>MWC#1*C1(:+M**JS^*QIGY,BJ]LED5(]/
M)$)%MN#V;9 ]<_TP)#3\LQTHT(D@56=$-@Y //U73:]9ZB+*W88-+\=?ADFH
M*_Q>8HK#Z6G7K@=@"X7*;F6, !?-(V![ZF_&TPG[1:R@UJ&YV W4 ;E)1FK^
M45OC3_[!/"V>7"0,O&B29O.!1J_"(S\H>Z5I'8Q*B '0<Q.*\&ZZA<BM>2GL
M1+7I1"VLJ&&@ :H^S6;C\^SL<M:;8?;?F4EG9'2&$?:S+F<'XM-YY'O(V?-#
MF-/1.%AUK[XB@_6G/M:77JY=*"BT\B>&VB%;-&[;N,GK)DQ>\1AH:(SXG*+V
MB]-O[;J>P!-OM'?QY_0P('\7-]*]C17UABAPN['OT,7Q,^P,:9I\9B=[S%3W
M<<NZQGGD&MD@9[B7L/6+E@\[@XTDL!/=?K33&_:-W_<&GD@+.=H/JB)\E\&L
MP17H*F:(-2^7-I]&DWHD/DAUM#]U3'IX=3J:!,>VHVB=MI;OP<,^']_E )5"
MDZYH+*@*46)JW^ ;/B"S'21I2$!8I/=?]H((E_KS\1)%DH1-4, WSJ+CT?Q+
M=D758$YG5PJS%<$UW+T8C\;);>AN:=EL-+<:B>[Y0TWV*/&M122.:_U<(TKI
M> P<7J8D#_!5XTZA#$ABW]\C^_M#H]WA/>GS<G21Z!,4//47,FS?-CX[COS0
M-38)*BZ=&#TQU'/EQ\YY(E%9R@>:-!:A/.!T<%DK>\BEA3&EA8XP4\&G__+0
MR>>NYYN&IX"BG^%(AL-)ISPWYI,^&Y,0&(P0<<1D]Y[2) )K>I<7P*.TH422
M+86%C<-Q1SXYV9H,G&Q%1P;?\[K%]UVF@[DW.C+X"XG7[OI,EO5SJ33+HF!0
M[X 6I1UANJ2;(4Z',RXW)5U'[\A2ZMW-)$<)2WU%1(@5#L'L*U"4TD59[D#V
M-)N/[=MO+\_?>]/W:7*XG.T_/_M7N-@QT>Z\,SG*,C3HZ-43_=<208K)N//1
M#%(,GGY H!9M3I0Z8W :^)''D@/[^'"]LQY"$9_AW'G!4*8[&XUG\1']+A%Z
M73S*>PN(U;KNI[TD%_4'"3LY;8G ^G\PC&>K0U!CL6\\NOP;V#<>G?\#[ NZ
MI_HA&'>;F"1^)7C/N_RT(4KWSX>KS_W]*1C<,__R/=V*SEK^QJY _2N3\&RH
MO&XINKK+X/)N\HOF_9'&MM/QY#P\<@S-VVPRC^:BY]G%>#R*QK1^%7#P?0N=
M"*R_"#=/+_!?MWJ>G8VGHVA6ZY9,+]@UA'Z)'[N;DVPZG[K_.QJS\WF\?U@W
M[[)>+/S%+)O-+OR?CLP$RK;+74;.TOP?6#F=9?/+\_ WHC-)!(K8"<?$I)PP
M@?-/GF7G9Q?9Q>P<M-R12W3;G2:.I[-A>N\[0;/IV7DV.1^_C-YY;^0]F</Z
MTVQZ.F73Z64VG^\??C\U% ^!^*(8Q"*\+&,4'SB^3F<8-G4\.1+:X@'EXI&-
MV$T;AD!8B#,<"Q5#QX]!FRFVBP?(U/7*CT-?G)5';.AW:"?1[P,KT:SH5Y"X
ML*V-_:E@N!I^:'EM?U_8/6Y_I0E1M\*?1I1B"4L!4N<']F5S_\6H#?W:<*&,
M415]7 MH*!I\ .XOE3+^"VX0?G[Z[G]02P,$%     @ ,HA^5ATI@ W("@
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M2+!184?R^<3QYI,7?0ZG[OP0S7#2%<-HHQ<J!8O'%X2A6=:G[(^=23CMDX[
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M;(2:OPY%O7+C:I[#*L%F<&#WD*S?OYM>33Z<(3H?B,[/H?\WHN>AKL?L!"W
M,%,,L-[DCVS#G<R91D%%@C4*NB H'<M-53<>!-L^,R'W4DB]8[Z$@SA>T+X-
M+0#B@N_!8D<SW51;1$)C <S1*H]F73"+4\)YK@,B#IB @K:E$2/L U_B/2K@
M!! (&+J8I&KC07O)E2)"JJ&^9@[RQDHOT8HL"$A:!D6!S4\^<)3O1<?LCE;H
MT#?RE_UK?]'5 ^.3&_C:R#U7Z)<[$Q6<-QXLC@$TVKB>E\=I[!K[?&1$%A<8
M-Z1%]"K 2 K7^7W6-(6 _+?2H6*@'U#D5B$'')A@+5X$Q1$S->7DE'"#O1\I
M8X'57#]_Y_ID!VE6*ZX#QY9;R\FHP,1UKD0W':ZYIP.'&='.VZ8:Z!T9&S.<
MS SK8- +O:C1Z1%IQWQJ@S''2K"@<X*+N7R9JH8<]H;E7.6-XAYHV&-/#"DC
MM[NL'KG+L=QTKIKPD3)%=.(?ZK,UC<+J@A=5^?[=(IO,/K#?RM[V*_79TR-S
MP;  %XS2B&1?^I#N$%&?BR(\Y277.^"46*G)\>.:H+)K2YF7%#TNA"2#7+UH
M1@RNI>JADBBLJ0*1TB@4& <W"J/PJT]Q&F+R5FNTE"UM#OV.F%VN8D-&DZ@F
MWNY>[DX[/T:ZQ/[$<(,. ;_H(WXS1/S__O\)W,:/W=^N\-,%H<)FT^$LI A_
MIMW0[=NGOY]=C>;7L\,VP^WBD-,!)EN,LMGET?YZ='DYZ?>O?7[2HP="!787
MGD$TZ1KMXUMA.!U>6A_C ^,@'I]IG[C=83$Q!06J3L;?7R;,QJ=/W'A3A^?&
MUGA\O(1EB:]%L"2 ]X7!4N@V9&!X?Z[_ E!+ P04    "  RB'Y6<5,Z[[<%
M  #=#P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6S%5VUOVS80_BN$
MVQ4MX-BR;"=-G!AHDA8KT )9^H9]I*63Q84259**FO[ZW9U>+#>V@6[%]L46
MR;N'S[V2/*^,O7,I@!??,IV[BT'J?7$V'KLHA4RZD2D@QY7$V$QZ'-KUV!46
M9,Q*F1Z'07 \SJ3*!\MSGKNQRW-3>JURN+'"E5DF[<,E:%-=#":#=N)6K5-/
M$^/E>2'7\ '\I^+&XFC<H<0J@]PIDPL+R<7@U>3L<D;R+/!90>5ZWX(L61ES
M1X.W\<4@($*@(?*$(/'O'JY :P)"&E\;S$&W)2GVOUOT-VP[VK*2#JZ,_J)B
MGUX,7@Y$#(DLM;\UU>_0V#,GO,AHQ[^BJF7#V4!$I?,F:Y210:;R^E]^:_S0
M4W@9[%$(&X60>=<;,<MKZ>7RW)I*6))&-/I@4UD;R:F<@O+!6UQ5J.>7;Z2R
MXK/4)8CW(%UI 3WNW?G8(SB)C*,&Z+(&"O< 34+QWN0^=>)U'D.\#3!&5AVU
ML*5V&1Y$O(9H)*:3H0B#,#R -^U,G3+>]-^;6@/-=@-1G9RY0D9P,<!"<&#O
M8;!\]F1R'"P.T)QU-&>'T'^&YF&@23 2>\#$QQ3$E<D*F3^(Q&@L38<%$IDR
M]RI?BW6I8IE'('PJO8"L2*53W\'5XX1 [QE4H1JFH[T#?T3%$8MLL\U0Y,8+
MF0O\5OY!N (BE:BH+]-0[-"PH-",6$@GGCUY&8;!PB/5PJJ63&5*'8L58$>(
M  LZ%MX(K')-&TGGL(\9*PJI>,%;F;L$+++42JZ4)AXJ)UEC8[#ZH1:1=8]8
M@:\ \L8B1+%>10J]A"[#O8E*C[N(I8<1TYPL^G9D?5=+"YU5U(80Q0((#?>@
M1:K 2ANE#V?B'4],D%U1>G<F/N4R_@L; *I]+0W]L1<<QLL*%9-/(ZEKDQW9
MW!JH4$:U_:XQQ2T:_+##_^,1J%.9TM*VD#*/#V,.?R"F6L<U>4*6<P:PUI X
MUIN+*E51RNMF1?4C5QK7JQ30PU;$"F/K,32LT(Z&-<=RY3S&0TE-L<. )"7&
MWH/-A$EXHDN"+N*M\=.><S<;MZ28,YX)=& P4%,@%.#)R0)]7'&&E5E!R8(.
M6N$IUV[9S>[*G3II2T=[L;>HR'9S)8G:/>0+K@F<]N0?E6!,T _-#NQ6TB"_
M[ ';E[34 !"\ @Z1P.S$<D>?XN[.V[+.W$:K25N,0FDM$<="I[IWY'!LTI"M
M,&A-HYXP=+]%H-"O@P\Y::1KF]89=XE@NOC?_U_MX=NN7X.+K.(<$1^-1U^T
M!=\69INC[S8U]]^9]T5:[(-^J^#;M:=B$@Q/3H][$UP3X>+@S ]*M=%]?$S.
MWOGT:W?K=GV4C%0/')G&9*Q.2><.M1!NTJ6C+)1\G<$F(*TVU!I++2EXHP[Z
M+;6-K=+G<OHGR5DGSR95>DG43C+E#]Y$=^*&3\.G(AB=;/+K]3>PD<(.4Z_V
M=^@[ZE:Y.Y'0 :30.KR]8,O#AM"M3T>G1[/1L?A-?#9D,'>1=O%T=C0)IKAV
M"W3?YR9&C??Y TCK7G1RDU%P-!\%C\R\Q@C0H8P1B*1+-3@GH.5=6'.O^*Z_
M,T@6\%IIV[[9TR)K(4F #QG-+>\[6#-LMM$1!:X]I$2!;G4IGSS[4@&^EIBH
MS!.Q4$QN-"*39<C0<1PXMSC43(O/$K8BIN06%I>.L#=7TL;M;M6.,NOZX/;5
MJNWJY%M!QL>/N\O/]X<_"8UOZ(^CLT'?SKI+J?DRB/Q6L%8Y!QX-0E\J$_>J
M\2W6 DOB(FM6K5\[O-DP/)V+JU3F:SX,MVMSEWM:U><GP]/I_ 7F7J2QZ/:)
MEP7&ITN/C5 /:#Z<'\]>],U"]VX9M-U,=EWJQ[TG5P9VS0]+)_@&7;^^NMGN
M[?JJ?K)MQ.N'[WMIT:EXS$."JEC4\X&P]6.R'GA3\ -N93P^!_DSQ?<W6!+
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MPFY[CN^.M[&?^KL]Y_Z)<VYVEMLGJT^V/:3 'G^&JF53DUJN\*QY#U,?=T+
M*K$!XM(8!%UH8.()-U!6&$<%M9@C*L<:"WH1>RS 1MP7F^-]]4Z#'=9/4T/N
M!]3P-F=+;@ZB+8-8X0?>*#1!"/DNP7JQ-G+))ZKTQF6WM%>E[8-\=?3SQ=#>
MBJ#/$FYS\)[1-? //C+_"D"A$!1O0';P.5-,YR7\M8Z?X[)^[R-6$-)4P@N,
M6=A@-M.4;>BPQX" TS[)KKB\R4'Y.9"^M=$0\(B-!_JSZ<1!W=+,'(<Y5AE
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M:(UJ5:JA%)?@QMZOE'6^YU$'<!4%YAI/"N%CIR%B7+Y&,SM@]"W7AW8FOJ+
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MQN/:C']K[.%D60#?*V/\\,(&QLU^]2]02P,$%     @ ,HA^5EWH9TI4 P
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MH^'U. #=-6AG6%7[IE@I2RWFMR7---0N@>)KI>S1< ?T4S+[ U!+ P04
M"  RB'Y6?BYVTID.   F+0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6RM6FUSVS82_BL8WTV;S,BR)3MO3>(9QTEZN2:MQXZ;SQ )26@H@@5 V[I?
M?\\N +[8%..T_6*+)+!8[.NS"[RZ,?:K6ROEQ>VF*-WKO;7WU4\'!RY;JXUT
M4U.I$E^6QFZDQZ-=';C**IGSI$UQ,#\\?'JPD;K<.WG%[\[MR2M3^T*7ZMP*
M5V\VTF[?J,+<O-Z;[:47%WJU]O3BX.15)5?J4OFKZMSBZ:"ADNN-*ITVI;!J
M^7KO=/;3F]D+FL C?M?JQG5^"]K*PIBO]/ A?[UW2!RI0F6>2$C\NU9GJBB(
M$OCX,Q+=:]:DB=W?B?I[WCPVLY!.G9GBB\[]^O7>\SV1JZ6L"W]A;OZCXH:>
M$+W,%([_BILP]LGQGLAJY\TF3@8'&UV&__(V"J(SX?GAC@GS.&'.?(>%F,NW
MTLN35];<"$NC08U^\%9Y-IC3)6GETEM\U9CG3RZ#-H19BDN]*O529[+TXC3+
M3%UZ7:[$N2ETII43C]*OQZ\./)8F @=97.9-6&:^8YG97'PRI5\[\:[,5=XG
M< ">&\;GB?$W\U&*;U4V%4>SB9@?SN<C](X:01PQO:._+8BAW0?:Q\.TR;-^
M<I7,U.L]N(Y3]EKMG?SPK]G3PY<CG!\WG!^/43^Y<HJX?N>\AI4.\S=.X?-:
M"3!622O954!MJ4M99EH6PGD0A1]Z)W0I,E-2*-!^"T/U:_'SZ>DYO///6F-C
M,,P2KDR#A3=X^JJ$2FP)6>9".KA_18LXX=?2"[E<PC_Q6X%*9:Q7&+0AD3MB
M ^.5=Q-1:+G0A?80_T2H6\0D1[^(I%6%I%FY=EEA7&U9&N"3E$:<!!H\MD-&
MR+!JCLDT@7YCDH.2<Z8W* $BLHO7Q);(:TOVTHZCITI9;?*I(%EOC//"=:RL
M%1)$3//.S*:2Y?9']P">@@!(X#++;(UA#2>)W:745ES+HN:M(JAD7_<IEN4@
MOZ&Q0>\T_$9:2RQI: IK*1=8C@QQ! 276+;E&3/7&D0M-E/PXE8K3&5Z^'@M
ML?4:X\"*'3 !:&RA"JVNP0]VL2"Q26=*N2C4)(K1(<JRE&_6.EL+LD'^ GZT
MHT>R-I+S'W6^BKI:( L%O6)/6_K((N@8UEVCF,+??8U-I 7A_ 69%JS4BJ4U
MM*AQ':N>BK.UA)VQYCJV;HGI)>4>;$J7K<$DRE'1P2SH*6P,[R!D!;4H\;4T
M-^5T)$(\:2+$DU'_/C/01NF#=P_&A^^9+W[XU_/YX=%+<695KKVXT.YK\^Y]
M8Z&Z=-[6016LY\IX/.!3L04(6/R1_#Z9%ADPF7N[%#MR6,32(N0+,#1^+=VZ
M9YG$P.S92\=?8+T(:!J,5+S<6D&+"P3W4G5\B#C4ON:5HCJN2DU*NO1!MZ?)
MNTMD^LHX,+*16PX=@";P@=M,D5NJ7%E>""01@,BF$")!X%,;$*.)1V&P5PYS
MXMH/)"EPD(=(!_<V-H<=%]L)80'86M&3C[J%=%P(S+"SBB5L=J^%#;(S()>J
MS0(6GO+II*>8M<S3]H.98]>.)][?>(J'$/:_C^;3%^"S*'BI9"&7=55!$K9O
M-[^5XE)5/K Q.QYB T)4EKV)+(79*&H'3 =I9Q3OA%Q9%83]B"82[?GA2Z(D
M/L8AIVD(?YR]?!RD]=:4J_U3<?D9JTTGXJ-'I'X4YX=O:?PD.FJ3\^+4$+AH
M681K19FP7@)R0BB6PQ,[NS5YG27+?GNZ/YL?SUBU]/O9_&DKI?A_Q/F?-L[_
M=-1YWU/L_SW%_M8_/[3^.1011HD.(YH'K-3L;\ASEX.QH^O'^%74N6(?GP3(
MHO,.'K"$P6GQFJPA8@<9(!PHR6U(*2E/]E!%@9RC^@BADPY[2>)S-Z=T$, P
M6R$-<N[+:FM;2#+(6O#SN^S%A)*R8C?Y,G2!X#LY'OE#UJZ!-6Z-U .+A#$2
M;@MO\1FA;H/==-3V"2O 8H/@1VSO66-[ST9M[TN4WL=V)T.V-DIDV-8&*/=P
M2B-9\CV*6U&1D*2["P,[DM. <?!KWQ!@( ?!>PXKG%84VR!"8LV@"TY]K1TG
M1HZ_-(-B2LPHR8":V)3LAV$#A=,^..O.N6\ F0%H_!_%6;SISFS)#4V.O/2P
M9 =!8EF4^2F]DPD2++1J3=4WQ5?C$GRGP!O'8I]D08EX0R]Y@EBBY,=N1^SH
M>6-'ST?MZ&=54IYA'DYS2GV.(0)X>Q>];,BNQHFF4/0 XF)HK.R/;=P]H10$
M+E24NF"/@\C@NZ4J]E.]DJ$(0 @((8V$Z62!X3%>[,3H<1J9=4.3K:@NLZ"_
MTG@@5MB*Q]*(- 8AE19,L$!)B_Q%B^3 (X6I6&G<'HGQ[3<.5MT"A5=MPF^A
M5I#!4BG75%]P!.1E51#B)0 -KP![Y$=L31;HEXH4!"$D\;!%#%D"1X#G1(PV
MU?&[-FZ2TVNJ149LZ45C2R]&U7[1E<#;C@3.:(]#9O1WZ#66<[%+\$&TY-[P
M8;L*LHS&1 X'H5/6 "#92:+--$2%7%>3W7 9'/7&),A.H!4NX"'?!]A"USXS
M[)PK/&\I1T=#;($.C^'U2(\+:*Z=$O2M]IL7E+R(#,?C&]@-_8])TA#^Y\(I
MZ7W20#RRDTG',M0MZ)2)G:GXU92HNP"9.4W*_)IJ6$JO(=(19RMC\NADD7R
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M:7K\=D*)[:9$9WC3Q,Y<&X]]'K<U#E:P(0'C&X-/WAOA@&%4%[\ 4$L#!!0
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MNJ $"%P/@.\QY^JQH2>H_C29_@U02P,$%     @ ,HA^5LR,B8F0 @  )P@
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M^=@:6BB#%=Y0^<!V7Z'))]!^*:/"_*)='1NIX'0C)"L:L2(H2%D_\;ZIPY'
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M>$;3#7&]?IJHI8DNTCPRB7LO5]3YQWC#\[/KQKB^XYX!V4=M47^2?F"^)J5
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M;,)ET4!__RB$>OU0=+!ZV=;H'U!+ P04    "  RB'Y6W1QI(;($  # (0
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M WU]R[EZ.BF>R3<O;83_ 5!+ P04    "  RB'Y6_EZKN3D&  #M+P  &0
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M;>PZE@<L8</I+Y*H?.U<."B!%%=4W?#]5VCBF1N^F%-IGVC?V'H.BBNI>-&
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M\[>"<T.+LMX];X4V>_'Z<(\D0VD[F.L[(?13PV[(VR\V\;]02P,$%     @
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M:AK5#*6Y ;9=V**E"SO:X?5S\)CD<7!_V%1;7-7]67[!MYO&S_<..-J1H9I
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M<5K^@>*_WR1)?OA-.<"W)/VZ>]GO_A]02P,$%     @ ,HA^5M9BWB8]!@
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MN[IN<K:#MB84U,.5:#4Y-^1B;!P<[NS@[D+Y@):",?@BPCZIUC2#NC<HM'I
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M5FUOVC 0_BM65DV=M#8OD-!U(5*![N5#MZJLVV>3',1J8F>V ]V_W]D)&5!
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M+G.<[""- I[/A=!KP3CH_BLDOP%02P,$%     @ ,HA^5I/K,\:H!P  &ST
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MJ L;2F@JT))F"T %"$>$>%+5Z%F9?P>!G6ZT_<%)J]/> TPVP.3? B_7R7J
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M*:] >'V<6!7/A;>[UT;&#=1':1%[N(=B\BHLY.V*O&V5?J 931=I':#5\%S
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MN1#>)D/8G@T=7W<M ]NM77<#KW<XLO45<1 <Q*6[<[)-@4_-@5^H1621R>+
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M+76$[D6J^U_."@>O4+#C<B4YS]!&BEU<=(T+RA6+D_R]_O[ID:*+=^_1.S1
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M8K:&;-MR.]&B=IWM06C3)]VP-"<9D#; /%\+DYUN8E_0GXVR/U!+ P04
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M'[&VF>F/(!!F@AY?<ZY>.^:<;3ZKDC]02P,$%     @ ,HA^5@*$.0X^ P
MX0<  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULC95M3]LP$,>_RBF;
M)I *:=-'6!N)4K8A#0G!&"^FO7"3:^/-L3/;:=FWW]E)0S="M3>)G^[OW]W9
MY^E6Z9\F0[3PE MI9D%F;7$>AB;),&?F5!4H:6:E=,XL=?4Z-(5&EGJC7(11
MMSL*<\9E$$_]V*V.IZJT@DN\U6#*/&?Z]QR%VLZ"7K ;N./KS+J!,)X6;(WW
M:!^*6TV]L%%)>8[2<"5!XVH67/3.YQ.WWB_XRG%K]MK@/%DJ]=-UKM-9T'5
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MZ* 3U!4,"KR@ ^^?->%8IG0),B8$2##GW]7RVF)N+U>)%MK1]*J]$&N<D,E
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M-3,N>&ULK5?;<MLV$/T5#)MVI)E4)$#=[$J:B>UDFH=,/;:3/D/D4D1# BH
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MW(RT.E$-F-5&\9V=T59<Z8G/+G,]E(,P!OK]AG/UO#$!FC$__0]02P,$%
M  @ ,HA^5@G,Y2-B!   J!,  !D   !X;"]W;W)K<VAE971S+W-H965T-34N
M>&ULK5AM;]HZ%/XK5NXT;=)H8B>\=8#4@:9-VK2*MKN?W6# :F)GMH'V_OIK
MAS0OQ/&*Q!?(RSG'SW,<G^?8DP,73W)+B +/:<+DU-LJE5W[OHRW),7RBF>$
MZ3=K+E*L]*W8^#(3!*]RIS3Q41 ,_!13YLTF^;-;,9OPG4HH([<"R%V:8O'R
MA23\,/6@]_I@23=;91[XLTF&-^2.J(?L5N@[OXRRHBEADG(&!%E/O1MX/4?(
M..06ORDYR-HU,%0>.7\R-]]74R\PB$A"8F5"8/VW)W.2)":2QO&G".J58QK'
M^O5K]*\Y>4WF$4LRY\F_=*6V4V_D@159XUVBEOSPC12$^B9>S!.9_X)#81MX
M(-Y)Q=/"62-(*3O^X^<B$34'&'4XH,(!O=4A+!S"G.@164YK@16>300_ &&L
M=31SD><F]]9L*#/3>*>$?DNUGYI]9S%/";C'ST2"'KBC&T;7-,9, ?TBXXPP
M)0%?F]00(<@**/P,L)1$/\9L!1**'VE"%=7^'Q9$89K(CSK2P]T"?'CW$;P#
ME('[+=]);2TGOM*@S=!^7 #\<@2(.@ N2'P%0O@)H  AB_O\[>ZPZ>[K5)7Y
M0F6^4!XO[(S72L.UC=0Q2F2/8M;FM<QP3*:>7GR2B#WQ9N__@8/@LXWBA8(U
M"(<EX= 5??:5K(C 23[74F%%@"XA BO*-B#A4H(8"_&BZ\D!"_O\'N/W\_BF
MJNQGX3"8^/LZP[8-'(^#J+1J0(]*Z)$;.A=Z%;.S 1^C#NI@AH,3P&V;$'7
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M%V?NSGJUA(S'7T-I'I3F0VD!E!9":1&*9LJNRXJX+M#-NM"\")3F06D^E!9
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MRE(YYIL+JIA1NP4T/U/*/G2<@Z8&3_\ 4$L#!!0    ( #*(?E86@1T?:@4
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M*RWB(MCT( Z3_-M_+838":## P&L"&#[ ?T# 6X1X.X'# X$](J WGY [T!
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M8]'J6:D,,G5Q/1A%-<:H- ^5QK%H]<Q4YIA:?=[XRSI].](5TJ::P\WB*5F
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M*@@3X; OYL5-H:M@(N="#\)N$PK<[5LV"-O)91@XN9',Z"!\./OX>R[U]8?
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ,HA^5GP(&OW2!   V28   \
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M4$L! A0#%     @ ,HA^5LJT07_M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ,HA^5IE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  RB'Y6O_>\VH8'  #$,   &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ,HA^5K>,.I9$!0  RA8
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M965T-BYX;6Q02P$"% ,4    "  RB'Y6O[ALKT$*  !!&0  &
M    @(%),   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M,HA^5D0%KM.0#0  /B4  !@              ("!P#H  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #*(?E9UA:GB&P,   4*   8
M          " @89(  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  RB'Y6 '[HA!P1   \-@  &0              @('72P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #*(?E:TX/N<QP8  (T1
M   9              " @2I=  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ ,HA^5@RG!A@ "P  0!\  !D              ("!*&0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  RB'Y68+KK
M4X<1  "*.@  &0              @(%?;P  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( #*(?E8=*8 -R H  /$B   9
M  " @1V!  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M,HA^5LPQ4N,7!   BPH  !D              ("!'(P  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  RB'Y6<5,Z[[<%  #=#P  &0
M            @(%JD   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( #*(?E:I9Z_GD@D  /4B   9              " @5B6  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ,HA^5C525.C[!
MY0L  !D              ("!(:   'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  RB'Y67>AG2E0#  !D!P  &0              @(%3
MI0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #*(?E;@
MS&TR1@(  #$%   9              " @=ZH  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ ,HA^5GXN=M*9#@  )BT  !D
M     ("!6ZL  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #*(?E;%+$(\<0(  +8%   9              "
M@1O*  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ,HA^
M5B2SY1$9 P  # D  !D              ("!P\P  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  RB'Y67WL%$K<%  ! &0  &0
M        @($3T   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( #*(?E;,C(F)D (  "<(   9              " @0'6  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ,HA^5I",3;T9 P  C0D
M !D              ("!R-@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  RB'Y6+X,_<.$"  "M"P  &0              @($8W
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #*(?E;-J#(&
MI (  '<'   9              " @3#?  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ ,HA^5BK]@1IN!P  >$L  !D
M ("!"^(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  R
MB'Y6W1QI(;($  # (0  &0              @(&PZ0  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( #*(?E;^7JNY.08  .TO   9
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M970S.2YX;6Q02P$"% ,4    "  RB'Y6QR(-X3 5   W10$ &0
M    @(&%!0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M #*(?E;68MXF/08  )HN   9              " @>P: 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ ,HA^5@P:3[EL!0  63,  !D
M             ("!8"$! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  RB'Y6)RXX+$,$  "O&@  &0              @($#)P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #*(?E8EW-],N (
M #<(   9              " @7TK 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ ,HA^5I/K,\:H!P  &ST  !D              ("!
M;"X! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  RB'Y6
M"'QYB3X#  #-"@  &0              @(%+-@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( #*(?E8^+8_4F0,  (X1   9
M      " @< Y 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ ,HA^5I5*";:<!@  $34  !D              ("!D#T! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  RB'Y6;LAH"ZP"   G"0
M&0              @(%C1 $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( #*(?E9AQHR"BP(  &()   9              " @49' 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ,HA^5@*$.0X^
M P  X0<  !D              ("!"$H! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    "  RB'Y6[>8W9M8$  #T&   &0
M@(%]30$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #*(
M?E9GJG(HZ@,  $ .   9              " @8I2 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ ,HA^5B^B8Y=A P  \@L  !D
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M=#4X+GAM;%!+ 0(4 Q0    ( #*(?E:^X*>P20,  ,H4   -
M  "  0)P 0!X;"]S='EL97,N>&UL4$L! A0#%     @ ,HA^5I>*NQS
M$P(   L              ( !=G,! %]R96QS+RYR96QS4$L! A0#%     @
M,HA^5GP(&OW2!   V28   \              ( !7W0! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( #*(?E83)^RZ[P$  *4B   :              "
M 5YY 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #*(
M?E9B(^<8V $  $@B   3              "  85[ 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !" $( !1(  (Y] 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>196</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Preferred Stock and Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Preferred Stock and Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Balance Sheet Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureBalanceSheetDetail</Role>
      <ShortName>Balance Sheet Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Dong-A ST License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureDongStLicenseAgreement</Role>
      <ShortName>Dong-A ST License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Beijing SL License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreement</Role>
      <ShortName>Beijing SL License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Balance Sheet Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureBalanceSheetDetailTables</Role>
      <ShortName>Balance Sheet Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureBalanceSheetDetail</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Stockholders Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40101 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Balance Sheet Detail - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Detail - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Balance Sheet Detail - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Detail - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Commitments and Contingencies - Operating Leases - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Leases - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Commitments and Contingencies - ANA Merger Milestone Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails</Role>
      <ShortName>Commitments and Contingencies - ANA Merger Milestone Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Commitments and Contingencies - License Agreement with Dong-A ST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails</Role>
      <ShortName>Commitments and Contingencies - License Agreement with Dong-A ST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Dong-A ST License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails</Role>
      <ShortName>Dong-A ST License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureDongStLicenseAgreement</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Beijing SL License Agreement - Beijing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails</Role>
      <ShortName>Beijing SL License Agreement - Beijing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stockholders Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stockholders Equity - Aggregate Consideration Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails</Role>
      <ShortName>Stockholders Equity - Aggregate Consideration Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stockholders Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Stockholders Equity - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails</Role>
      <ShortName>Stockholders Equity - Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Stock-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Stock-Based Compensation - Unvested stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Unvested stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Stock Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Stock-Based Compensation - Evergreen provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails</Role>
      <ShortName>Stock-Based Compensation - Evergreen provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share of Common Stock - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Fair Value Measurements - Recurring basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Recurring basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Income Taxes - Reconciliation of income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Income Taxes - Tax provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Tax provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Income Taxes - Significant components of deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant components of deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Defined Contribution Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails</Role>
      <ShortName>Defined Contribution Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureDefinedContributionPlan</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="nrbo-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyCosts in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. nrbo-20221231x10k.htm 118</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 16 fact(s) appearing in ix:hidden were eligible for transformation: nrbo:ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod, nrbo:ContractTerm, nrbo:CurePeriodForPetitionForBankruptcy, nrbo:DefinedContributionPlanEmployerMatchingContributionVestingPercentage, nrbo:PeriodForFailToCureBreachMayTerminateAgreement, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WarrantsAndRightsOutstandingTerm -  nrbo-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  nrbo-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="nrbo-20221231x10k.htm">nrbo-20221231x10k.htm</File>
    <File>nrbo-20221231.xsd</File>
    <File>nrbo-20221231_cal.xml</File>
    <File>nrbo-20221231_def.xml</File>
    <File>nrbo-20221231_lab.xml</File>
    <File>nrbo-20221231_pre.xml</File>
    <File>nrbo-20221231xex10d42.htm</File>
    <File>nrbo-20221231xex21d1.htm</File>
    <File>nrbo-20221231xex23d1.htm</File>
    <File>nrbo-20221231xex31d1.htm</File>
    <File>nrbo-20221231xex32d1.htm</File>
    <File>nrbo-20221231xex4d12.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nrbo-20221231x10k001.jpg</File>
    <File>nrbo-20221231x10k002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="481">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>81
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nrbo-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 481,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 196,
   "dts": {
    "calculationLink": {
     "local": [
      "nrbo-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nrbo-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nrbo-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nrbo-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrbo-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nrbo-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 554,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 15,
    "http://www.gemphire.com/20221231": 6,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 25
   },
   "keyCustom": 84,
   "keyStandard": 256,
   "memberCustom": 52,
   "memberStandard": 28,
   "nsprefix": "nrbo",
   "nsuri": "http://www.gemphire.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nrbo:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Dong-A ST License Agreement",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.gemphire.com/role/DisclosureDongStLicenseAgreement",
     "shortName": "Dong-A ST License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nrbo:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Beijing SL License Agreement",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreement",
     "shortName": "Beijing SL License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.gemphire.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.gemphire.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.gemphire.com/role/DisclosureNetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.gemphire.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.gemphire.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.gemphire.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Defined Contribution Plan",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.gemphire.com/role/DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.gemphire.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Balance Sheet Detail (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.gemphire.com/role/DisclosureBalanceSheetDetailTables",
     "shortName": "Balance Sheet Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IPbMK5DMBU-arb5dHnRBNg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nrbo:ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IPbMK5DMBU-arb5dHnRBNg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nrbo:ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Stockholders Equity (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.gemphire.com/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.gemphire.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.gemphire.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - The Company and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails",
     "shortName": "The Company and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nrbo:DepositsInExcessOfFederallyInsuredAmounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "nrbo:DepositsInExcessOfFederallyInsuredAmounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Balance Sheet Detail - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails",
     "shortName": "Balance Sheet Detail - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nrbo:AccruedOtherResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Balance Sheet Detail - Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Detail - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nrbo:AccruedOtherResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Commitments and Contingencies - Operating Leases - (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Operating Leases - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_5_31_2019_srt_StatementGeographicalAxis_country_KR_HvV-4l0BaEGxJ9yVDcToOA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nrbo:PercentageOfRoyaltyPayments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Commitments and Contingencies - ANA Merger Milestone Payment (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
     "shortName": "Commitments and Contingencies - ANA Merger Milestone Payment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_AssetAcquisitionAxis_nrbo_AnaTherapeuticsInc.AssetAcquisitionMember_IG_Y6UouBkm4R_t4WrbvGQ",
      "decimals": "INF",
      "lang": null,
      "name": "nrbo:AssetAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "nrbo:PercentageOfRoyaltyPayments",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40404 - Disclosure - Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails",
     "shortName": "Commitments and Contingencies - YourChoice and Pfizer License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_OtherCommitmentsAxis_nrbo_TierOneNetSalesMilestoneMember_SES_rbkbP0eNKOMs2xwA_A",
      "decimals": "-6",
      "lang": null,
      "name": "nrbo:SalesBasedMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nrbo:MilestonesAccrued",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40405 - Disclosure - Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails",
     "shortName": "Commitments and Contingencies - Gemphire Contingent Value Rights Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_3_23_2021_us-gaap_TypeOfArrangementAxis_nrbo_OriginalCvrAgreementMember_GAKGJeHh6UuULfG-TYy7pg",
      "decimals": "2",
      "lang": null,
      "name": "nrbo:PercentageOfProceedsFromGrantSaleOrTransferOfRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "nrbo:RoyaltyPaymentAccrued",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nrbo:RoyaltyPaymentAccrued",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40406 - Disclosure - Commitments and Contingencies - License Agreement with Dong-A ST (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
     "shortName": "Commitments and Contingencies - License Agreement with Dong-A ST (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Dong-A ST License Agreement (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
     "shortName": "Dong-A ST License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "nrbo:LicenseAgreementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_9_14_2022_To_9_14_2022_us-gaap_TypeOfArrangementAxis_nrbo_DongaStCoLtdLicenseAgreementMember_AxEDe7pICUeshbyQlPNHCQ",
      "decimals": null,
      "lang": "en-US",
      "name": "nrbo:CurePeriodForBreachingParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_kBvkGV4jekagMWbtRHE_aA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Beijing SL License Agreement - Beijing (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
     "shortName": "Beijing SL License Agreement - Beijing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_nrbo_LicenseAgreementWithBeijingSLMember_kBvkGV4jekagMWbtRHE_aA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_11_8_2022_To_11_8_2022_b6Tq9XMF9kWXMJVobfHIhw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stockholders Equity (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_11_8_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_4lxqPtFo3ke1REg6Wo35sQ",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_11_8_2022_To_11_8_2022_b6Tq9XMF9kWXMJVobfHIhw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stockholders Equity - Aggregate Consideration Received (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
     "shortName": "Stockholders Equity - Aggregate Consideration Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-5",
      "lang": null,
      "name": "nrbo:StockIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Stockholders Equity - Warrants (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
     "shortName": "Stockholders Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_11_8_2022_To_11_8_2022_b6Tq9XMF9kWXMJVobfHIhw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Stockholders Equity - Warrants - Narrative (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
     "shortName": "Stockholders Equity - Warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_11_1_2022_To_11_30_2022_us-gaap_ClassOfWarrantOrRightAxis_nrbo_November2022SeriesAndSeriesBWarrantsMember_datC9tjJm06_EI8OAxwL1A",
      "decimals": "INF",
      "lang": null,
      "name": "nrbo:ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAEVu6CnL02lDdU-rjBNQQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Stock-Based Compensation - Stock Options (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Stock-Based Compensation - Unvested stock options (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Unvested stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_3mplw-Kj6kacy2bX6Em9wA",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_q22L9nS6dUKuwRCCgKYReg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_ZSDV9J_B40CQQT5KCsfMHg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Stock Based Compensation - Assumptions (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "shortName": "Stock Based Compensation - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_JuCd3M2QzES9t-yyeehmcQ",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - Stock-Based Compensation - Evergreen provision (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
     "shortName": "Stock-Based Compensation - Evergreen provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nrbo_InducementPlanMember_Ry1oAKkWqkWxsb6iJ3oDuw",
      "decimals": null,
      "lang": "en-US",
      "name": "nrbo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_6mbAVgdr_kKuEsMIk2u25w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Net Loss Per Share of Common Stock - Antidilutive Securities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share of Common Stock - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember_6mbAVgdr_kKuEsMIk2u25w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Preferred Stock and Stockholders Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity",
     "shortName": "Consolidated Statements of Preferred Stock and Stockholders Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U5yxczfl5EWJI7rVa4lgUQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Fair Value Measurements - Recurring basis (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Recurring basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_M5ZnQGPjZkWP8Ybr6mWmSw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "nrbo:ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "nrbo:ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_1LLlt47r70ujsy8cWOlgrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Income Taxes - Reconciliation of income tax (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails",
     "shortName": "Income Taxes - Reconciliation of income tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_MqXTz5Zn2EeDdYDJ3QW8Gw",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Income Taxes - Tax provision (Benefit) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails",
     "shortName": "Income Taxes - Tax provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - Income Taxes - Significant components of deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Significant components of deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_oGq3lJW_gkCBDhH0Mz3Ocw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nrbo:MilestonesAccrued",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_6_7_2022_To_6_7_2022_us-gaap_RelatedPartyTransactionAxis_nrbo_ManufacturingAndSupplyAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nrbo_DongStMember_mrVIOz70GUG2r1JVXDTTRw",
      "decimals": null,
      "lang": "en-US",
      "name": "nrbo:PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nrbo:DefinedContributionPlanEmployeeEligibilityAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Defined Contribution Plan (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails",
     "shortName": "Defined Contribution Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nrbo:DefinedContributionPlanEmployeeEligibilityAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_10_1_2021_To_10_1_2021_us-gaap_SubsidiarySaleOfStockAxis_nrbo_RegisteredDirectOfferingMember_WUKKWwhTaUiyjtEcBjnwng",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_nrbo_SeriesWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e0tClQh0z0msDPqPsOTVmg",
      "decimals": "INF",
      "lang": null,
      "name": "nrbo:NumberOfWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_sYATjoN9r0SEhPAbLOYcTA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_R9LMtYiVoEqDKcFCcBXAjA",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - The Company and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation",
     "shortName": "The Company and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Balance Sheet Detail",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.gemphire.com/role/DisclosureBalanceSheetDetail",
     "shortName": "Balance Sheet Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nrbo-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_dLGO-V5LPEmsm4O9iV2AAg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 83,
   "tag": {
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gemphire.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nrbo_AccruedOtherResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "External research and development expenses"
       }
      }
     },
     "localname": "AccruedOtherResearchAndDevelopmentExpenses",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_AnaTherapeuticsInc.AssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to ANA Therapeutics, Inc., merger asset acquisition.",
        "label": "ANA Merger"
       }
      }
     },
     "localname": "AnaTherapeuticsInc.AssetAcquisitionMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_AssetAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the asset acquisition.",
        "label": "Asset Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Ownership acquired"
       }
      }
     },
     "localname": "AssetAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_ClassBUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Class B Units, each Class B Unit consisting of one share of Series B Convertible Preferred Stock, convertible into one share of common stock, one Series A Warrant and one Series B Warrant.",
        "label": "Class B Units [Member]"
       }
      }
     },
     "localname": "ClassBUnitsMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ClassOfWarrantOrRightNumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Number of Warrants Issued",
        "label": "Number of Warrants Issued",
        "terseLabel": "Number of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exchanged for each of securities called by warrants.",
        "label": "Class of Warrant or Right, Securities Called by Each Warrant or Right, Number of Warrants Exchanged",
        "terseLabel": "Number of warrants exchanged"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightSecuritiesCalledByEachWarrantOrRightNumberOfWarrantsExchanged",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_ClassUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Class A Units, each consisting of one share of Class A Common Stock and one Warrant [Member]",
        "label": "Class A Units [Member]"
       }
      }
     },
     "localname": "ClassUnitsMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which the entity will execute the clinical supply from effective date.",
        "label": "Clinical Supply Agreement Execution Period From Effective date",
        "terseLabel": "Clinical supply agreement execution period from effective date"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementExecutionPeriodFromEffectiveDate",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_CommonStockVotingRightsPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the voting rights per share for common stock of the entity.",
        "label": "Common Stock Voting Rights Per Share",
        "terseLabel": "Common stock, vote per share"
       }
      }
     },
     "localname": "CommonStockVotingRightsPerShare",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nrbo_ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The notice period for dismission of bankruptcy and other disputes other wise the agreement gets terminated.",
        "label": "Condition For Termination of Agreement, Either Party Not Dismissed Period",
        "terseLabel": "Period for dismission of allegations."
       }
      }
     },
     "localname": "ConditionForTerminationOfAgreementEitherPartyNotDismissedPeriod",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_ContingentLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a contingent liability to make payments if certain conditions are achieved.",
        "label": "Contingent Liability",
        "terseLabel": "Potential payments upon achievement of certain milestones"
       }
      }
     },
     "localname": "ContingentLiability",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nrbo_ContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for which the entity entered in to the contract.",
        "label": "Contract Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "ContractTerm",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of convertible preferred stock issued during the period.",
        "label": "Convertible Preferred Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares to be issued for upfront payment made to a related party"
       }
      }
     },
     "localname": "ConvertiblePreferredStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_CumulativeDividendsDeclared": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative cash dividends declared.",
        "label": "Cumulative Dividends Declared",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "CumulativeDividendsDeclared",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_CumulativeNetSalesMoreThan500MillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cumulative net sales more than 500 million.",
        "label": "500 million"
       }
      }
     },
     "localname": "CumulativeNetSalesMoreThan500MillionMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_CumulativeNetSalesMoreThanFiveBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cumulative net sales more than five billion.",
        "label": "5 billion"
       }
      }
     },
     "localname": "CumulativeNetSalesMoreThanFiveBillionMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_CumulativeNetSalesMoreThanOneBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cumulative net sales more than one billion.",
        "label": "1 billion"
       }
      }
     },
     "localname": "CumulativeNetSalesMoreThanOneBillionMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_CumulativeNetSalesMoreThanThreeBillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cumulative net sales more than three billion.",
        "label": "3 billion"
       }
      }
     },
     "localname": "CumulativeNetSalesMoreThanThreeBillionMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_CurePeriodForBreachingParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cure period for beaching party if cannot be cured within the 60-day period.",
        "label": "Cure Period for Breaching Party",
        "terseLabel": "Cure period for beaching party if cannot be cured within the 60-day period"
       }
      }
     },
     "localname": "CurePeriodForBreachingParty",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_CurePeriodForPetitionForBankruptcy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cure period for petition for bankruptcy.",
        "label": "Cure Period for Petition for Bankruptcy",
        "terseLabel": "Cure period for petition for bankruptcy"
       }
      }
     },
     "localname": "CurePeriodForPetitionForBankruptcy",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_Da1241Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The License Agreement covers the rights to DA-1241 for treatment of NASH .",
        "label": "DA-1241 [Member]",
        "terseLabel": "DA-1241"
       }
      }
     },
     "localname": "Da1241Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_Da1726Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The License Agreement covers the rights to DA-1726 for treatment of obesity and NASH.",
        "label": "DA-1726 [Member]",
        "terseLabel": "DA-1726"
       }
      }
     },
     "localname": "Da1726Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_DeferredIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for deferred issuance costs that have occurred.",
        "label": "Deferred Issuance Costs Incurred but Not yet Paid",
        "terseLabel": "Unpaid issuance costs"
       }
      }
     },
     "localname": "DeferredIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DeferredTaxAssetsAcquiredIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from acquired intangible assets.",
        "label": "Deferred Tax Assets Acquired Intangibles",
        "verboseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsAcquiredIntangibles",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs",
        "terseLabel": "Capitalized R&amp;D Costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as Lease Liability.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease Liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DeferredTaxAssetsTaxCreditCarryforwardsState": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards State",
        "terseLabel": "State research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsState",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DeferredTaxLiabilitiesLeaseLiabilitiesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from lease liabilities and other.",
        "label": "Deferred Tax Liabilities Lease Liabilities and Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeaseLiabilitiesAndOther",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DeferredTaxLiabilitiesRouAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as ROU Assets",
        "label": "Deferred Tax Liabilities, ROU Asset",
        "negatedLabel": "ROU Asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRouAsset",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DefinedContributionPlanEmployeeContributionDeferredPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employee contributions may be deferred to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employee Contribution Deferred, Percentage",
        "terseLabel": "Employee compensation deferred percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeContributionDeferredPercentage",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_DefinedContributionPlanEmployeeEligibilityAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee eligibility age criteria under defined contribution plan.",
        "label": "Defined Contribution Plan, Employee Eligibility Age",
        "terseLabel": "Minimum age of employee to cover under the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeEligibilityAge",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_DefinedContributionPlanEmployerMatchingContributionVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which the employer contribution will be vested under defined contribution plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Vesting Percentage",
        "terseLabel": "Employer matches vesting period"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionVestingPercentage",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_DepositsInExcessOfFederallyInsuredAmounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to deposits in excess of federally insured amounts.",
        "label": "Deposits In Excess Of Federally Insured Amounts",
        "terseLabel": "Deposits in excess of federally insured amounts"
       }
      }
     },
     "localname": "DepositsInExcessOfFederallyInsuredAmounts",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_DongStMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Dong-A.",
        "label": "Dong-A [Member]",
        "terseLabel": "Dong-A"
       }
      }
     },
     "localname": "DongStMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_DongaStCoLtdLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Dong-A ST Co., LTD  license agreement.",
        "label": "DongA ST Co LTD License Agreement [Member]",
        "terseLabel": "DongA ST Co LTD License agreement"
       }
      }
     },
     "localname": "DongaStCoLtdLicenseAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to change in fair value of warrants.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Fair Value of Warrants",
        "terseLabel": "Change in fair value of warrant liability (as percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrants",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to Section 382 limitation adjustment.",
        "label": "Effective Income Tax Rate Reconciliation, Section 382 limitation Adjustments, Percent",
        "terseLabel": "Section 382 limitation adjustment attributes (as percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSection382LimitationAdjustmentsPercent",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_EffectiveIncomeTaxRateReconciliationTransactionCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to transaction cost.",
        "label": "Effective Income Tax Rate Reconciliation, Transaction Cost",
        "verboseLabel": "Transaction costs (as percentage)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionCost",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_EmployeeCompensationVestingPercentageOnContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employee contribution vested on contribution made by employee.",
        "label": "Employee Compensation Vesting Percentage on Contribution",
        "terseLabel": "Percentage of employee contribution vested on their contribution"
       }
      }
     },
     "localname": "EmployeeCompensationVestingPercentageOnContribution",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_EmployeeConsultantsAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Stock options."
       }
      }
     },
     "localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of extinguishment of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Extinguishment",
        "negatedLabel": "Warrant liability extinguishment on exercise of warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExtinguishment",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_FirstAmendmentToOriginalCvrAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the First Amendment to the Original CVR Agreement.",
        "label": "First Amendment to Original CVR Agreement"
       }
      }
     },
     "localname": "FirstAmendmentToOriginalCvrAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_HeadquartersInBostonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to new Boston lease agreement for head quarters.",
        "label": "Head Quarters in Boston Lease"
       }
      }
     },
     "localname": "HeadquartersInBostonLeaseMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_IncreaseDecreaseInNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to increase or decrease in non cash lease expenses.",
        "label": "Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInNonCashLeaseExpense",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_IncreaseDecreaseInPrepaidExpensesAndDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance that provide economic benefits in future periods and deposits",
        "label": "Increase Decrease In Prepaid Expenses And Deposits",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndDeposits",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_InducementPlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2021 Inducement Plan..",
        "label": "Inducement Plan 2021 [Member]",
        "terseLabel": "2021 Inducement Plan"
       }
      }
     },
     "localname": "InducementPlan2021Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the Inducement Plan, an equity incentive plan used by the reporting entity targeted at individuals not previously employees or directors as an inducement into employment with the Company.",
        "label": "Inducement Plan",
        "verboseLabel": "2022 Plan"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_InitialMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of initial milestone payment to be made.",
        "label": "Initial Milestone Payment",
        "terseLabel": "Milestone Payment"
       }
      }
     },
     "localname": "InitialMilestonePayment",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_LesseeMonthlyOperatingLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of monthly operating lease cost.",
        "label": "Lessee Monthly Operating Lease Cost",
        "terseLabel": "Monthly rental cost"
       }
      }
     },
     "localname": "LesseeMonthlyOperatingLeaseCost",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_LesseeOperatingLeaseIncentiveFromLessor": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the operating lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.",
        "label": "Lessee Operating Lease Incentive From Lessor",
        "terseLabel": "Rent concessions granted by the landlord"
       }
      }
     },
     "localname": "LesseeOperatingLeaseIncentiveFromLessor",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Dong-A ST License Agreement."
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.gemphire.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nrbo_LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of developmental and regulatory milestone payments eligible to be received under the license agreement.",
        "label": "License Agreement, Developmental And Regulatory Milestone To Be Received",
        "terseLabel": "Developmental and regulatory milestone payment eligible to be received"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentalAndRegulatoryMilestoneToBeReceived",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_LicenseAgreementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureAbstract",
     "nsuri": "http://www.gemphire.com/20221231",
     "xbrltype": "stringItemType"
    },
    "nrbo_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for license agreement.",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "Dong-A ST License Agreement."
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nrbo_LicenseAgreementEarlyTerminationFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of early termination fee payable on termination of license agreement.",
        "label": "License Agreement, Early Termination Fee",
        "terseLabel": "Termination fee"
       }
      }
     },
     "localname": "LicenseAgreementEarlyTerminationFee",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive worldwide license to certain patent rights to make, use, sell, offer for sale and import product.",
        "label": "License Agreements",
        "terseLabel": "Dong A ST License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of threshold global net sales milestone payments eligible to be received under the license agreement.",
        "label": "License Agreement, Threshold Global Net Sales Milestone Payment To Be Received",
        "terseLabel": "Global net sales milestone payment to be received"
       }
      }
     },
     "localname": "LicenseAgreementThresholdGlobalNetSalesMilestonePaymentToBeReceived",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_LicenseAgreementUpfrontPaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment to be received under the license agreement.",
        "label": "License Agreement, Upfront Payment To Be Received",
        "terseLabel": "Upfront payment to be received"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentToBeReceived",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_LicenseAgreementWithBeijingSLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to merger agreement with Beijing SL.",
        "label": "License Agreement with Beijing SL"
       }
      }
     },
     "localname": "LicenseAgreementWithBeijingSLMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_LicenseTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for which the entity inform for the termination of license agreement.",
        "label": "License Termination, Notice Period",
        "terseLabel": "Notice period"
       }
      }
     },
     "localname": "LicenseTerminationNoticePeriod",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_ManufacturingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Manufacturing Agreement.",
        "label": "Manufacturing Agreement"
       }
      }
     },
     "localname": "ManufacturingAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ManufacturingAndSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to Manufacturing and Supply Agreement.",
        "label": "Manufacturing and Supply Agreement"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_MeasurementInputProbabilityFactorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using probability factor.",
        "label": "Measurement Input, Probability Factor [Member]",
        "terseLabel": "Probability factor"
       }
      }
     },
     "localname": "MeasurementInputProbabilityFactorMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_MilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment to make milestone payments contingent upon achieving specified goals.",
        "label": "Milestone Payments"
       }
      }
     },
     "localname": "MilestonePaymentsMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_MilestonesAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to milestones accrued.",
        "label": "Milestones Accrued",
        "terseLabel": "Amount of milestones accrued"
       }
      }
     },
     "localname": "MilestonesAccrued",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_MilestonesOrRoyaltyPaymentsTriggered": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to milestone or royalty payments triggered.",
        "label": "Milestones Or Royalty Payments Triggered",
        "terseLabel": "Milestones or royalty payments triggered"
       }
      }
     },
     "localname": "MilestonesOrRoyaltyPaymentsTriggered",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_MinimumExpectedPeriodToBeginFutureInstallmentPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected period to begin future milestone payments as decided in the terms of agreement.",
        "label": "Minimum Expected Period To Begin Future Installment Payment",
        "terseLabel": "Minimum expected period to begin future installment payment"
       }
      }
     },
     "localname": "MinimumExpectedPeriodToBeginFutureInstallmentPayment",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_ModificationOfRightOfUseAssetAndAssociatedLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of modification of right-of-use asset and associated lease liability.",
        "label": "Modification of Right-of-use Asset and Associated Lease Liability",
        "terseLabel": "Modification of right-of-use asset and associated lease liability"
       }
      }
     },
     "localname": "ModificationOfRightOfUseAssetAndAssociatedLeaseLiability",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_NetOperatingLossCarryforwardsWrittenOff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss carryforward written off.",
        "label": "Net Operating Loss Carryforwards, Written Off",
        "terseLabel": "Net operating loss carryforwards written off"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardsWrittenOff",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_November2022SeriesAndSeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series A and series B warrants issued in November 2022.",
        "label": "November 2022 Series A and B"
       }
      }
     },
     "localname": "November2022SeriesAndSeriesBWarrantsMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_November2022SeriesBWarrantExercisePrice3.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to November 2022 Series B warrants with exercise price of $ 3.00.",
        "label": "November 2022 Series B Warrant Exercise Price 3.00 [Member]",
        "verboseLabel": "$3.00"
       }
      }
     },
     "localname": "November2022SeriesBWarrantExercisePrice3.00Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_November2022SeriesWarrantExercisePrice3.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to November 2022 Series A warrants with exercise price of $ 3.00.",
        "label": "November 2022 Series A Warrant Exercise Price 3.00 [Member]",
        "terseLabel": "$3.00"
       }
      }
     },
     "localname": "November2022SeriesWarrantExercisePrice3.00Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_NumberOfCommonStockIssuedPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common stock per units issued under the arrangement.",
        "label": "Number Of Common Stock Issued Per Unit",
        "terseLabel": "Number of common stock per Unit"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedPerUnit",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of Proprietary compounds to be received by the company in a license agreement.",
        "label": "Number of Proprietary Compounds to Be Received Through License Agreement",
        "terseLabel": "Number of proprietary compounds in a license"
       }
      }
     },
     "localname": "NumberOfProprietaryCompoundsToBeReceivedThroughLicenseAgreement",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nrbo_NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of Series B Convertible Preferred Stock per units issued under the arrangement.",
        "label": "Number Of Series B Convertible Preferred Stock Issued Per Unit",
        "terseLabel": "Number of Series B Convertible Preferred Stock per Unit"
       }
      }
     },
     "localname": "NumberOfSeriesBConvertiblePreferredStockIssuedPerUnit",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the period.",
        "label": "Number of Warrants Exercised",
        "terseLabel": "Number of warrants exchanged for common stock"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_NumberOfYearsAfterFirstSaleOccurs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to number of years after the first sale occurs.",
        "label": "Number Of Years After The First Sale Occurs",
        "terseLabel": "Number of years after the first commercial sale"
       }
      }
     },
     "localname": "NumberOfYearsAfterFirstSaleOccurs",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nrbo_OperatingLossCarryForwardResearchCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss carry forward relating to research activity.",
        "label": "Operating Loss Carry Forward Research Credit",
        "terseLabel": "Federal research credit carry forward"
       }
      }
     },
     "localname": "OperatingLossCarryForwardResearchCredit",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_OriginalCvrAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the Original CVR Agreement",
        "label": "Original CVR Agreement"
       }
      }
     },
     "localname": "OriginalCvrAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_PatentCostPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Cost Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostPolicyPolicyTextBlock",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nrbo_PaymentsForSpecifiedGlobalNetSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to payments for specified global net sales milestones.",
        "label": "Payments For Specified Global Net Sales Milestones",
        "terseLabel": "Payments for specified global net sales milestones"
       }
      }
     },
     "localname": "PaymentsForSpecifiedGlobalNetSalesMilestones",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_PaymentsForTransactionCostsInConnectionWithMerger": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow related to transaction cost in connection with the merger.",
        "label": "Payments For Transaction Costs In Connection With Merger",
        "negatedLabel": "Transaction costs in connection with asset acquisitions"
       }
      }
     },
     "localname": "PaymentsForTransactionCostsInConnectionWithMerger",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_PercentageOfProceedsFromGrantSaleOrTransferOfRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to percentage of proceeds from grant sale or transfer of rights.",
        "label": "Percentage Of Proceeds From Grant Sale Or Transfer Of Rights",
        "terseLabel": "Percentage of proceeds from the grant, sale, or transfer of rights"
       }
      }
     },
     "localname": "PercentageOfProceedsFromGrantSaleOrTransferOfRights",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_PercentageOfRoyaltyOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty to be paid on net sales.",
        "label": "Percentage of Royalty on Net Sales",
        "terseLabel": "Percentage of royalty on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnNetSales",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_PercentageOfRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percent of annual worldwide income.",
        "label": "Percentage of Royalty Payments",
        "terseLabel": "Percentage of royalty payments"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPayments",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_PercentageOfSharesHeldByRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of shares held by related party.",
        "label": "Percentage of Shares Held by Related Party",
        "terseLabel": "Percentage of shares held"
       }
      }
     },
     "localname": "PercentageOfSharesHeldByRelatedParty",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nrbo_PeriodForFailToCureBreachMayTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for failing to cure the beach, the agreement may get terminated.",
        "label": "Period for Fail to Cure the Breach, May Terminate Agreement",
        "terseLabel": "Period for failing to cure the beach, the agreement may get terminated"
       }
      }
     },
     "localname": "PeriodForFailToCureBreachMayTerminateAgreement",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The notice period for purchase order prior to the requested delivery date.",
        "label": "Period for Receipts of Purchase Order Prior to Requested Delivery Date",
        "terseLabel": "Notice period for purchase order prior to requested delivery date"
       }
      }
     },
     "localname": "PeriodForReceiptsOfPurchaseOrderPriorToRequestedDeliveryDate",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_PeriodForTerminationNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for petition for termination notice for the other party's material breach that is not cured.",
        "label": "Period for Termination Notice",
        "terseLabel": "Period for termination notice when material breach not cured"
       }
      }
     },
     "localname": "PeriodForTerminationNotice",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from effective date within which upfront gross payment to be paid under the license agreement.",
        "label": "Period From Effective Date Within Which Upfront Gross Payment To Be Paid",
        "terseLabel": "Period from effective date within which upfront gross payment to be paid"
       }
      }
     },
     "localname": "PeriodFromEffectiveDateWithinWhichUpfrontGrossPaymentToBePaid",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_PeriodFromIssuanceDateWarrantsBecomeExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period from issuance date from which the warrants become exercisable.",
        "label": "Period From Issuance Date The Warrants Become Exercisable",
        "terseLabel": "Period from issuance date the warrants become exercisable"
       }
      }
     },
     "localname": "PeriodFromIssuanceDateWarrantsBecomeExercisable",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_PfizerInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Pfizer Inc.",
        "label": "Pfizer, Inc."
       }
      }
     },
     "localname": "PfizerInc.Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_PreferredStockFairValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value per share of preferred stock.",
        "label": "Preferred Stock, Fair Value per Share",
        "terseLabel": "Fair value per share of preferred stock"
       }
      }
     },
     "localname": "PreferredStockFairValuePerShare",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nrbo_PreferredStockMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding preferred stock.",
        "label": "Preferred Stock, Measurement Input"
       }
      }
     },
     "localname": "PreferredStockMeasurementInput",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "nrbo_PreferredStockStatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Stated Value Per Share",
        "terseLabel": "Stated value per share",
        "verboseLabel": "Preferred stock, stated value (in dollar per share)"
       }
      }
     },
     "localname": "PreferredStockStatedValuePerShare",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "nrbo_PrivateInvestmentInPublicEquityAndLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to private investment in public equity and license.",
        "label": "Private Investment in Public Equity and License [Member]",
        "terseLabel": "PIPE and license"
       }
      }
     },
     "localname": "PrivateInvestmentInPublicEquityAndLicenseMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The underwritten public offering.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering",
        "verboseLabel": "2022 Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to registered direct offering.",
        "label": "October 2021 Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ResearchCreditCarryforwardsWrittenOff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net operating loss carryforward relating to research credit written off.",
        "label": "Research Credit Carryforwards, Written Off",
        "terseLabel": "Research credit carryforwards written off"
       }
      }
     },
     "localname": "ResearchCreditCarryforwardsWrittenOff",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_RoyaltyAndMilestonePaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of royalty and milestone payment due under the agreement.",
        "label": "Royalty and Milestone Payments Due",
        "terseLabel": "Royalty and milestone payment due"
       }
      }
     },
     "localname": "RoyaltyAndMilestonePaymentsDue",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_RoyaltyPaymentAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to royalty payments accrued.",
        "label": "Royalty Payment Accrued",
        "terseLabel": "Amount of royalty payments accrued"
       }
      }
     },
     "localname": "RoyaltyPaymentAccrued",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_SalesBasedMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of mile stone payments to be made based on sales",
        "label": "Sales Based Milestone Payment",
        "terseLabel": "Sales based milestone payment"
       }
      }
     },
     "localname": "SalesBasedMilestonePayment",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_ScenarioStockholderApprovalToConvertCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to scenario of stockholder approving conversion to common stock.",
        "label": "Scenario, Stockholder Approval to Convert Common Stock"
       }
      }
     },
     "localname": "ScenarioStockholderApprovalToConvertCommonStockMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ScenarioStockholderNonApprovalToConvertCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to scenario of stockholder not approving conversion to common stock.",
        "label": "Scenario, Stockholder Non Approval to Convert Common Stock [Member]",
        "terseLabel": "Scenario, Stockholder Non Approval to Convert Common Stock"
       }
      }
     },
     "localname": "ScenarioStockholderNonApprovalToConvertCommonStockMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of consideration received for issue of equity.",
        "label": "Schedule of Consideration Received for Issuance of Equity [Table Text Block]",
        "terseLabel": "Schedule of consideration Received for issuance of equity"
       }
      }
     },
     "localname": "ScheduleOfConsiderationReceivedForIssuanceOfEquityTableTextBlock",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nrbo_ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future milestone payments to be paid up on achieving of milestone events.",
        "label": "Schedule of Future Milestone Payment Up On Achievement of Milestone Events [Table Text Block]",
        "terseLabel": "Schedule of milestone events"
       }
      }
     },
     "localname": "ScheduleOfFutureMilestonePaymentUpOnAchievementOfMilestoneEventsTableTextBlock",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nrbo_ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a roll-forward of the warrant liability.",
        "label": "Schedule Of Roll-forward of Warrant Liability [Table Text Block]",
        "terseLabel": "Schedule of a roll-forward of the warrant liabilities measured at fair value"
       }
      }
     },
     "localname": "ScheduleOfRollForwardOfWarrantLiabilityTableTextBlock",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nrbo_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Securities Purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities purchase agreement",
        "verboseLabel": "Dong-A Financing"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_SeriesBWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series B Warrant.",
        "label": "Series B Warrant [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_SeriesWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Series A Warrant.",
        "label": "Series A Warrant [Member]"
       }
      }
     },
     "localname": "SeriesWarrantMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to series A and series B redeemable convertible preferred stock.",
        "label": "Series A and Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesaAndSeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_SeriesaRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesaRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period over which the shares reserved for further issuance under share based compensation will increase annually.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Period Number of shares reserved for further issuance Increase Annually",
        "terseLabel": "Period of automatic increase in shares reserved"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPeriodNumberOfSharesReservedForFurtherIssuanceIncreaseAnnually",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nrbo_SharedServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Shared Services Agreement.",
        "label": "Shared Services Agreement [Member]",
        "terseLabel": "Shared Services Agreement"
       }
      }
     },
     "localname": "SharedServicesAgreementMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_StockAndWarrantsIssuedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock and warrants issued during the period.",
        "label": "Stock and Warrants Issued During Period, Shares",
        "terseLabel": "Issuance of common stock and warrants in connection with public offering (in shares)"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodShares",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_StockAndWarrantsIssuedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock and warrants issued during the period.",
        "label": "Stock and Warrants Issued During Period, Value",
        "terseLabel": "Issuance of common stock and warrants in connection with public offering"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValue",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_StockAndWarrantsIssuedDuringPeriodValueStocksIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued along with warrants.",
        "label": "Stock and Warrants Issued During Period, Value, Stocks Issued",
        "terseLabel": "Relative fair value attributable to the stock"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValueStocksIssued",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_StockConvertedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted into common stock during the period.",
        "label": "Stock Converted During Period, Shares",
        "negatedLabel": "Conversion of preferred stock to common stock (in shares)",
        "terseLabel": "Shares converted into common stock"
       }
      }
     },
     "localname": "StockConvertedDuringPeriodShares",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "nrbo_StockConvertedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares converted into common stock during the period.",
        "label": "Stock Converted During Period, Value",
        "negatedLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockConvertedDuringPeriodValue",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_StockIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock issuance cost.",
        "label": "Stock Issuance Cost"
       }
      }
     },
     "localname": "StockIssuanceCost",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_StockPlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2018 stock plan.",
        "label": "2018 Plan"
       }
      }
     },
     "localname": "StockPlan2018Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_StockPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2019 stock plan.",
        "label": "2019 Plan"
       }
      }
     },
     "localname": "StockPlan2019Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_StockPlan2022201And2019PlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2022,201 And 2019 plans..",
        "label": "Stock Plan 2022,201 And 2019 Plans"
       }
      }
     },
     "localname": "StockPlan2022201And2019PlansMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_StockPlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2022 plan.",
        "label": "Stock Plan 2022 [Member]",
        "terseLabel": "2022 Plan"
       }
      }
     },
     "localname": "StockPlan2022Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_TierFourNetSalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Tier Four Net Sales Milestone [Member]"
       }
      }
     },
     "localname": "TierFourNetSalesMilestoneMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_TierOneNetSalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Tier One Net Sales Milestone [Member]"
       }
      }
     },
     "localname": "TierOneNetSalesMilestoneMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_TierThreeNetSalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Tier Three Net Sales Milestone [Member]"
       }
      }
     },
     "localname": "TierThreeNetSalesMilestoneMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_TierTwoNetSalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Tier Two Net Sales Milestone [Member]"
       }
      }
     },
     "localname": "TierTwoNetSalesMilestoneMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_UndesignatedPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to undesignated preferred stock.",
        "label": "Undesignated Preferred Stock [Member]",
        "terseLabel": "Undesignated Preferred stock"
       }
      }
     },
     "localname": "UndesignatedPreferredStockMember",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of valuation allowance of domestic income tax expense (benefit).",
        "label": "Valuation Allowance of Domestic Income Tax Expense Benefit",
        "negatedLabel": "Change in valuation allowance - Domestic"
       }
      }
     },
     "localname": "ValuationAllowanceOfDomesticIncomeTaxExpenseBenefit",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_ValuationAllowanceOfForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of valuation allowance of foreign income tax expense (benefit).",
        "label": "Valuation Allowance of Foreign Income Tax Expense Benefit",
        "negatedLabel": "Change in valuation allowance - Foreign"
       }
      }
     },
     "localname": "ValuationAllowanceOfForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_WarrantLiabilitiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the warrant liabilities.",
        "label": "Warrant Liabilities, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilitiesPolicyPolicyTextBlock",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nrbo_WarrantLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Warrant Liability [Roll Forward]"
       }
      }
     },
     "localname": "WarrantLiabilityRollForward",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nrbo_WarrantsExercisePrice112.50Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price of $112.50",
        "label": "Warrants Exercise Price 112.50 [Member]",
        "terseLabel": "$112.50"
       }
      }
     },
     "localname": "WarrantsExercisePrice112.50Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_WarrantsExercisePrice180.90Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price of $180.90",
        "label": "Warrants Exercise Price 180.90 [Member]",
        "terseLabel": "$180.90"
       }
      }
     },
     "localname": "WarrantsExercisePrice180.90Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_WarrantsExercisePrice375.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price of $375.00",
        "label": "Warrants Exercise Price 375.00 [Member]",
        "terseLabel": "$375.00"
       }
      }
     },
     "localname": "WarrantsExercisePrice375.00Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_WarrantsExercisePrice5602.50Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price $5,602.50.",
        "label": "Warrants Exercise Price 5,602.50 [Member]",
        "terseLabel": "$5,602.50"
       }
      }
     },
     "localname": "WarrantsExercisePrice5602.50Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_WarrantsExercisePrice7800.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants with exercise price $260.00.",
        "label": "Warrants Exercise Price 7,800.00 [Member]",
        "terseLabel": "$7800.00"
       }
      }
     },
     "localname": "WarrantsExercisePrice7800.00Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nrbo_WarrantsIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrants issuance cost.",
        "label": "Warrants Issuance Cost"
       }
      }
     },
     "localname": "WarrantsIssuanceCost",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nrbo_YourchoiceTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to YourChoice Therapeutics, Inc.",
        "label": "YourChoice"
       }
      }
     },
     "localname": "YourchoiceTherapeuticsInc.Member",
     "nsuri": "http://www.gemphire.com/20221231",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r234",
      "r241",
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r276",
      "r431",
      "r453",
      "r473",
      "r474",
      "r487",
      "r493",
      "r501",
      "r539",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r276",
      "r431",
      "r453",
      "r473",
      "r474",
      "r487",
      "r493",
      "r501",
      "r539",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r198",
      "r432",
      "r488",
      "r499",
      "r534",
      "r535",
      "r541",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r198",
      "r432",
      "r488",
      "r499",
      "r534",
      "r535",
      "r541",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r258",
      "r276",
      "r308",
      "r309",
      "r310",
      "r407",
      "r431",
      "r453",
      "r473",
      "r474",
      "r487",
      "r493",
      "r501",
      "r533",
      "r539",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r258",
      "r276",
      "r308",
      "r309",
      "r310",
      "r407",
      "r431",
      "r453",
      "r473",
      "r474",
      "r487",
      "r493",
      "r501",
      "r533",
      "r539",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r234",
      "r241",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r163",
      "r277",
      "r512",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r199",
      "r200",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r489",
      "r500",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r199",
      "r200",
      "r460",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r489",
      "r500",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r163",
      "r277",
      "r512",
      "r513",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Balance Sheet Detail"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r498"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r122"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r127",
      "r449",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r16",
      "r19",
      "r86",
      "r391",
      "r454",
      "r455",
      "r516",
      "r517",
      "r518",
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r498"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r523",
      "r524",
      "r525",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r71",
      "r72",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r56",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "verboseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Potential common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Mergers"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesAnaMergerMilestonePaymentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r101",
      "r108",
      "r123",
      "r144",
      "r186",
      "r194",
      "r196",
      "r203",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r354",
      "r356",
      "r372",
      "r498",
      "r537",
      "r538",
      "r585"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r118",
      "r129",
      "r144",
      "r203",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r354",
      "r356",
      "r372",
      "r498",
      "r537",
      "r538",
      "r585"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r38",
      "r120",
      "r476"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "netLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r32",
      "r38",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash at end of period",
        "periodStartLabel": "Cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r32",
      "r97"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental non-cash investing and financing transactions:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r144",
      "r166",
      "r167",
      "r169",
      "r171",
      "r178",
      "r179",
      "r203",
      "r223",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233",
      "r238",
      "r239",
      "r243",
      "r247",
      "r254",
      "r372",
      "r475",
      "r511",
      "r519",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise Price",
        "verboseLabel": "Warrants exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of warrants per unit"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrants to purchase shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "verboseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "verboseLabel": "License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r103",
      "r112"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r51",
      "r217",
      "r218",
      "r461",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stocks, Including Additional Paid in Capital, Net of Discount [Abstract]",
        "terseLabel": "Voting Rights"
       }
      }
     },
     "localname": "CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r523",
      "r524",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollar per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r498"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value per share, 100,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 25,436,019 and 888,693 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "verboseLabel": "Significant components of deferred tax assets and liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "verboseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r20",
      "r132",
      "r134",
      "r139",
      "r445",
      "r450"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r107",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risks, Types, No Concentration Percentage [Abstract]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRisksTypesNoConcentrationPercentageAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from the agreement"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r521",
      "r572"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r36",
      "r82",
      "r336",
      "r342",
      "r343",
      "r521"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r80",
      "r571"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Federal and state operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]",
        "verboseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r80",
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "verboseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r80",
      "r571"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Foreign operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r80",
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "verboseLabel": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r80",
      "r571"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r79",
      "r80",
      "r571"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r80",
      "r571"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Amount of discretionary matching contributions on employee deferrals"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r36",
      "r47"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r282",
      "r313",
      "r314",
      "r316",
      "r321",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Common Stock [Abstract]",
        "terseLabel": "Dividends Rights"
       }
      }
     },
     "localname": "DividendsCommonStockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r140",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r164",
      "r166",
      "r169",
      "r170",
      "r171",
      "r175",
      "r361",
      "r362",
      "r446",
      "r451",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "verboseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average shares of common stock outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r140",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r166",
      "r169",
      "r170",
      "r171",
      "r175",
      "r361",
      "r362",
      "r446",
      "r451",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Net foreign exchange difference"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation of income tax:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r146",
      "r326",
      "r345"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax (benefit) provision at federal statutory rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Valuation allowance (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r345",
      "r569"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Provision to tax return (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income tax, net of federal benefit (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research credits (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Payroll related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized share-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]",
        "terseLabel": "Unrecognized share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation - Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r56",
      "r116",
      "r136",
      "r137",
      "r138",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r177",
      "r204",
      "r256",
      "r317",
      "r318",
      "r319",
      "r338",
      "r339",
      "r360",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r391",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r36",
      "r52"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r363",
      "r364",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r235",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r364",
      "r404",
      "r405",
      "r406",
      "r485",
      "r486",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r363",
      "r364",
      "r366",
      "r367",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r235",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r364",
      "r406",
      "r485",
      "r486",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value of financial instruments measured on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Issuance of 2022 warrants"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r235",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r404",
      "r405",
      "r406",
      "r485",
      "r486",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r201",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r237",
      "r252",
      "r358",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r484",
      "r529",
      "r530",
      "r531",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "verboseLabel": "Total liabilities at Fair Value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingInterestExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents interest incurred for borrowed money which was used to produce goods or render services.",
        "label": "Financing Interest Expense",
        "negatedLabel": "Financing expense",
        "verboseLabel": "Transaction costs allocated to issuance of warrants"
       }
      }
     },
     "localname": "FinancingInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossRealized": {
     "auth_ref": [
      "r580",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Realized",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossRealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on sale of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Lease liability extinguishment gain",
        "terseLabel": "Gain or loss of extinguished unamortized right-of-use asset and lease liabilities"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r145",
      "r344"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r21",
      "r100",
      "r104",
      "r114",
      "r186",
      "r193",
      "r195",
      "r197",
      "r447",
      "r483"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r145",
      "r344"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Loss before Income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r146",
      "r327",
      "r330",
      "r335",
      "r340",
      "r346",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r161",
      "r162",
      "r185",
      "r325",
      "r341",
      "r347",
      "r452"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "netLabel": "Provision for income taxes",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Total tax provision (benefit)",
        "verboseLabel": "Provision (benefit) for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Income Taxes",
        "verboseLabel": "Tax Provision (Benefit):"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTaxProvisionBenefitDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r323",
      "r324",
      "r330",
      "r331",
      "r334",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]",
        "verboseLabel": "Income tax:"
       }
      }
     },
     "localname": "IncomeTaxUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expenses"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Option to renew"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "verboseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r144",
      "r203",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r355",
      "r356",
      "r357",
      "r372",
      "r482",
      "r537",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r102",
      "r110",
      "r498",
      "r520",
      "r532",
      "r579"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r119",
      "r144",
      "r203",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r355",
      "r356",
      "r357",
      "r372",
      "r498",
      "r537",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.",
        "label": "Measurement Input, Discount for Lack of Marketability [Member]",
        "terseLabel": "Discount for a lack of marketability"
       }
      }
     },
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected Term",
        "terseLabel": "Remaining term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Price Volatility",
        "terseLabel": "Volatility rate"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk Free Interest Rate",
        "terseLabel": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r141"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net cash provided by (used in) investing activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r32",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r37",
      "r105",
      "r113",
      "r117",
      "r130",
      "r133",
      "r138",
      "r144",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r168",
      "r186",
      "r193",
      "r195",
      "r197",
      "r203",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r362",
      "r372",
      "r483",
      "r537"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r186",
      "r193",
      "r195",
      "r197",
      "r483"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r582"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "netLabel": "Lease liability, short-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r385",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating lease cash payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets and other"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r131",
      "r134"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "netLabel": "Other comprehensive loss, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedTerseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Expenses",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Detail"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Cash commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Legal and other fees"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r258",
      "r259",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r278",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollar per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r498"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of December 31, 2022 and December 31, 2021; no shares issued or outstanding as of December 31, 2022 and December 31, 2021."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r128",
      "r213",
      "r214",
      "r477"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of common shares, preferred shares and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Consideration received"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r70"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r48",
      "r121"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Balance Sheet Detail"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r50",
      "r111",
      "r448",
      "r498"
     ],
     "calculation": {
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r25",
      "r225",
      "r226",
      "r227",
      "r231",
      "r232",
      "r233",
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "terseLabel": "Related party costs"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r267",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r115",
      "r394",
      "r395",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r267",
      "r394",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementWithDongStDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r392",
      "r393",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and development equipment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "IPR&amp;D expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r58",
      "r109",
      "r457",
      "r459",
      "r498"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r116",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r204",
      "r317",
      "r318",
      "r319",
      "r338",
      "r339",
      "r360",
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r390",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "netLabel": "Non-cash expense related to Korea lease"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potential common shares not considered in computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax provision (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of statutory federal income tax rate to the provision (benefit)"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss before provision for taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBalanceSheetDetailPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r279",
      "r281",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "verboseLabel": "Schedule of stock option plan activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in the Black Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of unvested stock options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r60",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationAdditionalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Additional Information [Abstract]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingInformationAdditionalInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r514",
      "r515",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r514",
      "r515",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock",
        "terseLabel": "Series B Preferred stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation.",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of shares added (In shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Stock Options, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options Exercisable (in share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited/Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average fair value per share of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Options, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Number, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding, Number, Beginning Balance (in shares)",
        "verboseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)",
        "periodStartLabel": "Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "verboseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of the common shares outstanding (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r286",
      "r305",
      "r306",
      "r307",
      "r308",
      "r311",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Shares price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Exercisable (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Nonvested, Ending Balance",
        "periodStartLabel": "Nonvested, Beginning Balance",
        "terseLabel": "Remaining nonvested options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Nonvested Stock Options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited/Cancelled",
        "terseLabel": "Forfeited, nonvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value per share of options forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Nonvested, Ending Balance",
        "periodStartLabel": "Nonvested, Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Nonvested, Weighted Average"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested and expected to vest (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Gross",
        "negatedLabel": "Vested",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average fair value per share of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationEvergreenProvisionDetails",
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationUnvestedStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Offering shares (Per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmount": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount that would be paid, determined under the conditions specified in the contract, if the holder of the share has the right to redeem the shares.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current",
        "terseLabel": "Warrant liability, short-term"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r40",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r144",
      "r166",
      "r167",
      "r169",
      "r171",
      "r178",
      "r179",
      "r203",
      "r223",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233",
      "r238",
      "r239",
      "r243",
      "r247",
      "r254",
      "r372",
      "r475",
      "r511",
      "r519",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r15",
      "r56",
      "r116",
      "r136",
      "r137",
      "r138",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r177",
      "r204",
      "r256",
      "r317",
      "r318",
      "r319",
      "r338",
      "r339",
      "r360",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r391",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Preferred Stock and Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r177",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails",
      "http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsNarrativeDetails",
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Relative fair value attributable to the warrants",
        "verboseLabel": "Value of shares and warrants issued to purchase common stock"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r14",
      "r56",
      "r57",
      "r58",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "netLabel": "Conversion of preferred stock to common stock (in shares)",
        "terseLabel": "Conversion of convertible notes to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r56",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common Stock Issued",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r56",
      "r58",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of stock from exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r15",
      "r56",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r56",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r56",
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of stock from exercise of warrants",
        "verboseLabel": "Reclass of warrant liabilities upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r45",
      "r498",
      "r520",
      "r532",
      "r579"
     ],
     "calculation": {
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r143",
      "r239",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r256",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r380",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails",
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfPreferredStockAndStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Redeemable convertible Preferred Stock, Par Value (in dollar per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r201",
      "r202",
      "r237",
      "r252",
      "r358",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r529",
      "r530",
      "r531",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureBeijingSlLicenseAgreementBeijingDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesGemphireContingentValueRightsAgreementDetails",
      "http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesYourchoiceAndPfizerLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureDongStLicenseAgreementDetails",
      "http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r322",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "verboseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "verboseLabel": "Interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r180",
      "r181",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails",
      "http://www.gemphire.com/role/DisclosureNetLossPerShareOfCommonStockAntidilutiveSecuritiesDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Fair market value of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails",
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrant measurement"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityAggregateConsiderationReceivedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Class of Warrant or Right, Warrant Term",
        "verboseLabel": "Warrants term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/DisclosureStockholdersEquityDetails",
      "http://www.gemphire.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r165",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r164",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gemphire.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r503": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r505": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r506": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r507": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>82
<FILENAME>0001558370-23-005127-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-005127-xbrl.zip
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M-*KB'$M 4CK\6<Q ]-HT)@CQ8P]T2Z#A'^@:'ZCP6$X)@S+5]=MF3$W@'C>
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M^FDI;52OV+$GQT&J*\]RNJTCVRZ^O*J*(LU6-?)#[YS[#B%N('9!?A7N"WG
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MEOT_I<P8 .?=L=TASSU1=,-YIIJ'R^#%*_NS(]K:40$AS'^=/;,_.PJXV="
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M6G4(+F/-KJ#TXI252Y3YUT3?RD-\_9N3 Q@K%+I;0[9R6CY=;]L4KT]PN+?
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MMP<!4 X$W911XF]LOL 7 BK=*%S$9QDA['7+2L#Y,R7D-4Z2>^1%BOH*-@-
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M$&E67K:]VF+Y4L719'H[G>133S9S3XK)]^"22[,\O.IZBZ3MF,G=#]1*\Z@
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M3B=#,5^.]>!FW&W&$)_-_XD\DDSG*;5J6(H]LVEFOI\185:/02<(QYE!V65
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MZD)-0R@B#V\#YJJ6=NI-#C%$F-"J_S4%P3LK<5IPSS&%O"L$(+D$4$DRDX&
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MZ7?$P5$K9N\5)">V((+<**'")@5^Y%V%C8_O&57JW GX<W-.2B@;5=@"6<A
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M+#_!B0G-&,"?\ZQF9,E+(QJ%07;@)(FD/ E\Y\4/^(8 V>_81%C'0O:W:0U
M<#.A>6*PAG&TMV#?" KK*#/H7+9F&DB6$#=K40#MY5"9+CXX!_[G)5S@7>0
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M8<^,>'FR9S693-0%WCBOE$2N$&MB@)W01#FK,CLXK]L@N)&7?<HFR2DY,+P
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MX[.?J[:?+]E/.)KE^>;5=A=$!TJ?:/SJN[2^,, RX&) B8 54R=:A_[?J?=
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M#\3QJREX[T,\/MG/HWBRX;<U?J=0VTJ\PA8%I;>4B7%)$S?V=\6K4@I3-/=
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M;KP7PW^\9*I>.WX\)C)WE^*-XW7/SS)>T=96$=XPMO>U! ;$U[C?QYL04(&
M#O,>#:;^5H4UG<R:*S#A*] N3[Q)M"HJ<J_%[<!Y#1:B*,W]BO^:+/?I)HK]
MOU/C!60;^+Q5P&\SK1%(5S%YBZ#=JJM%6!:R 1P(Z4@IWNP =S0[ET9*A)$<
MI9&F04UW0[U]0.]75]M=$!TH?:+QJ^]2A>D"+@;[U_WJD;K1.@3)Q7AT$25I
M\@P;-ZJO,1(O[.@YIHDK"#H&(\PH.JJ^O9$TDPIB/)>+9((1%<RRE7<A'70L
MY<NFMH1+2#YS&4_>\IW%N=E=%+[R(\$JN#Y&07 =Q=!PI.UL+<;8060RXYL\
M!&OGBAE>IE,>PV*Z$+=F)O<9A":9U..\)#[ZH=8$GZ-@02K/BL\2K7^IL=6H
M.2LGK-XX(C<9V'QJ7)7/&T;=1G4'X2PY;\;9\PQGLW85G,VA($]6N\FW+,=X
MGJKC:RC8C"V(SG.0F= @LQA%BA&Q6CABHH%%G_L;'VLZ?H91E@#-K-_PB-35
M J@6 \7 54A]NCR8Z^@UU8>IJ5<SS]%M<H,M2)BSG/?PUWI6NWQ)>#[EV%^N
MBR!_E$&Q\\<997S4EN*/,%1V-P:J45,W$85\SO68^Z;:=!^LP<AO?(RP_@W_
M>TS0R$J<A/M_CP&H<A&;H1_5*T#S^#*2.:NO_%A_SF=V]CMYKF>6H^0O5H=(
M?>YO?'SL^!G,GV/]D4?&KA:P/BP6Q1EFD9@_@R_3.2'_+>R='6\V6E\G]1'H
MC8\+PS_6)&=.?^31PX!1, PHC2=3%D<9>X<O"(>=52[;O&Z"E9N52;+?YK4P
M1.FB7Z* D0G\]/#(;/O)#_WM?MOTJ:<28 XCRZ0?P\BELL[<L8\<TQIAV$C1
MDFA7C!0UB78+^71%$GM1UH8K)2<@^H)DPL^L O;T'Z>P8,*SF\7+;Z\%JP79
MUAORS8"^\]4RZ!<"_#?H'WV,J4%?</^#@_Z1$>8%^D+XMPOZACY..^C7&W)^
MH/_H)[]=QY3>A.S[L976Q//\9O9_),#7^!"CP7T#[S\*V.N8 "'4@]@$Y":Y
MX&]N>C_FE^'F6X'Y_-Q\,3??FYG4UUIONBE],_L_/+Y/-)UOX/V'QG?\4WDU
MOK^9F?R87T:-[_WG[V'\$G'0_OC]#Q\Y<,-?_G83>GN7*__ A/U$X6[(D?F:
MVB&%PE;5 +.4C2R#BQ>Y>Q"(>Z?NMQCN<W3'A*6B1N,JBK<""V(*J\=P#:]!
MI!N(YYPW >8+XH2$_KZ'M;K//D>8^J^4[-@O9 ]XP> #>L5T%\6<#+1@;5,G
M7E-^2I6R?I[_ZGM[)TA(&*5LV4I?_6B?! ="LYH\"8EBXODQ6]U&<4(<>,<=
M^N6BL#")LL;\O[_XZ88SAD!WPL/[40"G;A08[P,=67[J])OQ% -0JE5I *SQ
MFAY $W[Z_L/'9>BQ__\C_"51@YQ6+\R0IZ]V 8#M7;##80<-#( CH(H,D#L:
MI]F#$@R#0(0%XTZ8$ 2DX%B8O)\8@"8PB:B: Q1KE.:,Q@IGS?B=7\#J1.@,
M0])&#/*PLQETXT09^2SH3GP#<33UQACZJW,4]OM'W55-I2UFU&A34;&Z*1MB
MQX]6N:< D8_'BYVI1_'1K'"DEU#6(K2,IFC=5S0Y+>F[H23JB1T5-V1^&;]2
M[SJ*K_<Q\\[X)DGV< GL)G1CRD@LPY MDH-#+3I;$P4S4%K^0.44SHX<V&'>
MMEGZPLKSAN=20TG Z)7&Y,O&=\5^$\^N3DB<R0+)U60EI"%^)@[9AUZ1B"T2
MZ%UY^_V+'P2PF<9E)DXF]-23V9E^&@/7%[)BCR?5_YL_:JX)R56Q,46?Z4?+
M+,Y,[>S3".9C;AD ?GC\ >9UO,V4@WUQ9TWO5]+[;7PY-=*1MAY+I /WE 8W
M<G2MP>\M'E=W4=LNFF=B KY(@F9UO^=Y(CV%\:N6@]D-FZ9LHP*.(\F6[^!(
M#N9$T&-FCP#GP][2\WSHX@1B !S_=;%&CF\5GO7-;?3%,36[MPC.';1&\0I9
M*>=$#Y*-!\T3F/[T83+/8]9]=Y-C\TP1.#/4J^,'\'026WGP"])C?2$UN[>.
MO2V&'N.IQV->;QEUVU1& ;DYSN92\FT-+N=, 7<LJU<MM*ZST"3PJO5P7E%Y
M@ILF>8Y2)Y!_AZ?I[J+T/VE:/EO74L]Z"K[( 7<RT\O(.SI3Q! \G>Z][UKJ
M/Q=9EL$1@BZJX UBLC8I.="42(])VJXWC?\;_!S&I;D2R?[R><K;PNJIO]4?
M&)LGQ>0_(A;CQ^ W!KS3 "[[C^2-S9#% 25;461_@G8?I_YZ*B'^J/C<^%$F
M >U:"?Z(2-YL"+3P7N1ZP,)>$OV-P?XX7T=O+#@C)P4I1>:4G1UJ=T.]?4#O
M5\LP]3T_V,-]Q2?J[F-F%9I<?76#O4>]:X9@8-6]R%V[7UTY,60&)\R4_+L\
MPWZ0:B/+-!/D #^.42M[T$8Y( ;HD13MO=^<B<-/Z"2!2"D1R44BX!1$$@HZ
MY6(!SF8/+G_FHIUL:4P2_@.->GZH)[#\ZJM>Q1V7(W)@F,#<,DJ,R XQ9$RA
M=>^3$P5F? ;JF"#@SMG2RVCK^,=IZAVZS3(83Q5OCZBRS^S"HD9TP[[-EB*,
M!_DLN/3R<<5EHWQY<!&%R3Y(G3!-EJ%WF1?%X*E_6;EY]87'/D20.O8PHQ17
M<SI3P'ZIIK]"_4.!.%("PI<-C>G+@5>&R619L$5A+LT":KEL:9Z& 'FEYQ%;
MR\)_%%(2/Q&E8@(VLTPCPOY,(=#\D'=8[=-]S*@F^Y?_8AV@!:R*(1/5"1DE
M?C4#ZB;%OIN5I')(>)PUE1'+2M(X*6N3[*CKKWS&E!=/74"I&8^N_)#])6ON
MK&/*%9WX1L[TWU4D2&?O1)QH.X<9^RW[<#<IW8XT/9?)(T7)L0QI<.)=T)[=
M=&* BJ:GU)V7X2 2X3)92B] 8]*'*(4AP FJ]QOFB'?+;;17YLN:HOVVD:YJ
M0H,P)PB_78P[TL\RP"V(D&>6V&;(E)B 32ZA2OG,]=9W7N!9 F:83]1)V'S>
MNP\?P5@QLP5K<!?!"9/XSW,G\9.F0Q>3])$#G'%3RB!GC#ABH#.O8]\(E>HG
M9WQA80D%E'-F?#TK<[=Z@%)8[OP@R7L=T]_W-'0/#0<A>CWG$GGMZM?&E+K;
M'*)%0_J^<2 1)@5EF\<$A=)U*C>>%.CUG(NCMZM?Z^CJ;G-P= WIAP/^@BB<
M?L#)P2ANGQ1C4>VQ0L>N,W1\E0'://^XW\Q<7RE^_]J+&3W;4Y?BG__NTY@Y
MQ^9P2U^9CVG-7IH[S\6]M8R@F,,T])R#B^LI8&!&7U 7<_CE+]@F-,FI(3I/
M;9IHS"48NIBD%?15!.80&IWT&"="4,Q^;L+=/DTX*/R@-^FI[3$7_U>K6^OM
MI\WGX-L-4O?U9$Z,_##;_=230]T1]LENYW-$_O^W=[6]<>-(^J_PTTT&Z,5A
M;W# OAP.2!QG)XLX-NS,#@;YL)!;;+=VU%*/I+;3^^N/1>J%:E$2)5%DT7-?
M9N)NLEA5S7I8+!:+JZC4=&RU>^R)V.:,RFEBRRT8XJN-Q%*U$P])F@Q%7CEC
M"$[.$>KWF:_G!\E_<%>!*G\066%?TAOV$\(HYWL:4O%NWP,MBIAS^(5FAWSP
MP'P^->1(MU!-G?)0TTDA1J^E$LVVHR@)DBV<UGY,\B+C29XY>6@R'&M.2,/*
MAC3,$,[-IDSPJ1!OO5-P<8_OFJ$/0FV^"V)>ECLH"$UX;JGZVJ%!33P4058@
MU\4C?8H2_L;)NAK1J_;E0!<_\TSE@L3-BNG&?Z^L75JZZW7]?91OXQ26TCX/
M0+LW\I5HHAI:WK1>5\0KS50)EJ\LLM,KQ6&:L6R_*FI;%?R^O&S\ (J-)MQN
MY8>]>.ZV_Y2DC_ ( J2 \(@&7.EGBF,2 69J94B9&P8[N*RD6.6>WM 8F.%J
M+5%-[.S'M_.<KPV1.2.<-=+F#4N"5271^2H.\J$[YF-]?+'2(9%[CB*['7RP
MGT&^9P>C*Y*$TT1QUK@<*"Y5I7<^N>*XOAC3VJI?:0U4#^J#4:\NNX'SUL<S
MZ< $B@/7Y<K3/LLR.]3O!P[T3K8,CO/[,/IUSKE,>L,#QUT+JEF4<;@:CN[3
M./Z09E#4[D+I&LV16J&NH'4MBH&VV*M.Z+ ^^TH@83S$4*01R$%IB  *0LBS
M%)Z.).5/(6X(0JF&5K0[J)YL+=*R[$,H?VRYFL.:^JIBW,U:_Q7(DY(^G@3$
MGZ-BW\''O U ]Q?'UJ5(\!8I'5WL#8^%%&>LJ'@L\7'Q0#ZL]ZO(:_HNR0OC
M3+&PYQ<K^Z;K#=0<;DCUUF_G=,QRB@LJC5=*@74# (Z\"*1U?*7:C([^QK:!
MG](\_YB(6^H?D^I:NIW?:'#\WQ?RCO\4*Z)Q_^"_'X36T %*U :^R1O@_'M2
M\0YURRKN7P68K_CC7.VABAUH;-=D-3*P?[G(&CF[!?R)$88+O3VP71S_#6YW
M3(7I@5Y_*VB21ZS[IRCO2X:T-K@O4&_E1U#B_*HC^P#R=A1@,A!W5N#V:.RM
MA><;4O,-B"0XAU*:4$DHHWN0X)E6GW]M9"+7R>E ,T[19 3/,*HSAMEGIRC?
M R%5R&3M 9$"CSUEUW'(54?#'LFT(_SL6"A/@P4$H"W"\,FNSO.+Z@QRLH5C
M/E'2-H# :>W"5+<U0G+* 95.,AQ%PO<L]D%!& C$/ 6]KI7[74[2EX31RT\B
M5Y<$C^E)M&@^S,DAR'ZE!3D&61%MHR/LE,E+>HIA2.YE09%=-K;EV"ON7WC5
M#4*;5[-J_[-0>T*?V#JEO!3@@?8O\\//'3M+V"<TVT:YO#-P$P$2B_V7X-O;
M4[%/,\;M0)I8;V.DZYZ>D+*#K&Z)V*$=87AVF%+X@(PNJ0F[S ?KBCF8QC70
MW+NIVI\TU=?6J^EJ*$5)/6%=9B:QL>$]@>T5>%O9>; (1%];Y)-U4$1YIBH;
M(IZFP_S.G:,555<W9-:1Z@,-:1;$;BYK0SP#+J\SZO'?3UF4A^*UCD%K&^^%
MW.XTQ6Y=LA[N@M@6=3F?_T0)HR_J.< (1!Z"?!6#.*K28$5T-^<0:4:CIT1G
M;>QIBMQ$AP1L1>05[1 ;XR"[LU<00=2-ET9W-,MH""XI+X5R>^2![N0)0N97
M;&M^+I,&<XB2IPF45'C[F!=9L.T[YUI*$_G4-J*REG>XA"!B8S$CUVQOLQQ=
M[(GX^!M2<T" !=+B03QX+KA@>_V2CW66/AUOU:GV&D7%H*BM/)P3H+K>[>@6
M'@.IM]#W;/&^2A/&Y(GQ63*<)GW!NTD$D$/0=&7(>*/?&S&XS!!BKBW40Q$I
MR@*C=<X-[BB3T-6+.4XT4C!59*"*-_QH["@4\#T.7^9O&<,N77BM&B,W_6$A
M!]T*WA*Q28\P;-01X*37L5.HCS)I83<CIJC+$E;"@F$&G#P.6X3S2HX^;^,X
M?8$4<%WU*'OZ9J7]X@^:;+>;3_8[P+U18Z['(?5 ML_E;>J@$3=81UQ=CP/3
M#[XA' !Q@%W_5JTZ@UB^Z9,H^0:&^NJ9&2:IR/@$EA.DL1@2<7YFYT!-Y8D>
M26A!4L-QD)Y,X*Y4Y4WC>YI3>-_ABND@4N;TZG=%"A-S%%#GV6KVPYXQ.U6,
MY;FO?9.[KA&0T5A\5Z3LWX(+$L"N/RK.EM--;:E'A875G7]2C47$8'9=+JMJ
MJ "P_MFWG&Y[@AA$O\^TZ(?UG[.H*&ARN]NI5*+?%3/Z351 C7Z:_;"CWU0Q
MUD._"OQ>Q*"LZ<XRU-G2!1MGQ/4K!R-L- =89U,/0TZ>/!4,0EX;L2< GFY'
MS' W2?@:[+1Z88>Z:4*L#W1*+Z]<[MV!H!TM73ATN/#/L@ID#\\4])F/J[%_
M*/11":$;0ABE@A0[%ZIE,)8V3,*G.)JF)$9C:/!O-8A4XZ*)GZVLGAI0(*$X
MA-<=TZ.X1*L &!R@TN]FMO*/EP<H+\GY!C,3%34S=M^BY1/P3!7)8A3_(L<?
M#1C94IF0WV(\7Q-V.5\J[V]B?Z1(,EL5]9YO2F?L6[]9LBS< 3Y21I;R/(%M
M7>;WN9L_D,/GW=PA$A1%%CV>"EXL@6T10QJ>M@6OB9-SFX*FJJ7=\H;1JFX5
M -SK 1+E'2,+^T>K&A'XJCPN<.KK]:\O/2O48 >D**LOK.R1];=&['-I,&WR
MZ,_IW*VSN']BOWQ6!%$";Q&,7+T:[81\#NL)K2P"H>R!>"YK,FZ@($1K  0W
MF^Q(SCR3OS@QW)_@G?CT*8G^S5??=S2ANZCH6W'Z6R,WU1$Q91OM:8K8.,<X
MGCLW9;K<-BO*KFQQ/4%+T^8[A&.:1_SF$2:#K&'HCB9!S"$H"3\FS*VF>7']
M[4B3O.^.PC**?AKV%'5I&+\..?\ 8I)4QD%D(U]0K#G@<;^*!U(R@0QOK.BM
MUD&:D6,U#O++S.57[8NF(YL <]21(Y5A-<Z[(SU(&C&"F9;0VNUJ!#L8++J[
M>&@PW9'(\>9'K9D+\8LRP1C"AB?&P[G5>)+.IU+V$M%FJ6\<S2:1]0[)YDFW
M/HH%!:GRZVM>+CNAK"1A5Z%-%(>\>11>XO?DF*7/4<Y/K@JR*[68UUK$4HA"
M1W^M ^ZZ7>][C M)O@+8&U/85+SKH^<YT(V*M3["75:4;-K3?%UDF^VZ6=*A
MT$SCHVU$3LJNQK(2Z7P!,?'8U\=D?K4/\Z.\ JB;H=:IZ#=A",\!<8ZDZV-D
M\TR>*IM$6=_" ^"TJ6M%%11?8+-.Q1F[NC";V"L P7XE3<6Z+B7/(6U H/61
MJ\ET:VXW>+!?74%G%Y>G<E_@IT+IZR38%ARD%X;=>@F^ A@:5M9<MZM-S7,X
M&A%JKGG=U<&>(A5U1FEQRA(#5M:3M*\%(UF0Y %_A. J[;STNX ,4E-9JI@Z
MDW\&#>P)_4M$FFT48MH'3_SIO#!B+&047-]'6KQ0FC C.:99P=\LKP.H5!R@
M2X%4",[ I]O1ENRKXPE:/9Y)<#S&9TB1#<M26XH8K$2,AV.9[1Z9X;(_RV_>
MQ/QM=9A>C'AU8E9=S$F3?-.Y=5 T2F1=\L+RY0(7O_,$?TQ2#@QM>W_H3$5?
M+F:%\+^.M8'87AJJ9;!^G?-V5SZ%>1G4-T32]R5#0V&3EH\!>J]A*=$1[_^7
ME0G+RK:.P>W@P6"X%M=ZD!;A,K/F')@3O&Q>6@;%5:PXN.[F6GE7PW-)>@Q9
M6J1LKU /E*^6/_SIOSY%ATB@T=OP7Z>\ '#*2Q"8JUYMZKZO6]/4.&D)TR/]
M&E:SB9*:6=B*/76VN/&QM1>X?,8*UUG@2AT3IF0&0)6625"K&>$*9VE>3,AF
M4"M1XLE1]!N;2D=G6ST_:;YX%;02*+]E-IM)FEH0(U600KH,FE#0U+#X)1W/
M ^*]XJR/5GQH>^!D*&_ N,*$&A"<QS5/,][N.ED1D&)6[@O&K_;/HX0<9!:H
M1\:8&6000\P2:6;O7YNG3YF?K,I)XOF<S<@(;N&XT--#])1$NV@+>_IM2V>*
ME]>XSN*&"S=7<@3N0E63#\SV5)>4WO$J45*BZTV4I%E4G*L;D_PRIDSE^K<3
M^_J&%ON4??-,2]S6JDYBFQ/D$.CPY^G64;'*!F((=JF-A3=FWGQJP@0-XZ3A
MO"H*)_@A@B$B<;2YR-C_S"8Q(\24%@.E^AKURBO :-J7CS\2+RY5_@#-%2>/
MEH:1!^R647Q]4#WTH-T"<J\+.HV]W#85 MLXM^I;=VN@F;F' 7LDQPI"']B?
MS!$WI\F&X.N#H ME+42@DMKK J!+H=S@3\F%-_!C2FL]<EM]#: 6JRPV5!8F
M4NEA9).[C")R^#&@+M6S #/((08@$U(MKDTM'11<5P?4)0/?;WI0R?6&#H/B
MG**05%*COG_>4<.(\G1I>((TDU2BPA8M AZ@R30Y%N-'.5RGFL-&#2EN <.2
M;ESNDFI1A;/4 Y%C>AKK[ LH:"E!B0:#/7V  3T!EMN_&&?0CW!L].MJ O&N
M9)[[Y(]YS[!K?PUZ=4NV;\%I$<0+_/SE-\. @?:!?%,YKD[3-9A\WRUO<KNK
MO 4]&UY !JE1+U5,G3<_@P;V!/DE(LTVBCWSXNMWH15O@/$DEBI!?2B_W7+6
MN ME*0HP\;RH2CT*3"V'-JN;/PO=)/2)[6S"WBQP%RIJ;CRIYM(?>D_3#,/L
MI/W0?"J^@:S^#FDF"1\A=N4=@Q;"[LI]%7* 75E5/?@ZL.G$!J\K*V@,75WN
M3H?S;I=DL7MS#C9)!?J9ZOC/MJ;QOUXV.O;L<^/G>4U6N9M4P0EO=X_L^O4H
M( > &>I0A:TTNB,&@SE2+#:$!@2&7[WWX)'[Y3'J\AHYG,Z)][A-OV]O$S>&
ML_IF$7H]*#*0Q3>=RNO %%/Y9Y.AQ7&JG@,551LST_#2$^CI^E/;WTX1/S$H
MF #18]QY*&5*/Z2H,%GT.GRCTPE[P&:2#'/G\5L1GBG3;V%#O15[:W7 IN=B
M9Z?02DC#T[:(^%^4;0NR(#M+A69RD0H<E *Q77TE4>G26P[X6%&U:M=6C4.D
M@9S4J[0SV;J_-Q(?C/VC^JR,6\%NEOU?1+F2L'J7]6$?9/0=DR:4&R@J'Z\\
M%%+$MJ'@04_/P#@^^8(FQ37J+<*_ZR]*UB#+NAF;[]&:AYHY@W\ BF&[V6HE
M?*>[E1BT_5"DVU]+/6TEXFLZFY\H&ZXJ'G'66CXZ79 "UA2!^[W+=GOO',L>
M]I?YE!MMIW)CR*G<D&W,>D:[B)$)<L+%JDNTG%W[E(:UK(3="Y$=U-];6^P1
M"4W"WE5PC(H@COY-P^IE&X;Q[^DSC=,C6!@ NMZV6YN45S Y34']\*E'QSM8
MG2B6EUOX;2,CR:KGG\"S"QLQQ6,$KN'7TJ^AA&5I[/J),*XE:7CNZ+JH%.Y*
M4RVE_$=P./[UO5H'CHYEH&*B=L"Y;(P4OO6$'#Y"@98^;8W;#)L]"@'22/:D
M9L142N3&[CY3[5"::.J;S4D"#EH<:^>3O<GL&K6VS^)%<$6&I-O+.D8E5]S0
M"4KYRQ?1%:X<IF3'Q75[7U.YWF55>E]%<5[+-7F]*,2[ADY:^9!+2^N.1T8D
M$>[3$\>_D3V%N@=2NYX@KBJ<H6CN4=1BB/N%P8G+D$/S^E/G:<O@6] ?<V@'
M>.]O?RJ]!&>QA35TU@=LFT9@)[<^5A:[5SCCR-4*20,8)Z%JMS^/@G_(-J:.
M$:3KZ^XG\HU*@P0)>?0UYH<ATJK/@XHI\.LNW&I#F;V^7_MXJ-+("@&;19BY
MFEX0Q7$D\2:$=#J]D,+I1+$' SWM+HBW>KJ<FP[_((GS&)86XEJ*@(\YZ\VS
M0K)<]E=CM>R/?]YE*9SPW68/-'N.MO3MM^CR,'N@&5*['!,,#+&O#4++&V5U
M[N0KB?+5L:1+O@+E3LQD[?D'BU_) =1O#Z)+9VVL+?Z9V"_BQ73L-L0])P?X
M-3HQ!>U94[-G8W@3)*==L"U.690\O7W**(6]P@T]/*JW@2/MD<Y!;5'K+=Y0
M8^P;.BW>9T<GZ!'R6R#V# \71\DNS0[B/.9(LX)-3_ZF<4I:7)":#<O[L55U
MT2/B:N;)0.8$KT9/MM/^COX8[(CP/9;;T\LO$QX38KXM,Z\[[QHK7W/XB$CL
M=BT%C(MMT):A2CT<=7VAV4$E\L7WF"U3)4IM@/*7V.U,R>N2,E]L#8S2$(IY
MD9=]M-WS19)Q (%-RM^6@UM_/*S)OMB6PULV+J-25\0(4'.0MFGV)V1$(#0=
MK&#_Y7/;P1.]W?&+4?F/- [?G>]I#*'3NR!3WRG2[(<9+Z:(7N.(3B?L^#))
MAH6X4PX$TS?G0Y$]&XL\GDDF1B-'&,XRUEC1P%U+>C$,^;&4OAR)\*$< )0#
M#4B_OY-#$%DTU>6@H79(<6Q4-/EHH],(8?AJG-?YVPK)X%Q<YUA?-(ZDXCZ/
M60^!.8\?TNR>;FETA*RY.Z:4/1OZ-@MI=L>^SKZD]_2W$\T9&^]I'#W3[/R>
M\=2#/$OH(;5$8ZJ2/8W9Q#SP0);+ML0S2=("8M?2QNA8CD]28( <@8-J1Y15
M?)"P9(2$C!/[3HL[I=TUFJJ&AS6]8H!P#LA=I;6:"5)Q08 --XZ..ZU]UIYF
M/5/,;*0GC, @F2Y@1QDEW#QO=W58Z3J"!!6^,#'&WT?Y(<ISME)Q[GMVN0M)
M8D9S0PJ30U!+Z&''=%/BF87U4(Q2WKA^#))?L].QV)Z;7#QH<CP5</6:__D2
M,>L$U*_#+>0)JH$5I4PTM!\8<ZK8>GRH(TDD#D"C-0\;(K@H'6S&!ZD9(8(3
M-W$XI[J[ZYN)01Q#<B(\"MN93K92 J,$2B E(K&5<7+'A/P"6:T].Y>1+DBQ
M?(K %YF O>T1[YRUV%Z0 PC$B4R= 'GRE0]@,#]I^51FMKR-T_R4T4_LZX\%
M/0S4>M<GX.<T'U"&QJ17]/;/!(:$,&\0S6CD*XQ'^( FLZ1ZQ+P^'./T3.EU
M'#U%XO;"VR=E)&8J :0S?[XRY+LS^KVQ.^+SA)EK 1590ANZ!"+^VRQBOED4
MD%,".]VPM)2M;"E'-JC]NS 6M=.+#\Q=KA0G#<G<:1<Q$KLZN8F2Z' ZD/)8
MB%9Z*%(V.9[95!$3!K9@,#^L(69V$Q3;?90\R=__ UX%3)Z:DZSI^M.FZR^^
M3E.=)NSJ$?4;C2?*N' ;*B7_E,.WX?@EBF/R2,FSB$2. /<&<H:^NTM^26Z2
M]U^2']G_'KXC(O-VP[>\]%O QJ$;UNJ/O_SWS1]_>/\=R=JINNS/-(/!(.,-
MX"!EKM*9!AFC$#U3<F"C[O,-#]<4^X@UI0D)@[.#BG7N?\;QU20C%2>M1AM2
M,D,:;M"M,Y:46&OJ ,/1G,]V4,U1&:1:ST&7/Z^NLRU99\8)^KO :"I+UZ$?
MIN;WDJ(KG)FDGMI[DY>'G-G6&1:2Y@9E2@)?M@ KZT]G2]#ZKN)A@QF\U];:
M=3//I.<'ZOEU[-7, OQN1&N&[*Q'MXDLN4IQ\\A@QNH%BJD1>@8-[+B\1*05
MT;ARY]F_6A\?@I!"*FK5R3(*N]"6!+ 2BG1]8\*?-FD&=@"W^"<3V[Y%[0TD
MIM.?RLV'.'Q&X=,@.\N-1,F?:4<(^D21PK=9I6F<'&E2].\T::I@:^[Y6SRT
M6PHNG)7#=JDYJ:972S^'*D+2WK(P9=6()_S*('93[?[A])A#.F!27#^S_PRE
M9/0T18X^0P+*F*)JAQ@I!MF=.XL;HH13=9II<2DA&TI1F&B\M6?S\T+,H2E:
M-O5HEEYR;&RB F7C98N6359E"2.=]OY-V&XIH]'&?DU:0R6->J;M@J)&IB>N
MLI[*6%N_)FRW:LI@0W\FJJ&2()>3%,.T_#225#G0W*_)V1%T8'[6;?V9HEV6
MS;FJG]2)C__SGPU?K,FO[,/JHY+8__X?4$L#!!0    ( #*(?E:ZR*]*#F$
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M7UT6=DO]K$=H@5T4+XT^?HEH5Q[(3J#!@L1JJ*=]X$N _HP(X:_>F@V>:@N
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MT) 7($.EXU/TC;WPI]$<DW:F88B"1''7CK6L 85=>!B8*/8_@Z27.^RG%=D
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M42XH>#'#GOT:H$7DW.(%:_LE41,NHGQPJJ@V%79DX>$JN?^"9_*UX-XK_/"
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MM/L!%B9*>MUA(A 'BN=5:H!](#/XYMFWW(#LT*EBV9M53@TPP.G;I*I*J\E
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M'D0V:N/W[G,TZ(UR?GK:O\^TLL:K-P/R@@XZ*I+FUQ8 L)<'K@JZO(2#!AW
MPPH 1)$'NV9VT""[65]2M;BGDC$_(<"F0_6E;:6B]!)OC?M?Q$7^!'*Q1T
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MIYVO<O5S[X5H=YTAR'$A61LN0?A82]R4*0ALU .N^\1"M7.M^$955 T<5]I
M+FDY%HEO)*I]GVGK:K50V'MM?PS27P-6.M%&;>TCRQKIQ.AR][G?F_Y[^M\0
MOR'5*_^/BE?^'R;;3PW]^I]5:&AN &?]QQ-HYPYPUO];8:AN P"PE4"NL=O
M:)'7XUX  'TU(%NX%XBH,&!K$E08.3!HLB8!&-_,/"0Y<SHO\TBE&!AL=2!3
MPEE67+" GDLB>KYGD$K(VV?J,<!71&.<O)LH8-"9Z;3=" !@0Z/]N*1< .>
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M!C(%+*H *L@V$""Y]^6LXN# 5,!%!E2.E%"NI4D741!B^X*NY_Z&>SU=6W8
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MI79@VFJG:ZVX!/*LW"1)I3X93*D:@V$:J[P!JIYR)?E]H_4HE#!M-,%0MFP
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MR#&55D/MH1HXW^*<<-_)M7XK!^3]AZH>UTW=2K6<F*ABD:/;[4QSP:WJV:?
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M\[&OVZ._]I%S NH^IA#8J0?26/S5UTV(=GPA_(  8.F*+!'_(?'_;@CWG:G
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M4#=K$O$'[:ZQ#YT->+\_ABM S^-'X4MH%MXX^*!H/ D\2<&RB21)2,+2>OA
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MXL<55'78]R+*J/;P%52JNH65%E21$"$X" !0\ "*%UV3_-.:IPX^%NCA*_+
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M/T;[:QZC+4F"$*% G$\"$?"1I"#PB0$=Y4F*[,>CD3 9P;WH/^F@9@Q8BMX
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M8UWD)**#O$P4"Y%7[E?  '[11L-Z)U7^A!3BQTM$OU7<3SC^ND^<ONX3]Y-
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MQX=Y_,^DHH>>GD13;DA'QE@AQ1%@^I/$Q73:"T(=53))%_"@)!9=7>%C;^3
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MCIDOG[XG-1G\H3FMZQR29]I!+;@3/4VTF._PZ)"LW44BF=>?=\@H\*2-VJW
MA@N\.)1THJ1W9"KL/=K9ZR"T8SR=B.MP#6@O]QQ%I'_-CN A7=(12:K 1UYH
MXX$"!/H0ZW1_LN0L1U*8ODHO*!%I0%/O%QPN.J+Y1"?343!:C2,U=2%;@0+U
ME]G\:?_Q3E^F,_33R<%G,DM^IPE(&\E*"?V>& .D\0">:[EZ\#;W,NU N5+X
M!GX_AM,_Z>\\:;Z;C!1:RB<"K')E.DF>@R]:>0&9 6GK\.#%VVVLU<.=1W^.
MO9;[^=2UD)5]@'[&3CQXW*;JU,^-953,YL?KP\G<^^>NW*;,VD"UKH5J/=Y
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MEPQ+XN"M N5R^+6TB0%//!\L$&6@QA!Q-?8]@@I:_Z!4R%"KU#%M) Y%@.=
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M#2D8EHLV6Q+^8V+("/]J#/E.TT%7+AM'UF?SJ1;_HH) HQ[L)<8HQY74+==
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MEK5*:/NA%S56;B4R:@KTY&4M7@M=NIW($O/TC2IUD5D)L ZY3X*@&&ES]+J
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M+0/_90F,;#=$LX78PYWA$\(;9W5QFC"39"DO-] M/1H):-GH0"C.)LS 8CF
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M&8#XA')-2 YZ/N4D:\,GNE&0=469@$VX(7HZ9=RUC_#AF6[_S[(##8=,8A$
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M!W!S9SB#: [)T3W-Z_P,CJ3SV?/_2A^1&%KWKJISSQNW[U+.P ^:8":10>X
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M%(AMD917KX4I6AIL;!-^I:5C*.M:+=?!T3&BOHL<770Z!Y3*E[M(2@)SWV*
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M3>%EMOZ'39(87%\@9F"Z\)^GTBQ\"JIV4?J1JL^O=ZP31K)D%FM[:+7</9J
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M>VP/(#+-%'7RUP,INL.I^'K#XNNCJ?@Z%5^_C>+KIW:L_M7<Q&>7F'NFBI6
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M+*2,A-LS7P<Y%;B=R![0SR7QE?%94Q*F?\L'6W)G M$V%]R!B>-#W2'$N.8
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MTN&=],L<.*/#HV'CT-F>4*L48Z4D59I20\%I<9GIZ% GAA^H<\@MUSM*;D&
M!F\08C:I2<21_VT26>CI..8"AU?'JX$8L^-FJVW9=CW)R'"H\^[\\-6'$S),
M],[A%1Z.-*.C# >#Z3E?7;E13H+YTF%S-7O?@RW2_!21*H^LJ64NE;&*Y,;4
M6);DSZ5&PBXW%DZRL2ASFR/]]R;GDECM7*$9.AN01O))=&$2\ZCFZC1):_VM
M5%1^$@^B*O5MX5$W8#REVG)#)T:PR7&GX3T*CGOL-3(*[7H%S=#R;^BTF9?/
M/I]--,S2B=#[EB-=0&'^FU1>:?V6]9Y%P=JR>VW4S<S[=V_ )U8/J ],CJIJ
MO%PZALV*5:A'HL=D#G1XZ# (Z^X%AG$H7-2+%1$)2&",9,XT5JNI!6^JO 0O
M[T!*%NCH0N1'HA;!H-<GGY'-1BXB'KTM^8BBK]:).*3^Y;IDU3?VKZ7,D"OP
M9EI=IVMI27)B[X5H7^LS.J^^/J\$OA+$[,7J.VHMS0]'RJ>'M-,@?(55Y7:6
M/'8N%41+&@_LGX>6SG#ZI@TMT*/Q3SW4N#7@\0.N47V*JZ73%Y"?@JJ<&0TI
M.S._W5@#/+.?% X]-*1G1 P"%2D:ZNVF*Z!,"'F'8M'B=(24C.4?L/+'$7:*
MWUFU:?9-Y=^P9MYJMZO*':M^BJ_O'U(X]U:8)D"1NRV.#-7#R5=^RC,@VA>8
M"4*_J8,ECBN*V?=03L,%016K>D?YYK3K+8Z4!5*E@A5EN-%\\+W(4A=+)*N.
M=ZU@]U1?I<T'7];9@PU#]5W>%I6@C0_(W$@MWMCBB$HDS="C[FLVOQK$".$Y
M/K"W:H B7SS\[///+[\2H$A""?[A48*%HS(X%BQ($^H6I6(\:H,X=((Z)_,Z
M!W4FWT3(;UMW'/K< _5LC:TF!^.*%6!R0H)0VWDRKV1>R^:%#F#1YM<Y(5#B
MR$60/R4,*;4_)C,ZOTOI(8BE=$] Q:EA#H^0>BI94;*B,U9DCS/&!J#2)8<T
MGIX/(3\0C7 TG>PIV=,9>S)A[*&I74\%9=B="B:OGAQREL0BF58RK3-1'P'5
M?1<87#G?49GP+W_^].O'77"_N31E172UKR$96#*P,YR>#>?8I.DK\3 E:[FA
M534JH]\&ZCQ34$IFELSL1H[L [&Z8PD[$-G@(4?RPU2H2[WUR9)NFS (W>$4
M\EV<V8'>FR;Y_ZH&T;NC9KC^*!UG%K)H>@L0926M\]COI] [5U^5;5.SN(.7
M-*=<-E&T,=24D8P[X2VR]<DU<K)BE7_]LVC";0EOBH&;J^%B0BW =4Q)(@1A
MMV4@%VY>4DI5 ,-[TH#\7AO/<RI*<*,)-Y*$7A,LY)=7#(D2JEP!D5)?:H50
M ,9N6M+'??X?"-"1)%?"]TTLI[#9NP/EJ FT7#95LZ/_5 *$CGH<AX"B6S30
MBQ6./K99+,U9XW(%0O R02O@):L&[S9GIK-07<9)K-LF5SDV?(@J7S<MH[D)
M#EO W;6SEQ"MXSX=^"H$F+!@X#N5 FJQ;Z7I^"S6)E?J5/93Z"?E8O4$%AH"
M@7 MH0J NW(!&!!- H6P=EQ8T<2UL OWYR'% Q%X%#.&^3M'RQ]1,!5A@'UW
MIPI#RRIG4 /]QA%BUR&&KF9_U7G@%H&.//Z8%CS5R4(+*[DD.BO(ON$G)347
MW;*YZ//47)2:BS[$YB*[[<7HMUQA>PL;B(<2L@,18$S4 [3!HV!#\#<^$!#:
MR$=$U"F*%X"?]^0 13U+T<Z8$\,&_%<['/O(Y;"\.ZOOA7SC2MK=T7_9(-,$
MMG,:SPB\*8(<>\*"(C\P29(X1S!]TJ).3I-OD[=H+;J6>[-QKA#$ :L],VM"
MP3V=XD:=8FJG& ,-._7Y;7CA;")^#43^7S<02NII1'1:=<=O*]S5MY,.G73>
M:$<IJH[4V#0;O<]B< S?9N";PBH<G#;-R5$;571^F)<W,W!BO>C,<+2-55M8
M?"=)Z&(09%X@(8[P=4_QW"OI6@S-#-)K]_*<$;_*,T$$V@1,'UH"C 94;G3E
MZ-<T<8=C7K9J"]..8FW,4$XT<*FQ'2SS%#&SI#XW\E!1:]L?@X;JO7P8PLU3
M;YV'K^.66=:\@I0T@[(UY,L2T1TXV36ZT2WA1)63Q5J+Q%8^9O!=B<:,#*H^
MD3^]B_X(8A.337/3*W>0OFLB D0Z*'I_T3OW&'+SYBONA9*^B?%.,=L+0WNP
M]LL2AE*[4&]I)7A&!IXB.A750I\UX.H]B1H+I?MV5EY^9*O/GCRX?/39)=T7
M__WEHR\N5G@W]"%Q^'2O?5YD>BC.+!;Z!+MVAZY3LL-P ,C44?1$G8U#S4<H
M#4\58T9L;M1Z+*<J#+FD])G0*A&KRK7S^1?R\[E7@WAZY'R-EVZ^:YWC/F7J
MB<Z[IF82%=<>//5$54UZV[13+GJ'X7"Y[2L,7@R1A6"C-N<*U%S,C(T;3*0_
M:X\]$9F/^]D7H&Z+FTS08]\I)_D;[#EVD_C\%CL._O#S.>?_G6XN\=T??3Y-
M_>B^@%QHBX>!Y%.0IH28-%?U<%@C!<B6PGF;W<F(<Q-=*,_NTK A;.':S35F
MK'^C!WS$0=TM7@Q_\[ZO)A4__O#%CW_/4E4I79_EXVL- ;&/Q#2A/;O88+-K
MF/#K+FY6PJ(D>[W17M=*Y\A=L2U*Y<%_=ON8I1A_&V7L,<5157 "#$S""+$<
M9E ,J]J(@$JND8PR&>59HPS,C8A^04:6T!H#VQKF_3:N1'X'2>:4;<%A@K,A
MZETVRN#@^SR8[MN!E&C#+(TU_C:0S(7;GXA1/<=>V\"-<I *"F4G:?2<'O2/
M10DX/3?HSO01\SDBD<6Q11+*U6[(L1'7*2T&^\(UP17]TX]#'QS@+[ ^T:GW
M=$I2A%%Q&3^RM##3PEQ>F$_F71,+,X,80/013.^_*ZGY'%9+V7>NVG)2/LXV
M&'6/Z(AI:N:@15Y(B0Y5@*%ITT&2[/6,O3XG8YESIC%ZN_SR<2RR-693IRU2
M^</65:DT#\QRT,07Q\,):1)VDFI1C0N&HV"RE0 I?&CX8A#<92V5JHYY2DV?
M#&4]"'N0SS^&/$47KB=ZV">"Z7W2M&EYI.5QD_./J>&VI$R/9_/-!&G5LI:U
MP%\T[Y;]VMR_5NN8?J>UQ5H83=GZ]'%L]LMP)+/RSDCQO(O<V8=59'B[SZ+X
M0>9 U^Q'$$- >A_EUM0(<9,?0VD9OJTJ/%C]1)ZD,]3W1#H9R?J0ZB;ZLO[Z
MED H#,F+\+"L'?5A_!:\-'>8WO?9#K['E8EGWJW?#[,<&6YJ!#-P>;HZ4=J@
MIDS#>BBKPBYG9L>[KME6SJ82+)#"PPP$\B8M6["YY >(J)!-WUU1M<7L=N1Q
MDKE(99N)6N-RC)8B:,]K"<:&MC0EFKP.XA*!N ?G@9Y1"J8(.###?H7@#UT>
MOHHQL['BC)B"R=Q"PD?EMEHN1]G6D&[4#.)'ZA$$'!J6,\R>6#^A<R'J-:GR
MH=[LWRKUY7_+8CF[!7K<R,WV;7?&)1$$OY'I>Y'-;$2]3LCJ0+%)^08R 67P
M"C$;+8H#ONH@YL)9:;]\*4-!@D'><E ;3UDYYXPS CW=1:EM?O_FX;J8(4L!
M.(+%(H5YG7=7V"+JAV6T"<]Z,Y[UBX1G37C6]Q+/^O8][,S34 _<0O!K/&XF
M!0=/#AD:KPB5'S E!CDB\D<VS<Z_J\S5%YWU^/"*W2.+V5C6(24A$CQH]JZ>
M.OZ_L^_^@8=Y8_2O6 TABM1HRGK;YN"<#-1)(KTH5^0'&X]:#!-_/V)VC3WW
M[9*7#2YQ$&2U#J_T;RW1>\?B3JTC&-2<\6-A!-G=8\=JZ'R2.N2Q9_T8(PO(
M;7(]E^[%ZP 72/A7L4PO0G!FT7C(MUF[!"G?-TWG3$0$#[0A)L^Y48Q>AB[$
M#KV\,RS&9U?0.[.V]XG"_OQ(6?2*M X1S*2=;@73T7/3H^ZTNG/YT/7<ILN5
M1NJ9[+E0R-NMS1_/;[BPTDB>@JTMB(U$E,FMV[1#Z8.*OA5=+C5IN,+&1?AQ
M'_VM[A;]?;\=0_GXD[B%?$&"388Y&E8LG[DP@66G6$+:6U1ZJ]E@)X#N$8QT
M9"'FT")Z;-TAQV7#T@Y#73O<6?*VK*25@$ 0-+]3.*'V'I!JB4_RL_Q%P">"
MH< CL+2$8A\K%)@I+;VO[%($AU<'A'X^9S_PXN%A:O=V]>G^2T+N[_)-3Z*.
M*BY>UGL8&_LCFMN94&<L;),J_7!=*\?W;X5+_(UF/%5V_N"5G85N@&8LR.(W
M8.HLHLW(IZ<8R$O@$.ZDQU/B[,;T>+5*%#/)*.]HE#&]$4*1R,:\59$?S7I!
M.8< Z 5YM5]N@&R[(;<]><9XS5>I3T2:TZT@VD(H0B7T9-+)I,_DH ;$\(&G
MZ.JY_M2Q>C16T\4K!YL/C5<W!9IG*MKOCC?G-D4/FSJZ?2QS<R5$XYPL\MFT
MU"%B<5K>\#L)^_#C;XO+SN*$K$I(8[]V'$F/ZYM1%6VL(=:@A!R$A!S71XUC
MB_FN.\=\MTNRJ5![5"<IX-<-X6BIU8O5<EKL'[MJ6OW2T'G\*45(,']]9<"O
MV(1-5=)H9"(34^M4'^@"VIBFO0KP7C2^.IDV!_JIY]$\_XQ=<$"JDS; 2;[J
M#HE.6RK*--EC?/U%2.+HJ;7,^RMRF>\NU_+!1'!WSX,_^14:[Z$CT1 "13E"
MTD124)YATA^QX652_ P25?YR@;.JC%HV+6>.42,W0J/,<L4;:DBMPJ*NF<VX
MY[0GK-Z#;!EVM208R^) R61FG;V[6U" >O@W+GW!>35ZF5L)L*Y*> XC2T_9
M(MJ&YE7I"1[2N?AJ*CL&]SV4VG.\5:*(<,DCN",/HHQQU$.!&2>B<H!;$]^Q
M_Z22/E][UVRU^?N//XW^Y'L*/ R&,X8MI]@)\4(=R:ZF3ZG/#16?>9LNFLW
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MP>V0;TD*H4AE*M2SM,5ADZ>F#W-L723:4=)0W;H'_1X_=[0E!TE,U660!SF
M/TQ$WHJRUY,23;(H6K3$H3[ F:%"<;5SA9X191>NG(7+$N^1.)!8E&&@/1Y2
M\]-]L?I'<XV.9N8[5I!(E?7.$23=NM DQT!X:65 ]D6_N/AX<-*+813*<R/K
M-]^+ 5_<E:IXZ^5]_:4S5!T3+A5J0G$KB-I\:P&-^%H(;%!3E_@RL;T#?A>Z
M0T*7CYD&VI(B6QOO+V(G+-@[M;-CWN^O\U/4"6J:N?R^(OMIQ5SPU,QA-Q;9
M-[*Y/85=.!;L@?=]Q<V4\ $^=Y!X#RT/. Y-/<:S;Y\-IJ3L]25U83:C[R#=
MSJIJZIWCPE_3"K$]J9L$;1)%JHV>":G!D]KKNSKLGXHLL%'?K+#K2X()D5 F
MIG=IN,)NH*$2]XP.^.#5+G13C>*<178=ZORE?EYQ]EBNDU<)WR()P_ZJA_E^
M*>PC>C@,'V =1Y&,Y[:FF&F-; 96R=$;B_"$&5=')2JDWPM;J@K_Q[B-CU6M
M-Q3BGF#O.ZC6'6[0&AV2&XED8_-6MD0OJ:CM$5#6QNG![$8BIYX5^33I]Q^'
M7S>WA5ZL7CI>1)WCYBS!5J(Q/'KX^'M\[DMJ)GOT^&\BVB'_^7=L.B*I[M4+
M'^K3[RX?PX#ATW<9_GPXCN-MA)!_6#9A-EL,AH/U'W+V%N#$)LN.K"H":?/%
MQ/H"!X'ON8NM\ R]_,4*DQ;BS5#+'RR4Z[VCQ(&VJ"&_GGD276B>S+W.-]2[
M2K;*/\6#W^B^9ZO=4'+?)!$>@ ]R1.HGU7OF"_&%]4*YKQFAS)BJA>G-);*?
MJ6*RIUR?LC.Q'S<XCM@S]#2"+6O3PCS!BI2,U[\N7EX@QG+72GY#_+R__/G3
MKQ]WDWB+(XH@J4/>%6XOY-_QEC,=>(:1Y37M!5[A%O-6U#V+VY=O&0UTB-PA
MLO+68D@H0ENO;?@.-O3?>]PEL/C-8/&O$E@\@<7?2^+RMQZ'! <GE)^FGJHJ
MPW"#_DH=.XP3E)((>^/)%:-4QDA@372H"*OECZ#?@A3EO\:!@K.70@-?\\E,
M;J Z2997/M-#]]L!U7[A">'M:9H)7Y(H6@O1WI%\X-CEH:J#J7+MO%E04H/>
ML-)D=_&HY/JUVX%SY7V6?A]?PQ:TL"R!!0WB-0:#$](KF*X5;8TT;JH0'?MY
M,!8GG_2H)WYR7P8K#VO,F6L.6,<7BB73F;V>%5S61K]\U-RG,1)E>CJ?;W_@
M&;%4P!4QBM,<FN<@IP0_/SK\9WYD)O+M^!%B$!"^IZ$./Z44YH'6*C[8!MX_
M):1(T#P3TB*= WS'6-,"SZGNX%5U6^+HQ=3ZE:N$R<W(( H?$UH*.IZP]F&!
M5!@((EL:)N5_KX31>[UV[[X+/Z?M4<*!?7F4%63"<^)1*;"YGM/295L\8&WC
M8WY"FN49[B-!^:.9Z!S<>618-'SPNMR\1G<G6VW;?&!IL'RMG"ILS6:L57[=
MV8@.'^K> ]!CA:T1D7%P6W;\/?RDRVO-F3 VQ>-1,B_%C!1017X +XQR$\>!
MXROX*YJWT!O"Y5B72"'&)CWGN#NSBTD^ J,89]OJ#G803"?_WB'$A[-"%M(#
M_[BK\1^)$!\WNP,1&S:5+QDA"=4!MM,B4&I%AZ&40^]+/':QP@6\P!H9CY2L
M9.@@[L''$:7/8-)4R*E.=NG>>\D%YO4-EZYD,OP&C\".$GG \%"+1L]7LOM1
MOV])RL]/AG+M>9)(3[[@?N5<OK!T#_2T$YE?.ST.'0@>0H?>ZHW3@A_4C9R8
M-BWXEO*![]ZM_3:PZ5LJK^@TOXG3E):0I3PR<WS3C-)O!0]BL2;,OPM.38^N
MA[@/,KA%[U &(I1ZTP<YXFY.!0JMX=E1BR >V3;OVV@4@V2DPY 1O8BU%7@>
M&;GIGYM;=@A?N,VJ(Q>.^$N]NAZSNV*F@)8X[4I795/E=N_QW+ATT0BB%$W5
M[ +GTC$&:/T"15FD88UG9!:.3WK(@LZ^7K6LPP'J#TUISH$8L"V[IF8)4?<&
MWE.G^+FHS34,>R4BA+$_0UK$ 3;R(U7-1<:(_Z,L,E^%AQ<+.T85H!TJM2/!
M33SE5M"0HJ"(G'SR(L,!@Y@"Y%Y@2T1%F3T\BK!^\E0633#&LHM>+%HC,\Z"
M'04B/&-6^'8S)MF;OB1](UF V([>B_%TF'02G]Z_@[M,/'ON^:HL_L^?_N\_
MJM>?7EX^?/35%P__Q"F/]])1_G!\FML"OD;@4DJEDXO@6H8_2&50.D*(PI#;
M1$+:Q=B$.ZQA2 T308/CCL2? [LX;'A,#PV?@ L+)HC"0 437\_O94]'EBQ;
ME-NAUPV[?)$C=2C[YEB+*%N*>DTI3U5!47L8G)X.MF[ABX08LE8?G/T !HEB
M>@ "4Q<V*!B!7# X/XKAL2XWN1A^9^TT<H#KD8^/(].5F[SSLZBOD5V*^2G[
MN#'#.;.Q>Y,O$'W+EWAB]C.PRA?V5UQ((N>XBZ]WE?/+!C>^;@YB07"-PNR(
ML8\GMW$M0V#\,%YA$6N \."90\\'-TFI4SU'@ 6E@+^31?>DZ\ F*2/,*\U?
M1;_QE-?7ZB?ODSSA:MSEUU]^226K_$!(-/-;OPK6J'F!X%QV4)10EOW2RZ_H
MVT\OP"N]_.++QZM'#R\S^QCYE:OP;O+'ET]6/SUY]>+[YZ_XCV:A]*RI7JS\
M:J,=0&]_PY8@/G+(-<(?O!?O4V2^G'JQ>C*S\9 ]^<(FOA*-<[@NR\)00=M8
M#GW831SL/\W)T8ZV$]ICB>B;MK//B:^SQB.<SD#Q*/]#O'!8^87UA?]LMEMZ
MN$P0KG#L"W4<Q(@]RX\AX2O_%WL[Z%9@_.9YP,&Q('+/E:N880[BEL&)>D]Y
M+(44FCV/ :*7C60BKTADVN'8/;V_JW?P9"-OG'B$8TJQL]TAGJX_RA7FC L4
M/%N "P7V?VX_A'F$,9(^!J:9>V;>#1S4T3S/8=8#N)]GSLXBO_=\8S+##2XU
M>B:"(>HKQB<SOHOOF6BL"_P@AQ]7W-VQ;[HC'J\POJ$NL>10!A4$'JV5[ C'
M"R8U7570P2)01C9R7L[>1810A(XZ Q<05_/N=IEYO"68NE?'@YT5IKY$RU.3
MI5B#13\Y;844MY4K=L[7^>UZP]2#.?/$.F;CM$*$=@H.56/RVCAP(_^3/!$]
MA,G]YP4;@H,X&* ;-YS\UA[65D\*-/\2II-B"K?&G#+])G]#HH!@>YUPZF*5
ME.4*=4HY#T<1&2I'[ 10/$GCV7D?Y>(^J&,^%>EO+M)_G8KTJ4C_EHOT(1S^
M_/*+R\O/)1@V4?+G7W_ZV6>??OX^1\E<3C(A&*6OX$__?/X#2R!OMU@&E/P8
M;, TK>"S8UET)BLAL:A15_@ 2O=AY7_SYRW\#ZSYW[6:#TX"YJDSR6"_E)SS
MIU\]0H/^GJ/A"@(B5L1ZVK"G=_GU5U_80&+U$1ZRDJG&+TGR^>,,Z]1->U29
M),H-TKTP'X ]$7_Y96CZQ\TU.B/[\BA@0?[KJ/P_$M(8A?1#7Q*:'/^\R=OV
M!/[3-24";C N=E;<&U$S 7N,?T]..5IIQLI?LR."6()\>?'SZ]7XB;ARX;3Q
M9?6L@>WTR>H[+G6H_C)\\!.[YL\E)("PC@>M*,I2E'_[!KM/]"Z9E_3F, A#
M&^.:4XL%1XR9)$:"B[4=6O9*1T/NYJT"!XGOF-I%6FJ_ 6<7.^!0^YI?<:&!
MQQC_'3*K@>C&(T.%&9OGVKN[1CF/=9H%$N#?F*J+R=NE#<479LLV9,FOR\Z)
MZEE .8R-0W8<]  UPT,>[?N;L[NO/S<^0"[?ZS0K'K1O$.314]@2)W/,XM#M
MAE]AR[!_\"CS7>NB0E/^AHS'%'DT@Q1()6IX6OBBL]E$#QS#]<.AERFJ8$C@
MRY<>T?O?B]Q];RKST_R@K.00?/&;7"0[B(LU&9;NO5P4OVLJ!!&@2A)X8&'A
M\B5<L22O#0/@>O7,;1QUQCQZE&&F[,MLQ-.@5BM' IVN?,1 L$$9-SQC\NM,
M1;FPX5C:1/ 'N"">#E(9_Y]FS8D^>Q;C-^!O>AQSAY_\407"BK@,IV,*+3<!
M6*7V3]VK<(AZ[I5PQ%/6YC7NY7:-3A5HLO'3AW5K=F#\[\P>LW+^X&<%=I9[
M62/*Y[BN5TU5JGWY@IA^*)<^5D,'4<#_HC)G\?/0T<$<NYP?N3<;=^2&=74V
M.WP%_K*N^QAS#=A8B\/VX^FBW^ 64M9@$[W*LL'=\H*DKN)?%.Z(F3I^4'T,
MTM1$%")G$0Y-46Y/PL?>NJ/+*U9/P\X'?5QS74Z68$=^M_HHO(_1W-OF:)Q:
M_@7_./ZF7#I(I^+)G+=XI(N>;5M*39B> "XSM&I.OOO$RX1'S=,C\R2GPMMH
M/F,%L0742&'#RQ?3Q V^H-5'LA#0*=!5(%ZO8BW@=L1> 2.#'8?:K1GPZ=?O
MIY>\?G$2OF*KT8H^_G)L.>K)B7.-S<F8K/*+!9U+# 0Z=78F Z*K\:"40W=^
M1!>KN/7Z:=,VX-R4+=CW$RQ4O\#NW"W;SK=:IP"';J"&9=HNU&U_\N+;EW:S
M&.]"Z*7]2*_ZT9=X]T</,RU1%_Q^I\^21T]C9A@^@_%_14_Q-3E[?$%&3UQ3
M:Q',4XG[++99;]%::$;@D:,6('QL?"FCEV"LI42H.*;[P$<G7;H#T@UGR$C2
M7(O+3P9.BJ_J#J(YC0.%U3^;'IT'*C*J[]%Z*_15B<6=C!;;%5I%9;JD>FOU
ML3/+B4@2/R:,K>XJ>EX%),V\XQ'PLF/T.W*DO(J:M6XW#+CF'AP&$4WGP.)P
M0/$EBDA@E+C_DZL=#W<\DE3LO+'825N@\6@XGFJEQQ^3]V]RW5JTCC[07B_5
MQ>]?O(S]G['+*Y0,G2<D&L1-NE@]J>!KA*X+3 SR,:HIEP=VG%HG81FN%*&\
M&-WHY/WOSF@PBIM-+=U46$#T/2MBLZE0N=TT--J0[&2]"W^\1W4 C4^EM%(W
M1G^4MBLIGH7Z1;@5(]4[IB/:,AX)_ 257%1X%":J!T]<A943KI!XE\FOKOK6
M,8/.2VKA75H8N"B0Q60LAU@CSXM3U!SS,)<=>W8+2!+< *D7UG<UM+ZGE",%
M.#/@/##I"!-J]BP<6GFK&/?)CG95O@I,-*PV]+>G:O%X_(&%T-K2-G.A 9;$
M3E1*%1A+%A39D66$MU?QLM3T++[VG#4FLHUWE<[XOLX+]\M (.2!W0DM^<::
MSW/59]XA(9(JG)>&#;G0?=EJ]SH=OZ\=$U5)>L^4@>$O35V[*O-=SABOA%H]
MXI==>T4H$DIMKAT.5%A:6)4X8O-0MP_FDGIRX.)MG(#3&\'9@,!Q?2*Z.HP'
MG0QJW:* -]CM-M!_UD8MV5NN>B/^!UQ'1KB$[=6HW8Y"]!#,VA]] "6$WYG0
M,D1^:JCDEQ#G$/D?(OX1F9$<P39UDA-\RO&EM@I0"&>Z,?KU4.R<DM+P0M'6
ML-X,:<'NO8GS\#84U),#$H[_ >9CM74*TF#L4].>L@A70AW[L)A],AM\)/3E
M*;E/$]#3A L+ EFV;,O;"E'!&A5A%Z'$CL1,F<M6/"(W&"%F%5*\N"=$ZP(6
MY9I@6Q9K(J RXWN$16(3JDTG+A+>-P[Q(\K2 $")*S7LWV'F?!,H%G0=$A4:
M>F;$L@ S4S*B?:B/F';84-4_>3]S(WU6=@)@\U86'Q7>%@A_3]$#Q+B<,L-.
MUH"QXHS)=9!;7ZL5.X_-\LH\ZY/YY8SIZ:ME#K79/NNPPT8,>9S>(F@0^.\)
M9G([F,GG#Q/,),%,/D0NB,Y1]DO./H\<-GL*,D=V^P'1B-<P1_)].5E-$\(,
MCW4H+O?*>4VG[YXI6K=#6U%"8]/*R;3H9P?T)_L#S3'\R,(<OQ<=9R(X+.P5
M\!'H"9K-9B#71LLI,<N0J:C,^U;B21L7RY,V#Q'NE932NHY30=;E'><DS@>(
M"#@@/$"F4 .;JD!G1<###(P&ST%RA#,//U,V-=X:^F)=9_'(TG A_94C5/ F
M)U@MC:JEL(<HV6!PE?\0 2#2\MR7B%@9-6"]O_'@>^UWW#VX_4X:8"U])/O?
M;$CKDVD!J!I<5SM#^D+\NBQ"@\03"-7U01Y[+!0N:B.2[0,0]S,J[UKO=OJ;
M:TH3]L)^*]SZ346LY> ]N5:Y)WLLDLV5C^/U-NO_A,J4I%W^J.GOK^]E;OX9
M/?TS-V-1 JST-< EVD?/2X]U']8-V+L<.RCR2CJ^D,*V@]]OD*%YWK@H)*+=
M%/S&#1$R6*ZAU83 QG#V8?#LFTE_;&!U:%!&]19IL^FXHM:-.N49048GI5T,
M/J?)[(/RFE;GIF])D(>'779]1S$B7?5ZWU0.F0I;_6/8N[7?3V:1NAP$Z(\I
M2 T<J*(LC*]';JF/VW&?YG5>Y%E8@RU7/LQA$D\RS60782?FY\6GY(G41\ZZ
MH:ZT6(9BYA4MY9<.":KQB('1,\$#?>,? Y@R?"KI+W0\X-RV3,<1K2(1)M2-
M+2,P(*XQ1YQ$X/MPER[?.NDAI,L$7%X> 3-FRHR="@]*$IG8@;H!21PHE? _
M Y4SL;1ZN?H)+EP6.*%_P_\'87@W4*@'UN,V Y7C_;D*NSB13O,X'VRX4ZH8
MNKX]18M.QN(K,$@"BULF)0E9D@XG[V+UA! @0CXD-)I4XH*)Z?8A\]DTG UX
MAC\>]>7!P*Z;]C6GPSO?8N1;.0QWACDDV,2P;(R3>*!5QO$N80KW%!\CB'$C
M).5('1%XAY^RF^.K^J,5[F>%7"-:,G_4G?U6(UU'=XF=AA>P7#J$+"A0]IE#
M" GQH,.;>47-:#]Q,]K__F3]UY0C>EL=WW2HM5CD+>Q.A-M''1'&W)LQR?<-
M^FQBU 2W^NCIB^?=Q_>_OJ%&8R? ^3MV/7A^&CW&[8L4P7'[.-Y?!7H@C,2H
M@_$@A-=!,+7462+NIJ&77L"#<RKL@^>>RXN*F2D,K3^FP!5S?(,^TJBJ<HXC
M?9X>+1;78;*TM#&=+2S;14"%?PJVJ[R6DY4C2BIWP)32-\AH(KLB60,83Z[*
MP)&5$S$P1 [4KEO(]T0*0=Q7."8;]I."!4=W\%P9$4)#N^";&DU683>$Z]#V
M2ZP1^MP%&2:#-TCNPZMG$%</EP' R]&>1VXYX'4DJB'#1D%>FPTX#A$=@R47
M@?'VS48:]*ES=5)6Z3;8G4PE<<_?D'GCQE>2RQE )S*O5.E5;06:,G@\4B2P
M(P_G8?P*((@V-]_A?(M=9.:!_XY.RP^J2W;RC?=4[__[#S]E4R9P? [SBR=U
MB<7.?[MJB^_$]^M_\45,  W?X.8';WB1> 8S079E .98XLB E(A("8C[B]&,
M]"!/]6J>/X"?X^E/F7?E11!.0Z3H\49\3[UG],^LKTLI7GIE1Q@(SPL3P?1.
M#6NT62OM#O:7X(I!IW-'\**R$UF7XD+)&\BT#-!)AC0FP8&G&HU>*,40R-I
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M;EORVV2CL3>=OWRBZ;QQ"[CIC68H88TK_.<&7NF*&NE:GG,Z&->J5G[G5R]
MNX@?980*I(H:[TI" ;K*AQW_DPK\1D$K8G+P!=LM/%\_+\X:2?,9Z/\,KM#V
M$LI-+U9/ZM/,A$TF9H;+CZO#=5,_:%$_VI,]>%G,=B>M[,RSA:.M4?69)1[
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M88?MB*<*TSVY$+YSZEH[&TSSEZNTS[65.:,?X#FRHR8$SG3)K;A+HY(3Q&=
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MI:?H>N*Q450AV3&ZY3!'1'25^=5Y T-$Z%[R!_ \_3ZC?+F*3^I$<'G;@61
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M 0G6ER)\IDW[A/3TBC1DY'2ECF-:\YJW&IZ:J[-S#D<MN;6DZ<;00N2<W3*
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M?>[(S38../?,EMR[+O[RLHF]&S@@00*_F,Z@F!;A(.D]OLLX]+Q'+8&6*?!
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M&7^Q6CWQ2XG5IC'A]) ']O+;IX'N.4?)ORLDT*N(10(/U4(?"]>QEX)O"-
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MNC5A4;$?Q"IR;K;O.,@GBP1G35BX&;=UEXB#3EBSS$$]KDII/-UE(RSK^K$
MW;M^_&R%L+UK.Y!E^760BKY=0P=V&Z%Q?P,!4<XY0I40UA-9/25U=C?$.$_5
M!"M&>=:9N-FG\#JD1,8MKYL/G'](/]"^7>*?S7 )+DAC71=\$VE2%<=S8*!R
MYNLXN;%5'&!H,R"8U4KB/O5>X438CI7$0$EH/K&&20F9*9P5-GC4(1Y&Z&C_
M&6A^&,9 "O=N,;T <S(4NS3US+;:KJ.[H>;P:%A'E:OM$;:5:/<PUE;>7:GF
M3+'/!'%@I3WK!%N.A$XV#=&'LCA?E$R+P00#=(=@@6U,%3Z_X9Z7V9R_I'Y@
MTM5PAIT@'\\K5K_DE'ECKKEA%7?XP5!<;5%_DL\DH^;=8NRB6.@@JWN1(DYY
M,@CVY"ICNS 9P0JY+ZJV&ZU3I'#='#2O!W>\'6OW&@O1AC F7#A58G&*;37D
M'CVQR4B"H<9_P?L@</[N!ID>E)QYE<RT/P;#9_ _[,4KLT0Q^R*CT\3V,+F?
M8&9L@V*%^H[NREAJYLV0.Y')'&PJ'DR8<HK42S&/;P)I6&_I#X%4R]I&Z2-V
M_4CZZ+0&Y&[0O-]-X"B3(#8-,D.E(@;%L=H((X,1!!0M5L2,AD&BJ>*L1:[4
MF2H7 !#S5/AY*(WM0WLG':>?"?+TO-_:B)E71819*%T([0(T"<4V7:6&M\^I
M4N@$J!QY[:_@-7/[> C[T@UDIT@))P+ZMR#Z)7)0)PM*'Q'1V6!1,?$FSE;"
M:'&S>P9+.[J+$FX3/8XR"#0&%"7!4 Y ,G-; SI]DNNM8D<$OE'EH1/PGOFZ
MAX:KE"[5+;F-T#)/\6(',"_GT9W <UV!B&%P$7Z:P:YC9[54W^U;AO/"DYY,
M\8WF<LLU7.HZYM;!5%/TW?N>^?!6OT?Z4!N^YDUQ-6\24/KZ9OAQNDXVHY-H
MHK5S.HE-7Z6Q7#<T:G ^O]&HN1J@93P93HMR8(U/I*/=KW1<V%JOU-WN==+T
M8C;EM)8S5E9P%R5H.,(ETS#=E$IN"EOO0^? %9MD-)PCOW4)W5$44[)FZ[A^
M;2"@('(,V+XNREX&DRCHCF9]N6'%F\)BGA$_.3/64$SY24$R0VDKX.&D11=C
MU_%A4^F-.\%M ,;%-S/S2Q/$L:#F1O6QT)AU $R^4KHO(>H:ZBDS"C?[B,_J
M3=W-B8EJU- HL]OT&OF18'$N.@92$.3,0*G0Z=64KV/ 6AT?2N/P5SW'N?ES
M'ESA+H04/]+B]8IL9PL>C#+4[)EH?C7/_]S.N/A(E6NSPJ*HNGG^;MK<3994
M$[;;+05^]Z3W&%$#5BKG0JMNS0:1BPG@TA>UNBFKASI)YK%NC*YM<VH^[)I!
ME(])9&2JI*B)"+&CKE+O#D=>L^B++_C;+(JVWH&*\MG['2$5+LL<V\Q<*+0G
MZ*!.,!L,C ),K1=L>OMST]QAKB3-PI$8):2:9B[$W[RZ)?UFK._=J;]S))K-
MNQ4+E/.NJ".)4]KGSB9ME.W5:O T.)RQ@5R_)M8/FMQKQQQK)*O:"H16Q/TI
MU3:%2MIE.H1O%\R^F50EFOJ#&OT'$[!QN Y ;@(SV@7WP;-X$/S<@IUS+7/V
M-<VOS0PO-SV52EJJ[7(:3W)?(YC;%B403FQCB*+$!JQ_RV[5G?/A-#Z$'7/Z
M&<"YSKCI::ER4"1+ZS'"K43$,\PG%[\I"T93 ,.9VV$L89!&5TIJ.FKM<'(:
MRFF1SMLE=:R8U''0)75T21T;F=1QAWQ4W)J5U%/BK< A4AC\NHHCYJN%MNDC
M1C^VOD]@7\SFJ0MS%L7<G2!N)M!*-3LGZDGM73ES2I\=3CO!<F_)QA[#O)7V
MFJ:*XG EY38@_%9ZG;'\U8@]! E6DU/M8NAR#E/RAD)"5&(F&>+3+)'8G4IO
MXCQ+C;QRG\+I@>"X403EY$02B%D3I)@$E)QMRUF]0/8*]"!Q%ROJ</-K0B%=
M5#GNMC?1(SDM_UJ%EQ2?M&$/V^[(=<L+'T#GM\6GL-XAG',83ZFC<J=]WC'3
MQ66R'99$AR6Q>5@2'ODW;,?849)Q$\1@B.6@/Q_L>1-L(X,LSA@^"0+.&=X1
M!:94;X(!:VQO0XS#5F& ?9.1TET@M_U/I='G*"XU1%ZI)(I%Q2G$I4@QMCW'
MFK0J*'N:[@Q]^*X7VCT?#8098&=V,"4T*7$JA>W&!AN,MAK^2G8E"+%=(M'_
M*,9,.*D:TY93*L!I:Q6T=^ENRTQZ=-N/8W6C&C?=N<$&X<\]9H6-+I6&G,MT
M*KUN-,:Y'^Q5;*]W7GABQC=7>*C@B>''-N 8F6UZ3>=*N7JQOJG,;A'-.J(Z
MBE+9-YI0MP]Z!O)1*]KY_:SA./1GC&C?(I_"'&31"->'+*A6X48A?;Q0" 0
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M!^7&V+OZW"=LC8UMH-)K Z ,]R7$P@";6<EU #<!J/Q#%'WSK4A7!K0#*D
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MDOCPR[2H$NKCA-]GP(7&*H@6OA-.52^X]P1W83G]W$MT1_'-7_\+_J-_%R9
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MF2!^#2PM'./;8&G X^@U*ARGP!.O2?J.0"D0R>0W=AA/(5<A,KX(A;D]8;F
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M5(;XBK**8LW=]8=E#MQ;5"Z13*1KKD*8(H@B&(@5(>+C\,N%FB*J;.X/2/2
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M</!Q*=F#CYN7?-_*YS=948+V2/,M7CW1+#=3S?NJJL/SU/L5U(S^KDX2!D6
MQ!(5(F \6^KQ4A"<S)ILTA01"YJV,:A5899/,U( QBJ(0.O+893"2[*0<L=
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MD-Y,>%/KUCCKF0^O@?>@3_'_9^]+>Q17DK6_O]+]#ZAG[M6,5/1X7_J<:<F
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MG6$H6L@1)C3ZK6ZP"*RY40MFS897@0I=-9SU)1,*"H8CI$A) J+@<*C:U8E
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M<'(S<"_0[$Z>]]'4(_J_5^G4W&YEX1A+I5G>XK66PLTT(08+@0GJ?#;?W8D
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MWYO:3J@WY*-',">6^;'1U!:\"#%L;=#;%'+3]ELL?0(J7@M#OXN*8L]1@UI
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M.W$-U7JXV7#:(_J],G=7W4;-58PL)3:WK7F[HB.A?B>CB!:-/Y!T\G418/P
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M1$>:QHFTLK)23'L1I1"?3#VE:_N7N9V^IXX-_CI152&4%J" RY41%OQ=FKT
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M#<D5W0CSB6[%BQTXNN<I%J>J1ZX(3\@W*L7A.(!*@<9K(VFM3W!&("+;D7I
MX#-A& (5<2>;OE H[%+->RX> /MB,R==9MY+RZ>D6(HCFK&1(\ISW=)=SXES
M9($#?'X'.'4PI)>FTVMQMM01ZFX,K+V"".TKYIEZV#O<1^PERI=<M&5E+6@
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MT:/\N&)6VT8M7X5'37W4&J]#'Q)[._)XM<39N]8)&GV,/)&+C3S@)/I (,?
M/\^%.@PT:BITS%EK.5*WVU1IU(\'XKY2H_9KFX:B9/D<*Z+0LJV/@WP#9R*5
M\6:<\FJ)\P&-^AOR1!J5).$'#$&^2)_>1=3RM>VG-9 )(C4@4G-I.H 8)I ,
M(!D@AGEG,<S_Q!7)Z5WI^;T;28D0G9^OM*LH&5&*T&)$:Q.>9\:R/<7]?LX5
MG8Y2LNXN3'$3V<[*7R=;9/3OU]?XZX-'-_=>MI3UU<^_PS\.TTJF(CJ18$[_
M.NPJYM?]2@[^,D)^1_%H?>&/]E^+$N&_#U<[]+_1>I_,^VRRK*28YE^_"]\?
M9OAJ9D2P)X'['=4IX@FEGOSY/__OZ?Y^*:FL9)NV\^,01GA"T/T*D%AK:4IV
MXBBBD175\/M_B&8@;MR#UT!_1P\1BA^/D0@T?DR 0L+_;^;)WR,R)8YQ+JZS
M3RBY5Y)94U&]']2O?\=QAO@'MJM'+M\/1S%#5W>EO#B^_>E[]N(' G\GGI\\
M!G\G\<3A?\T#"_KKH/X6,U,G<M?_T;.EH](2_3T4TM /-W??$^PFWO_HV\]>
MQ)U1-D<$7!\RAOLH*^+;\O*2YL=(*L8NNB"C"$91""(@-"4*&"9! H72F  A
M*BG)E(PAQ.3;[EO_F(S4)[3QWY-GW[HGT\0VY3AUWG?LG)UI3<60;)+BQU+L
M/F0JEA0J[,F.4KN=LDL_5$$%1=4EW1,HFH3QU.XK//,8NT6,$GRZ7OA_\X@%
M(G9H*-NM:(5?EMEM*'[&ZT:I/M/PLXKCQLB_Y%_[7S\2(7V;_)=N9;RI[;OA
M#L(C4]:2$@I0' O+B/-0?WGNOT^W_$^9 J]<<Q$I$AMZYS6W%SM%5A$9GI "
M!,.D@*$P)$QP211@$9^H)(43*DGLV5,\Q-*:XH3M# +'@G1?E.!R>9MK($P4
M"4P,=:HEJ\-@'8Y?BD+9ZO-]J+%MQR'#ET/'^J!I3=<3CN^.1,E7O<60I0,!
M$>"7(PFRX*Z&)IEGN]N*MC*\]CR_B48FOK[1[=&LNR#&O#YO,UQAL&UXO7C.
MQ*1K9P(QDCV%(*5%4_C:MXH+-1Z:F)4>-^$27LY565'*U^?%GL-1;#L<FMQ4
M1R='ZPXM#OF\;,Y;"T;*M0M:-!1Y.;0VP!AUBQ.<(<IM:X6JWGJ[C1: X"^'
M8O5!>;QQ69)5FH.MVNZYE#75!#1)JEYGS8_Q7%4TN"+%KC:-+;9=12/1ER/;
M4%V<9#>LPM9J<*$MC]RA5FB'(Q/;QXS"9*:.R:4Q;_$;KK.9M^;M:$[JY4BI
M+;0*,H>S!D?,ZD'7\2PS9!3T"/FMSMSH]2JSH9$=JY#D+UAXDH^WE%@I:_C4
MJ(5Z*,19RS*^<$F'D*.5)D^J480KS%RC-4C)3R9J#9JB A\-39Z451"*8LVV
M/;;;,#U[,,3X<3<>FCBIB=X0Y@[L3HUY@$)5>SPH])!X:.*DO%+-*37-H G5
M<GH'#; U-QYJ0GBMO1PYR&L3'/>%-M]M$OVRK_.2[;;#D0E2"37!Y_F>*AM(
ML<$X]7J/62ZC.1.4TK+V=FQ+9H.?-]FFSU)JMLXQX4@L<5+AJAC-R WXC8C1
ME(6L4+\:C4R0M-\:KK1.I=8QYMW9!,\6"*M=#\*1B=/WZ945H UTS(H&H8Y:
M\REB]*(YZ9<C%1N'I\W"T GWCL'=U0@B!F0T,GGXT" HMB:,2K-SI\K/9^VF
MFG.CKS\BIG[+=Y6LIO/+,M3?]H5@U9A'=((3"UCT9S2IYF4&R@^1*;_ T!PW
MCA:0/'R_01)^D#.:[+S+M1?"K&IG@V@!R<-?<0,)8VVF92 (GC-M>3FWI$#
MDX>/BUZG+PQ&,Q:9MK3.*,C/Q_5V.#)Q^%[3&UGK&C[AEXH\@DJ25:^7F7!D
MXD@562IW6:(T@[AEMV8/%,Y5J6C.!*&6FT8E"YD-G-=GN84V@-KL(A1H/'E0
M?%5PM/5R:T/$1$)'7*[>"?DF6F?BZPN::?<G=6W-;E9%1(3715Z>1$.3HC=I
MZ&9E,G!,:(YJ*\@HM#8(%'T_DCC^K-PLLK-%.US 5H1K8YFK%>N:0"1)6L<;
MHM!A1Q.>,WP3Y:>C*M6,1B9(6I]I<M.&\[RQ5-MU7%C0X^4R"$<F]K0DE+'/
MX5"/1;8N677++(D4&8%(DC3/#SA-[RQJAMYO+J:+Z@PN=:,Y$R3-%0LEIXLI
MM#$ODLAXV#/G#24:F=219*%(BT&NW^5]A['+MEMOP%H\-+%2&*VUJL-&OL+[
MDP&_6$IKJCB/5IJDONR5W!)?5]<&PO*K5C.H3P(_FC5)?;^'B2*]T0<&4M?+
MPUFGW,POVP)YA/J]8J&_@"8*A*SD+#PNC:>#:30RL:EY8RB5A,6ZPY9R+)KS
MB2K;KT8C$WO:(.RX7BF'U\/<[^ATO9(O31@F')F@_JR9A[O^H#,-K]+ZQJC6
ML$[5#L*12<%OKTQ+; VG1BE0YQTJJY6ZJVC.)$G#W>?J-AV*/E*I^0B\*7IY
M30N')DE:7K0HQ(1:%-O5JML%"C?RI![M*4G2>;D^:V)E= D1W2%J<I.M@DB,
M0"5):C::L-%2\BZK4^%UEBOF%DNC'8Y,D'3D+8>=DD7S!N)753A0AO,&$80C
M$WN2;4MI\AM3-[A\;E!JT&4Z4*)O3Y TJ+2V'=BHT1 A0>ZP.QOFQ&XT,D'2
M/M-J36420_F!#RV,EL>:[4"+UIE8*%^961:]-51>S-4Z8V:88R=\-&F2^@9&
MJZQ<JTHL8G*0N\3&?F,8[2E)?5&>%B#147,\L=DJN6E!Z>>JT0*2U"_66PL7
M7F(5B&"%T+)HDIBN,P*=I/Y*+[A&"V&JAK(DPG&KIB57HY&)3;4L%Z[JJ%8V
M$'Z+=^RZT/*8:&1B3[T.,[/FULKF!^4)A5 5KZ.5-8%.4K\C+9I<KUH+=Y_-
MY[-3WT$&>#L<F:!^HRT%Q+).U""$0QKM)6I:L!2O,[%0N"DT&YT*NV1]41D7
M)&(BJ$$T:9+ZRJA;G D#> LIQIIJT,RL[A7B6<F$CI#Y;+M=)V0H7^A[2JZZ
M7H_D:&B2^AZ'9Y?L9ANP\VE[V.O0XYK4")T#*$E^J[,VEZ8]+T'<O.>WT W:
M0&I:-#2QK5*]6&F/E[D^/Z\)8VCBR5@C%T1#$]MJDE6VB$U7.0@1>D%K[>G3
MI1,O('$"YK(1WC,P6S.X!N<T&I+J9\-[-QR:. )7[O*JHA56;![=,OE&O61V
M9_&LR3.8=!17G75G>2-+(M,A5.;IAK(;FUCML#C2:PL1IUG=;9H#SNVU*"O>
M6/(45BO/,D9\0V5+?HD6FC#3+1GQ<I/RLN@&J%!BR="=FQM;NY5C@K(9K@%.
M'L.T,84VPP;D0MG%Q*DS@DB6VT$T-+&SZ;Q0'0P8M,SGIYT1O5Q4NE2)B88F
M->MJLVE450WE:U*QT,)GT*!LQ+,FCB''X>.2SK6;4#?77181;5V1F'C6Q#%(
MU;ZP;9=;14.W48SC:QA1"Z]U&$EN2X:)DI++!3DVZ^-PW^@JP1AK1T,3"]AT
M"JMUE>!(MK;0BDZ9G,Y8+IXUL8 Z6Y!'S#K/A.*]\KHM/I_=5N)9DWS@694L
MVIF.5L9@X$GN3 Z@2GXW-D&N":N, F%-!;R^*=%975>J[>QN;((/=&PQQYM]
M,L=V5P9&<)NIY'KQV"0?H.7U6E]4!SC4W0RG7 EM.<8LWEI2=*?8&+'D(N>S
MRU9=ZA!FL9,?[^9-D(R8MIP*3.5#0OG<RM_VAEXI]"QA-'D0N2&\@)U9K@IU
ME]B"K?&%#1,MX8AGVQ\TA@@_J*ZA4KEF\9JVA%T_GC5IBA+(JAP@[1';Y;!-
M0REN8#942? Q-U#N-NL]5&8GT" K:2)1#/K53;R")!&&'N4W9Z%ES6X*&M$I
ML)-@'!HY\!'O;CG(X_AZVH/8DL*I\YE2=+PA$PU-WMX.:Y>6(\<([0RMX+<*
M8@O?QK,F*$OF%T250)T2K_.-.1Y>">6R$@]-,&->\Y@F5?8"=H/UMS:R'G2I
MT":(%I!8 2N6ZA89NBELJ25AA>G6;W3'\;1)9B15OS?5B.7"X&8KM<])B@@S
M\;Q)VHX,NVCG-]N-(4Z#N:S*RK M:/'8!&VKM;D%U8()P2Z[A&GD)BV24-M1
MU_O$M#5EO.4;940Q=&M%4,)T61FB6C0T0;"RA_6Q9G.C036Q[[-9K5EM64PT
M-$&PLLI/Y[3;"UTH$9=M9[AHSXQXUN3&FJA,-JTJ0H:7;M/4I+&5#[S=V,3&
MW DTL[<K6.(YQ+&V8J^#;R-F/.+"3$8,84(%JP5U&_D!-H6:=C87#TT<V=98
M05K;T A(M.KELME:=PPL;O::.#%ZY6NV,=(*AKC <EZ@-CO!<#=K0GVLIT-O
MP(:WK<%UIGD/[O>,4-2BL4DB;.=M8JXU@RKD]\KS4FG;Z*!\W)[ZB!N7->>P
M)U<#7N&V3@%5G6TYXD;BB/K84#W<D[?CI>$7R\:8KT]@N1*./>)U,'!E28GU
MU1 :2*JQ+LS6Z#:Z>8^X'7THG]4VV5*/SZZI?KN2]>?;@18-31!L6FXTA()H
M;(RY2,\WLS5;1>OQK,EX$XRK0I:J#'FNU:T6M%XC!P?Q6A/\56+QD'/=89_=
M;!"DI'O+/MN-9TV2=EB1IMELE]FP W1C%!J=V83CXVF3I"7I;IU9*E4*RF9+
MOKD5UWPMNG>/>!1Z?V,9K(QOC8U)=YD\@A7Q3CL:FO32W.&B@CD(RQ*6WJIA
MQJQ?[P71T 2YMNJLH$I5NFH@PWFALIG6F6&EO6]P\WPH(JTK\S&[5/C25@ZO
M)6VUUJ6X%TZ"7)#&]B<A:X6V,F/8QJQ:&Q=J\0*2^FL@;Z-(GYPUE#)JU)?9
MF>%GXVF3^JNWFM*LTFO1_!(5+,\K00MM&I,K>0Q^>V$OE[HX@KB10I.2;(Y=
M)YXW>0SE)=5K4[9<9K.!TI;I?!,;9./&#$FNA22VHG;[)*]SN$8A4Q2:KIEH
M:#)4,=Q4IA(R*/.$.O7M\; ZW):#:&C22B#PS;"R;C>-DB,/%IO)+&=SVAZ[
M_85W 37J&W&-MZ':9N LM^:ZI?5BF/?$,0P='E>6;@TV\M4IX:]5*+N$XZ')
M8Q#4%;;6M"UG#!ASVH#&*PWI[L8F5IL/Y:[4[\.<X9?&2V\MH\RD&J\VJ91:
MICE16;.#&X2I9DT=QJ35#I4^>0P5C,7[>;R*\$M$:$!9O3N2"C'2<>(8VL$$
MWX3?7844"!E13I8PJRLF&IK8674T#/H+I5E@!]616V\B@@+-M&AH,A##E3K;
MYE"FC:S3('VA*E7&&V:/L_K"]"BVA6)IW)_R_E:72F:.4.O9>&CR-J_U%[AI
M6D-V7B[6!FZA)?MDC-Z:/(8^WUPR>KE1Y1&O4V\ORE37\79C$ZM=:#8O;M5V
MW] U4B3LT(MWU_$2DM* $RUD.7)MCB=&QH22I9X:-:!#CK@-3;7H* U$6O#Z
M*%A4M*+84(UX:&*UHF(.6PNZ)?#(<DTS6,YE9^UX:.)LI76NU$!F9&B*%R7,
M&>DYK&>UHZ&)?94V>&?!%W(>*XZJ7G&$;29DP$1#D_'M]:"\Y1I\ -7:IJRB
ME$V-^7@!B0"WT@H9P&RW*P8'"]D-!5GKH1U$0Q,'5LQFH4YC42>@++RH])%E
MZ&I7XJ')$+=?]\MJ?>38[-S41;8M]X?;8KRO9(R[7&P.1O:4*?$ECI2HLC )
M8J:%CP2Y::1:+8_8)@-M*DBC)76:734;KR%YN"2JS,L(VFR'\PZ7'I+O3ICY
M;FPB(JY;@V95Z74I=MZ@VSPF%9G^+%[#8T@\3G%YS O9E9E(MFF*"U?Y<?C+
MTT?2*)UB_SX:Y1!(N]R#0\9-G+,A^IY]^,$N:2/^R;.\CB?9</LQ4"(IPW,.
M"SL\R.Z>7-]75(L0W['?9O,_28QX,K\=SJF:=G!XHCW\.QNE^OW89<$$(9W>
MS$+9)Q_%7WP8*DY<.RJ,^.KLD]<?JJ,M?RC]:O_G'Z5*XM\)<#!I/!CX._+;
M!I3@9"YU,M!W$BBS5)X,_AT&VBR5)Q-J,PR<3!I/AOA. 9E)Y<G <98V.)GT
MG0P$9":E)X-]AREP,FD\F= "  >3QH,AOT- 9%)Y,D!D4GHPT'<2G$PJ3P;]
MC@%EELJ3 <HLI0<#?2= .#.5)X-_1VEP,FD\&:#,4GHP0)FE]62H[Q!XSTSE
MR0!EEMJ#@8'(I/)D\.\$L,Q2>3) F:7T8(!EEM:3P=^ 6@8G<SF90<'!G/%@
M/M@;Z,TTYM3A7GT0;56RS>B'__V&??OL]8M\)XF731+@Q3H3(Z2EHD?"%T&'
MG3=?+G5D^A*JO)6K=I]4>2M/[#ZI\E:.UGU2Y:W\J/NDRAM.XWT2Y:V\H/ND
M"F"53^3#W"=5WLI%N4^JW+@ /;I0R&==*.([=%XG\^38T$RXOB@Z()J/"-#W
MQ2.7\1'?BJ@",KWKX3F%\B1)_MPW8SSY.Y6H+[J*?O^^>I]4>>MM\SZI<N,"
M].=F"_Z=NJZ(Y:4N[=\^Z=P6E<#[RH7>5_:_=_:/@E_X_')R8Z@;?D/XY4RF
MY2BJXCC*OH'.Z0PC[)&>,1S25;]6?3U#HM\1\J(/?N?BN-SY. [HN#=T''Y;
M')6WYW/;^K]_P 3T%V E$$O[#:NT1%V.F\+!?U6L.V43$$Y+,9FN+YP6:M^%
MHTP5R]57"@BH?9GJI:Z,3YZ$70&3W$C0Z.1,TK.]DSUSG3L6])G-[XQ4$,(Y
M>4S]MCR:;M3XUSV=FDS?5;$3A.2?)]> -'I7\3PF;A9]&]&[L_'5GZ1' S5S
MJ3SI5*L9Z,9B:J?6(]?)&7^2VGM+W'!J>^0ZN>'/]006FV*WQ!E 3YPRE'Y+
MG)$7%_KIG/FK98T_B9:#.L^31--O2:HJEF3/KR;,GFJ%2]T8:Q0459=T<!>?
M*&Q^2ZS!+OU0T8*X^AMQ]8DH&9H3&K3RCW](DJ*HZCGW21_;Y[-=Y413M"0E
M(WJ9JFCYHK/)P \9!$+@DP7-+[_C)R<;!V"?+""#AO]!N__"!63BS WD%/;5
M+B;^M;O_/ @+_54/*;O>:RE@BF=4^>=)N!T^SNZ7B_VG2AJPWQ$G+8F[J9*5
M_7/ Y67E0BP31?N! CT*BY("ICBY MU!FZ1@9Y?2D(#;7WOHN"J>^%M?AYNP
MBHXH147U&=_2O8ZB_O<;'_Y%Z'JB)8N.++CQBX?@CIC>S&[2#M1EIRUF4N=&
M4H_YEHF;@:]W'V1<@5,%&!'0J(LY @F^F]5$<1%-YBGST%O9N5]1HJ1MA?]T
MF;7N/H[:9:_'>>L-93Y1'(''-VMIJYHX.ZA62*<O8J;&M[]E9$72YZ+I_O=;
MI5G\EE%M9RYZ__VFK[T?EC^7;6\_X%O&$N<AB???\&/W>E-Q75^10Y\X/-_P
ME]"W0^]TN^VN&YQ;:;"B["IYN<@5)*,M8 (,?_M)X/@#02!__^<YV4X680 R
M=13L)04R=?(;9 ?8DH*=G5Y;\-V"T*'K#6^D]VUV6:A)Q;R4&S*SRZN*+/H1
M31%-/;7-T.AW=RMYU!?HH[YHV,N*OFB7+,B?DWVAQN%VQ0HB?8%]^PD#3?%U
MFH*X66<]ZLR3@IU=K:;XA1D453Q5K/UC[%YK]"FVQU@:ZD'=^5I;U.PQA!MG
MUAJ<OX%85=V6("2[K"/UOFHV%2;2&N2WGR3Z0**W;63\AI6 +CFC+MD_ 5]^
M9]>K2WX5[G#>5'&>%7SMWJ/W>J766+@<G%4U:"D,LUB5DZ=BY\QZ136==:=4
MLRR6Z])Y7S(I:[2.] H"A=8(=M,Z)54J9 ?WE )!.X,Y0J3>'(G4QK_2I3<Z
MBB>&.Y!9T;%"TKA[)6&-IRM1WQ(S2'>[%6,C\F7!/;&2""D43G-$6\S6?(7-
M-VR6SVY[H_*J&5#F+-86Z+>?!/& 8TF-\6^@,H#5\:FF+RG868JL#KO@=OEJ
MH0A#\UJ3:R[9<;>A!^>U#K)!@<W/Q&K/&/AL3FM!ZIQ::)&\$Z'7\1"R\SD,
MA#A#YE:E/74EJV]+=!3ZCA-I;#5DT2B&%GYGR#V9D*4S@>@X8GAW970KXE]+
MV7%_H'O3S,*?F+H4?DP-O]323I5UDV(E<.H4FYM@^3_,I[EO&NPS;T":S:7+
M::^ 5\[>@2A-S'"1MD*I.NX+-1%*%0W.WC(H32Q_";R>5)WVV;O^I"\]IN [
M8C25  NQ(P@+/?N76PC_\1,XI#H5OMH1*A#'%:>E!=)S1\-/9,M8SL3>.96,
M)0_V3L$N:2;<0GA&K9#6MKQ+ICF21D/D[9KB93M=ED-)JEMPR$FCS0AXG$:#
M(,0#C>)GBT;?MU1=J$%2JFAP]G9(X!Y)T6E?"$TS533898FDF.-/'% ][47Z
M^PP1S:N7 UHH(BR"FUU9K;;MAL]\.%;[SCNU+YJ^<B1Z2VR+[JC20BQV@$M-
M!&6TQ=H(HBN5#*]4["%TF&_G1KV&!!% E*\%ZP5W;HI.^T+]K%)%@[-WKP(<
MGZ+3!E;FX24_Q1S_Q5;FN%OHTU4AAT'Y=KN'U_*NVBAK7VT9-J%L5?>1EFDL
M!WQM2TQ*<FT<68;1N_[Y+,/+M!=+SRM^"A):GA&C%[*-N^=[R7:_]!$_!;0
MT!GIN2<N 9UQ!60!N!L =P/@;@#<C1O$W;@"L@#0#L 3MP#: 7CB]D GKH L
MUXA8 43E]FJ6KH LUP#9\-<9:B2O\%'^4$#%R#/?]:(UN3W[E6^.([2[L.RA
MB"8?Q=F.A&2G:)ONS8K-!=_M+ ;(<&Q[2J4M$+O'^@>(HF^[LC+=3]7I45OI
MIM,UPD6 *__VD VN@"S7 (L 1.5>KYE4D>4:X  N81V?*)G@3!;MFH1+F[ZC
MJ=!RX))%H=71H8X66K1QDL'9+%J 'I N] !VK3B2[L;H 3O8 'L1';8+X
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MK5GQ+*_AN^8PVML,-!.'"&6&>:RZU#J*)E#QDSY!(#?=UCW=#]KI47'IIA-
M$D@%DZ2*)P"2 $ 2 *)R9==,JLAR#4@"MY5]< 'KMZ&,5[8M5#;L0%W1/7&U
M@F=8.[1^HV2%,UF_ '4@7:@#1=L)?V5E)-]Q%$O:9+RHUX$9,U9&?.1)@$$
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MYN?_^P=,0*>X%P"2R\UF$0$D%X#D I!<TLQ1UX#D<N[<#:!F #[(K>"#@,H
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MH.#^(P7W0+M_JB ?R!I(D_]HP3[@&< S'RWH!^KY4P7_0-2 J'VTB@F(VJ<
M U)'MG0_<:=&*---INN1TG33\=62=W!#IDD84\4SKY;$IT[V4D6V5TOFKTC4
MTI_OU%$\,=R0S(J.%5+*W2<W<1US6)KT>0/*%LA621-88])E/OVJVU2\7>Y4
M](#[NX=;2VNXVRDR=?B!ULZQ@EM93YI:N#$!0;_]A-$'FB#/E\0$5-?5F@VI
M(MNK$ 9 =7UE+LF[M0YLKU;!?,WH[+)'\%/4XSL]IAUK'>*L6@<@$J0+D2 G
MFJ(E*1G1RQ04*;X*,RC\D(FX\V1Y),]T !KJ -GV)Z:21B4 < J^($4DQ?P@
MA?:BXCRGVC]/C4[P^LY!3@> +WAW D>*Q0C@&UP@-R/%_' NM;I/KTCQSD&-
MQM=G3EPQ.[S3_W0C<#I7<$=,;V8W:0?JLM,6,ZES(ZGWP@5E7(%33]F=?HEF
MY]5&3I=8 I[_?_:^M#=Q)EOX^Y7N?[!Z[HRZ)<B8';J?MR5V2$C8(<D79.P"
M'(P-7ECRZ]]SJFQCP-FZ0T(2CS1/)\24JTZ=?1TURZ:L= H[GK+J5>DEXP#I
M6=@\0-=4Y5U3M2M<9^=D?*GR=<'LYQ<W1B$V&@^B8%%'OOV.)D+Q6#+$1S*?
M9RKT29&4G5ARPB1U+-EBYX:<\,G?N$GG.W"2E\\5G6@*W)?!=N+C^5JO>^9%
M)1HI%MMWPVGT;MR*"XDF92=Q9"<!&SFF7_V$B>EXEC_->SGADW\L-O+XG(SD
MJ+?JY5.BRL]F-_5U:6,T%K&_'%7\%$N9FZE!N*28ZR)IEKK"[?36R!6RE*6D
MOOV.1%*A1)3_/'SEM/-5OBZCL3-U3OCD@2W\]DDX)XP.QY.XR0\F<8\1>OY+
M,?M FLRJ?VM(L4YR/!4RG78C+5]TE[>O+%\?C%J/ZS<5U9IT*]-9L\OG.@,A
M.K:HH,5<F4PBE,H<ZN]!PY] KKY&;LL)G_R]%7BMO(@IY_W!>)K/%285_O(^
M5A=7QU6Z(UHYIZ_BY=@T*8TG::F=GW62U(['#)9H))1*'$7G_F1-3_YK"H#$
M[[KO]//W?7R+QH^)M GA!%$$.2FH&[AK3M5,8IP=<T</P^VED))D8ZX(&R0#
M\NO5-HF_/^=N?0_W7"25Y.7O?^ _SK*B0@0="73RRSD5Q5Y[)PYOCJ;.8@G<
M'WQDOS:6A-]M4<[S_\;]>M;=62PL$D7Y]5C:EK/"6R-C-+[EZC9G3Z<\D/+\
M]W__QWN^;;I=6-043?_IB"P/0.T=1"E'&Y/P4"?"-"R,X/T_!64E; S'RG1S
M,WZZ,B^&.TK_F[/_1> <7-Y,6(<]\+/9IIW?P=,@OO.9G?UB?Z@9U-WS4R<X
M)V=)]B[/OGM3F_^,1LZ2N_<>CYRE$@=7?W2:I3<4VU[3/P(WT5%R_JNCB;ZT
M@C\#B8* 5-A[5FQA^Z-OOSN(FYPVXO(HB$%9=RE%>)I:]F'O!U*!"M;!B(P
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M?I;,R.W;ME8F1;KJ(0Y(,U-)%L9SOAZ?W)8O6A$E'Z:/.GNE#@77"F<.9+#
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M&_:]7LSJ%# C8 %OH>F=P@$_]UR5O^(!B?.N<E?+;<;=?O?^JB8:%YG"F/(
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M4(KPLXNK^M6B>-N^E%<GPQM&Y>2H)%<MH9N\KQC#Y<KD^>LL[AYS 7G?XHG
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M$N*N<F'GGRA# 3(30852R=F;*=V>@U%W<^H7['Y.F(%FP%F7F-^G&D@(>&Q
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M!9,'##L7"165M<R::%-Q2"EEB(D)F.PG$^;P<S';(]>I9]6DO2_-K0<M$N6
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MTLI6%O'.*1>G:]!GO3UO!',KE=SHPU.Q2(<W^NW5V18GT9X8GN>H44P#C\Q
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M=0;0(,S&==1EYMEP+E.ZBD[#ABYD-MWBO'KS/E&0E[O>\*A<SW&I;VG*<]S
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M"B:4LQI UYKP[M*Q2$2WT2=M[7?&Y5G,4Z'C- @M'3_YJ=K8Z1>3T%=@[8!
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MP:"XZ=1+D4TW6C96X[=C%Y%\R>S%S$*S6"?]D1Z++^+*.7!RGW#I<Y#*92F
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M03D37+4(TP"1-+?*VL&ZU#$@'JX-A#J$OVFJPV[9;<-6@2_)$JA$@KSML\-
M+=F*U@XC1DRV]2]:GDUY >NFA-J6!4R9L)0IU*Y,V^N,7 VSAI"?[F_:SWW<
MLK4JK-K[\;A*Z578L*_)4)''3J&)97A3AVCJKV!H*@WFDA%F"U/UT<Y?HL#;
M/@XO>G.?YXFSLGWH,W>376%+&=(N/N]?Y1D6W7H>^3ZT3":"!%V1\8JW59H_
M]F)F^";JYA2PZ]><F,#T0EN+(627Q\X%60I;\Y"CF(='L%?7B-B*Q3T<=T,R
MM+D;RV>GM+=K7=B8$MI%DY!C7+CE@BO9H/2G:/(#)H>/Z77&%66:=,YB@S/!
M4X3LB_RN8:=MO^8&P##974<&A%DE0&TC(#)M14F8$U%K "C*FH14*\-9))DE
MQ]-;=)00&6/Z2Z**&PX.CGH%"TNC0J;MO_G,V1]NW+OD$X>PQ1)] 7,VN"YO
M^^YM-Q@@%.IXPF@$%$$Y">4X0_LJ#2:@:$<^'>LY@:F %#%"#F.BY(YK&2!%
MZ5VCY2KKTC88:Z^PLT"(VYK3%++:2L48GSRGZ=FZ@SI8<6#?!^6I,A9#$!7N
M2"2V)DUW(J(NJ8V<(U'/(>.S6Z1\6'W#);:>WQ<!"*M;!5FA+,]6OA\76:X*
MB*JEJX-LG++YI%-*_^5Y8\G2D0YF8'V$;,5LR\B<2SZXR:&K (ZV%T@O!-89
M:TAE3%[M]?ZB7F7#^2YK_ODD'^20#X:VOI:0ZXS641R&MDR5>4MTG2PUD4I*
MCP>&]BF +;BY@]Z\E"![\#G9@XD@>S#('@RR!X/LP=/-'HR^*'LP]D;35&6X
M!&HG6DR-IHT$7;U=E['09!MZ]=2D4&W.HZ^[4GEK1^_5G=#>(*@=ZH)$8!-3
MN#6LBI%'&WR))V"+#Z) IUCLAG<]-CRJ8NK8;C=B^P'IP[;XAKW-45<P76<0
M:*&Z9AAA8#I$Q_9&CE&R0;\0M9R?7'_'2\#*%;?=$IYE5L#-@D(NT_=3C>8C
M.X-\VF))PL:O^LO3)@B8$WS6H%:2QT.46T0N\M956^3;]2LAF;I*5%?)%0AV
M_L _!.]PTY%6NFP"[T=K5[:OU';6,EN FL";';UQ1([2$N9O(R!_?CUDT,W<
MUWM9L]A/7Z:NE)@4O>)WVZ,F_K1:KXC@\]Q>B1#?N$4MM;P=1!6^6IP1.5[+
M*I5,2VY^^QT[.\SL<"KR N?/ P5;NPU9=*<#$]B?HDR+"%7;DV!N6,0:0QHZ
M"S1H=AZJ9IG G-THN.LH,=%Y8;AI>XX%#5_5:!<;[WM&H"C;3@G;T/>:4[0U
MS*,QDH/X.@O-T,-@UX%WZ(/R)@1Y/K]:F=D\R19E8QDE[8(U7PX>ZU?\O#27
MNFX[_9P(9P>D]!AC'+Z9+_UL81[-:$V>S\?+]]*EL!XWE\WC-:D[52GUME#O
M]=2[:+^3GW3KL<DT,RYF(_V+Y@.=[O89HV]?=-K4;*_-T[YN\<59Z=_G,&6O
MLD[:O7OUG'/C[W 6WJ_NA47\;2G![_6.$1>6C.'.XV4F[TT4^O_LO6>/XLJV
M,/S]E9[_@.;<<S4C06]C\LS5E@@FY]CT%V1L P9C@P.A?_U;R0E,G(:F9SC2
MV=/=&%?56JM6#JCU61(NBZTC^X(F9=99,@-O]^[#Y,X6<H-^M*,8J=D\W!SH
MX9XZ7.4:QQJ>'-%==M=P9JUV%>A>+Z"\=$W7D@1:WEFJY77NK6-$<CR32Z7T
M25#@>F,T4(,ZD*8*J<=5)&0GC\%./AEP>=?0"#6;]Z,@#4D& ]^UJV"<K7D
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M,(%'#(B; /8^_LRC?P;Q;KZ3?S>ZD<[RK;OILBQ5KJ:3GB[N:SG/F;D!42H
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MJ&Y';7$$Z/'!A7;/K/PKL_+CSZS\9U;^,RO_F97_R5GY1S.6[Z,DN(NU#S>
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MVD-@KZY_^ ]W #@T6@MP$$EPJ@YD%HI&8M+:S\<"XO$&R!:W?4$=CP]K^I(
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M8#<_?I&=HS(&-,T4NZE5N*CK+=C=NC]^&Y*#.63+[YLKJCYFQ_#;L'$#;%\
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M8QHY)BLZP(I:?\%4,KAG1'"HH 3]&7R,U_W?_X02O[0S0H/8?8R\J'O3([T
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MTQ1)]^$04;E!]V$,W(Y!_?P/QPG":'1_L)T TJ&JH ]CS%\ !H\@Q;#5^P6
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MI#IMGF;8J<)VC+Y4S>8^-S,%(6<>+Z]TI2*-9P$NWRQWYG)(,Y('_-WGZ#Y
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MYL4?26. G#X !0D^X/^*M8+[F0M$0/2L1["AJ89D*4"+$@!&]GVS,=OQO:<
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MAPIM/__>&PA[*R5(V@O5_#CBM:>M 2\#-H,QLN+;%@ (1EOOD1D3K"&9^/$
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M2A*PJ3V),KT1<)$X^@_@S@),204OG"O.U)2]S[%_$MZ4;*"6(_ GL,@VETT
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M!$@LF:)"4G#=S>,,Q_XK)J86M%/_U3&ELRE7\&=@! '#03])NPH^ C:*I])
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M$'@E"'RGXJS'N3 Q3$0>)L[R_X0$__<OC$;_"?\; \ # !#O!0",3F+T]P(
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MC1,?X]_,M6'3NV,$1$\;0@!]V3?U\^+#8,LV10YWF?9:ND$-NKM"-^&7#,Y
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M$*)0L&)'$K9+),_::63#J=)D,YG-M+P\;0HD#&<AZ#OR3+)JK/974_M@)XP
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MYKD,8&$AV;/E3)ZBRVPVDZ\W^MA&7_L7-J<CVQ,&Z_4Y7=:RXH#);Q?X+$/
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MAUA%8A7YKBIR=!:*=23R.O)R)YRGFR/%TG^9&*US8A\Y%V!&U$5#4J O9*2
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MF#/1Y$P,9Q$IHO(4BUX\VWS/0/273*"HK_K0R81^JI/)2Q0@;E "X",10OG
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M@6@JF3VI@6%BP[%]HI(Y82W)5'_."#UAKF5NF=+I0(93*,PEZK)3TKZA9,A
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MM1W/_?J_74OZ^Y\7'SLQ'9[3 H"A:E;*AMG1#)"H:#L21T55W.8U%& E>3D
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M*S((.-0?S&^2 =JH:3M$K(8CY(R8V/&LGS!&&,8!S^/1Y+CT+RMD-8M=<X=
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M#D5C<<(T.869Q*E=&D32<W5_2H$:VN^_B]DL_P'()ETC>$WMA4XY<]DH+*>
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MMM\*4?M\I/^D;EN?SA,6L^[SA<QL5[V$)20LX?U9@K_#A"DLC2D4%U,4"B^
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M,GJLLQ0H$ZQ'.T/B&@#< :]$6:_C8&FW9 #T-J3[2B7IOL+73;JO_&GWE<\
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M[C.=9(??)2='0W!R@$9]QUY373UC&%[YM.:6-7%F)6S94B<+69GI:QJU9+2
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MBO<&[(OIW%?81RR>X&T?-<JM+7)OQ&\;#\H]G?DSXU]Q.E48>2JMNLH^N=X
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M'/9WU(?L_(\0"[2B[\$=GYQA=CTRG83'\96W5H@U.[N+,NV=H>DR!)QV'ZF
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M*7E=Y\#!U#<KL$KZ_Y7LI^;@OZ$LDH!/BR^!Z8)U20=^1?[@3\ CA;_@#C=
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M<70>+HB_M'HL<7U&@S_Q<+,]BL;'QVYEM(CLK(@ )3E1SRA@/+571F_R!4V
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MV/=>MR(,CLO+:["ZY^3I1#89*5=\/-KL1^U%=ON))WD3DY/(OK!= \K;)K3
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MJNSB>E?5O?(GD7D$9)D3JF%.:*?U-ACWD>Q+JQFZ\6NWD/S1]@#?Z(PY^5H
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M5#96+WLE_?MI^$;Q:7:TI 1C96G]Q6Q]QJYEN:$38+!2WG#,2CSI&ZWX/2U
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M'.1T;[[91F1+)^SV\KA;4M[(GWA:-DH^XN@4?\OS)"_B:B)V;STG:7":*XT
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M E-;[N3@R7<#^A@Z,)O^4^"C8%8JE#,-+H>,,E1M6=%<VV(/0M$+5;G:DHC
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MA$\29//,4HOU4?FIMU/PR%3E&_&DT)F*HPZ:!\Y_(:Q+ .%>C.$L?*QO/8P
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M8\0(FODK#3?\(L_;HEF+RG\7[(5'1*CTZ3&)>WL< @Y?T[^"68 HT7^ON3)
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MZ<L4AWI7/EHQ@+L\S9UNE<+D(%'A 9.;M]6<1A7"W]91>$; 49:P=/075Q1
MHQJGW)]-!Q/&>[_#C;/Y'9WRQE?U>[5VM#TA^_6>4F8[D.4FZV-M0-Y5MP'"
M*!H#X\?/]5O=>-UNFUJG<%:BU*/->Q0AJQ_KW<)8PW)@7VF@I33PH^!ZY=-+
M"DL*D#WG[B!.^)8*7W(B&!)^HQQ8R67G_F) 0BK'0&JJ^8%@3AGX]K/"07(0
M+WE9VU3WY=+,TSNV=9KRL)F\1-_Q"_F\[L%H6C'B?V/WVYG96,M2#R6E^G7
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MG,;'I$Y>_UN)C;.^PV<%G%I<E5(+5.*5R).VO  \2)\+59K81+3E5B3[I^H
MA;,0(UX1YB+UF]W,2)HM^BM$(700S'BZ3%-@^G"/\5>A0Q*R.TUPOS9FNCAX
MV32$2J(& N8O52O,+T^-^3,2UA"6<>1!]/>I7+8#GO. ."7'[)%#+XVF VH#
MA%"^>1RBZ5 1$P$?N*+M_KP>:2!>IG]S%"_;RTRTX:-'9>[XT$UVP_=V6OBP
MU&$/!P.2]HJ.X@,MTD_.?8H2#+<?4GZ5K27F17WGTI^MA42KF6)B1'Q-*NRA
MSVR:IB&.QL+(Q8G%$3 D>"SENZ#Z^(;\_;;AAZ;J0F^AA4.G/]$@WH-!%P'D
M5 /)?:T#9 925,$5[V-H1IL3EK_:TG,.I?;),PR_>RK9RW</B*!09ZD %B@I
MG<K)8?T:MS+4YYZ-A2B2_%AD?$H61]3C=>M_V^^SZ Q;I!VZ)J(8\#M'A1'5
MO_E\6J=D(3RZD^=3=R*LEHWWG5$<PYH>PS\I!4*2K@->TQ> SP6A'?=1B-69
MS%(Q F\N7W]'-QW%%"34+!@DKW%#0]]Q*!H2Q P^\.3_[&T/JW"K=:4X,]_>
MJ8.^("*&7'AFFDO"C284QC\X 5F7)&>WD1HV9 K!U&7Y*^UM.8.<++G"K3D=
M$5]?YV>2+?CQ74;QWM[_J(53QM9IQK C0BH\9.AN-\/0]46T1&M4!$7@8%F9
MIQ!%)I/)+%X9W46^.E@2XO-Z?@30\6KQ^^+W[V;AD'"E&5?YJ+22]:*C-V(^
MW@(6CP(! !Z1?[L,I"VEVG7/XRBW?YQ[3SW@=8TX.W_B-.=X"II3HSMY#7_H
M8)8926%3\[C8TI$?:1KXDD)0"L281*:[QK[&7J<J1OX*$\,%-=+&P\Z9,23I
M-[]1+*UP.^^)'85?CQOS5'28RK7?,]3L@GHRE1Z$%/MD:+(3U88^*;&ZW,*7
MIN#4U"B9[!<VL4^4+19NL]-Q#E<(D&=F!CDKWB2[E+=)XTQH1Y;\T>>E [/6
MI+J-IM8T%X['[LC<G$P6_AP==L$FDNE*[ WHY.$<@3+EL MR.)K?U0AZ\%DM
M$1C8'6;7\N[;6I,,U9^Z]O_LKRZ9T>0FFCL2'B!P(*.^4\4+0)K"BLVH7?L4
M+F]_FON'T1WQ4&Y$NY&50UH9L''+RI^F&BO3H-AN/_J6ZJ:3R94[[?H8CR #
MH+!;Q0K;8\I;#1;:W,M),9Q$O9Z6]OR?R23)-]#( ZN<L>B@2N#$@DG8B7!S
M;3K-J[S@>95;G]:FI%:G?::%FN-E=P7AU/4%MT7R%&0\#)]XOB\2YN<E"QNR
MLO%]36M.0^1"QU"9'N)_7H9&IDA3T-7I+/-9S3TD\-MWJ9<WP2'Q!2JB//X!
M_VJF\Q_BH^WD(RAAL'.#O,P3)'N0WX:=P)S"+S"3J-#57"^;Z\9K@NT.8N29
M^ M +S@%Q30)H>/3PXLFAX)$'X;F[:/-)W=6$M9SUCF-)Z^T65ZCIF2OTV(A
M:>);X OF8":BOS&!!CB5\5+H_3>#4) 7CW#V%ZO&9,HOK8H3%MH,+G8+?JP;
M2YM+DB^H;>3NQT_G"SQ?(?0"LG6O>F_%T."/TR :DA8SASQWK*<5BNZ?1G_?
M>15BZB/ +DOSX9;2L27=D__LF>"(C$UJ=A9%-_JRJAHD%232\GEEF[9\,MZQ
MY/88921KOG47>TWN$4D2?]R'NCKQ8Q*FN%K'A\:J)V7\/K5^:C.[[;C'S.UW
M\V<W]YR. 2!$=1Q-?XV8W1=6RCK3*5+F5\K>#!>K.W3\KL116V;<P_A>][.%
M;MR5N+L #Y86WF<>K 4*TQ];S.X:_*!13-/7=)%K\I9KX?9@'W!\$R>G;O(/
MV8T^^#1UR37TOR/7DYK?J;.VYS\/9S00C!ZRA@C81S'(J]E,L+/SB/O^+VI0
M@:5V_M"8U 6\AF]@/>5&:8=YA"UO6S_'Z_!D>4)=>UPX\(9QH;(WH.$F$PJZ
M3B7*IHWIV 79XPM 6#K;QL@X]^S.3;(O6UJT,!Z<+!66:&MSN8?>$5TF!=.7
M]3NGW(L_W\PD8ZJ@K;S)#Q CC[L[$) E_P78/8_#D+FO1_!Y[0_EKZ\%C+T8
M7 S*]&#Q3@?T$T3C22IK/*H+YG,DK<JM E9,!=YAT\9BT>!FVC&/]722U[;V
M\(ZCMIM;X+_%\?]]T%_,_Q=02P,$%     @ ,HA^5@M/+U<T=0  HY8  !@
M  !N<F)O+3(P,C(Q,C,Q>#$P:S P,BYJ<&?LO LX5/WZ/[RD4CH(482I*$I2
M))),/265))7S82H)B4G.C%FE(L=)DJ),)2FGR2F$F9RC).=S8TQR9F8P%C.S
MYEW3\]M[_W;:_[U__W>___=]KVO/T^JZGM7,=WV_:^[[<W\^G^^]AM_![P/6
MG#AZ_"@@M @ A)#_ 'XW<!@07K1(\ =Y+4;^+%FV9,GBQ4M$1426+ELING+E
M"M$5*U:MEEBS:K7XZA4KUDBO$9=<*R4EM5)LW7KIM>LEUDJM%0PB)(Q\9O&2
MY4N6+%^[:L6JM?_C%_\#(+Y,*&O1 6&AS< B<2%A<2%^)8!"YKE$Z.<+^*^7
MT")DCDM%EBT778&\(7\-L$A(6'C18F'!K)%_#4+^'5@LOD1BT^Y#2R5-+XAL
M]EBK<3/F^3+%/[++I,XT,I0T+UX/7BXJO6Z]C.R6K<HJV[;OT=JKK;-/]_ 1
M@Z.&QXZ?.'O.S-S"TLK:X9+C92=GERN>7MX^OG[^ ;=NWPD)O1L6?C_V0=S#
M^$>/$UXDOTQYE?KZ35I.;E[^NX+"HO?E%955U34?:^N:FEM:V]H[.KMH_?3O
M S\&AX9'F*RIZ1GV+#0W+UB7$" L])?7;]<ECJQKT>+%PHM%!.L26N0K>(/X
MXB6;=B^5.&0J<L%#<K/&S65K_XAYGEVV7%'S#$/JXO5&46FE/;0M3,'2?J[L
M7UM8\/_6ROZZL+^MJPM8*2R$?'G"X@ :X)U]$:X"_.?X?^N8JZDFYH\I2$#I
M*= IK-@5IJVXOWS;PWG/XX'>&SO91_,O>6Y0HI1\3]H[52!',R_57:X;W?YU
M)F>,))-X+FZ'W+Z!M=^;QF+=8%2@74/RZRQ4#74M#?*FK4"+C[S?FN$UV(4U
MSENA.?S:8NOQ1IO]Y_IV&W>,-A6)=1;0IRER.$U7CYT$7_G/YF6D?)W,D[K^
MA3V'0C:/63U:*1EY,RE/=[K5X#C%?_3B\P<.RL%)%];;/Y"-B#_2.\U%2_6P
M U1>%.A=^]]=>]I#Z_SH9$\0ZQ*(]?:XL.M=2;B,65?76=D3BO>$'SC(99.;
M;[T[<F"]I'M)>A^5^P 3367OZP9'#B2?%DEK-%@+F/[?/OQ(U13(F0*=R 1I
MIF YB0_<QHX=9Q,@8S /W\G.9+EWLK&Q=9T##NB]X[SL@PJM]HK]F,YU'^RW
M,N.R\CU3NH^[E\_EJP;>]G]%>4B_8+6J+&C(8;L/_=5D/!8O!FL&PIE\@ ^H
M/@"KL6 KA0\,7,]Y<^*IXY48DY;I:U;1FFJ);VZEJ^Q-\/%I?$6QVW_ +"F5
M[)=*LPC!N3X;#MA;D/KT[,EF.Z6"_/<)QQ4O'U%Y9:86=FWU-4[18*8G<3$?
M<&I8S5W;K';TJ:Q1)B_L*LE;13RS;5KUH87?X1RL3/6$C?QH+86N31FA\@%6
MD2'W\BS/A@_ %MMT]_2TGC+[_#Y.KF&#W!Z&1Z:ZH[+OAN*])#A@UL=]7#7(
MS "7S@=D2OF N6 )<75L4C"1D8^F21?S@3O(L0SD*A'=P%P^4"[%)F7SXB^Z
M4=E$8CWUQR!J9^_3*1N%"T-K30V _\DA53&"D=7;E(*S:H1EC=,5_1K,<A)/
MWS(.,\HYA+*X%[U&P6>B>CPS.J0X'&JWA6QH8"B&<1J9S^PW5)-#-H4I'==_
MX*Q9R<XF8]]K/[9^*K[OD]4O)=1UZPYP6J01UH-Z^_A R#=UAN^=_/%S-J[P
MSF)7M<U5BBX*OJ=7[/XP=]KQD,/-^TNN:V/>*9='J(=7T+Z3%>^Y\H$NEQ<R
M=R)_5'FOL_MTV9WMK^\A=[7W:2>F9!GI%KSK"AG]EO<2)\Q<40TNPQFH1TS@
M\/>&-0RU"A[,GQ3__"[!FS09+5]0PM*\O7*L=]%KV82"\+R7#$HT?K6!H@M5
M.E\]FHI]UUB?K>UIL/7YJA9?Z/3QT+'1XOJKJU[O=U,2GI'^-04LMC&-8%DB
M+%EJ DO5<+?Q >@PVILM!IT \\$\L%4Y\<<<"OF2;'ZX=7/W>WYQYMT':3H<
MBVHT9,D'& 3D2W/B \N?@%@DYFT:X"]\X)Y"[("_/3B);O4/+ "EQSS"@?E%
MX2K/_KT'C>O(;*855#RU=;'? =VA859>B9+XLL/[Z96N)D\9)9%.Q70W)3DY
MAUO#EAA&&WHQ>B@'AT9F^Z*&#T1_11+?;,]3ZQI,4\;, 0TVU;09>\$HT>;3
M<7-+I[ 6C6/1+T/,SRP[?VQC\/;>?SGH-*R2;ZZH&Y5=G3&XZ.$^Z7.K(^7%
M-CWX+CO7-L5>"3GT\ZSR"7=#,=#SC#Q6CUI-N%9ZV(5;>$^YO8WO_XAYK6/6
M<0WX'I/P75\>;B NSQ,C)"DQJ!7+N!:,3Y7Z:]PT+5JJP]+KWIN_D?]P_6VM
MF])]Q3>65C;?_]!(L=&[(98U(I+][N'$_M2"L(F+2\Y</F@G-"+L#;1,GUZ\
M3GIO.W9% W9MPPILV,N#U7MG;*?U^^\-LS,#U%?E;1VW.%^XF[!+_=5$(3M]
M[6DA>S,&%CZA7H/ER(U39A0:TUM=Z\BK^$"M 33.!QR>%L#)75I 0.9:TX-+
M_HV''#J2O(2[%XI*C[*H(HKA5/N#3"]:+F'GONBV^Z*X^%[B]Z-NSV)O/KD>
MY/I#O8/.]H),^X-$^A\D-%2@EHXT67&/,I=$Y5*=I6/7J]&+*J\]=_[2\?5:
MFH[P,REV)JZ3LQK\6,P,A.M"P]#3:3?T[S9Y)<H+G\AMWO-)-6B_<<X=M<RK
MXYLMGP<KG7XCN_F&E-E!H8,(34OW^M=7@%H[3,E#5?(!:;_P46/&;(U))SN0
MD*=W;3@WY6OIZ?4WHF3>F^_0$5G1_I9TEO<47H,[R*BI0MU%KX$W0K<J=+\E
M]Q<?V-NTA5%:\K6[\EVP]Y<MEY4WFW(-[[F*L5-;O2GK(,XAR+2/&JJPB!D?
MIN6VG6Y?1(:BW"\WC8V[#8;LO'BL<\#'_^"&8QT^3]:<VL2+]AH%ET(-_>K!
MWB8A>"DHB)ZIH+:7?JZ(L;^ K9^^>'1?L'/R>86MYM'>*J-)0DMNK@?F'X:K
M1K7 ZI#A<2@Y&:=;U'910;,UXU6+F]=+<_]5)6" X<8UX<?.%]_M,7LWZ/)!
MQ-' [UL^YSQN,V.VZC4L.Z*@45# ]+2MN.0655*];,)Q<95PSV+6?4/1:Y%]
ML37VV[I"Q_T9L490L5C%?N+Z[IK^.??F4]+4RT\^[.SUW9)K>YME;CZTIO#B
M,5OWC:=%LBWB<!OXP/T(9C=<LQ_+,\R[,F/-(MT"6:;X_6#'H!L?>,V..JB0
M;H $[K_MD*KR:Z?[5I!"WF=8.T5P@VB@Z,B9\IT.N6TSB:[[DC9_?G'PON[]
ME)B0OMUQBMG/5K>1K_)"T=_M(*3(.1ZN),Z;V<URM0AE8O,[B&((2K[.Y@/T
M_"D^,.;!,>"J,*IO,4\<<.KWO>7U6%U?T2]XOE,]GW/L))ME^V/?O3VWO-SW
MF<N)?TT ..;A+!+DB@I&35OIH_@ S=2!#]2XMCK_J]Q(F&[23:Q06-D";_);
M"O,!#%1"66/>-$+]XRM9_,N; ,8ZPKAF]NX8"5SC4I\8(5$=MU0YPM@;QHHR
M?2VF>7:6,TH:CW;6W_DU/]&&) D95G7-V_3J]:D>9D/F**K!'E.55263D0Z*
MZQ7J.:9^03A5.F$Y]TPC>3MTEN8;/K9CPFL7[FHC>/D*.U;C1-OD^V.]5I?"
ME%9M<!K8&+P\A1>;D==K4V6OSTP9K&H0Q9DSO[S?<;&%0EN=).F08OWA_@H_
MB3T/#8'<GKVS&PN>=1T'YD^0U5MA23\'&H6[UH;V+OUY1ZWTF_XHS4KK5Z1
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MS1!R;@O6AG$U$'I"1(B48$35J5 VC7<#%L:A> _U NEBRR!)CF*E]27I29=
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MYN2C1^5*.^I$'LD?7N2K&;AN[$&!_FIHF#E*JR:21LA*#$SHSNG$*%VWBZS
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MNPS(9AYW *1>W:0>$8@NNBFG/7Y$;XWG2Y?:T[') ?[^NTI0V(35@W*-QO6
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M.[OH;)#:;'>7GB#9]%=>J-ZKBIS>WZXE![[POVRWH%2OY*@^N&4,U)!LR-G
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M&!C["&8A(C+=B2^IC5E8_L@[]O)WM@\FB+J5=@67^"\7_U>HK>,'9W?J*=6
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MBS>7(+->,M^FGWKXE9N<K_8H>&(EADI1C++$Z"\\@2H$G!M5^\BHM:) V&R
M #3*;V;"<R1/OT'#IK*\;(?IXQE^U1K;B_-C*W 6928\Y/_=Z+: +H+Z.P'!
M^! T=+ST$/1IYK]GE/SCGC;+_K[%,&5.*Z*#704J=S)+J19$[=Q2JSOD.?.
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M>7I.+'50VWHN ?&8]D8N5,$]3\+N_D'W<S?L]P]3L_2M;C?5AN+Y>@^A"=W
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M"+GY;\;5_)_R83J<_[\ 4$L#!!0    ( #*(?E:T>_1DJPP  .*/   9
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MS9AO% J#P4 9%!5"^X7.?<%FKE,J.(0$2+&8E3L_%5?X=P2M\U,7,0A,&](
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M(A$L-]KINE)]:[R;DL)4]817V7/(8"3 T=]R4L.(NLX!%\'"+FW*3,:/PFY
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MU28\3>^TA3F+C/+"UWX5OUN''AP8R6D93B Y,<SI7<P"IJ'3MML#%)@\I?_
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MT[<=W>H8<Z0T?;/TCU/+K:LX#RS#5!*FME[,HHAR-'A_=FF;CM\Q<L,WS>N
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M.F?M#)11'V(<TH7@7@'!#SN#VR"7-77-_IWL)[[V-\/'_P=02P,$%     @
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MN)VE"\;]AD9X-5& G$R!4@:8<30.2MA!)[.Q@MVDR<V4&S;C"S:"ZS. R7!
MD5%LH<KVTU&I0R";<ER=8''*-:$A(,_/()1P^Z+U.Z-F,WA%&Q5_C%C."W;+
MTU*P?^^VNV!'Y#"LGB+:=[^&SG&*&YQBB8:>'L,5(GAIIJJ T8  >8ZKL4A!
M M* 9\(^&!%1U_Y8M-#5<(%1A;D*E14.+7GOK1LB+\08+$687-\WRE?LQ/MJ
MEI7-Z#[99KP#S(G<B-D(5KBW'S&P@/<;Q(I$FJ<"S63.>MT6<&]K#\C_5H!A
MZG9)YZDD 2AAI\(-:;,3V%QX6I>I\7P!(XB) B40,1QE 1=E819LM]=]L6%C
MF2J-!N& UBB;<R(8A4($] %('\MG">UP(8A=0>#!!9F!,$$6WMUS0R^/_$1X
MO\S86W5KT;Z"\HHM1HH7"4*<2%B6487^2HURB@,NZSQ0P6!PD"/4BUYWN\^?
M[;U:&GP^E4:T= Y*N _<TIH7/(?A@MUB2^2-6O &L 1W3V!=V2TJH5$JEI\#
ML5<6NG1RG[,K"?8:$-;)I!""'#MRZ,X5N"$G[&8(8[79E4G:-2?:Y7PY,NR8
MZU[?L-Q:^2:$K8!S7EK.(0KDH8GPOBR .C<M:/-(;<;>!31RL(XSI=:EW[1@
M*]:BW6X*H-A.W,;1ST7L*' =XU=42#P^!9P!QS.>HV4 L^*3,4V 5D)M'+FY
M5\@!$5-; 1N?LT,:S[L@DGJ]'OYLD QMOW\_$!L3EX5LM1^]ZNY'AX>O@T5L
MYI?3N_G%81%H-)ZR.5@@G@X0Q:&<1+LK!ELOP7")I3J>L0]HK<R1.N&1FBA'
MPLR%R!KTA0-><<##J"PF;#CE*: O8\_Y+!\0'Z(=3O8N:$H2[S!^Z<<W,%I>
MCH#YX XL ><;+<()2#O 6V\X\ C;/R0B[$4AG:Q0]>D*XJ8<+%@$?8ETZE=5
M63R:S'^@-W9.;D]N'.LTK;1'\]#V#K[ 0TN:("XC$4W_RNHG4JFL?I#H:,NC
MM!F)RGX <B%_09>C/T&9D;B'M_XJ03X[94WV P *V@[L 2 6VFJ!Y(MZ'" 8
M@JF0L!/G7N'[UP(('C?]K.GF7(9NSC=TRNZ:9EFS6HXDWT!E&\ ^)>?K:_4Z
M#;+B(PH.?%7)"L!][?N)I(E?Q$_&A(M_ ;81GI,L@]T!6&D[8>=_ ]<-;.C6
M?]2C@O&FV1(Y7Y-S5(!2KY1(H!*)<%!BM-F_!&QW#"CBX":!TX<3%X);K-V]
MH:>!TXJP@F("Y' 4F:LN<>6_NB@(4'+M E_Q.=JD#(.=-F@;.JG?25C(S?N]
M<_Q?BJ3U-6ZY;K.CCCS^P^GC94,9%XD<9%+4T=;XO54F=&&4]<=A>09'P+L8
M O?".53W$5),6I(ZP7LB=5YN:).VV3J7[J[=HTUSA)\H*S-PSQ)R#EA<SDH;
M(4;@G"K;//T/L$'G$H%'MG[ %L$Z!*XU<8,@UE&5+DAJN?!(@FX-*KUQH6;,
MP"J(2?&WVS=K=3@AFDA@2&%Q59)J'H-BUBP5$_*8^"V7*3$+(AQ?S_F"# %"
MK0/D1T#ME?RKE(DEFQ"[EXXD;AW0ZRS7M'[76F;3>DO6/=_8ICEFCD;-K;(,
M!$0,J%N0@05F4H*R3HY*$]C!*P$.K05L"Q\#RX6H1D9,Q AOH:Z 5PN FH]D
M:F6EEVYY):G1V%K0S@$\P7HV6Y;P?A8:AIZ\'F=W<4-#_862F):SZ$]E F3E
M'*EN;Q":[C8[9?^?%O[E$8\_3@H%I-N*5:J*_K,N_1L$6:;FC:G5BT!=@U1F
MHN6^=QV$+7C%J)E-BKE+0<++70GS7<N9M!Q456L$2NICBW:SS],Y7^B!370=
M'+3W7_XT&('5+0J7_.HN9<C^F7DWGZ]XH$%\4JOO$V"XUI!_%.!9%4#-7ID_
M7>KB1AB4D^! C018QTW3UW'\FCC\?1J0I+;5@A0)!T,H3<"? 5U H@V\)IM7
M2&#C%J@'05;G!8D\_,9=X L%$4;:"Y4NR1^KFM?;]"NA>X+)QO1KHWS9"+]O
M85&X*AN/2\4MAG<>8)4]/-AZ_OO9U2.&NQ]L)_@5-VD<UHHJ[<GC\4ONF4]I
M@*RNM@SPVF[<F-B] T*"#2;O@<Q[Z_A7ZPU)7Y?@-H!E4VIKS(ALPB<^8,&>
M_U4J,QB5&J2WIA3)2&;THKU3!3+L5XG)7?"E?/#>:D3W*%GU:/E*E=@5% +\
M#!"4.F *7)<UJ) )ETQ@X/@8'$><</U4$2NS%"#MT^X9DF!6_/^ZT]UAL4A3
M)\ZK[QA8]-^]HK,* W19RG,M^O[#X!N0J==YP1749D0F"&X+A N8!_VQ_"22
M0: X+%!>J9L"?I(J1$J/$6EA;8E)PIM?!31%OF*>.KU"E SP#L*@;*8H).M@
M/2"U3#AVP#Y_=OCJ]>%@&:[F0ZM2Y:$@!ZR>H=^8-D22N[1SG ,=%EZ(.HK[
M4F+#-]:D!1Q[-C2,C]0*268EO;F&K9AS -!?U]PRMG7M;=K&1F;60*IFI(0V
MP5J;=[@)'22?#M';EDNV7'('EY2Y(G.&K)+0I_K6!!JY>H1U]YB:9QBI,^ Q
M<VW8P2\_>3!<2,)F/M?P71B"=_JDXO5P"9C\1ZLJB9CXY(,LJ+$H?*JM+Y<(
M@ Z6X?545E*N(?#W@MEV>9T_)?#!> /EI]'DFD\5!1YJD6$S,EIA=%[&PEW9
M';U@8I:G:B%\=C=/ 6A$L45Z=1=#>#*68#B8*HQ3&:_DNJ"L\RN@;-$8XPI&
MDKDPGPJ22P[BJ0#;-S ^R*:&F2L_W&#PM+";S=TWE%W"EUE0EF$ E[:"YY$$
MS_X_6O  LP(Y 0EJ\5<I,O,M-/4Z?2N#+*J+W5F-3AQ95\( /!P=18K!(V2Y
MB(%UV$P(DD H!!JQ6GP?F1 &]0DXE*.PE,A/Q('7*;!]Z\+"&(/R0N[5J]9^
MIU<)NE"T-(1>E4[ R2I)LUF8MC<SY/J292*TJF3Y"=S]VKU)Q!AW$"3.VKT$
M$K$1<K&U_[>6S7T"!CSLF2@F5F\A:ZK4A[9E=JO26Z_FUT6*ME;VEA:_+2UJ
MGHJ(9+^(*C,J8C-5F G'3WDJ$OQ-9NO8DJW-4212^[ RVP6##-.,H7%+@1=M
M2S90G=2W](LE6M]D@&/!YT\X$, CO$YR>90U9O<N/(FQIQG_$_2G6;2L8D)U
M+A/)B\6++:ML6>4AK!(X)< D@J+G9&TM&B1/T4/KD6KOD&)E%E5?88S%,Y&S
ME1H^(R7D-ON4SA+=JH M77]WNMYLF1#%8Y-$G:V*7( !_'N4QYG_%KG.DP*4
MC1\*7""L*\**&R/JZNS*TR(E@@7HMOVB"/7)$B0CD8&='MO PF=X) .TJK9L
MLV6;![ -1;>P9"<W=Q.9)U1+G!M9@^U:[FOR R9F*<O<'(]R9P'EOXB\[D@5
M)^Y-;E'AP*=)R;$"3^!G:\CIVGX#IQ8>PVB"@PX>4BY-P+.J"\S?!-;S&7"9
MA>F_R!=N$<-1)J%0Y62ZS*%_MQ# 9>83FQ%;&P[8%/>QA90+6S5$&+$1V!41
MA5)P[Y<5 W=CT&5=A@?C1>OF(L$L"4H,^*22,O4(FU:Q=&E[(J7E5[]/3=!J
M:GQ;)?0/KA)Z:+7$&9@$6"]W[LYXT#]$D<075[CZTM:JO,!6:HY\Q:?K5[#%
M"63LN-R/3]50'6@&&P>20V!I#@IAEPG"Y@NE-;:*1+8T@HJ^K<T$R[ZUA4(@
M4R83RI[0-"VL@6"8F+$50KYE+G85&@L0:S.$P5;<8N50E3?"@E3,OE!R1VI?
MO<VIC2]I859H80L[9ORCG=TG:\9A#&$N-;QE8**<9L!BY1%IG:"6J81%2"H]
M6H72J]?5;'A=D^),3M=>GDA,=8&#1E5;A<A3,N$ 0A\U6"IL!C7@J\*C>VO2
M@SW_?QD,W@.I]LO6DOR2>I! ,%##E34T"F!RB;QJU?(,4SF)ZZ8Q_*.@4GVD
MQD9GWJS4ANJ5R1%S^2.6E-@?"[Q ?2>?F4HB2D8^IVQ2,.1H83TRFU6BG+#M
M)-O&(+9<\$ NP$:H42KUU/LN2'4R%IX-2/-3842&!1TD:NWWJAW$-8=9O0HW
MJ(H"O2F*-?A&%UMCR]$41T[#DQNPU(38)+3@'5-L27I+TM]"L%/:HL[JUQ4\
M39,*.R7=,094EDV%UUJEY=VVSC:2U:34+9D^D$R73(*J<;II8SA"M?:$IU.R
MS:<<"TLJ2B59'+E;4H G\4G$)=6=N'HS7W=JI7;S%(B \GFB<F]Z-,QT*LU1
M>%1,S5(!GX7]@7^KT-/0E=E[OS%T9VJ!LJZ.9P4]KK0N[&"CAZ6N;4S$-_8E
M8S=)[<L\?]8[Q -(7).M+7%?^\B=ITNY6?#-"9VU2 8MGLB&+B-&I+  $0L#
MK8(6X,S.X2%2S$OA+C??/6VGSN=VA.I;OF$F\/8$3XF0MM[95CI^7IS_?C9#
M$5DK<FJUQ'(($G';6M0M_7U[^EOJ8]Y4O>F2!U:>NDYC),]6F&%HGI'2/'IM
M16N$4;4[V_'_=NJV.I'L2[LX4<U8*VB3KOE,;=TLR__[;OT3Q>8QDESUSP=[
MZ,Z?K#M$[MQ-V#EG/MA.7&J[Q:M!F%LK+ 9?Y*MU;4&A!.;=8N-B;3D@D'H>
MUG7K%L%%0 O,,*-R[>#8C>84KOBZ:953KT4=5/<'2G!L%I[)<N8/>9!5MP6U
MG9*VBLNB$-2>*REM[$-_J9Q)9VO:Q-Q*D)".KIC!2-48]0K(MK-%[LT56%]C
MV:=(A)BY *?=*(D5]MI425;B"W(G"H'<&KDMX@F=0XC9<MLM;0M+,'SD*3LX
M8_.;$^AGM[[?F>>ZP/8?C3OVFRI@MZJ6]Z?+=UVN/3M,5("."="*TYKU 74'
M>.4Y!#WI/GJL@_"Q+W#3H5Q!+DIA^S,K!&E*?T)=:<\;.Z.CX.LF_!OC&+MJ
M/-Y5A3OOPOFK<ORE0Z0\_ECW1=MH(ONS+*1.9.Q.EZ+B/7PQIG%3%5>'T3N$
MK(Z[!C*4U)27#P;3!,#=\^,$8Y%0$[T]CB0V#A1_OLNYOQR 0.UBKKL*L:]2
M*T>7]]F/$?1,>PGH^=I&7&,A$@H>V#-QJZ7B<DI0$0M;^$X<";?ZU+)&9Z@
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MRMI;)9/[1&W'_IT@^L-#Q_\'4$L! A0#%     @ ,HA^5FK5WC24%P  ^?\
M !$              ( !     &YR8F\M,C R,C$R,S$N>'-D4$L! A0#%
M  @ ,HA^5M.U $!:#@  %M   !4              ( !PQ<  &YR8F\M,C R
M,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( #*(?E:P-JHJU$,  -&3!  5
M          "  5 F  !N<F)O+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4
M"  RB'Y6+R$M7EJ,  " #PD %0              @ %7:@  ;G)B;RTR,#(R
M,3(S,5]L86(N>&UL4$L! A0#%     @ ,HA^5KK(KTH.80  UTD' !4
M         ( !Y/8  &YR8F\M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    (
M #*(?E82.+Q,OT4$ "$D)P 5              "  258 0!N<F)O+3(P,C(Q
M,C,Q>#$P:RYH=&U02P$"% ,4    "  RB'Y6>JZMMY=;   O;P  &
M        @ $7G@4 ;G)B;RTR,#(R,3(S,7@Q,&LP,#$N:G!G4$L! A0#%
M  @ ,HA^5@M/+U<T=0  HY8  !@              ( !Y/D% &YR8F\M,C R
M,C$R,S%X,3!K,# R+FIP9U!+ 0(4 Q0    ( #*(?E:T>_1DJPP  .*/   9
M              "  4YO!@!N<F)O+3(P,C(Q,C,Q>&5X,3!D-#(N:'1M4$L!
M A0#%     @ ,HA^5G'$5QMF P  +Q$  !@              ( !,'P& &YR
M8F\M,C R,C$R,S%X97@R,60Q+FAT;5!+ 0(4 Q0    ( #*(?E;@]XZZ!@0
M #$0   8              "  <Q_!@!N<F)O+3(P,C(Q,C,Q>&5X,C-D,2YH
M=&U02P$"% ,4    "  RB'Y6"BS2&N<)   '/0  &               @ $(
MA 8 ;G)B;RTR,#(R,3(S,7AE>#,Q9#$N:'1M4$L! A0#%     @ ,HA^5FC5
M%[KZ!@  ]R   !@              ( !)8X& &YR8F\M,C R,C$R,S%X97@S
M,F0Q+FAT;5!+ 0(4 Q0    ( #*(?E:U!^ASR!,  $QI   8
M  "  565!@!N<F)O+3(P,C(Q,C,Q>&5X-&0Q,BYH=&U02P4&      X #@"_
) P  4ZD&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
